Clustering O 0 0.00010891476995311677
of O 0 8.077720394794596e-07
missense O 0 0.00010569168080110103
mutations O 0 8.058734238147736e-05
in O 0 2.3929277404022287e-07
the O 0 1.1177589840372093e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 1.0
gene O 0 0.00012827150931116194
in O 0 2.379428707399711e-07
a O 0 2.6143129616684746e-07
sporadic B-Disease 0 0.006261687260121107
T I-Disease 1 0.9999377727508545
- I-Disease 1 0.9884784817695618
cell I-Disease 1 0.8642897605895996
leukaemia I-Disease 1 0.9823603630065918
. O 0 6.401803602784639e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.012565232813358307
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 3.00467632996515e-08
is O 0 3.1665312594242323e-09
a O 0 1.6105712319358645e-08
recessive B-Disease 1 0.5626175403594971
multi I-Disease 1 0.999901533126831
- I-Disease 1 0.9999945163726807
system I-Disease 1 0.8754000663757324
disorder I-Disease 0 0.02417496219277382
caused O 0 2.163044570124839e-07
by O 0 1.4649377710895806e-08
mutations O 0 1.1087814755228464e-06
in O 0 1.164198160097385e-08
the O 0 1.0352242618694163e-08
ATM O 0 1.5766034948683227e-06
gene O 0 5.573667749558808e-07
at O 0 1.5866763192207145e-07
11q22 O 0 5.8939722293871455e-06
- O 0 3.7408761272672564e-05
q23 O 0 5.1920683290518355e-06
( O 0 4.2302310987452074e-08
ref O 0 8.849088771967217e-06
. O 0 5.8635915678451056e-08
3 O 0 1.0333781830240696e-07
) O 0 1.7829073328812228e-07
. O 0 1.2559249853438814e-06

The O 0 2.4352589207410347e-06
risk O 0 2.0895551642752253e-05
of O 0 3.046700314257578e-08
cancer B-Disease 0 1.4800618373556063e-05
, O 0 6.406458918917224e-09
especially O 0 2.835020218583395e-08
lymphoid B-Disease 0 5.871011126146186e-06
neoplasias I-Disease 0 0.0003576413437258452
, O 0 1.887400102873471e-08
is O 0 1.284875139617725e-08
substantially O 0 1.3266868563732714e-06
elevated O 0 5.914257781114429e-05
in O 0 3.4042880088236416e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0038171946071088314
and O 0 5.076519116187228e-08
has O 0 1.1558483947737841e-07
long O 0 5.0907152626678e-07
been O 0 3.110245359039254e-07
associated O 0 3.4045891084133473e-07
with O 0 1.4741559652975411e-06
chromosomal O 1 1.0
instability O 1 0.9999994039535522
. O 0 3.7484787753783166e-05

By O 0 2.149133706552675e-06
analysing O 0 3.9664373616687953e-05
tumour B-Disease 1 0.999993085861206
DNA O 0 1.0888572433032095e-05
from O 0 1.0232459146664041e-07
patients O 0 6.259261340346711e-07
with O 0 2.425097278546673e-08
sporadic B-Disease 0 0.00040733153582550585
T I-Disease 1 0.9995081424713135
- I-Disease 1 0.6423436999320984
cell I-Disease 0 0.047623783349990845
prolymphocytic I-Disease 0 0.16035957634449005
leukaemia I-Disease 1 0.8867702484130859
( O 0 1.1153062473567843e-07
T B-Disease 0 0.009981431066989899
- I-Disease 0 6.683697392873e-06
PLL I-Disease 0 2.4396134904236533e-05
) O 0 1.381220116059012e-08
, O 0 2.1929738025505685e-09
a O 0 3.301544593270478e-09
rare O 0 5.786519707839943e-08
clonal B-Disease 0 3.1493236747337505e-06
malignancy I-Disease 0 0.05008028820157051
with O 0 8.977319332359457e-09
similarities O 0 3.2452194886900543e-07
to O 0 2.0502465503113854e-08
a O 0 2.598962289823703e-08
mature B-Disease 0 1.9370643258298514e-06
T I-Disease 0 0.0012842339929193258
- I-Disease 0 3.521741018630564e-05
cell I-Disease 0 0.0004679208796005696
leukaemia I-Disease 0 0.11373405158519745
seen O 0 1.522404909337638e-05
in O 0 3.800075205617759e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
, O 0 1.6124586110777273e-08
we O 0 8.385677041644612e-09
demonstrate O 0 7.99919686045314e-09
a O 0 3.9286986996955875e-09
high O 0 1.6746524167388088e-08
frequency O 0 6.530076035460297e-08
of O 0 6.08182437744631e-09
ATM O 0 8.904927199182566e-06
mutations O 0 3.92888387068524e-06
in O 0 6.753381285307114e-07
T B-Disease 0 0.008953952230513096
- I-Disease 0 8.620452717877924e-05
PLL I-Disease 0 0.0009107126388698816
. O 0 5.838954621140147e-06

In O 0 8.724857707420597e-07
marked O 0 5.022738491788914e-07
contrast O 0 1.2684080274993903e-07
to O 0 8.561317876853991e-09
the O 0 9.345304086139095e-09
ATM O 0 1.635156309021113e-06
mutation O 0 5.209142273088219e-07
pattern O 0 3.849925633403473e-06
in O 0 0.00018008894403465092
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 5.514102507930829e-09
the O 0 1.2226684109606367e-09
most O 0 3.689333505363379e-09
frequent O 0 3.3622931994159444e-08
nucleotide O 0 2.756684409632726e-07
changes O 0 4.889094995519372e-08
in O 0 2.5179581086831604e-08
this O 0 9.153773561365597e-08
leukaemia B-Disease 0 0.025584381073713303
were O 0 6.273472195061913e-07
missense O 0 8.208893268601969e-05
mutations O 0 7.289540371857584e-05
. O 0 4.3823492887895554e-06

These O 0 2.9923660349595593e-07
clustered O 0 1.2258468586878735e-06
in O 0 5.090190668965988e-08
the O 0 6.712195244062968e-09
region O 0 1.7797093576632506e-08
corresponding O 0 3.0193717748261406e-08
to O 0 6.333149560333595e-09
the O 0 1.8178657468226334e-09
kinase O 0 7.73955690647199e-08
domain O 0 9.971507353156994e-08
, O 0 3.7132374952619784e-09
which O 0 3.5475913318094854e-09
is O 0 1.2582216379897204e-09
highly O 0 9.371078135700373e-09
conserved O 0 1.3883145300042088e-08
in O 0 7.39329353294238e-09
ATM O 0 9.764783499122132e-06
- O 0 7.761670985928504e-07
related O 0 4.0165318182516785e-08
proteins O 0 2.6471909109204717e-08
in O 0 1.2282483474734818e-08
mouse O 0 4.4967066514800536e-07
, O 0 1.67613531942834e-08
yeast O 0 7.394424414997047e-07
and O 0 1.0532151861752936e-07
Drosophila O 0 1.4695575600853772e-06
. O 0 1.3703167951462092e-06

The O 0 1.6819739130369271e-06
resulting O 0 9.64329842645384e-07
amino O 0 9.521339734419598e-07
- O 0 1.3179464986023959e-06
acid O 0 1.2216344202897744e-07
substitutions O 0 4.416061472056754e-08
are O 0 8.081395108661127e-09
predicted O 0 6.217211989678617e-08
to O 0 3.921870828094143e-09
interfere O 0 6.371195837573396e-08
with O 0 8.713572086094246e-09
ATP O 0 6.375383918566513e-07
binding O 0 6.238820446924365e-07
or O 0 4.951720029566786e-07
substrate O 0 7.891986751928926e-05
recognition O 0 6.282156846282305e-06
. O 0 6.583290996786673e-06

Two O 0 6.152925493552175e-07
of O 0 6.242569838832424e-08
seventeen O 0 9.362958053316106e-07
mutated O 0 7.456083039869554e-06
T B-Disease 0 9.41973557928577e-05
- I-Disease 0 2.261725740027032e-06
PLL I-Disease 0 7.416808784910245e-06
samples O 0 3.721773396136996e-07
had O 0 4.5483758981390565e-08
a O 0 1.658131232318283e-08
previously O 0 2.285903974552639e-06
reported O 0 0.0007706757169216871
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999971389770508
T I-Disease 1 0.9999998807907104
allele O 0 0.000587554182857275
. O 0 7.643569915671833e-06

In O 0 5.222313461672456e-07
contrast O 0 4.3686443973456335e-07
, O 0 1.9309794652144774e-08
no O 0 1.5620289062212578e-08
mutations O 0 2.543420691836218e-07
were O 0 3.3805491739258287e-08
detected O 0 2.470436868406978e-07
in O 0 2.9182636307467646e-09
the O 0 2.6226640859050576e-09
p53 O 0 2.2884155015390206e-08
gene O 0 2.5907068490482743e-08
, O 0 1.6588421747343318e-09
suggesting O 0 3.269330761668243e-08
that O 0 7.539328272798684e-09
this O 0 6.260240326128041e-08
tumour B-Disease 1 0.9999998807907104
suppressor O 0 1.8621551134856418e-05
is O 0 3.844315443757296e-08
not O 0 2.805467502753345e-08
frequently O 0 8.642106763545598e-08
altered O 0 1.9559281554393237e-06
in O 0 1.868160381945927e-07
this O 0 9.438400070393982e-07
leukaemia B-Disease 0 0.15340055525302887
. O 0 3.713041678565787e-06

Occasional O 0 6.434144597733393e-05
missense O 0 0.00034211904858238995
mutations O 0 4.363156040199101e-05
in O 0 1.4791565661198547e-07
ATM O 0 7.967336387082469e-06
were O 0 2.4025476363931375e-07
also O 0 2.3455495323787545e-08
found O 0 4.984088519677243e-08
in O 0 2.2586705483718106e-07
tumour B-Disease 1 1.0
DNA O 0 1.7232294339919463e-05
from O 0 1.798587234702609e-08
patients O 0 6.237963390276491e-08
with O 0 1.1626869245162652e-08
B B-Disease 0 0.0012653906596824527
- I-Disease 0 6.857382686575875e-05
cell I-Disease 0 0.003926924895495176
non I-Disease 0 0.00021362830011639744
- I-Disease 1 0.8517270684242249
Hodgkins I-Disease 1 0.9949336647987366
lymphomas I-Disease 0 0.24905943870544434
( O 0 6.738751068269266e-08
B B-Disease 0 8.357978003914468e-06
- I-Disease 0 9.955665518646128e-07
NHL I-Disease 0 9.001549727827296e-08
) O 0 3.760951550191294e-09
and O 0 4.510774420651842e-09
a O 0 2.4230168094163673e-08
B B-Disease 0 0.00033775248448364437
- I-Disease 0 1.1742729839170352e-05
NHL I-Disease 0 1.7233278413186781e-06
cell O 0 1.0403090527688619e-05
line O 0 1.1475003702798858e-05
. O 0 1.9627784695330774e-06

The O 0 3.3799506127252243e-07
evidence O 0 1.1891172135847228e-07
of O 0 3.6459202323868567e-09
a O 0 8.111353366757612e-09
significant O 0 5.6361972866625365e-08
proportion O 0 1.282739503949415e-06
of O 0 4.747817694550349e-09
loss O 0 5.122525180922821e-05
- O 0 1.048643116519088e-05
of O 0 7.715763139515275e-09
- O 0 0.00015507165517192334
function O 0 2.94649424859017e-07
mutations O 0 1.043602310346614e-06
and O 0 9.701725645072656e-09
a O 0 5.098777400291965e-09
complete O 0 3.2741606759145725e-08
absence O 0 9.433954062387784e-09
of O 0 5.353559817677933e-10
the O 0 3.801664316682718e-09
normal O 0 2.1663677074457155e-08
copy O 0 3.7382317685796806e-08
of O 0 1.1480014716624964e-09
ATM O 0 9.715391797726625e-07
in O 0 1.1805100896822296e-08
the O 0 1.4366964506962177e-08
majority O 0 1.0669786121297875e-07
of O 0 1.820225925541763e-08
mutated O 0 0.01698318123817444
tumours B-Disease 1 1.0
establishes O 0 8.68911911311443e-07
somatic O 0 1.6397520994360093e-06
inactivation O 0 3.932711479137652e-06
of O 0 1.8561255865634507e-09
this O 0 5.290454740958239e-09
gene O 0 6.363896432048932e-08
in O 0 1.2092246315376087e-08
the O 0 1.0605949007924664e-08
pathogenesis O 0 3.7443624023580924e-07
of O 0 1.293064499918728e-08
sporadic B-Disease 0 0.0004820676986128092
T I-Disease 1 0.9934855103492737
- I-Disease 0 0.0007961808005347848
PLL I-Disease 0 7.80084592406638e-05
and O 0 1.8775510923774164e-08
suggests O 0 1.4741875276058636e-08
that O 0 2.745688565397586e-09
ATM O 0 4.649182585581002e-07
acts O 0 1.2590052733685297e-07
as O 0 1.1939819444251043e-07
a O 0 1.5161193687163177e-06
tumour B-Disease 1 0.9999996423721313
suppressor O 0 0.0014017713256180286
. O 0 2.2156242266646586e-05

As O 0 2.642091772031563e-07
constitutional O 0 1.1967726720740757e-07
DNA O 0 7.634068310835573e-07
was O 0 9.15677773605239e-08
not O 0 4.815222887089021e-09
available O 0 1.2576776065031936e-08
, O 0 2.772173157694624e-09
a O 0 1.86087660836165e-08
putative O 0 1.4142751751933247e-05
hereditary O 0 0.25445449352264404
predisposition O 0 0.00039184826891869307
to O 0 1.5485825315408874e-06
T B-Disease 0 0.17336973547935486
- I-Disease 0 0.00010142729297513142
PLL I-Disease 0 4.894181256531738e-05
will O 0 2.6271012032452745e-08
require O 0 2.992922176758839e-08
further O 0 2.4556358724225902e-08
investigation O 0 1.5653787954761356e-07
. O 0 1.6639741318158485e-07
. O 0 1.0738513083197176e-06

Myotonic B-Disease 1 0.9998688697814941
dystrophy I-Disease 1 0.998412013053894
protein O 0 2.002921792154666e-05
kinase O 0 2.448148552502971e-05
is O 0 1.7646044625507784e-07
involved O 0 9.897816255488578e-08
in O 0 8.038964161016793e-09
the O 0 4.844896039912783e-09
modulation O 0 4.213723059365293e-07
of O 0 1.1198782345900327e-08
the O 0 8.005412155398517e-08
Ca2 O 0 2.2470447220257483e-05
+ O 0 7.786739843140822e-06
homeostasis O 0 4.403556522447616e-05
in O 0 5.896170591768168e-07
skeletal O 0 6.0238577134441584e-05
muscle O 0 6.62856109556742e-05
cells O 0 5.9152167523279786e-05
. O 0 9.790668627829291e-06

Myotonic B-Disease 1 0.9999959468841553
dystrophy I-Disease 1 0.9999982118606567
( O 0 8.201249875128269e-05
DM B-Disease 1 1.0
) O 0 2.899452056226437e-07
, O 0 3.9313374777805166e-09
the O 0 3.663892078620279e-09
most O 0 3.096875644814645e-08
prevalent O 0 2.8018075681757182e-05
muscular B-Disease 0 0.00016599477385170758
disorder I-Disease 0 0.000887958041857928
in O 0 9.692204372413471e-08
adults O 0 1.740856873766461e-06
, O 0 8.53845527615249e-09
is O 0 1.7759656856242145e-08
caused O 0 1.0542281358993932e-07
by O 0 1.4054299057875141e-08
( O 0 1.6443241435126765e-08
CTG O 0 2.83222630059754e-06
) O 0 1.4102067957821873e-08
n O 0 1.7968852716876427e-06
- O 0 4.828118562727468e-06
repeat O 0 1.7312872842012439e-06
expansion O 0 2.513395003234109e-08
in O 0 5.2220916479939206e-09
a O 0 3.6534593128578763e-09
gene O 0 4.140814269248949e-08
encoding O 0 6.389547735352608e-08
a O 0 2.6558897303630147e-08
protein O 0 3.263334917846805e-07
kinase O 0 3.41917666446534e-06
( O 0 1.0033837583023342e-07
DM B-Disease 1 0.9999010562896729
protein O 0 2.836346482126828e-07
kinase O 0 1.337908543064259e-06
; O 0 5.6062201991835536e-08
DMPK O 0 4.46145486421301e-06
) O 0 7.749036079474081e-09
and O 0 2.9954849711799625e-09
involves O 0 2.2401120958193133e-08
changes O 0 9.156166669299637e-08
in O 0 6.40856328004702e-08
cytoarchitecture O 0 7.090736744430615e-06
and O 0 4.1058567035179294e-07
ion O 0 1.2845469427702483e-05
homeostasis O 0 0.00023362964566331357
. O 0 6.04506021772977e-06

To O 0 2.3610085975178663e-07
obtain O 0 3.3863645398923836e-07
clues O 0 3.39463582577082e-07
to O 0 1.3758142181075073e-08
the O 0 3.994656161410148e-09
normal O 0 5.277607328935119e-08
biological O 0 1.1850462300344589e-07
role O 0 1.2977045216189254e-08
of O 0 1.4145811189081314e-09
DMPK O 0 2.614659933897201e-06
in O 0 1.5318779134076976e-08
cellular O 0 3.695427892580483e-07
ion O 0 4.756494718094473e-07
homeostasis O 0 4.7098437789827585e-06
, O 0 1.5933505181919827e-08
we O 0 1.4927231006822694e-08
have O 0 1.0413753415150495e-08
compared O 0 3.1843814696230766e-08
the O 0 7.1221273323374135e-09
resting O 0 2.3933247916829714e-07
[ O 0 1.571772401121052e-07
Ca2 O 0 5.801167617391911e-07
+ O 0 3.033263169527345e-07
] O 0 1.3894408823489357e-07
i O 0 1.2094463386347343e-07
, O 0 7.138117319449577e-10
the O 0 8.014250374444032e-10
amplitude O 0 3.144990401438008e-08
and O 0 2.2158388901516446e-08
shape O 0 3.364010012774088e-07
of O 0 6.334466284840801e-09
depolarization O 0 1.223345293510647e-06
- O 0 1.1417170753702521e-05
induced O 0 2.414966729702428e-06
Ca2 O 0 3.053736463698442e-06
+ O 0 4.078935091911262e-07
transients O 0 1.5398803725474863e-06
, O 0 3.882646648634136e-09
and O 0 1.5095433791856294e-09
the O 0 1.0192440225154087e-09
content O 0 8.567477394194611e-09
of O 0 1.4808770876229005e-09
ATP O 0 5.385204531194177e-07
- O 0 3.92676071214737e-07
driven O 0 8.34854319009537e-08
ion O 0 1.5462566693713597e-07
pumps O 0 5.444974817692128e-07
in O 0 1.492108303580153e-08
cultured O 0 9.82849883257586e-07
skeletal O 0 2.6423715553391958e-06
muscle O 0 6.725936145812739e-07
cells O 0 7.158301684739854e-08
of O 0 1.8875285778818807e-09
wild O 0 5.8676079106589896e-08
- O 0 8.205904305214062e-05
type O 0 4.612713019014336e-05
and O 0 1.688831048340944e-07
DMPK O 0 2.0507357476162724e-05
[ O 0 6.506070349132642e-07
- O 0 7.634499525011051e-06
/ O 0 3.17796116178215e-06
- O 0 2.666560612851754e-05
] O 0 3.713668547788984e-06
knockout O 0 0.00032967497827485204
mice O 0 6.585629307664931e-05
. O 0 4.481129053601762e-06

In O 0 3.607208554967656e-06
vitro O 0 6.029069481883198e-05
- O 0 4.0266080759465694e-05
differentiated O 0 1.902198710013181e-05
DMPK O 0 1.9969616914750077e-05
[ O 0 1.7131845879703178e-06
- O 0 8.113142030197196e-06
/ O 0 2.7985950055153808e-06
- O 0 2.3996333311515627e-06
] O 0 3.684093599076732e-07
myotubes O 0 6.457286758632108e-07
exhibit O 0 4.7657298551939675e-08
a O 0 3.550639604554817e-08
higher O 0 1.763917936159487e-07
resting O 0 4.1243174564442597e-07
[ O 0 1.5243092832406546e-07
Ca2 O 0 4.201484671284561e-07
+ O 0 1.724842348949096e-07
] O 0 7.814479374701477e-08
i O 0 2.120167508223858e-08
than O 0 9.814433710175763e-10
do O 0 4.769101114021623e-09
wild O 0 6.578190436812292e-09
- O 0 6.595995500902063e-07
type O 0 2.5635545171098784e-06
myotubes O 0 2.511253478587605e-05
because O 0 4.639907302816937e-08
of O 0 3.0571287168434935e-10
an O 0 1.6712820016806518e-09
altered O 0 4.82801715406822e-06
open O 0 3.794943381763005e-07
probability O 0 3.0382803828388205e-08
of O 0 3.894172095897375e-09
voltage O 0 1.0835452485480346e-05
- O 0 0.0016937837935984135
dependent O 0 2.8991173167014495e-05
l O 0 0.000639045552816242
- O 0 1.6616824723314494e-05
type O 0 2.608209570098552e-06
Ca2 O 0 4.523435109149432e-06
+ O 0 1.693984472694865e-06
and O 0 3.0745698609280225e-07
Na O 0 1.2780074030160904e-05
+ O 0 3.5125760859955335e-06
channels O 0 7.185398317233194e-06
. O 0 3.87599948226125e-06

The O 0 1.0871759741348797e-06
mutant O 0 5.659698672388913e-06
myotubes O 0 1.1724849173333496e-05
exhibit O 0 4.499769659105368e-07
smaller O 0 5.44177225947351e-07
and O 0 1.434859484561457e-07
slower O 0 1.3176411357562756e-06
Ca2 O 0 7.955962246342096e-06
+ O 0 7.235114480863558e-07
responses O 0 1.2625282863609755e-07
upon O 0 2.012010646978979e-08
triggering O 0 3.299985564808594e-07
by O 0 1.9012963647924153e-08
acetylcholine O 0 6.803292762924684e-06
or O 0 0.0008719827746972442
high O 0 9.200608474202454e-05
external O 0 0.004210247192531824
K O 0 4.361841274658218e-05
+ O 0 1.2605021765921265e-05
. O 0 3.3810283639468253e-06

In O 0 5.408653578342637e-07
addition O 0 9.039521842169052e-08
, O 0 1.0794833471550191e-08
we O 0 7.442800153967255e-09
observed O 0 1.0735309530218728e-08
that O 0 1.1103321595484772e-09
these O 0 5.416213699760419e-09
Ca2 O 0 8.106854352263326e-07
+ O 0 7.461123914254131e-07
transients O 0 6.991638201725436e-06
partially O 0 2.139265779987909e-05
result O 0 4.3106382463520276e-08
from O 0 3.143255433712966e-09
an O 0 1.6744312603123035e-09
influx O 0 5.097934163700302e-08
of O 0 2.4510347085282547e-09
extracellular O 0 1.5332318525906885e-07
Ca2 O 0 8.564104518882232e-07
+ O 0 1.552806025983955e-07
through O 0 1.5013778664751953e-08
the O 0 5.017931314910129e-08
l O 0 3.795413067564368e-05
- O 0 5.372537543735234e-06
type O 0 1.0498239134903997e-05
Ca2 O 0 8.098639227682725e-06
+ O 0 2.7796404538094066e-06
channel O 0 9.47719036048511e-06
. O 0 1.6925649788390729e-06

Neither O 0 5.147185220266692e-06
the O 0 4.528345698417979e-08
content O 0 1.6796242618966062e-07
nor O 0 1.3027816692101624e-07
the O 0 5.370744737831501e-09
activity O 0 7.578952931908134e-08
of O 0 1.2398664317458952e-08
Na O 0 2.4469487470923923e-05
+ O 0 2.473292170179775e-06
/ O 0 1.5002277677922393e-06
K O 0 2.2997364794719033e-06
+ O 0 1.610533331586339e-06
ATPase O 0 3.160759661113843e-05
and O 0 4.55047143077536e-07
sarcoplasmic O 0 2.9360890039242804e-05
reticulum O 0 4.723090387415141e-05
Ca2 O 0 9.143302304437384e-05
+ O 0 3.5874603781849146e-05
- O 0 2.0983115973649547e-05
ATPase O 0 0.00016547925770282745
are O 0 7.460612039267289e-08
affected O 0 1.10668807451475e-07
by O 0 4.307613821197265e-08
DMPK O 0 6.795999797759578e-05
absence O 0 2.805165422614664e-06
. O 0 2.683667844394222e-06

In O 0 6.648083399340976e-07
conclusion O 0 2.0320659643857653e-07
, O 0 1.1661650312078109e-08
our O 0 6.569150112767375e-09
data O 0 1.7827160192496194e-08
suggest O 0 1.809826422061178e-08
that O 0 2.2486297268642375e-09
DMPK O 0 7.120703457985655e-07
is O 0 2.0972090730708715e-09
involved O 0 4.714914680903348e-09
in O 0 3.6777130230092325e-09
modulating O 0 1.3855267866347276e-07
the O 0 3.0319395882827394e-09
initial O 0 2.6472616099226798e-08
events O 0 8.014207963924491e-09
of O 0 2.092302775480448e-09
excitation O 0 8.297891440633975e-07
- O 0 1.7459631635574624e-05
contraction O 0 2.7751800644182367e-06
coupling O 0 9.895736639009556e-07
in O 0 1.2766943768838246e-07
skeletal O 0 2.954937008325942e-05
muscle O 0 1.7436768757761456e-05
. O 0 6.890408599247166e-07
. O 0 1.4408122979148175e-06

Constitutional O 0 8.723638893570751e-05
RB1 O 0 0.0025868986267596483
- O 0 9.700767259346321e-05
gene O 0 8.45938666316215e-06
mutations O 0 1.592486114532221e-05
in O 0 2.1529274363274453e-07
patients O 0 1.4988963812356815e-06
with O 0 9.920969290533321e-08
isolated O 0 1.7957965610548854e-05
unilateral B-Disease 0 0.0004708526539616287
retinoblastoma I-Disease 0 0.003235182026401162
. O 0 1.7641379599808715e-05

In O 0 6.081583592276729e-07
most O 0 1.7411679209544673e-07
patients O 0 3.5976296430817456e-07
with O 0 9.528895894561629e-09
isolated O 0 1.0619854720061994e-06
unilateral B-Disease 0 8.20649802335538e-06
retinoblastoma I-Disease 0 0.0002250780671602115
, O 0 2.4563436795688176e-07
tumor B-Disease 0 6.836124157416634e-06
development O 0 1.8876088248021006e-08
is O 0 6.32128704936008e-09
initiated O 0 2.591883152547325e-08
by O 0 6.2044631654600835e-09
somatic O 0 5.616290081889019e-07
inactivation O 0 4.252764028933598e-06
of O 0 3.8249456935091075e-09
both O 0 3.1275707357281135e-08
alleles O 0 9.227861710314755e-07
of O 0 6.491207926728748e-08
the O 0 8.388893775190809e-07
RB1 O 0 0.0007239248952828348
gene O 0 1.5995959984138608e-05
. O 0 4.820762114832178e-06

However O 0 1.724662865854043e-06
, O 0 1.6612272446536736e-08
some O 0 9.760985353324259e-10
of O 0 6.845752853479325e-10
these O 0 1.0320934329399734e-08
patients O 0 1.12376866923114e-07
can O 0 4.2182826121006656e-08
transmit O 0 2.555577793827979e-06
retinoblastoma B-Disease 0 2.3350621631834656e-05
predisposition O 0 1.8349699530517682e-05
to O 0 2.2703301283399924e-07
their O 0 9.724179790282506e-07
offspring O 0 1.6950067220022902e-05
. O 0 7.292386271728901e-06

To O 0 3.3588233350201335e-07
determine O 0 2.0414556445302878e-07
the O 0 7.648582212027577e-09
frequency O 0 6.056348524907662e-07
and O 0 1.1784988984686606e-08
nature O 0 3.3472499438857994e-08
of O 0 5.754686061010261e-09
constitutional O 0 8.575227070650726e-07
RB1 O 0 0.00020267772197257727
- O 0 1.6669029037075234e-06
gene O 0 4.7116989776441187e-07
mutations O 0 1.0807120816025417e-06
in O 0 3.465043008077373e-08
patients O 0 1.23297596132943e-07
with O 0 6.4928031839883715e-09
isolated O 0 9.087603984880843e-07
unilateral B-Disease 0 3.7985892049618997e-06
retinoblastoma I-Disease 0 1.1740166883100756e-05
, O 0 3.283441429857703e-08
we O 0 8.68939054043949e-09
analyzed O 0 6.022366960678482e-08
DNA O 0 1.461606018438033e-07
from O 0 7.226520271075287e-09
peripheral O 0 1.342653149549733e-06
blood O 0 3.395391331650899e-06
and O 0 7.805125079585196e-08
from O 0 1.2731392473597225e-07
tumor B-Disease 0 0.0006009641219861805
tissue O 0 0.0016474378062412143
. O 0 6.7339474298933055e-06

The O 0 5.570905159402173e-07
analysis O 0 6.131644454399066e-07
of O 0 4.878168979871589e-08
tumors B-Disease 1 0.9999996423721313
from O 0 1.9116086491521855e-08
54 O 0 6.038941791075558e-08
( O 0 5.389122925691936e-09
71 O 0 9.997102523584545e-08
% O 0 9.195856520705092e-09
) O 0 2.4262154507681544e-09
of O 0 9.562610703284236e-10
76 O 0 5.3678800071566e-08
informative O 0 6.286972507041355e-07
patients O 0 4.4929356590728275e-06
showed O 0 2.1757236936537083e-06
loss O 0 2.080068810528246e-07
of O 0 4.44683401212842e-09
constitutional O 0 7.566219437649124e-07
heterozygosity O 0 0.001331066945567727
( O 0 1.6265276769900083e-07
LOH O 1 0.9999649524688721
) O 0 1.1661075660640563e-07
at O 0 2.215260650473283e-07
intragenic O 0 1.665272247919347e-05
loci O 0 1.7465643395553343e-05
. O 0 4.177682058070786e-06

Three O 0 5.878350179955305e-07
of O 0 6.084692927288415e-08
13 O 0 3.447659651101276e-07
uninformative O 0 0.0002998892741743475
patients O 0 2.2198097212822177e-05
had O 0 4.343759769653843e-07
constitutional O 0 2.6041607270599343e-06
deletions O 0 5.006846913602203e-05
. O 0 9.50928279053187e-06

For O 0 4.5563470507659076e-07
39 O 0 5.168150778445124e-07
randomly O 0 8.331830940733198e-07
selected O 0 1.3722456060349941e-06
tumors B-Disease 1 1.0
, O 0 7.570067594997454e-08
SSCP O 0 2.559969107096549e-05
, O 0 6.863526635925155e-08
hetero O 0 2.9726359571213834e-05
- O 0 3.971525075030513e-06
duplex O 0 1.2349203643680084e-05
analysis O 0 9.867373762517673e-08
, O 0 1.5035607203728318e-09
sequencing O 0 3.160679895586327e-08
, O 0 3.1732059202482787e-09
and O 0 5.028343075252906e-09
Southern O 0 2.4673450838008648e-08
blot O 0 4.906694812234491e-06
analysis O 0 8.647317173426927e-08
were O 0 1.3053181646682788e-08
used O 0 3.298695006037633e-08
to O 0 6.410580510873842e-08
identify O 0 6.562742782989517e-06
mutations O 0 3.169606497976929e-05
. O 0 4.2652172851376235e-06

Mutations O 0 9.713799954624847e-05
were O 0 4.3684482875505637e-07
detected O 0 8.81087373727496e-07
in O 0 2.6426100419030263e-08
21 O 0 3.0687694163589185e-08
( O 0 3.7701370914078325e-09
91 O 0 2.4476909388226886e-08
% O 0 1.1406683597670053e-08
) O 0 9.066040362881722e-09
of O 0 2.1455276666415557e-08
23 O 0 0.041980355978012085
tumors B-Disease 1 1.0
with O 0 0.00023565697483718395
LOH O 1 0.9999990463256836
. O 0 2.748033875832334e-05

In O 0 1.2604473340616096e-06
6 O 0 2.0998923844217643e-07
( O 0 2.1648723702583084e-08
38 O 0 4.5046384400393435e-08
% O 0 1.403185301285248e-08
) O 0 4.389213437150374e-09
of O 0 5.361860289099241e-09
16 O 0 0.002099742880091071
tumors B-Disease 1 1.0
without O 0 0.0024551081005483866
LOH O 1 0.9999879598617554
, O 0 3.0458680022604767e-09
one O 0 3.3796516696327217e-09
mutation O 0 5.801637925628711e-08
was O 0 7.793818923573781e-08
detected O 0 1.1721484582949415e-07
, O 0 1.686781936349746e-09
and O 0 2.4121054043035883e-09
in O 0 5.0147046515292004e-09
9 O 0 9.290528346639348e-09
( O 0 6.94385604571579e-10
56 O 0 9.565151337653788e-09
% O 0 4.263691621986254e-09
) O 0 1.6705044014742043e-09
of O 0 1.3098940820910343e-09
the O 0 0.00014798597840126604
tumors B-Disease 1 1.0
without O 0 0.0008249390521086752
LOH O 1 0.9999842643737793
, O 0 1.4835523032274978e-08
both O 0 3.141507320947312e-08
mutations O 0 1.4633790215157205e-06
were O 0 1.845677530809553e-07
found O 0 3.348872610331455e-07
. O 0 1.7475737195127294e-06

Thus O 0 3.727769581018947e-06
, O 0 4.395985087057852e-08
a O 0 6.115278061713525e-09
total O 0 4.549032706080425e-09
of O 0 1.7994304934987326e-09
45 O 0 1.107150016110836e-08
mutations O 0 5.939887728345639e-07
were O 0 7.652101885469165e-08
identified O 0 1.8083690065395785e-06
in O 0 9.485517512075603e-05
tumors B-Disease 1 1.0
of O 0 1.0589862853294107e-07
36 O 0 1.924150637933053e-06
patients O 0 4.989442459191196e-06
. O 0 1.3548235529015074e-06

Thirty O 0 8.208689905586652e-06
- O 0 2.6926460122922435e-05
nine O 0 4.67323104658135e-08
of O 0 1.8017108915913127e-09
the O 0 4.938870645787574e-09
mutations O 0 7.48744014344993e-07
- O 0 3.429547916766751e-07
including O 0 3.425632666420597e-09
34 O 0 1.4437699924485514e-08
small O 0 2.8850257294266157e-08
mutations O 0 2.3544839677924756e-06
, O 0 8.023889996877642e-09
2 O 0 1.221230938597273e-08
large O 0 5.460029228743224e-08
structural O 0 0.000510436249896884
alterations O 0 5.005805360269733e-05
, O 0 5.356453058880106e-09
and O 0 9.732473493784255e-09
hypermethylation O 0 2.0539864635793492e-06
in O 0 1.5607311354415287e-07
3 O 0 3.662018934846856e-05
tumors O 1 1.0
- O 0 0.02293330617249012
were O 0 6.873024176456966e-07
not O 0 3.323514619069101e-08
detected O 0 2.52346637807932e-07
in O 0 6.221005932616208e-09
the O 0 1.864934340289892e-08
corresponding O 0 4.1937423134186247e-07
peripheral O 0 3.608142651501112e-05
blood O 0 8.476619768771343e-06
DNA O 0 6.109798414399847e-05
. O 0 4.332285243435763e-06

In O 0 1.0654264315235196e-06
6 O 0 3.7105920114299806e-07
( O 0 1.6150224269040336e-08
17 O 0 1.0587192456057437e-08
% O 0 3.590121311347616e-09
) O 0 8.565168019281089e-10
of O 0 3.344738652710788e-10
the O 0 4.650324125776706e-09
36 O 0 3.776148460588047e-08
patients O 0 6.697516852227636e-08
, O 0 1.0889623647258873e-09
a O 0 4.481651494359085e-09
mutation O 0 7.380854754046595e-07
was O 0 6.169959760882193e-07
detected O 0 7.172898222052027e-07
in O 0 5.532601932145553e-09
constitutional O 0 1.6698871618814337e-08
DNA O 0 1.5529659549429198e-06
, O 0 2.1039199271655207e-09
and O 0 2.272017907145596e-09
1 O 0 1.6415061532271125e-09
of O 0 2.8535113161254344e-10
these O 0 7.689348713313393e-09
mutations O 0 2.695443583888846e-07
is O 0 2.785651931347388e-09
known O 0 2.0240042530872415e-08
to O 0 1.0356745683282043e-08
be O 0 4.434470568526194e-08
associated O 0 5.6543619564308756e-08
with O 0 3.5409954080023454e-08
reduced O 0 4.940672624798026e-06
expressivity O 0 0.003064114134758711
. O 0 5.0551261665532365e-06

The O 0 2.0858095695075463e-07
presence O 0 4.6859234714702325e-08
of O 0 2.29350916036708e-09
a O 0 3.2180658138258877e-09
constitutional O 0 5.809400249745522e-08
mutation O 0 8.230828143496183e-07
was O 0 2.3958741621754598e-06
not O 0 2.7098845833961605e-08
associated O 0 5.929426283302064e-09
with O 0 1.0579799258891853e-09
an O 0 8.772371273835233e-09
early O 0 9.605239938537125e-06
age O 0 5.549916295422008e-07
at O 0 1.0009084405737667e-07
treatment O 0 1.0812863138198736e-06
. O 0 1.5077463331181207e-06

In O 0 1.8242926671518944e-06
1 O 0 5.594234266936837e-07
patient O 0 1.0493766922081704e-06
, O 0 3.0954169005781296e-08
somatic O 0 9.506586025054276e-07
mosaicism O 0 0.00020983023568987846
was O 0 4.979792265658034e-06
demonstrated O 0 1.0384046333911101e-07
by O 0 7.248566191719874e-09
molecular O 0 4.953689654030313e-07
analysis O 0 9.295105485307431e-08
of O 0 4.381567997313596e-09
DNA O 0 2.6823015559784835e-06
and O 0 5.923822143927282e-08
RNA O 0 5.578039576903393e-07
from O 0 5.6477983179092917e-08
peripheral O 0 2.1949261281406507e-05
blood O 0 3.5790031688520685e-05
. O 0 2.6779334802995436e-06

In O 0 1.3362011941353558e-06
2 O 0 5.46034129911277e-07
patients O 0 4.4507996221909707e-07
without O 0 3.66196566403687e-08
a O 0 2.8654094208491188e-08
detectable O 0 3.4500779293011874e-05
mutation O 0 2.393460135863279e-06
in O 0 4.053256219549439e-08
peripheral O 0 2.6172814614255913e-05
blood O 0 4.6824814489809796e-05
, O 0 1.0377112502624186e-08
mosaicism O 0 1.0178284355788492e-05
was O 0 1.2090525842722855e-06
suggested O 0 9.609902207330379e-08
because O 0 1.8433198079037538e-08
1 O 0 2.220940764630086e-09
of O 0 5.41994227276632e-10
the O 0 2.1036361985693475e-08
patients O 0 1.360739929623378e-06
showed O 0 5.527580469788518e-06
multifocal O 1 0.9999432563781738
tumors B-Disease 1 1.0
and O 0 1.1969923434662633e-06
the O 0 2.4135056619911666e-08
other O 0 1.6684895243201936e-08
later O 0 4.062800371684716e-07
developed O 0 1.1195641036465531e-06
bilateral B-Disease 0 4.876568709732965e-06
retinoblastoma I-Disease 0 0.00025762885343283415
. O 0 8.453708687738981e-06

In O 0 1.0661175338100293e-06
conclusion O 0 3.5422118571659666e-07
, O 0 2.765873752252901e-08
our O 0 3.2546100925401333e-08
results O 0 3.824065331059501e-08
emphasize O 0 4.870377878773979e-08
that O 0 1.8192738426847654e-09
the O 0 2.00789984639016e-09
manifestation O 0 4.7198660979574925e-08
and O 0 1.4626818867213842e-08
transmissibility O 0 4.4832867729382997e-07
of O 0 7.434496351876874e-10
retinoblastoma B-Disease 0 1.272245953032325e-07
depend O 0 2.609308502599106e-08
on O 0 7.706409732577413e-09
the O 0 3.088061584222146e-09
nature O 0 4.6377195417335315e-09
of O 0 3.101909007430237e-10
the O 0 1.5647504403304424e-09
first O 0 2.75292126872273e-08
mutation O 0 9.06058090777151e-08
, O 0 6.132164220851166e-10
its O 0 1.2088779977048603e-09
time O 0 2.245219477003957e-08
in O 0 3.4068863286051965e-09
development O 0 2.147327871071525e-09
, O 0 1.7733617907467192e-09
and O 0 3.3113516373362017e-09
the O 0 1.6505449229597957e-09
number O 0 8.199675605169432e-09
and O 0 1.813786631998937e-08
types O 0 3.334352882689018e-08
of O 0 1.3454997116468803e-09
cells O 0 1.21416391607454e-07
that O 0 1.221873979773136e-08
are O 0 1.5459963975672508e-08
affected O 0 1.602097370323463e-07
. O 0 1.7221204018369463e-07
. O 0 1.0058361112896819e-06

Hereditary B-Disease 1 0.9999929666519165
deficiency I-Disease 1 0.9999152421951294
of I-Disease 0 2.981942159863138e-08
the I-Disease 0 1.9919637495036113e-08
fifth I-Disease 0 3.3242346830775205e-07
component I-Disease 0 1.593314777892374e-07
of I-Disease 0 5.459433349841447e-09
complement I-Disease 0 1.6306015027112153e-07
in O 0 2.453560341564298e-07
man O 0 1.4194855793903116e-05
. O 0 3.574296670194599e-06

I O 0 0.002679399913176894
. O 0 4.640955739887431e-05

Clinical O 0 0.00013954794849269092
, O 0 5.281685844238382e-07
immunochemical O 0 8.760294804233126e-06
, O 0 6.373030458917128e-08
and O 0 7.575975047302563e-08
family O 0 1.120123670261819e-06
studies O 0 8.878336302586831e-06
. O 0 3.205098664693651e-06

The O 0 1.113558482757071e-06
first O 0 2.7427125814938336e-07
recognized O 0 2.0443586379315093e-07
human O 0 6.32262739941325e-08
kindred O 0 2.1633675260090968e-06
with O 0 4.697395752373268e-07
hereditary B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.999744713306427
of I-Disease 0 9.383634314019673e-09
the I-Disease 0 5.908058753334444e-08
fifth I-Disease 0 1.035428567774943e-06
component I-Disease 0 6.01747558448551e-07
of I-Disease 0 9.151134072737932e-09
complement I-Disease 0 8.116663252621947e-07
( O 0 4.446963686177696e-08
C5 O 0 9.339404641650617e-06
) O 0 4.1945259710018945e-08
is O 0 3.942941262380373e-08
described O 0 1.0579037734714802e-06
. O 0 2.1458404262375552e-06

The O 0 5.719496698475268e-07
proband O 0 6.725090770487441e-06
, O 0 1.3724515746105226e-08
a O 0 9.442360671130245e-09
20 O 0 1.7132510521378208e-08
- O 0 5.262851345833042e-07
year O 0 1.30755253735515e-07
- O 0 1.5642846847185865e-05
old O 0 4.718921445601154e-06
black O 0 5.515724978977232e-07
female O 0 4.91377591060882e-07
with O 0 9.196243695441808e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.999981164932251
erythematosus I-Disease 1 0.9999998807907104
since O 0 0.0004357720026746392
age O 0 5.573854195972672e-07
11 O 0 3.057563091601878e-08
, O 0 8.435775633586218e-09
lacked O 0 1.3032579317950876e-06
serum O 0 1.4010041923029348e-05
hemolytic O 0 2.060437145701144e-05
complement O 0 1.575782704321682e-07
activity O 0 1.6032895189255214e-07
, O 0 1.4589983443613619e-08
even O 0 8.298486875446542e-08
during O 0 4.541271891866927e-07
remission O 0 8.539061127521563e-06
. O 0 2.0496991055551916e-06

C5 O 0 0.0008036388899199665
was O 0 2.9291281862242613e-06
undetectable O 0 5.962196610198589e-06
in O 0 1.8572420046325533e-08
her O 0 6.975229638328528e-08
serum O 0 6.308497972895566e-07
by O 0 1.2164884211074423e-08
both O 0 8.609153212546516e-08
immunodiffusion O 0 2.2455709768109955e-05
and O 0 7.482171895389911e-07
hemolytic O 0 0.0012316778302192688
assays O 0 0.00281489547342062
. O 0 1.033361695590429e-05

Other O 0 2.103006835341148e-07
complement O 0 1.235758873008308e-07
components O 0 1.3794935682653886e-07
were O 0 1.7778432948034606e-08
normal O 0 4.786481966334577e-08
during O 0 7.141118629760967e-08
remission O 0 6.512016739179671e-07
of O 0 1.008725547535505e-08
lupus O 0 0.00022113726299721748
, O 0 9.97367166633012e-09
but O 0 1.5875511394369823e-07
C1 O 0 0.0002138447161996737
, O 0 1.0868339117564574e-08
C4 O 0 2.0153404420852894e-06
, O 0 2.12682618183635e-08
C2 O 0 5.257581051409943e-06
, O 0 1.1355648865674084e-08
and O 0 4.3552823569825705e-08
C3 O 0 4.730969885713421e-05
levels O 0 1.601429744368943e-06
fell O 0 1.1265782632108312e-05
during O 0 2.1319879124348518e-06
exacerbations O 0 0.00219262158498168
. O 0 8.99736005521845e-06

A O 0 2.5054266643564915e-06
younger O 0 1.083961478798301e-06
half O 0 1.599907903937492e-07
- O 0 1.2408906968630617e-06
sister O 0 6.342448273244372e-07
, O 0 7.3231349873026375e-09
who O 0 4.435028699845134e-08
had O 0 3.854425358440494e-06
no O 0 3.550440510480257e-07
underlying O 0 0.4764297902584076
disease O 0 0.0023495773784816265
, O 0 2.3616971489559546e-08
was O 0 3.903453762177378e-05
also O 0 4.600832426149282e-08
found O 0 5.363049382367535e-08
to O 0 6.585562317695803e-08
lack O 0 1.6824600379550247e-06
immunochemically O 0 0.0006352205527946353
detectable O 0 0.0036803283728659153
C5 O 0 0.0001336147979600355
. O 0 4.845660896535264e-06

By O 0 5.493034677783726e-06
hemolytic O 0 0.0012290142476558685
assay O 0 0.002506017219275236
, O 0 2.0081849072539626e-07
she O 0 3.5881862459063996e-07
exhibited O 0 1.6627654986223206e-07
1 O 0 5.2714504761297576e-08
- O 0 7.913261015346507e-07
2 O 0 2.4033445455984292e-08
% O 0 3.9315923849869705e-09
of O 0 4.868738745500423e-10
the O 0 1.1031175972675555e-08
normal O 0 2.858338632449886e-07
serum O 0 4.408320819493383e-06
C5 O 0 3.1721112918603467e-06
level O 0 2.415361777252656e-08
and O 0 7.54037809969077e-09
normal O 0 3.805271475698646e-08
concentrations O 0 2.2449417258485482e-07
of O 0 1.0978465914135427e-09
other O 0 5.879143838427581e-09
complement O 0 1.6206732311729866e-07
components O 0 2.8438021217880305e-06
. O 0 1.8344866248298786e-06

C5 O 0 0.0002417340292595327
levels O 0 3.935694167012116e-06
of O 0 6.657407958243766e-09
other O 0 4.2332963801072765e-09
family O 0 1.0793906213280025e-08
members O 0 2.3518469394190333e-09
were O 0 4.609147730150198e-09
either O 0 1.1499436958217757e-08
normal O 0 2.0861191885046537e-08
or O 0 7.682502634054345e-09
approximately O 0 4.845506218487117e-09
half O 0 2.677027168829227e-07
- O 0 7.433040445903316e-05
normal O 0 1.411466854506216e-07
, O 0 4.580673174103822e-09
consistent O 0 4.2766600927279796e-08
with O 0 1.9777669280074406e-08
autosomal O 0 0.006352740805596113
codominant O 0 1.7969494365388528e-05
inheritance O 0 8.247281471085444e-07
of O 0 6.90808654724151e-09
the O 0 8.166060894154725e-08
gene O 0 1.8966033167089336e-05
determining O 0 0.36464062333106995
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.9659122699522413e-05

Normal O 0 0.00032918158103711903
hemolytic O 0 0.07931017875671387
titers O 0 0.00665834778919816
were O 0 6.798823051212821e-07
restored O 0 5.887517318114988e-07
to O 0 2.2719714110053246e-08
both O 0 1.0243531534115391e-07
homozygous O 0 0.40963223576545715
C5 B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
deficient I-Disease 1 1.0
( O 0 3.09970062062348e-07
C5D B-Disease 1 1.0
) O 0 1.1523462006834961e-07
sera O 0 1.8263436629695207e-07
by O 0 2.1075103884271584e-09
addition O 0 7.931528323013026e-09
of O 0 3.6647935797162745e-09
highly O 0 4.96867869514972e-07
purified O 0 3.622780923251412e-06
human O 0 1.4718521015311126e-06
C5 O 0 6.135488365544006e-05
. O 0 1.7852122482509003e-06

In O 0 2.3467634946428007e-06
specific O 0 1.1917902611457976e-06
C5 O 0 1.237649757968029e-05
titrations O 0 3.1255727662937716e-05
, O 0 2.042549596126264e-08
however O 0 8.233496551213193e-09
, O 0 2.0215071838691756e-09
it O 0 2.2690784362566774e-08
was O 0 3.637830161551392e-07
noted O 0 5.615034659456342e-09
that O 0 9.216115648413847e-10
when O 0 3.6953056170574428e-09
limited O 0 3.116225943955442e-09
amounts O 0 6.5785541458751595e-09
of O 0 1.121095771772218e-09
C5 O 0 1.9124772165923787e-07
were O 0 8.189547706649591e-09
assayed O 0 3.3585382652745466e-07
in O 0 5.9842006905341805e-09
the O 0 5.3097028995807705e-09
presence O 0 2.314211577925107e-08
of O 0 3.7121892226821274e-09
low O 0 2.326267320995612e-07
dilutions O 0 5.229886937740957e-06
of O 0 9.04332964068999e-09
either O 0 4.0279786617247737e-07
C5D B-Disease 1 0.9999995231628418
serum O 0 6.728888365614694e-06
, O 0 3.2221563195378167e-09
curving O 0 2.555547595761709e-08
rather O 0 6.450796341539444e-09
than O 0 2.743934635063283e-09
linear O 0 3.6736764741363004e-08
dose O 0 2.387400627412717e-06
- O 0 3.444077663061762e-07
response O 0 1.9604604162282158e-08
plots O 0 2.530365463826456e-07
were O 0 2.7175346417607216e-08
consistently O 0 1.1780982589471023e-07
obtained O 0 3.313500940294034e-08
, O 0 3.929290670612318e-09
suggesting O 0 6.517931439020686e-08
some O 0 1.1166659596995032e-08
inhibitory O 0 1.0424026868349756e-06
effect O 0 2.1927946818323107e-06
. O 0 2.3492020773119293e-06

Further O 0 3.0799160413153004e-06
studies O 0 7.497715728277399e-07
suggested O 0 1.495642010240772e-07
that O 0 2.404316390425265e-08
low O 0 3.2966264029710146e-07
dilutions O 0 1.368622270092601e-05
of O 0 2.390470399404876e-08
C5D B-Disease 1 0.9999992847442627
serum O 0 2.2349090613715816e-06
contain O 0 6.560374998798579e-08
a O 0 1.4088114674848384e-08
factor O 0 4.495025862638613e-08
( O 0 2.7170043992441606e-09
or O 0 1.552491468714834e-08
factors O 0 2.3376710345246465e-08
) O 0 2.3074362420771877e-09
interfering O 0 2.3389242542748434e-08
at O 0 6.57135545978349e-09
some O 0 1.1521384957191572e-09
step O 0 2.5503519296421473e-08
in O 0 1.1446437575557411e-08
the O 0 3.905807588466814e-08
hemolytic O 0 4.8009293095674366e-05
assay O 0 6.795449007768184e-05
of O 0 8.646719784621837e-09
C5 O 0 4.78484389532241e-06
, O 0 3.5170244494509006e-09
rather O 0 5.447117867873885e-09
than O 0 5.847873740805198e-09
a O 0 3.3899766549438937e-08
true O 0 7.360497988884163e-07
C5 O 0 1.1411020750529133e-05
inhibitor O 0 2.8137526442151284e-06
or O 0 6.268926995289803e-07
inactivator O 0 5.3393170674098656e-05
. O 0 3.165330326737603e-06

Of O 0 1.9579348986553669e-07
clinical O 0 3.532816435836139e-06
interest O 0 1.500213357985558e-07
are O 0 1.3973255441612764e-08
( O 0 3.190508524042457e-09
a O 0 6.092807591784322e-09
) O 0 5.9228817406165035e-09
the O 0 5.081379761406879e-09
documentation O 0 1.208932047802591e-07
of O 0 2.674847010553094e-08
membranous O 1 0.9991532564163208
glomerulonephritis B-Disease 1 1.0
, O 0 0.0011004542466253042
vasculitis B-Disease 1 1.0
, O 0 8.885128863767022e-07
and O 0 0.002404127735644579
arthritis B-Disease 1 1.0
in O 0 1.9493829483963054e-07
an O 0 2.5589226737565696e-08
individual O 0 5.644265570481366e-07
lacking O 0 2.910686089308001e-05
C5 O 0 1.3891448361391667e-05
( O 0 2.691996847659084e-09
and O 0 1.9702208753358263e-09
its O 0 2.0161969871423935e-09
biologic O 0 9.75449907514303e-08
functions O 0 5.005826420045878e-09
) O 0 2.2590458392812707e-09
, O 0 1.12770981441912e-09
and O 0 4.365476424794679e-09
( O 0 3.2973721530993316e-09
b O 0 2.3865987941462663e-07
) O 0 1.0541205686109834e-09
a O 0 1.1872091087994363e-09
remarkable O 0 2.7321803486302088e-08
propensity O 0 6.367575338117604e-07
to O 0 3.32683839587844e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 6.149281972511744e-08
the O 0 8.55735127203161e-09
proband O 0 7.731906407570932e-06
, O 0 3.4424070260996587e-09
even O 0 5.895122612287196e-09
during O 0 3.4513218949427937e-09
periods O 0 2.08495762876737e-08
of O 0 3.049309249547605e-09
low O 0 2.312051265107584e-06
- O 0 1.1008854698957293e-06
dose O 0 6.12138421729469e-07
or O 0 1.6463513219378e-08
alternate O 0 6.566534693774884e-08
- O 0 1.386842427564261e-06
day O 0 2.498592550637113e-07
corticosteroid O 0 2.9832144718966447e-05
therapy O 0 1.3144256627128925e-05
. O 0 1.527912900201045e-06

Other O 0 2.2772822205752163e-07
observations O 0 2.674857739748404e-07
indicate O 0 1.0587843490839077e-07
that O 0 6.993784218423116e-09
the O 0 1.78490040525503e-08
C5D B-Disease 1 0.9999998807907104
state O 0 1.2195480181276253e-08
is O 0 2.0037986825371945e-09
compatible O 0 4.281051246834977e-08
with O 0 4.469631775805283e-09
normal O 0 5.709557271416088e-08
coagulation O 0 2.3130471049626067e-07
function O 0 4.921373175648114e-08
and O 0 9.679692603015155e-09
the O 0 6.398484853065156e-09
capacity O 0 1.8384250566327864e-08
to O 0 6.585785250479148e-09
mount O 0 5.098547148918442e-07
a O 0 4.2296383639950363e-07
neutrophilic O 0 0.0013818757142871618
leukocytosis O 0 0.00026955213979817927
during O 0 2.503167252143612e-06
pyogenic B-Disease 0 0.25978225469589233
infection I-Disease 0 0.05287230387330055
. O 0 1.1607811529756873e-06
. O 0 2.93857942779141e-06

Susceptibility O 0 0.0020075372885912657
to O 0 4.640867337002419e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00035501038655638695
twins O 0 5.644693010253832e-05
: O 0 2.5720611418478256e-08
the O 0 2.8123128270607367e-09
role O 0 1.2580638752979212e-08
of O 0 1.6963515037105026e-09
genes O 0 9.808884016138109e-08
, O 0 1.6483937770317425e-08
HLA O 0 9.914799647958716e-07
, O 0 1.2239219415732805e-08
and O 0 2.465759507686016e-08
the O 0 1.5507370676459686e-07
environment O 0 3.0036621865292545e-06
. O 0 1.8885326653617085e-06

OBJECTIVE O 0 2.1031979485997e-05
To O 0 1.4916592760982894e-07
determine O 0 1.4316637475531024e-07
the O 0 3.3882618932778996e-09
relative O 0 3.470824339046885e-08
effects O 0 1.8667606127564795e-07
of O 0 2.1343347089697318e-09
genetic O 0 2.8043389193044277e-06
and O 0 1.039567862903823e-07
environmental O 0 7.862756490339962e-08
factors O 0 6.662059348627736e-08
in O 0 2.3545769778365866e-08
susceptibility O 0 1.2133159543736838e-05
to O 0 0.00011007025022991002
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 7.68660320318304e-05
AS B-Disease 1 0.9999858140945435
) O 0 6.6197401338286e-07
. O 0 1.3371393379202345e-06

METHODS O 0 1.5739769878564402e-05
Twins O 0 3.489681148494128e-06
with O 0 2.8572829435802305e-08
AS B-Disease 1 0.9760202169418335
were O 0 6.384308903761848e-08
identified O 0 6.406864372365817e-08
from O 0 6.786538442327128e-09
the O 0 4.4244000463322664e-08
Royal O 0 0.000323939515510574
National O 0 2.7552650294637715e-07
Hospital O 0 3.2533678222534945e-06
for O 0 1.111744040827034e-06
Rheumatic B-Disease 1 0.9951417446136475
Diseases I-Disease 0 0.09710372984409332
database O 0 1.5561472537228838e-05
. O 0 7.154239028750453e-06

Clinical O 0 9.580476034898311e-05
and O 0 5.565254923567409e-07
radiographic O 0 0.0003668727003969252
examinations O 0 2.5595567421987653e-05
were O 0 7.194601892024366e-08
performed O 0 3.090821110163233e-08
to O 0 4.207906023623309e-09
establish O 0 5.3502475338973454e-08
diagnoses O 0 0.00026498589431867003
, O 0 1.726750831210211e-08
and O 0 6.653576178905496e-07
disease O 0 6.543581548612565e-06
severity O 0 7.915532478364184e-05
was O 0 7.083478408276278e-07
assessed O 0 5.885317477805074e-08
using O 0 1.6657262236208226e-08
a O 0 8.893892733397024e-09
combination O 0 2.0953514479060686e-07
of O 0 1.082119904793899e-08
validated O 0 3.054706439797883e-06
scoring O 0 7.013537128841563e-07
systems O 0 8.094315489870496e-06
. O 0 2.4403293537034187e-06

HLA O 0 0.0008617755374871194
typing O 0 0.00012440032151062042
for O 0 8.899036174625508e-07
HLA O 0 3.198589547537267e-05
- O 0 1.0387258953414857e-05
B27 O 0 4.829016233998118e-06
, O 0 5.430191052369082e-08
HLA O 0 1.5646028259652667e-06
- O 0 1.5643836377421394e-06
B60 O 0 1.3877129276806954e-06
, O 0 1.2379146596686041e-08
and O 0 3.413034121990677e-08
HLA O 0 4.612017619365361e-06
- O 0 0.00047537076170556247
DR1 O 1 0.7594512104988098
was O 0 9.446432045479014e-07
performed O 0 2.882072358545429e-08
by O 0 2.982759594871709e-09
polymerase O 0 1.4050498009510193e-07
chain O 0 1.3656749615620356e-06
reaction O 0 2.369213625286193e-08
with O 0 1.1043339576133349e-09
sequence O 0 3.856476737951198e-08
- O 0 3.9373617255478166e-07
specific O 0 2.4217690963723726e-08
primers O 0 1.8402831756247906e-06
, O 0 5.302415839736341e-09
and O 0 6.310288735988934e-09
zygosity O 0 5.428274789665011e-07
was O 0 6.94208779350447e-08
assessed O 0 1.4034132789220166e-07
using O 0 1.40299846407288e-07
microsatellite O 0 5.089162368676625e-05
markers O 0 2.1422829377115704e-05
. O 0 4.850108325626934e-06

Genetic O 0 0.00022995816834736615
and O 0 7.016072913756943e-07
environmental O 0 2.4632311124150874e-07
variance O 0 1.2050863062995631e-07
components O 0 4.428093518527021e-07
were O 0 5.1697774949843733e-08
assessed O 0 7.486526953925932e-08
with O 0 2.6086250937140676e-09
the O 0 7.331939499977125e-09
program O 0 3.070601906074444e-08
Mx O 0 1.6895462806587602e-07
, O 0 4.99561836342366e-10
using O 0 3.0119620131330294e-09
data O 0 1.853360132031412e-08
from O 0 9.389753419242197e-10
this O 0 1.5916002960025821e-09
and O 0 1.2245617853068325e-08
previous O 0 1.2279341490284423e-06
studies O 0 1.9729824884962e-07
of O 0 1.5787836593617044e-09
twins O 0 2.3977781893336214e-06
with O 0 7.77819693098536e-08
AS B-Disease 1 0.9999896287918091
. O 0 5.192603111936478e-06

RESULTS O 0 7.843078492442146e-05
Six O 0 4.2888973439403344e-07
of O 0 2.9199076934105506e-08
8 O 0 2.6888324100582395e-07
monozygotic O 0 1.8616065062815323e-05
( O 0 2.137807655344659e-07
MZ O 1 0.8787445425987244
) O 0 1.4047603258404706e-07
twin O 0 4.302114393794909e-05
pairs O 0 9.166471500066109e-06
were O 0 6.829093035776168e-05
disease O 0 1.6358441143893288e-06
concordant O 0 3.754531689992291e-06
, O 0 2.92193558237841e-08
compared O 0 6.133678454034452e-08
with O 0 2.9842393001189293e-09
4 O 0 8.414515306753856e-09
of O 0 1.6195809138253026e-09
15 O 0 1.9649302629431986e-08
B27 O 0 1.3931016837887e-06
- O 0 3.1139838938543107e-06
positive O 0 8.030752951526665e-08
dizygotic O 0 1.3501170315066702e-06
( O 0 1.7229016435749145e-08
DZ O 0 6.623531953664497e-05
) O 0 2.457327319405067e-08
twin O 0 9.538161975797266e-07
pairs O 0 1.883225593246607e-07
( O 0 5.618559839604131e-09
27 O 0 1.4353927824117818e-08
% O 0 2.934371856611051e-09
) O 0 1.7237423710625421e-09
and O 0 4.2002321620771e-09
4 O 0 5.190582630376639e-09
of O 0 1.939949090257187e-09
32 O 0 1.9183298149982875e-07
DZ O 0 0.1692069172859192
twin O 0 0.0005420712986961007
pairs O 0 2.0841403056692798e-06
overall O 0 1.4170386748446617e-06
( O 0 9.592556970972055e-09
12 O 0 1.3336172166589222e-08
. O 0 2.4730129055683392e-08
5 O 0 6.066325397569017e-08
% O 0 4.70363588078726e-08
) O 0 1.3724284997351788e-07
. O 0 1.3404718401943683e-06

Nonsignificant O 0 0.00035462609957903624
increases O 0 4.55606550531229e-06
in O 0 2.086509098830902e-08
similarity O 0 5.42103286704787e-08
with O 0 2.316149050329841e-09
regard O 0 2.160528822514607e-08
to O 0 2.7064958274536366e-08
age O 0 5.416303565652925e-07
at O 0 8.654244538774947e-07
disease O 0 7.562865107502148e-07
onset O 0 1.5280133993655909e-06
and O 0 2.9081911989692344e-08
all O 0 9.180149973531115e-10
of O 0 7.992497774722551e-10
the O 0 3.5205906101509754e-07
disease O 0 2.326504727534484e-05
severity O 0 1.7117021343437955e-05
scores O 0 2.1729690047322947e-07
assessed O 0 5.304952424012299e-07
were O 0 3.5756901439754074e-08
noted O 0 7.607005159115943e-08
in O 0 9.219021421813522e-07
disease O 0 0.006622083019465208
- O 0 0.04252493008971214
concordant O 0 0.15830513834953308
MZ O 1 0.9995928406715393
twins O 0 2.353068339289166e-05
compared O 0 1.2459327081160154e-06
with O 0 3.4092744272129494e-07
concordant O 0 0.0008551864884793758
DZ O 1 0.972655177116394
twins O 0 0.0001802964834496379
. O 0 9.62498234002851e-06

HLA O 0 0.0035989198368042707
- O 0 0.0017424941761419177
B27 O 0 1.3568907888839021e-05
and O 0 8.629852032981944e-08
B60 O 0 6.896937634337519e-07
were O 0 2.5117319779610625e-08
associated O 0 2.1105970304802213e-08
with O 0 4.8739998703695164e-09
the O 0 1.6231821575729555e-07
disease O 0 9.948764727596426e-07
in O 0 9.12048303547408e-09
probands O 0 8.28707343316637e-05
, O 0 2.5395405778283475e-09
and O 0 1.5771703942846216e-09
the O 0 2.7955253667499846e-09
rate O 0 2.990868210872577e-07
of O 0 4.031996070352761e-09
disease O 0 2.823532270213036e-07
concordance O 0 3.4295121054128686e-07
was O 0 6.193345711835718e-07
significantly O 0 2.5215271648448834e-07
increased O 0 7.350341491019208e-08
among O 0 3.6045733509126876e-08
DZ O 0 0.008227791637182236
twin O 0 1.6761032384238206e-05
pairs O 0 3.642044248408638e-07
in O 0 2.9345580188078202e-08
which O 0 4.283101162627645e-08
the O 0 3.885982380325004e-08
co O 0 0.004741710145026445
- O 0 0.0019633846823126078
twin O 0 0.028481628745794296
was O 0 1.2115167464799015e-06
positive O 0 1.6020905491131998e-08
for O 0 2.6904720673570637e-09
both O 0 4.52337332035313e-08
B27 O 0 3.5354389638087014e-06
and O 0 7.422580097227183e-07
DR1 O 0 0.008645878173410892
. O 0 3.781796067414689e-06

Additive O 0 1.890562998596579e-05
genetic O 0 1.280365449929377e-05
effects O 0 2.3947136469359975e-06
were O 0 2.8311783140111402e-08
estimated O 0 5.955347326391802e-09
to O 0 5.766134680840196e-09
contribute O 0 1.3203321103105736e-08
97 O 0 2.2108871178261325e-08
% O 0 3.746381871394533e-09
of O 0 7.74329989017275e-10
the O 0 1.943197780462924e-08
population O 0 2.5931299774129e-07
variance O 0 2.009458285101573e-06
. O 0 3.475638550298754e-06

CONCLUSION O 0 8.239866474468727e-06
Susceptibility O 0 1.6070665878942236e-05
to O 0 2.182755594049013e-07
AS B-Disease 1 0.9846910834312439
is O 0 7.421735226387227e-09
largely O 0 1.9338985524086638e-08
genetically O 0 5.2642263881352847e-08
determined O 0 1.4320967522962746e-07
, O 0 1.4553288574248313e-09
and O 0 3.1305593672925625e-09
the O 0 5.838645567024514e-09
environmental O 0 4.001513431717285e-08
trigger O 0 3.316922345675266e-07
for O 0 1.0753670842689189e-08
the O 0 2.180211140512256e-07
disease O 0 4.111654561711475e-06
is O 0 5.118511481327914e-08
probably O 0 5.35009462510061e-07
ubiquitous O 0 6.8834342528134584e-06
. O 0 2.5353515411552507e-06

HLA O 0 0.0012203824007883668
- O 0 7.694311352679506e-05
B27 O 0 4.649839411285939e-06
accounts O 0 1.246777401320287e-07
for O 0 1.0001141248494605e-08
a O 0 1.3403237630882359e-08
minority O 0 3.703249262798636e-07
of O 0 2.336849602713187e-09
the O 0 1.4850980889491439e-08
overall O 0 2.0360555481602205e-06
genetic O 0 3.610874045989476e-06
susceptibility O 0 1.0124041182280052e-05
to O 0 7.216632980089344e-07
AS B-Disease 1 0.9998304843902588
. O 0 5.242380666459212e-06

Cell O 0 0.0009531566756777465
cycle O 0 9.899552242131904e-05
- O 0 0.00011104710574727505
dependent O 0 4.955186341248918e-06
colocalization O 0 5.738889285566984e-06
of O 0 4.280618526308899e-08
BARD1 O 0 1.390727538819192e-05
and O 0 7.735690132903983e-08
BRCA1 O 0 2.799542698994628e-06
proteins O 0 1.0371061165415085e-07
in O 0 1.825719664338976e-08
discrete O 0 2.6911311579169706e-06
nuclear O 0 3.936318898922764e-05
domains O 0 9.399735063198023e-06
. O 0 4.7223606998159084e-06

Germ O 0 0.08513162285089493
- O 0 0.10596924275159836
line O 0 6.651052899542265e-06
mutations O 0 1.5646311339878594e-06
of O 0 9.4094421143609e-09
the O 0 3.851470964377768e-08
BRCA1 O 0 6.429661425499944e-06
gene O 0 7.825784109627421e-07
predispose O 0 1.6384390164603246e-06
women O 0 8.259310391167674e-08
to O 0 8.766534165260964e-09
early O 0 2.8371769644763845e-07
- O 0 0.0017634511459618807
onset O 0 0.070929616689682
breast B-Disease 1 0.999998927116394
and I-Disease 1 0.9999270439147949
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 3.119682645547073e-08
compromising O 0 1.2525504644145258e-05
the O 0 2.5154907490332334e-08
genes O 0 7.641162937943591e-07
presumptive O 0 0.00022434726997744292
function O 0 2.665222496034403e-07
as O 0 4.344413895296384e-08
a O 0 2.211925220763078e-07
tumor B-Disease 0 6.380237027769908e-05
suppressor O 0 0.0002137831470463425
. O 0 8.238828741014004e-06

Although O 0 3.0020410122233443e-06
the O 0 8.151059915917358e-08
biochemical O 0 1.2933378457091749e-06
properties O 0 2.016698488205293e-07
of O 0 1.1849972558763966e-08
BRCA1 O 0 2.9021680347796064e-06
polypeptides O 0 6.728168386871403e-07
are O 0 2.81802208235149e-08
not O 0 8.461692146966016e-08
understood O 0 3.8444659367087297e-07
, O 0 2.7560038695639832e-09
their O 0 3.747646637464186e-09
expression O 0 6.35498125234335e-08
pattern O 0 9.911717597788083e-07
and O 0 6.302087740550633e-08
subcellular O 0 3.3174742384289857e-06
localization O 0 4.884928443971148e-07
suggest O 0 1.539335556799415e-07
a O 0 1.2321340392418278e-08
role O 0 1.1333549565506473e-07
in O 0 7.052661032957985e-08
cell O 0 0.0009741245303303003
- O 0 0.023834139108657837
cycle O 0 1.404916383762611e-05
regulation O 0 3.8896228033991065e-06
. O 0 1.7520209212307236e-06

When O 0 1.0097150152432732e-05
resting O 0 2.831594201779808e-06
cells O 0 9.039036967806169e-07
are O 0 1.440246766293285e-08
induced O 0 1.1934035626381956e-07
to O 0 7.501289367439767e-09
proliferate O 0 5.833043701386487e-07
, O 0 1.6351127118952036e-09
the O 0 1.9416148688833346e-09
steady O 0 9.243268550562789e-08
- O 0 5.083467158328858e-07
state O 0 1.5334272518430225e-08
levels O 0 1.3562188705407152e-08
of O 0 1.349171996345433e-09
BRCA1 O 0 4.838282166019781e-07
increase O 0 2.174792790299307e-08
in O 0 6.708662514398611e-09
late O 0 7.875995322592644e-08
G1 O 0 1.719666784083529e-06
and O 0 8.348109759026556e-09
reach O 0 1.2520291470252687e-08
a O 0 8.118101746390494e-09
maximum O 0 5.211059672660667e-08
during O 0 4.980961989531352e-07
S O 0 3.7771245843032375e-05
phase O 0 9.385922567162197e-06
. O 0 5.244841304374859e-06

Moreover O 0 1.519614306744188e-05
, O 0 1.1719807702093021e-07
in O 0 7.584505823388099e-08
S O 0 9.354843314213213e-06
phase O 0 9.123476729655522e-07
cells O 0 9.190352443511074e-07
, O 0 1.55265134083038e-08
BRCA1 O 0 1.4554206018146942e-06
polypeptides O 0 4.6865582703503605e-07
are O 0 1.460212128989724e-08
hyperphosphorylated O 0 8.127832415993907e-07
and O 0 1.889864087445403e-08
accumulate O 0 2.4547233579141903e-07
into O 0 1.9634915915389684e-08
discrete O 0 1.6431223457402666e-06
subnuclear O 0 5.347673868527636e-05
foci O 0 9.835560376814101e-06
termed O 0 4.038728093291866e-06
" O 0 8.262443884632376e-07
BRCA1 O 0 5.751333446823992e-05
nuclear O 0 1.1027401342289522e-05
dots O 0 7.123759860405698e-05
. O 0 9.130421858571935e-06

" O 0 1.7325099179288372e-05
BRCA1 O 0 0.00019987123960163444
associates O 0 2.436495924484916e-05
in O 0 1.8221125230866164e-07
vivo O 0 9.006183972815052e-06
with O 0 2.197714721319244e-08
a O 0 1.6872083108410152e-07
structurally O 0 0.002151105785742402
related O 0 3.4455076729500433e-06
protein O 0 6.299230790318688e-06
termed O 0 8.266276563517749e-05
BARD1 O 0 0.0029923408292233944
. O 0 9.221068467013538e-06

Here O 0 1.1292127055639867e-06
we O 0 6.267910634960572e-08
show O 0 1.7859184353596902e-08
that O 0 1.7506734950600844e-09
the O 0 1.8287472647315894e-09
steady O 0 1.1218026685355653e-07
- O 0 8.659363288643362e-07
state O 0 1.3074361149278957e-08
levels O 0 2.12568238566746e-08
of O 0 4.442008427751887e-10
BARD1 O 0 7.296368380593776e-07
, O 0 1.807576088808105e-09
unlike O 0 5.004680669884465e-09
those O 0 2.5263995340196743e-09
of O 0 1.7946251151812476e-09
BRCA1 O 0 1.2379129657347221e-05
, O 0 1.7254897954899207e-08
remain O 0 3.513104118724186e-08
relatively O 0 2.5808084558320843e-08
constant O 0 1.2319510744873696e-07
during O 0 3.177105156737525e-07
cell O 0 6.11723808106035e-05
cycle O 0 2.3646873160032555e-05
progression O 0 2.6689904188970104e-05
. O 0 6.728125299559906e-06

However O 0 4.13898897022591e-06
, O 0 1.7755246517481282e-07
immunostaining O 0 5.5365176194754895e-06
revealed O 0 1.1041912557629985e-06
that O 0 3.2484020806577973e-08
BARD1 O 0 3.7669155972253066e-06
resides O 0 1.7089436710193695e-07
within O 0 3.004378612558867e-08
BRCA1 O 0 4.774555691255955e-06
nuclear O 0 7.114655318218865e-07
dots O 0 9.894887398331775e-07
during O 0 2.23630678419795e-07
S O 0 1.0958461643895134e-05
phase O 0 5.6753883370674885e-08
of O 0 1.1783679587651363e-09
the O 0 4.610968051821374e-09
cell O 0 6.254444542719284e-06
cycle O 0 4.717022079603339e-07
, O 0 2.9623148378732367e-09
but O 0 1.9160109943072712e-08
not O 0 1.6424841930984257e-08
during O 0 3.473109089213722e-08
the O 0 5.720391982322326e-08
G1 O 0 4.3132633436471224e-05
phase O 0 4.347864432929782e-06
. O 0 2.5600688786653336e-06

Nevertheless O 0 2.4638831746415235e-05
, O 0 2.133465386577882e-07
BARD1 O 0 1.753237711454858e-06
polypeptides O 0 7.69463269989501e-07
are O 0 1.3640405249759624e-08
found O 0 6.646204919746879e-09
exclusively O 0 7.594302076086024e-09
in O 0 5.85305182099205e-09
the O 0 3.5875340476110296e-09
nuclear O 0 7.06174674292015e-08
fractions O 0 1.7118694017881353e-08
of O 0 1.7220170844822746e-09
both O 0 1.5736706160396352e-08
G1 O 0 0.0001128509538830258
- O 0 4.108122084289789e-05
and O 0 2.0282828927520313e-07
S O 0 0.00010771490633487701
- O 0 6.631140422541648e-06
phase O 0 2.079165369650582e-06
cells O 0 5.081487870484125e-06
. O 0 2.0114273411309114e-06

Therefore O 0 4.594256097334437e-06
, O 0 4.9586191153139225e-08
progression O 0 2.413158881608979e-07
to O 0 5.9271677343986084e-08
S O 0 4.4289176003076136e-05
phase O 0 2.4274487486763974e-07
is O 0 4.93618657060324e-09
accompanied O 0 4.440655398951776e-09
by O 0 2.0969210812182837e-09
the O 0 5.436427308325165e-09
aggregation O 0 7.949645919325121e-08
of O 0 6.550994857690284e-09
nuclear O 0 1.6623087049083551e-06
BARD1 O 0 2.866426257241983e-06
polypeptides O 0 1.7608467715035658e-06
into O 0 2.4437264301013784e-07
BRCA1 O 0 4.127796637476422e-05
nuclear O 0 9.170650628220756e-06
dots O 0 4.8402151151094586e-05
. O 0 5.190068350202637e-06

This O 0 8.730709737392317e-07
cell O 0 1.3008740097575355e-05
cycle O 0 9.4104452728061e-06
- O 0 7.098286459950032e-06
dependent O 0 6.713112838951929e-07
colocalization O 0 1.7336400333078927e-06
of O 0 6.570252786275432e-09
BARD1 O 0 6.001164820190752e-06
and O 0 6.983842837371412e-08
BRCA1 O 0 6.03257421971648e-06
indicates O 0 1.4119864033546037e-07
a O 0 1.2466769838681557e-08
role O 0 8.152429131769168e-08
for O 0 2.302939350329325e-08
BARD1 O 0 9.757960469869431e-06
in O 0 1.6355508591914258e-07
BRCA1 O 0 0.0005957414396107197
- O 0 5.03940464113839e-05
mediated O 0 5.555463576456532e-05
tumor B-Disease 0 0.0001071708757081069
suppression O 0 1.0182147889281623e-05
. O 0 5.576173862209544e-06

Ethnic O 0 8.359515049960464e-05
differences O 0 8.518817776348442e-05
in O 0 8.107789426503587e-07
the O 0 9.221079153576284e-07
HFE O 0 0.0019883476197719574
codon O 0 6.306395516730845e-05
282 O 0 1.3508998563338537e-05
( O 0 9.917996521835448e-07
Cys O 0 0.01111571490764618
/ O 0 2.8209180527483113e-05
Tyr O 0 7.571448804810643e-05
) O 0 1.3937155927123968e-06
polymorphism O 0 7.456027378793806e-05
. O 0 7.521782208641525e-06

Recent O 0 8.875754247128498e-06
studies O 0 1.3875488775738631e-06
have O 0 8.846204480050801e-08
shown O 0 2.3032298201997037e-07
that O 0 3.339398972457275e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 5.238917947281152e-05
HH B-Disease 1 0.9969821572303772
) O 0 3.625174826993316e-08
is O 0 4.68618033266921e-09
likely O 0 4.88420184296956e-08
to O 0 6.366358551446183e-09
be O 0 1.9017097230289437e-08
caused O 0 1.2402543880796202e-08
by O 0 2.276173249882163e-09
homozygosity O 0 5.47770980574569e-07
for O 0 5.634388511310817e-09
a O 0 1.7369048421755906e-08
Cys282Tyr O 0 4.174866262474097e-06
mutation O 0 1.4154190921544796e-06
in O 0 5.620094967184741e-08
the O 0 7.184002015492297e-08
HFE O 0 3.951208418584429e-05
gene O 0 1.3757835404248908e-06
located O 0 8.664410415804014e-07
4 O 0 7.957258958413149e-07
. O 0 3.1158524507191032e-06

5 O 0 1.0048149306385312e-05
Mb O 0 5.1766714022960514e-05
telomeric O 0 0.00018872853252105415
to O 0 1.0538939250182011e-06
HLA O 0 6.344458233797923e-05
- O 0 0.00012334645725786686
A O 0 2.889481038437225e-06
. O 0 4.789431841345504e-06

Population O 0 8.334919584740419e-06
studies O 0 7.302758717742108e-07
of O 0 3.576179574693583e-09
this O 0 4.4016377209743496e-09
polymorphism O 0 1.6976637198240496e-06
are O 0 7.116804034978941e-09
facilitated O 0 1.6471711106191833e-08
by O 0 2.464634496490703e-09
the O 0 2.611597382795594e-09
fact O 0 1.4231335221381869e-08
that O 0 2.8829503229133024e-09
the O 0 1.8034480575579437e-08
Cys282Tyr O 0 5.801399765914539e-06
mutation O 0 1.0018305829362362e-06
creates O 0 2.2946049682559533e-07
a O 0 6.76941169786005e-08
Rsal O 0 5.115660314913839e-06
restriction O 0 7.000072059781814e-07
site O 0 1.9416252143855672e-06
. O 0 1.6210578905884176e-06

We O 0 4.196957434032811e-06
have O 0 1.6448142048375303e-07
studied O 0 2.031705719218735e-07
the O 0 4.447337076385338e-08
codon O 0 3.0885280466463882e-06
282 O 0 1.425840423507907e-06
( O 0 1.3878755567020562e-07
Cys O 0 0.0005299687618389726
/ O 0 2.7963592401647475e-06
Tyr O 0 4.403842012834502e-06
) O 0 1.4455583396966176e-08
polymorphism O 0 5.166549499335815e-07
in O 0 1.7516530448347112e-08
different O 0 4.1603996692174405e-08
ethnic O 0 7.43182283713395e-07
groups O 0 1.0731816928455373e-06
. O 0 3.6863714285573224e-06

In O 0 6.106108685344225e-07
agreement O 0 2.02139304406046e-07
with O 0 1.0530801120012256e-08
previous O 0 7.49126982668713e-08
observations O 0 8.539664264617386e-08
the O 0 8.345037549872814e-09
Tyr O 0 8.940199336393562e-07
allele O 0 3.7121989748811757e-07
appeared O 0 4.784729412676825e-08
to O 0 2.1557489127133067e-09
be O 0 2.8248279271281262e-09
rare O 0 1.0998528310324218e-08
or O 0 1.1971059166171472e-07
absent O 0 2.213490972735599e-07
in O 0 3.876876064623502e-08
Asiatic O 0 3.2789108672659495e-07
( O 0 3.6926142144011465e-09
Indian O 0 2.568213020026633e-08
, O 0 4.944072706791758e-09
Chinese O 0 1.0163694774689702e-08
) O 0 4.6585117985387114e-08
populations O 0 1.465132868361252e-06
. O 0 1.4889803878759267e-06

The O 0 3.3097433060902404e-07
highest O 0 5.850068305335299e-07
allele O 0 2.416911456748494e-06
frequency O 0 1.959752125912928e-06
( O 0 1.6810721703564013e-08
7 O 0 1.5918439899564873e-08
. O 0 6.340329150589241e-09
5 O 0 7.122860967712086e-09
% O 0 3.6735345876337533e-09
) O 0 3.980213048038195e-09
was O 0 5.604952093563043e-07
found O 0 1.0851709930648212e-07
in O 0 1.766362345279049e-07
Swedes O 0 0.040896445512771606
. O 0 3.986521733168047e-06

Saamis O 0 0.00013955753820482641
( O 0 4.754553515340376e-07
2 O 0 1.0557755558693316e-07
% O 0 1.792580306414493e-08
) O 0 2.914041896673325e-09
and O 0 7.938415258479381e-09
Mordvinians O 0 4.690510877480847e-07
( O 0 1.5284740140231179e-09
1 O 0 2.458385495174298e-09
. O 0 2.642276175635061e-09
8 O 0 4.888569993255487e-09
% O 0 3.946438287272258e-09
) O 0 1.8548658164974086e-09
had O 0 1.8056066153349093e-07
significantly O 0 2.3687330497068615e-07
lower O 0 2.1049048370969103e-07
frequencies O 0 2.4240594598268217e-07
of O 0 6.34539842891968e-09
the O 0 9.688525892670441e-08
Tyr O 0 1.4140471648715902e-05
allele O 0 1.664783303567674e-05
. O 0 2.772122343230876e-06

Comparisons O 0 1.960978579518269e-06
with O 0 3.9048021704957137e-08
allele O 0 6.919376573932823e-07
frequencies O 0 6.805420298405807e-07
based O 0 8.09109934607477e-08
on O 0 7.249536793096922e-08
prevalence O 0 9.818382750381716e-06
estimates O 0 1.5112675555428723e-07
of O 0 8.156950670468177e-09
HH B-Disease 1 0.9789561629295349
showed O 0 2.23570850721444e-06
some O 0 3.2030567087559803e-09
disagreements O 0 3.2946400096989237e-07
with O 0 2.687646105670183e-09
the O 0 5.6680189430835526e-09
RFLP O 0 1.1468899856481585e-06
data O 0 1.1754912065953249e-07
, O 0 6.690900278272238e-09
particularly O 0 3.8704630611618995e-08
in O 0 1.570546714901866e-07
Finns O 0 7.277586701093242e-05
. O 0 1.938363539011334e-06

The O 0 2.5790252493607113e-06
newly O 0 3.930278126063058e-06
described O 0 6.967018180148443e-07
HFE O 0 3.204748281859793e-05
marker O 0 9.361538673147152e-07
provides O 0 3.6917992218832296e-08
a O 0 1.451243747396802e-08
new O 0 1.4920768620640956e-08
approach O 0 6.60639543070829e-08
to O 0 4.050904500729757e-09
the O 0 1.2274818939062015e-09
screening O 0 1.7769279381241176e-08
of O 0 6.513513617356637e-10
HH B-Disease 0 2.252848571515642e-05
as O 0 2.643768537424762e-09
well O 0 4.890323701545185e-09
as O 0 2.317514402605525e-09
studies O 0 2.124000531011916e-08
of O 0 3.8342057306905986e-10
the O 0 4.110194851136839e-09
relationship O 0 8.343322122073005e-08
between O 0 1.5512334528011706e-08
the O 0 3.839676665506886e-08
HFE O 0 0.00015994958812370896
Tyr O 0 3.5852078781317687e-06
allele O 0 1.94887525140075e-06
and O 0 1.2093701684534608e-07
different O 0 7.312627303690533e-07
disorders O 0 0.003199499798938632
including O 0 4.680395250034053e-06
cancer B-Disease 0 0.23984070122241974

Autosomal B-Disease 1 0.9991389513015747
dominant I-Disease 1 0.9968476891517639
neurohypophyseal I-Disease 1 0.9998444318771362
diabetes I-Disease 1 0.9999980926513672
insipidus I-Disease 1 0.9990621209144592
associated O 0 3.5924866097047925e-05
with O 0 2.0828260005600896e-07
a O 0 3.010691784766095e-07
missense O 0 4.110151712666266e-05
mutation O 0 6.406298780348152e-06
encoding O 0 3.148885298287496e-06
Gly23 O 0 0.0022690282203257084
- O 0 0.026720423251390457
- O 0 0.0021974779665470123
> O 0 1.4577331967302598e-05
Val O 0 0.00030267919646576047
in O 0 6.517391284432961e-07
neurophysin O 0 0.00012283705291338265
II O 0 6.597157334908843e-05
. O 0 2.519534746170393e-06

Autosomal B-Disease 1 0.9985678195953369
dominant I-Disease 1 0.9883163571357727
neurohypophyseal I-Disease 1 0.9996249675750732
diabetes I-Disease 1 0.9999891519546509
insipidus I-Disease 1 0.994999885559082
( O 0 9.249324079974031e-07
ADNDI B-Disease 0 0.00036841502878814936
) O 0 1.1360397422777169e-07
is O 0 5.826067095426879e-08
an O 0 0.0006205739919096231
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.010929340496659279
by O 0 1.011095207559265e-07
progressive O 0 0.0006241632509045303
degeneration O 0 0.0009934395784512162
of O 0 9.79095560182941e-09
the O 0 4.9964331338969714e-08
magnocellular O 0 2.144541940651834e-05
neurons O 0 5.321689400261675e-07
of O 0 2.637709162200963e-09
the O 0 5.96344040815211e-09
hypothalamus O 0 2.0052129912073724e-07
leading O 0 8.367546655563274e-08
to O 0 1.1843216185525307e-08
decreased O 0 2.174287345724224e-07
ability O 0 6.583388767467113e-08
to O 0 1.302497931732205e-08
produce O 0 6.491034554301223e-08
the O 0 3.3102036667287393e-08
hormone O 0 1.0189509112024098e-06
arginine O 0 4.6486857741001586e-07
vasopressin O 0 1.9725130186998285e-06
( O 0 4.094828653933291e-08
AVP O 0 6.8618774093920365e-06
) O 0 2.9461571671163256e-07
. O 0 1.2337658290562104e-06

Affected O 0 7.921545147837605e-06
individuals O 0 9.111723642263314e-08
are O 0 9.720154459103014e-09
not O 0 1.1827594015301202e-08
symptomatic O 0 1.4512139046019001e-07
at O 0 2.522721942455064e-08
birth O 0 5.152412541065132e-08
, O 0 4.65925564796521e-09
but O 0 7.423252412763759e-08
usually O 0 3.6179156381876965e-07
develop O 0 7.660141818632837e-06
diabetes B-Disease 0 0.03315897285938263
insipidus I-Disease 0 0.0006032412056811154
at O 0 2.3903342594167043e-07
1 O 0 1.435513752312545e-07
- O 0 0.00017747348465491086
6 O 0 5.606572131000576e-07
yr O 0 1.1409333637857344e-05
of O 0 1.9703945142168777e-08
age O 0 7.677011808482348e-07
. O 0 1.257455323866452e-06

The O 0 8.801652029433171e-07
genetic O 0 6.1977875702723395e-06
locus O 0 6.224228400242282e-06
of O 0 1.3310962110324454e-08
the O 0 4.1930624661290494e-07
disease O 0 1.3655700968229212e-05
is O 0 1.2623881495699152e-08
the O 0 3.864171205236744e-08
AVP O 0 0.0003062965115532279
- O 0 0.00021298357751220465
neurophysin O 0 0.000188317964784801
II O 0 5.253766630630707e-06
( O 0 3.906222900695866e-09
NPII O 0 3.7358054782998806e-07
) O 0 2.0582464621554664e-09
gene O 0 8.188672850906187e-09
, O 0 1.2530605442151455e-09
and O 0 7.48392547933463e-09
mutations O 0 4.717373371931899e-07
that O 0 9.498647202121902e-09
cause O 0 3.9435583687463804e-08
ADNDI B-Disease 0 0.00011908284068340436
have O 0 1.017085509147364e-07
been O 0 7.875484442365632e-08
found O 0 1.5380026141542658e-08
in O 0 1.931243609476496e-09
both O 0 2.728939518803486e-09
the O 0 3.7987066825451166e-09
signal O 0 3.034671891555263e-08
peptide O 0 2.2720927361774557e-08
of O 0 9.665961364646591e-10
the O 0 1.0005549277991577e-08
prepro O 0 1.968232936633285e-05
- O 0 9.089753802982159e-06
AVP O 0 1.4919446584826801e-05
- O 0 1.7294044027948985e-06
NPII O 0 4.419252945808694e-06
precursor O 0 4.063633411988121e-07
and O 0 4.231619143979515e-08
within O 0 7.829338954934428e-08
NPII O 0 1.551606874272693e-05
itself O 0 2.7925693757424597e-06
. O 0 2.8458396172936773e-06

An O 0 6.461401085289253e-07
affected O 0 6.393863145603973e-07
girl O 0 3.7550296383415116e-06
who O 0 4.491871763434574e-08
presented O 0 1.7342564717637288e-08
at O 0 1.2517951120116777e-08
9 O 0 3.7211924652780226e-09
months O 0 7.127318735200561e-09
of O 0 4.0533759682048753e-10
age O 0 2.448886604611289e-08
and O 0 7.69780150733368e-09
her O 0 2.0926275112742587e-07
similarly O 0 8.872918328961532e-07
affected O 0 3.6151146076690566e-08
younger O 0 1.8753894437395502e-08
brother O 0 1.4837899797726095e-08
and O 0 3.523510372360761e-09
father O 0 1.8493276243702894e-08
were O 0 1.259151360955002e-08
all O 0 6.922090123318014e-10
found O 0 1.4252496072231224e-08
to O 0 5.581123119213771e-09
have O 0 1.4678914084242933e-08
a O 0 6.323276569020209e-09
novel O 0 3.5499493833413e-07
missense O 0 1.8739518054644577e-05
mutation O 0 3.261525534981047e-06
( O 0 2.3411246274918085e-08
G1758 O 0 2.934941676357994e-06
- O 0 0.00016027690435294062
- O 0 0.0007218939135782421
> O 0 1.4183865459926892e-06
T O 0 4.6597656364610884e-06
) O 0 3.6175200612831304e-09
encoding O 0 2.267430154745398e-08
the O 0 1.091310330991746e-08
amino O 0 1.3611781923827948e-07
acid O 0 1.1555640355709329e-07
substitution O 0 1.3508700646980287e-07
Gly23 O 0 6.349411250994308e-06
- O 0 8.342807632288896e-06
- O 0 6.785545338061638e-06
> O 0 5.62361356060137e-06
Val O 0 2.822602618834935e-05
within O 0 1.0163373644900275e-06
NPII O 0 0.00010585811105556786
. O 0 3.828739863820374e-06

The O 0 1.9695901301020058e-06
mutation O 0 3.967000884586014e-05
was O 0 1.7622882069190382e-06
confirmed O 0 1.7245595529402635e-07
by O 0 1.9897765213272578e-08
restriction O 0 6.78094465911272e-07
endonuclease O 0 3.443993045948446e-05
analysis O 0 8.166360203176737e-06
. O 0 4.521619302977342e-06

A O 0 4.832167633139761e-06
T1 O 0 0.00023455097107216716
- O 0 8.085219633358065e-06
weighted O 0 1.237326614500489e-06
magnetic O 0 5.621155878543505e-07
resonance O 0 2.197047933805152e-06
imaging O 0 1.4040966561879031e-05
of O 0 1.766145807380326e-08
the O 0 1.4883995902437164e-07
fathers O 0 2.097039669024525e-06
pituitary O 0 5.536274784390116e-06
gland O 0 3.103995140918414e-06
demonstrates O 0 3.1709151926406776e-07
an O 0 5.0697945397359945e-08
attenuated O 0 3.776962694246322e-05
posterior O 0 0.005953698884695768
pituitary O 0 0.0034629611764103174
bright O 0 6.143393693491817e-05
spot O 0 4.96133288834244e-05
. O 0 1.0991358067258261e-05

This O 0 7.621642907906789e-07
mutation O 0 3.2703651413612533e-06
may O 0 1.4643768508904031e-07
be O 0 3.923995794963275e-09
valuable O 0 8.887059976814271e-09
for O 0 2.09516981541924e-09
developing O 0 2.8537590068822283e-08
models O 0 1.2248565894878993e-07
of O 0 8.455541156138224e-09
dominantly B-Disease 0 0.14953726530075073
inherited I-Disease 1 0.9998021721839905
neurodegeneration I-Disease 1 1.0
, O 0 5.580051265496877e-08
as O 0 1.873947663710851e-09
the O 0 1.8115625666226265e-09
early O 0 9.073188778074837e-08
age O 0 1.2462870735419074e-08
of O 0 1.1038769898163991e-09
onset O 0 1.6760990320108249e-06
of O 0 2.1953226791993075e-08
symptoms O 0 3.2995590117934626e-06
suggests O 0 3.960344585607345e-08
that O 0 1.5590485569205725e-09
this O 0 3.2778331160443486e-09
mutation O 0 6.960185032767185e-07
may O 0 2.443456139644695e-07
be O 0 7.0034760213388836e-09
particularly O 0 3.1741578254695924e-08
deleterious O 0 1.4836437003395986e-06
to O 0 3.798752246098047e-08
the O 0 5.092880428492208e-08
magnocellular O 0 1.8292252207174897e-05
neuron O 0 8.11505287856562e-06
. O 0 7.848018412914826e-07
. O 0 1.586130110808881e-06

Frequent O 0 0.00022955835447646677
inactivation O 0 0.0003033702087122947
of O 0 7.420668453050894e-07
PTEN O 0 0.0003327298618387431
/ O 0 4.470174462767318e-05
MMAC1 O 0 0.0007417122251354158
in O 0 1.3515286809706595e-05
primary O 1 0.9998785257339478
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 3.354953514644876e-05

Sporadic B-Disease 1 0.890137791633606
prostate I-Disease 1 0.9999972581863403
carcinoma I-Disease 1 1.0
is O 0 6.192306614138943e-07
the O 0 1.6403458147351557e-08
most O 0 2.0661099497942814e-08
common O 0 5.14926910000213e-07
male B-Disease 0 0.00010572414612397552
cancer I-Disease 0 0.00031319394474849105
in O 0 7.219617792486588e-09
the O 0 4.431095046442124e-09
Western O 0 5.657976132056319e-08
world O 0 5.800940243716468e-07
, O 0 1.371367575053739e-09
yet O 0 3.905254786218393e-09
many O 0 3.6671901626483816e-10
of O 0 1.150284797968304e-10
the O 0 1.6225120136326154e-09
major O 0 1.9185268484989138e-08
genetic O 0 8.142995255866481e-08
events O 0 9.317929539065517e-09
involved O 0 1.5286525822943986e-08
in O 0 5.561188398672812e-09
the O 0 2.745850880003786e-09
progression O 0 3.007336601967836e-08
of O 0 8.445157351211208e-10
this O 0 3.992548158748832e-08
often O 0 0.0014260237803682685
fatal O 1 0.9948784112930298
cancer B-Disease 0 0.14036664366722107
remain O 0 1.5438430978065298e-07
to O 0 4.0223429920160925e-08
be O 0 1.5919296458832832e-07
elucidated O 0 3.142521745758131e-05
. O 0 2.326214826098294e-06

Numerous O 0 4.361552328191465e-06
cytogenetic O 0 0.00010969628783641383
and O 0 4.817669037038286e-07
allelotype O 0 2.0054678316228092e-05
studies O 0 1.2430036804289557e-06
have O 0 1.0100793446099487e-07
reported O 0 4.276085405763297e-07
frequent O 0 6.001944257150171e-07
loss O 0 4.943189196637832e-06
of O 0 1.521836523465936e-08
heterozygosity O 0 0.0003535160794854164
on O 0 7.353061164394603e-07
chromosomal O 1 0.646068811416626
arm O 0 0.00468075554817915
10q O 0 2.130913344444707e-05
in O 0 1.841939024416206e-06
sporadic B-Disease 1 0.9987965822219849
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.869150946731679e-05

Deletion O 0 8.943389548221603e-05
mapping O 0 1.3393444532994181e-05
studies O 0 2.66060806097812e-06
have O 0 9.989954463662798e-08
unambiguously O 0 1.8077498680213466e-06
identified O 0 3.149955603021226e-07
a O 0 1.7639205651676093e-08
region O 0 7.712295513329082e-08
of O 0 2.5106772216787476e-09
chromosome O 0 1.3063513506494928e-06
10q23 O 0 2.1255482351989485e-06
to O 0 1.752000500232498e-08
be O 0 1.0757260859861617e-08
the O 0 5.041461026422667e-09
minimal O 0 1.7238754423942737e-07
area O 0 1.578664665657925e-07
of O 0 5.127022362216849e-08
loss O 0 8.147875632857904e-05
. O 0 3.414800403334084e-06

A O 0 6.932190444786102e-06
new O 0 1.4088565194469993e-06
tumor B-Disease 0 1.055770644597942e-05
suppressor O 0 8.966248969954904e-06
gene O 0 1.9421474917180603e-06
, O 0 1.1778454478417189e-07
PTEN O 0 1.6335698092007078e-05
/ O 0 2.523695002309978e-06
MMAC1 O 0 0.0001742086315061897
, O 0 3.497525824514014e-08
was O 0 1.2984713748664944e-07
isolated O 0 8.477780966131832e-07
recently O 0 0.0001225923770107329
at O 0 5.01062444868694e-08
this O 0 3.3450080483277134e-09
region O 0 1.8639209287130143e-08
of O 0 2.772421625607535e-09
chromosome O 0 8.760534342400206e-07
10q23 O 0 9.343993951915763e-07
and O 0 4.788981211589771e-09
found O 0 2.4896424921649896e-09
to O 0 8.288751351948065e-10
be O 0 1.898483148465857e-09
inactivated O 0 3.6211392995255665e-08
by O 0 1.2601694132641228e-09
mutation O 0 2.464495310050552e-07
in O 0 1.789632477766645e-07
three O 0 0.11380087584257126
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0009156469022855163
lines O 0 0.00154598499648273
. O 0 7.997467037057504e-06

We O 0 1.4462898434430826e-05
screened O 0 3.211329021723941e-05
80 O 0 5.092714218335459e-06
prostate B-Disease 1 0.9831148982048035
tumors I-Disease 1 1.0
by O 0 4.683555587803312e-08
microsatellite O 0 3.468750219326466e-05
analysis O 0 1.3541376802095328e-06
and O 0 9.177776405522309e-08
found O 0 1.1943578215323214e-07
chromosome O 0 1.5666618082832429e-06
10q23 O 0 8.058216280915076e-07
to O 0 1.137461591582678e-08
be O 0 1.3410883958897557e-08
deleted O 0 2.411997002127464e-07
in O 0 4.322733104800136e-08
23 O 0 1.402955689400187e-07
cases O 0 3.617784329890128e-07
. O 0 1.970486437130603e-06

We O 0 3.0598525881941896e-06
then O 0 1.3045843161307857e-07
proceeded O 0 3.762215783353895e-08
with O 0 1.3760708128529586e-09
sequence O 0 2.4449567703754838e-08
analysis O 0 2.996223713580548e-08
of O 0 1.995666742971025e-09
the O 0 1.5354524762756228e-08
entire O 0 3.2965067475743126e-07
PTEN O 0 4.7982237447286025e-05
/ O 0 8.79114907093026e-07
MMAC1 O 0 5.428536042018095e-06
coding O 0 4.098547378816875e-06
region O 0 6.041038602688786e-08
and O 0 1.373658875536421e-08
tested O 0 1.1302087443709752e-07
for O 0 1.1515057796174233e-09
homozygous O 0 1.1052262038901972e-07
deletion O 0 1.4285487281995302e-07
with O 0 3.242179857920746e-09
new O 0 1.768879975827531e-08
intragenic O 0 4.37076124626401e-07
markers O 0 3.313018339667906e-07
in O 0 9.508653420198243e-09
these O 0 8.579545074383077e-09
23 O 0 8.133103968077648e-09
cases O 0 1.8034789661669492e-08
with O 0 1.9596079425809876e-08
10q23 O 0 0.00010169022425543517
loss O 0 2.2578144580620574e-06
of O 0 7.689322956139222e-08
heterozygosity O 0 0.00030918969423510134
. O 0 5.728827090933919e-06

The O 0 3.583367913506663e-07
identification O 0 2.077455860671762e-07
of O 0 3.871982290348797e-09
the O 0 7.291885761873118e-09
second O 0 6.128299645524748e-08
mutational O 0 5.855260042153532e-06
event O 0 3.46354397606774e-07
in O 0 1.713875263931186e-08
10 O 0 7.324922446372284e-09
( O 0 4.260789498999884e-09
43 O 0 5.843941153216292e-08
% O 0 6.861380796863159e-08
) O 0 1.950954356289003e-06
tumors B-Disease 1 1.0
establishes O 0 3.3637545584497275e-06
PTEN O 0 6.60929799778387e-05
/ O 0 1.353849711449584e-06
MMAC1 O 0 2.7675690944306552e-05
as O 0 1.4070928422427187e-08
a O 0 1.3047681157729585e-08
main O 0 1.7103133131968207e-07
inactivation O 0 1.2244938261574134e-05
target O 0 3.392836447346781e-07
of O 0 3.244283064418596e-09
10q O 0 1.2204100130475126e-06
loss O 0 4.226545797791914e-07
in O 0 1.1395717791629068e-07
sporadic B-Disease 1 0.9983850717544556
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1365492557379184e-06
. O 0 3.3171136237797327e-06

Risk O 0 0.0009025485487654805
reversals O 0 1.3697896065423265e-05
in O 0 2.951170756659849e-07
predictive O 0 1.1456174433988053e-05
testing O 0 9.33528190216748e-06
for O 0 3.3534984140715096e-06
Huntington B-Disease 1 0.9999990463256836
disease I-Disease 1 0.999997615814209
. O 0 1.3217654668551404e-05

The O 0 1.4869863207422895e-07
first O 0 5.38276658801351e-08
predictive O 0 2.067115246973117e-06
testing O 0 9.466624533160939e-07
for O 0 4.234687764892442e-07
Huntington B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999912977218628
( O 0 1.9155359964884155e-08
HD B-Disease 0 0.004189872648566961
) O 0 2.5810152237681905e-08
was O 0 3.3130686460935976e-07
based O 0 1.340533462013127e-08
on O 0 8.163425491147791e-09
analysis O 0 3.202551113190566e-08
of O 0 1.8859378503321977e-09
linked O 0 7.142671734072792e-07
polymorphic O 0 3.6307943673818954e-07
DNA O 0 5.392255388869671e-07
markers O 0 1.5232745909088408e-07
to O 0 6.870334967601366e-09
estimate O 0 1.759904755260777e-08
the O 0 3.823078742470898e-09
likelihood O 0 8.738374646100056e-08
of O 0 2.6389519458547284e-09
inheriting O 0 4.294295479212451e-07
the O 0 8.290592745652248e-08
mutation O 0 2.2537635686603608e-06
for O 0 1.7853915323939873e-07
HD B-Disease 0 0.00030735338805243373
. O 0 4.667833763960516e-06

Limits O 0 3.131193352601258e-06
to O 0 7.130897472507058e-08
accuracy O 0 1.8798664314090274e-07
included O 0 1.0811997519510896e-08
recombination O 0 9.139206724739779e-08
between O 0 1.2318378317388579e-08
the O 0 4.999328950816562e-09
DNA O 0 2.6672159947338514e-07
markers O 0 2.922610917721613e-07
and O 0 1.175737374126129e-08
the O 0 1.399592797213245e-08
mutation O 0 3.3215740131709026e-06
, O 0 1.8024886472289836e-08
pedigree O 0 2.4258918074338e-06
structure O 0 2.800792344714864e-06
, O 0 1.0375132752926675e-08
and O 0 7.001792479144342e-09
whether O 0 1.0359511470880989e-08
DNA O 0 1.196701902017594e-07
samples O 0 3.306190521357166e-08
were O 0 1.1259565724230924e-08
available O 0 1.8354889164129418e-08
from O 0 8.053866018542521e-09
family O 0 1.255698265367755e-07
members O 0 1.3278257426918572e-07
. O 0 1.0460893236086122e-06

With O 0 1.683395964846568e-07
direct O 0 1.578568316062956e-07
tests O 0 2.888803862788336e-07
for O 0 3.3769453899878954e-09
the O 0 4.015633159326626e-09
HD B-Disease 0 3.200501851097215e-06
mutation O 0 2.0313453319431574e-07
, O 0 2.654191755269153e-09
we O 0 3.966458272941509e-09
have O 0 2.9012479085821496e-09
assessed O 0 1.0462650301690246e-08
the O 0 1.3537035936650454e-09
accuracy O 0 2.497489504094119e-07
of O 0 8.330561795943936e-10
results O 0 8.842442866807687e-08
obtained O 0 1.1759078155648695e-08
by O 0 1.962749296424704e-09
linkage O 0 1.0141158668375283e-07
approaches O 0 3.8454885498140357e-08
when O 0 9.096421393905985e-09
requested O 0 2.3512367608446993e-09
to O 0 2.825334632916565e-09
do O 0 5.094267230276728e-09
so O 0 1.772959445922595e-09
by O 0 1.1882511641303495e-09
the O 0 1.1564102564420864e-08
test O 0 6.019955094416218e-07
individuals O 0 2.1526973625896062e-07
. O 0 1.6681511851857067e-06

For O 0 1.5599215430484037e-07
six O 0 1.6045921924501272e-08
such O 0 2.8443132293887174e-09
individuals O 0 4.3908126023950445e-09
, O 0 3.589108121815343e-09
there O 0 1.388468007235133e-08
was O 0 8.423252779721224e-07
significant O 0 7.511557953421288e-08
disparity O 0 2.399928007434937e-07
between O 0 1.9566014586303027e-08
the O 0 1.0081181756049773e-07
tests O 0 3.1605370622855844e-06
. O 0 1.842601363932772e-06

Three O 0 3.967035695495724e-07
went O 0 1.5560345900667016e-07
from O 0 6.062783608484779e-09
a O 0 1.3637178497560853e-08
decreased O 0 4.255271051079035e-06
risk O 0 3.548297854649718e-06
to O 0 4.692629396174652e-09
an O 0 2.570162083159744e-09
increased O 0 2.4968204570541275e-07
risk O 0 7.841226761229336e-06
, O 0 1.2400076521146275e-09
while O 0 4.3509462699375945e-09
in O 0 1.7977289656911921e-09
another O 0 5.358844035185939e-09
three O 0 9.906480968879805e-09
the O 0 1.6459063090223935e-07
risk O 0 0.0007882310310378671
was O 0 3.824707164312713e-06
decreased O 0 7.119207566574914e-06
. O 0 2.7208830033487175e-06

Knowledge O 0 1.2161796121290536e-06
of O 0 1.274431316033997e-08
the O 0 6.522431483801938e-09
potential O 0 3.2095957891442595e-08
reasons O 0 1.3017553257554937e-08
for O 0 3.5368807882463216e-10
these O 0 7.963721349035779e-10
changes O 0 5.228001587198605e-09
in O 0 1.8436081106187885e-08
results O 0 1.9471570340101607e-05
and O 0 3.433870432445474e-08
impact O 0 2.5038302098323584e-08
of O 0 4.552676291513791e-10
these O 0 1.2643351254837398e-08
risk O 0 2.7231340027356055e-07
reversals O 0 8.589159961047699e-08
on O 0 4.1989509647066825e-09
both O 0 1.110701308704165e-08
patients O 0 4.408807185996011e-08
and O 0 1.5432205513477015e-09
the O 0 1.4709007345459213e-09
counseling O 0 3.038192986082322e-08
team O 0 5.828431515197963e-09
can O 0 1.4002116133227105e-09
assist O 0 1.196052812346693e-09
in O 0 2.088722084181427e-09
the O 0 1.2305081398267248e-09
development O 0 1.1527958587720377e-09
of O 0 3.6230285438421106e-10
strategies O 0 1.8981584304356147e-08
for O 0 7.182475170175451e-10
the O 0 1.737205490570659e-09
prevention O 0 8.230120585039913e-09
and O 0 2.9647229116136486e-09
, O 0 6.100572824685457e-10
where O 0 2.93200530521176e-09
necessary O 0 2.3220909639576348e-08
, O 0 2.2917336917060993e-09
management O 0 3.0579583309986447e-09
of O 0 3.7159916810303173e-10
a O 0 4.525072938577068e-08
risk O 0 1.4857137102808338e-06
reversal O 0 1.8187409978054347e-07
in O 0 9.814776547045767e-09
any O 0 2.3088196243747916e-08
predictive O 0 1.277470573768369e-06
testing O 0 4.439878864559432e-07
program O 0 1.6650965051212552e-07
. O 0 1.229362140975354e-07
. O 0 6.894096600262856e-07

A O 0 7.555608135589864e-06
novel O 0 8.13395126897376e-06
common O 0 2.9521747819671873e-06
missense O 0 8.89045768417418e-05
mutation O 0 2.33691116591217e-05
G301C O 0 8.779681593296118e-06
in O 0 7.335160034926957e-08
the O 0 4.8969720722880083e-08
N O 0 0.00028838281286880374
- O 0 3.697002466651611e-05
acetylgalactosamine O 0 0.0004483141237869859
- O 0 2.6740757675725035e-05
6 O 0 3.952486054004112e-07
- O 0 3.0589978905481985e-06
sulfate O 0 9.188377589453012e-06
sulfatase O 0 3.0478384360321797e-05
gene O 0 2.8976492103538476e-06
in O 0 5.611215101453126e-07
mucopolysaccharidosis B-Disease 0 0.00013118745118845254
IVA I-Disease 0 0.0008390360744670033
. O 0 1.2601080015883781e-05

Mucopolysaccharidosis B-Disease 0 0.004490063991397619
IVA I-Disease 0 0.06061001867055893
( O 0 6.554698757099686e-06
MPS B-Disease 1 0.9999904632568359
IVA I-Disease 1 0.9999985694885254
) O 0 1.426370488388784e-07
is O 0 1.5155796617705164e-08
an O 0 1.4110010226886516e-07
autosomal B-Disease 1 0.9999638795852661
recessive I-Disease 1 0.9999908208847046
lysosomal I-Disease 1 0.9999923706054688
storage I-Disease 1 0.9999974966049194
disorder I-Disease 1 0.9999822378158569
caused O 0 4.7496811021119356e-05
by O 0 7.732828066764341e-08
a O 0 4.716460171039216e-05
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.2070374850736698e-06
N O 0 0.29773464798927307
- O 0 0.030614597722887993
acetylgalactosamine O 0 0.04442288726568222
- O 0 0.0025254138745367527
6 O 0 1.094892240871559e-06
- O 0 4.118775905226357e-05
sulfate O 0 0.0001818614691728726
sulfatase O 0 0.00012750201858580112
( O 0 1.6317122231157555e-07
GALNS O 0 2.653957017173525e-05
) O 0 4.6885250526429445e-07
. O 0 1.5678351701353677e-06

In O 0 7.341653827097616e-07
previous O 0 2.988923881730443e-07
studies O 0 1.6538773195406975e-07
, O 0 4.3981045472207825e-09
we O 0 1.504112390193768e-08
have O 0 5.381418866079457e-09
found O 0 7.216740538495969e-09
two O 0 4.170098044653514e-09
common O 0 7.27130640143514e-08
mutations O 0 9.797942084333044e-07
in O 0 2.4522144315142214e-08
Caucasians O 0 1.447438080504071e-06
and O 0 1.452180242722534e-07
Japanese O 0 7.272061566254706e-07
, O 0 9.631775554908018e-08
respectively O 0 1.599649976924411e-06
. O 0 1.9600736322900048e-06

To O 0 1.4169643236527918e-06
characterize O 0 7.267753062478732e-06
the O 0 6.063676494250103e-08
mutational O 0 3.3199175959452987e-06
spectrum O 0 3.4451878150321136e-07
in O 0 7.488495157303987e-09
various O 0 4.748125448372775e-09
ethnic O 0 4.541423592741012e-08
groups O 0 5.1721048777153555e-08
, O 0 1.355481860088048e-08
mutations O 0 4.3044272501902014e-07
in O 0 7.995322626186407e-09
the O 0 1.0020158924817224e-08
GALNS O 0 9.268829330721928e-07
gene O 0 1.0326098021096186e-07
in O 0 3.559481243087248e-08
Colombian O 0 1.133366254180146e-06
MPS B-Disease 1 0.9999972581863403
IVA I-Disease 1 0.9999991655349731
patients O 0 1.3034471521677915e-05
were O 0 2.9375373244988623e-08
investigated O 0 1.9692380703872914e-07
, O 0 2.442787971901339e-09
and O 0 3.377325308306922e-09
genetic O 0 2.0904732878079813e-07
backgrounds O 0 9.542595336142767e-08
were O 0 9.481903262553715e-09
extensively O 0 4.504045492126352e-08
analyzed O 0 1.7198539126184187e-07
to O 0 5.940123060099722e-09
identify O 0 1.1601863292298731e-07
racial O 0 6.384991024788178e-08
origin O 0 6.39292423443294e-08
, O 0 2.8183755329536098e-09
based O 0 1.0875721656589121e-08
on O 0 3.209718357766178e-08
mitochondrial O 0 1.525770926491532e-06
DNA O 0 1.2444136700651143e-05
( O 0 4.9849532501866634e-08
mtDNA O 0 2.23476195060357e-06
) O 0 1.8254189626532025e-07
lineages O 0 3.3594844808249036e-06
. O 0 2.6912798603007104e-06

Three O 0 1.739705226100341e-06
novel O 0 4.50250945505104e-06
missense O 0 4.420326877152547e-05
mutations O 0 1.8804717910825275e-05
never O 0 4.185490524832858e-06
identified O 0 1.4695308436785126e-07
previously O 0 9.697011194020888e-08
in O 0 3.841417850480866e-09
other O 0 2.1656063609043485e-09
populations O 0 2.979327007324173e-08
and O 0 1.0378160553159432e-08
found O 0 3.6665642966227097e-08
in O 0 5.947673908934803e-09
16 O 0 2.873091542454631e-09
out O 0 1.8018346814585584e-09
of O 0 2.2232762297846875e-09
19 O 0 1.0580595954934324e-07
Colombian O 0 1.5540490494458936e-06
MPS B-Disease 1 0.9999781847000122
IVA I-Disease 1 0.9998548030853271
unrelated O 0 2.4025828224694123e-06
alleles O 0 1.3260493005873286e-06
account O 0 4.068953955993493e-07
for O 0 1.1412313938308216e-07
84 O 0 1.7770825024854275e-06
. O 0 2.537792397561134e-06

2 O 0 3.982174348493572e-06
% O 0 1.742174475793945e-07
of O 0 3.250941738031088e-09
the O 0 8.296014541997465e-09
alleles O 0 4.0007091683946783e-07
in O 0 2.882995886466233e-08
this O 0 3.816843729964603e-08
study O 0 5.560639237955911e-07
. O 0 1.2991553148822277e-06

The O 0 1.1430344102336676e-06
G301C O 0 8.601826266385615e-06
and O 0 1.2355609158021252e-07
S162F O 0 3.644091066234978e-06
mutations O 0 2.627633421070641e-06
account O 0 3.75753359094233e-07
for O 0 6.69318751533865e-08
68 O 0 3.2777090837043943e-06
. O 0 2.329002882106579e-06

4 O 0 2.3100888938643038e-05
% O 0 1.7409731754014501e-06
and O 0 5.688143005500024e-07
10 O 0 7.682637033212814e-07
. O 0 2.1729761101596523e-06

5 O 0 2.4652081265230663e-06
% O 0 1.0751418955123881e-07
of O 0 2.8943443197704255e-09
mutations O 0 5.843037911290594e-07
, O 0 7.21795201386044e-09
respectively O 0 1.464175767296183e-07
, O 0 2.5656998747791704e-09
whereas O 0 1.552319695008464e-08
the O 0 4.4018393374756215e-09
remaining O 0 1.532255424763207e-07
F69V O 0 0.00019475370936561376
is O 0 5.478428377614364e-09
limited O 0 9.429348857281639e-09
to O 0 5.297219995981095e-09
a O 0 1.8221086861558433e-08
single O 0 1.4785657640459249e-06
allele O 0 2.9463266400853172e-05
. O 0 3.2926120638876455e-06

The O 0 1.790368173715251e-06
skewed O 0 1.1224164154555183e-05
prevalence O 0 6.0184333960933145e-06
of O 0 9.029283098982432e-09
G301C O 0 4.7378151180055283e-07
in O 0 5.790204316014069e-09
only O 0 6.771036176189682e-09
Colombian O 0 7.799931012186789e-08
patients O 0 1.3899577311349276e-07
and O 0 5.5322431080639944e-09
haplotype O 0 7.234128247546323e-07
analysis O 0 5.983461193181938e-08
by O 0 6.255165274637875e-09
restriction O 0 3.0936757156041494e-08
fragment O 0 1.6101081712349696e-07
length O 0 1.4448256990817754e-07
polymorphisms O 0 3.6410897337191273e-06
in O 0 2.330161130714714e-08
the O 0 1.0852244436421188e-08
GALNS O 0 2.817732138282736e-06
gene O 0 1.6215544462738762e-07
suggest O 0 1.2805159599338367e-07
that O 0 4.9049995176631e-09
G301C O 0 1.9022598962692427e-07
originated O 0 4.7130651381621647e-08
from O 0 9.32319110802382e-09
a O 0 3.826326633316057e-08
common O 0 5.091991965855414e-07
ancestor O 0 5.561547823162982e-06
. O 0 5.645284090860514e-06

Investigation O 0 3.1881456834526034e-06
of O 0 2.6859460433570348e-08
the O 0 1.0687625007221868e-08
genetic O 0 3.3706606927808025e-07
background O 0 9.295353464722211e-08
by O 0 4.512444196080878e-09
means O 0 3.366702117091336e-08
of O 0 1.6158350213402173e-09
mtDNA O 0 3.9162932807812467e-07
lineages O 0 1.295775859944115e-07
indicate O 0 1.6629334709250543e-07
that O 0 5.738890695994314e-09
all O 0 2.33131602911385e-09
our O 0 1.635597079996387e-08
patients O 0 3.31844702827766e-08
are O 0 1.5180001700088042e-09
probably O 0 2.1523847593130085e-08
of O 0 2.5031079431414582e-09
native O 0 2.1598413013634854e-07
American O 0 3.1079196105565643e-06
descent O 0 0.0014173910021781921

Low O 0 4.4176169467391446e-05
frequency O 0 1.4033095794729888e-05
of O 0 3.011932108165638e-07
BRCA1 O 0 6.699289224343374e-05
germline O 0 3.2327574444934726e-05
mutations O 0 7.243438176374184e-06
in O 0 1.0221145885225269e-07
45 O 0 6.55449696296273e-07
German O 1 0.9971801042556763
breast B-Disease 1 1.0
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0634068530634977e-05
. O 0 7.479342457372695e-06

In O 0 3.426497983127774e-07
this O 0 1.8349570751752253e-08
study O 0 2.988489811173167e-08
we O 0 2.2596330140345344e-08
investigated O 0 9.923467558792254e-08
45 O 0 6.076075464989117e-08
German O 1 0.7156937718391418
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2517287473201577e-07
for O 0 2.3416337313619806e-08
germline O 0 3.7803205486852676e-05
mutations O 0 1.4271519830799662e-05
in O 0 1.082419629483411e-07
the O 0 3.758486855076626e-07
BRCA1 O 0 0.00013550682342611253
gene O 0 3.625962199294008e-05
. O 0 8.150333997036796e-06

We O 0 5.042636075813789e-06
identified O 0 7.662997063562216e-07
four O 0 7.312083738497677e-08
germline O 0 6.866492640256183e-06
mutations O 0 3.200843593731406e-06
in O 0 3.080204180605506e-08
three O 0 3.916098876288743e-07
breast B-Disease 1 0.9997445940971375
cancer I-Disease 0 0.002324911532923579
families O 0 9.428413605405694e-09
and O 0 3.5365521622310325e-09
in O 0 1.8710590410364603e-08
one O 0 0.009537933394312859
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.4261665626236208e-07
. O 0 4.084545590643529e-09
among O 0 1.233238400288883e-09
these O 0 1.1638001673475173e-09
were O 0 3.2548644668395355e-08
one O 0 2.1648064674195666e-08
frameshift O 0 0.004065185319632292
mutation O 0 3.6514172734314343e-06
, O 0 1.3902939244303525e-08
one O 0 3.0338732415202685e-08
nonsense O 0 5.259255885903258e-06
mutation O 0 2.8084980385756353e-06
, O 0 1.5232711092494355e-08
one O 0 9.76311387290707e-09
novel O 0 1.6754695764120697e-07
splice O 0 2.766368561424315e-05
site O 0 1.088755084310833e-06
mutation O 0 2.4854173261701362e-06
, O 0 1.1638983998807362e-08
and O 0 1.9875612267128417e-08
one O 0 1.632649286875676e-07
missense O 0 9.219947969540954e-05
mutation O 0 7.613346679136157e-05
. O 0 3.2797720450616907e-06

The O 0 2.1192513486312237e-06
missense O 0 8.376742334803566e-05
mutation O 0 4.48114333266858e-05
was O 0 4.733470632345416e-06
also O 0 5.981829787060633e-08
found O 0 7.562707082797715e-08
in O 0 7.650832145600361e-08
2 O 0 7.43776467970747e-07
. O 0 2.4870487322914414e-06

8 O 0 1.920883278216934e-06
% O 0 7.4162471719319e-08
of O 0 1.2341324628906136e-09
the O 0 3.4043983188070115e-09
general O 0 4.443926115982322e-09
population O 0 8.404891893576405e-09
, O 0 1.487543865863472e-09
suggesting O 0 2.433725221351324e-08
that O 0 1.685958594954684e-09
it O 0 1.56917767668574e-08
is O 0 2.7098224109067814e-08
not O 0 3.948626726923976e-06
disease O 0 2.1539678982662736e-06
associated O 0 1.552321805320389e-06
. O 0 2.8213889891048893e-06

The O 0 5.162515890333452e-07
average O 0 1.648958800615219e-06
age O 0 2.2129127330572373e-07
of O 0 1.848671615789499e-08
disease O 0 4.382449787954101e-06
onset O 0 6.13047859587823e-06
in O 0 1.0465069522069825e-07
those O 0 1.2575652874602383e-07
families O 0 2.1540365935379668e-07
harbouring O 0 0.000402973557356745
causative O 0 0.0018379759276285768
mutations O 0 0.0003451986995059997
was O 0 9.756365670909872e-07
between O 0 1.587127371749375e-07
32 O 0 1.1045893870686996e-06
. O 0 2.373896677454468e-06

3 O 0 2.7723106541088782e-05
and O 0 1.9532590158632956e-06
37 O 0 6.1562682276417036e-06
. O 0 5.4658398767060135e-06

4 O 0 3.494910060908296e-06
years O 0 4.651284655210475e-07
, O 0 1.56497215186846e-08
whereas O 0 5.117223622619349e-08
the O 0 1.0006942829932086e-08
family O 0 1.0300112762706704e-07
harbouring O 0 2.458575409036712e-06
the O 0 1.527839366133321e-08
missense O 0 4.558151886158157e-06
mutation O 0 2.6366901693108957e-06
had O 0 1.5239807282796392e-07
an O 0 4.235137573971315e-09
average O 0 1.7905202298607037e-07
age O 0 9.308233472893335e-08
of O 0 1.0249018522756614e-08
onset O 0 5.936279649176868e-06
of O 0 1.251458883189116e-07
51 O 0 6.69946666675969e-06
. O 0 5.02316879646969e-06

2 O 0 6.347968155751005e-05
years O 0 2.1779844246339053e-05
. O 0 1.3486856914823875e-05

These O 0 7.323696422645298e-07
findings O 0 5.616981297862367e-07
show O 0 1.805369009844071e-07
that O 0 2.0793855526335392e-08
BRCA1 O 0 1.8731659565673908e-06
is O 0 1.4323023656004352e-08
implicated O 0 1.5805598252427444e-07
in O 0 4.653234242368853e-09
a O 0 2.7321478413000477e-09
small O 0 1.183526787684741e-08
fraction O 0 1.7516839534437167e-07
of O 0 2.1242603054361098e-07
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4238318613024603e-07
suggesting O 0 4.5842023155273637e-07
the O 0 1.635132207411516e-08
involvement O 0 1.2521275039034663e-07
of O 0 9.212675067260534e-09
another O 0 1.1495538387862325e-07
susceptibility O 0 9.080094059754629e-06
gene O 0 1.3289270100358408e-05
( O 0 7.144687970139785e-07
s O 0 0.0005908737075515091
) O 0 1.1086885024269577e-05

Paternal O 0 0.0007551852613687515
transmission O 0 0.0135493203997612
of O 0 2.3371429051621817e-05
congenital B-Disease 1 0.9999984502792358
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
. O 0 0.0005045215366408229

We O 0 7.4187046266160905e-06
report O 0 2.0983068793611892e-07
a O 0 2.4741074966527776e-08
rare O 0 8.176503030199456e-08
case O 0 1.4022440097960498e-07
of O 0 8.46438794610549e-08
paternally O 0 0.0853058397769928
transmitted O 1 0.9519466161727905
congenital B-Disease 1 0.9999980926513672
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.0002648282970767468
DM B-Disease 1 1.0
) O 0 1.3441941518976819e-05
. O 0 8.527278623660095e-06

The O 0 3.053606576486345e-07
proband O 0 4.6503005250997376e-06
is O 0 1.428864226937776e-08
a O 0 1.1016457968082705e-08
23 O 0 1.3843903801102897e-08
year O 0 1.61925122199591e-08
old O 0 6.154081688691804e-07
, O 0 1.426865878784156e-07
mentally B-Disease 1 0.9999988079071045
retarded I-Disease 1 0.9999637603759766
male O 0 0.0002672717091627419
who O 0 3.906256824848242e-05
suffers O 1 0.9425001740455627
severe O 1 0.7332578897476196
muscular B-Disease 1 0.7258346080780029
weakness I-Disease 1 0.9398773312568665
. O 0 2.3138658434618264e-05

He O 0 2.0826264517381787e-06
presented O 0 1.866710590547882e-07
with O 0 7.230452325757142e-08
respiratory O 0 0.0007916318718343973
and O 0 3.375421329110395e-07
feeding O 0 3.7556631014012964e-06
difficulties O 0 2.57887841144111e-05
at O 0 5.367592734728532e-07
birth O 0 4.910187271889299e-06
. O 0 2.8541512619995046e-06

His O 0 1.2919490472995676e-05
two O 0 4.588852789311204e-06
sibs O 0 0.3194807469844818
suffer O 0 0.0016780138248577714
from O 0 1.8844575606635772e-06
childhood O 0 0.0002818235952872783
onset O 1 0.8851617574691772
DM B-Disease 1 1.0
. O 0 0.00012424064334481955

Their O 0 6.390839644154767e-07
late O 0 6.001337169436738e-07
father O 0 1.7211550584761426e-07
had O 0 5.736453800864183e-08
the O 0 5.518658419134681e-09
adult O 0 1.2515567959781038e-07
type O 0 3.672525053843856e-06
of O 0 3.073267507147648e-08
DM B-Disease 1 1.0
, O 0 6.304792776745671e-08
with O 0 1.302560015403742e-08
onset O 0 3.0740909551241202e-06
around O 0 9.16546198936885e-08
30 O 0 1.454320113225549e-07
years O 0 5.860673013557971e-07
. O 0 1.8598476572151412e-06

Only O 0 3.1988827231543837e-07
six O 0 4.9255241663104243e-08
other O 0 1.0447156917336997e-08
cases O 0 3.049432706347943e-08
of O 0 5.037674277730275e-09
paternal O 0 1.4432655007112771e-05
transmission O 0 0.025096336379647255
of O 0 4.34776325164421e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.19522276520729065
been O 0 0.00011561135033844039
reported O 0 1.2798796888091601e-05
recently O 0 4.430013177625369e-06
. O 0 2.2124872884887736e-06

We O 0 3.1423394375451608e-06
review O 0 2.895086765875021e-07
the O 0 1.586978370937686e-08
sex O 0 1.6979878125766845e-07
related O 0 1.151219208850307e-07
effects O 0 1.030597445605963e-06
on O 0 1.1843412295320377e-07
transmission O 0 0.00017239953740499914
of O 0 1.6264871192106511e-06
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 1.0
. O 0 0.00011792268924182281

Decreased O 0 8.544373122276738e-05
fertility O 0 3.5543202102417126e-05
of O 0 4.356927618687223e-08
males O 0 4.407104654546856e-07
with O 0 2.6876886494164864e-08
adult O 0 7.920804819150362e-06
onset O 0 0.3267483711242676
DM B-Disease 1 1.0
and O 0 1.993907972064335e-06
contraction O 0 4.144291381180665e-07
of O 0 2.329551218593906e-09
the O 0 5.64222846222151e-09
repeat O 0 7.618881454618531e-07
upon O 0 1.2766475876446748e-08
male O 0 4.95375118703123e-08
transmission O 0 1.409021592735371e-07
contribute O 0 8.599958079003045e-09
to O 0 2.0897978902922887e-09
the O 0 3.2329849908308006e-09
almost O 0 1.60434119322872e-08
absent O 0 1.426770666057564e-07
occurrence O 0 3.528627416926611e-07
of O 0 1.6029831684249984e-08
paternal O 0 1.71846058947267e-05
transmission O 0 0.12129733711481094
of O 0 1.017819613480242e-05
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
. O 0 0.00017426545673515648

Also O 0 6.657333528892195e-07
the O 0 2.688724087818173e-08
fathers O 0 7.972939641831545e-08
of O 0 1.2805415616767846e-09
the O 0 9.755835250757627e-09
reported O 0 9.14082534109184e-07
congenitally O 0 4.340846317063551e-06
affected O 0 1.4033196293894434e-07
children O 0 2.6888267612434902e-08
showed O 0 4.5722782004986584e-08
, O 0 1.5910508466276951e-09
on O 0 4.405291242903786e-09
average O 0 5.534283076258362e-08
, O 0 8.480884439165948e-09
shorter O 0 7.263238330779132e-07
CTG O 0 3.9256665331777185e-06
repeat O 0 8.217925824283157e-07
lengths O 0 1.2998382317164214e-06
and O 0 1.502128377239842e-08
hence O 0 4.806297226878087e-08
less O 0 8.004710139175586e-08
severe O 0 0.0002956282696686685
clinical O 0 0.006421202328056097
symptoms O 0 2.1334990378818475e-06
than O 0 1.1150569356743745e-08
the O 0 1.6942212965886938e-08
mothers O 0 1.980921808808489e-07
of O 0 5.84869930264631e-09
children O 0 2.1832136098964838e-07
with O 0 3.2713010114093777e-06
congenital B-Disease 1 0.9999991655349731
DM I-Disease 1 1.0
. O 0 0.00016959158529061824

We O 0 7.17067359801149e-06
conclude O 0 1.249097408617672e-06
that O 0 3.601363829375259e-08
paternal O 0 1.1313102277199505e-06
transmission O 0 3.9074420783435926e-05
of O 0 2.6658858587325085e-07
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
is O 0 1.8139253370463848e-06
rare O 0 1.853442057608845e-07
and O 0 2.26259579960697e-08
preferentially O 0 2.6510141992730496e-07
occurs O 0 2.806805454724781e-08
with O 0 8.536044759921424e-09
onset O 0 8.52867401590629e-07
of O 0 1.9261607420162363e-08
DM B-Disease 1 1.0
past O 0 1.0865147714866907e-06
30 O 0 2.9429603642938673e-08
years O 0 1.2730998477650246e-08
in O 0 7.197934692726449e-09
the O 0 2.6306413047905153e-08
father O 0 4.990005209037918e-07
. O 0 1.950885746282438e-07
. O 0 1.4746846090929466e-06

The O 0 5.440886980068171e-06
RB1 O 0 0.00016855115245562047
gene O 0 4.8747465370979626e-06
mutation O 0 6.112247319833841e-06
in O 0 5.7230110428463377e-08
a O 0 1.052237266208067e-07
child O 0 6.025370112183737e-06
with O 0 1.724195726637845e-06
ectopic B-Disease 1 0.9999984502792358
intracranial I-Disease 1 0.9999966621398926
retinoblastoma I-Disease 1 0.9940871000289917
. O 0 8.137019904097542e-05

The O 0 7.774296136631165e-06
RB1 O 0 0.00025016290601342916
gene O 0 8.326125680468976e-06
mutation O 0 1.488095131207956e-05
was O 0 6.791163400521327e-07
investigated O 0 1.5478368595722714e-06
in O 0 2.4964720068965107e-08
a O 0 7.415879821337512e-08
child O 0 2.9833386179234367e-06
with O 0 3.225269722406665e-07
ectopic B-Disease 1 0.9999749660491943
intracranial I-Disease 1 0.9927243590354919
retinoblastoma I-Disease 0 1.3661368029715959e-05
using O 0 3.5293106748213177e-07
DNA O 0 1.8340966789764934e-06
obtained O 0 1.3101612239552196e-07
from O 0 5.006418835051818e-09
both O 0 8.032801979140913e-09
the O 0 2.261245413137658e-08
pineal B-Disease 0 5.537267497857101e-06
and I-Disease 0 3.0368373700184748e-06
retinal I-Disease 1 0.9480394721031189
tumours I-Disease 1 1.0
of O 0 4.339494452665349e-08
the O 0 1.193031948787393e-06
patient O 0 2.361140650464222e-05
. O 0 3.4321303701290162e-06

A O 0 1.036695084621897e-05
nonsense O 0 1.8575929061626084e-05
mutation O 0 8.69506493472727e-06
in O 0 1.1206478234271344e-07
exon O 0 2.889971483455156e-06
17 O 0 1.4322455399451428e-07
( O 0 1.2868691889877937e-08
codon O 0 2.499948834611132e-07
556 O 0 1.0885169388075155e-07
) O 0 5.042509521047123e-09
of O 0 1.2934929793928518e-09
the O 0 9.678696066828252e-09
RB1 O 0 2.11665383176296e-06
gene O 0 1.0283387297249647e-07
was O 0 1.6129760638250445e-07
found O 0 9.865299688271989e-09
to O 0 2.3763133683019078e-09
be O 0 2.166846035933645e-09
present O 0 2.341252969273455e-09
homozygously O 0 1.3700005183636677e-06
in O 0 6.714551581410433e-09
both O 0 1.4977397100324197e-08
the O 0 2.5110901802349872e-08
retinal B-Disease 0 1.1108390026492998e-05
and I-Disease 0 8.672404874232598e-07
the I-Disease 0 1.5740361050120555e-06
pineal I-Disease 0 0.020349115133285522
tumours I-Disease 1 0.9999998807907104
. O 0 1.2419997801771387e-05

The O 0 3.12183487949369e-07
same O 0 1.1343616534986722e-07
mutation O 0 5.684569259756245e-07
was O 0 3.294507422424431e-08
present O 0 4.59314897227614e-09
heterozygously O 0 7.867344606893312e-07
in O 0 7.597606099807308e-09
the O 0 2.493719897245228e-09
DNA O 0 3.9949520669324556e-07
from O 0 1.4959516958512609e-09
the O 0 1.801202298423732e-09
constitutional O 0 1.670753668747693e-08
cells O 0 2.8178339661621976e-08
of O 0 4.0128519951387887e-10
the O 0 4.029266698069023e-09
patient O 0 5.2930417382413e-08
, O 0 1.5606909098409005e-09
proving O 0 8.302745868604688e-08
it O 0 4.690991595168725e-09
to O 0 4.055326741081444e-09
be O 0 6.9008962988448275e-09
of O 0 5.674000380651023e-09
germline O 0 6.4310170273529366e-06
origin O 0 1.8956601479658275e-06
. O 0 2.386082769589848e-06

The O 0 4.036969869503082e-07
initial O 0 1.6129173445733613e-06
mutation O 0 2.810277010212303e-06
was O 0 1.5451836077318148e-07
shown O 0 3.095210487913391e-08
to O 0 1.145366557153693e-08
have O 0 2.199467630248364e-08
occurred O 0 1.0031885011585473e-07
in O 0 4.1907437520194435e-08
the O 0 1.9721397848115885e-07
paternally O 0 4.0879411244532093e-05
derived O 0 6.125465006334707e-06
RB1 O 0 0.00032140102121047676
allele O 0 6.866864714538679e-05
. O 0 4.73060026706662e-06

The O 0 2.445715381327318e-07
mutation O 0 1.5062846614455339e-06
is O 0 1.3534331877451677e-08
in O 0 9.546469392773815e-09
an O 0 3.0016047425363013e-09
area O 0 3.6639846712205326e-08
of O 0 7.720206141037522e-10
the O 0 5.621668464073082e-09
gene O 0 3.659556568891276e-08
that O 0 2.2501527308094182e-09
encodes O 0 1.2905167601218182e-08
the O 0 4.252621810252322e-09
protein O 0 5.489905774425097e-08
- O 0 1.2888818901046761e-06
binding O 0 8.798750883443063e-08
region O 0 2.5004084136526217e-08
known O 0 1.515411973684877e-08
as O 0 3.2476012989945957e-09
the O 0 5.203786734853111e-09
pocket O 0 0.04454928636550903
region O 0 1.459715690543817e-07
and O 0 9.06379682419356e-08
has O 0 5.929485524802658e-08
been O 0 4.3007258199168064e-08
detected O 0 2.640177569901425e-07
in O 0 5.692058824280366e-09
other O 0 6.474772273890039e-09
cases O 0 4.550137333581006e-08
of O 0 1.320153319994688e-08
retinoblastoma B-Disease 0 1.2318152585066855e-05
. O 0 7.728477271484735e-07
. O 0 3.140607759632985e-06

Low O 0 0.0033313895110040903
levels O 0 2.66207257482165e-06
of O 0 1.0676825645816734e-08
beta O 0 1.4585523899768305e-07
hexosaminidase O 0 8.193830467462249e-07
A O 0 2.7448102457583445e-08
in O 0 1.570345276036278e-08
healthy O 0 4.9310415306536015e-08
individuals O 0 1.6334396946149354e-08
with O 0 3.675021886806462e-08
apparent O 1 0.7246785759925842
deficiency O 1 0.9289166927337646
of O 0 1.2833394791300634e-08
this O 0 1.437908849766245e-07
enzyme O 0 1.4776672287553083e-05
. O 0 4.410297606227687e-06

Appreciable O 0 0.0002473924832884222
beta O 0 3.349250619066879e-05
hexosaminidase O 0 0.000131817432702519
A O 0 5.006134529139672e-07
( O 0 2.4166011414195054e-08
hex O 0 6.645192911491904e-07
A O 0 2.9540785817516735e-08
) O 0 9.191507110983821e-09
activity O 0 2.080869698772858e-08
has O 0 1.5942747566555227e-08
been O 0 3.211090060517563e-08
detected O 0 1.9402132522827742e-07
in O 0 1.201541000028783e-08
cultured O 0 1.4025839618625469e-06
skin O 0 6.777115049771965e-05
fibroblasts O 0 1.4346832131195697e-06
and O 0 9.50627793372405e-07
melanoma B-Disease 0 0.08398841321468353
tissue O 0 2.5590311452106107e-06
from O 0 8.740737911239194e-09
healthy O 0 4.894917537967558e-08
individuals O 0 4.2721821635893775e-09
previously O 0 2.831330334629456e-07
reported O 0 1.491876901127398e-06
as O 0 1.5768982564168255e-07
having O 0 0.22081851959228516
deficiency B-Disease 0 0.015547383576631546
of I-Disease 0 3.412218951837076e-09
hex I-Disease 0 2.678840246517211e-06
A I-Disease 0 9.633151165644449e-09
activity O 0 1.5512039652776366e-08
indistinguishable O 0 2.5505416445525952e-08
from O 0 6.265168384089748e-10
that O 0 9.522133082029427e-10
of O 0 1.6816068537650608e-09
patients O 0 2.6941972919303225e-07
with O 0 8.068407623795792e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.4551050662994385
( O 0 3.2112743042489456e-07
TSD B-Disease 0 0.00021576315339189023
) O 0 4.899330861007911e-07
. O 0 1.6339745343429968e-06

Identification O 0 4.9631885303824674e-06
and O 0 2.9148560543035273e-07
quantitation O 0 2.2545014871866442e-05
of O 0 2.1701229258042076e-08
hex O 0 3.208958560207975e-06
A O 0 5.9504682070610215e-08
, O 0 1.034955765533141e-08
amounting O 0 5.6733210129777945e-08
to O 0 5.231046174003495e-08
3 O 0 3.149760345877439e-07
. O 0 1.243058250111062e-06

5 O 0 3.879398718709126e-05
% O 0 4.2421311263751704e-06
- O 0 0.0001224915322382003
6 O 0 4.399669251142768e-06
. O 0 2.8317617761786096e-06

9 O 0 3.6758465284947306e-06
% O 0 1.3160972400783066e-07
of O 0 3.38877903516277e-09
total O 0 5.980731909716042e-09
beta O 0 1.0993646526458178e-07
hexosaminidase O 0 1.6595049601164646e-06
activity O 0 8.95145291224253e-08
, O 0 8.739737822338611e-09
has O 0 6.262709906224018e-09
been O 0 1.1580061354266036e-08
obtained O 0 3.625548572472326e-08
by O 0 2.554431688395198e-08
cellulose O 0 8.19201613921905e-06
acetate O 0 3.3371607059962116e-06
gel O 0 0.00012498126307036728
electrophoresis O 0 4.678096956922673e-06
, O 0 2.5995470664952336e-08
DEAE O 0 3.279121756349923e-06
- O 0 1.0904979035331053e-06
cellulose O 0 3.494390284686233e-06
ion O 0 1.2237268265380408e-06
- O 0 1.1528796903803595e-06
exchange O 0 3.761635127830232e-07
chromatography O 0 1.585422410244064e-06
, O 0 1.3949555288661486e-08
radial O 0 5.48919331322395e-07
immunodiffusion O 0 2.622165993670933e-06
, O 0 3.838534112787784e-08
and O 0 1.2725953979497717e-07
radioimmunoassay O 0 2.018967643380165e-05
. O 0 1.6026733646867797e-06

Previous O 0 1.4766613276151475e-05
family O 0 1.0630280939949444e-06
studies O 0 2.59217046050253e-07
suggested O 0 7.725191863983127e-08
that O 0 2.541570953695782e-09
these O 0 1.7857031409107549e-09
individuals O 0 4.258327912509685e-09
may O 0 2.087134198802687e-08
be O 0 3.463164865991075e-09
compound O 0 5.67505296089621e-08
heterozygotes O 0 5.487534053827403e-07
for O 0 4.54365656210598e-09
the O 0 7.786847611157555e-09
common O 0 1.0109814496672698e-07
mutant O 0 6.227008952919277e-07
TSD B-Disease 0 7.122861916286638e-06
gene O 0 7.04027513620531e-07
and O 0 5.4134591920274033e-08
a O 0 4.081136850686562e-08
rare O 0 3.0125184480311873e-07
( O 0 6.874007851820352e-08
allelic O 0 4.33002151112305e-06
) O 0 1.8361619424922537e-07
mutant O 0 3.7536333366006147e-06
gene O 0 1.3435545952233952e-05
. O 0 6.770044819859322e-06

Thus O 0 6.655596280324971e-06
, O 0 7.071047036788514e-08
the O 0 1.8759475750584897e-08
postulated O 0 3.9444537947019853e-07
rate O 0 1.4205387799393066e-07
mutant O 0 1.3072445881334716e-07
gene O 0 7.277508018432854e-08
appears O 0 4.098141559438773e-08
to O 0 1.6722896400978016e-09
code O 0 2.6538578001833457e-09
for O 0 7.087405662353774e-10
the O 0 7.780874833329676e-10
expression O 0 5.305278438783034e-09
of O 0 1.556181628004083e-09
low O 0 4.868074938713107e-07
amounts O 0 6.52413802981755e-08
of O 0 1.4393570779702713e-08
hex O 0 4.091873051947914e-06
A O 0 4.416925492023438e-07
. O 0 2.2187437025422696e-06

Heterozygotes O 0 5.951269486104138e-05
for O 0 1.2098662693915685e-07
the O 0 2.0188069882465243e-08
rare O 0 7.352893760526058e-08
mutant O 0 7.984625085555308e-07
may O 0 1.4293676997567673e-07
be O 0 4.8682302633551444e-09
indistinguishable O 0 7.528698375836029e-08
from O 0 5.447148954118575e-09
heterozygotes O 0 4.4548124833454494e-07
for O 0 1.3720196534450224e-08
the O 0 7.363616560951414e-08
common O 0 1.82809810667095e-06
TSD B-Disease 0 0.0003460885782260448
mutant O 0 3.759031824301928e-05
. O 0 4.579156666295603e-06

However O 0 1.2302409686526516e-06
, O 0 1.8035546389683077e-08
direct O 0 2.1736441979669507e-08
visualization O 0 3.8474775010399753e-07
and O 0 3.152575800413615e-08
quantitation O 0 1.0924954949587118e-05
of O 0 5.574654959872305e-09
hex O 0 5.0631929298106115e-06
A O 0 1.606245625396241e-08
by O 0 2.4495485639874914e-09
the O 0 3.790361802202824e-09
methods O 0 1.150907792180078e-06
described O 0 3.5406850429353653e-07
may O 0 2.0748304052631283e-07
prevent O 0 8.860828870638215e-08
false O 0 1.8783649124998192e-07
- O 0 9.646480521041667e-07
positive O 0 7.85542653147786e-08
prenatal O 0 1.9882641936419532e-05
diagnosis O 0 3.449084488238441e-06
of O 0 3.439453610809551e-09
TSD B-Disease 0 4.1064308788918424e-06
in O 0 3.7590240253848606e-08
fetuses O 0 4.698436532635242e-05
having O 0 1.5380413742605015e-07
the O 0 6.323819246034645e-09
incomplete O 0 2.0249895271717833e-07
hex B-Disease 0 0.00456702196970582
A I-Disease 0 2.189543010899797e-06
deficiency I-Disease 0 0.0002804793475661427
of O 0 1.6980541417410677e-09
the O 0 1.1341903416450805e-08
type O 0 8.623855683254078e-05
described O 0 8.810705480755132e-07
in O 0 2.8383803751808045e-08
the O 0 3.3902352924997103e-08
four O 0 2.5174114171022666e-07
healthy O 0 2.4142852907971246e-06
individuals O 0 2.0774568838533014e-06

The O 0 3.270421302659088e-06
tumor B-Disease 0 3.668975114123896e-05
suppressor O 0 1.587544466019608e-05
gene O 0 6.402292001439491e-06
Smad4 O 0 3.0452240025624633e-05
/ O 0 4.718516265711514e-06
Dpc4 O 0 5.4718275350751355e-06
is O 0 1.6588145967944e-08
required O 0 1.3786617181210659e-08
for O 0 1.879266520177225e-09
gastrulation O 0 1.2618542655218334e-07
and O 0 1.7293118048655742e-08
later O 0 1.193426442114287e-07
for O 0 1.3169969115267577e-08
anterior O 0 2.013529956457205e-05
development O 0 3.369445167322738e-08
of O 0 7.474539209795239e-09
the O 0 7.03079550135044e-08
mouse O 0 1.2461354344850406e-05
embryo O 0 2.9995804652571678e-05
. O 0 5.187202987144701e-06

Mutations O 0 0.00043157284380868077
in O 0 8.875838375388412e-07
the O 0 3.0838319275972026e-07
SMAD4 O 0 0.0002491797786206007
/ O 0 9.948462320608087e-06
DPC4 O 0 6.95132912369445e-05
tumor B-Disease 0 5.397145741881104e-06
suppressor O 0 2.2223416635824833e-06
gene O 0 1.2406113683027797e-06
, O 0 2.5941087500314097e-08
a O 0 8.849576182967667e-09
key O 0 1.118000554356513e-07
signal O 0 2.1798348370793974e-07
transducer O 0 3.164893769280752e-07
in O 0 1.2053605225048614e-08
most O 0 2.379716157463463e-08
TGFbeta O 0 4.974692637915723e-05
- O 0 1.1098245522589423e-05
related O 0 7.083141184693886e-08
pathways O 0 5.724758267433572e-08
, O 0 1.3621366257154932e-09
are O 0 6.244993411286259e-10
involved O 0 3.267116355232247e-09
in O 0 5.588729479200083e-09
50 O 0 2.4033855794414194e-08
% O 0 2.3147766370357203e-08
of O 0 7.910787758191873e-08
pancreatic B-Disease 1 0.9999535083770752
cancers I-Disease 1 0.999964714050293
. O 0 5.899134521314409e-06

Homozygous O 0 0.0009074766421690583
Smad4 O 0 0.0002991938672494143
mutant O 0 6.225272227311507e-05
mice O 0 0.0006869268254376948
die O 0 0.00034708777093328536
before O 0 5.819791795147466e-07
day O 0 3.005478959039465e-07
7 O 0 7.956272725095914e-07
. O 0 1.908089870994445e-06

5 O 0 8.7813141362858e-06
of O 0 6.38944982256362e-07
embryogenesis O 0 7.084232493070886e-05
. O 0 1.754564254952129e-05

Mutant O 0 2.0306655642343685e-05
embryos O 0 7.123201157810399e-06
have O 0 2.879888540974207e-07
reduced O 0 1.938352909292007e-07
size O 0 2.605554243473307e-07
, O 0 1.9300809839251087e-08
fail O 0 4.043510671181139e-06
to O 0 5.855195883697206e-09
gastrulate O 0 2.763925749604823e-06
or O 0 1.5610555692546768e-07
express O 0 7.521966693957438e-08
a O 0 1.3668479681427925e-08
mesodermal O 0 2.869771378755104e-06
marker O 0 6.124027549958555e-06
, O 0 1.7197301360738493e-08
and O 0 3.1210753093091625e-08
show O 0 1.4677003719043569e-06
abnormal O 0 5.921431693423074e-06
visceral O 0 8.721615813556127e-06
endoderm O 0 0.00026676920242607594
development O 0 4.168306077190209e-06
. O 0 6.94387563271448e-06

Growth B-Disease 1 0.9999973773956299
retardation I-Disease 1 0.9999605417251587
of O 0 2.7796984269912173e-08
the O 0 5.98173812704772e-08
Smad4 O 0 0.00027788785519078374
- O 0 0.0006007493939250708
deficient O 0 1.2054559192620218e-05
embryos O 0 3.202851246442151e-07
results O 0 8.105912741029897e-08
from O 0 4.201057279829001e-09
reduced O 0 1.1027458413082059e-07
cell O 0 5.390556452766759e-06
proliferation O 0 4.078682422914426e-07
rather O 0 4.009283216532822e-08
than O 0 2.0503403419525057e-08
increased O 0 1.8353267705606413e-07
apoptosis O 0 1.9245910607423866e-06
. O 0 2.4242244762717746e-06

Aggregation O 0 5.802139639854431e-05
of O 0 6.59299530525459e-07
mutant O 0 2.4246075554401614e-05
Smad4 O 0 7.296968396985903e-05
ES O 0 9.936306923918892e-06
cells O 0 1.0665640957085998e-06
with O 0 3.988704477819738e-08
wild O 0 3.757300817142095e-07
- O 0 9.263182437280193e-05
type O 0 1.7677806681604125e-05
tetraploid O 0 6.264157855184749e-05
morulae O 0 8.672925468999892e-05
rescues O 0 1.2628220247279387e-05
the O 0 3.7586622170238115e-07
gastrulation B-Disease 0 7.001511403359473e-05
defect I-Disease 0 0.00011532353528309613
. O 0 4.481201813177904e-06

These O 0 7.961684787005652e-07
results O 0 1.0828611038959934e-06
indicate O 0 2.075986316185663e-07
that O 0 7.273688762410302e-09
Smad4 O 0 3.65499516874479e-07
is O 0 5.347684073342407e-09
initially O 0 1.0093548219458626e-08
required O 0 3.3983584835084457e-09
for O 0 6.71831423826319e-10
the O 0 6.230906346438303e-10
differentiation O 0 6.811969655018402e-09
of O 0 1.0891160195924954e-09
the O 0 5.290232696353314e-09
visceral O 0 1.3365919926400238e-07
endoderm O 0 9.851820323092397e-06
and O 0 3.6068840358893794e-08
that O 0 3.2360571999845433e-09
the O 0 6.8065411085171945e-09
gastrulation B-Disease 0 5.177938646738767e-07
defect I-Disease 0 8.256930073002877e-07
in O 0 7.310239968916221e-09
the O 0 9.761604857772e-09
epiblast O 0 1.025792516884394e-05
is O 0 3.402056947265919e-08
secondary O 0 4.23160315676796e-07
and O 0 9.267807854485e-08
non O 0 1.8602557929625618e-06
- O 0 3.52995193679817e-05
cell O 0 1.4969212315918412e-05
autonomous O 0 3.3014446216839133e-06
. O 0 3.6880310290143825e-06

Rescued O 0 4.751397136715241e-05
embryos O 0 1.602333395567257e-05
show O 0 3.062296173084178e-06
severe O 0 1.8579685274744406e-05
anterior O 0 0.00011700298637151718
truncations O 0 4.703013109974563e-05
, O 0 8.79395329889121e-08
indicating O 0 2.6703719413490035e-07
a O 0 2.2937946653200925e-08
second O 0 1.1398662991268793e-07
important O 0 1.886313150123442e-08
role O 0 5.098682720472425e-08
for O 0 1.7143264585683937e-08
Smad4 O 0 8.131964932545088e-06
in O 0 1.4243805424030143e-07
anterior O 0 3.476094934740104e-05
patterning O 0 0.00022484597866423428
during O 0 4.063520009367494e-06
embryogenesis O 0 3.7060457543702796e-05
. O 0 9.856528777163476e-06

Prevalence O 0 0.0013887666864320636
of O 0 3.43788542522816e-07
p16 O 0 1.752846765157301e-05
and O 0 4.774163926413166e-07
CDK4 O 0 6.917716382304206e-05
germline O 0 9.844124724622816e-05
mutations O 0 3.391622522030957e-05
in O 0 3.5589187064033467e-07
48 O 0 3.452678129178821e-06
melanoma B-Disease 1 0.9994679093360901
- O 1 0.8938261270523071
prone O 0 0.28359219431877136
families O 0 1.0480705441295868e-06
in O 0 7.825799457350513e-07
France O 0 7.634081703145057e-05
. O 0 6.659558039245894e-06

The O 0 1.9059756596107036e-05
French O 0 0.00039697784814052284
Familial B-Disease 1 0.7248084545135498
Melanoma I-Disease 1 0.9997854828834534
Study O 0 1.3111343832861166e-05
Group O 0 3.3231899578822777e-06
. O 0 3.445366019150242e-06

Germline O 0 0.0022054517176002264
mutations O 0 0.00013353099348023534
in O 0 1.2361006440642086e-07
the O 0 1.6685689274709148e-08
p16 O 0 4.895314305031206e-07
and O 0 2.5636417433361203e-08
CDK4 O 0 1.641865992496605e-06
genes O 0 8.955944963418005e-08
have O 0 2.165682033705707e-08
been O 0 8.309812216111823e-08
reported O 0 7.392775103198801e-08
in O 0 2.7962399062886334e-09
a O 0 3.0359323943685013e-09
subset O 0 5.450654327887605e-08
of O 0 1.0319891607935006e-08
melanoma B-Disease 0 0.3228299021720886
pedigrees O 0 7.720882422290742e-06
, O 0 2.5763378985743657e-08
but O 0 5.80786050363713e-08
their O 0 3.992814612274742e-08
prevalence O 0 0.0003591487475205213
is O 0 5.2852733745112346e-08
not O 0 7.876010243990095e-08
well O 0 8.200711931749538e-08
known O 0 8.27553492399602e-07
. O 0 2.0642864910769276e-06

We O 0 1.149101535702357e-06
searched O 0 1.0425558230053866e-06
for O 0 9.866297112637312e-09
such O 0 1.1918768194618679e-08
germline O 0 6.057531663827831e-06
mutations O 0 1.5944335700623924e-06
in O 0 4.390245322838382e-08
48 O 0 3.4409194427098555e-07
French O 0 0.00016326810873579234
melanoma B-Disease 1 0.9998468160629272
- O 0 0.4541907012462616
prone O 0 0.0059604523703455925
families O 0 1.3991685143821542e-08
selected O 0 4.239631312685788e-09
according O 0 1.770107505016938e-09
to O 0 1.245937020222243e-09
two O 0 1.42193079533115e-09
major O 0 2.4398604026032444e-08
criteria O 0 2.272028325478459e-07
families O 0 1.7315948674934134e-09
with O 0 8.765526637866117e-10
at O 0 5.001840008844738e-08
least O 0 4.124369734626043e-09
three O 0 6.520266992993129e-09
affected O 0 2.908473994978067e-08
members O 0 3.3580105363029134e-09
( O 0 1.2507014313101195e-09
n O 0 4.815454985873657e-07
= O 0 5.394467166297545e-07
20 O 0 3.625719280364592e-09
) O 0 1.2660091863736511e-09
or O 0 4.438419853869391e-09
families O 0 1.7729424595103183e-09
with O 0 4.691069754869659e-10
two O 0 1.2409760330456265e-08
affected O 0 2.2171157354478055e-08
members O 0 9.64618163123987e-10
, O 0 7.186202188869117e-10
one O 0 3.573518425614708e-10
of O 0 1.0658034177435383e-10
them O 0 1.4226795297389572e-09
affected O 0 3.6530554137215177e-09
before O 0 3.584278207569014e-09
the O 0 1.1796812415809654e-09
age O 0 3.757782085500594e-09
of O 0 5.535354397068204e-10
50 O 0 3.6765557265283633e-09
( O 0 1.2623007084044957e-09
n O 0 1.5305072338378523e-06
= O 0 7.97175925981719e-06
28 O 0 1.9617584001707655e-08
) O 0 1.496824997282431e-09
, O 0 7.390442147148235e-10
and O 0 3.0975118026077553e-09
one O 0 9.458150707075674e-09
additional O 0 4.449203316880812e-08
minor O 0 1.7420228459741338e-06
criterion O 0 1.4463520528806839e-05
. O 0 1.9633514511951944e-06

Sixteen O 0 1.0640541404427495e-05
different O 0 1.2617871334441588e-06
p16 O 0 1.844466896727681e-05
germline O 0 3.321165786474012e-05
mutations O 0 8.622218047094066e-06
were O 0 1.082855334288979e-07
found O 0 4.003193154744622e-08
in O 0 1.5176855328036254e-08
21 O 0 1.703953422804716e-08
families O 0 7.175673388815085e-09
, O 0 1.381722625204418e-09
while O 0 5.08875119820118e-09
one O 0 1.0474232148283136e-08
germline O 0 4.576336323225405e-06
mutation O 0 9.060829597729025e-07
, O 0 6.5635643586858805e-09
Arg24His O 0 2.625706940762029e-07
, O 0 9.40875999333457e-09
was O 0 1.6913453748657048e-07
detected O 0 4.0374547438659647e-07
in O 0 1.762787071868388e-08
the O 0 6.772549454581167e-08
CDK4 O 0 7.028019899735227e-05
gene O 0 6.6215984588779975e-06
. O 0 2.8060403565177694e-06

The O 0 4.442716772246058e-07
frequency O 0 1.4934770433683298e-06
of O 0 2.2336312355264454e-08
p16 O 0 1.7092858115574927e-06
gene O 0 5.59542968403548e-07
mutation O 0 4.972722535967478e-07
in O 0 1.5323454505278278e-08
our O 0 8.816654961663062e-09
sample O 0 2.3733882414944674e-08
( O 0 2.530363474306796e-09
44 O 0 4.680829501779726e-09
% O 0 5.533741909147238e-09
) O 0 1.746611189012981e-09
is O 0 1.6381002110321674e-09
among O 0 3.2155809126521717e-09
the O 0 6.000910879322419e-09
highest O 0 2.029939423664473e-05
rates O 0 3.0117222195258364e-05
yet O 0 1.7929124851434608e-07
reported O 0 8.949387364509676e-08
and O 0 5.410421444196345e-09
the O 0 7.064169249559882e-09
CDK4 O 0 1.547603460494429e-05
mutation O 0 8.434476939100932e-08
is O 0 9.361319497358522e-10
the O 0 2.5528570368749115e-09
second O 0 6.413430497786976e-08
mutation O 0 6.361869964166544e-07
detected O 0 4.0999796624419105e-07
in O 0 6.90402934822032e-09
this O 0 1.2061102339089302e-08
gene O 0 5.450809226204001e-07
worldwide O 0 1.453448248867062e-06
. O 0 2.5999645458796294e-06

In O 0 8.701865681359777e-07
summary O 0 4.6257690655693295e-07
, O 0 3.385227387298073e-08
our O 0 2.7267764934890693e-08
results O 0 8.923667138560631e-08
show O 0 4.5544354065896187e-08
frequent O 0 7.964231230062069e-08
involvement O 0 9.460733707555846e-08
of O 0 1.927968007464642e-09
the O 0 6.069956981491487e-09
p16 O 0 2.3746838451188523e-07
gene O 0 1.0632506786123486e-07
in O 0 5.27192263177767e-08
familial B-Disease 0 0.46486955881118774
melanoma I-Disease 1 0.9999420642852783
and O 0 1.5839201523704105e-06
confirm O 0 1.1810498108388856e-05
the O 0 1.0425161178773124e-08
role O 0 3.96400210433967e-08
of O 0 1.06864361804071e-09
the O 0 2.1165876162854147e-08
CDK4 O 0 6.438067885028431e-06
gene O 0 1.0461457122801221e-07
as O 0 2.1866803479042574e-08
a O 0 1.5855327717417822e-07
melanoma B-Disease 1 0.9812167882919312
- O 0 0.00018684309907257557
predisposing O 0 2.1190886400290765e-05
gene O 0 4.195353085378883e-06
. O 0 6.998376420597197e-07
. O 0 2.704101916606305e-06

Progression O 0 9.878428681986406e-05
of O 0 8.495384236084647e-07
somatic O 0 4.075539254699834e-05
CTG O 0 0.0001548770524095744
repeat O 0 1.871330096037127e-05
length O 0 1.2245147900102893e-06
heterogeneity O 0 5.448904630611651e-06
in O 0 9.815940416046942e-08
the O 0 6.799497498377605e-08
blood O 0 2.411788273093407e-06
cells O 0 5.202507054491434e-06
of O 0 8.909991606742551e-07
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
patients O 0 0.04905111715197563
. O 0 1.8122989786206745e-05

The O 0 1.0066105460282415e-06
genetic O 0 4.062136667926097e-06
basis O 0 2.3861616682552267e-07
of O 0 1.5096226491095877e-07
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999996423721313
( O 0 9.821455023484305e-06
DM B-Disease 1 1.0
) O 0 2.668928402727033e-07
is O 0 4.422094690426093e-09
the O 0 2.2971824442663547e-09
expansion O 0 2.9761974218445175e-08
of O 0 3.795310288268183e-09
an O 0 1.9229487335792328e-08
unstable O 0 7.942404772620648e-05
CTG O 0 6.34642674413044e-06
repeat O 0 4.93879724672297e-06
in O 0 2.2379468944677683e-08
the O 0 1.9986162058671653e-08
34 O 0 3.111001234401556e-08
UTR O 0 1.1214062851649942e-06
of O 0 6.623261938898395e-09
the O 0 2.0770873732089967e-07
DM B-Disease 1 0.9999791383743286
protein O 0 6.321361070149578e-07
kinase O 0 9.507066920377838e-07
gene O 0 7.278035241142788e-07
on O 0 2.8910056926179095e-07
chromosome O 0 2.9709297450608574e-05
19 O 0 2.2243264083954273e-06
. O 0 2.6478733161638957e-06

One O 0 8.949214702624886e-07
of O 0 8.528217243508607e-09
the O 0 8.090957237527618e-09
principal O 0 3.823226535359936e-08
features O 0 1.4756335708909774e-08
of O 0 2.687005506984974e-09
the O 0 3.036892906038702e-07
DM B-Disease 1 1.0
mutation O 0 7.060573989292607e-05
is O 0 7.203909024866562e-09
an O 0 2.6339483927273477e-09
extraordinarily O 0 1.3183588407628122e-06
high O 0 5.663450224346889e-07
level O 0 1.225629642220838e-08
of O 0 6.367229521409001e-10
somatic O 0 1.655799621858023e-07
mosaicism O 0 6.032332748873159e-06
, O 0 1.0504923153575874e-08
due O 0 2.4512416985089658e-08
to O 0 3.791048808210462e-09
an O 0 4.4388768216663266e-09
extremely O 0 2.931577398612717e-07
high O 0 1.6553796911011887e-07
degree O 0 1.248078689286558e-07
of O 0 4.4235286544846986e-09
somatic O 0 1.505107206867251e-06
instability O 0 1.4661951581729227e-06
both O 0 4.5148571103936774e-08
within O 0 1.5288099675103695e-08
and O 0 2.2804547583632484e-08
between O 0 3.103723145159165e-08
different O 0 1.7825740883381513e-07
tissues O 0 2.121654870279599e-05
. O 0 4.7815592552069575e-06

This O 0 1.0131238923349883e-06
instability O 0 2.1834853214386385e-06
appears O 0 2.803697327635746e-07
to O 0 2.2540801225545692e-08
be O 0 1.3425498046615303e-08
biased O 0 9.208655882275707e-08
towards O 0 4.824700639005641e-09
further O 0 2.4396915598856594e-09
expansion O 0 4.210828574713332e-09
and O 0 3.600757692012735e-09
continuous O 0 1.3113396590824777e-08
throughout O 0 1.3258714126607174e-08
the O 0 3.3633629215046312e-09
life O 0 2.4581885416097293e-09
of O 0 1.2660471282455177e-10
an O 0 4.790897123463367e-10
individual O 0 3.1535543065785987e-09
, O 0 6.783830164280857e-10
features O 0 7.74806085956925e-09
that O 0 2.2757097539738425e-08
could O 0 5.449777290778002e-06
be O 0 1.3588573821721184e-08
associated O 0 8.837060860855672e-09
with O 0 2.2514192732359106e-09
the O 0 2.6808637088038267e-08
progressive O 0 5.827611744280148e-07
nature O 0 6.028859900197858e-08
of O 0 1.1048126857815532e-08
the O 0 1.42855571994005e-06
disease O 0 4.806467404705472e-05
. O 0 1.6724377474020002e-06

Although O 0 1.9493638774292776e-06
increasing O 0 3.647073754109442e-07
measured O 0 6.234769784896343e-07
allele O 0 1.3283047337608878e-06
size O 0 2.765816589089809e-07
between O 0 5.381934897741303e-08
patients O 0 7.207031558209565e-07
clearly O 0 3.443617302423263e-08
correlates O 0 3.9682536367990906e-08
with O 0 3.3940119603670382e-09
an O 0 4.555197552491563e-09
increased O 0 1.0260542637752224e-07
severity O 0 1.2229917956574354e-05
of O 0 1.4496226441451654e-08
symptoms O 0 2.4081546143861488e-06
and O 0 2.4521069619254376e-08
an O 0 3.5007412524379333e-09
earlier O 0 2.004957877943525e-06
age O 0 2.4107546181539874e-08
of O 0 7.564402992876751e-10
onset O 0 6.952980129426578e-07
, O 0 1.709656083370703e-09
this O 0 6.303885191627501e-10
correlation O 0 9.390691957378294e-08
is O 0 4.3253618464689225e-09
not O 0 3.1037452608018157e-09
precise O 0 4.974391742962325e-08
and O 0 5.800462332672396e-09
measured O 0 6.745824521203758e-08
allele O 0 1.4872189524339774e-07
length O 0 1.7430684806640784e-07
cannot O 0 5.822245157105499e-07
be O 0 1.7440544564095717e-09
used O 0 5.793629132000433e-09
as O 0 7.667084189755258e-10
an O 0 8.563534881211865e-10
accurate O 0 9.325859764430788e-07
predictor O 0 1.3349630535230972e-05
of O 0 8.352553315660316e-09
age O 0 1.4635881484537094e-07
of O 0 4.532614283903058e-08
onset O 0 0.00013834929268341511
. O 0 7.106326393113704e-06

In O 0 7.805644486325036e-07
order O 0 7.791991407657406e-08
to O 0 1.4006503512575819e-08
further O 0 1.679447336755402e-08
characterize O 0 8.399669013670064e-07
the O 0 4.802484809829366e-08
dynamics O 0 2.522020622564014e-06
of O 0 1.41562964017794e-07
DM B-Disease 1 0.9999996423721313
CTG O 0 7.117765198927373e-05
repeat O 0 4.1907505874405615e-06
somatic O 0 9.062324011210876e-07
instability O 0 1.122836124523019e-06
, O 0 1.1092743612550748e-08
we O 0 9.540462642121383e-09
have O 0 3.794470515572357e-09
studied O 0 3.401576620376545e-08
repeat O 0 2.626425725793524e-07
length O 0 3.800107251095142e-08
changes O 0 1.704424690274209e-08
over O 0 4.8210124781178365e-09
time O 0 2.8525889206321153e-08
in O 0 4.394140518115819e-08
111 O 0 4.249642643117113e-06
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999979734420776
patients O 0 6.514851065730909e-06
with O 0 8.659493566653964e-09
varying O 0 2.6567340682959184e-07
clinical O 0 6.97317227604799e-05
severity O 0 0.0001160210813395679
and O 0 2.28327778017956e-07
CTG O 0 5.63627918381826e-06
repeat O 0 4.937770881952019e-06
size O 0 1.2580980524035112e-07
over O 0 1.4390304059475056e-08
time O 0 2.0089430563530186e-08
intervals O 0 8.647415938867198e-08
of O 0 4.346350834794066e-09
1 O 0 1.1482894279879474e-07
- O 0 9.233608579961583e-06
7 O 0 2.020494775933912e-07
years O 0 4.1129661099148507e-07
. O 0 1.4957719258745783e-06

We O 0 4.96606253364007e-06
have O 0 7.068134522114633e-08
found O 0 1.4168310968898368e-08
a O 0 2.4225994543769502e-09
direct O 0 1.2236465174453315e-08
progression O 0 2.412318735878216e-07
of O 0 1.5051733193160999e-09
the O 0 4.4681489619335935e-09
size O 0 8.978299348427754e-08
heterogeneity O 0 1.0438456143901931e-07
over O 0 5.385814016989343e-09
time O 0 4.809513676207189e-09
related O 0 7.677478208734101e-09
to O 0 4.055836999583562e-09
initial O 0 7.386080369542469e-08
CTG O 0 6.68319842134224e-07
repeat O 0 8.172027037289809e-07
size O 0 4.0191295624936174e-08
and O 0 1.7828953868814779e-09
the O 0 6.187029222282092e-10
time O 0 5.6606501708245105e-09
interval O 0 5.2458837274116377e-08
and O 0 1.0644576775575842e-08
always O 0 4.579286638772828e-08
biased O 0 5.129624014443834e-07
towards O 0 3.830299277751692e-08
further O 0 5.753525655904923e-08
expansion O 0 1.6986515447570127e-06
. O 0 2.4409741854469758e-06

Attempts O 0 5.075133685750188e-06
to O 0 1.9033578269045393e-07
mathematically O 0 6.343548761833517e-07
model O 0 1.4422320759877039e-07
the O 0 8.10267941631082e-09
dynamics O 0 2.744920948316576e-07
have O 0 5.528385216280185e-08
proved O 0 2.794024283048202e-07
only O 0 6.914282035808128e-09
partially O 0 1.035336708810064e-06
successful O 0 7.749216734964648e-08
suggesting O 0 2.8982901412177853e-08
that O 0 1.2333370991157722e-09
individual O 0 3.375373980318841e-09
specific O 0 1.3818683974875512e-08
genetic O 0 2.8249141337255423e-07
and O 0 8.57750421801029e-08
/ O 0 6.230151257113903e-07
or O 0 3.1073211630427977e-06
environmental O 0 3.812173474670999e-07
factors O 0 1.1103077213192591e-07
also O 0 1.662070125973969e-08
play O 0 2.500913964809115e-08
a O 0 1.1778427122521862e-08
role O 0 2.3065268806021777e-07
in O 0 9.682244694886322e-08
somatic O 0 6.929361916263588e-06
mosaicism O 0 0.00013490230776369572
. O 0 8.570435738874949e-07
. O 0 2.089206645905506e-06

Aspartylglucosaminuria B-Disease 1 0.9999806880950928
among O 0 2.470584149705246e-05
Palestinian O 0 0.00013865345681551844
Arabs O 0 0.00018013754743151367
. O 0 2.2934833395993337e-05

Aspartylglucosaminuria B-Disease 1 0.9999973773956299
( O 0 4.395496944198385e-05
AGU B-Disease 1 0.999998927116394
) O 0 2.2756844941795862e-07
is O 0 1.1596704041494377e-08
a O 0 3.144090499063168e-08
rare O 0 1.533563954581041e-05
disorder B-Disease 0 0.0009415169479325414
of I-Disease 0 7.550409186762863e-09
glycoprotein I-Disease 0 1.906113902805373e-05
metabolism I-Disease 0 0.003502514911815524
caused O 0 7.872712558310013e-06
by O 0 5.2594788968463035e-08
the O 0 2.5303947950305883e-06
deficiency B-Disease 0 0.030359812080860138
of I-Disease 0 7.045465100219417e-09
the I-Disease 0 1.822338475676588e-07
lysosomal I-Disease 0 0.0010446287924423814
enzyme I-Disease 0 5.157557097845711e-05
aspartylglucosaminidase I-Disease 0 0.00020697487343568355
( O 0 2.138460075684634e-07
AGA O 0 5.6164476518461015e-06
) O 0 4.447116737082979e-07
. O 0 1.8109922166331671e-06

AGU B-Disease 1 0.9999978542327881
is O 0 1.8308862763660727e-06
inherited O 0 2.808122917485889e-05
as O 0 4.9751697872579825e-08
an O 0 4.72237857707114e-08
autosomal O 1 0.8748785257339478
recessive O 1 0.9898001551628113
trait O 0 0.444084495306015
and O 0 4.560807553843915e-07
occurs O 0 6.045995348813449e-08
with O 0 3.466799958218303e-09
a O 0 2.988079472743266e-08
high O 0 5.482203846440825e-07
frequency O 0 1.6539072021259926e-05
in O 0 1.0940409822524089e-07
Finland O 0 0.0003383596776984632
because O 0 1.5234373051953298e-07
of O 0 3.5506917406280536e-09
a O 0 5.970806427058051e-08
founder O 0 1.3158642104826868e-06
effect O 0 3.1668760129832663e-06
. O 0 1.8301459476788295e-06

While O 0 2.5791878215386532e-06
very O 0 2.9168026571824157e-07
few O 0 3.680290774354944e-07
patients O 0 7.29771841179172e-07
with O 0 5.5761251616104346e-08
AGU B-Disease 1 0.9999998807907104
have O 0 7.889975677244365e-07
been O 0 6.933036900136358e-08
reported O 0 8.669248074966163e-08
from O 0 8.461316980401534e-09
non O 0 4.6167872369551333e-07
- O 0 1.8192982679465786e-05
Finnish O 0 3.4051410580104857e-07
origin O 0 3.904757406303361e-08
, O 0 1.0225977398192754e-08
we O 0 5.886141707378556e-07
diagnosed O 0 0.00011700476898113266
the O 0 2.368413909437095e-08
disorder O 0 2.855365210052696e-06
in O 0 1.2672153104631434e-08
8 O 0 1.1881815531467055e-08
patients O 0 1.96224867465844e-08
originating O 0 1.046684250383123e-08
from O 0 2.4706965362497613e-09
3 O 0 7.197564322325434e-09
unrelated O 0 7.09582508306994e-08
families O 0 1.2538429849939803e-08
, O 0 2.537211774011894e-09
all O 0 3.3204210492243647e-09
Palestinian O 0 2.4270652829727624e-06
Arabs O 0 8.97020163392881e-06
from O 0 1.1495380647374986e-08
the O 0 1.8817422287042973e-08
region O 0 1.0058478494556766e-07
of O 0 3.6562219918323535e-08
Jerusalem O 0 0.004280347377061844
. O 0 6.183346613397589e-06

The O 0 1.500365101492207e-06
clinical O 0 4.831181649933569e-05
diagnosis O 0 0.0018642392242327332
of O 0 1.1499442109652591e-07
AGU B-Disease 1 1.0
is O 0 1.7133466201357805e-07
often O 0 4.5215787736196944e-07
difficult O 0 2.023603519774042e-05
, O 0 2.629315654090192e-09
in O 0 1.3395079490052808e-09
particular O 0 3.8126510837344085e-09
early O 0 9.1493923548569e-08
in O 0 7.358881504160308e-09
the O 0 7.164295379169516e-09
course O 0 1.4919595514584216e-06
of O 0 8.075443647115321e-10
the O 0 2.003972241482188e-07
disease O 0 7.804751476214733e-07
, O 0 1.2146329497753072e-09
and O 0 1.0476424172622956e-09
most O 0 1.0608574019244088e-09
of O 0 1.6531685742560143e-10
the O 0 1.1440739910995035e-08
patients O 0 1.2244548486251006e-07
are O 0 1.987068465325592e-08
diagnosed O 0 7.701614958932623e-05
after O 0 4.813535525727275e-08
the O 0 2.037576685154363e-08
age O 0 5.271490621794328e-08
of O 0 4.081103455177981e-09
5 O 0 7.942961843809826e-08
years O 0 9.311125381827878e-07
. O 0 2.4632763597765006e-06

However O 0 1.63516244811035e-06
, O 0 3.9480813285308614e-08
since O 0 3.196180387021741e-08
these O 0 1.144925310114786e-08
patients O 0 2.026754764017369e-08
excrete O 0 3.1098384312144844e-08
early O 0 1.0861148425078682e-08
large O 0 5.560467641885225e-09
amounts O 0 1.4970742867603803e-08
of O 0 1.2211791577954045e-09
aspartylglucosamine O 0 5.678831485056435e-07
in O 0 9.759110852769481e-09
urine O 0 9.883233076379838e-08
, O 0 4.37341052261786e-09
biochemical O 0 3.88955726293716e-07
screening O 0 3.5401384934630187e-07
is O 0 1.3295028189475033e-08
easy O 0 1.0774000003266337e-07
by O 0 2.4057017711243134e-08
urine O 0 1.1321628790028626e-06
chromatography O 0 1.4437597201322205e-05
. O 0 4.51409079005316e-07
. O 0 1.785978497537144e-06

Detection O 0 2.784427306323778e-05
of O 0 1.3198064152675215e-07
heterozygous O 0 2.6761056233226554e-06
carriers O 0 7.309399165933428e-07
of O 0 1.478089828310658e-08
the O 0 2.585228230600478e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 6.081067454033473e-07
ATM O 0 1.566688297316432e-05
) O 0 3.376019463985358e-08
gene O 0 2.585743743566127e-07
by O 0 4.2710031067372256e-08
G2 O 0 1.555905328132212e-05
phase O 0 4.946612534695305e-06
chromosomal O 0 0.00041573206544853747
radiosensitivity O 0 2.4258886696770787e-05
of O 0 1.8080707775425253e-07
peripheral O 0 0.00017658795695751905
blood O 0 0.0007438279571942985
lymphocytes O 0 0.001269842148758471
. O 0 1.8348842786508612e-05

In O 0 9.723039693199098e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.07760239392518997
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 3.294520638519316e-07
patients O 0 3.185074888278905e-07
, O 0 3.622138811110176e-09
mutations O 0 1.4317757290882582e-07
in O 0 4.43119629878197e-09
a O 0 4.271424547397373e-09
single O 0 3.5137873055646196e-08
gene O 0 7.457681761025015e-08
, O 0 3.3580873637362174e-09
ATM O 0 3.240735111376125e-07
, O 0 3.1108216003161715e-09
result O 0 2.283841382677565e-08
in O 0 8.675137053160142e-08
an O 0 0.030470581725239754
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.7419550601971423e-07
embraces O 0 1.459598877318058e-07
a O 0 1.77778556320618e-08
variety O 0 3.875390319763028e-08
of O 0 7.389599598894847e-09
clinical O 0 8.235765562858433e-06
features O 0 7.631462040080805e-07
and O 0 2.0501025232988468e-07
manifests O 0 2.1108148473558686e-07
extreme O 0 4.928295993522624e-07
radiosensitivity O 0 6.541702168760821e-05
and O 0 4.439666767552808e-08
a O 0 1.8966817449950213e-08
strong O 0 2.733734447701863e-07
pre O 0 0.0023674210533499718
- O 0 8.686160435900092e-05
disposition O 0 2.93711991616874e-06
to O 0 8.627578154118964e-07
malignancy B-Disease 0 0.00563483452424407
. O 0 3.00371380035358e-06

Heterozygotes O 0 6.653837044723332e-05
for O 0 1.1568761948410611e-07
the O 0 2.0884840523649473e-08
ATM O 0 6.823337344030733e-07
gene O 0 2.432772134852712e-07
have O 0 9.863008187949163e-08
no O 0 1.6688300519263066e-08
clinical O 0 1.872052024509685e-07
expression O 0 4.000750308819079e-08
of O 0 1.19540120024908e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 3.1721287086838856e-05
may O 0 3.308302666482632e-06
be O 0 3.6519080026664597e-07
cancer B-Disease 0 0.00010865894728340209
prone O 0 7.792955329932738e-07
with O 0 3.634838652288863e-09
a O 0 5.1913183085616765e-08
moderate O 0 5.574738224822795e-06
increase O 0 1.8368169207860774e-07
in O 0 5.88915760602049e-08
in O 0 1.4555051564002497e-07
vitro O 0 5.452393816085532e-05
radiosensitivity O 0 4.834140054299496e-05
. O 0 1.7753022802935448e-06

We O 0 1.1092691238445695e-05
performed O 0 1.0688377187761944e-06
a O 0 1.197676908759604e-07
blind O 0 2.768452759482898e-06
chromosomal O 0 4.0063921915134415e-05
analysis O 0 6.473626399383647e-07
on O 0 1.232898370062685e-07
G2 O 0 1.697080188023392e-05
- O 0 5.017547664465383e-06
phase O 0 5.599048336080159e-07
lymphocytes O 0 7.222664066830475e-07
from O 0 1.1090331319962843e-08
7 O 0 2.6048578405379885e-08
unrelated O 0 1.14872466383531e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 5.049729224992916e-06
, O 0 3.4953702154894017e-09
13 O 0 4.760893901334384e-09
obligate O 0 1.9937890272103687e-07
A B-Disease 1 0.9999953508377075
- I-Disease 1 0.9999922513961792
T I-Disease 1 0.9999997615814209
heterozygotes O 0 3.165565658491687e-06
( O 0 7.381739219880501e-09
parents O 0 1.5865333935494164e-08
of O 0 5.597111107924491e-10
the O 0 4.6982266965756025e-09
patients O 0 6.522234485828449e-08
) O 0 2.1377735137662057e-09
, O 0 1.8172416904604916e-09
and O 0 2.244217611746535e-08
14 O 0 1.4352860233657339e-08
normal O 0 5.59865434013318e-08
controls O 0 2.2121867004898377e-07
following O 0 4.1213837675968534e-08
X O 0 5.325697202351876e-06
- O 0 2.2039573366328113e-07
irradiation O 0 1.4778142087834567e-07
with O 0 3.963531725048597e-09
1 O 0 1.8495816433983236e-08
Gy O 0 1.0570847734925337e-06
in O 0 2.126476106312225e-09
order O 0 1.6496636279228483e-09
to O 0 2.5699169459159066e-09
evaluate O 0 2.7241876310313273e-08
this O 0 1.7693009279895477e-09
cytogenetic O 0 1.2117207859319024e-07
method O 0 2.008897048710878e-08
as O 0 3.273010307225377e-09
a O 0 4.295452438185521e-09
tool O 0 3.764441771636484e-07
for O 0 6.421554843427657e-09
detection O 0 2.2295245116765727e-07
of O 0 2.0538827527616377e-08
ATM O 0 5.08106459164992e-05
carriers O 0 1.2691025403910317e-05
. O 0 3.3479607282060897e-06

Both O 0 3.202392690582201e-05
A B-Disease 1 0.9998118281364441
- I-Disease 1 0.9999393224716187
T I-Disease 1 0.9999984502792358
homozygotes O 0 8.786689431872219e-05
and O 0 7.872075258319455e-08
heterozygotes O 0 4.598806299327407e-06
showed O 0 3.7850546164008847e-07
significantly O 0 2.2782293740419846e-07
increased O 0 2.6745256676008466e-08
levels O 0 6.515607253732014e-08
of O 0 2.3064503640313205e-09
radiation O 0 0.0029994621872901917
- O 0 0.0003089283127337694
induced O 0 1.0544706128712278e-05
chromatid O 0 0.0618482306599617
damage O 0 0.0024105291813611984
relative O 0 2.0069404627065524e-07
to O 0 8.68728644576322e-09
that O 0 3.767283374145336e-09
of O 0 1.4411068782749226e-08
normal O 0 1.1158673487443593e-06
controls O 0 7.64040305512026e-05
. O 0 7.52458026909153e-06

These O 0 9.599513077773736e-07
results O 0 8.789959338173503e-07
show O 0 1.741051676162897e-07
that O 0 7.604898932811466e-09
the O 0 1.2479473454618528e-08
G2 O 0 1.2338585293036886e-05
- O 0 6.947962447156897e-06
phase O 0 4.1998220012828824e-07
chromosomal O 0 4.959469151799567e-06
radiosensitivity O 0 1.2826124020648422e-06
assay O 0 1.8725354493653867e-06
can O 0 2.391592524020325e-08
be O 0 1.3180793123623857e-09
used O 0 3.4700942119769707e-09
for O 0 7.304020166465364e-10
the O 0 1.6291233917442582e-09
detection O 0 1.9414089535985113e-07
of O 0 2.013604039063921e-08
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999983310699463
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.0004045117530040443
. O 0 4.7442536015296355e-06

In O 0 1.001717919280054e-06
combination O 0 1.4242463066693745e-06
with O 0 2.4822373489996608e-08
molecular O 0 1.0228376368104364e-06
genetic O 0 1.3736859045820893e-06
analyses O 0 7.435821771650808e-07
, O 0 9.130004308133266e-09
this O 0 6.639363281379929e-09
test O 0 1.614685743334121e-06
may O 0 4.6418634269684844e-08
be O 0 1.0499549008002873e-09
of O 0 1.2174806995890464e-10
value O 0 5.665705682389444e-09
in O 0 5.647838197120336e-09
studies O 0 1.9830475039839257e-08
of O 0 9.147953505816986e-10
familial B-Disease 0 2.649730049597565e-06
and I-Disease 0 3.244517188250029e-07
sporadic I-Disease 0 0.0018818768439814448
cancers I-Disease 1 0.9999732971191406
aimed O 0 1.6693829820724204e-06
at O 0 3.4063294407360445e-08
determination O 0 8.94656793093418e-09
of O 0 4.566077238532529e-10
the O 0 3.2009437322955137e-09
potential O 0 1.8228524467645002e-08
involvement O 0 1.603692645346655e-08
of O 0 1.4456569275012043e-09
ATM O 0 5.452880941447802e-06
mutations O 0 1.7031984498316888e-06
in O 0 1.326810377122456e-07
tumor B-Disease 0 0.0029045534320175648
risk O 0 2.16232019738527e-05
or O 0 1.0316904308638186e-07
development O 0 1.1990266557404539e-07
. O 0 3.8303653582261177e-07
. O 0 2.6458715183252934e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
: O 0 1.115196141654451e-06
identification O 0 2.7973891292276676e-07
and O 0 2.4517515129218737e-08
detection O 0 4.0524338373870705e-07
of O 0 3.4562361861389945e-09
founder O 0 8.260537356363784e-07
- O 0 0.005024009849876165
effect O 0 3.3235894534300314e-06
mutations O 0 7.074634709169914e-07
in O 0 8.886110514083612e-09
the O 0 1.2194201204351884e-08
ATM O 0 1.124546429309703e-06
gene O 0 5.05604361933365e-07
in O 0 1.358070136348033e-07
ethnic O 0 2.0666086584242294e-06
populations O 0 4.176404036115855e-05
. O 0 6.0738152569683734e-06

To O 0 2.67240494622456e-07
facilitate O 0 1.376421181475962e-07
the O 0 1.3190884828873095e-08
evaluation O 0 3.33727356860436e-08
of O 0 1.3946568344636034e-09
ATM O 0 5.598621442004514e-07
heterozygotes O 0 6.269130494729325e-07
for O 0 4.6773220852003305e-09
susceptibility O 0 2.2803205013133265e-07
to O 0 2.474079252579031e-08
other O 0 3.035366802350836e-08
diseases O 0 4.550954599835677e-06
, O 0 5.845105510715598e-10
such O 0 9.602748596293509e-10
as O 0 1.2151438966157002e-07
breast B-Disease 1 0.9811550974845886
cancer I-Disease 0 0.0022373581305146217
, O 0 4.543752041286098e-09
we O 0 4.978375489628206e-09
have O 0 1.7018608744479025e-09
attempted O 0 2.9639327436825624e-08
to O 0 1.7949913777570714e-09
define O 0 5.788495727188092e-08
the O 0 3.5480922644381963e-09
most O 0 5.826252813534438e-09
common O 0 4.938731734682733e-08
mutations O 0 3.818817901901639e-07
and O 0 3.2574032360344063e-09
their O 0 6.035163035988944e-09
frequencies O 0 6.2799526858725585e-06
in O 0 1.7059837773558684e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0006066950154490769
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 9.257384192551399e-08
homozygotes O 0 3.76810498892155e-06
from O 0 2.378128094449039e-08
10 O 0 4.558945931876224e-08
ethnic O 0 3.9518678818240005e-07
populations O 0 1.228109704243252e-05
. O 0 2.9921573059255024e-06

Both O 0 1.5868139371377765e-06
genomic O 0 1.9854125639540143e-05
mutations O 0 3.1552841392112896e-05
and O 0 1.7807271035508165e-07
their O 0 7.974080773465175e-08
effects O 0 2.0638512978621293e-06
on O 0 4.130961173132164e-08
cDNA O 0 1.3529552234103903e-06
were O 0 4.009826852779952e-07
characterized O 0 3.98416887037456e-06
. O 0 5.352540938474704e-06

Protein O 0 2.4007980755413882e-05
- O 0 1.747230635373853e-05
truncation O 0 6.3792726905376185e-06
testing O 0 7.718563210801221e-07
of O 0 4.279342658009e-09
the O 0 4.412540111076169e-09
entire O 0 3.2267831073795605e-08
ATM O 0 5.473845021697343e-07
cDNA O 0 6.604366831197694e-07
detected O 0 1.268665869247343e-06
92 O 0 1.1310604719483308e-07
( O 0 8.64892957253005e-09
66 O 0 8.196005296667863e-08
% O 0 2.886666017332118e-08
) O 0 1.9755274749400087e-08
truncating O 0 2.1000817014282802e-06
mutations O 0 3.438905878283549e-06
in O 0 6.414763475959262e-08
140 O 0 2.0545179779674072e-07
mutant O 0 4.418093794811284e-06
alleles O 0 2.1194708097027615e-05
screened O 0 3.595844827941619e-05
. O 0 5.8892860579362605e-06

The O 0 1.1336688885421609e-06
haplotyping O 0 9.722578397486359e-06
of O 0 3.7606085356856056e-08
patients O 0 4.73650970889139e-07
with O 0 9.348655183316623e-09
identical O 0 0.0001271055662073195
mutations O 0 0.0004385072097647935
indicates O 0 5.265863478598476e-07
that O 0 3.8978127392397255e-09
almost O 0 3.095385725515598e-09
all O 0 4.761264160713097e-10
of O 0 2.2074758687651297e-10
these O 0 1.3871755966121668e-09
represent O 0 5.593026486394592e-09
common O 0 1.3621846051137254e-07
ancestry O 0 4.6109224058454856e-05
and O 0 5.013587838220701e-07
that O 0 3.933139325340562e-08
very O 0 1.1578242720133858e-07
few O 0 2.9181381933085504e-07
spontaneously O 0 2.8955166726518655e-06
recurring O 0 5.1989013627462555e-06
ATM O 0 0.0001047078039846383
mutations O 0 4.7402369091287255e-05
exist O 0 1.6615096683381125e-05
. O 0 8.181116754713003e-06

Assays O 0 3.0322238671942614e-05
requiring O 0 1.5778113038322772e-06
minimal O 0 1.0046416036857408e-06
amounts O 0 1.0963157848209448e-07
of O 0 3.975388018773174e-09
genomic O 0 4.483132727273187e-07
DNA O 0 2.122991645592265e-06
were O 0 3.125698100348018e-08
designed O 0 7.654043088223261e-08
to O 0 2.611891369852515e-09
allow O 0 1.1328196158899573e-08
rapid O 0 2.1466533439706836e-08
screening O 0 1.1779577846482425e-07
for O 0 8.523874939214693e-09
common O 0 2.0688474933194811e-07
ethnic O 0 1.5182521337919752e-06
mutations O 0 0.00045965606113895774
. O 0 5.558335033128969e-06

These O 0 1.4169143014441943e-06
rapid O 0 1.6977010091068223e-06
assays O 0 1.1361171345924959e-05
detected O 0 2.8802342058042996e-06
mutations O 0 1.5653297396056587e-06
in O 0 3.678724880273876e-08
76 O 0 1.7426563658773375e-07
% O 0 1.8534944246084706e-08
of O 0 2.2348147776796168e-09
Costa O 0 2.605837607916328e-07
Rican O 0 4.944863007949607e-07
patients O 0 1.8533218337779545e-07
( O 0 1.5122407770462587e-09
3 O 0 1.9808239493102064e-09
) O 0 1.3974741364108922e-09
, O 0 1.3070863280617573e-09
50 O 0 3.406730453292539e-09
% O 0 2.355168726708712e-09
of O 0 2.2462121052058137e-09
Norwegian O 1 0.951561689376831
patients O 0 1.3844082786818035e-06
( O 0 2.2935835453097297e-09
1 O 0 3.833125372665336e-09
) O 0 1.164892737826051e-09
, O 0 1.3699428258462376e-09
25 O 0 1.8531683965150592e-09
% O 0 2.380732055939916e-09
of O 0 1.320071940646983e-09
Polish O 0 0.007028218824416399
patients O 0 5.145145678397967e-07
( O 0 1.1982493886009138e-09
4 O 0 2.7690765236343395e-09
) O 0 1.2288241535429734e-09
, O 0 9.008034318469527e-10
and O 0 2.9262283707254255e-09
14 O 0 2.721511682679534e-09
% O 0 2.1583819176385077e-09
of O 0 1.0189524779491421e-09
Italian O 0 0.00028243582346476614
patients O 0 3.719027006354736e-07
( O 0 1.0898330016217983e-09
1 O 0 3.4543909954720675e-09
) O 0 8.971170473159873e-10
, O 0 2.696301515392463e-10
as O 0 1.077392841608571e-09
well O 0 4.0623633346115184e-09
as O 0 6.128215712664087e-09
in O 0 2.301182888686526e-08
patients O 0 6.956960163506665e-08
of O 0 4.519765894883676e-09
Amish O 0 2.7074722765974e-06
/ O 0 4.4111627062193293e-07
Mennonite O 0 2.171739652112592e-06
and O 0 7.325247111111821e-07
Irish O 0 3.989319793618051e-06
English O 0 1.8777625427901512e-06
backgrounds O 0 7.865823135944083e-06
. O 0 2.5530566745146643e-06

Additional O 0 9.992295417760033e-07
mutations O 0 3.918522452295292e-06
were O 0 4.092533245625418e-08
observed O 0 6.044992062470556e-08
in O 0 1.7592904910657126e-08
Japanese O 0 7.301826343564244e-08
, O 0 3.3354325967849263e-09
Utah O 0 1.3888096894731916e-08
Mormon O 0 6.310387590247046e-08
, O 0 3.813050764023274e-09
and O 0 9.760897867749918e-09
African O 0 3.392389302803167e-08
American O 0 7.891721907071769e-07
patients O 0 2.065954504359979e-06
. O 0 1.0637492096066126e-06

These O 0 3.02919573869076e-07
assays O 0 2.8962183478142833e-06
should O 0 2.2056388715441244e-08
facilitate O 0 1.509961755630229e-08
screening O 0 8.709405818763116e-08
for O 0 1.0977151632118876e-08
A B-Disease 1 0.9999505281448364
- I-Disease 1 0.9999741315841675
T I-Disease 1 0.9999998807907104
heterozygotes O 0 8.221177267841995e-06
in O 0 2.995721004594998e-08
the O 0 2.2003110444757112e-08
populations O 0 2.9663345912922523e-07
studied O 0 6.081780838940176e-07
. O 0 2.0976706593955896e-07
. O 0 1.3689609659195412e-06

The O 0 2.2603742763749324e-05
von B-Disease 1 0.9839863777160645
Hippel I-Disease 1 0.996296226978302
- I-Disease 1 0.9756478071212769
Lindau I-Disease 1 0.9777451157569885
tumor I-Disease 0 5.549257548409514e-05
suppressor O 0 5.379130470828386e-06
gene O 0 6.330821520350582e-07
is O 0 1.641876501423667e-08
required O 0 2.805526477800413e-08
for O 0 1.5698303101885358e-08
cell O 0 3.0767940188525245e-05
cycle O 0 2.096479875035584e-06
exit O 0 7.643509434274165e-07
upon O 0 1.214766029988823e-07
serum O 0 8.555217391403858e-06
withdrawal O 0 1.236926436831709e-05
. O 0 4.147820618527476e-06

The O 0 1.5136142792471219e-06
inactivation O 0 1.7004400433506817e-05
of O 0 4.268861175660277e-08
the O 0 3.733622122581437e-07
von B-Disease 1 0.9969417452812195
Hippel I-Disease 1 0.999847412109375
- I-Disease 1 0.9998506307601929
Lindau I-Disease 1 0.9998594522476196
( I-Disease 0 7.194286126832594e-07
VHL I-Disease 0 0.00030368773150257766
) I-Disease 0 1.8385800615305925e-07
tumor I-Disease 0 2.2859323962620692e-06
suppressor O 0 4.054404143971624e-06
gene O 0 1.0557326959315105e-06
predisposes O 0 3.481344492684002e-06
affected O 0 9.612028861738509e-08
individuals O 0 6.452642864474001e-09
to O 0 4.202917125439853e-09
the O 0 3.314361052275672e-08
human O 0 4.684539362642681e-06
VHL B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999884366989136
and O 0 1.2729572063108208e-07
is O 0 2.8098051885194764e-08
associated O 0 1.9655286109809822e-07
with O 0 1.9294631670163653e-07
sporadic B-Disease 1 0.9998257756233215
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.00013606071297544986
RCC B-Disease 1 0.9944067001342773
) O 0 5.088055559099303e-07
and O 0 6.399744734153501e-07
brain B-Disease 0 0.0057899528183043
hemangioblastomas I-Disease 0 0.002474260749295354
. O 0 8.121069186017849e-06

VHL O 0 0.07641317695379257
- O 0 0.11475852876901627
negative O 0 3.2564934372203425e-05
786 O 0 2.6978508685715497e-05
- O 0 0.0003533784474711865
0 O 0 1.0303074304829352e-06
RCC B-Disease 0 7.775303856760729e-06
cells O 0 2.415219455542683e-07
are O 0 6.516922557153748e-09
tumorigenic O 0 8.657142416268471e-07
in O 0 3.317333252539356e-08
nude O 0 0.0009562698542140424
mice O 0 3.0136470741126686e-06
which O 0 1.0999661625987756e-08
is O 0 5.830388616345772e-09
suppressed O 0 7.545273916775841e-08
by O 0 6.6711738355706984e-09
the O 0 4.618451754367925e-08
reintroduction O 0 3.2776652005850337e-06
of O 0 4.41066617895558e-07
VHL B-Disease 0 0.0004552787868306041
. O 0 5.004835202271352e-06

Remarkably O 0 3.520344034768641e-05
, O 0 1.1909774144669427e-07
this O 0 7.1848083038617006e-09
occurs O 0 1.201967325670239e-08
without O 0 1.1489439621925612e-08
affecting O 0 1.523491732768889e-08
the O 0 4.048656965238706e-09
growth O 0 8.85832776020834e-08
rate O 0 1.9313078780669457e-07
and O 0 3.125048664287533e-08
cell O 0 8.934709512686823e-06
cycle O 0 3.3628168694121996e-07
profile O 0 1.4054802477403427e-06
of O 0 2.396097764645333e-09
these O 0 2.110049557302318e-08
cells O 0 3.3762134421522205e-07
in O 0 6.299311650082018e-08
culture O 0 1.2976496464034426e-06
. O 0 1.953642822627444e-06

The O 0 1.558445092086913e-06
786 O 0 1.1879969861183781e-05
- O 0 1.3926281098974869e-05
0 O 0 2.2977582148087095e-07
cell O 0 6.593417083422537e-07
line O 0 4.4799529064221133e-07
, O 0 3.911575952031399e-09
like O 0 9.20445497598621e-09
many O 0 2.2835145330191153e-08
cancer B-Disease 0 5.1326810535101686e-06
cells O 0 1.669919811320142e-07
, O 0 5.717694762097381e-09
fails O 0 3.989279093730147e-07
to O 0 9.447153281882947e-09
exit O 0 2.1642826197876275e-07
the O 0 1.8030627657594778e-08
cell O 0 1.931559609147371e-06
cycle O 0 4.1175539422511065e-07
upon O 0 1.3198528847624402e-07
serum O 0 9.469954420637805e-06
withdrawal O 0 1.2114648598071653e-05
. O 0 4.077498942933744e-06

Here O 0 9.958979489965714e-07
, O 0 1.9795557193447166e-08
it O 0 5.139248138164021e-09
is O 0 1.0282731333077777e-09
shown O 0 2.635697438080342e-09
that O 0 7.475775554155462e-10
reintroduction O 0 1.2669446824986608e-08
of O 0 7.688655823123725e-10
the O 0 6.972527000215223e-09
wild O 0 1.4252461255637172e-07
- O 0 0.00039678034954704344
type O 0 1.6059068002505228e-05
VHL B-Disease 0 1.4109330550127197e-05
gene O 0 2.9433937243084074e-07
restores O 0 5.732832164540014e-07
the O 0 1.0087178203832536e-08
ability O 0 7.624654330129488e-08
of O 0 1.1016543233210996e-08
VHL O 0 0.003283475758507848
- O 0 0.060507237911224365
negative O 0 0.008567621000111103
RCC B-Disease 1 0.5965436697006226
cancer I-Disease 0 5.055877772974782e-05
cells O 0 2.015064382021592e-07
to O 0 9.72236069429755e-09
exit O 0 2.3808291871318943e-07
the O 0 1.5427032096226867e-08
cell O 0 2.438133378745988e-06
cycle O 0 4.4708107793667295e-07
and O 0 9.179773030609795e-08
enter O 0 5.700628094018612e-07
G0 O 0 3.442998058744706e-05
/ O 0 1.0855308119062101e-06
quiescence O 0 1.1820887266367208e-05
in O 0 4.892201559414389e-07
low O 0 2.0255032723071054e-05
serum O 0 6.67154454276897e-05
. O 0 2.8754834602295887e-06

Both O 0 8.719337529328186e-06
VHL O 0 0.0007014407310634851
- O 0 0.001525091240182519
positive O 0 6.152215519250603e-07
and O 0 2.6197514557679824e-07
VHL O 0 0.0015264786779880524
- O 0 0.02611459046602249
negative O 0 4.0203845856012776e-05
RCC B-Disease 0 0.0004006809613201767
cells O 0 2.2927420104679186e-06
exit O 0 1.1581782928260509e-06
the O 0 3.520240809962161e-08
cell O 0 2.277007297379896e-06
cycle O 0 4.869783651884063e-07
by O 0 4.439065648398355e-08
contact O 0 2.016568942053709e-06
inhibition O 0 1.343955682386877e-05
. O 0 4.697606982517755e-06

The O 0 7.121163434931077e-06
cyclin O 0 0.0013224201975390315
- O 0 2.2797756173531525e-05
dependent O 0 1.7366980955557665e-06
kinase O 0 3.3747658108040923e-06
inhibitor O 0 1.905736780827283e-06
, O 0 2.3392320969151115e-08
p27 O 0 1.3927470945418463e-06
, O 0 5.4556439366137965e-09
accumulates O 0 4.23673967020477e-08
upon O 0 4.110916052013636e-09
serum O 0 1.6492876397933287e-07
withdrawal O 0 1.4079658683385787e-07
, O 0 3.173847407111907e-09
only O 0 2.2337494076651865e-09
in O 0 1.8308656812848767e-09
the O 0 3.1036149206187247e-09
presence O 0 1.2888392575405305e-08
of O 0 2.3718031982866705e-09
VHL B-Disease 0 1.7215330444741994e-05
, O 0 4.7573540662426694e-09
as O 0 3.7243594874780683e-09
a O 0 6.129875718130506e-09
result O 0 6.52137615020365e-08
of O 0 1.4286128946494614e-09
the O 0 9.473858142428071e-09
stabilization O 0 1.026956937266732e-07
of O 0 5.355533350126507e-09
the O 0 4.655829144439849e-08
protein O 0 6.903182452333567e-07
. O 0 1.228723704116419e-06

We O 0 1.4967308743507601e-06
propose O 0 6.680203910036653e-07
that O 0 1.6043749440086685e-08
the O 0 7.224067122280076e-09
loss O 0 3.2700292251774954e-08
of O 0 2.0451136339971754e-09
wild O 0 1.7210565772529662e-07
- O 0 0.006188495550304651
type O 0 0.0010407784720882773
VHL B-Disease 0 6.524506898131222e-05
gene O 0 1.0689437885957886e-06
results O 0 8.199310741474619e-07
in O 0 8.719523769684656e-09
a O 0 4.535517739157058e-09
specific O 0 3.804741766089137e-08
cellular O 0 5.455226983031025e-06
defect O 0 2.0662598672060994e-06
in O 0 2.3688658146170383e-08
serum O 0 1.0353414836572483e-05
- O 0 2.264940121676773e-05
dependent O 0 4.280967459635576e-06
growth O 0 1.1931412018384435e-06
control O 0 8.241935347541585e-07
, O 0 1.1497594876175299e-08
which O 0 3.333869358357333e-08
may O 0 1.34052115186023e-07
initiate O 0 7.913426429695392e-07
tumor B-Disease 0 1.1038574484700803e-05
formation O 0 1.7382474197802367e-06
. O 0 2.7364706056687282e-06

This O 0 6.108600700827083e-07
is O 0 6.20412308194318e-08
corrected O 0 6.11561347341194e-07
by O 0 3.380773661021408e-09
the O 0 2.2700556989718734e-09
reintroduction O 0 8.740509116478279e-08
of O 0 2.5716526685926056e-09
wild O 0 1.999100902594364e-07
- O 0 0.008170893415808678
type O 0 0.016159579157829285
VHL B-Disease 0 0.0024085966870188713
, O 0 4.6864240488275755e-08
implicating O 0 7.606212761857023e-07
VHL B-Disease 0 8.13008864497533e-06
as O 0 5.738638897412329e-09
the O 0 3.1549740597824893e-09
first O 0 4.0781024779334984e-08
tumor B-Disease 0 4.1618056911829626e-07
suppressor O 0 4.417233014919475e-07
involved O 0 2.9940071755163444e-08
in O 0 7.05771752151918e-09
the O 0 5.484753540230258e-09
regulation O 0 2.1114667347887917e-08
of O 0 1.137873351098051e-09
cell O 0 3.1557246984448284e-06
cycle O 0 2.5799084824029705e-07
exit O 0 1.9804581370408414e-06
, O 0 8.700153486529416e-09
which O 0 2.6152724430517083e-08
is O 0 2.992835090864787e-09
consistent O 0 3.9430993581390794e-08
with O 0 2.734566795226101e-09
its O 0 1.936308891004046e-08
gatekeeper O 0 8.060337108872773e-07
function O 0 1.522217445426577e-07
in O 0 8.793735162271332e-08
the O 0 2.37440303862968e-07
kidney O 0 4.2344414396211505e-05
. O 0 2.5981796625274e-07
. O 0 2.0016298094560625e-06

Piebaldism B-Disease 1 0.9999995231628418
with O 0 0.001935071311891079
deafness B-Disease 1 1.0
: O 0 4.5777977675243164e-07
molecular O 0 1.3942154737378587e-06
evidence O 0 1.5772741335240426e-07
for O 0 2.033306145676761e-08
an O 0 1.8004035950980324e-07
expanded O 0 0.127474844455719
syndrome O 1 0.999924898147583
. O 0 8.984087799035478e-06

In O 0 5.393227411332191e-07
a O 0 2.3509606705829356e-07
South O 0 1.2693689654952323e-07
African O 0 9.930889177667268e-08
girl O 0 3.188819164279266e-07
of O 0 7.806328028436837e-09
Xhosa O 0 2.811255217238795e-05
stock O 0 2.0573133951984346e-05
with O 0 4.088117222522669e-08
severe O 0 2.156004666176159e-05
piebaldism B-Disease 0 0.003352860687300563
and O 0 8.667369115755719e-07
profound O 0 1.7887665308080614e-05
congenital O 1 0.9999983310699463
sensorineural B-Disease 1 0.9999986886978149
deafness I-Disease 1 1.0
we O 0 0.055729322135448456
identified O 0 1.3542151009460213e-06
a O 0 1.7180319389353826e-08
novel O 0 1.4761661759621347e-07
missense O 0 1.4313063729787245e-06
substitution O 0 2.3527258008471108e-07
at O 0 1.4146969817829813e-07
a O 0 1.8470997176223136e-08
highly O 0 8.728746792030506e-08
conserved O 0 1.835689147355879e-07
residue O 0 8.897831094145658e-07
in O 0 2.8718988076548158e-08
the O 0 2.7918288125761137e-08
intracellular O 0 6.946643793526164e-07
kinase O 0 3.138686395232071e-07
domain O 0 1.0305753050943167e-07
of O 0 6.2267866418608264e-09
the O 0 4.732161329457085e-08
KIT O 0 1.6427353330072947e-05
proto O 0 9.84692233032547e-05
- O 0 1.3150250197213609e-05
oncogene O 0 2.7297555789118633e-05
, O 0 2.4131219333867193e-07
R796G O 0 1.4775431736779865e-05
. O 0 2.2452595658251084e-06

Though O 0 1.0998131074302364e-05
auditory B-Disease 0 4.2218372982461005e-05
anomalies I-Disease 0 0.0001252136571565643
have O 0 1.3979098412164603e-07
been O 0 1.6386852763616844e-08
observed O 0 3.4134640003458117e-08
in O 0 1.565760499033786e-08
mice O 0 1.865733338490827e-06
with O 0 2.8631477633211944e-08
dominant O 0 0.04931482672691345
white O 0 0.002828607801347971
spotting O 0 0.0165964774787426
( O 0 4.5547999150130636e-08
W O 0 0.1992965042591095
) O 0 1.2204159460793562e-08
due O 0 3.3555664913365035e-08
to O 0 1.9194127176547227e-08
KIT O 0 0.0004168607119936496
mutations O 0 4.297599662095308e-05
, O 0 2.620311079226667e-07
deafness B-Disease 1 1.0
is O 0 2.4584085167589365e-07
not O 0 1.2845644903336506e-07
typical O 0 1.5170493838922994e-07
in O 0 6.50117044642684e-08
human O 0 3.5384033481022925e-07
piebaldism B-Disease 0 8.659802551846951e-05
. O 0 2.999351181642851e-06

Thus O 0 6.030601070960984e-06
, O 0 8.430117759417044e-08
the O 0 2.073927518608798e-08
occurrence O 0 1.295143647439545e-06
of O 0 9.218461372029196e-08
sensorineural B-Disease 1 0.9999121427536011
deafness I-Disease 1 1.0
in O 0 1.6443198546767235e-05
this O 0 9.174941340006626e-08
patient O 0 5.941236054241017e-07
extends O 0 7.455690109736679e-08
considerably O 0 2.1547103301600146e-07
the O 0 6.1310214682919195e-09
phenotypic O 0 3.0319213806251355e-07
range O 0 6.287607590138578e-08
of O 0 2.684520827855863e-09
piebaldism B-Disease 0 3.910209215973737e-06
due O 0 8.783592875261093e-08
to O 0 1.4406974280234408e-08
KIT O 0 1.0341279903514078e-06
gene O 0 1.9045525334604463e-07
mutation O 0 2.3597840481670573e-07
in O 0 5.299766847599585e-09
humans O 0 2.4363259853998898e-08
and O 0 1.7174158983834786e-08
tightens O 0 5.481519838212989e-05
the O 0 3.0201032785726056e-08
clinical O 0 3.987282468642661e-07
similarity O 0 9.280596913185946e-08
between O 0 3.0961135877305423e-08
piebaldism B-Disease 0 0.00016599507944192737
and O 0 2.729638559628711e-08
the O 0 5.454759310907775e-09
various O 0 1.1847643754947512e-08
forms O 0 4.870224756814423e-07
of O 0 4.568949407257605e-06
Waardenburg B-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999841451644897
. O 0 7.61026910822693e-07
. O 0 2.6137997792829992e-06

Cycloheximide O 0 0.00011145523603772745
facilitates O 0 3.5433238281257218e-06
the O 0 8.426581388221166e-08
identification O 0 1.389499146853268e-07
of O 0 9.427766123337733e-09
aberrant O 0 6.234210445654753e-07
transcripts O 0 9.921022865455598e-07
resulting O 0 3.072714491736406e-07
from O 0 1.6812645498021084e-08
a O 0 2.039925384167418e-08
novel O 0 3.9721504663248197e-07
splice O 0 0.00015653393347747624
- O 0 0.0001402763882651925
site O 0 6.049151011211507e-07
mutation O 0 8.68563120093313e-07
in O 0 1.8821657121748103e-08
COL17A1 O 0 6.606272108911071e-06
in O 0 2.421806222230316e-08
a O 0 4.604747871894688e-08
patient O 0 6.965962029426009e-07
with O 0 1.9765286651818315e-07
generalized O 0 0.0004464062221813947
atrophic B-Disease 1 0.9995087385177612
benign I-Disease 1 0.994989812374115
epidermolysis I-Disease 1 0.994207501411438
bullosa I-Disease 1 0.9800062775611877
. O 0 5.393953324528411e-05

Patients O 0 0.00038988940650597215
with O 0 3.0938761028664885e-06
generalized O 0 0.00026935304049402475
atrophic B-Disease 1 0.9995145797729492
benign I-Disease 1 0.9942973256111145
epidermolysis I-Disease 1 0.9913057684898376
bullosa I-Disease 1 0.9803274273872375
often O 0 3.882955206790939e-05
show O 0 1.574594534758944e-06
decreased O 0 1.018034026856185e-06
expression O 0 3.0669616535305977e-07
of O 0 4.132592579253469e-08
type O 0 2.58339787251316e-05
XVII O 0 3.317943628644571e-05
collagen O 0 3.940073384001153e-06
, O 0 7.818415781457588e-08
a O 0 9.071544582184288e-08
transmembrane O 0 6.787214715586742e-06
hemidesmosomal O 0 8.372202501050197e-06
protein O 0 4.6283108190436906e-07
encoded O 0 4.5181997165855137e-07
by O 0 1.883545479586246e-07
COL17A1 O 0 0.00018096873827744275
. O 0 7.126829586923122e-06

This O 0 4.959726425113331e-07
report O 0 2.7221213372286e-07
documents O 0 1.017966511085433e-07
a O 0 2.0327243888118574e-08
novel O 0 2.1134496819286142e-07
splice O 0 0.000327732355799526
- O 0 0.0002682384802028537
site O 0 3.7999194546500803e-07
mutation O 0 3.896447822171467e-07
in O 0 1.1182944348320234e-08
COL17A1 O 0 3.519305209920276e-06
in O 0 1.0859201537982699e-08
a O 0 2.4795497211016482e-08
patient O 0 4.403470938996179e-07
with O 0 3.469017428869847e-08
generalized O 0 1.799504752852954e-05
atrophic B-Disease 1 0.9907928109169006
benign I-Disease 1 0.6899184584617615
epidermolysis I-Disease 0 0.1544065922498703
bullosa I-Disease 0 0.4389355182647705
, O 0 1.3506846130439953e-07
and O 0 1.4492798072751611e-08
applies O 0 6.04627174993766e-08
a O 0 1.4236466228112477e-08
new O 0 2.8403137619648078e-08
methodology O 0 1.8312810823317704e-07
to O 0 7.708790938920629e-09
define O 0 1.7901548687859759e-07
and O 0 2.9943326040893226e-08
characterize O 0 1.380732214784075e-06
the O 0 1.7503414539987716e-07
resulting O 0 1.4924975175745203e-06
mRNA O 0 3.774057176997303e-06
splice O 0 0.0001053823361871764
variants O 0 3.584744990803301e-05
. O 0 9.292255526816007e-06

Mutational O 0 0.0005680586327798665
analysis O 0 8.606756637163926e-06
of O 0 1.2421914163951442e-07
COL17A1 O 0 3.4099037293344736e-05
identified O 0 7.191418376351066e-07
a O 0 6.98245727903668e-08
maternally O 0 1.5442359654116444e-05
inherited O 0 0.0003627637925092131
G O 0 0.0003092203114647418
- O 0 6.21144354226999e-05
to O 0 1.9772791404193413e-07
- O 0 0.0001838420721469447
T O 0 2.4750694137765095e-05
transversion O 0 9.052019436239789e-07
at O 0 1.2304148810926563e-08
the O 0 4.037198131356945e-09
- O 0 4.875220724898099e-07
1 O 0 2.1914946302104e-08
position O 0 5.330954877535987e-08
of O 0 1.0195829958092872e-08
exon O 0 4.490964784054086e-06
32 O 0 1.1493229976622388e-06
. O 0 1.4423217180592474e-06

This O 0 1.527250105937128e-06
acceptor O 0 8.751660061534494e-06
splice O 0 0.00014125273446552455
- O 0 8.739558688830584e-05
site O 0 9.444918873668939e-07
mutation O 0 1.0756316441984382e-06
led O 0 4.73203485285012e-08
to O 0 5.944679859481994e-09
the O 0 3.25200222306421e-09
formation O 0 8.61386340034187e-09
of O 0 1.188092624282433e-09
aberrant O 0 1.2824077089135244e-07
transcripts O 0 2.6798855401466426e-07
present O 0 6.760018322893302e-08
at O 0 1.1626030982370139e-07
extremely O 0 6.256599931475648e-07
low O 0 1.5283547327271663e-05
levels O 0 5.019328000344103e-06
. O 0 2.3416685053234687e-06

Based O 0 3.04452987620607e-06
on O 0 1.283906811977431e-07
our O 0 9.519598620499892e-08
recent O 0 7.605757446071948e-08
finding O 0 8.597240253038763e-08
that O 0 1.3761344952456511e-08
cycloheximide O 0 3.844608727376908e-06
stabilized O 0 5.8389991863805335e-06
mutant O 0 7.269405841725529e-07
COL17A1 O 0 1.6664467921145842e-06
transcripts O 0 2.859344476746628e-07
in O 0 1.2391524251142982e-08
keratinocytes O 0 2.702189476622152e-07
homozygous O 0 5.145302566234022e-07
for O 0 4.214765425558653e-09
a O 0 1.9805225903724022e-08
frameshift O 0 0.0001907918631331995
mutation O 0 6.031360953784315e-06
, O 0 1.3028084389077321e-08
the O 0 7.297646487103293e-09
effects O 0 9.775169473869028e-07
of O 0 2.8704514321020724e-09
the O 0 1.2516852443411608e-08
splice O 0 0.011398295871913433
- O 0 0.00022052181884646416
site O 0 2.886430081616709e-07
mutation O 0 1.0046610299241365e-07
on O 0 2.142851895925446e-09
splicing O 0 7.141201052718316e-08
of O 0 2.327845693983477e-09
COL17A1 O 0 6.048325644769648e-07
transcripts O 0 1.255300787761371e-07
were O 0 1.4809399928594758e-08
determined O 0 3.931751635377623e-08
using O 0 5.937962654911644e-08
reverse O 0 1.2158525350969285e-06
transcriptase O 0 5.33377897227183e-06
polymerase O 0 1.5240650554915192e-06
chain O 0 1.322863795394369e-06
reaction O 0 1.4936179582036857e-07
of O 0 5.174223272064182e-09
total O 0 1.4379493151750466e-08
RNA O 0 2.2330014814997412e-07
from O 0 2.3666617110507104e-08
keratinocytes O 0 1.2660505035455571e-06
incubated O 0 7.157632353482768e-07
for O 0 5.3080444928355064e-08
2 O 0 2.4898534434214525e-07
. O 0 1.092287106985168e-06

5 O 0 4.611727490555495e-06
h O 0 1.4608335732191335e-05
in O 0 4.8357772897134055e-08
the O 0 1.1880501027405899e-08
presence O 0 6.471181990264085e-08
or O 0 1.2993719167297968e-07
absence O 0 4.478321002920893e-08
of O 0 9.320346272545521e-09
10 O 0 7.087304254582705e-08
microg O 0 3.7877080103498884e-06
cycloheximide O 0 1.3053801922069397e-05
per O 0 9.793552635528613e-07
ml O 0 4.202969284961e-05
. O 0 3.6189373986417195e-06

Using O 0 9.55628024712496e-07
this O 0 4.554522448074749e-08
approach O 0 4.069477768098295e-07
, O 0 2.2630100460219182e-08
an O 0 1.3402982723675905e-08
abnormally O 0 9.428944736100675e-07
spliced O 0 7.678567271796055e-06
transcript O 0 0.00013941162615083158
was O 0 5.311267159413546e-06
identified O 0 3.956358085588363e-08
that O 0 9.340559437021057e-10
contains O 0 8.785779881392841e-10
an O 0 9.498805075836003e-10
extra O 0 6.669825136640384e-09
264 O 0 1.7977058064388984e-08
bases O 0 1.3372596363581124e-08
upstream O 0 2.8051998057776473e-08
from O 0 3.1826494772957403e-09
exon O 0 1.9199514156298392e-07
32 O 0 2.311617741668215e-08
, O 0 2.1583199671937336e-09
resulting O 0 3.231642509149424e-08
in O 0 2.9609946494701944e-08
a O 0 1.1196779325928219e-07
premature O 0 1.6489179870404769e-06
termination O 0 8.174645813596726e-07
codon O 0 1.4895839512973907e-06
27 O 0 9.807724410393348e-08
bp O 0 6.308221145445714e-07
downstream O 0 1.1000526001225808e-07
from O 0 8.959529118612863e-09
the O 0 3.67149795010846e-08
cryptic O 0 4.198971055302536e-06
splice O 0 7.371616084128618e-05
site O 0 1.2482919373724144e-05
. O 0 4.054311375512043e-06

Three O 0 3.56774052079345e-07
other O 0 4.185950430724006e-08
splice O 0 1.4085529755902826e-06
variants O 0 4.691428046044166e-07
, O 0 7.4189885346243045e-09
including O 0 2.066834259295547e-09
one O 0 1.7476776692504359e-09
derived O 0 8.719258204337166e-09
from O 0 1.1222852647208015e-09
the O 0 1.3021047573502642e-09
skipping O 0 4.413468346342597e-08
of O 0 1.7170219690498811e-09
exon O 0 2.2959402201649937e-07
32 O 0 3.045364138642981e-08
, O 0 5.537859504300968e-09
were O 0 3.0370575387905774e-08
also O 0 1.1911136965636615e-07
identified O 0 4.182222255622037e-06
. O 0 1.4764606248718337e-06

These O 0 1.5893690488155698e-06
results O 0 1.8963401089422405e-06
indicate O 0 1.5220112459246593e-07
the O 0 9.926890420786094e-09
usefulness O 0 1.3424171640963323e-07
of O 0 1.8819423797111767e-09
cycloheximide O 0 1.3257647424325114e-06
treatment O 0 1.945646062040396e-07
in O 0 1.3560558898007002e-08
evaluating O 0 1.4180969287735934e-07
the O 0 1.781784497723038e-08
abnormal O 0 2.614081324736617e-07
processing O 0 5.577029327241689e-08
of O 0 2.6737387859299133e-09
mRNA O 0 6.595882240389983e-08
due O 0 4.1685176199735e-08
to O 0 7.044309580095387e-09
splice O 0 2.8405191187630408e-05
- O 0 5.854383289261023e-06
site O 0 3.455797070728295e-07
mutations O 0 5.159843112778617e-07
, O 0 4.401142117416157e-09
because O 0 1.9199617895537813e-08
( O 0 2.9986804150894386e-09
i O 0 3.442073648329824e-08
) O 0 1.5103152062323488e-09
aberrant O 0 2.7887047338026605e-08
splicing O 0 2.493246427093254e-07
often O 0 5.323049734329288e-08
generates O 0 4.8814452924261786e-08
a O 0 7.595566131612941e-08
premature O 0 1.339114874099323e-06
termination O 0 4.513419469276414e-07
codon O 0 9.289253171118617e-07
, O 0 1.25525954075556e-08
( O 0 3.0446596355204747e-09
ii O 0 8.735425893746651e-08
) O 0 3.249658542259226e-09
transcripts O 0 7.161852977333183e-08
with O 0 9.857945570956872e-09
premature O 0 4.559898627576331e-07
termination O 0 1.82752827981858e-07
codons O 0 2.974589676796313e-07
can O 0 1.749582878574074e-08
occur O 0 1.438223673488892e-08
at O 0 1.7783316152986117e-08
low O 0 6.453137757489458e-07
or O 0 2.1791949222915719e-07
undetectable O 0 0.0001513992465334013
levels O 0 2.8033016974404745e-07
due O 0 2.0748455398234e-08
to O 0 1.3658889130852003e-08
nonsense O 0 7.893038969086774e-07
- O 0 1.7708555333229015e-07
mediated O 0 9.713689763657385e-08
mRNA O 0 2.5010809423520186e-08
decay O 0 4.7382940238094307e-08
, O 0 1.7909799199244958e-09
and O 0 2.0639978615122345e-09
( O 0 8.213289492964293e-10
iii O 0 3.837223871983042e-08
) O 0 2.160424728003818e-09
the O 0 2.70943867342055e-09
levels O 0 1.1734991645084847e-08
of O 0 6.078107461782167e-11
these O 0 8.396507933383646e-10
transcripts O 0 4.742009807046088e-08
can O 0 1.603307353548189e-08
be O 0 4.132219899588563e-09
increased O 0 1.2489118184078052e-08
by O 0 3.7971368271882966e-08
cycloheximide O 0 2.5705865482450463e-05
. O 0 2.6279892608727096e-06

A O 0 2.7519952254806412e-06
deletion O 0 1.014246117847506e-05
mutation O 0 6.174984719109489e-06
in O 0 5.778369427389407e-08
COL17A1 O 0 1.5617059034411795e-05
in O 0 3.59953027384563e-08
five O 0 4.97594783155364e-08
Austrian O 0 1.7718497474561445e-05
families O 0 7.907469523615873e-08
with O 0 4.899223426946264e-08
generalized O 0 8.517802780261263e-05
atrophic B-Disease 1 0.9998488426208496
benign I-Disease 1 0.9907515048980713
epidermolysis I-Disease 1 0.9566888809204102
bullosa I-Disease 0 0.17860464751720428
represents O 0 2.70999862550525e-06
propagation O 0 1.4573707858289708e-06
of O 0 4.377869800009648e-08
an O 0 8.938794593404964e-08
ancestral O 0 1.6967387637123466e-05
allele O 0 0.00044312761747278273
. O 0 1.6101301298476756e-05

Patients O 0 0.00033416959922760725
with O 0 2.361045289944741e-06
generalized O 0 0.00021537077554967254
atrophic B-Disease 1 0.9987949132919312
benign I-Disease 1 0.9861418604850769
epidermolysis I-Disease 1 0.9806922674179077
bullosa I-Disease 1 0.9580296277999878
, O 0 3.5509043527781614e-07
a O 0 4.04671354203856e-08
usually O 0 6.797967699867513e-08
nonlethal O 0 8.879775350578711e-07
form O 0 3.38854874826211e-07
of O 0 1.5048188117816608e-07
junctional B-Disease 0 0.19447369873523712
epidermolysis I-Disease 1 0.5845310688018799
bullosa I-Disease 0 0.20277072489261627
, O 0 8.206313850678271e-08
have O 0 3.553146044055211e-08
generalized O 0 2.1973129094021715e-07
blistering B-Disease 0 4.709534096036805e-06
, O 0 2.8592029366336646e-07
nail B-Disease 1 0.9906525611877441
dystrophy I-Disease 0 0.00029046423151157796
, O 0 3.4608464716257004e-07
patchy B-Disease 0 0.002581115113571286
alopecia I-Disease 1 0.9996923208236694
, O 0 7.363166218965489e-07
and O 0 3.5969783311884385e-06
dental B-Disease 1 0.9997702240943909
abnormalities I-Disease 1 0.9999308586120605
. O 0 2.2537125914823264e-05

Skin B-Disease 1 0.99880051612854
fragility I-Disease 0 0.0008452670881524682
in O 0 1.5057563018672226e-07
most O 0 3.019337313503456e-08
cases O 0 8.660654060577144e-08
is O 0 2.1051734577781644e-08
due O 0 1.3794935682653886e-07
to O 0 3.7557988719072455e-08
mutations O 0 6.204962801348302e-07
in O 0 8.255700123527276e-09
the O 0 9.850032789415764e-09
gene O 0 2.214381993326242e-07
encoding O 0 6.063780801923713e-07
type O 0 0.00018514523981139064
XVII O 0 8.610724762547761e-05
collagen O 0 1.4821410331933293e-05
( O 0 3.362775089499337e-07
COL17A1 O 0 4.034669109387323e-05
) O 0 6.724807235514163e-07
. O 0 2.592296596048982e-06

Recently O 0 1.77570000232663e-05
, O 0 1.0471059397332283e-07
we O 0 6.548486197743841e-08
reported O 0 7.811797786416719e-08
five O 0 1.7058948031944965e-08
Austrian O 0 7.104848918970674e-06
families O 0 9.36275625917915e-08
with O 0 4.542610554381099e-08
generalized O 0 8.017358049983159e-05
atrophic B-Disease 1 0.9986369013786316
benign I-Disease 1 0.7066553831100464
epidermolysis I-Disease 0 0.4284777045249939
bullosa I-Disease 1 0.8490452766418457
who O 0 6.862597729195841e-06
share O 0 1.0685829465728602e-06
the O 0 2.377429630939787e-08
same O 0 2.482152865468379e-07
COL17A1 O 0 0.0026653390377759933
mutation O 0 4.7654186346335337e-05
. O 0 5.15077999807545e-06

Affected O 0 6.355197001539636e-06
individuals O 0 1.614936877558648e-07
in O 0 1.4866370356969583e-08
three O 0 5.226127086643828e-09
families O 0 7.920613498413331e-09
are O 0 9.268594780564854e-10
homozygous O 0 6.530711260666067e-08
for O 0 2.3038344565406987e-09
4003delTC O 0 1.5160529187596694e-07
, O 0 2.064675097557256e-09
whereas O 0 2.2572464786208002e-08
those O 0 7.368333942991967e-09
in O 0 9.454057092739276e-09
two O 0 9.563709824078614e-09
others O 0 8.573087484364805e-08
are O 0 3.092602085530416e-08
compound O 0 2.4176606530090794e-06
heterozygotes O 0 0.00018156450823880732
. O 0 6.235195542103611e-06

To O 0 7.308959766305634e-07
determine O 0 4.385659053696145e-07
if O 0 3.005433057978735e-08
the O 0 2.7739450736419258e-09
occurrence O 0 9.740777784372767e-08
of O 0 1.4857035601778534e-09
4003delTC O 0 3.0351586133292585e-07
in O 0 4.9573780636080755e-09
these O 0 3.884802257658748e-09
unrelated O 0 9.4375209869213e-08
families O 0 1.1829039081590054e-08
signifies O 0 1.0175662978895161e-08
propagation O 0 1.6210403686045538e-08
of O 0 8.666825590530891e-10
an O 0 1.8291553827154416e-09
ancestral O 0 2.428126890663407e-07
allele O 0 2.1098439901834354e-06
or O 0 9.246531362805399e-08
a O 0 2.0830137614780142e-08
mutational O 0 6.885003585921368e-06
hot O 0 1.2772872651112266e-05
spot O 0 9.028542990563437e-06
, O 0 9.642691090050448e-09
haplotypes O 0 3.8842267713334877e-07
were O 0 1.0236441738697977e-07
determined O 0 1.9240866322434158e-07
for O 0 6.5023582074275055e-09
polymorphisms O 0 2.1585678950941656e-06
both O 0 2.0686297119709707e-08
within O 0 2.3292146877906816e-08
and O 0 1.6970876970390236e-07
flanking O 0 0.00038669936475344
COL17A1 O 0 0.02159418724477291
. O 0 4.892457582172938e-06

Five O 0 4.798936970473733e-06
intragenic O 0 3.4822398447431624e-05
polymorphisms O 0 4.4604654249269515e-05
were O 0 4.1546635998201964e-07
chosen O 0 1.9812637219729368e-07
based O 0 4.6637570250140925e-08
on O 0 4.393085006881847e-08
their O 0 4.378767641810555e-07
informativeness O 0 0.00016479368787258863
. O 0 6.1855994317738805e-06

One O 0 2.4931870257205446e-07
of O 0 3.6396741176503156e-09
these O 0 3.2403870697805814e-09
, O 0 1.27674926186927e-09
not O 0 5.0946944440966035e-09
previously O 0 1.5298491007342818e-07
reported O 0 3.0493927738461934e-07
, O 0 3.520668867551535e-09
was O 0 2.643800769419613e-07
2988 O 0 1.971900900343826e-07
A O 0 3.2967953700335784e-08
or O 0 1.089769057216472e-06
C O 0 1.2442403203749564e-05
that O 0 1.940230198727022e-09
introduces O 0 8.177638122219832e-09
a O 0 4.71769467935701e-09
new O 0 5.910039568846059e-09
restriction O 0 1.9883348301164006e-08
site O 0 3.907625867327624e-08
for O 0 8.055893729874697e-09
Eco0109 O 0 3.876872142427601e-06
I O 0 2.4732307792874053e-06
. O 0 1.1187668178536114e-06

All O 0 4.848698154091835e-07
the O 0 1.1002351385513975e-07
4003delTC O 0 2.705453653106815e-06
alleles O 0 1.2365717338980176e-06
showed O 0 1.7243785066511919e-07
the O 0 9.21706888590279e-09
same O 0 2.3176218277853877e-08
haplotype O 0 1.0893097623920767e-06
for O 0 1.1657935949926923e-08
these O 0 2.2526704057668212e-08
five O 0 6.371997329779333e-08
polymorphic O 0 9.02294777915813e-06
markers O 0 7.330913649639115e-05
. O 0 6.570633104274748e-06

Fourteen O 0 1.0614614438964054e-05
microsatellite O 0 9.359047544421628e-05
polymorphisms O 0 6.078051956137642e-05
were O 0 4.473971557672485e-07
selected O 0 3.662580283503303e-08
based O 0 2.249300123935427e-08
on O 0 1.7025239884560506e-08
their O 0 4.815271026359369e-08
high O 0 2.1498572095879354e-06
heterozygosity O 0 1.4665862181573175e-05
and O 0 4.92157994358422e-08
their O 0 2.8806542928805356e-08
location O 0 6.623744184253155e-07
within O 0 7.401198587331237e-08
10q23 O 0 1.3561468222178519e-05
- O 0 5.139768836670555e-05
q25 O 0 2.79269261227455e-05
near O 0 2.991164365084842e-06
COL17A1 O 0 0.0002093063376378268
. O 0 6.740307071595453e-06

Three O 0 1.5671580513298977e-06
families O 0 1.0125868357135914e-06
shared O 0 6.262766305553669e-07
microsatellite O 0 1.5685331163695082e-05
polymorphisms O 0 2.074131043627858e-05
covering O 0 1.5066495961946202e-06
at O 0 3.452236398970854e-07
most O 0 1.7974008059695734e-08
19 O 0 2.5986796714505545e-08
cM O 0 1.9851977128837461e-07
, O 0 5.414695358751942e-09
whereas O 0 2.347375627209658e-08
the O 0 8.35174152058471e-09
others O 0 2.7454593265474614e-08
shared O 0 1.4695412886567283e-08
smaller O 0 9.563513003740809e-08
regions O 0 2.343993266151756e-08
consistent O 0 1.9708612342128617e-07
with O 0 5.630328203665158e-09
cross O 0 6.45599629933713e-06
- O 0 0.0002142112352885306
over O 0 2.003264576444508e-08
events O 0 1.3474188875761683e-08
during O 0 6.830287890835507e-09
passage O 0 1.6312664996576132e-08
of O 0 1.5387294771684878e-09
this O 0 9.0896232762816e-09
mutation O 0 1.873752495384906e-07
through O 0 2.2478589656316217e-08
several O 0 1.3935971310274908e-07
generations O 0 3.711317503984901e-06
. O 0 2.380025989623391e-06

These O 0 1.653002186685626e-06
results O 0 1.3886159422327182e-06
indicate O 0 1.3522441122404416e-07
that O 0 1.1102734731593955e-08
4003delTC O 0 6.844662152616365e-07
occurs O 0 2.6626459259659896e-08
on O 0 6.905676031010444e-09
a O 0 1.0609388034765743e-08
single O 0 2.821228122229513e-07
ancestral O 0 1.5460783515663934e-06
allele O 0 2.6913367037195712e-05
. O 0 8.693089625921857e-07
. O 0 2.974520384668722e-06

The O 0 8.849831829138566e-06
haptoglobin O 0 0.00033425880246795714
- O 0 4.013198122265749e-05
gene O 0 6.422074420697754e-06
deletion O 0 2.202720133936964e-05
responsible O 0 2.3112600047170417e-06
for O 0 3.389000937659148e-07
anhaptoglobinemia B-Disease 0 0.00015643220103811473
. O 0 8.820072253001854e-06

We O 0 7.551603175670607e-06
have O 0 1.0547933015914168e-07
found O 0 3.709968510179351e-08
an O 0 4.350033222522143e-09
allelic O 0 5.395860966928012e-07
deletion O 0 1.188384203487658e-06
of O 0 9.002405931823887e-09
the O 0 5.820824355851073e-08
haptoglobin O 0 7.592764632136095e-06
( O 0 1.2118382741732603e-08
Hp O 0 8.510557591989709e-08
) O 0 3.157062833381019e-09
gene O 0 3.492546341021807e-08
from O 0 4.713404333500648e-09
an O 0 5.090566634891047e-09
individual O 0 1.0019876128808392e-07
with O 0 1.1878805850074059e-07
anhaptoglobinemia B-Disease 0 0.0021600802429020405
. O 0 3.4455076729500433e-06

The O 0 1.1373530242053675e-06
Hp O 0 1.977195324798231e-06
gene O 0 5.711746098313597e-07
cluster O 0 4.836136895391974e-07
consists O 0 2.2748507078063085e-08
of O 0 5.041720818610429e-09
coding O 0 3.276607458246872e-05
regions O 0 2.5249298118978913e-07
of O 0 5.752930132274514e-09
the O 0 3.2241558756140876e-08
alpha O 0 6.362888882449624e-08
chain O 0 7.237603767862311e-06
and O 0 3.65388643785991e-08
beta O 0 8.960558517401296e-08
chain O 0 4.779256528308906e-07
of O 0 2.2969808277650827e-09
the O 0 9.49332168431738e-09
haptoglobin O 0 8.928959687182214e-07
gene O 0 1.0154998619782418e-07
( O 0 2.9527815748053854e-09
Hp O 0 2.6959751764366047e-08
) O 0 2.085815742347563e-09
and O 0 1.4428086503315285e-09
of O 0 6.3834509900218e-10
the O 0 7.402789936605814e-09
alpha O 0 2.8321611722503803e-08
chain O 0 7.552064289484406e-06
and O 0 1.5150765975135982e-08
beta O 0 3.1444326253904364e-08
chain O 0 1.6153619242231798e-07
of O 0 8.092496117662051e-10
the O 0 2.7283373782438503e-08
haptoglobin O 0 1.2398270882840734e-05
- O 0 1.4916379313945072e-06
related O 0 6.747754355274083e-08
gene O 0 1.1227338347907789e-07
( O 0 5.92375126728939e-09
Hpr O 0 5.242473548605631e-07
) O 0 4.732619185432441e-09
, O 0 1.5422347843241369e-09
in O 0 4.9970787507902514e-09
tandem O 0 7.727607567176165e-07
from O 0 1.935293347798961e-08
the O 0 3.8765435306231666e-08
5 O 0 1.6612976594387874e-07
side O 0 7.342897333728615e-06
. O 0 2.5619565349188633e-06

Southern O 0 1.0812999789777678e-05
blot O 0 4.7802157496334985e-05
and O 0 1.4558771965766937e-07
PCR O 0 4.573422302200925e-06
analyses O 0 6.056383199393167e-07
have O 0 5.1573582737773904e-08
indicated O 0 3.095983558409898e-08
that O 0 1.607017074967132e-09
the O 0 1.0622788204628364e-09
individual O 0 2.8941014029726375e-09
with O 0 1.3023505607279162e-09
anhaptoglobinemia B-Disease 0 1.5314227539420244e-06
was O 0 2.745585092611691e-08
homozygous O 0 7.699009074713103e-08
for O 0 8.155967012868359e-10
the O 0 1.383637426854989e-09
gene O 0 2.0342914908155763e-08
deletion O 0 1.980545931701272e-07
and O 0 1.1682264933199349e-08
that O 0 1.051806974849967e-09
the O 0 1.1974473634879246e-09
gene O 0 2.653226438553702e-08
deletion O 0 2.67970904133108e-07
was O 0 8.849799826293747e-08
included O 0 1.7106672745015317e-09
at O 0 6.263438656617382e-09
least O 0 1.1565530755319742e-09
from O 0 1.268968152778882e-09
the O 0 4.013948728953665e-09
promoter O 0 2.910225589403126e-07
region O 0 4.912239148779918e-08
of O 0 5.463516306036809e-09
Hp O 0 2.2993145876171184e-07
to O 0 2.6978939970945248e-08
Hpr O 0 8.722254278836772e-07
alpha O 0 3.820004579324632e-08
but O 0 1.874205679541774e-08
not O 0 1.3172732238331264e-08
to O 0 3.0712929088849705e-08
Hpr O 0 4.497903773881262e-06
beta O 0 5.3976629033059e-07
( O 0 5.188041640735719e-08
Hpdel O 0 3.551744612195762e-06
) O 0 3.1228859143084264e-07
. O 0 1.0571684470050968e-06

In O 0 3.2567717767051363e-07
addition O 0 5.5489746131343054e-08
, O 0 1.1372707220402845e-08
we O 0 9.43292821631303e-09
found O 0 4.622785709784694e-09
seven O 0 1.7279756514554379e-09
individuals O 0 6.038567978983167e-10
with O 0 5.501797906148909e-10
hypohaptoglobinemia B-Disease 0 2.85945566247392e-06
in O 0 1.1035764302391726e-08
three O 0 5.997455421180575e-09
families O 0 7.1505072973820916e-09
, O 0 2.103498486505373e-09
and O 0 4.921981044958557e-09
the O 0 4.317103563522551e-09
genotypes O 0 2.2316984882309043e-07
of O 0 3.8805123003804454e-10
six O 0 2.7122306622828773e-09
of O 0 3.3967625934216983e-10
the O 0 2.4687087929464724e-09
seven O 0 1.8997292627886964e-09
individuals O 0 1.236632574119767e-09
were O 0 5.728589158593422e-09
found O 0 9.97367166633012e-09
to O 0 7.01797109314839e-09
be O 0 1.0288960083926213e-07
Hp2 O 0 1.3433278581942432e-05
/ O 0 4.0625241126690526e-06
Hpdel O 0 6.0352369473548606e-05
. O 0 4.76350351164001e-06

The O 0 1.5580377521473565e-06
phenotypes O 0 8.275825166492723e-06
and O 0 1.3162917866793578e-07
genotypes O 0 3.981365807703696e-06
in O 0 3.876994725260374e-08
one O 0 8.591629629961517e-09
of O 0 3.6716832352290396e-10
these O 0 4.376564888275425e-09
three O 0 5.955631543486106e-09
families O 0 1.0860153665248617e-08
showed O 0 1.1559255597148876e-07
the O 0 2.36739206016523e-09
father O 0 1.761862655769164e-08
to O 0 4.201377912238513e-09
be O 0 9.490587871141543e-09
hypohaptoglobinemic B-Disease 0 3.346104904267122e-07
( O 0 3.327585096357666e-09
Hp2 O 0 2.075333043194405e-07
) O 0 4.028437139425023e-09
and O 0 4.6295181022060206e-09
Hp2 O 0 8.684852446094737e-07
/ O 0 1.1549613532224612e-07
Hpdel O 0 1.0594192190183094e-06
, O 0 2.2144226452525118e-09
the O 0 1.0975429454163077e-09
mother O 0 2.6062295432893734e-08
to O 0 2.910786722765124e-09
be O 0 5.467394537106429e-09
Hp2 O 0 3.898187230788608e-07
- O 0 1.908126847638414e-07
1 O 0 5.147950066231033e-09
and O 0 5.5286144551303096e-09
Hp1 O 0 4.349824394012103e-07
/ O 0 5.4823924955371695e-08
Hp2 O 0 2.427796061965637e-07
, O 0 1.7688047693198428e-09
one O 0 6.461308710292712e-10
of O 0 2.087358896840641e-10
the O 0 2.1472132960553836e-09
two O 0 4.233740025227917e-09
children O 0 8.237423188006687e-09
to O 0 2.866063830708754e-09
be O 0 5.351265652819848e-09
hypohaptoglobinemic B-Disease 0 1.438284584764915e-07
( O 0 1.2318371878095036e-09
Hp2 O 0 9.086853225426239e-08
) O 0 2.4439763546268978e-09
and O 0 5.5469722148870915e-09
Hp2 O 0 8.344164257323428e-07
/ O 0 1.0194763433446496e-07
Hpdel O 0 6.098159133216541e-07
, O 0 1.3091248085572715e-09
and O 0 1.1041612069107032e-09
the O 0 5.960355542455886e-10
other O 0 1.0879658285389837e-09
child O 0 7.997853934682553e-09
to O 0 1.7435356491901643e-09
be O 0 3.2270643934850796e-09
Hp1 O 0 1.2114088576709037e-07
and O 0 1.2066303511915066e-08
Hp1 O 0 1.178896695819276e-06
/ O 0 9.837381753641239e-08
Hpdel O 0 4.125926409415115e-07
, O 0 4.220300109381014e-09
showing O 0 2.618966377099241e-08
an O 0 3.2329292576349644e-09
anomalous O 0 4.492471532557829e-07
inheritance O 0 1.5795426406839397e-06
of O 0 8.546552798804896e-09
Hp O 0 1.0080505035148235e-06
phenotypes O 0 2.321412694072933e-06
in O 0 2.980656788054148e-08
the O 0 5.620288234808868e-08
child O 0 6.931264806553372e-07
with O 0 1.2779879909885494e-07
Hp1 O 0 0.00025610337615944445
. O 0 3.768618853428052e-06

The O 0 1.8357519593337202e-06
Hp2 O 0 2.23805800487753e-05
/ O 0 3.6203907711751526e-06
Hpdel O 0 1.852358423093392e-06
individuals O 0 4.512033058290399e-08
had O 0 2.0814061940654938e-07
an O 0 5.848185935519723e-09
extremely O 0 1.057887516253686e-06
low O 0 0.00026767238159663975
level O 0 1.9058062150634214e-07
of O 0 4.9915445110571e-09
Hp O 0 4.413401200054068e-07
( O 0 8.705166365530204e-09
mean O 0 7.914545818721308e-08
+ O 0 5.260061470835353e-07
/ O 0 6.316522558336146e-07
- O 0 3.324639328639023e-05
SD O 0 0.0004183802811894566
= O 0 1.6186958191610756e-06
0 O 0 4.8615980574595596e-08
. O 0 1.5997576596760155e-08
049 O 0 2.4220291834353702e-06
+ O 0 4.3975072117063974e-07
/ O 0 4.271662987775926e-07
- O 0 1.062218416336691e-06
0 O 0 6.317323908433536e-08
. O 0 3.184053909421891e-08
043 O 0 1.3722980156671838e-06
mg O 0 8.007334599824389e-07
/ O 0 2.0110827847474866e-07
ml O 0 5.2841448905383e-07
; O 0 2.017936928666586e-08
n O 0 4.797303745363024e-07
= O 0 3.9577665233991866e-07
6 O 0 6.6997758452203016e-09
) O 0 1.3739203108542597e-09
, O 0 5.039257344741088e-10
compared O 0 9.776921494619728e-09
with O 0 2.045511315884596e-09
the O 0 2.07919939043677e-08
level O 0 1.3662490516708203e-07
( O 0 9.545116919085217e-10
1 O 0 2.6547639642160448e-09
. O 0 3.5721914315445247e-09
64 O 0 9.635410691544166e-09
+ O 0 1.3311017710293527e-07
/ O 0 1.351942415794838e-07
- O 0 7.687158927183191e-07
1 O 0 2.3483607947127894e-08
. O 0 1.6959640802838294e-08
07 O 0 3.6046284890289826e-07
mg O 0 3.730077366981277e-07
/ O 0 1.1807740918357013e-07
ml O 0 2.3471747567782586e-07
) O 0 2.135047472151541e-09
obtained O 0 1.1991553527934684e-08
from O 0 4.594586044959215e-09
52 O 0 4.3530732796170923e-08
healthy O 0 3.099085432722859e-08
volunteers O 0 1.941856453413493e-08
having O 0 4.523735341877e-08
phenotype O 0 1.7336797100142576e-06
Hp2 O 0 1.1827040680145728e-06
, O 0 6.684242048748956e-09
whereas O 0 1.612652233973222e-08
the O 0 4.208540183014975e-09
serum O 0 2.9048547389720625e-07
Hp O 0 7.004974378332918e-08
level O 0 1.654182746335664e-08
of O 0 4.712763512770834e-10
an O 0 3.1994846771965513e-09
individual O 0 1.390994253114286e-08
with O 0 1.3882879734694598e-08
Hp1 O 0 0.00011642692697932944
/ O 0 1.5213016695270198e-06
Hpdel O 0 3.277979703852907e-05
was O 0 1.3809246866003377e-06
0 O 0 7.441042271238985e-07
. O 0 2.2766359961678972e-06

50 O 0 6.7703676904784516e-06
mg O 0 1.2383144166960847e-05
/ O 0 2.201687493652571e-06
ml O 0 3.24911015923135e-05
, O 0 8.31131430345522e-09
which O 0 3.1876008499409636e-09
was O 0 1.0551067575192974e-08
approximately O 0 1.6736297903108266e-09
half O 0 1.0510574632860425e-08
the O 0 3.5933687136946446e-09
level O 0 1.317431586045359e-08
of O 0 1.0383401916058688e-09
Hp O 0 1.4170856843520596e-07
in O 0 3.588001007415187e-08
control O 0 2.920403630923829e-06
sera O 0 1.8149223990349128e-07
from O 0 2.085863481937622e-09
the O 0 9.512753251783579e-09
Hp1 O 0 2.919323151218123e-06
phenotype O 0 1.4387815099325962e-06
( O 0 4.592640934220071e-09
1 O 0 4.791374852430863e-09
. O 0 8.724348354860467e-09
26 O 0 9.751110141564823e-09
+ O 0 7.240279131792704e-08
/ O 0 1.429857263701706e-07
- O 0 7.626674687344348e-07
0 O 0 3.7588019807799355e-08
. O 0 1.0256254512341911e-08
33 O 0 2.5492235877777603e-08
mg O 0 3.892165523211588e-07
/ O 0 2.2490175410894153e-07
ml O 0 1.4900329006195534e-06
; O 0 3.2518553183535914e-08
n O 0 2.0027353002660675e-06
= O 0 2.8423842195479665e-06
9 O 0 2.8496145887402236e-08
) O 0 4.108251072665325e-09
, O 0 2.089251882608778e-09
showing O 0 5.194012331344311e-08
a O 0 2.395025155976782e-08
gene O 0 9.477880666963756e-07
- O 0 2.7883015718543902e-05
dosage O 0 0.00021356598881538957
effect O 0 5.358241196518065e-06
. O 0 2.3255092855833936e-06

The O 0 3.0278934559646586e-07
other O 0 3.1572213288200146e-08
allele O 0 1.0473771681063226e-06
( O 0 1.495093826520133e-08
Hp2 O 0 6.731698363182659e-07
) O 0 3.5528189279432354e-09
of O 0 4.240130468957659e-10
individuals O 0 2.006785848607251e-09
with O 0 2.357843253975034e-09
Hp2 O 0 3.454944089753553e-05
/ O 0 5.964666343061253e-07
Hpdel O 0 4.9960035539697856e-06
was O 0 2.083515369122324e-07
found O 0 7.122304079842934e-09
to O 0 2.898631334957713e-09
have O 0 1.2837753082806103e-08
, O 0 6.805654373387426e-10
in O 0 4.2739159433757834e-10
all O 0 7.05303093706533e-10
exons O 0 1.3564392986609164e-07
, O 0 1.1997227211679728e-08
no O 0 2.2300257640495147e-08
mutation O 0 1.299722640624168e-07
, O 0 2.581481695074217e-09
by O 0 8.116552763226537e-09
DNA O 0 9.860879117695731e-07
sequencing O 0 5.173380941414507e-06
. O 0 2.0056156699865824e-06

On O 0 3.398490378003771e-07
the O 0 1.51320520558329e-08
basis O 0 6.383040318524991e-09
of O 0 7.174287830480353e-10
the O 0 3.1743316863952487e-09
present O 0 2.402583731964114e-08
study O 0 1.4135703274575917e-08
, O 0 1.2803902382785282e-09
the O 0 7.283055825091367e-10
mechanism O 0 4.043879897608349e-09
of O 0 5.223373955587363e-10
anhaptoglobinemia B-Disease 0 1.7978931055040448e-06
and O 0 7.270748447751885e-09
the O 0 2.7185647066829688e-09
mechanism O 0 1.2211611277734846e-08
of O 0 1.5683569998259372e-09
anomalous O 0 5.545440444620908e-07
inheritance O 0 2.635875716805458e-06
of O 0 1.6971775096408237e-08
Hp O 0 1.0564579042693367e-06
phenotypes O 0 5.188474915485131e-06
were O 0 3.0986987553660583e-07
well O 0 5.043878559263248e-07
explained O 0 8.598430213169195e-06
. O 0 2.975970119223348e-06

However O 0 9.797917300602421e-06
, O 0 1.5366309469300177e-07
the O 0 3.9645769334129e-08
mechanism O 0 2.986980121022498e-07
of O 0 1.53232264210601e-07
hypohaptoglobinemia B-Disease 0 0.00040341331623494625
remains O 0 1.2887496268376708e-05
unknown O 0 3.886059857904911e-05

ATM O 0 0.00039036860107444227
mutations O 0 0.00014294247375801206
and O 0 6.989372423049645e-07
phenotypes O 0 5.0141377869294956e-05
in O 0 6.621724878641544e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
families O 0 4.0455492126056924e-05
in O 0 2.1107868519720796e-07
the O 0 1.0630033386860305e-07
British O 0 0.009674007073044777
Isles O 0 4.560739398584701e-06
: O 0 2.698515189081263e-09
expression O 0 3.2728728616149283e-09
of O 0 5.072101072478574e-10
mutant O 0 3.3998254878042644e-08
ATM O 0 2.5414928472855536e-07
and O 0 5.72104363882886e-09
the O 0 1.4551575056032107e-08
risk O 0 5.441211214929353e-07
of O 0 1.0051762977525414e-08
leukemia B-Disease 1 0.9533618688583374
, O 0 2.8818561986554414e-05
lymphoma B-Disease 1 1.0
, O 0 5.812265158056107e-07
and O 0 0.0001450424751965329
breast B-Disease 1 0.9999805688858032
cancer I-Disease 0 0.19043642282485962
. O 0 5.430255441751797e-06

We O 0 1.0928873052762356e-05
report O 0 1.3483936811553576e-07
the O 0 4.56124871206498e-09
spectrum O 0 6.061906532295325e-08
of O 0 3.5607972126427967e-09
59 O 0 9.995767413784051e-08
ATM O 0 5.245501142780995e-06
mutations O 0 2.965343583127833e-06
observed O 0 7.107391866156831e-07
in O 0 6.689613769594871e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.005354151129722595
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 1.2219328482387937e-07
patients O 0 1.901519794955675e-07
in O 0 1.5516862461595338e-08
the O 0 1.3908487517255708e-07
British O 0 0.0006110653048381209
Isles O 0 0.00011333580187056214
. O 0 3.1000249691715e-06

Of O 0 6.502838232336217e-07
51 O 0 2.452856278978288e-06
ATM O 0 1.8760851162369363e-05
mutations O 0 5.8407536016602535e-06
identified O 0 5.092691139907402e-07
in O 0 1.7397594476165068e-08
families O 0 1.3248905972318425e-08
native O 0 2.2055548498656208e-08
to O 0 1.4937455716790282e-08
the O 0 2.0070242356950985e-08
British O 0 0.00023187337501440197
Isles O 0 3.7708045965700876e-06
, O 0 7.196370166440147e-09
11 O 0 3.5264753339703248e-09
were O 0 8.55702442237316e-09
founder O 0 1.8690508696295183e-08
mutations O 0 2.882721901187324e-07
, O 0 2.6210138504012548e-09
and O 0 3.2017313245091827e-09
2 O 0 1.2282570516219948e-09
of O 0 1.9183053756588464e-10
these O 0 3.291616312850465e-09
11 O 0 3.494030398343284e-09
conferred O 0 1.9528469508145463e-08
a O 0 9.209828455425395e-09
milder O 0 3.221401129849255e-06
clinical O 0 6.404168379958719e-05
phenotype O 0 2.109801698679803e-06
with O 0 3.2539320127256133e-09
respect O 0 8.806537721284258e-09
to O 0 1.561960338847257e-08
both O 0 2.229056548230801e-07
cerebellar B-Disease 0 0.0030361777171492577
degeneration I-Disease 0 0.022096462547779083
and O 0 1.0851343859030749e-06
cellular O 0 3.585227022995241e-05
features O 0 1.915785287565086e-05
. O 0 7.477032795577543e-06

We O 0 7.734428436378948e-06
report O 0 1.691790600943932e-07
, O 0 5.065896147016247e-09
in O 0 5.44624523257653e-09
two O 0 7.598245019835304e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 6.135820029840033e-08
, O 0 1.88877469220472e-09
an O 0 3.111320090454228e-09
ATM O 0 3.6576177535607712e-06
mutation O 0 1.0050968057839782e-06
( O 0 1.2020934470058364e-08
7271T O 0 7.062675422275788e-07
- O 0 7.403608378808713e-06
- O 0 2.98931922770862e-06
> O 0 1.6141700598382158e-07
G O 0 1.1618510598054854e-06
) O 0 1.6597062613143976e-09
that O 0 9.952630941612028e-10
may O 0 3.016672565081535e-07
be O 0 4.847502843574603e-09
associated O 0 4.075471959907873e-09
with O 0 3.8636147059456505e-10
an O 0 2.4262063469393524e-09
increased O 0 3.1680161782787764e-07
risk O 0 6.24010954197729e-06
of O 0 1.2621594436268424e-08
breast B-Disease 1 0.9968921542167664
cancer I-Disease 0 0.000159393428475596
in O 0 6.1408282903130385e-09
both O 0 2.349203143126033e-08
homozygotes O 0 7.098773949110182e-06
and O 0 4.0471689999321825e-08
heterozygotes O 0 7.51507570839749e-07
( O 0 1.051755305070401e-08
relative O 0 6.729163146701467e-07
risk O 0 8.101218554656953e-05
12 O 0 1.3246656216381325e-08
. O 0 6.680163533445693e-09
7 O 0 1.2350915845615873e-08
; O 0 2.783889918589466e-08
P O 0 0.00924715120345354
= O 0 2.328023583686445e-06
. O 0 1.859549669802618e-08
0025 O 0 6.20669084128167e-07
) O 0 1.6043035788726456e-09
, O 0 3.1801358768568377e-10
although O 0 1.7950186892434772e-09
there O 0 1.6871358754499965e-09
is O 0 8.605796075755734e-10
a O 0 5.475492947937255e-09
less O 0 1.8224234281660756e-06
severe O 1 0.9376941323280334
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.0018564739730209112
in O 0 1.3516093133603135e-08
terms O 0 2.6819634513230994e-08
of O 0 1.1808067856833304e-09
the O 0 1.4272245607571676e-08
degree O 0 6.320354941635742e-07
of O 0 7.288009840067389e-08
cerebellar B-Disease 0 0.015223944559693336
degeneration I-Disease 0 0.42386260628700256
. O 0 2.461278927512467e-05

This O 0 1.0442682878419873e-06
mutation O 0 5.303366833686596e-06
( O 0 5.8565163385537744e-08
7271T O 0 2.4314206257258775e-06
- O 0 9.426828910363838e-06
- O 0 4.21114646087517e-06
> O 0 5.63603521186451e-07
G O 0 7.460450888174819e-06
) O 0 6.107817362988044e-09
also O 0 2.2245061348513673e-09
allows O 0 3.4289993067204705e-09
expression O 0 7.0394743367785395e-09
of O 0 7.765218468236412e-10
full O 0 1.7480617842124957e-08
- O 0 1.176958406290396e-07
length O 0 5.335125052852163e-08
ATM O 0 4.574511649479973e-07
protein O 0 2.1051814513839417e-08
at O 0 4.219213423084511e-09
a O 0 1.060175724987289e-09
level O 0 5.534375180360485e-09
comparable O 0 4.4060833204184746e-08
with O 0 1.332718935209698e-09
that O 0 5.966899419007632e-09
in O 0 1.6885209674910584e-08
unaffected O 0 2.832609879988013e-06
individuals O 0 1.5669620267999562e-07
. O 0 8.457785725113354e-07

In O 0 1.628590524660467e-07
addition O 0 3.1874261452458086e-08
, O 0 5.973276095971869e-09
we O 0 7.051904837851453e-09
have O 0 2.6859856561145534e-09
studied O 0 4.3000207483601116e-07
18 O 0 1.0483789480986161e-07
A B-Disease 1 0.999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 2.094572664645966e-05
, O 0 1.2499715706937309e-09
in O 0 1.2824946660217051e-09
15 O 0 2.9545053070734184e-09
families O 0 4.787702678754613e-09
, O 0 1.931788951026192e-09
who O 0 3.1730262861628944e-08
developed O 0 2.8110112907597795e-05
leukemia B-Disease 1 0.9765556454658508
, O 0 0.00027872074861079454
lymphoma B-Disease 1 1.0
, O 0 1.1601066773891944e-07
preleukemic O 0 0.0021716528572142124
T O 0 0.08647903800010681
- O 0 1.558376243337989e-05
cell O 0 7.352630291279638e-06
proliferation O 0 6.144616122583102e-07
, O 0 2.414233080116901e-08
or O 0 0.00012201590288896114
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.0636989600243396e-07
mostly O 0 7.484685227154841e-08
in O 0 1.7377340100210859e-07
childhood O 0 2.0503681298578158e-05
. O 0 3.91136518373969e-06

A O 0 2.533345423216815e-06
wide O 0 6.292040666266985e-07
variety O 0 1.2151252803960233e-07
of O 0 9.665265920943966e-09
ATM O 0 8.150457688316237e-06
mutation O 0 2.3208681341202464e-06
types O 0 4.856657938034914e-07
, O 0 9.269995437932721e-09
including O 0 9.578569937218617e-09
missense O 0 4.035465099150315e-05
mutations O 0 0.00010059805208584294
and O 0 1.232865542988293e-07
in O 0 8.901058379251481e-08
- O 0 9.67704108916223e-05
frame O 0 0.004483614582568407
deletions O 0 6.819266218371922e-06
, O 0 2.1097235958222882e-08
were O 0 3.335504317192317e-08
seen O 0 1.2733505627693376e-07
in O 0 2.7921110756778944e-08
these O 0 2.492198234449461e-07
patients O 0 3.7869278912694426e-06
. O 0 1.929446170834126e-06

We O 0 2.7825658435176592e-06
also O 0 4.27923083634596e-08
show O 0 5.2655419580105445e-08
that O 0 3.774749401941335e-09
25 O 0 2.8750155589563064e-09
% O 0 1.1024104962231718e-09
of O 0 4.1322337218652194e-10
all O 0 5.570756229644758e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.6537469238974154e-05
carried O 0 1.2236796465003863e-07
in O 0 1.727132925566366e-08
- O 0 4.5481897359422874e-07
frame O 0 3.3774094845284708e-06
deletions O 0 7.767431497995858e-07
or O 0 9.100555331542637e-08
missense O 0 1.7462310779592372e-06
mutations O 0 8.67304095208965e-07
, O 0 2.8629221215936695e-09
many O 0 7.315634209525967e-10
of O 0 4.4158382506154226e-10
which O 0 7.278486009454355e-07
were O 0 6.234255124581978e-05
also O 0 5.515346401807619e-07
associated O 0 7.07647060949057e-08
with O 0 4.094123706721575e-09
expression O 0 6.623782411452339e-08
of O 0 1.371224378488023e-08
mutant O 0 1.757250061018567e-06
ATM O 0 6.450666660384741e-06
protein O 0 3.3078545129683334e-06
. O 0 2.7283767849439755e-06

The O 0 1.644596068217652e-06
DMPK O 0 2.8143267627456225e-05
gene O 0 2.3871548364695627e-06
of O 0 2.3685612404733547e-07
severely O 0 0.06244093179702759
affected O 0 4.3254844058537856e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 0 0.06698662787675858
is O 0 6.170864708110457e-08
hypermethylated O 0 3.0912215152056888e-06
proximal O 0 2.5585627554391976e-06
to O 0 1.8472621832188452e-07
the O 0 7.484285902137344e-08
largely O 0 6.954034574846446e-07
expanded O 0 2.6699287900555646e-06
CTG O 0 7.109015132300556e-05
repeat O 0 3.611629654187709e-05
. O 0 4.1545426938682795e-06

Using O 0 4.1811017581494525e-06
methylation O 0 9.065557605936192e-06
- O 0 1.7568128896527924e-05
sensitive O 0 1.7422388509658049e-06
restriction O 0 6.37986588003514e-08
enzymes O 0 2.071698474992445e-07
, O 0 9.750700691313341e-09
we O 0 8.632087045157277e-09
characterized O 0 2.665349008168505e-08
the O 0 5.057130270103016e-09
methylation O 0 8.387871730519691e-08
pattern O 0 8.498261081513192e-07
on O 0 4.7840632788620496e-08
the O 0 8.728859413054124e-09
5 O 0 1.4803299919208257e-08
side O 0 6.16668813790966e-08
of O 0 1.9193384659388357e-09
the O 0 1.2165231488836525e-08
CTG O 0 1.794446689018514e-06
repeat O 0 6.878374847474333e-07
in O 0 3.2200306865348693e-09
the O 0 3.595233444286805e-09
DMPK O 0 4.890545710622973e-07
gene O 0 2.8298879684029998e-08
of O 0 6.874499858255945e-10
normal O 0 2.0038493531160384e-08
individuals O 0 2.559878087282641e-09
and O 0 2.9868871820326603e-09
of O 0 3.034982931637842e-09
patients O 0 2.8575180976986303e-07
affected O 0 9.338500461808508e-08
with O 0 9.965803116074312e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999997615814209
, O 0 8.132084161616149e-08
showing O 0 1.278209964539201e-07
expansions O 0 8.92546950126416e-07
of O 0 1.9525938199649318e-08
the O 0 7.401537516216194e-08
repetitive O 0 2.752114596660249e-05
sequence O 0 1.383948347211117e-05
. O 0 9.017219781526364e-06

The O 0 1.5861483007029165e-06
gene O 0 4.723107849713415e-06
segment O 0 3.7260281260387274e-06
analyzed O 0 9.443784279028478e-07
corresponds O 0 2.2803487809142098e-07
to O 0 2.344028793288544e-08
the O 0 3.0432623532306025e-08
genomic O 0 4.131582500122022e-06
SacI O 0 1.9359327779966407e-05
- O 0 3.943813226214843e-06
HindIII O 0 4.373398496682057e-06
fragment O 0 6.69801465846831e-07
carrying O 0 9.061739802973534e-08
exons O 0 2.3011207304080017e-06
11 O 0 4.3531733240342874e-07
- O 0 5.641075858875411e-06
15 O 0 8.707784218131565e-07
. O 0 1.983151605600142e-06

There O 0 1.03720060451451e-06
is O 0 8.439497634071813e-08
constitutive O 0 4.346622972661862e-07
methylation O 0 5.718297302337305e-07
in O 0 3.591314623463404e-08
intron O 0 7.086957339197397e-06
12 O 0 5.810552750062925e-08
at O 0 8.418753694172665e-09
restriction O 0 7.953980585284626e-09
sites O 0 1.2155861206508689e-08
of O 0 1.238953273308141e-09
SacII O 0 4.5617818500431895e-07
and O 0 1.9974422116320056e-08
HhaI O 0 3.204861798167258e-07
, O 0 2.014098443581247e-09
localized O 0 6.139531194548908e-08
1 O 0 1.3856002567536052e-08
, O 0 3.1203117867306673e-09
159 O 0 3.0740064715928384e-08
- O 0 1.343187250313349e-06
1 O 0 2.661620079891236e-08
, O 0 2.2075021810508133e-09
232 O 0 2.730804915529461e-08
bp O 0 1.9740006962365442e-07
upstream O 0 1.2274309568738317e-08
of O 0 6.06376338030401e-10
the O 0 6.886025527563788e-09
CTG O 0 8.519845664523018e-07
repeat O 0 4.113491627322219e-07
, O 0 7.516796074469312e-10
whereas O 0 3.8134508884013485e-09
most O 0 1.5849476175944233e-09
, O 0 9.90861281913169e-10
if O 0 5.635678146376222e-09
not O 0 3.212301313837429e-09
all O 0 2.404717813764279e-10
, O 0 2.0570641023898162e-10
of O 0 5.0294601816602835e-11
the O 0 2.7472324415356297e-10
other O 0 3.112351487644105e-10
sites O 0 3.7010967623984925e-09
of O 0 2.4808669008002937e-10
SacII O 0 2.3329012321937626e-07
, O 0 2.0222745700237965e-09
HhaI O 0 8.626938807765328e-08
, O 0 1.5641179462733135e-09
and O 0 2.3006727634111712e-09
HpaII O 0 7.16316392868066e-08
in O 0 2.4487125660499487e-09
this O 0 1.474611432961126e-09
region O 0 9.449729887478497e-09
are O 0 2.1773940428460037e-09
unmethylated O 0 2.1741421107890346e-07
, O 0 2.160004397566695e-09
in O 0 1.954772788081982e-09
normal O 0 1.3641628271443551e-08
individuals O 0 2.21226525987106e-09
and O 0 2.2921797793173937e-09
most O 0 3.5761931194144836e-09
of O 0 2.9271551849063826e-09
the O 0 1.8138460688987834e-07
patients O 0 3.845595529128332e-06
. O 0 1.2148234418418724e-06

In O 0 6.716039706589072e-07
a O 0 2.7282487380375642e-08
number O 0 8.974511800374785e-09
of O 0 2.812978072697092e-09
young O 0 3.8602596674763845e-08
and O 0 9.951196489055292e-08
severely O 0 0.009419972077012062
affected O 0 1.583701276786087e-07
patients O 0 4.897167968920257e-07
, O 0 3.1666216315784368e-09
however O 0 3.833990547263966e-08
, O 0 1.1173812985987297e-09
complete O 0 1.5743002457213606e-09
methylation O 0 8.040773380457722e-09
of O 0 3.4733241283113614e-10
these O 0 1.6087805532194466e-09
restriction O 0 4.773887951614597e-09
sites O 0 3.960669303637587e-08
was O 0 8.693987041397122e-08
found O 0 1.2286841766240286e-08
in O 0 6.86013423845111e-09
the O 0 4.0365453202184653e-08
mutated O 0 1.7927526641869918e-05
allele O 0 2.99155326501932e-05
. O 0 4.323869234212907e-06

In O 0 2.79714100770434e-07
most O 0 1.8779703125915148e-08
of O 0 1.1541180233720638e-09
these O 0 7.601968832204875e-09
patients O 0 8.924075700633693e-08
, O 0 1.3301235668450317e-09
the O 0 6.8615215731426815e-09
onset O 0 7.96965309746156e-07
of O 0 7.841201465907943e-09
the O 0 9.857356417342089e-06
disease O 0 0.16726113855838776
was O 0 0.05427850782871246
congenital O 1 0.9997091889381409
. O 0 2.5418798031751066e-05

Preliminary O 0 2.3094698917702772e-05
in O 0 1.3194379562264658e-06
vivo O 0 1.19815513244248e-05
footprinting O 0 5.24026618222706e-05
data O 0 5.759003443017718e-07
gave O 0 5.42314282370171e-08
evidence O 0 5.710188943908179e-08
for O 0 7.073660768242007e-09
protein O 0 9.087893459991392e-08
- O 0 6.213691108314379e-07
DNA O 0 1.0056768360300339e-06
contact O 0 1.5957813559452916e-07
in O 0 1.8169375337606652e-08
normal O 0 1.0241948444900117e-07
genes O 0 2.38840442534638e-07
at O 0 7.621208197861051e-08
an O 0 1.1517721887344123e-08
Sp1 O 0 7.110924116204842e-07
consensus O 0 2.2607409277952684e-08
binding O 0 5.113613354978952e-08
site O 0 6.126102647385778e-08
upstream O 0 2.4270498499845417e-08
of O 0 1.5616378190586033e-09
the O 0 7.4261530258468156e-09
CTG O 0 9.071455338016676e-07
repeat O 0 1.7258113302887068e-06
and O 0 1.3133395704301165e-08
for O 0 1.129707660751933e-09
a O 0 2.8891486980597847e-09
significant O 0 2.6285849941132255e-08
reduction O 0 3.5198915782075346e-08
of O 0 3.751692567721676e-10
this O 0 2.233344842395013e-09
interaction O 0 6.620786585642691e-09
in O 0 1.4663382508217637e-08
cells O 0 1.496823642810341e-07
with O 0 1.0784789949980222e-08
a O 0 1.212354163726559e-07
hypermethylated O 0 1.3502725778380409e-05
DMPK O 0 2.008610863413196e-05
gene O 0 2.370087258896092e-06
. O 0 5.935397098255635e-07
. O 0 1.8750480421658722e-06

The O 0 1.122352114180103e-05
hemochromatosis B-Disease 1 0.999914288520813
gene O 0 1.28118263091892e-05
product O 0 1.223237859449e-06
complexes O 0 9.129273621510947e-07
with O 0 3.6456093255310407e-08
the O 0 4.5650807578567765e-08
transferrin O 0 3.926277258869959e-06
receptor O 0 6.487006203315104e-07
and O 0 9.987668647681858e-08
lowers O 0 3.4398767638776917e-06
its O 0 2.358298623050814e-08
affinity O 0 1.77617323515733e-07
for O 0 1.7676219599138676e-08
ligand O 0 1.052556967806595e-06
binding O 0 5.902026259718696e-06
. O 0 4.9305526772513986e-06

We O 0 1.3447736819216516e-05
recently O 0 1.9168608105246676e-06
reported O 0 1.8558969827608962e-07
the O 0 3.346342092314103e-09
positional O 0 1.6469581964884128e-07
cloning O 0 8.441268306569327e-08
of O 0 3.787283375800143e-09
a O 0 2.3025791051622946e-08
candidate O 0 8.283517445306643e-07
gene O 0 3.050072109544999e-06
for O 0 3.373719300725497e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.2670269012451172
HFE O 1 0.9985591769218445
. O 0 4.288326817913912e-05

The O 0 5.330741146281071e-07
gene O 0 1.100911731555243e-06
product O 0 5.050294475950068e-07
, O 0 1.7117615769279837e-08
a O 0 8.927749206577573e-09
member O 0 8.115176086676001e-09
of O 0 5.092671284678829e-10
the O 0 7.509535215888263e-09
major O 0 2.395391334175656e-07
histocompatibility O 0 1.6865993529791012e-05
complex O 0 7.164296221162658e-06
class O 0 1.222285209223628e-05
I O 0 5.076695015304722e-05
- O 0 1.362732859888638e-07
like O 0 1.3103245599666025e-08
family O 0 1.268197014070438e-08
, O 0 1.90539028999126e-09
was O 0 3.234028866927474e-08
found O 0 4.137377995760971e-09
to O 0 2.73871636480294e-09
have O 0 9.556416102896037e-09
a O 0 1.2075465960492693e-08
mutation O 0 1.115292889153352e-06
, O 0 3.1321853555255075e-08
Cys O 0 0.00010237069363938645
- O 0 7.1854392444947734e-06
282 O 0 1.289275246563193e-06
- O 0 2.265756847918965e-05
- O 0 3.484596390990191e-06
> O 0 5.428409508567711e-07
Tyr O 0 7.555842671536084e-07
( O 0 3.230747447346971e-09
C282Y O 0 7.194560680545692e-08
) O 0 2.3918100833242306e-09
, O 0 1.1559929680160508e-09
in O 0 3.402820913933624e-09
85 O 0 2.5967523242798052e-08
% O 0 1.1198952876156909e-08
of O 0 1.4304895046279853e-08
patient O 0 2.6840825739782304e-06
chromosomes O 0 1.72218478837749e-05
. O 0 5.007929303246783e-06

This O 0 8.91481079179357e-07
mutation O 0 4.005907612736337e-06
eliminates O 0 2.6597176656650845e-06
the O 0 3.331930642502812e-08
ability O 0 1.3767888162874442e-07
of O 0 3.916204693865666e-09
HFE O 0 4.01284996769391e-05
to O 0 4.100362005488023e-08
associate O 0 7.072395646900986e-08
with O 0 7.902957399608113e-09
beta2 O 0 0.0014634423423558474
- O 0 0.0026251589879393578
microglobulin O 0 5.01958274981007e-05
( O 0 7.353507580631913e-09
beta2m O 0 9.078812013285642e-07
) O 0 8.440363075123969e-09
and O 0 1.656860426635376e-08
prevents O 0 1.9617364444002305e-07
cell O 0 0.0001679756387602538
- O 0 0.001782730920240283
surface O 0 7.660844858037308e-05
expression O 0 7.306078714464093e-06
. O 0 4.183495093457168e-06

A O 0 2.3869044980528997e-06
second O 0 4.5160587092141213e-07
mutation O 0 8.66522043452278e-07
that O 0 9.330912043026274e-09
has O 0 1.0230737146343927e-08
no O 0 9.201330364305704e-09
effect O 0 3.865424247351257e-08
on O 0 1.468283361560907e-08
beta2m O 0 3.7291706576070283e-06
association O 0 8.37348146376371e-09
, O 0 1.8847945426614388e-09
H63D O 0 4.6971672418294474e-07
, O 0 3.603182863187726e-09
was O 0 2.4033948164969843e-08
found O 0 4.893617067125433e-09
in O 0 1.4951757609793503e-09
eight O 0 2.8991071765460674e-09
out O 0 3.188360908623622e-09
of O 0 1.1292552448693982e-09
nine O 0 2.829315803865029e-08
patients O 0 9.044075000019802e-08
heterozygous O 0 6.987760059473658e-08
for O 0 5.030972083375218e-09
the O 0 2.573125890137362e-08
C282Y O 0 9.956120265997015e-06
mutant O 0 1.1082000128226355e-05
. O 0 2.4577689146099146e-06

In O 0 1.2812406566808932e-06
this O 0 1.0066040090350725e-07
report O 0 7.362071841043871e-08
, O 0 8.637702997305041e-09
we O 0 6.848512423829334e-09
demonstrate O 0 1.4637647538506826e-08
in O 0 9.946373502600636e-09
cultured O 0 5.928733344262582e-07
293 O 0 1.828185531849158e-07
cells O 0 2.401473295776668e-07
overexpressing O 0 3.42295493283018e-06
wild O 0 1.6481037334870052e-07
- O 0 4.134759819862666e-06
type O 0 1.3954193036624929e-06
or O 0 6.771180238729357e-08
mutant O 0 4.7505648126389133e-07
HFE O 0 4.207850452075945e-06
proteins O 0 2.7614564857003643e-08
that O 0 1.6182778450613e-09
both O 0 1.6158165916380085e-09
the O 0 2.688943290252155e-09
wild O 0 7.092766907135228e-08
- O 0 0.00043199167703278363
type O 0 6.97299255989492e-05
and O 0 2.1387212711942993e-07
H63D O 0 0.00010478161129867658
HFE O 0 3.7742836866527796e-05
proteins O 0 2.76384156450149e-07
form O 0 2.940879539892194e-07
stable O 0 5.985059488011757e-07
complexes O 0 4.2850419390561e-07
with O 0 2.146542854575273e-08
the O 0 1.6670269076257682e-07
transferrin O 0 2.8017142540193163e-05
receptor O 0 5.413569851953071e-06
( O 0 1.547507650911939e-07
TfR O 0 1.8537686628405936e-05
) O 0 2.661047062701982e-07
. O 0 9.459341754336492e-07

The O 0 1.3154676707927138e-06
C282Y O 0 1.276131752092624e-05
mutation O 0 3.455820660747122e-06
nearly O 0 3.27719135384541e-07
completely O 0 3.806400627581752e-06
prevents O 0 2.6230662797388504e-07
the O 0 1.7443680278006468e-08
association O 0 1.5462322977555232e-08
of O 0 1.9821393415497823e-09
the O 0 1.8974414928152328e-08
mutant O 0 1.908455715238233e-06
HFE O 0 1.8498289136914536e-05
protein O 0 2.351660413069112e-07
with O 0 3.538132986591336e-08
the O 0 4.102795969629369e-07
TfR O 0 0.000692624191287905
. O 0 5.029438398196362e-06

Studies O 0 1.3219331776781473e-05
on O 0 2.751037584403093e-07
cell O 0 1.2714088370557874e-05
- O 0 1.7401782315573655e-05
associated O 0 1.5881720116794895e-07
transferrin O 0 6.829599783486628e-07
at O 0 1.1325755444602237e-08
37 O 0 3.86998877388578e-09
degrees O 0 4.986684132290975e-08
C O 0 2.9745401661784854e-06
suggest O 0 2.6533276908935477e-08
that O 0 1.3405225818274857e-09
the O 0 2.606665772120209e-09
overexpressed O 0 1.0677812269932474e-06
wild O 0 7.763227216628366e-08
- O 0 1.00049492175458e-05
type O 0 2.7729340672522085e-06
HFE O 0 2.6935320420307107e-05
protein O 0 2.40934610928889e-07
decreases O 0 1.9904565817796538e-07
the O 0 4.295321431868615e-09
affinity O 0 7.30905824752881e-08
of O 0 5.112508194571319e-09
the O 0 9.507604659120261e-08
TfR O 0 2.769478305708617e-05
for O 0 1.4837820572211058e-07
transferrin O 0 3.295038914075121e-05
. O 0 2.8898944037791807e-06

The O 0 3.5996310998598346e-06
overexpressed O 0 3.585346712497994e-05
H63D O 0 6.876275620015804e-06
protein O 0 1.827744426918798e-07
does O 0 4.8986535716721846e-08
not O 0 8.962759423525313e-09
have O 0 3.168131978981137e-09
this O 0 9.449490079305178e-10
effect O 0 1.8528936607253854e-08
, O 0 9.69084590352054e-10
providing O 0 1.7621240022691609e-09
the O 0 7.691897119244118e-10
first O 0 3.2612388345398813e-09
direct O 0 7.882243302503866e-09
evidence O 0 7.767062726315999e-08
for O 0 2.1387687176854797e-09
a O 0 8.718825661446772e-09
functional O 0 2.086634140141541e-06
consequence O 0 6.261482212721603e-07
of O 0 5.8342370934383325e-09
the O 0 1.5561505506411777e-07
H63D O 0 0.001417581457644701
mutation O 0 3.3959302527364343e-05
. O 0 3.4095385217369767e-06

Addition O 0 1.6380000715798815e-06
of O 0 5.2744777434554635e-08
soluble O 0 4.520683432929218e-06
wild O 0 7.064265332701325e-07
- O 0 0.0016590022714808583
type O 0 0.0005694355932064354
HFE O 0 0.22932398319244385
/ O 0 4.602843091561226e-06
beta2m O 0 3.400381274332176e-06
heterodimers O 0 1.6821743429318303e-06
to O 0 2.3985636588008674e-08
cultured O 0 5.172909709472151e-07
cells O 0 2.911444596520596e-07
also O 0 1.8461875583852816e-08
decreased O 0 5.983061868164441e-08
the O 0 5.538472347410561e-09
apparent O 0 1.0045536669167632e-07
affinity O 0 7.86395659702066e-08
of O 0 1.7616266223541288e-09
the O 0 9.161787772882235e-09
TfR O 0 2.455685944369179e-06
for O 0 1.4790479951898305e-09
its O 0 1.2104284241587493e-09
ligand O 0 1.9983568577686128e-08
under O 0 5.850484541269907e-09
steady O 0 1.5289477062196966e-07
- O 0 2.1386490516306367e-06
state O 0 3.220204192189158e-08
conditions O 0 6.124840865595615e-07
, O 0 2.7011621828165744e-09
both O 0 3.809321746928163e-09
in O 0 1.4394778702353506e-08
293 O 0 1.2741134014504496e-07
cells O 0 2.9262224643389345e-07
and O 0 5.1437716308555537e-08
in O 0 1.0761656454860713e-07
HeLa O 0 2.0314539142418653e-05
cells O 0 6.011091045365902e-06
. O 0 2.4403502720815595e-06

Furthermore O 0 6.154354650789173e-06
, O 0 9.017531965582748e-08
at O 0 2.2038854297079524e-08
4 O 0 9.483766660878246e-09
degrees O 0 3.1722277071821736e-07
C O 0 0.0007097509223967791
, O 0 7.0730674650576475e-09
the O 0 8.811998242208574e-09
added O 0 1.1158169144209751e-07
soluble O 0 1.4787265172344632e-06
complex O 0 2.0275092538213357e-07
of O 0 2.2415395761754553e-08
HFE O 0 0.0010831371182575822
/ O 0 1.7482637986176996e-06
beta2m O 0 3.5925456813856727e-06
inhibited O 0 7.097205525496975e-07
binding O 0 1.2847310415509128e-07
of O 0 9.759594910008218e-09
transferrin O 0 1.7123580846600817e-06
to O 0 7.05135647649513e-08
HeLa O 0 6.790724000893533e-06
cell O 0 2.2550018456968246e-06
TfR O 0 4.939834070682991e-06
in O 0 3.764598943689634e-08
a O 0 8.641067950065917e-08
concentration O 0 2.2824775442131795e-05
- O 0 2.7787851649918593e-05
dependent O 0 4.826268195756711e-06
manner O 0 7.772635399305727e-06
. O 0 2.810368187056156e-06

Scatchard O 0 0.0001553757902001962
plots O 0 6.669326467090286e-06
of O 0 2.617518291003762e-08
these O 0 1.177600150725766e-08
data O 0 8.92344615976981e-08
indicate O 0 1.1833759572255076e-07
that O 0 6.254807338734736e-09
the O 0 8.115160099464447e-09
added O 0 4.691074551033125e-08
heterodimer O 0 4.163790663369582e-07
substantially O 0 1.3498788575816434e-06
reduced O 0 1.4736821185579174e-07
the O 0 8.109744875639535e-09
affinity O 0 1.397448698980952e-07
of O 0 2.19387015221173e-08
TfR O 0 9.988179044739809e-06
for O 0 1.8154000258618908e-07
transferrin O 0 6.615628080908209e-05
. O 0 5.126159976498457e-06

These O 0 9.24240225685935e-07
results O 0 1.242860207639751e-06
establish O 0 2.779550811737863e-07
a O 0 3.777257973069936e-08
molecular O 0 1.1789327345468337e-06
link O 0 9.489805051998701e-06
between O 0 9.431348502175751e-08
HFE O 0 0.16398701071739197
and O 0 3.7800401742060785e-07
a O 0 1.7426156517785785e-08
key O 0 7.55897247017856e-08
protein O 0 2.2995639170630966e-08
involved O 0 1.9529847961052837e-08
in O 0 1.2807084281973857e-08
iron O 0 0.004778892267495394
transport O 0 5.226977464189986e-07
, O 0 1.573120522735394e-09
the O 0 3.5737111048206316e-09
TfR O 0 1.8414981468595215e-06
, O 0 2.478862670685089e-09
and O 0 4.287528998503376e-09
raise O 0 5.5684274968825775e-09
the O 0 1.091434720379425e-09
possibility O 0 1.0962213359277939e-08
that O 0 1.1331777738377014e-09
alterations O 0 1.607254631608157e-07
in O 0 5.425385030122243e-09
this O 0 1.6774104327765826e-09
regulatory O 0 1.1193426985300903e-07
mechanism O 0 4.25739621334742e-08
may O 0 7.770693599695733e-08
play O 0 2.0988497606566625e-09
a O 0 2.4644699614384535e-09
role O 0 1.722402309667359e-08
in O 0 6.702651322854081e-09
the O 0 5.02929502488314e-08
pathogenesis O 0 6.193414719746215e-06
of O 0 1.8083326267515076e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0010315979598090053
. O 0 9.1196307039354e-06

Genomic O 0 0.00020085187861695886
organization O 0 2.2688288936478784e-06
of O 0 8.407012330735597e-08
the O 0 1.9052863819979393e-07
UBE3A O 0 0.00010190795728703961
/ O 0 8.74179295351496e-06
E6 O 0 2.03459076146828e-05
- O 0 0.001861382508650422
AP O 0 9.66273873928003e-05
gene O 0 6.744035658812209e-07
and O 0 1.0846474651771132e-07
related O 0 1.4889178601151798e-06
pseudogenes O 0 5.5950615205802023e-05
. O 0 1.037713900586823e-05

The O 0 6.792679869249696e-06
UBE3A O 0 0.000194116699276492
gene O 0 1.120740307669621e-05
encodes O 0 3.548869926817133e-06
the O 0 4.2243374309691717e-07
E6 O 0 2.8613860195036978e-05
- O 0 0.0018177503952756524
AP O 0 2.627339563332498e-05
ubiquitin O 0 6.79096217481856e-07
- O 0 3.1595891414326616e-07
protein O 0 1.7352490999655856e-08
ligase O 0 1.5745412085266253e-08
and O 0 5.023943039361711e-09
has O 0 2.6445350354009634e-09
recently O 0 1.9000962581117165e-08
been O 0 2.4331159309554096e-09
shown O 0 1.6856562812250786e-09
to O 0 1.3028151890637218e-09
be O 0 1.3829388301189738e-08
mutated O 0 8.101528692350257e-06
in O 0 0.09187077730894089
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.01681053452193737
who O 0 3.257209755247459e-07
lack O 0 3.2931069426922477e-07
15q11 O 0 1.2037166925438214e-05
- O 0 3.098367596976459e-05
q13 O 0 5.446659997687675e-06
deletions O 0 4.6691739044035785e-06
or O 0 9.050249900610652e-07
chromosome O 0 5.504930959432386e-05
15 O 0 1.8321474044569186e-06
paternal O 0 0.00010548809223109856
uniparental B-Disease 0 0.14220201969146729
disomy I-Disease 0 0.027681589126586914
. O 0 4.5018266973784193e-05

Previous O 0 2.8876029318780638e-05
UBE3A O 0 0.00021403073333203793
cDNA O 0 1.961947236850392e-05
analysis O 0 2.8334095532045467e-06
has O 0 1.1284036105507766e-07
shown O 0 5.9133800078825516e-08
a O 0 4.484834548179606e-08
coding O 0 9.469746146351099e-06
region O 0 5.259464614937315e-07
of O 0 1.1931209797921838e-08
approximately O 0 1.2592707321346097e-07
2 O 0 5.243103373686608e-07
. O 0 1.8421691265757545e-06

6 O 0 1.3786711861030199e-05
kb O 0 4.184823774266988e-05
and O 0 1.7667733231974125e-07
a O 0 8.653916694356667e-08
3 O 0 4.206487744795595e-07
- O 0 0.0004657057870645076
untranslated O 0 0.005142918322235346
region O 0 8.789976391199161e-07
( O 0 2.577266577930004e-08
UTR O 0 1.0611311154207215e-06
) O 0 7.590348793939938e-09
of O 0 1.3003896848218233e-09
< O 0 5.977529582423813e-08
50 O 0 7.356762310450904e-09
bp O 0 2.1804088135013444e-07
, O 0 1.2636641733010379e-09
whereas O 0 1.0597354993535646e-08
Northern O 0 1.533055815627904e-08
analysis O 0 1.1712031522392863e-07
has O 0 3.0578373610978815e-08
indicated O 0 1.1729330395837678e-08
mRNA O 0 1.0220907675773105e-08
sizes O 0 6.591455559146198e-08
of O 0 2.8471736079893617e-09
5 O 0 6.273209152141135e-08
- O 0 9.445402611163445e-06
8 O 0 4.748657715936133e-07
kb O 0 2.951630267489236e-05
. O 0 3.0643000172858592e-06

We O 0 1.185477344733954e-06
have O 0 3.0487001367873745e-08
analyzed O 0 6.547262643152862e-08
additional O 0 6.8810757092307995e-09
cDNA O 0 6.34520773701297e-08
clones O 0 1.1902870511448782e-07
and O 0 7.1658674549723855e-09
provide O 0 7.3745343165398936e-09
evidence O 0 2.7367804023015196e-08
for O 0 2.20081775026415e-09
an O 0 4.484310700547667e-09
additional O 0 5.845356554345926e-08
0 O 0 5.193764422983804e-07
. O 0 1.4023686389919021e-06

5 O 0 3.927527814084897e-06
kb O 0 1.1107076716143638e-05
of O 0 6.862807566676565e-08
5 O 0 2.3874682142377424e-07
- O 0 4.396787517180201e-06
UTR O 0 3.4075797884725034e-05
and O 0 1.3018228628425277e-07
> O 0 2.1020723295350763e-07
2 O 0 5.21754479620995e-08
kb O 0 1.81842688107281e-06
of O 0 3.739465981311696e-08
3 O 0 9.947721082426142e-07
- O 0 0.00018747161084320396
UTR O 0 0.0010151288006454706
. O 0 6.403226507245563e-06

We O 0 2.935355723820976e-06
have O 0 5.299880712072991e-08
established O 0 3.988103358665285e-08
the O 0 1.0454572318963073e-08
genomic O 0 6.984215019656403e-07
organization O 0 4.2260698052132284e-08
of O 0 6.284991638239035e-09
UBE3A O 0 2.4807050067465752e-06
and O 0 3.241031620859758e-08
the O 0 1.3174918933600566e-08
sequence O 0 9.131679234997137e-08
of O 0 4.824482502385763e-08
intron O 0 0.00015362698468379676
- O 0 0.00011767882097046822
exon O 0 7.295500108739361e-05
borders O 0 2.8030850444338284e-05
. O 0 8.293300197692588e-06

We O 0 6.495861725852592e-06
have O 0 7.116290845488038e-08
also O 0 7.239985500007151e-09
mapped O 0 2.32822941370614e-07
two O 0 6.108062056142671e-09
highly O 0 3.896960265592497e-08
homologous O 0 8.641728044267438e-08
processed O 0 1.428941089898217e-07
pseudogenes O 0 5.965069931335165e-07
, O 0 1.6550727011122035e-08
UBE3AP1 O 0 1.8880932657339144e-06
and O 0 2.911121477211509e-08
UBE3AP2 O 0 9.635135711505427e-07
, O 0 1.4248737745248263e-09
to O 0 1.3812773147492408e-09
chromosomes O 0 3.4231788959004916e-08
2 O 0 9.336503126178286e-09
and O 0 6.92256874046393e-09
21 O 0 7.570251980837384e-09
, O 0 1.568883578606517e-09
respectively O 0 2.326648207429116e-08
, O 0 3.2101696856301487e-09
and O 0 1.675665295408635e-08
determined O 0 1.7689932292341837e-06
their O 0 1.4537683057369577e-07
genomic O 0 7.684097909077536e-06
organization O 0 1.3606685342892888e-06
. O 0 2.349616352148587e-06

These O 0 4.6106185891403584e-07
results O 0 2.342586412851233e-06
will O 0 6.27478646819668e-09
form O 0 4.517628493516668e-09
the O 0 1.227421053684452e-09
basis O 0 4.967875444350511e-09
for O 0 3.678842563914486e-09
studies O 0 2.4847432555930027e-08
of O 0 1.4167006456844433e-09
mutation O 0 4.5942948645461e-07
and O 0 3.43112098732945e-08
imprinting O 0 5.371789484343026e-06
of O 0 3.473056722214096e-07
UBE3A O 0 0.0002856233040802181
. O 0 6.00160501562641e-06

Mutation O 0 7.821068720659241e-05
spectrum O 0 8.933056051319e-06
and O 0 9.302852959081065e-07
genotype O 0 0.010508285835385323
- O 0 0.032664407044649124
phenotype O 0 0.00020506161672528833
analyses O 0 2.9221864679129794e-06
in O 0 3.3787870279411436e-07
Cowden B-Disease 0 0.3277333974838257
disease I-Disease 0 0.00011986778554273769
and O 0 6.111112611506542e-07
Bannayan B-Disease 1 0.9914150834083557
- I-Disease 1 0.9999890327453613
Zonana I-Disease 1 0.999974250793457
syndrome I-Disease 1 0.9999842643737793
, O 0 2.2910668917575094e-07
two O 0 9.407792163074191e-07
hamartoma B-Disease 1 0.8226026296615601
syndromes I-Disease 1 0.7153937220573425
with O 0 1.9928186247852864e-06
germline O 0 0.0049891225062310696
PTEN O 0 0.015382260084152222
mutation O 0 0.0007652273634448647
. O 0 2.430200038361363e-05

The O 0 2.0127677998971194e-05
tumour B-Disease 1 0.9999817609786987
suppressor O 0 0.000130949352751486
gene O 0 1.4852878848614637e-05
PTEN O 0 0.00017401207878720015
, O 0 1.8183041561314894e-07
which O 0 5.825844695550586e-08
maps O 0 8.549243943889451e-07
to O 0 6.273131134548748e-07
10q23 O 0 5.47198869753629e-05
. O 0 5.824594609293854e-06

3 O 0 3.052956117244321e-06
and O 0 9.85432109246176e-08
encodes O 0 5.197114205657272e-07
a O 0 8.655931083012547e-08
403 O 0 4.064102654410817e-07
amino O 0 4.825126893592824e-07
acid O 0 1.7249392385565443e-06
dual O 0 1.1322221325826831e-05
specificity O 0 1.0154830306419171e-05
phosphatase O 0 0.007030724082142115
( O 0 8.47663486069905e-08
protein O 0 2.2158437218422478e-07
tyrosine O 0 6.963477972021792e-07
phosphatase O 0 3.053838008781895e-05
; O 0 1.0512343351365416e-07
PTPase O 0 1.908455715238233e-06
) O 0 1.2372584734521297e-08
, O 0 3.3566978085985966e-09
was O 0 6.246131079024053e-08
shown O 0 1.291728413121973e-08
recently O 0 1.2828481033011485e-07
to O 0 4.347976201302117e-09
play O 0 1.53421115811625e-08
a O 0 9.957060065346468e-09
broad O 0 1.3775189700027113e-07
role O 0 3.2020756179917953e-07
in O 0 1.8256818634654337e-07
human O 0 9.907446383294882e-07
malignancy B-Disease 0 0.06652899831533432
. O 0 5.67313236388145e-06

Somatic O 0 0.00040091024129651487
PTEN O 0 0.00038882187800481915
deletions O 0 2.245581526949536e-05
and O 0 4.3547430550461286e-07
mutations O 0 4.678529876400717e-06
were O 0 6.148108866455004e-08
observed O 0 8.570503950977582e-08
in O 0 2.654461361828453e-08
sporadic B-Disease 0 0.00018484304018784314
breast I-Disease 1 0.9998100399971008
, I-Disease 0 4.126040664687025e-07
brain I-Disease 0 0.0034355055540800095
, I-Disease 0 1.2630124501811224e-07
prostate I-Disease 0 0.06509105116128922
and I-Disease 0 9.928727376973256e-05
kidney I-Disease 0 0.42601901292800903
cancer I-Disease 0 0.0074755167588591576
cell O 0 7.774630648782477e-05
lines O 0 0.00034784252056851983
and O 0 1.1868615246157788e-07
in O 0 1.0573147690706719e-08
several O 0 2.6165247746234854e-08
primary O 0 0.21678383648395538
tumours B-Disease 1 1.0
such O 0 6.599682933483564e-08
as O 0 2.3155178041633917e-06
endometrial B-Disease 1 0.9999934434890747
carcinomas I-Disease 1 1.0
, O 1 0.682643473148346
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9733024835586548
thyroid B-Disease 1 0.9999992847442627
tumours I-Disease 1 1.0
. O 0 7.005404040683061e-05

In O 0 4.245455897944339e-07
addition O 0 1.247833694151268e-07
, O 0 3.1126990762686546e-08
PTEN O 0 9.946736099664122e-06
was O 0 5.831481075802003e-07
identified O 0 7.230894283338785e-08
as O 0 3.6713281303946133e-09
the O 0 4.482044513309802e-09
susceptibility O 0 2.983660749578121e-07
gene O 0 1.1458565296607048e-07
for O 0 3.6784090440278305e-08
two O 0 1.6980961845547426e-06
hamartoma B-Disease 1 0.9998726844787598
syndromes I-Disease 1 0.9999970197677612
Cowden B-Disease 1 0.9999771118164062
disease I-Disease 1 0.5562952756881714
( O 0 3.754645661047107e-08
CD B-Disease 0 1.6280017689496162e-06
; O 0 1.435697072338371e-07
MIM O 0 0.0012195614399388433
158350 O 0 1.3944442116553546e-06
) O 0 1.7861774281868747e-08
and O 0 3.2810000050176313e-08
Bannayan B-Disease 0 0.0007006957894191146
- I-Disease 0 0.012717558071017265
Zonana I-Disease 0 0.00020619605493266135
( I-Disease 0 4.566770073211046e-08
BZS I-Disease 0 4.0806967263051774e-06
) I-Disease 0 1.553252637620517e-08
or I-Disease 0 7.442789495826219e-08
Ruvalcaba I-Disease 0 4.7973368054954335e-05
- I-Disease 0 0.0014899868983775377
Riley I-Disease 0 5.1187020289944485e-05
- I-Disease 1 0.9850401878356934
Smith I-Disease 1 0.9670646786689758
syndrome I-Disease 1 0.9984227418899536
( O 0 1.7206069458097772e-07
MIM O 0 0.0011094523360952735
153480 O 0 1.8162596461479552e-05
) O 0 4.778655124937359e-07
. O 0 2.088877863570815e-06

Constitutive O 0 3.0475683161057532e-05
DNA O 0 9.520172170596197e-06
from O 0 5.5236004214975765e-08
37 O 0 5.513979317584017e-08
CD B-Disease 0 1.4311368090602627e-07
families O 0 3.612501942029667e-08
and O 0 2.9754652075553167e-08
seven O 0 4.4061842174869525e-08
BZS B-Disease 0 8.817086381895933e-06
families O 0 4.7607692010842584e-08
was O 0 9.492293173707367e-08
screened O 0 1.219002569996519e-06
for O 0 1.6854070850058633e-07
germline O 0 9.262882667826489e-05
PTEN O 0 0.00036980706499889493
mutations O 0 0.00014855859626550227
. O 0 9.435039828531444e-06

PTEN O 0 0.0019497741013765335
mutations O 0 0.00011679086310323328
were O 0 4.952834729010647e-07
identified O 0 1.937160902798496e-07
in O 0 1.2315184427791337e-08
30 O 0 1.252650072558481e-08
of O 0 1.506856528443734e-09
37 O 0 3.6739216113801376e-08
( O 0 3.911874379980418e-09
81 O 0 4.6917548957026156e-08
% O 0 1.0900809144231971e-08
) O 0 4.220090943363175e-09
CD B-Disease 0 5.735271315643331e-07
families O 0 2.6465951208365368e-08
, O 0 1.3516704422400494e-09
including O 0 6.9747612130299785e-09
missense O 0 1.17361369120772e-05
and O 0 1.50117230646174e-07
nonsense O 0 3.3591381907172035e-06
point O 0 5.331290253707266e-07
mutations O 0 5.872545330021239e-07
, O 0 2.73799050098944e-09
deletions O 0 1.8489966180368356e-07
, O 0 8.683874064274733e-09
insertions O 0 1.0937839078906109e-06
, O 0 1.5717267487502795e-08
a O 0 2.1582099662964538e-08
deletion O 0 8.923724635678809e-06
/ O 0 8.256284900198807e-07
insertion O 0 1.4450271237365087e-06
and O 0 3.8392084888982936e-07
splice O 0 0.00029765290673822165
site O 0 3.946937795262784e-05
mutations O 0 0.0002773069136310369
. O 0 6.944749202375533e-06

These O 0 5.712955157832766e-07
mutations O 0 1.3299069223648985e-06
were O 0 3.1115590104491275e-08
scattered O 0 2.928664599721742e-08
over O 0 2.359288231446044e-08
the O 0 1.3521095354462886e-08
entire O 0 4.066389180934493e-08
length O 0 1.4452419350163836e-07
of O 0 3.891973854308617e-09
PTEN O 0 1.0487141480552964e-05
, O 0 3.585023611307747e-09
with O 0 6.595096690986679e-10
the O 0 2.610845095674108e-09
exception O 0 1.7450702216592617e-08
of O 0 4.6215137272653806e-10
the O 0 3.0742510759296238e-09
first O 0 2.2724637460669328e-07
, O 0 1.0566071573236968e-08
fourth O 0 2.7298685267851397e-07
and O 0 5.461133412154595e-08
last O 0 4.855759812016913e-07
exons O 0 8.408978828811087e-06
. O 0 3.299681793578202e-06

A O 0 3.844315870082937e-06
hot O 0 4.545706360659096e-06
spot O 0 2.6084780984092504e-06
for O 0 7.141814251099277e-08
PTEN O 0 1.144032103184145e-05
mutation O 0 1.3554802080761874e-06
in O 0 2.123008080445743e-08
CD B-Disease 0 5.501603368429642e-07
was O 0 3.234991652334429e-07
identified O 0 3.82038365387416e-08
in O 0 6.991103695952461e-09
exon O 0 3.799194701059605e-07
5 O 0 1.0931165306260482e-08
that O 0 1.4316079433029927e-09
contains O 0 3.2433362662231957e-09
the O 0 9.938048606272787e-09
PTPase O 0 1.019359160636668e-06
core O 0 1.6132806024415913e-07
motif O 0 1.4802812131620158e-07
, O 0 2.942229127000928e-09
with O 0 1.583334241495038e-09
13 O 0 4.668133435359323e-09
of O 0 1.310143882271575e-09
30 O 0 7.615291508500377e-09
( O 0 2.2647101971529082e-09
43 O 0 2.523530540088359e-08
% O 0 1.0588566468072713e-08
) O 0 7.615436281582788e-09
CD B-Disease 0 4.844344516641286e-07
mutations O 0 1.2159511015852331e-06
identified O 0 1.610231095128256e-07
in O 0 1.7150460607240348e-08
this O 0 6.925966289372809e-08
exon O 0 1.7807245967560448e-05
. O 0 3.506207121972693e-06

Seven O 0 7.745861694274936e-07
of O 0 2.440940249925916e-08
30 O 0 3.58173117831484e-08
( O 0 5.061395302874416e-09
23 O 0 9.790264599018883e-09
% O 0 4.931415276132611e-09
) O 0 2.2670874066932356e-09
were O 0 1.3345764493521983e-08
within O 0 7.155401271496942e-10
the O 0 3.2627258672590642e-09
core O 0 8.308478527396801e-07
motif O 0 5.278644721329329e-07
, O 0 3.326696695893361e-09
the O 0 3.1306308656553483e-09
majority O 0 4.318818724868834e-08
( O 0 9.921112820165945e-10
five O 0 1.0150806861730644e-09
of O 0 4.178559442902241e-10
seven O 0 4.022862487573775e-09
) O 0 8.337540102765217e-10
of O 0 1.593415954737054e-10
which O 0 1.9758665814606502e-08
were O 0 5.290447191441672e-08
missense O 0 4.143661044508917e-06
mutations O 0 2.136923967555049e-06
, O 0 8.056677991419292e-09
possibly O 0 4.620178373215822e-08
pointing O 0 1.2580811414864002e-07
to O 0 1.0557086760343282e-08
the O 0 1.1011795031379279e-08
functional O 0 3.491647930786712e-07
significance O 0 1.1035432123662758e-07
of O 0 7.58119078625441e-09
this O 0 7.79306148501746e-08
region O 0 2.5131466827588156e-06
. O 0 3.69536815014726e-06

Germline O 0 0.004280843771994114
PTEN O 0 0.0010049667907878757
mutations O 0 9.754931670613587e-05
were O 0 6.911146215315966e-07
identified O 0 2.229558333510795e-07
in O 0 6.882676650832309e-09
four O 0 6.176915867683874e-09
of O 0 2.7808264579931574e-09
seven O 0 1.7299418786365095e-08
( O 0 1.0137345185512459e-08
57 O 0 1.4117844671091007e-07
% O 0 1.0802107652807535e-07
) O 0 1.932627071710158e-07
BZS B-Disease 0 4.720091601484455e-05
families O 0 4.652700056340109e-07
studied O 0 4.252609869581647e-06
. O 0 2.6629409148881678e-06

Interestingly O 0 2.606100679258816e-05
, O 0 2.4080506477730523e-07
none O 0 5.631447663745348e-08
of O 0 1.300989982411238e-09
these O 0 1.0771406877552181e-08
mutations O 0 2.7706184937414946e-06
was O 0 1.0118010322912596e-06
observed O 0 2.200034572297227e-07
in O 0 2.1859131393853204e-08
the O 0 6.623782411452339e-08
PTPase O 0 2.474984466971364e-05
core O 0 5.101458555145655e-06
motif O 0 1.022450396703789e-05
. O 0 4.0429981709166896e-06

It O 0 1.7697627754387213e-06
is O 0 2.2470187488465854e-08
also O 0 6.936592633621785e-09
worthy O 0 1.6052778661901357e-08
of O 0 5.480474407626446e-10
note O 0 1.3891387595776905e-07
that O 0 3.5577558676891385e-09
a O 0 5.01716312939493e-09
single O 0 5.008474772694171e-07
nonsense O 0 1.8703688056120882e-06
point O 0 1.2823612394186057e-07
mutation O 0 3.0369915293704253e-07
, O 0 4.177812762407029e-09
R233X O 0 1.128149662577016e-07
, O 0 3.041705332051947e-09
was O 0 1.8846947114070645e-08
observed O 0 1.8680315960750704e-08
in O 0 4.295378719376686e-09
the O 0 8.500577131087539e-09
germline O 0 1.1662538099699304e-06
DNA O 0 5.364511821426277e-07
from O 0 6.050815404279319e-09
two O 0 4.5441939100498985e-09
unrelated O 0 2.1442845365982066e-07
CD B-Disease 0 1.1769071761591476e-06
families O 0 1.1072476269191611e-07
and O 0 9.685162893902088e-08
one O 0 3.14900034936727e-07
BZS B-Disease 0 0.0001154304773081094
family O 0 1.932766735990299e-06
. O 0 1.541331926091516e-06

Genotype O 1 0.7938807010650635
- O 0 0.4247657358646393
phenotype O 0 8.638580038677901e-05
studies O 0 8.689839887665585e-07
were O 0 5.7781047502203364e-08
not O 0 9.453263061232065e-09
performed O 0 1.537198990320121e-08
on O 0 3.5956584376606315e-09
this O 0 4.276845988471223e-09
small O 0 1.1924207399260922e-07
group O 0 1.30653162955241e-07
of O 0 3.7249865414423766e-08
BZS B-Disease 0 7.719393033767119e-05
families O 0 1.1025729236280313e-06
. O 0 1.1775056236729142e-06

However O 0 4.8151155169762205e-06
, O 0 2.476714371368871e-07
genotype O 0 5.689022509614006e-05
- O 0 8.212080138036981e-05
phenotype O 0 1.2721548046101816e-05
analysis O 0 5.152103312866529e-07
inthe O 0 6.60809291730402e-06
group O 0 8.406514950820565e-08
of O 0 3.4233271772876606e-09
CD B-Disease 0 1.0710652986745117e-06
families O 0 1.7380845207526363e-08
revealed O 0 1.1904902663673056e-07
two O 0 2.692787548497222e-09
possible O 0 2.4859424740952818e-08
associations O 0 6.678112729474606e-09
worthy O 0 2.2050290482411583e-08
of O 0 9.816961688002834e-10
follow O 0 5.113622947305885e-08
- O 0 5.161404988029972e-05
up O 0 1.2171224739176978e-07
in O 0 5.0563713216433825e-08
independent O 0 5.469206030284113e-07
analyses O 0 4.81757251691306e-06
. O 0 1.2553070973808644e-06

The O 0 5.370131930249045e-07
first O 0 4.1365126435266575e-07
was O 0 5.882242248844705e-07
an O 0 4.405652731520604e-09
association O 0 7.806893798090186e-09
noted O 0 2.595841053221193e-08
in O 0 1.0515587511861213e-08
the O 0 7.996633577533885e-09
group O 0 2.2555122214384937e-08
of O 0 1.0354646029497871e-09
CD B-Disease 0 5.916340910516737e-07
families O 0 6.212008685224646e-08
with O 0 4.4164369228383293e-07
breast B-Disease 1 0.9999890327453613
disease I-Disease 0 0.019087083637714386
. O 0 6.371739800670184e-06

A O 0 1.2352869589449256e-06
correlation O 0 3.689100367409992e-06
was O 0 2.8189987233417924e-07
observed O 0 5.4924715442439265e-08
between O 0 8.13203371308191e-09
the O 0 1.2360177770176506e-08
presence O 0 1.2246790959125065e-07
/ O 0 4.614159365701198e-07
absence O 0 1.2402590954252446e-08
of O 0 9.556593294490767e-10
a O 0 1.3420018873944173e-08
PTEN O 0 7.049593023111811e-06
mutation O 0 5.392743673837685e-07
and O 0 1.0789213966688749e-08
the O 0 6.5499579093852844e-09
type O 0 1.5115948599486728e-06
of O 0 3.5717093282983114e-08
breast O 0 0.33895090222358704
involvement O 0 2.986922481795773e-06
( O 0 7.34613649910898e-08
unaffected O 0 7.691603968851268e-06
versus O 0 3.729008312802762e-05
benign O 0 0.009920584969222546
versus O 0 0.0007369497325271368
malignant O 1 0.8657512664794922
) O 0 1.7733037793732365e-06
. O 0 3.5783625662588747e-06

Specifically O 0 1.4054573966859607e-06
and O 0 3.276709747979112e-08
more O 0 1.5898860006302584e-09
directly O 0 6.506923888593974e-09
, O 0 4.935273523187789e-09
an O 0 3.2011513440011186e-09
association O 0 6.233346283579522e-09
was O 0 0.00028929131804034114
also O 0 3.0838840814340074e-08
observed O 0 1.4486331245677775e-08
between O 0 1.2333417620524756e-09
the O 0 2.5503992251429963e-09
presence O 0 8.814368790410754e-09
of O 0 2.3922390735009458e-09
a O 0 3.863898356826212e-08
PTEN O 0 0.00010633432248141617
mutation O 0 1.971249730559066e-05
and O 0 8.502220225636847e-06
malignant B-Disease 1 0.9999794960021973
breast I-Disease 1 0.9999934434890747
disease I-Disease 0 0.11958351731300354
. O 0 8.028936463233549e-06

Secondly O 0 7.630005711689591e-05
, O 0 1.7208006397595454e-07
there O 0 1.2981228536546041e-08
appeared O 0 2.9313023119925674e-08
to O 0 7.4203332367517305e-09
be O 0 8.891500868912772e-09
an O 0 4.925906793573631e-09
interdependent O 0 5.326113750925288e-06
association O 0 1.9441616316839827e-08
between O 0 8.445338650631129e-09
mutations O 0 4.0582773408459616e-07
upstream O 0 4.869839287380273e-08
and O 0 8.911043458681434e-09
within O 0 3.1316580439977315e-09
the O 0 1.1655401088717099e-08
PTPase O 0 1.6230936807914986e-06
core O 0 3.907261429958453e-07
motif O 0 3.1379744314108393e-07
, O 0 6.236366978384922e-09
the O 0 3.759316413720626e-09
core O 0 8.951675312118823e-08
motif O 0 6.663864127176566e-08
containing O 0 1.8963344672329185e-08
the O 0 9.684605117854517e-09
majority O 0 3.4710364360535095e-08
of O 0 1.6565941951540708e-09
missense O 0 4.147994786762865e-06
mutations O 0 2.6807570066011976e-06
, O 0 3.3728642101493733e-09
and O 0 4.582980217548993e-09
the O 0 1.8336090423787255e-09
involvement O 0 4.210597737142052e-08
of O 0 8.945045815167418e-10
all O 0 3.1896929542085672e-09
major O 0 6.10365091802123e-08
organ O 0 6.945498171262443e-05
systems O 0 0.00028855609707534313
( O 0 6.287377285474349e-09
central O 0 3.519804536722404e-08
nervous O 0 1.0382979780843016e-05
system O 0 5.080951268610079e-07
, O 0 5.611804354543892e-08
thyroid O 0 0.020122919231653214
, O 0 6.298410681893074e-08
breast O 0 0.45535436272621155
, O 0 2.542421384532645e-07
skin O 1 0.9995991587638855
and O 0 0.042283136397600174
gastrointestinal O 1 0.9996516704559326
tract O 1 0.9826543927192688
) O 0 4.628594524547225e-06
. O 0 5.944777967670234e-06

However O 0 1.7225161172973458e-06
, O 0 9.872885620154648e-09
these O 0 2.3440187568724014e-09
observations O 0 2.1820515172521482e-08
would O 0 6.383636730333819e-09
need O 0 3.0646380988486044e-09
to O 0 1.1526705145925575e-09
be O 0 2.4098889550572267e-09
confirmed O 0 4.284471444293558e-09
by O 0 6.34214014638701e-10
studying O 0 7.633730980671771e-09
a O 0 4.68837058065219e-09
larger O 0 5.820346871132642e-08
number O 0 1.3359747086383322e-08
of O 0 7.237569210616357e-09
CD B-Disease 0 3.6130647913523717e-06
families O 0 9.439498285246373e-07
. O 0 1.4271109876062837e-06

Molecular O 0 0.3081945776939392
defects O 1 0.9891089200973511
leading O 0 1.0785221320475102e-06
to O 0 8.201212864378249e-08
human O 0 1.2092388601558923e-07
complement B-Disease 0 2.7443763883638894e-06
component I-Disease 1 0.8023599982261658
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2447362962575426e-07
an O 0 1.8603159901431354e-08
African O 0 1.2355066303371132e-07
- O 0 1.4789247870794497e-05
American O 0 8.628804266663792e-07
family O 0 8.795350936452451e-07
. O 0 1.6141298146976624e-06

Complement B-Disease 0 0.0006512248073704541
component I-Disease 1 0.9819207787513733
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.092472861178976e-07
C6D B-Disease 0 2.9163593353587203e-05
) O 0 1.3408434540451708e-07
was O 0 6.060937084839679e-05
diagnosed O 0 0.0009015777613967657
in O 0 1.5187076485290163e-08
a O 0 2.3943536930914888e-08
16 O 0 6.902478588699523e-08
- O 0 1.4634440049121622e-05
year O 0 7.359852247645904e-07
- O 0 8.141027137753554e-06
old O 0 6.255887910810998e-06
African O 0 3.4786843627898634e-08
- O 0 4.494751522088336e-07
American O 0 1.986781086316114e-07
male O 0 6.308185334091831e-07
with O 0 6.585304390682722e-07
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999996423721313
. O 0 2.0744968423969112e-05

The O 0 1.8365979030932067e-06
patients O 0 4.609963980328757e-06
father O 0 1.4180726282120304e-07
and O 0 1.4424791139333593e-08
two O 0 6.38680353048926e-09
brothers O 0 3.9822509734221967e-07
also O 0 3.222661959512152e-08
had O 0 1.5616869575296732e-07
C6D B-Disease 0 1.6783296814537607e-05
, O 0 1.5199530523091198e-09
but O 0 4.613334159131455e-09
gave O 0 5.987375040206189e-09
no O 0 3.942977055970687e-09
history O 0 1.2039062191604444e-08
of O 0 9.837791914435456e-09
meningitis B-Disease 1 0.9999972581863403
or O 0 2.179416014769231e-06
other O 0 2.606513476166583e-07
neisserial B-Disease 0 0.15037645399570465
infection I-Disease 0 0.12061604112386703
. O 0 4.590130629367195e-06

By O 0 6.564154659827182e-07
using O 0 4.881878226115077e-07
exon O 0 6.112130904512014e-06
- O 0 2.2958270164963324e-06
specific O 0 8.512375870850519e-08
polymerase O 0 1.547422129988263e-06
chain O 0 3.3728997550497297e-06
reaction O 0 4.835306981476606e-07
( O 0 1.1902138830066633e-08
PCR O 0 2.2298570456769085e-06
) O 0 2.9903546305831696e-08
/ O 0 1.8274934632245277e-07
single O 0 3.2913175118665094e-07
- O 0 6.920769465068588e-06
strand O 0 1.0420854778203648e-05
conformation O 0 4.825812425224285e-07
polymorphism O 0 1.1923835927518667e-06
as O 0 1.3265291087805053e-08
a O 0 8.22476931006122e-09
screening O 0 9.158645752904704e-08
step O 0 2.456136982686985e-08
and O 0 3.497830913801181e-09
nucleotide O 0 4.7899337829448996e-08
sequencing O 0 3.0090237856938984e-08
of O 0 1.2024391482512442e-09
target O 0 2.302219037630948e-08
exons O 0 1.0815838180633364e-07
, O 0 3.9085406022820735e-09
we O 0 2.315305280831126e-09
determined O 0 7.581204997109126e-09
that O 0 7.933082524225199e-10
the O 0 3.3171545510413125e-09
proband O 0 3.5282378121337388e-06
was O 0 1.8885528163536947e-07
a O 0 6.123495044363381e-09
compound O 0 1.3851396829522855e-07
heterozygote O 0 1.8720427306107013e-06
for O 0 3.454471553254734e-08
two O 0 9.444633519706258e-08
C6 O 0 0.00010441086487844586
gene O 0 9.837502148002386e-06
mutations O 0 6.029219730407931e-05
. O 0 5.754513949796092e-06

The O 0 1.2761554444296053e-06
first O 0 1.6479481246278738e-07
, O 0 1.535007498887353e-08
1195delC O 0 1.9866750733399385e-07
located O 0 1.3147757549347716e-08
in O 0 3.3106062335974684e-09
exon O 0 2.98626247285938e-07
7 O 0 2.212730620954062e-08
, O 0 1.0936269667638499e-09
is O 0 8.408976293061698e-10
a O 0 1.8630135212305277e-09
novel O 0 9.874057838032968e-08
mutation O 0 3.9245296079570835e-07
, O 0 4.9965929171946755e-09
while O 0 4.362763039722495e-09
the O 0 2.1219221935098176e-09
second O 0 4.725162483509848e-08
, O 0 2.5850732665588794e-09
1936delG O 0 9.326218020078159e-08
in O 0 2.564026990725665e-09
exon O 0 1.9021128139229404e-07
12 O 0 1.510163372131501e-08
, O 0 1.4258197955641094e-09
has O 0 3.229921663461255e-09
been O 0 1.0994900101479743e-08
described O 0 1.0029662433908015e-08
before O 0 1.2050663578122567e-08
to O 0 5.9255031992222484e-09
cause O 0 3.249895641488365e-08
C6D B-Disease 0 2.8993686100875493e-06
in O 0 7.993889106217011e-09
an O 0 3.4959368733211704e-09
unrelated O 0 3.287841536803171e-07
African O 0 1.1904118935035513e-07
- O 0 2.818073426169576e-06
American O 0 5.124524591337831e-07
individual O 0 1.2758135881085764e-06
. O 0 3.5787788874586113e-06

Both O 0 1.0100721738126595e-05
mutations O 0 0.00013345143815968186
result O 0 6.7971836870128755e-06
in O 0 7.297648494386522e-07
premature O 0 1.3352278074307833e-05
termination O 0 6.749853127985261e-06
codons O 0 2.6818699552677572e-05
and O 0 1.6817638197608176e-06
C6 O 0 0.0014280605828389525
null O 0 0.0002821314556058496
alleles O 0 6.910179217811674e-05
. O 0 8.442840226052795e-06

Allele O 0 0.00032774265855550766
- O 0 3.815899617620744e-05
specific O 0 3.413262845697318e-07
PCR O 0 3.840969839075115e-06
indicated O 0 1.0715121590010313e-07
that O 0 2.330697856933739e-09
the O 0 3.227569322916679e-09
probands O 0 8.597516512054426e-07
two O 0 1.7619299796933774e-08
brothers O 0 6.435437853724579e-07
also O 0 5.274135617128195e-08
inherited O 0 2.364655301789753e-06
the O 0 8.024977127263355e-09
1195delC O 0 4.5773742840538034e-07
mutation O 0 1.3187079161980364e-07
from O 0 1.8388872646823984e-09
their O 0 5.974837069544492e-09
heterozygous O 0 3.320581072330242e-07
mother O 0 1.076559854595871e-07
and O 0 5.153038440397495e-09
the O 0 4.71064520723985e-09
1936delG O 0 1.2364113217699924e-06
mutation O 0 3.1216117690746614e-07
from O 0 6.584905953843645e-09
their O 0 2.58481360759788e-08
homozygous O 0 2.9610848741867812e-06
father O 0 7.05922786892188e-07
. O 0 3.052034287520655e-07
. O 0 2.2194080884219147e-06

PAX6 O 0 0.027612922713160515
mutations O 0 0.0032353296410292387
reviewed O 0 0.0002936462115030736
. O 0 4.3172884033992887e-05

Mutations O 0 0.00011192469537490979
in O 0 4.5694275740970625e-07
PAX6 O 0 1.1268124580965377e-05
are O 0 4.1177610654585806e-08
responsible O 0 3.551113536559569e-08
for O 0 3.054711372740826e-09
human O 0 9.17619846774187e-09
aniridia B-Disease 1 1.0
and O 0 3.27247249742868e-07
have O 0 3.255280844882691e-08
also O 0 8.387564420786475e-09
been O 0 3.6039750739291776e-08
found O 0 1.5096764727218215e-08
in O 0 8.718692434683817e-09
patients O 0 7.62548353350212e-08
with O 0 1.5510856599121325e-08
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999998807907104
, O 0 2.891609085509117e-08
with O 0 2.045774465386785e-07
congenital B-Disease 1 0.9999988079071045
cataracts I-Disease 1 0.9999263286590576
, O 0 1.2617121569746814e-07
with O 0 1.5977366274455562e-07
autosomal B-Disease 1 0.9996733665466309
dominant I-Disease 1 0.9923591017723083
keratitis I-Disease 1 0.9975207448005676
, O 0 2.588751328858052e-07
and O 0 6.306945721235024e-08
with O 0 3.722206258771621e-07
isolated B-Disease 1 0.656160831451416
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 0.9999998807907104
. O 0 7.945479592308402e-05

No O 0 5.2228292588551994e-06
locus O 0 6.235570253920741e-06
other O 0 3.962686889735778e-08
than O 0 2.8575827926147213e-08
chromosome O 0 1.8000205272983294e-06
11p13 O 0 2.168349737985409e-06
has O 0 4.373045925376573e-08
been O 0 1.9064527734258263e-08
implicated O 0 1.5524150853707397e-07
in O 0 5.5089543593567214e-08
aniridia B-Disease 1 1.0
, O 0 1.5722005031193476e-08
and O 0 7.249810085596664e-09
PAX6 O 0 1.959890596481273e-06
is O 0 1.2324560039189691e-08
clearly O 0 1.814814432066214e-08
the O 0 1.1340859362718447e-09
major O 0 7.114306921351954e-09
, O 0 1.5431175226510163e-09
if O 0 7.934555235067364e-09
not O 0 4.54972726160463e-09
only O 0 2.0136798895009633e-09
, O 0 3.753462429756382e-09
gene O 0 1.844403527684335e-07
responsible O 0 1.254933636118949e-06
. O 0 2.0805143776669865e-06

Twenty O 0 1.201681970997015e-05
- O 0 6.98474541422911e-05
eight O 0 2.1454054888181417e-07
percent O 0 2.452509590966656e-07
of O 0 3.7499492400172585e-09
identified O 0 1.7890693015942816e-07
PAX6 O 0 6.161413693916984e-06
mutations O 0 2.026037691393867e-06
are O 0 5.667189029168185e-08
C O 0 0.0051321652717888355
- O 0 0.17077422142028809
T O 0 0.0010874365689232945
changes O 0 5.370409184024538e-08
at O 0 1.2946611782638229e-08
CpG O 0 1.3396009990174207e-07
dinucleotides O 0 3.4006012583631673e-07
, O 0 1.6758914256342905e-09
20 O 0 1.7895080972607502e-09
% O 0 1.312685182774942e-09
are O 0 3.3283834022235226e-10
splicing O 0 1.2025411422200705e-07
errors O 0 1.0466492312843911e-06
, O 0 1.0476424172622956e-09
and O 0 7.961898917940857e-10
more O 0 4.21339740874771e-10
than O 0 3.063247433487959e-09
30 O 0 6.84698386876903e-09
% O 0 4.083556159883983e-09
are O 0 4.71437511251338e-09
deletion O 0 7.156710921663034e-07
or O 0 1.453748836865998e-07
insertion O 0 1.2183132866994129e-06
events O 0 3.0133282962196972e-06
. O 0 3.1251997825165745e-06

There O 0 1.546356998005649e-06
is O 0 8.313188004649419e-08
a O 0 4.6383146212747306e-08
noticeably O 0 7.097062848515634e-07
elevated O 0 2.817216227413155e-06
level O 0 8.773262294425876e-08
of O 0 2.71589573053177e-09
mutation O 0 2.8391065143296146e-07
in O 0 1.4746712295732323e-08
the O 0 5.706397132598795e-09
paired O 0 1.903731572383549e-07
domain O 0 8.358629344229485e-08
compared O 0 2.587909762041818e-07
with O 0 2.4774966522755903e-09
the O 0 9.451965432560883e-09
rest O 0 1.3578935309510598e-08
of O 0 2.6733615321461457e-09
the O 0 8.141535090544494e-08
gene O 0 3.8402372410928365e-06
. O 0 4.1613234316173475e-06

Increased O 0 6.43865723759518e-06
mutation O 0 8.2838159869425e-06
in O 0 5.057249197193414e-08
the O 0 1.6023900428763227e-08
homeodomain O 0 1.4572511872756877e-06
is O 0 1.1123486132191829e-08
accounted O 0 7.460769069211892e-08
for O 0 2.5810975579076967e-09
by O 0 1.1110614650533535e-08
the O 0 9.2618350322482e-08
hypermutable O 0 2.9126547815394588e-05
CpG O 0 2.3442098608938977e-05
dinucleotide O 0 1.9126491679344326e-05
in O 0 2.877953306779091e-07
codon O 0 9.455271538172383e-06
240 O 0 1.7303415233982378e-06
. O 0 1.9652920855151024e-06

Very O 0 7.55693861265172e-07
nearly O 0 7.242129385076623e-08
all O 0 1.0131043559624686e-08
mutations O 0 4.2574450276333664e-07
appear O 0 1.1805353494764859e-07
to O 0 4.2126462318492486e-08
cause O 0 1.4761283182451734e-06
loss O 0 3.9048248368089844e-07
of O 0 4.466578773509866e-10
function O 0 8.471684687094694e-09
of O 0 5.766054855804725e-10
the O 0 1.7862311629812666e-09
mutant O 0 1.0943770689664234e-07
allele O 0 1.7550600261984073e-07
, O 0 1.3488761219093703e-09
and O 0 8.378701621403195e-10
more O 0 4.657831897958431e-10
than O 0 1.0190613908278578e-09
80 O 0 5.416854076401023e-09
% O 0 2.9962621272972e-09
of O 0 1.5202719083617922e-09
exonic O 0 1.5393194416901679e-06
substitutions O 0 4.964686013408937e-07
result O 0 5.734976298299443e-07
in O 0 1.0351990198387284e-07
nonsense O 0 9.511641110293567e-06
codons O 0 2.2033653294784017e-05
. O 0 2.601499772936222e-06

In O 0 7.467288583029585e-07
a O 0 3.990735919501276e-08
gene O 0 1.2185010689336195e-07
with O 0 5.737993191701207e-09
such O 0 1.4661928560144588e-08
extraordinarily O 0 5.8053788052347954e-06
high O 0 4.0124970723809383e-07
sequence O 0 5.617480169917144e-08
conservation O 0 7.474967311793534e-09
throughout O 0 6.653815720625289e-09
evolution O 0 9.000139300496812e-09
, O 0 2.7649440514920798e-09
there O 0 5.898350252664386e-09
are O 0 1.5512956252905497e-08
presumed O 0 1.938099376275204e-05
undiscovered O 0 7.691361133765895e-06
missense O 0 4.359867944003781e-06
mutations O 0 3.64763423021941e-06
, O 0 2.122160891460112e-09
these O 0 2.026185441650341e-09
are O 0 1.528578930098945e-09
hypothesized O 0 7.818385938662686e-08
to O 0 4.128312802720302e-09
exist O 0 3.147780702761338e-08
in O 0 8.235631732134152e-09
as O 0 8.382865956946262e-08
- O 0 0.003166183829307556
yet O 0 3.95635424865759e-06
unidentified O 0 4.4897915358887985e-06
phenotypes O 0 1.8484072370483773e-06
. O 0 2.0643578579893074e-07
. O 0 1.94818767340621e-06

Genetic O 0 0.0002770093851722777
heterogeneity O 0 7.94839725131169e-05
and O 0 7.64889819038217e-07
penetrance O 0 2.004689486057032e-05
analysis O 0 3.4013569916169217e-07
of O 0 1.3371498575054375e-08
the O 0 4.17787049400431e-08
BRCA1 O 0 2.2806696506449953e-05
and O 0 1.5876965164807189e-07
BRCA2 O 0 2.008400042541325e-05
genes O 0 2.6413263185531832e-06
in O 0 4.176805305178277e-06
breast B-Disease 1 0.9999710321426392
cancer I-Disease 1 0.7353068590164185
families O 0 3.969578301621368e-06
. O 0 4.886456281383289e-06

The O 0 0.0007116853375919163
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Linkage O 0 0.0030692534055560827
Consortium O 0 0.0003519475576467812
. O 0 3.5395758459344506e-05

The O 0 4.438443568233197e-07
contribution O 0 3.959975174439023e-07
of O 0 2.496767237403219e-08
BRCA1 O 0 8.24436210677959e-06
and O 0 1.458567737699923e-07
BRCA2 O 0 0.00021289262804202735
to O 0 9.621283425076399e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00037811847869306803
assessed O 0 4.231506522955897e-07
by O 0 5.986598328178161e-09
linkage O 0 1.5618313682352891e-06
and O 0 1.483496276932783e-07
mutation O 0 3.309361318315496e-07
analysis O 0 3.848416341156735e-08
in O 0 3.044561047715888e-09
237 O 0 2.4952248267595678e-08
families O 0 6.432808952183677e-09
, O 0 7.619486153132016e-10
each O 0 1.0633897096212763e-09
with O 0 2.103948126830346e-09
at O 0 2.4986061220033662e-08
least O 0 1.963486928602265e-09
four O 0 3.375399959537617e-09
cases O 0 2.0544037582226338e-08
of O 0 2.024571621461746e-08
breast B-Disease 1 0.999932050704956
cancer I-Disease 0 0.0006679564830847085
, O 0 1.7617678427228611e-09
collected O 0 3.320452579558264e-09
by O 0 1.5136121689351967e-08
the O 0 0.0038886212278157473
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.00023101519036572427
Consortium O 0 4.094835094292648e-05
. O 0 6.054262485122308e-06

Families O 0 5.605167643807363e-06
were O 0 1.094508519372539e-07
included O 0 5.5873861093402866e-09
without O 0 1.2461349285786127e-08
regard O 0 1.8936887613563158e-08
to O 0 2.8817241926049064e-09
the O 0 4.943478959518188e-09
occurrence O 0 1.9181284187652636e-06
of O 0 6.082824199893366e-08
ovarian B-Disease 1 0.9948432445526123
or I-Disease 0 2.421253384454758e-06
other I-Disease 0 1.4079714674153365e-06
cancers I-Disease 1 0.9986711740493774
. O 0 2.9149359761504456e-06

Overall O 0 0.0005067646852694452
, O 0 1.6308050589941558e-06
disease O 0 7.392615771095734e-06
was O 0 1.800626705517061e-07
linked O 0 1.8487180852844176e-07
to O 0 8.96537599714975e-09
BRCA1 O 0 1.1032797146981466e-06
in O 0 4.259514074789195e-09
an O 0 1.5725776236763522e-09
estimated O 0 9.219636609714144e-09
52 O 0 1.3365507811613497e-08
% O 0 2.7741302588424332e-09
of O 0 4.286169474898571e-10
families O 0 3.7885476977805865e-09
, O 0 6.345539649288412e-10
to O 0 4.0190046846078076e-09
BRCA2 O 0 6.424878051802807e-07
in O 0 6.0161764459110145e-09
32 O 0 6.412522512988517e-09
% O 0 1.6675469893812078e-09
of O 0 4.75133932198446e-10
families O 0 8.00991450944366e-09
, O 0 1.4328918052086692e-09
and O 0 2.0313049020614926e-09
to O 0 2.492398065712109e-09
neither O 0 2.5223419797271163e-08
gene O 0 2.2823998691023917e-08
in O 0 8.390844463690428e-09
16 O 0 1.1487379936170328e-08
% O 0 4.36725056118803e-09
( O 0 1.3120945441258414e-09
95 O 0 1.0486465029657666e-08
% O 0 3.455064856439094e-08
confidence O 0 3.7551333775809326e-07
interval O 0 5.857828568878176e-07
[ O 0 1.9683723451180413e-07
CI O 0 1.0572641713224584e-06
] O 0 7.255665224192853e-08
6 O 0 1.7757759707137666e-08
% O 0 1.2714303387895143e-08
- O 0 3.339128306834027e-05
28 O 0 8.002969309472974e-08
% O 0 6.1798028916371095e-09
) O 0 1.4211118948281865e-09
, O 0 1.5149430598881963e-09
suggesting O 0 9.677832224497251e-08
other O 0 6.605224456279757e-08
predisposition O 0 4.042897671752144e-06
genes O 0 6.283618859015405e-06
. O 0 3.1408114864461822e-06

The O 0 2.5886602088576183e-06
majority O 0 2.298287199664628e-06
( O 0 5.732887586873403e-08
81 O 0 1.0086162660627451e-07
% O 0 1.5820610599348583e-08
) O 0 2.7177924355470395e-09
of O 0 1.1002594391129605e-09
the O 0 1.7216429114341736e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.116328528562917e-08
were O 0 3.108000257157073e-08
due O 0 1.5936393538140692e-08
to O 0 1.5495745131488547e-08
BRCA1 O 0 7.806107532815076e-06
, O 0 2.5862667563103514e-09
with O 0 1.390683124213865e-09
most O 0 2.2590469939132163e-08
others O 0 1.0549421602945586e-07
( O 0 4.99640195883444e-09
14 O 0 2.2293452417443405e-08
% O 0 1.7455796808008017e-08
) O 0 1.0975351294462143e-08
due O 0 2.057624044482509e-07
to O 0 3.0368610737241397e-07
BRCA2 O 0 0.0004254684317857027
. O 0 3.0138048714434262e-06

Conversely O 0 1.2594760846695863e-05
, O 0 9.015691659897129e-08
the O 0 1.11526547996732e-08
majority O 0 3.331168230147341e-08
of O 0 1.1511194220048537e-09
families O 0 9.313326998494631e-09
with O 0 3.6136718062351747e-09
male B-Disease 0 1.5277264537871815e-06
and I-Disease 0 6.884681056362751e-07
female I-Disease 0 0.012929926626384258
breast I-Disease 1 0.9999597072601318
cancer I-Disease 0 0.08121947944164276
were O 0 1.8267128609750216e-07
due O 0 1.5817660425909708e-07
to O 0 7.692271708492626e-08
BRCA2 O 0 3.490957897156477e-05
( O 0 2.4548210575403573e-08
76 O 0 2.912660761467123e-07
% O 0 1.0587237397885474e-07
) O 0 1.5423891852606175e-07
. O 0 1.2462584209060878e-06

The O 0 8.39937229102361e-07
largest O 0 7.715692618148751e-07
proportion O 0 6.322844683381845e-07
( O 0 2.2109670538839055e-08
67 O 0 1.0668829730775542e-07
% O 0 1.5611025361295106e-08
) O 0 1.298297913621127e-09
of O 0 4.503920847387377e-10
families O 0 1.2349056000005021e-08
due O 0 6.848188860431037e-08
to O 0 1.2936484106162993e-09
other O 0 8.440873555670692e-10
genes O 0 2.146747490883172e-08
was O 0 1.182472828986647e-06
found O 0 3.012239346844581e-08
in O 0 5.750735887488645e-09
families O 0 1.6462123886284985e-09
with O 0 6.954659070856906e-10
four O 0 5.118401702475239e-09
or O 0 2.8766297788251904e-08
five O 0 3.6590244167911123e-09
cases O 0 2.4947775401074068e-08
of O 0 1.034606356142831e-08
female O 0 0.03157319128513336
breast B-Disease 1 0.999962329864502
cancer I-Disease 0 0.02062487043440342
only O 0 2.2803553179073788e-07
. O 0 1.9559618067432893e-06

These O 0 7.335705163313833e-07
estimates O 0 3.805863570960355e-07
were O 0 3.1057780347509834e-08
not O 0 1.1718953807360322e-08
substantially O 0 9.082071272814574e-08
affected O 0 7.190922968192126e-09
either O 0 6.1600089473756725e-09
by O 0 2.4576869428472037e-09
changing O 0 1.4519697799642017e-07
the O 0 1.4273497939143454e-08
assumed O 0 9.754915026860544e-07
penetrance O 0 1.698254891380202e-06
model O 0 1.0724895105340693e-07
for O 0 5.949261971949227e-09
BRCA1 O 0 1.5821417491679313e-06
or O 0 1.9530295602976366e-08
by O 0 1.2196148535537077e-09
including O 0 5.824897453265976e-09
or O 0 2.2314856096272706e-07
excluding O 0 6.981251317483839e-06
BRCA1 O 0 0.00032391631975769997
mutation O 0 1.3116471563989762e-05
data O 0 4.819350579055026e-06
. O 0 5.528624114958802e-06

Among O 0 1.0380080084360088e-06
those O 0 6.992826939722363e-08
families O 0 5.159601457194185e-08
with O 0 3.8048142414481845e-08
disease O 0 5.928721293457784e-06
due O 0 8.502996706738486e-08
to O 0 9.952502821874987e-09
BRCA1 O 0 2.9330947199923685e-06
that O 0 3.728865660690417e-09
were O 0 1.0484885848427439e-08
tested O 0 2.9552904123875123e-08
by O 0 6.887059256222017e-10
one O 0 1.1652795395278304e-09
of O 0 3.543795534799443e-10
the O 0 3.54774032373939e-09
standard O 0 2.827558205353853e-07
screening O 0 2.395363374319004e-08
methods O 0 5.4142642369470195e-08
, O 0 2.7759563536733367e-09
mutations O 0 8.17185679125032e-08
were O 0 9.666851319423131e-09
detected O 0 1.7466528845488938e-07
in O 0 4.364336003703784e-09
the O 0 7.806089996620358e-09
coding O 0 6.587710004168912e-07
sequence O 0 4.495402805559934e-08
or O 0 2.1397408289658415e-08
splice O 0 9.918866226144019e-07
sites O 0 6.688491538398011e-08
in O 0 4.070313863735464e-09
an O 0 2.9089164410578405e-09
estimated O 0 2.3747286803654788e-08
63 O 0 4.1463305677780227e-08
% O 0 4.4233599005849555e-09
( O 0 1.3233972806503402e-09
95 O 0 1.664439963633413e-08
% O 0 2.4094811479358214e-08
CI O 0 6.3637239691161085e-06
51 O 0 1.5414069309827028e-07
% O 0 9.671687450918398e-08
- O 0 0.0007509856368415058
77 O 0 3.0095461056589556e-07
% O 0 1.571682588519252e-07
) O 0 1.2677695337970363e-07
. O 0 1.5486873508052668e-06

The O 0 5.129908231538138e-07
estimated O 0 1.428518743296081e-07
sensitivity O 0 3.0724302746421017e-07
was O 0 1.0978705233810615e-07
identical O 0 5.675572722907418e-08
for O 0 1.7247091532723857e-09
direct O 0 1.2314244735023294e-08
sequencing O 0 1.481791116475506e-07
and O 0 1.6979093686586566e-08
other O 0 2.5331464925670844e-08
techniques O 0 8.100153536361177e-06
. O 0 3.5692999063030584e-06

The O 0 2.0072861843800638e-06
penetrance O 0 3.106005897279829e-05
of O 0 9.697936320662848e-08
BRCA2 O 0 5.533773946808651e-05
was O 0 2.8331780299595266e-07
estimated O 0 1.977842423173115e-08
by O 0 3.949645943635005e-09
maximizing O 0 2.3616661337655387e-07
the O 0 4.352732929646663e-08
LOD O 0 0.298325777053833
score O 0 2.2662676713025576e-07
in O 0 5.971512706537396e-08
BRCA2 O 0 0.00040347230969928205
- O 0 4.7653549700044096e-05
mutation O 0 1.22321341677889e-06
families O 0 1.5903568240105415e-08
, O 0 1.639372304573783e-09
over O 0 8.056754374763386e-09
all O 0 1.3724960723493496e-08
possible O 0 4.594886604536441e-07
penetrance O 0 1.6428622984676622e-05
functions O 0 1.5481956552321208e-06
. O 0 3.2682887649571057e-06

The O 0 3.842043270196882e-07
estimated O 0 2.1201114464020065e-07
cumulative O 0 9.74164890976681e-07
risk O 0 2.5615950107749086e-06
of O 0 3.4944850568763286e-08
breast B-Disease 1 0.9670084714889526
cancer I-Disease 0 0.0010603549890220165
reached O 0 1.332582684199224e-07
28 O 0 6.583828593420549e-08
% O 0 8.288739472561701e-09
( O 0 2.7927327117538425e-09
95 O 0 4.3606522837080774e-08
% O 0 3.863456399244569e-08
CI O 0 3.758386810659431e-05
9 O 0 3.7953483911223884e-08
% O 0 1.771915592030382e-08
- O 0 3.932658728444949e-06
44 O 0 2.6636922001443963e-08
% O 0 4.541265585800147e-09
) O 0 7.575289284744713e-10
by O 0 1.1996627025112616e-09
age O 0 1.2488737155536e-08
50 O 0 2.201846482918768e-09
years O 0 1.173062802450886e-08
and O 0 7.079005381882553e-09
84 O 0 2.3427954687349484e-08
% O 0 5.605896191696047e-09
( O 0 1.3094918482892126e-09
95 O 0 9.208563689355742e-09
% O 0 1.7031897669994578e-08
CI O 0 1.8501426666261978e-06
43 O 0 6.859548307147634e-08
% O 0 2.6038744493916965e-08
- O 0 1.6498773902640096e-06
95 O 0 7.704841209488222e-08
% O 0 7.89485188334993e-09
) O 0 2.695521361673059e-09
by O 0 6.907467486882979e-09
age O 0 1.6668012392528908e-07
70 O 0 1.0931398719549179e-07
years O 0 3.85731965479863e-07
. O 0 1.1558223604879458e-06

The O 0 1.5882835214142688e-05
corresponding O 1 0.9422255754470825
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 1 0.6257387399673462
were O 0 1.5296463971026242e-06
0 O 0 2.2736244318366516e-06
. O 0 3.9339979593933094e-06

4 O 0 7.799329068802763e-06
% O 0 3.818249467713031e-07
( O 0 1.9257418770735057e-08
95 O 0 5.920828627381525e-08
% O 0 4.581461965358358e-08
CI O 0 3.074398591706995e-06
0 O 0 4.8070120328702615e-08
% O 0 2.1473617550782365e-08
- O 0 2.159300720450119e-06
1 O 0 1.670543348097908e-08
% O 0 3.0026352515477583e-09
) O 0 3.7018221821227826e-10
by O 0 5.620689469409967e-10
age O 0 1.1636098307121756e-08
50 O 0 3.1856133286822796e-09
years O 0 6.049453826761919e-09
and O 0 5.759890786549704e-09
27 O 0 9.35263244628004e-09
% O 0 2.493082851273698e-09
( O 0 1.1243851405495775e-09
95 O 0 1.6122125856554703e-08
% O 0 1.732517418417956e-08
CI O 0 2.248188593512168e-06
0 O 0 4.619579385689576e-08
% O 0 2.450278735466327e-08
- O 0 4.387166882224847e-06
47 O 0 1.3478897642471566e-07
% O 0 1.0106917969210372e-08
) O 0 1.471624599957977e-09
by O 0 3.6244747203539873e-09
age O 0 1.1649427733573248e-07
70 O 0 4.786938490042303e-08
years O 0 5.157530722499359e-07
. O 0 1.8389779370409087e-06

The O 0 1.6494196870553424e-06
lifetime O 0 8.62088654685067e-06
risk O 0 1.4036173524800688e-05
of O 0 8.602620482633938e-08
breast B-Disease 1 0.9996854066848755
cancer I-Disease 0 0.006312387529760599
appears O 0 8.780175875244822e-08
similar O 0 3.672107240504374e-08
to O 0 1.7161454479719396e-08
the O 0 3.3650202624357917e-08
risk O 0 1.0535944738876424e-06
in O 0 8.404763995883968e-09
BRCA1 O 0 4.4000762500218116e-06
carriers O 0 2.6914443651548936e-07
, O 0 1.785573799928386e-09
but O 0 1.0878170364492235e-08
there O 0 2.2635486818245454e-09
was O 0 1.3062520842765935e-08
some O 0 1.0330225563848217e-09
suggestion O 0 4.4177298264003184e-08
of O 0 1.2692538131631181e-09
a O 0 9.432410053022977e-08
lower O 0 0.005623917561024427
risk O 0 6.9237999014148954e-06
in O 0 2.8350310543601154e-08
BRCA2 O 0 1.0115422810486052e-05
carriers O 0 5.464279411171447e-07
< O 0 2.166694770266986e-07
50 O 0 1.6358653098791365e-08
years O 0 2.979753155329945e-08
of O 0 1.2290099604683746e-08
age O 0 1.2307878023420926e-06
. O 0 2.108526359734242e-06

Eye B-Disease 1 0.520804226398468
movement I-Disease 0 4.4404710934031755e-05
abnormalities I-Disease 0 0.009002692066133022
correlate O 0 1.2174503353890032e-05
with O 0 5.321121534507256e-07
genotype O 0 0.0026180818676948547
in O 0 2.9646225812030025e-06
autosomal O 1 0.9993625283241272
dominant O 1 0.9954071044921875
cerebellar B-Disease 1 0.9973366856575012
ataxia I-Disease 1 0.9999231100082397
type I-Disease 1 0.999970555305481
I I-Disease 1 0.6981855034828186
. O 0 1.0993348951160442e-05

We O 0 1.3622456208395306e-05
compared O 0 3.3106919090641895e-06
horizontal O 0 0.00012560551112983376
eye O 0 0.044995300471782684
movements O 0 6.602386292797746e-06
( O 0 8.497467973711537e-08
visually O 0 1.2559740980577772e-06
guided O 0 3.229634160106798e-07
saccades O 0 1.1436830391176045e-05
, O 0 2.1288716567369192e-08
antisaccades O 0 5.138329584042367e-07
, O 0 4.621745208766015e-09
and O 0 3.85748988307455e-09
smooth O 0 7.115571776239449e-08
pursuit O 0 5.477615445670381e-07
) O 0 9.30468058157885e-09
in O 0 8.642794924185182e-09
control O 0 1.0667928336260957e-06
subjects O 0 1.6551948647247627e-06
( O 0 5.240341049983499e-09
n O 0 1.4830849295321968e-06
= O 0 2.9891198209952563e-06
14 O 0 7.506284482872161e-09
) O 0 3.041513707557897e-09
and O 0 1.4038492146539738e-08
patients O 0 2.401561971510091e-08
with O 0 5.488235421680088e-10
three O 0 5.04402919432323e-09
forms O 0 1.0195599742246486e-07
of O 0 6.05598984293465e-08
autosomal O 1 0.9903753399848938
dominant O 0 0.20845404267311096
cerebellar B-Disease 0 0.005494861397892237
ataxias I-Disease 0 0.04636628180742264
type I-Disease 0 0.0878867357969284
I I-Disease 0 3.3256856113439426e-05
spinocerebellar B-Disease 0 7.946480036480352e-05
ataxias I-Disease 0 6.682380626443774e-05
1 I-Disease 0 6.51247589189552e-08
and I-Disease 0 1.139283334339325e-08
2 I-Disease 0 1.129583271364254e-08
( O 0 3.3459846005001737e-09
SCA1 B-Disease 0 5.1553111006796826e-06
, O 0 2.2619314421490344e-08
n O 0 3.432441189943347e-06
= O 0 2.534544137233752e-06
11 O 0 2.8818304187439026e-08
; O 0 1.809619298853704e-08
SCA2 B-Disease 0 3.517312279655016e-06
, O 0 1.3615425231705558e-08
n O 0 7.091387033142382e-07
= O 0 2.7562794002733426e-07
10 O 0 6.341707603496616e-09
) O 0 5.485527587723027e-09
and O 0 3.18703712309798e-08
SCA3 B-Disease 1 0.9999998807907104
/ O 0 2.856830860764603e-06
Machado B-Disease 0 1.8765470031212317e-06
- I-Disease 0 3.942174953408539e-05
Joseph I-Disease 0 3.9829716115491465e-05
disease I-Disease 0 1.885431629489176e-05
( O 0 4.7354841825608673e-08
MJD B-Disease 1 0.9999998807907104
) O 0 7.100536691950765e-08
( O 0 1.4877092446852203e-08
n O 0 7.376727808150463e-06
= O 0 1.2032760423608124e-05
16 O 0 1.8193065898230998e-07
) O 0 1.1567283308977494e-07
. O 0 9.992580771722714e-07

In O 0 2.2708743472321657e-06
SCA1 B-Disease 0 3.323821147205308e-05
, O 0 1.0456171395389902e-07
saccade O 0 5.422482900030445e-06
amplitude O 0 2.0791337647096952e-06
was O 0 6.128463496679615e-07
significantly O 0 5.309781272444525e-07
increased O 0 1.2890093614714715e-07
, O 0 3.132740999944872e-08
resulting O 0 3.6907505318595213e-07
in O 0 4.219650691084098e-07
hypermetria B-Disease 0 0.00014812858717050403
. O 0 3.928321802959545e-06

The O 0 1.3971571206639055e-06
smooth O 0 6.367579317156924e-06
pursuit O 0 7.087031917762943e-06
gain O 0 0.00010510413267184049
was O 0 1.0333577847632114e-05
decreased O 0 1.815521864045877e-05
. O 0 4.53008760814555e-06

In O 0 3.791119752349914e-06
SCA2 B-Disease 0 4.6744109567953274e-05
, O 0 1.571814323142462e-07
saccade O 0 1.8465840184944682e-05
velocity O 0 5.101862370793242e-06
was O 0 1.3088005061945296e-06
markedly O 0 1.6576417692704126e-05
decreased O 0 1.799741767172236e-05
. O 0 4.635202913050307e-06

The O 0 7.502808330173139e-07
percentage O 0 1.6096611261673388e-06
of O 0 7.467129137239681e-09
errors O 0 1.47937385008845e-07
in O 0 8.96359786395351e-09
antisaccades O 0 9.125512406171765e-06
was O 0 2.4572716483817203e-07
greatly O 0 1.9850684651601114e-08
increased O 0 1.053532194816853e-08
and O 0 1.196961729732493e-08
was O 0 1.4386493774054543e-07
significantly O 0 7.535278001569168e-08
correlated O 0 1.6772968081113504e-07
with O 0 1.9697445452493412e-08
age O 0 1.6758305037001264e-06
at O 0 3.8764210330555215e-06
disease O 0 2.7464462618809193e-05
onset O 0 0.00012773614434991032
. O 0 1.7699567251838744e-05

In O 0 7.681845204388082e-07
addition O 0 3.088953235419467e-07
, O 0 2.314789959712016e-08
a O 0 1.0471195466266181e-08
correlation O 0 1.332491166294858e-07
between O 0 1.3952748290080308e-08
smooth O 0 3.274192295066314e-07
pursuit O 0 4.157443981966935e-06
gain O 0 0.00038973346818238497
and O 0 5.321486540310616e-08
the O 0 8.54885140455508e-09
number O 0 1.9904710768514633e-08
of O 0 2.5225777022797047e-08
trinucleotide O 0 1.445488760509761e-05
repeats O 0 3.058700031033368e-06
was O 0 1.3664097195942304e-06
found O 0 5.884604092898371e-07
. O 0 1.5327012761190417e-06

In O 0 1.2305799828027375e-05
SCA3 B-Disease 1 0.9999904632568359
, O 0 4.0761665331956465e-07
gaze B-Disease 0 1.6576668713241816e-05
- I-Disease 0 1.1793817066063639e-05
evoked I-Disease 0 1.5428173583131866e-06
nystagmus I-Disease 0 7.19697482054471e-06
was O 0 1.191028900393576e-06
often O 0 3.135843940071936e-08
present O 0 7.3569026426412165e-09
as O 0 5.7305671319340945e-09
was O 0 3.128555192688509e-08
saccade O 0 1.295290644520719e-06
hypometria O 0 1.602814108991879e-06
and O 0 1.440098529315037e-08
smooth O 0 1.547413148728083e-07
pursuit O 0 8.70842313815956e-07
gain O 0 2.7755935661843978e-05
was O 0 4.200725470582256e-06
markedly O 0 1.1942286619159859e-05
decreased O 0 1.81071663973853e-05
. O 0 3.7859963413211517e-06

Three O 0 1.0769331311166752e-06
major O 0 6.902826612531499e-07
criteria O 0 6.510322236863431e-07
, O 0 2.1528489213551438e-08
saccade O 0 2.2236010863707634e-06
amplitude O 0 4.4506893459583807e-07
, O 0 2.1684762430140836e-08
saccade O 0 1.9228407381888246e-06
velocity O 0 7.528367973463901e-07
, O 0 1.2417479489101879e-08
and O 0 1.5840509348663545e-08
presence O 0 1.9374502002733607e-08
of O 0 8.167941878411966e-09
gaze B-Disease 0 3.13750933855772e-05
- I-Disease 0 6.504756584035931e-06
evoked I-Disease 0 5.807754632769502e-07
nystagmus I-Disease 0 6.718749432366167e-07
, O 0 4.213929649665715e-09
permitted O 0 1.03382724603307e-08
the O 0 2.822038380756453e-09
correct O 0 9.403883893810416e-08
assignment O 0 1.866859733468118e-08
of O 0 3.0606292500401366e-10
90 O 0 1.6740512309709743e-09
% O 0 1.1692223855774841e-09
of O 0 2.1933532767803854e-10
the O 0 2.489386030646301e-09
SCA1 B-Disease 0 6.608452167711221e-06
, O 0 2.209073368675263e-09
90 O 0 1.745445565859427e-09
% O 0 1.654800407813184e-09
of O 0 2.996569381519265e-10
the O 0 2.5843389650503923e-09
SCA2 B-Disease 0 2.185898119932972e-05
, O 0 2.141066657301849e-09
and O 0 2.2060924198541443e-09
93 O 0 1.2701892870836673e-08
% O 0 1.9698112030397397e-09
of O 0 3.4494049283573247e-10
the O 0 2.42639739411743e-08
patients O 0 1.9567512765661377e-07
with O 0 1.0652904336438951e-08
SCA3 B-Disease 1 1.0
to O 0 1.3874541515690453e-08
their O 0 7.162054505016613e-09
genetically O 0 7.397007095732988e-08
confirmed O 0 2.621175951844634e-07
patient O 0 1.283376747096554e-07
group O 0 4.15236911521788e-08
and O 0 1.9479141855072157e-08
, O 0 2.496299389420642e-09
therefore O 0 1.06256301535268e-08
, O 0 4.254723240393332e-09
may O 0 1.0450608556311636e-07
help O 0 1.5292650701326238e-08
orient O 0 2.917016956871521e-07
diagnoses O 0 7.236039323288423e-07
of O 0 1.4163710204684321e-09
SCA1 B-Disease 0 1.9584144865802955e-06
, O 0 3.564806450029323e-09
SCA2 B-Disease 0 7.460603796971554e-07
, O 0 4.8011088438215666e-09
and O 0 2.236670937350027e-08
SCA3 B-Disease 1 0.9999998807907104
at O 0 1.0981847253788146e-07
early O 0 1.0298050057144792e-07
clinical O 0 4.706355127837014e-07
stages O 0 1.329607215438955e-07
of O 0 7.045156014129361e-09
the O 0 1.4629742963734316e-06
diseases O 0 0.003766265232115984
. O 0 2.4046724433901545e-07
. O 0 1.1870827165694209e-06

Genetic O 0 4.072252704645507e-05
basis O 0 8.125584827212151e-07
and O 0 3.4258869163750205e-07
molecular O 0 1.544448059576098e-05
mechanism O 0 3.658357309177518e-05
for O 0 8.482955308863893e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.999991774559021
fibrillation I-Disease 1 1.0
. O 0 0.0008363811066374183

Ventricular B-Disease 0 0.00458035571500659
fibrillation I-Disease 0 0.02735188789665699
causes O 0 3.0723235795449e-06
more O 0 3.020235794792825e-08
than O 0 1.0895798929766443e-08
300 O 0 1.3381526109412789e-08
, O 0 3.99939059647636e-09
000 O 0 2.567380441576006e-08
sudden O 0 6.716654610272599e-08
deaths O 0 3.058519837395579e-08
each O 0 5.547078352208246e-09
year O 0 2.5600749964382885e-08
in O 0 1.5956619137114103e-08
the O 0 8.516160221461178e-08
USA O 0 5.500860879692482e-06
alone O 0 1.2547565120257786e-06
. O 0 7.764809311083809e-07

In O 0 3.681638816033228e-07
approximately O 0 8.071000223708324e-08
5 O 0 5.248546131042531e-08
- O 0 1.696580966381589e-06
12 O 0 1.6796203539115595e-08
% O 0 1.3757925909629876e-09
of O 0 9.053572475048455e-11
these O 0 2.888167927039831e-09
cases O 0 1.7023259246684574e-08
, O 0 1.1661599463863581e-09
there O 0 1.7921177875024341e-09
are O 0 1.586357045724185e-09
no O 0 9.985435589499048e-09
demonstrable O 0 6.269417644944042e-05
cardiac O 0 0.00022731088392902166
or O 0 7.555853699159343e-06
non O 0 0.0016985523980110884
- O 0 0.366348534822464
cardiac O 0 0.0004736072733066976
causes O 0 2.8632133108885682e-08
to O 0 1.9244483784319755e-09
account O 0 6.426615684063108e-09
for O 0 6.281021813769883e-10
the O 0 2.625561990043934e-09
episode O 0 1.1650337938817756e-07
, O 0 2.277384947291239e-09
which O 0 4.289934185663924e-09
is O 0 4.076622595050594e-09
therefore O 0 4.29057465112237e-08
classified O 0 1.2640558452403639e-05
as O 0 0.0005428807926364243
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999094009399414
fibrillation I-Disease 1 1.0
( O 0 1.3132329513609875e-05
IVF B-Disease 1 0.9999996423721313
) O 0 3.108616510871798e-06
. O 0 3.667446435429156e-06

A O 0 1.6719671975806705e-06
distinct O 0 7.480716703867074e-07
group O 0 1.4826872529738466e-07
of O 0 2.3330029463863866e-08
IVF B-Disease 1 1.0
patients O 0 0.001308154547587037
has O 0 1.0197641131526325e-07
been O 0 7.899750897877311e-08
found O 0 2.4942160337104724e-08
to O 0 4.605210879304877e-09
present O 0 7.405756008438402e-09
with O 0 4.931302477473309e-09
a O 0 1.0011336826210027e-07
characteristic O 0 0.0002592722012195736
electrocardiographic O 0 0.010144374333322048
pattern O 0 0.0008925002184696496
. O 0 1.758504004101269e-05

Because O 0 3.2146492685569683e-06
of O 0 6.6785070806929525e-09
the O 0 5.5877271698534514e-09
small O 0 1.101946356385497e-08
size O 0 2.3203861942988624e-08
of O 0 5.041074224720887e-10
most O 0 4.76324668596817e-09
pedigrees O 0 1.3676612979907077e-06
and O 0 2.3656582470721332e-07
the O 0 3.389478564486126e-08
high O 0 2.2589434593101032e-05
incidence O 0 0.0012805141741409898
of O 0 4.0284677815805026e-09
sudden B-Disease 0 1.0911802519331104e-06
death I-Disease 0 5.66445486072098e-08
, O 0 4.171418765963608e-09
however O 0 2.022981426819115e-08
, O 0 2.33849939412778e-09
molecular O 0 1.481697751160027e-07
genetic O 0 5.145641353010433e-07
studies O 0 4.762749128417454e-08
of O 0 2.7478574970984937e-09
IVF B-Disease 1 0.9999998807907104
have O 0 2.318388169442187e-06
not O 0 5.971956795747246e-08
yet O 0 1.4484997734598437e-07
been O 0 1.5289711541299766e-07
done O 0 6.549285558321571e-07
. O 0 7.803545827300695e-07

Because O 0 0.0001569527230458334
IVF B-Disease 1 0.9999988079071045
causes O 0 0.0004976119962520897
cardiac O 0 0.24562326073646545
rhythm O 0 0.00017222076712641865
disturbance O 0 8.52848188515054e-06
, O 0 6.386379425293853e-08
we O 0 2.7141467739966174e-08
investigated O 0 1.5721576573923812e-07
whether O 0 4.509177031764011e-08
malfunction O 0 1.6888034224393778e-06
of O 0 9.390540567366656e-10
ion O 0 1.5385900553610554e-07
channels O 0 3.0269282433437183e-05
could O 0 0.0002912509080488235
cause O 0 5.298541623233177e-07
the O 0 5.9422109899287534e-08
disorder O 0 2.7654048153635813e-06
by O 0 4.944195719502886e-09
studying O 0 1.859468596876468e-07
mutations O 0 2.826524905685801e-06
in O 0 6.768171800786149e-08
the O 0 1.2965224982508516e-07
cardiac O 0 1.4079261745791882e-05
sodium O 0 6.9045058808114845e-06
channel O 0 1.4395774087461177e-05
gene O 0 1.911927029141225e-05
SCN5A O 0 0.0004666518943849951
. O 0 1.1668050319713075e-05

We O 0 1.494106641075632e-06
have O 0 8.1495983295099e-08
now O 0 2.6526496554879486e-08
identified O 0 6.115116946148191e-08
a O 0 1.1839285996018134e-08
missense O 0 8.347225048055407e-06
mutation O 0 3.665764324978227e-06
, O 0 9.76607417157993e-09
a O 0 1.837997309905859e-08
splice O 0 0.0013547634007409215
- O 0 0.0006690337904728949
donor O 0 5.463570573738252e-07
mutation O 0 4.313560111768311e-06
, O 0 1.3252721586809457e-08
and O 0 1.0867862165753195e-08
a O 0 4.050041368941493e-08
frameshift O 0 0.0006546073709614575
mutation O 0 3.922335963579826e-06
in O 0 2.4387203367837174e-08
the O 0 1.9760852509875804e-08
coding O 0 2.6233010430587456e-05
region O 0 1.3556839917328034e-07
of O 0 6.731580626251343e-09
SCN5A O 0 2.5596153136575595e-05
in O 0 4.950416609972308e-08
three O 0 1.1923468434815732e-07
IVF B-Disease 1 0.9999985694885254
families O 0 2.162670398320188e-06
. O 0 1.97427834791597e-06

We O 0 3.7154682104301173e-06
show O 0 2.1407169015219552e-07
that O 0 7.036292881679174e-09
sodium O 0 5.418696602532691e-08
channels O 0 8.014441732484556e-08
with O 0 3.3454932157894746e-09
the O 0 2.2768736229750175e-08
missense O 0 7.901588105596602e-06
mutation O 0 2.1306464077497367e-06
recover O 0 1.209314177685883e-06
from O 0 3.6470817477152195e-09
inactivation O 0 5.756631367148657e-07
more O 0 1.5463408331584105e-09
rapidly O 0 3.250956126521487e-08
than O 0 2.623860018147184e-09
normal O 0 1.255422343859891e-08
and O 0 8.65500204838554e-09
that O 0 7.126774725918494e-09
the O 0 1.8080665853403843e-08
frameshift O 0 3.9584152546012774e-05
mutation O 0 6.908952059347939e-07
causes O 0 3.288417715907599e-08
the O 0 3.238051382581375e-09
sodium O 0 1.0978286724139252e-07
channel O 0 2.5241811840714945e-07
to O 0 9.492724828419341e-09
be O 0 2.416886957234965e-08
non O 0 2.58327162327987e-07
- O 0 9.636619324737694e-06
functional O 0 7.367798389168456e-06
. O 0 1.5816499399079476e-06

Our O 0 6.000838766340166e-06
results O 0 1.068594087882957e-06
indicate O 0 1.2233950030804408e-07
that O 0 2.173059598931104e-08
mutations O 0 4.812608267457108e-07
in O 0 2.6146738107968304e-08
cardiac O 0 2.5014253424160415e-06
ion O 0 4.139632437727414e-06
- O 0 0.0001472056028433144
channel O 0 2.8342960831651e-06
genes O 0 1.4911131529515842e-07
contribute O 0 1.6890428611304742e-08
to O 0 4.687914501033674e-09
the O 0 1.0824873442061289e-08
risk O 0 2.8063567469871487e-07
of O 0 5.434892536015923e-09
developing O 0 6.071876441637869e-07
IVF B-Disease 1 0.9999874830245972
. O 0 6.576160558324773e-07
. O 0 1.2056752893840894e-06

Molecular O 0 0.00012530286039691418
heterogeneity O 0 6.25452448730357e-05
in O 0 4.808314315596363e-07
mucopolysaccharidosis B-Disease 0 2.3212078303913586e-05
IVA I-Disease 0 4.2563486204016954e-05
in O 0 1.2912633451378497e-07
Australia O 0 1.0457088706061768e-07
and O 0 2.8353500880484717e-08
Northern O 0 5.688241699886021e-08
Ireland O 0 1.3338724329514662e-06
: O 0 5.1865942651829755e-09
nine O 0 6.26483664944999e-09
novel O 0 6.30770387033408e-08
mutations O 0 1.4854782648399123e-07
including O 0 4.070950243573179e-09
T312S O 0 4.391342827148037e-07
, O 0 2.8740285706874147e-09
a O 0 8.265532258633357e-09
common O 0 1.94433454225873e-07
allele O 0 2.934692474809708e-06
that O 0 6.276129482785109e-08
confers O 0 1.7673339698376367e-06
a O 0 9.442217674404674e-07
mild O 0 0.00018893486412707716
phenotype O 0 0.01767769455909729
. O 0 1.7702959667076357e-05

Mucopolysaccharidosis B-Disease 0 0.0057674795389175415
IVA I-Disease 0 0.023718226701021194
( O 0 7.4084391599171795e-06
MPS B-Disease 1 0.9999922513961792
IVA I-Disease 1 0.999998927116394
) O 0 1.3629954764837748e-07
is O 0 1.784216152600493e-08
an O 0 9.327089856014936e-08
autosomal B-Disease 1 0.9998806715011597
recessive I-Disease 1 0.9999879598617554
lysosomal I-Disease 1 0.9999879598617554
storage I-Disease 1 0.9999970197677612
disorder I-Disease 1 0.9999845027923584
caused O 0 7.842756167519838e-05
by O 0 1.289078142008293e-07
a O 0 0.00012098558363504708
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.903320806690317e-07
N O 0 0.0900895968079567
- O 0 0.004507907200604677
acetylgalactosamine O 0 0.023484669625759125
- O 0 0.0014352962607517838
6 O 0 1.0702351573854685e-06
- O 0 3.738154555321671e-05
sulfate O 0 0.00012473470997065306
sulfatase O 0 0.00013780526933260262
( O 0 1.7845998456778034e-07
GALNS O 0 2.0811308786505833e-05
) O 0 4.79101231576351e-07
. O 0 1.0400533483334584e-06

Previous O 0 2.902688493122696e-06
studies O 0 3.89095191621891e-07
of O 0 5.342239983718855e-09
patients O 0 9.749309271001039e-08
from O 0 3.6157954408366777e-09
a O 0 2.0498047703654265e-08
British O 0 0.026014668866991997
- O 0 0.06655765324831009
Irish O 0 2.7636393497232348e-05
population O 0 2.2415010292320403e-08
showed O 0 6.477380765090857e-08
that O 0 2.4119950481349406e-09
the O 0 2.49337284152773e-09
I113F O 0 1.8860887962546258e-07
mutation O 0 9.491315466902961e-08
is O 0 1.3828247436009633e-09
the O 0 1.0728261612413803e-09
most O 0 3.791374325601282e-09
common O 0 3.223006217467628e-08
single O 0 2.3268671611731406e-06
mutation O 0 6.329283496597782e-05
among O 0 3.812577006101492e-06
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 0.9999998807907104
patients O 0 4.107973290956579e-05
and O 0 4.110831852699448e-08
produces O 0 3.040376270746492e-07
a O 0 1.3924044424129534e-06
severe O 0 0.06909949332475662
clinical O 0 0.030751917511224747
phenotype O 0 0.04653690382838249
. O 0 1.4455438758886885e-05

We O 0 4.5430624595610425e-06
studied O 0 1.6459908920296584e-06
mutations O 0 1.3937316225565155e-06
in O 0 2.4763830097640493e-08
the O 0 1.4598779962682329e-08
GALNS O 0 1.8578322169560124e-06
gene O 0 1.2895381473754242e-07
from O 0 1.1498581642399586e-08
23 O 0 2.5576492035384035e-08
additional O 0 7.158670456419713e-08
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 0.9999995231628418
patients O 0 5.3103854043001775e-06
( O 0 1.85353588033621e-09
15 O 0 1.0189835641938316e-09
from O 0 9.257198896328589e-10
Australia O 0 5.081709275600588e-09
, O 0 7.481452679591882e-10
8 O 0 8.189106615041908e-10
from O 0 9.444175441686298e-10
Northern O 0 1.514914771405529e-08
Ireland O 0 4.015589922801155e-07
) O 0 1.155038620304083e-09
, O 0 3.902073109074422e-10
with O 0 5.027199212470634e-10
various O 0 1.827562634559854e-08
clinical O 0 0.0003263240505475551
phenotypes O 0 2.7978931029792875e-05
( O 0 4.500421724173975e-08
severe O 0 0.00030187430093064904
, O 0 1.9712892651568836e-08
16 O 0 1.454425024860484e-08
cases O 0 2.731039394632262e-08
; O 0 1.1273791677979261e-08
intermediate O 0 2.1254884075005975e-07
, O 0 5.51196821518829e-09
4 O 0 5.5903925932909715e-09
cases O 0 4.581741563924879e-08
; O 0 1.1166579128030207e-07
mild O 0 4.726361112261657e-06
, O 0 3.540326787287995e-08
3 O 0 6.741695557366256e-08
cases O 0 7.303775646505528e-07
) O 0 3.5219002825215284e-07
. O 0 1.3561822242991184e-06

We O 0 3.5677173855219735e-06
found O 0 7.19987340858097e-08
two O 0 6.430502352827716e-09
common O 0 2.9747672769531164e-08
mutations O 0 1.9471310963581345e-07
that O 0 1.0078077261610474e-09
together O 0 2.345056371311216e-09
accounted O 0 2.101181983960032e-08
for O 0 1.5000346520466223e-09
32 O 0 6.145069786356316e-09
% O 0 1.4624355060277594e-09
of O 0 3.7010100539802693e-10
the O 0 7.750573516318582e-09
44 O 0 2.0407657785881383e-08
unrelated O 0 2.3779065827511658e-07
alleles O 0 5.096723612041387e-07
in O 0 5.3659654497550946e-08
these O 0 1.5337671754878102e-07
patients O 0 5.517826139112003e-06
. O 0 2.033306145676761e-06

One O 0 5.28595421656064e-07
is O 0 3.3868616355903214e-08
the O 0 1.6199864560917376e-08
T312S O 0 2.0483878415689105e-06
mutation O 0 1.2891202914033784e-06
, O 0 8.120083272444845e-09
a O 0 1.0196976596432705e-08
novel O 0 1.7620517667182867e-07
mutation O 0 6.771399512217613e-07
found O 0 4.545323406546231e-08
exclusively O 0 8.91133637992425e-08
in O 0 1.1332230798188903e-07
milder O 0 3.61395905201789e-05
patients O 0 4.338936196290888e-05
. O 0 3.035907866433263e-06

The O 0 2.4635696149744035e-07
other O 0 3.0865496825072114e-08
is O 0 7.2421260099986284e-09
the O 0 7.17749415457547e-09
previously O 0 3.561091546089301e-07
described O 0 1.0020372798180688e-07
I113F O 0 7.470479204130243e-07
that O 0 1.9334116529989842e-08
produces O 0 3.3948430200325674e-07
a O 0 9.594524499334511e-07
severe O 0 0.001600400311872363
phenotype O 0 0.016325589269399643
. O 0 1.4968312825658359e-05

The O 0 1.238155277860642e-06
I113F O 0 1.1371316759323236e-05
and O 0 1.526468054180441e-07
T312S O 0 2.574005520727951e-06
mutations O 0 1.57217118612607e-06
accounted O 0 2.7144480441165797e-07
for O 0 1.2269862459390879e-08
8 O 0 1.6228749899482864e-08
( O 0 6.905280347524467e-09
18 O 0 1.1672464772516378e-08
% O 0 4.243943418913432e-09
) O 0 3.40252226394e-09
and O 0 1.682598949059866e-08
6 O 0 1.5228236449615906e-08
( O 0 1.8029072679226488e-09
14 O 0 4.858712543409638e-09
% O 0 3.901725609267714e-09
) O 0 1.889502554419664e-09
of O 0 1.95660043722512e-09
44 O 0 3.316877794645734e-08
unrelated O 0 6.848207476650714e-07
alleles O 0 1.4924434026397648e-06
, O 0 9.95106432810644e-08
respectively O 0 1.6493519297000603e-06
. O 0 2.5254357751691714e-06

The O 0 7.315082370951131e-07
relatively O 0 7.750028316877433e-07
high O 0 6.382178980857134e-07
residual O 0 7.42464999348158e-06
GALNS O 0 1.210912705573719e-05
activity O 0 6.021666649758117e-07
seen O 0 4.646593936286081e-07
when O 0 2.2179364123076084e-08
the O 0 1.0353446988631276e-08
T312S O 0 4.1156496877192694e-07
mutant O 0 1.3737799520185945e-07
cDNA O 0 1.797325808183814e-07
is O 0 1.1036269675912536e-08
overexpressed O 0 2.9753556418654625e-07
in O 0 6.889454340353041e-09
mutant O 0 1.153241129259186e-07
cells O 0 6.994427081963295e-08
provides O 0 2.3905786239453164e-09
an O 0 4.968621625245362e-10
explanation O 0 8.430951048410407e-09
for O 0 3.13219583603086e-09
the O 0 2.5156777994084223e-08
mild O 0 9.02380907064071e-06
phenotype O 0 0.002343493513762951
in O 0 2.127313507571671e-07
patients O 0 4.5317540298128733e-07
with O 0 1.9033935316770112e-08
this O 0 2.64021025486727e-07
mutation O 0 5.269768735161051e-05
. O 0 5.029261046729516e-06

The O 0 2.2652046993698605e-07
distribution O 0 1.0826818197529064e-07
and O 0 2.4124931385927084e-08
relative O 0 3.5381461316319474e-08
frequencies O 0 9.837006587076758e-08
of O 0 3.2873372912689547e-09
the O 0 1.3019787914458902e-08
I113F O 0 4.832596118831134e-07
and O 0 7.1042998150971925e-09
T312S O 0 2.332411810357371e-07
mutations O 0 1.646452716386193e-07
in O 0 4.660597685557377e-09
Australia O 0 3.896579059414762e-09
corresponded O 0 3.9247813887755e-09
to O 0 9.823030167055435e-10
those O 0 7.524111889090079e-10
observed O 0 4.568022404782823e-09
in O 0 3.3732632243044236e-09
Northern O 0 3.542447757354239e-08
Ireland O 0 1.2120401606807718e-06
and O 0 1.1001403343868787e-08
are O 0 2.468798276922257e-09
unique O 0 2.8071627244941055e-09
to O 0 2.5985193996547196e-09
these O 0 1.211948541524066e-09
two O 0 1.357017720415854e-09
populations O 0 1.4758586353025294e-08
, O 0 7.288795123017167e-10
suggesting O 0 5.221245213959946e-09
that O 0 9.549870894076662e-10
both O 0 1.3929820630309564e-09
mutations O 0 5.986771611787844e-08
were O 0 5.412403414339906e-09
probably O 0 6.876693880997209e-09
introduced O 0 8.297977416305002e-09
to O 0 3.4220277722596393e-09
Australia O 0 1.0464845878743745e-08
by O 0 4.175669587880293e-09
Irish O 0 1.1521725440388764e-07
migrants O 0 3.24314619604138e-08
during O 0 1.4488929167555398e-08
the O 0 3.0096721559402795e-08
19th O 0 2.0865147689619334e-06
century O 0 6.8442582232819404e-06
. O 0 2.2842325506644556e-06

Haplotype O 0 0.00026674859691411257
analysis O 0 3.770883722609142e-06
using O 0 5.757300982622837e-07
6 O 0 2.3097760504242615e-07
RFLPs O 0 1.1142170706079924e-06
provides O 0 1.564261964404068e-08
additional O 0 5.9678098018878245e-09
data O 0 4.816290655185185e-08
that O 0 4.195916503135777e-09
the O 0 8.589647215728746e-09
I113F O 0 6.885607604090183e-07
mutation O 0 2.6074559400512953e-07
originated O 0 5.53738708219953e-08
from O 0 5.625433008304981e-09
a O 0 2.6277678699671014e-08
common O 0 3.5432051959105593e-07
ancestor O 0 5.7274669416074175e-06
. O 0 5.025540758651914e-06

The O 0 4.287286117232725e-07
other O 0 3.583555496788904e-08
9 O 0 4.148110122059734e-08
novel O 0 6.526191498323897e-08
mutations O 0 4.113491627322219e-07
identified O 0 1.1908445429753556e-07
in O 0 5.682469605972074e-09
these O 0 9.073652051938552e-09
23 O 0 3.2605129263174604e-08
patients O 0 5.975591221840659e-08
were O 0 7.0832060217185244e-09
each O 0 2.4736956927284837e-09
limited O 0 2.6773939509894262e-08
to O 0 1.405539773458031e-08
a O 0 3.5760720606958785e-08
single O 0 3.621938049036544e-06
family O 0 2.533543465688126e-06
. O 0 2.186331585107837e-06

These O 0 5.735681725127506e-07
data O 0 2.762189410532301e-07
provide O 0 2.1674754435707655e-08
further O 0 1.2577423547099897e-08
evidence O 0 2.6271813169387315e-08
for O 0 5.151555182436596e-09
extensive O 0 2.1447712583722023e-07
allelic O 0 7.279511009983253e-06
heterogeneity O 0 2.0713656340376474e-05
in O 0 1.1720712791429833e-05
MPS B-Disease 1 0.9999973773956299
IVA I-Disease 1 0.9999992847442627
in O 0 2.358621486564516e-06
British O 0 0.043090470135211945
- O 0 0.0178152397274971
Irish O 0 1.697878360573668e-05
patients O 0 9.813731338681464e-08
and O 0 1.8986390237785145e-09
provide O 0 1.184698228406944e-09
evidence O 0 7.1983055072166735e-09
for O 0 6.85909773423532e-10
their O 0 2.137822585623894e-09
transmission O 0 5.049673177381919e-07
to O 0 1.3421606048780177e-08
Australia O 0 1.2746695254861606e-08
by O 0 6.178270783863127e-09
British O 0 0.0003600872587412596
- O 0 0.00017066809232346714
Irish O 0 1.2800267086277017e-06
migrants O 0 2.445824804908625e-07
. O 0 1.1809092370640428e-07
. O 0 8.548200298719166e-07

Identification O 0 5.271659574646037e-06
of O 0 1.3229315243279416e-07
constitutional O 0 1.5355248024206958e-06
WT1 O 0 7.567486318293959e-05
mutations O 0 1.073490329872584e-05
, O 0 2.766432949385944e-08
in O 0 2.4996834824264624e-08
patients O 0 1.9136668072405882e-07
with O 0 2.0171942338720328e-08
isolated O 0 0.00019178922229912132
diffuse B-Disease 1 0.9987457990646362
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.4245367196963343e-07
and O 0 1.4153886951362438e-08
analysis O 0 4.748327242509731e-08
of O 0 1.4444366591703783e-08
genotype O 0 0.09114114940166473
/ O 0 3.679598739836365e-05
phenotype O 0 1.3493006917997263e-05
correlations O 0 9.02873296126927e-07
by O 0 4.6539088138786155e-09
use O 0 5.2784226767244036e-08
of O 0 5.8326348195691935e-09
a O 0 7.71782779906971e-08
computerized O 0 7.903781079221517e-05
mutation O 0 2.0740399122587405e-05
database O 0 1.2314169907767791e-05
. O 0 5.208831680647563e-06

Constitutional O 0 1.7480873793829232e-05
mutations O 0 1.9198345398763195e-05
of O 0 5.5422688660655695e-08
the O 0 8.289880781831016e-08
WT1 O 0 9.419584785064217e-06
gene O 0 7.307747296181333e-07
, O 0 1.4701721617882413e-08
encoding O 0 1.2479502231599326e-07
a O 0 1.2384937519982486e-07
zinc O 0 0.28701725602149963
- O 0 2.0867297280346975e-05
finger O 0 1.8118869320460362e-06
transcription O 0 2.762666326816543e-07
factor O 0 1.968546996522491e-07
involved O 0 4.1653464677438024e-08
in O 0 1.3363549555833742e-07
renal O 0 0.2501606345176697
and O 0 1.033062403621443e-06
gonadal O 1 0.8981096148490906
development O 0 2.721881742218102e-08
, O 0 2.1437593922257747e-09
are O 0 6.621048154187292e-10
found O 0 4.220066518456633e-09
in O 0 4.0116296950998276e-09
most O 0 3.144804239241239e-08
patients O 0 3.617504944486427e-07
with O 0 1.119750479006143e-07
Denys B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999995231628418
Drash I-Disease 1 0.9999978542327881
syndrome I-Disease 1 0.9999991655349731
( O 0 3.5323009228704905e-07
DDS B-Disease 1 1.0
) O 0 1.8176972105266032e-07
, O 0 3.099286516317079e-08
or O 0 3.269685294071678e-06
diffuse B-Disease 1 0.9987945556640625
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.5064679195784265e-06
DMS B-Disease 1 0.9568310976028442
) O 0 1.2721707776108815e-07
associated O 0 1.0080777457233125e-07
with O 0 6.872985380823593e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0006965040811337531
/ O 0 0.0005536016542464495
or O 0 0.00034215280902571976
Wilms B-Disease 1 0.9995437264442444
tumor I-Disease 1 0.7665324211120605
( O 0 2.3989032342797145e-06
WT B-Disease 1 0.9999983310699463
) O 0 1.4179415757098468e-06
. O 0 3.796803639488644e-06

Most O 0 3.119027269349317e-06
mutations O 0 4.929996794089675e-05
in O 0 2.674812094483059e-06
DDS B-Disease 1 1.0
patients O 0 0.028696343302726746
lie O 0 1.810229878174141e-05
in O 0 7.804618462614599e-08
exon O 0 2.1316604943422135e-06
8 O 0 8.53525108368558e-08
or O 0 4.41264340622638e-08
exon O 0 1.284257450606674e-06
9 O 0 3.6506889955489896e-08
, O 0 3.6143750214989723e-09
encoding O 0 1.7767763438314432e-07
zinc O 0 0.014565772376954556
finger O 0 9.188762487610802e-05
2 O 0 1.2252922942934674e-07
or O 0 1.5086538951436523e-07
zinc O 0 0.006442313548177481
finger O 0 0.0002594302059151232
3 O 0 6.201720736953575e-08
, O 0 3.927777214585149e-09
respectively O 0 2.4391203723439503e-08
, O 0 1.6273686842538382e-09
with O 0 1.664702820036723e-09
a O 0 4.445013246368035e-08
hot O 0 0.00020642383606173098
spot O 0 0.0005713121499866247
( O 0 2.2726997173094787e-08
R394W O 0 1.095826178243442e-06
) O 0 1.8975937265963694e-08
in O 0 3.0091957370359523e-08
exon O 0 7.1053846113500185e-06
9 O 0 2.180755018343916e-06
. O 0 3.0293281270132866e-06

We O 0 2.5422762064408744e-06
analyzed O 0 7.377124688900949e-07
a O 0 1.794920301279035e-08
series O 0 2.6205254854971827e-08
of O 0 3.3563520851487283e-09
24 O 0 9.016981294962534e-08
patients O 0 1.0154804641615556e-07
, O 0 3.5904159645383515e-09
10 O 0 4.065115355444959e-09
with O 0 9.988787574854996e-09
isolated B-Disease 0 0.0003845598257612437
DMS I-Disease 1 0.9846571087837219
( O 0 5.754952425718329e-08
IDMS B-Disease 0 0.0005246728542260826
) O 0 1.6399077651385596e-08
, O 0 2.3388295744553034e-09
10 O 0 1.9938861672841313e-09
with O 0 9.084597074604517e-09
DDS B-Disease 1 1.0
, O 0 1.1861101256727125e-07
and O 0 4.231740291515962e-08
4 O 0 3.795977931986272e-08
with O 0 6.065608459948635e-08
urogenital B-Disease 1 0.7941548228263855
abnormalities I-Disease 1 0.9999809265136719
and O 0 1.7228909200639464e-05
/ O 0 0.0008774640155024827
or O 0 0.025904277339577675
WT B-Disease 1 1.0
. O 0 1.6198700905079022e-05

We O 0 1.3390686035563704e-05
report O 0 1.9143105873808963e-06
WT1 O 0 3.968495730077848e-05
heterozygous O 0 4.0356326280743815e-06
mutations O 0 3.901135642081499e-06
in O 0 7.101037624579476e-08
16 O 0 9.325719929620391e-08
patients O 0 3.7109600725671044e-07
, O 0 5.632884381157055e-09
4 O 0 1.2186295528238134e-08
of O 0 5.866128027776085e-09
whom O 0 1.2418945516401436e-06
presented O 0 6.572391839654301e-07
with O 0 6.722883085785725e-07
IDMS B-Disease 1 0.9953107237815857
. O 0 2.16667540371418e-05

One O 0 1.739758317853557e-06
male O 0 8.722304301045369e-07
and O 0 5.610359821162092e-08
two O 0 7.099846044411606e-08
female O 0 3.849830318358727e-05
IDMS B-Disease 1 0.9939445853233337
patients O 0 1.581350625201594e-05
with O 0 2.0611905426903832e-07
WT1 O 0 0.005541349295526743
mutations O 0 0.00035727021167986095
underwent O 0 6.470773951150477e-05
normal O 0 3.951623148168437e-05
puberty O 0 0.0002897658268921077
. O 0 1.0001400369219482e-05

Two O 0 2.6053160127048614e-06
mutations O 0 3.650972212199122e-05
associated O 0 7.755033948342316e-07
with O 0 3.83970615303042e-08
IDMS B-Disease 0 0.1978779286146164
are O 0 9.425590086209468e-09
different O 0 6.139540431604473e-09
from O 0 6.001140029354701e-09
those O 0 4.179002388582376e-08
described O 0 1.4380104857991682e-06
in O 0 2.9385426387307234e-05
DDS B-Disease 1 1.0
patients O 0 0.004649722017347813
. O 0 5.876293471374083e-06

No O 0 1.0768534593807999e-05
WT1 O 0 6.135014700703323e-05
mutations O 0 8.213310138671659e-06
were O 0 5.928196245008621e-08
detected O 0 2.1500896707493666e-07
in O 0 4.979125556303643e-09
the O 0 3.219158495326724e-09
six O 0 2.2940048083341935e-08
other O 0 3.3252582909426565e-08
IDMS B-Disease 1 0.8525987267494202
patients O 0 1.2309217254369287e-06
, O 0 6.0284208736050005e-09
suggesting O 0 1.731916796643418e-07
genetic O 0 6.56865154269326e-07
heterogeneity O 0 1.5876615861998289e-06
of O 0 4.7473129427544336e-08
this O 0 4.167642146057915e-06
disease O 0 0.00017285003559663892
. O 0 4.992054982722038e-06

We O 0 1.0135943739442155e-05
analyzed O 0 1.2027321645291522e-05
genotype O 0 0.00011479328532004729
/ O 0 1.580412754265126e-05
phenotype O 0 2.2121912479633465e-05
correlations O 0 0.0002004479756578803
, O 0 1.5143717391197242e-08
on O 0 6.424262899429323e-09
the O 0 2.9739999352074165e-09
basis O 0 6.812437280956374e-09
of O 0 7.936564183630423e-10
the O 0 8.770180137673833e-09
constitution O 0 1.4530995073869235e-08
of O 0 1.0781268100501507e-09
a O 0 1.9340424373126552e-08
WT1 O 0 4.680359324993333e-06
mutation O 0 2.535196585995436e-07
database O 0 3.114432800543909e-08
of O 0 2.502267726356422e-09
84 O 0 7.5758883610888e-08
germ O 0 0.0011454124469310045
- O 0 0.0007404836942441761
line O 0 1.7199608919327147e-05
mutations O 0 7.078130010995665e-07
, O 0 1.8504910936911756e-09
to O 0 7.663750745123821e-10
compare O 0 2.7404212232795544e-08
the O 0 1.1298628699307756e-09
distribution O 0 6.649653716550574e-09
and O 0 2.21825793289554e-08
type O 0 8.16830208805186e-07
of O 0 2.9706210824542723e-09
mutations O 0 4.766193796967855e-06
, O 0 5.1878705775720846e-09
according O 0 2.4172637225206017e-09
to O 0 5.483958620544627e-09
the O 0 1.7005021391014452e-08
different O 0 3.8072576558079163e-07
symptoms O 0 1.0982117601088248e-05
. O 0 1.7681735471342108e-06

This O 0 3.347036852119345e-07
demonstrated O 0 7.622108455507259e-07
( O 0 9.799399514065499e-09
1 O 0 1.0512058778999744e-08
) O 0 4.155456867493967e-09
the O 0 2.3104615998192912e-09
association O 0 5.6863944664087285e-09
between O 0 5.5195426007514925e-09
mutations O 0 1.8121066602816427e-07
in O 0 5.798824975755679e-09
exons O 0 2.069873801247013e-07
8 O 0 1.9318045829663788e-08
and O 0 1.5685403198517633e-08
9 O 0 1.9313366905748808e-08
and O 0 3.749693533450227e-08
DMS B-Disease 0 0.0011799345957115293
; O 0 6.6538410337102505e-09
( O 0 8.29387503120671e-10
2 O 0 3.010801830072296e-09
) O 0 2.38720687661953e-09
among O 0 5.06585751125499e-09
patients O 0 3.916841251339065e-08
with O 0 4.918011331511707e-09
DMS B-Disease 0 0.12621191143989563
, O 0 3.5058462799497647e-09
a O 0 3.176294116613576e-09
higher O 0 4.353679372570696e-08
frequency O 0 8.692129682685845e-08
of O 0 1.9919665916745544e-09
exon O 0 3.879007124396594e-07
8 O 0 3.591951980297381e-08
mutations O 0 2.1922265602825064e-07
among O 0 1.2937700688553377e-08
46 O 0 8.703793241693347e-08
, O 0 3.762007949603685e-08
XY O 0 0.0001285482430830598
patients O 0 4.36779430401657e-07
with O 0 9.581511584144664e-09
female O 0 5.282779511617264e-07
phenotype O 0 2.095949866998126e-06
than O 0 1.2800392745759837e-08
among O 0 2.435759149932437e-08
46 O 0 1.5094441607743647e-07
, O 0 6.434725463577706e-08
XY O 0 0.0008240967872552574
patients O 0 2.610658214052819e-07
with O 0 2.733023363177267e-09
sexual O 0 6.979208677648785e-08
ambiguity O 0 1.0671510608517565e-06
or O 0 2.8291162834648276e-06
male O 0 7.090804047038546e-06
phenotype O 0 6.1011232901364565e-05
; O 0 4.026518496402787e-08
and O 0 1.5650677198664198e-08
( O 0 1.9138988172073823e-09
3 O 0 5.171214567667448e-09
) O 0 2.8828734954799984e-09
statistically O 0 6.058693458044218e-08
significant O 0 1.8828263392833833e-08
evidence O 0 1.9085852898115263e-07
that O 0 1.5181196744151748e-08
mutations O 0 2.105714003164394e-07
in O 0 6.857740153520808e-09
exons O 0 3.8326527374010766e-07
8 O 0 2.4160481615354e-08
and O 0 9.650584331666323e-09
9 O 0 1.7810540597906765e-08
preferentially O 0 1.7244279604256008e-07
affect O 0 5.97457727735673e-08
amino O 0 4.113216078849291e-08
acids O 0 3.7803136621050726e-08
with O 0 1.6849042161481975e-09
different O 0 1.2089709677809424e-08
functions O 0 7.402285007174214e-08
. O 0 2.212893690511919e-07
. O 0 1.282113430534082e-06

The O 0 1.6014894299587468e-06
185delAG O 0 1.822005106077995e-05
BRCA1 O 0 2.027114896918647e-05
mutation O 0 1.2348464224487543e-06
originated O 0 1.58051463472475e-07
before O 0 1.5724253898952156e-08
the O 0 1.253873449513776e-09
dispersion O 0 1.027923062224545e-07
of O 0 6.463811152990218e-10
Jews O 0 1.0906532565968519e-07
in O 0 6.510946448656796e-09
the O 0 4.0891290353783916e-09
diaspora O 0 9.660183053483706e-08
and O 0 3.224925038125548e-08
is O 0 5.213482978660977e-09
not O 0 2.8800830165209845e-08
limited O 0 9.638245046517113e-08
to O 0 1.7281782049849426e-07
Ashkenazim O 0 2.1097628632560372e-05
. O 0 2.3126665382733336e-06

The O 0 8.504162565259321e-07
185delAG O 0 8.13237602415029e-06
mutation O 0 3.309302883280907e-06
in O 0 6.055655177306107e-08
BRCA1 O 0 6.44373085378902e-06
is O 0 3.128184999923178e-08
detected O 0 5.411775418906473e-07
in O 0 1.7479084846172555e-08
Ashkenazi O 0 2.303301016581827e-06
Jews O 0 4.485998061909413e-08
both O 0 6.771216920498091e-09
in O 0 2.7290553816783358e-08
familial B-Disease 1 0.8510997891426086
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.607824913207878e-07
in O 0 2.356329353858655e-08
the O 0 3.270447024306122e-08
general O 0 6.948936714934462e-08
population O 0 9.705038337415317e-07
. O 0 3.3975934456975665e-06

All O 0 2.0701197627204238e-06
tested O 0 2.0171222786302678e-05
Ashkenazi O 0 4.697047916124575e-05
mutation O 0 5.6713365665927995e-06
carriers O 0 2.347817826375831e-06
share O 0 9.508662515145261e-07
the O 0 2.573710133901841e-08
same O 0 6.933341012427263e-08
allelic O 0 4.600157353706891e-06
pattern O 0 5.1405728299869224e-05
at O 0 3.147079041809775e-07
the O 0 3.6966969219065504e-07
BRCA1 O 0 0.00039184620254673064
locus O 0 0.00019710812193807214
. O 0 4.788601017935434e-06

Our O 0 2.783768195513403e-06
previous O 0 6.107459284976358e-07
study O 0 1.7572824617673177e-07
showed O 0 1.008025876103602e-07
that O 0 5.7635176631265495e-09
this O 0 1.0127836347351149e-08
Ashkenazi O 0 8.088775211945176e-05
mutation O 0 9.719192348711658e-07
also O 0 2.280541799848379e-08
occurs O 0 1.835923235660175e-08
in O 0 1.2886228972774916e-08
Iraqi O 0 1.2501419632826583e-07
Jews O 0 1.3384722308273922e-07
with O 0 4.18299528348598e-09
a O 0 6.649288053495184e-08
similar O 0 7.989492587512359e-07
allelic O 0 3.808469045907259e-05
pattern O 0 0.0006591618293896317
. O 0 1.6731584764784202e-05

We O 0 2.543527671150514e-06
extended O 0 1.8148115543681342e-07
our O 0 3.17765902480005e-08
analysis O 0 3.076951315961196e-08
to O 0 4.734172165399286e-09
other O 0 8.699937659173429e-09
non O 0 1.5967860633736564e-07
- O 0 1.5924382523735403e-06
Ashkenazi O 0 1.15084083063266e-06
subsets O 0 1.261341679992256e-07
354 O 0 7.896181131172852e-08
of O 0 2.452316127943277e-09
Moroccan O 0 4.7263884539461287e-07
origin O 0 5.68757982932766e-08
, O 0 5.079257903162215e-09
200 O 0 6.2043801207778415e-09
Yemenites O 0 6.840981541245128e-07
and O 0 2.3472994215012477e-08
150 O 0 3.35862715417079e-08
Iranian O 0 6.790787097088469e-07
Jews O 0 1.529751443740679e-06
. O 0 1.0951272315651295e-06

Heteroduplex O 0 0.0002519058180041611
analysis O 0 5.443513146019541e-06
complemented O 0 1.0931519227597164e-06
by O 0 2.6042320300234678e-08
direct O 0 4.750555504529075e-08
DNA O 0 5.389381385612069e-07
sequencing O 0 2.824485534347332e-07
of O 0 7.538250024197168e-09
abnormally O 0 8.465266319035436e-07
migrating O 0 2.2377511754712032e-07
bands O 0 8.510588713761535e-07
were O 0 3.642819024207711e-07
employed O 0 4.484305463847704e-06
. O 0 4.200373041385319e-06

Four O 0 8.97449581316323e-07
of O 0 3.93049184310712e-08
Moroccan O 0 1.2554496606753673e-06
origin O 0 1.1091118778949749e-07
( O 0 3.599693432221329e-09
1 O 0 3.710794782563198e-09
. O 0 2.3495916323668098e-09
1 O 0 5.097941180309817e-09
% O 0 3.4457834363621487e-09
) O 0 9.292385194648034e-10
and O 0 5.5426152556492525e-09
none O 0 1.2623062595196188e-08
of O 0 3.131268300204937e-10
the O 0 4.178649426478387e-09
Yemenites O 0 3.8818271264062787e-07
or O 0 2.6794376495331562e-08
Iranians O 0 4.909475492809179e-08
was O 0 6.4691953127749e-08
a O 0 9.789648203195611e-09
carrier O 0 2.008974178124845e-07
of O 0 3.5403111553478084e-09
the O 0 5.887708809382275e-08
185delAG O 0 1.2936268831253983e-05
mutation O 0 9.577142009220552e-06
. O 0 1.3711872952626436e-06

BRCA1 O 0 0.0007152180769480765
allelic O 0 5.745631642639637e-05
patterns O 0 5.880126991542056e-06
were O 0 1.6280657177958346e-07
determined O 0 1.194792957903701e-07
for O 0 1.948976091625809e-09
four O 0 1.1008828293412876e-09
of O 0 1.4145398741227666e-10
these O 0 1.2736530718981953e-09
individuals O 0 1.8168534454687801e-09
and O 0 1.950649863857734e-09
for O 0 2.9304958459874797e-09
12 O 0 4.99287722277586e-09
additional O 0 1.2379524072514414e-08
non O 0 5.888140890419891e-07
- O 0 2.8627600840991363e-06
Ashkenazi O 0 4.5353481255006045e-06
185delAG O 0 5.265727622827399e-07
mutation O 0 4.4993575443186273e-07
carriers O 0 4.554209738216741e-07
who O 0 2.2450444703281391e-07
had O 0 4.3050324165960774e-05
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 0.9999940395355225
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.9579158106353134e-05

Six O 0 7.1465674409409985e-06
non O 0 1.1969161278102547e-05
- O 0 0.0007746318005956709
Ashkenazi O 0 0.0004988781292922795
individuals O 0 6.292059140378115e-08
shared O 0 4.788016028101083e-08
the O 0 1.524730208757319e-08
common O 0 5.245373699835909e-07
Ashkenazi O 0 0.001687066163867712
haplotype O 0 1.154871097241994e-05
, O 0 1.8141948388006313e-08
four O 0 2.257173470354701e-08
had O 0 2.787407765936223e-06
a O 0 9.007575130226542e-09
closely O 0 9.176883963846194e-08
related O 0 2.554373850216507e-07
pattern O 0 0.00012555260036606342
, O 0 6.996668844294618e-08
and O 0 2.0886753659965507e-08
the O 0 9.736817574435008e-09
rest O 0 6.213667802512646e-08
( O 0 8.40431546578202e-09
n O 0 5.220857474341756e-06
= O 0 5.971335667709354e-06
6 O 0 3.456884201114008e-08
) O 0 8.707524479234507e-09
displayed O 0 7.721980921360228e-08
a O 0 7.56993756567681e-08
distinct O 0 3.5537061648938106e-06
BRCA1 O 0 0.00034793655504472554
allelic O 0 9.787869203137234e-05
pattern O 0 0.00023254532425198704
. O 0 1.79124872374814e-05

We O 0 4.5668498387385625e-06
conclude O 0 1.8961139858220122e-06
that O 0 1.707320507193799e-08
the O 0 1.0729045207824583e-08
185delAG O 0 1.5091043223947054e-06
BRCA1 O 0 6.003088401485002e-06
mutation O 0 4.1009181472873024e-07
occurs O 0 2.0163518854587892e-08
in O 0 3.9059546708131165e-09
some O 0 7.375012156529692e-09
non O 0 2.0928439425915712e-06
- O 0 0.04980072006583214
Ashkenazi O 0 0.04033250734210014
populations O 0 3.432659809732286e-07
at O 0 2.433298007531448e-08
rates O 0 6.400513541393593e-08
comparable O 0 8.586785327224788e-08
with O 0 4.984637147487092e-09
that O 0 2.241984375928041e-08
of O 0 5.530621294269622e-08
Ashkenazim O 0 4.953721145284362e-05
. O 0 2.855901811926742e-06

The O 0 1.0131045655725757e-06
majority O 0 3.7370918448687007e-07
of O 0 4.338101877721101e-09
Jewish O 0 1.978922199441513e-07
185delAG O 0 1.154573055828223e-06
mutation O 0 9.5744610462134e-07
carriers O 0 4.512652935773076e-07
have O 0 3.8281299907794164e-08
a O 0 1.1414693190658909e-08
common O 0 1.2439340935088694e-07
allelic O 0 1.8659752640814986e-06
pattern O 0 5.691801197826862e-05
, O 0 3.521772029557724e-08
supporting O 0 4.889664140250716e-08
the O 0 5.057303908984068e-09
founder O 0 5.7588174229294964e-08
effect O 0 4.1993452271071874e-08
notion O 0 6.523391249402266e-08
, O 0 2.9120972300233916e-09
but O 0 5.056301155548226e-09
dating O 0 2.853922431711453e-08
the O 0 3.7135632346974035e-09
mutations O 0 4.586270563322614e-08
origin O 0 1.3042753543857089e-08
to O 0 2.1318571352679783e-09
an O 0 1.4107253143436083e-09
earlier O 0 2.655930231298953e-08
date O 0 2.7098980126538663e-07
than O 0 1.483314626682386e-08
currently O 0 1.1216337014730016e-07
estimated O 0 2.0959349456006748e-07
. O 0 9.56486019276781e-07

However O 0 2.845242761395639e-06
, O 0 3.00378815154545e-08
the O 0 6.5859113718147455e-09
different O 0 1.0027271457602183e-08
allelic O 0 8.905734603104065e-07
pattern O 0 7.065289082675008e-06
at O 0 1.0222217383670795e-07
the O 0 8.489510427978075e-09
BRCA1 O 0 1.8166501831728965e-06
locus O 0 4.1189085209225595e-07
even O 0 2.029961976290906e-08
in O 0 1.6385750534197996e-09
some O 0 1.138133809419628e-09
Jewish O 0 1.5334892111695808e-07
mutation O 0 3.3312355185444176e-07
carriers O 0 1.0926021332124947e-07
, O 0 3.2985423281672865e-09
might O 0 4.4695827483565154e-08
suggest O 0 4.3046405551194766e-08
that O 0 4.6470431946943336e-09
the O 0 1.1635033381196536e-08
mutation O 0 5.271586474009382e-07
arose O 0 3.3479881267339806e-07
independently O 0 5.058213901065756e-07
. O 0 2.5973199058171303e-07
. O 0 2.100544406857807e-06

Crystal O 0 0.003976511303335428
structure O 0 4.250777237757575e-06
of O 0 7.095690079950145e-08
the O 0 2.854843330624135e-07
hemochromatosis B-Disease 1 0.9999992847442627
protein O 0 5.191281161387451e-06
HFE O 0 0.03164186328649521
and O 0 1.226004258114699e-07
characterization O 0 1.0308893934052321e-06
of O 0 7.710820426609644e-09
its O 0 4.2327009452947095e-08
interaction O 0 1.7953489361843822e-07
with O 0 1.282398045532318e-07
transferrin O 0 4.5287171815289184e-05
receptor O 0 1.7572150682099164e-05
. O 0 5.698389486497035e-06

HFE O 0 0.02775207720696926
is O 0 2.081808361253934e-06
an O 0 1.4141588167149166e-07
MHC O 0 0.00020991230849176645
- O 0 5.306133061822038e-06
related O 0 5.434750605104455e-08
protein O 0 2.6916129769460895e-08
that O 0 2.0868105021776273e-09
is O 0 1.2961454132209838e-09
mutated O 0 9.593878047553517e-08
in O 0 1.052614262420093e-08
the O 0 4.7794937785283764e-08
iron B-Disease 1 0.999824583530426
- I-Disease 1 0.9999982118606567
overload I-Disease 1 0.9999265670776367
disease I-Disease 1 0.9999668598175049
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0014529513427987695

HFE O 0 0.0021042220760136843
binds O 0 2.6110314138350077e-05
to O 0 5.147481942913146e-07
transferrin O 0 6.068552465876564e-06
receptor O 0 2.7087739908893127e-06
( O 0 4.257509900185141e-08
TfR O 0 2.6575826268526725e-06
) O 0 1.9665648665068147e-08
and O 0 1.653993386696584e-08
reduces O 0 1.2064720067428425e-07
its O 0 8.491226388684936e-09
affinity O 0 9.096546449427478e-08
for O 0 2.1977861308641877e-08
iron O 0 0.012669087387621403
- O 0 4.312440796638839e-05
loaded O 0 4.442615022526297e-07
transferrin O 0 2.592195187389734e-06
, O 0 3.8770981092284273e-08
implicating O 0 1.5477808119612746e-06
HFE O 0 0.00030952945235185325
in O 0 5.15760405050969e-07
iron O 0 0.0026950878091156483
metabolism O 0 0.00020528036111500114
. O 0 4.176471065875376e-06

The O 0 1.0538844435359351e-05
2 O 0 1.2717387107841205e-05
. O 0 1.0848812053154688e-05

6 O 0 3.0619183235103264e-05
A O 0 1.8280196627529222e-06
crystal O 0 0.00019457754387985915
structure O 0 2.2541978523804573e-06
of O 0 3.394758252284191e-08
HFE O 0 0.0004289116768632084
reveals O 0 5.748369176217238e-07
the O 0 2.3425405615284944e-08
locations O 0 1.8343591534630832e-07
of O 0 4.678582499195727e-08
hemochromatosis B-Disease 1 1.0
mutations O 1 0.5472657680511475
and O 0 1.0152524509976502e-06
a O 0 1.6446949757664697e-07
patch O 0 0.003709958866238594
of O 0 5.155673665768745e-09
histidines O 0 7.436285613948712e-06
that O 0 1.0335472033773385e-08
could O 0 3.5696800182449806e-08
be O 0 4.164836031606001e-09
involved O 0 1.4278181303950532e-08
in O 0 5.9067517099720135e-08
pH O 0 2.2252123017096892e-05
- O 0 2.0339406546554528e-05
dependent O 0 3.7718623389082495e-06
interactions O 0 1.8036565734291798e-06
. O 0 1.9374597286514472e-06

We O 0 4.2537863009783905e-06
also O 0 1.256532016213896e-07
demonstrate O 0 3.5628715977509273e-07
that O 0 4.1770100267513044e-08
soluble O 0 2.3159352622315055e-06
TfR O 0 7.082775027811294e-06
and O 0 8.759518266288069e-08
HFE O 0 1.1430265658418648e-05
bind O 0 1.0419563523100805e-06
tightly O 0 1.0873834526137216e-06
at O 0 6.01951839485082e-08
the O 0 3.5515450580447805e-09
basic O 0 4.947868248450504e-08
pH O 0 2.1433255881220248e-07
of O 0 6.553865783409663e-10
the O 0 3.218133315385785e-09
cell O 0 3.092201586696319e-05
surface O 0 0.006553430575877428
, O 0 1.8627266840098855e-08
but O 0 1.0390941440618917e-07
not O 0 4.619464988309119e-08
at O 0 2.16439364209009e-08
the O 0 4.71223806641774e-08
acidic O 0 7.954762622830458e-06
pH O 0 3.036593852812075e-06
of O 0 9.12022599663942e-08
intracellular O 0 3.0499029890052043e-05
vesicles O 0 0.00012398784747347236
. O 0 8.484174031764269e-06

TfR O 0 0.15061910450458527
HFE O 0 0.014348240569233894
stoichiometry O 0 0.0003384059527888894
( O 0 1.8012569853453897e-06
2 O 0 3.960148831083643e-07
1 O 0 1.1584770476247286e-07
) O 0 2.463630011106943e-08
differs O 0 1.912469969056474e-07
from O 0 1.0086355217708842e-07
TfR O 0 1.1501154403958935e-05
transferrin O 0 2.7397113626648206e-06
stoichiometry O 0 1.1693421129166381e-06
( O 0 1.6768481714279915e-08
2 O 0 1.012578909609374e-08
2 O 0 5.947310643961146e-09
) O 0 1.4134671211252225e-09
, O 0 7.380229205544708e-10
implying O 0 1.6925580936799633e-08
a O 0 1.8190240425042248e-09
different O 0 2.7153468362683952e-09
mode O 0 2.8550223518664097e-08
of O 0 6.685284548169079e-10
binding O 0 6.3873301314743e-08
for O 0 1.0706476594180003e-08
HFE O 0 6.094000582379522e-06
and O 0 8.963221276303557e-09
transferrin O 0 4.6365013872673444e-07
to O 0 9.890131380529965e-09
TfR O 0 9.158905527328898e-07
, O 0 5.279940484825829e-09
consistent O 0 1.822278861141058e-08
with O 0 4.16853973561615e-09
our O 0 2.242959595832872e-08
demonstration O 0 5.146146264678464e-08
that O 0 8.192391653949471e-09
HFE O 0 4.246810476615792e-06
, O 0 7.433805127021742e-09
transferrin O 0 6.465013484557858e-07
, O 0 1.6220207399442188e-08
and O 0 7.043909278081628e-08
TfR O 0 6.324742116703419e-06
form O 0 2.0226927688327123e-07
a O 0 2.269957803946454e-07
ternary O 0 1.3524751921067946e-05
complex O 0 9.331529145129025e-05
. O 0 1.0223100616713054e-05

Identification O 0 2.0677225620602258e-06
of O 0 2.939762389075895e-08
three O 0 1.8303603965819093e-08
novel O 0 1.6558786342102394e-07
mutations O 0 1.2436273664206965e-06
and O 0 1.5992512203411025e-08
a O 0 1.058448706459103e-08
high O 0 1.3109499263919133e-07
frequency O 0 6.143332598185225e-07
of O 0 3.833725337187843e-09
the O 0 4.000346010002431e-08
Arg778Leu O 0 9.827207577473018e-06
mutation O 0 2.6081002033606637e-06
in O 0 7.495214049413335e-08
Korean O 0 1.0692986052163178e-06
patients O 0 8.848683137330227e-07
with O 0 1.0358270685628668e-07
Wilson B-Disease 0 0.00025765979080460966
disease I-Disease 0 2.6067620638059452e-05
. O 0 3.879061296174768e-06

Four O 0 3.3012681797117693e-06
mutations O 0 4.2868465243373066e-05
- O 0 0.00012233734014444053
- O 0 8.22388301457977e-06
R778L O 0 1.1447766610217514e-06
, O 0 4.014783172578973e-09
A874V O 0 1.293489333420439e-07
, O 0 2.1186059573352622e-09
L1083F O 0 3.5774636586438646e-08
, O 0 9.77035452542907e-10
and O 0 2.7151187964591372e-09
2304delC O 0 6.055343533262203e-07
- O 0 5.030306965636555e-06
- O 0 2.378662429691758e-06
in O 0 5.779358325241901e-09
the O 0 1.0911522352330394e-08
copper O 0 2.7883626898983493e-05
- O 0 3.114795674719062e-07
transporting O 0 5.016907422827899e-08
enzyme O 0 7.954712089031091e-08
, O 0 5.484534160160592e-09
P O 0 1.0781966011563782e-05
- O 0 3.0573091862606816e-06
type O 0 2.7928679173783166e-06
ATPase O 0 5.88987586525036e-06
( O 0 8.25177970398272e-09
ATP7B O 0 3.993721406914119e-07
) O 0 2.353453210091061e-09
, O 0 8.757822800298243e-10
were O 0 6.037949251691543e-09
identified O 0 6.461968382609484e-08
in O 0 4.973556499976439e-08
Korean O 0 4.12015197071014e-06
Patients O 0 4.158560216183105e-07
with O 0 8.156052189178808e-08
Wilson B-Disease 0 0.0006413753726519644
disease I-Disease 0 3.456572085269727e-05
. O 0 3.3701828670018585e-06

Arg778Leu O 0 0.00016761086590122432
, O 0 2.1953525219942094e-07
the O 0 1.470581612039723e-08
most O 0 1.770932378519774e-08
frequently O 0 2.296938959034378e-07
reported O 0 9.866545980230512e-08
mutation O 0 6.423738341254648e-08
of O 0 8.002366547188444e-10
this O 0 2.6005473330315e-09
enzyme O 0 1.3500896045570698e-07
, O 0 4.912480200403024e-09
was O 0 9.479013840518746e-08
found O 0 1.1160399715492986e-08
in O 0 2.9511995069952945e-09
six O 0 2.9506983523219787e-09
of O 0 7.85618348153605e-10
eight O 0 1.4591041264111482e-08
unrelated O 0 5.795477022729756e-07
patients O 0 2.464986437189509e-07
studied O 0 1.5886143955867738e-07
, O 0 3.558047412255405e-09
an O 0 6.182939049637071e-09
allele O 0 5.847168722539209e-07
frequency O 0 7.949431051201827e-07
of O 0 4.8866432678096317e-08
37 O 0 1.2858506579505047e-06
. O 0 1.8163418644689955e-06

5 O 0 3.2073521651909687e-06
% O 0 2.889173060793837e-07
, O 0 1.0702352781777336e-08
which O 0 5.253701473861838e-09
is O 0 1.190476717205513e-09
considerably O 0 3.951757676645684e-08
higher O 0 2.7383364908928343e-08
than O 0 3.7785454765071336e-09
those O 0 2.1130610594610744e-09
in O 0 4.221266447501648e-09
other O 0 1.9329435829718022e-08
Asian O 0 5.253829158391454e-07
populations O 0 1.8623734376888024e-06
. O 0 9.373509897159238e-07

The O 0 6.424180014619196e-07
novel O 0 8.163567599694943e-07
single O 0 3.3923834052984603e-07
nucleotide O 0 1.4554206018146942e-06
deletion O 0 2.20591391553171e-06
, O 0 2.1830340202200205e-08
2304delC O 0 4.914085707241611e-07
, O 0 1.1633857432968853e-08
was O 0 1.407348264592656e-07
found O 0 2.944240584668023e-08
in O 0 2.849598246257301e-08
one O 0 2.1254722071262222e-07
patient O 0 9.074691661226097e-06
. O 0 3.094637122558197e-06

Since O 0 8.498880561091937e-06
a O 0 8.18865146356984e-07
mutation O 0 5.242075985734118e-06
at O 0 1.6900038701805897e-07
cDNA O 0 2.8099395876779454e-06
nucleotide O 0 9.918820069287904e-06
2302 O 0 3.602243305067532e-05
( O 0 2.299568357955195e-08
2302insC O 0 2.501381857200613e-07
) O 0 8.79453576629885e-09
had O 0 6.75045797038365e-08
been O 0 3.861400799110015e-08
previously O 0 2.1693495000363328e-07
described O 0 1.1527463072980026e-07
, O 0 1.898059709404265e-09
this O 0 1.933315063595842e-09
region O 0 8.333728374054772e-09
of O 0 1.1824159429352221e-09
the O 0 1.524593606916369e-08
ATP7B O 0 8.7579219325562e-06
gene O 0 2.3105339153062232e-07
may O 0 1.1706805480571347e-07
be O 0 8.189329214758345e-09
susceptible O 0 3.2324288667950896e-07
to O 0 1.8548844238353013e-08
gene O 0 1.5097953109943774e-06
rearrangements O 0 4.436226299731061e-05
causing O 0 0.0001435400336049497
Wilson B-Disease 0 0.0004211676132399589
disease I-Disease 0 0.00016375252744182944
. O 0 5.787849659100175e-06

Disruption O 0 3.5294739063829184e-05
of O 0 9.569625802896553e-08
splicing O 0 4.550937319436343e-06
regulated O 0 1.0151634342037141e-06
by O 0 2.3170604990241372e-08
a O 0 5.183838069910962e-08
CUG O 0 6.567774107679725e-05
- O 0 3.0043038350413553e-06
binding O 0 1.4529175587085774e-06
protein O 0 1.5176267424976686e-06
in O 0 1.118889485951513e-06
myotonic B-Disease 1 0.9999912977218628
dystrophy I-Disease 1 0.999992847442627
. O 0 3.834188828477636e-05

Myotonic B-Disease 1 0.9999927282333374
dystrophy I-Disease 1 0.9999980926513672
( O 0 6.125614891061559e-05
DM B-Disease 1 1.0
) O 0 3.895629561156966e-06
is O 0 1.0145183182430628e-07
caused O 0 1.9771904646859184e-07
by O 0 6.959094633884888e-09
a O 0 1.3213347749285731e-08
CTG O 0 1.0441747235745424e-06
expansion O 0 4.5623735900335305e-08
in O 0 3.344831256413272e-08
the O 0 1.7751224490325512e-08
3 O 0 4.527991137592835e-08
untranslated O 0 3.111825890300679e-06
region O 0 1.0132516337080233e-07
of O 0 1.746298927685075e-08
the O 0 1.3620069694297854e-06
DM B-Disease 1 0.9999991655349731
gene O 0 3.301782635389827e-05
. O 0 6.591118562937481e-06

One O 0 3.57054227606568e-06
model O 0 2.32442766900931e-06
of O 0 1.9692492969625164e-07
DM B-Disease 1 0.9999996423721313
pathogenesis O 0 1.9456887457636185e-05
suggests O 0 3.005224016305874e-07
that O 0 7.550783998055977e-09
RNAs O 0 1.9091059755282913e-07
from O 0 1.4835063177898178e-09
the O 0 9.156524982678604e-10
expanded O 0 1.0265060801373238e-08
allele O 0 4.78913939616632e-08
create O 0 1.393017345918679e-08
a O 0 8.946534180154231e-09
gain O 0 3.581195869628573e-06
- O 0 1.4423658285522833e-06
of O 0 3.4680298632849826e-09
- O 0 3.483948376015178e-06
function O 0 9.754461416378035e-08
mutation O 0 7.225255416187792e-08
by O 0 2.2944672828373314e-09
the O 0 4.907366957240811e-09
inappropriate O 0 1.333709178652498e-07
binding O 0 2.3575340790671362e-08
of O 0 6.582580036607055e-10
proteins O 0 8.585454125409342e-09
to O 0 1.2120184855746174e-08
the O 0 6.532679464044122e-08
CUG O 0 4.445331069291569e-05
repeats O 0 1.1887846994795837e-05
. O 0 2.1987248146615457e-06

Data O 0 8.43298312247498e-06
presented O 0 4.901027637060906e-07
here O 0 5.976971095833505e-08
indicate O 0 1.0692990315419593e-07
that O 0 7.972936089117866e-09
the O 0 1.2147493677616694e-08
conserved O 0 2.6904177730102674e-07
heterogeneous O 0 1.7601416857360164e-06
nuclear O 0 6.482599474111339e-06
ribonucleoprotein O 0 5.497436632140307e-06
, O 0 2.3200721344096564e-08
CUG O 0 1.650230046834622e-06
- O 0 2.1290549057084718e-07
binding O 0 1.046872384335984e-07
protein O 0 7.798280421411619e-08
( O 0 6.5402456783658636e-09
CUG O 0 2.9067937248328235e-06
- O 0 1.3457576642394997e-05
BP O 0 1.7559101252118126e-05
) O 0 4.714384438386787e-09
, O 0 2.6817166265402648e-09
may O 0 1.8501037146734234e-08
mediate O 0 1.2020572626170178e-07
the O 0 1.4661118541425822e-08
trans O 0 2.0963677798135905e-06
- O 0 1.8136528524337336e-05
dominant O 0 7.942679985717405e-06
effect O 0 1.1749106221259353e-07
of O 0 3.73478092896562e-09
the O 0 6.229901572396557e-08
RNA O 0 5.7281718000012916e-06
. O 0 1.9025006849915371e-06

CUG O 0 0.004282673355191946
- O 0 0.052438944578170776
BP O 0 0.0003745073627214879
was O 0 1.7119387507591455e-07
found O 0 1.7591228029800732e-08
to O 0 3.981268648090008e-09
bind O 0 4.493456629006687e-08
to O 0 9.752076479685456e-09
the O 0 1.8179532546014343e-08
human O 0 1.5826111621208838e-07
cardiac O 0 4.529028228716925e-05
troponin O 0 5.188384238863364e-05
T O 0 1.2777612028003205e-05
( O 0 1.1681262179763507e-08
cTNT O 0 2.937885597020795e-07
) O 0 2.438608781574203e-08
pre O 0 8.49534717417555e-06
- O 0 3.467335318418918e-06
messenger O 0 3.351617294811149e-07
RNA O 0 2.549659541273286e-07
and O 0 1.1428352486575477e-08
regulate O 0 2.4080068783405295e-07
its O 0 6.665732854571615e-08
alternative O 0 1.3095458371026325e-06
splicing O 0 2.260253495478537e-05
. O 0 3.7927179619146045e-06

Splicing O 0 2.991407563968096e-05
of O 0 1.490612788757062e-07
cTNT O 0 9.177825631923042e-06
was O 0 1.1972708762186812e-06
disrupted O 0 2.3526488803327084e-05
in O 0 4.7626949140067154e-07
DM B-Disease 1 0.9999997615814209
striated O 0 0.0004285044560674578
muscle O 0 3.8680100260535255e-05
and O 0 1.0812640738322443e-07
in O 0 5.4325948184441586e-08
normal O 0 2.474136238106439e-07
cells O 0 6.011521804794029e-07
expressing O 0 9.723217431201192e-08
transcripts O 0 7.802087225172727e-07
that O 0 7.185811057297542e-08
contain O 0 1.1664307066894253e-06
CUG O 0 5.1177114073652774e-05
repeats O 0 2.9459277357091196e-05
. O 0 3.922451924154302e-06

Altered O 0 8.773912850301713e-05
expression O 0 2.478349642842659e-06
of O 0 9.472507400687391e-08
genes O 0 7.927052934064704e-07
regulated O 0 9.047229809766577e-07
posttranscriptionally O 0 2.1629468847095268e-06
by O 0 3.671365078616873e-08
CUG O 0 0.0001042867879732512
- O 0 0.00023639982100576162
BP O 0 1.5310828530346043e-05
therefore O 0 6.244212613637501e-08
may O 0 6.09706489740347e-08
contribute O 0 2.291944944943225e-08
to O 0 1.2789806191904063e-07
DM B-Disease 1 0.9999978542327881
pathogenesis O 0 2.691523877729196e-05
. O 0 5.174966872800724e-07
. O 0 3.306201961095212e-06

Identification O 0 7.547045697720023e-06
of O 0 6.65828636670085e-08
a O 0 1.1371324148967688e-07
novel O 0 9.115075840782083e-07
nonsense O 0 6.392012892320054e-06
mutation O 0 3.195951194356894e-06
and O 0 4.9219458730931365e-08
a O 0 1.769581814414778e-08
missense O 0 1.149587092186266e-06
substitution O 0 1.089540972998293e-07
in O 0 2.3688837558211162e-08
the O 0 1.9168004072867006e-08
vasopressin O 0 1.7116429944508127e-06
- O 0 1.919331043609418e-05
neurophysin O 0 6.342542747006519e-06
II O 0 3.5326479519426357e-07
gene O 0 6.239260841311989e-08
in O 0 7.049954842131001e-09
two O 0 1.668381344188674e-08
Spanish O 0 9.905452316161245e-07
kindreds O 0 2.425107049930375e-05
with O 0 8.176103847290506e-07
familial B-Disease 1 0.9811760783195496
neurohypophyseal I-Disease 1 0.9998637437820435
diabetes I-Disease 1 0.9999507665634155
insipidus I-Disease 1 0.9898762106895447
. O 0 3.3929329219972715e-05

Familial B-Disease 1 0.9997014403343201
neurohypophyseal I-Disease 1 0.9999098777770996
diabetes I-Disease 1 0.9999980926513672
insipidus I-Disease 1 0.9997262358665466
( O 0 2.0020166630274616e-05
FNDI B-Disease 1 1.0
) O 0 3.645745323410665e-07
is O 0 1.8532610113197734e-08
an O 0 1.4864788511204097e-07
autosomal B-Disease 1 0.999977707862854
dominant I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9995300769805908
caused O 0 0.0014162010047584772
by O 0 1.6918210121730226e-06
deficiency O 1 0.7990096211433411
in O 0 9.674824497096779e-08
the O 0 1.7100654758905875e-07
antidiuretic O 0 6.720238161506131e-05
hormone O 0 4.318890660215402e-06
arginine O 0 1.0181020115851425e-06
vasopressin O 0 2.2147587515064515e-06
( O 0 3.048124241900041e-08
AVP O 0 8.02751230821741e-07
) O 0 5.415666581853884e-09
encoded O 0 8.098213655216568e-09
by O 0 7.165511295426086e-09
the O 0 4.06070022052063e-08
AVP O 0 1.1770726814575028e-05
- O 0 8.436263669864275e-06
neurophysin O 0 2.481100455042906e-05
II O 0 4.2697915887401905e-06
( O 0 1.822299644516079e-08
AVP O 0 2.219605221398524e-06
- O 0 3.3550661555636907e-06
NPII O 0 1.012767188512953e-05
) O 0 3.246605828621796e-08
gene O 0 2.980378894790192e-07
on O 0 2.229224662642082e-07
chromosome O 0 2.2323092707665637e-05
20p13 O 0 4.523102325038053e-05
. O 0 3.2707550872146385e-06

In O 0 3.878489280850772e-07
this O 0 1.4148110238920708e-08
study O 0 2.107218044500314e-08
, O 0 2.9034232795766e-09
we O 0 3.0638140913197276e-09
analyzed O 0 2.0720415605524067e-08
two O 0 2.851358260613779e-09
families O 0 3.924399916144239e-09
with O 0 1.9289354558083005e-09
FNDI B-Disease 1 0.9999791383743286
using O 0 2.5255141977709172e-08
direct O 0 1.1460112858685534e-08
automated O 0 7.078427302076307e-07
fluorescent O 0 4.698497946264979e-07
, O 0 3.911583501547966e-09
solid O 0 5.244203293841565e-08
phase O 0 4.4242394636739846e-08
, O 0 4.272361575630157e-09
single O 0 2.2670286625725566e-07
- O 0 2.2023448309482774e-06
stranded O 0 5.772046307583878e-08
DNA O 0 6.348330572336636e-08
sequencing O 0 4.510794227030601e-08
of O 0 2.8320032985362786e-09
PCR O 0 4.741684278997127e-06
- O 0 4.8415267883683555e-06
amplified O 0 1.2751244867104106e-05
AVP O 0 3.721029861480929e-05
- O 0 8.902320587367285e-06
NPII O 0 4.3567695684032515e-05
DNA O 0 1.4323400137072895e-05
. O 0 2.134846454282524e-06

In O 0 3.9695413533991086e-07
one O 0 2.4539875909113107e-08
of O 0 1.6742428554650246e-09
the O 0 5.533077107600093e-09
families O 0 2.2585902925698065e-08
, O 0 5.050238449655353e-09
affected O 0 2.4220000227614946e-08
individuals O 0 2.860542469562688e-09
presented O 0 1.5563397681717106e-08
a O 0 1.3064937576245939e-08
novel O 0 1.687417494622423e-07
nonsense O 0 8.461335028187023e-07
mutation O 0 2.9222431408015836e-07
in O 0 6.3120220161749785e-09
exon O 0 2.3191257980670343e-07
3 O 0 6.788363648979612e-09
of O 0 3.548834837108217e-10
the O 0 2.5685840121525416e-09
gene O 0 3.4824687134005217e-08
, O 0 1.8847945426614388e-09
consisting O 0 1.7296638565866829e-09
in O 0 7.3477033346591725e-09
a O 0 2.4509846596743046e-08
G O 0 3.858165655401535e-05
to O 0 5.6290211603027274e-08
T O 0 5.622691332973773e-06
transition O 0 1.723139035902932e-07
at O 0 4.302366818365044e-08
nucleotide O 0 3.97346525460307e-07
2101 O 0 1.1487487654449069e-06
, O 0 4.682784826570696e-09
which O 0 2.996742187733048e-09
produces O 0 4.7107078238184386e-09
a O 0 3.1138016609588703e-09
stop O 0 4.0830364866906166e-08
signal O 0 1.1311252023915586e-07
in O 0 2.5486984966960335e-08
codon O 0 9.33949479531293e-07
82 O 0 3.128301955257484e-07
( O 0 2.9317050120880594e-08
Glu O 0 5.12790074935765e-06
) O 0 2.1865679045163233e-08
of O 0 1.7559884213369514e-08
NPII O 0 0.00010978345380863175
. O 0 2.8813772132707527e-06

The O 0 1.4816442899245885e-06
premature O 0 7.431578524119686e-06
termination O 0 1.0169376309931977e-06
eliminates O 0 6.916698112036102e-07
part O 0 1.4226531064309711e-08
of O 0 1.7536478935653577e-09
the O 0 1.5001985431695175e-08
C O 0 0.009131494909524918
- O 0 2.4037395633058622e-05
terminal O 0 8.958624562183104e-07
domain O 0 1.5414501675081738e-08
of O 0 1.4972534323476339e-09
NPII O 0 4.394607458380051e-06
, O 0 1.001858707105896e-09
including O 0 4.5425885275562905e-10
a O 0 1.4797166825175623e-09
cysteine O 0 1.1558015877710659e-08
residue O 0 1.0413996420766125e-07
in O 0 5.701740413144307e-09
position O 0 9.126366080636217e-07
85 O 0 5.117230639228865e-09
, O 0 1.2196706977718463e-09
which O 0 2.7415754111359547e-09
could O 0 8.072478152598705e-08
be O 0 3.766435607843732e-09
involved O 0 7.283559977366849e-09
in O 0 7.771297383385445e-09
the O 0 2.1595935706386626e-08
correct O 0 0.0008273361600004137
folding O 0 5.9462977333168965e-06
of O 0 2.0780099418971076e-08
the O 0 2.526211062559014e-07
prohormone O 0 0.0001323377073276788
. O 0 2.4494829631294124e-06

In O 0 3.4139009130740305e-07
the O 0 3.8019706494196726e-08
second O 0 1.9519278282587038e-07
family O 0 3.819545568717331e-08
, O 0 2.507355878478279e-09
a O 0 2.1461732391259147e-09
G279A O 0 5.258345581182766e-08
substitution O 0 2.109892527357715e-08
at O 0 2.0105222375832454e-08
position O 0 2.1776834273623535e-06
- O 0 7.46197770240542e-07
1 O 0 4.242106221852282e-09
of O 0 2.5570565109767074e-10
the O 0 2.4319282143636656e-09
signal O 0 3.662321645947486e-08
peptide O 0 2.6113795570381626e-08
was O 0 2.1914486225682595e-08
observed O 0 1.733654464430856e-08
in O 0 2.9776552334936923e-09
all O 0 7.95965604538651e-09
affected O 0 1.833617631064044e-07
individuals O 0 1.2909703173136222e-07
. O 0 9.894141612676322e-07

This O 0 1.2299876743782079e-06
missense O 0 5.1496204832801595e-05
mutation O 0 1.475224235036876e-05
, O 0 7.038657656721625e-08
which O 0 3.871983977887794e-08
replaces O 0 7.79399613293208e-07
Ala O 0 9.236586606675701e-07
with O 0 1.00381782885961e-08
Thr O 0 1.9533596059773117e-05
, O 0 7.067740614985496e-09
is O 0 1.952592754150828e-09
frequent O 0 6.481657521817397e-08
among O 0 2.5812201442931837e-07
FNDI B-Disease 1 1.0
patients O 0 0.0003801263519562781
and O 0 1.2056641018887149e-08
is O 0 3.9670484675013995e-09
thought O 0 7.92175001151918e-08
to O 0 7.971460824762744e-09
reduce O 0 9.855223481736175e-08
the O 0 4.793376806588867e-09
efficiency O 0 3.7224577198458064e-08
of O 0 1.404292904183535e-09
cleavage O 0 1.0025427172877244e-06
by O 0 5.158135607530312e-08
signal O 0 1.828415406635031e-06
peptidases O 0 1.0703968655434437e-05
. O 0 3.142412481338397e-07
. O 0 1.4825574226051685e-06

Genetic O 0 0.00016760383732616901
heterogeneity O 0 5.2313193009467795e-05
of O 0 6.144439907984633e-07
Saethre B-Disease 1 0.6654548645019531
- I-Disease 1 0.9999732971191406
Chotzen I-Disease 1 0.9999926090240479
syndrome I-Disease 1 0.9999983310699463
, O 0 5.001438907470401e-08
due O 0 9.82489325451752e-08
to O 0 2.9475273777279654e-08
TWIST O 0 5.409613731899299e-05
and O 0 6.43526618659962e-07
FGFR O 0 0.0010419371537864208
mutations O 0 0.00011715180880855769
. O 0 3.959649347962113e-06

Thirty O 0 1.5381001503556035e-05
- O 0 0.0005419119261205196
two O 0 8.427481645867374e-08
unrelated O 0 2.24283894567634e-06
patients O 0 3.8847676364639483e-07
with O 0 1.3428077538790717e-09
features O 0 2.8402377338920815e-08
of O 0 1.0550342821602499e-08
Saethre B-Disease 1 0.9806064963340759
- I-Disease 1 0.999954342842102
Chotzen I-Disease 1 0.9999415874481201
syndrome I-Disease 1 0.9998028874397278
, O 0 1.276513739156826e-08
a O 0 1.7904069338214867e-08
common O 0 6.163799298519734e-06
autosomal B-Disease 1 0.9998725652694702
dominant I-Disease 1 0.9998205304145813
condition I-Disease 0 0.047686800360679626
of O 0 6.140081154626387e-08
craniosynostosis B-Disease 1 0.9914934635162354
and O 0 2.5391032977495342e-05
limb B-Disease 0 0.4191610813140869
anomalies I-Disease 1 0.543338418006897
, O 0 1.9778386928237524e-08
were O 0 2.0237841624748398e-08
screened O 0 3.2899114899009874e-07
for O 0 8.194517064907814e-09
mutations O 0 5.03752346503461e-07
in O 0 1.4312263374449685e-08
TWIST O 0 2.3729464373900555e-05
, O 0 5.0040917187743617e-08
FGFR2 O 0 5.0774960982380435e-06
, O 0 1.8986362704254134e-08
and O 0 1.6259538426766085e-07
FGFR3 O 0 0.00018851952336262912
. O 0 3.894514975399943e-06

Nine O 0 1.5066179912537336e-06
novel O 0 5.285434667712252e-07
and O 0 6.41683186586306e-08
three O 0 3.125095915379461e-08
recurrent O 0 1.3420883078651968e-05
TWIST O 0 0.0010209758765995502
mutations O 0 0.00012144907668698579
were O 0 1.6706907501884416e-07
found O 0 1.206962281230517e-07
in O 0 4.383409546449002e-08
12 O 0 2.592195187389734e-07
families O 0 4.865457299274567e-07
. O 0 1.2309111525610206e-06

Seven O 0 8.681424219503242e-07
families O 0 2.1862638277525548e-07
were O 0 2.1369306324459103e-08
found O 0 9.78852732202995e-09
to O 0 5.572528660735543e-09
have O 0 6.514524031331348e-09
the O 0 5.688173043694178e-09
FGFR3 O 0 2.8194365313538583e-06
P250R O 0 3.3361095574946376e-07
mutation O 0 1.0361472391196003e-07
, O 0 1.5566833377889111e-09
and O 0 2.2414530231884555e-09
one O 0 4.59981208678073e-09
individual O 0 2.4701090950429716e-08
was O 0 6.666458830295596e-06
found O 0 3.4046145458432875e-08
to O 0 8.904994075464856e-09
have O 0 2.283701938665672e-08
an O 0 3.0252749638748355e-08
FGFR2 O 0 3.5563916753744707e-05
VV269 O 0 1.3226518603914883e-05
- O 0 1.2960683307028376e-05
270 O 0 5.0429343900759704e-06
deletion O 0 7.244897278724238e-05
. O 0 9.931664862961043e-06

To O 0 9.151048061539768e-07
date O 0 5.385065833252156e-07
, O 0 9.779495435680019e-09
our O 0 1.0626643565103677e-08
detection O 0 8.035993914745632e-08
rate O 0 4.2538246702861215e-08
for O 0 2.72812772372788e-09
TWIST O 0 5.852172648701526e-07
or O 0 8.315741695241741e-08
FGFR O 0 5.197468453843612e-06
mutations O 0 5.290619355946546e-07
is O 0 4.828327959671697e-09
68 O 0 2.8678808661197763e-08
% O 0 1.4485862287472173e-08
in O 0 1.2431770279874854e-08
our O 0 1.2427246076640586e-07
Saethre B-Disease 0 0.0075067151337862015
- I-Disease 1 0.9607624411582947
Chotzen I-Disease 1 0.9995484948158264
syndrome I-Disease 1 0.9998751878738403
patients O 0 1.251060893991962e-06
, O 0 3.988961161383031e-09
including O 0 3.1800282407346003e-09
our O 0 2.850054769965027e-08
five O 0 4.796095609549411e-08
patients O 0 4.041399677134905e-07
elsewhere O 0 1.7662354139247327e-06
reported O 0 8.267213047474797e-07
with O 0 5.374497646926102e-08
TWIST O 0 0.10138419270515442
mutations O 0 0.0012366275768727064
. O 0 6.98507392371539e-06

More O 0 1.6738196961796348e-07
than O 0 4.607875325746136e-08
35 O 0 3.206603693683974e-08
different O 0 2.044155245073398e-08
TWIST O 0 5.531989245355362e-06
mutations O 0 7.090499821060803e-06
are O 0 2.1885455225856276e-08
now O 0 2.391551312541651e-08
known O 0 2.4407540877291467e-08
in O 0 1.183316822306324e-08
the O 0 5.8901687083334764e-08
literature O 0 2.3818720364943147e-06
. O 0 2.9564573651441606e-06

The O 0 5.655753056998947e-07
most O 0 9.22016667459502e-08
common O 0 1.0857839072286879e-07
phenotypic O 0 8.965684514805616e-07
features O 0 3.1889743468127563e-07
, O 0 8.714204469129072e-09
present O 0 4.222490357363995e-09
in O 0 1.151958417544563e-09
more O 0 6.299606392090595e-10
than O 0 1.8274433077891672e-09
a O 0 5.5731663728408876e-09
third O 0 3.57159763098025e-07
of O 0 1.9083945534958957e-09
our O 0 2.2018627987563377e-07
patients O 0 4.516002505283723e-08
with O 0 2.6569118016794846e-09
TWIST O 0 0.00020456990750972182
mutations O 0 4.872859335591784e-06
, O 0 2.9447611016308883e-09
are O 0 2.025439815867003e-09
coronal B-Disease 0 9.642241138863028e-07
synostosis I-Disease 0 4.642692601919407e-06
, O 0 1.1354283735443005e-08
brachycephaly B-Disease 0 1.927864559547743e-06
, O 0 7.353286690658933e-08
low B-Disease 0 0.0013670633779838681
frontal I-Disease 1 0.9999288320541382
hairline I-Disease 1 0.9999973773956299
, O 0 5.000204055249924e-07
facial B-Disease 0 0.4224745035171509
asymmetry I-Disease 0 0.0011531974887475371
, O 0 4.7282279069804645e-07
ptosis B-Disease 1 0.9843738079071045
, O 0 1.3613561122838291e-07
hypertelorism B-Disease 0 7.789947267156094e-05
, O 0 5.4647280478548055e-08
broad B-Disease 0 4.6596227321060724e-07
great I-Disease 0 8.743833177504712e-07
toes I-Disease 0 0.0007470053969882429
, O 0 9.366435449464916e-08
and O 0 3.225386535632424e-07
clinodactyly B-Disease 0 0.00010254773224005476
. O 0 5.323219284036895e-06

Significant O 0 7.222854492283659e-06
intra O 0 4.732373417937197e-05
- O 0 0.000149852829053998
and O 0 3.4582302532726317e-07
interfamilial O 0 9.169400073005818e-06
phenotypic O 0 6.560602287208894e-06
variability O 0 4.251052814652212e-06
is O 0 3.2442166286728025e-08
present O 0 2.5372179024429897e-08
for O 0 7.166768956068381e-09
either O 0 1.3727519387884968e-07
TWIST O 0 0.0007949860882945359
mutations O 0 9.650169522501528e-05
or O 0 1.9276217244623695e-06
FGFR O 0 0.0011235388228669763
mutations O 0 0.00010751131776487455
. O 0 6.126083917479264e-06

The O 0 6.07995389145799e-07
overlap O 0 1.9686794985318556e-06
in O 0 9.726019101208294e-08
clinical O 0 8.931259571909322e-07
features O 0 9.62360360290404e-08
and O 0 3.351140520635454e-08
the O 0 5.102075206764312e-09
presence O 0 1.3166327583746806e-08
, O 0 1.799118298784208e-09
in O 0 2.1641366476643498e-09
the O 0 1.6341619168969146e-09
same O 0 6.07717431932997e-09
genes O 0 1.1424058143916227e-08
, O 0 6.717353340235377e-10
of O 0 1.3880428750834284e-10
mutations O 0 3.562428929626549e-08
for O 0 4.0113137811381705e-10
more O 0 3.909813861557865e-10
than O 0 1.6820913550930072e-09
one O 0 1.2742368049600827e-08
craniosynostotic B-Disease 0 0.0011266468791291118
condition I-Disease 0 4.123319376958534e-05
- O 0 3.64980877520793e-07
such O 0 2.9581987970317414e-09
as O 0 1.3599775527950442e-08
Saethre B-Disease 0 4.360625098343007e-06
- I-Disease 0 1.957704853339237e-06
Chotzen I-Disease 0 6.709810236316116e-07
, I-Disease 0 4.135106035363378e-09
Crouzon I-Disease 0 3.045007304081082e-07
, I-Disease 0 6.7465166786462305e-09
and I-Disease 0 3.113482804906198e-08
Pfeiffer I-Disease 0 0.0019035435980185866
syndromes I-Disease 0 0.001738029415719211
- O 0 7.764507245155983e-06
support O 0 2.3944497939965004e-08
the O 0 6.071277258712371e-09
hypothesis O 0 1.0746170886477557e-07
that O 0 3.734018871881517e-09
TWIST O 0 4.191295488453761e-07
and O 0 1.0628387059341549e-08
FGFRs O 0 1.7979000688228552e-07
are O 0 1.0602546618443398e-09
components O 0 1.8068256224523793e-08
of O 0 4.150860488660868e-10
the O 0 3.48568995889309e-09
same O 0 1.5710433842741622e-08
molecular O 0 1.3430138778858236e-07
pathway O 0 3.545604343457853e-08
involved O 0 2.3353312172957885e-08
in O 0 6.370427740876039e-09
the O 0 6.991250689480921e-09
modulation O 0 5.815653025820211e-07
of O 0 1.4780673573966396e-08
craniofacial O 0 0.08929332345724106
and O 0 1.7479620737503865e-06
limb O 0 0.0014268305385485291
development O 0 6.630797599882499e-08
in O 0 6.279937281306047e-08
humans O 0 3.0593662359024165e-07
. O 0 1.0669887728909089e-07
. O 0 6.791551641072147e-07

Mutation O 0 0.0004590358876157552
analysis O 0 1.6544418031116948e-05
of O 0 1.169856318483653e-06
UBE3A O 0 0.2938033938407898
in O 1 0.585574746131897
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.5731894373893738
. O 0 1.3691170352103654e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.519469363614917e-05
AS B-Disease 1 0.9999958276748657
) O 0 2.4709152057766914e-07
is O 0 4.784473617291951e-08
caused O 0 3.79816555096113e-07
by O 0 4.041722689862581e-08
chromosome O 0 3.8605507143074647e-05
15q11 O 0 2.6361236450611614e-05
- O 0 4.659907517634565e-06
q13 O 0 1.0513982715565362e-06
deletions O 0 4.0795731592879747e-07
of O 0 6.813724251486519e-09
maternal O 0 4.209814790101518e-07
origin O 0 1.7609497149351228e-07
, O 0 1.2443180708032742e-08
by O 0 5.784500345384913e-08
paternal O 0 4.495743633015081e-05
uniparental B-Disease 0 0.3456805348396301
disomy I-Disease 0 0.21715134382247925
( O 0 8.961341677604651e-07
UPD B-Disease 1 0.9999997615814209
) O 0 1.4137475545794587e-07
15 O 0 1.325552734243729e-08
, O 0 2.482378302914867e-09
by O 0 1.5285039012269408e-08
imprinting O 0 0.054929811507463455
defects O 1 0.9999254941940308
, O 0 2.7557474524542158e-08
and O 0 1.2700439810942044e-08
by O 0 1.875478794488572e-08
mutations O 0 4.646558863896644e-06
in O 0 7.92070764532582e-08
the O 0 2.3323450193402095e-07
UBE3A O 0 0.00010120692604687065
gene O 0 1.6461917766719125e-05
. O 0 4.726018687506439e-06

UBE3A O 0 0.001406570547260344
encodes O 0 1.866000093286857e-05
a O 0 7.127347885216295e-07
ubiquitin O 0 4.373414867586689e-06
- O 0 3.156356569888885e-06
protein O 0 1.5006054354671505e-07
ligase O 0 2.676843280369212e-07
and O 0 2.7188825413304585e-08
shows O 0 2.9660262157449324e-07
brain O 0 0.0001718838029773906
- O 0 1.965010778803844e-05
specific O 0 9.175254263027455e-07
imprinting O 0 0.00012389813491608948
. O 0 1.0478553122084122e-05

Here O 0 3.590621190596721e-06
we O 0 5.618293812403863e-07
describe O 0 9.422795983482501e-07
UBE3A O 0 3.1688963645137846e-05
coding O 0 0.0012983795022591949
- O 0 0.0002979883283842355
region O 0 5.30038619217521e-07
mutations O 0 3.054741455343901e-06
detected O 0 5.958286806162505e-07
by O 0 6.078159309197417e-09
SSCP O 0 1.2529962987173349e-06
analysis O 0 4.986807766726997e-08
in O 0 1.5146259357834424e-08
13 O 0 4.089755023528596e-08
AS B-Disease 1 0.9570767283439636
individuals O 0 3.743112131360249e-08
or O 0 2.7699422844307264e-07
families O 0 4.3767678903350316e-07
. O 0 1.4578655509467353e-06

Two O 0 1.500561097600439e-06
identical O 0 8.15421390143456e-06
de O 0 5.149704520590603e-06
novo O 0 4.292106950742891e-06
5 O 0 4.0801489831210347e-07
- O 0 2.790636699501192e-06
bp O 0 3.770394869206939e-06
duplications O 0 2.054785682048532e-06
in O 0 4.751697701976809e-08
exon O 0 2.011099240917247e-06
16 O 0 1.3675526133738458e-07
were O 0 1.0161004126985063e-07
found O 0 3.813126170371106e-07
. O 0 1.3694623248738935e-06

Among O 0 2.0003283225378254e-06
the O 0 4.151426580278894e-08
other O 0 1.8246403499233566e-08
11 O 0 1.5644529227643034e-08
unique O 0 2.915383312540598e-08
mutations O 0 1.3979195045976667e-06
, O 0 5.860480545294422e-09
8 O 0 6.269032404304653e-09
were O 0 5.0801491902063844e-09
small O 0 6.806774699441576e-09
deletions O 0 4.328471732151229e-07
or O 0 1.1705287050745028e-07
insertions O 0 6.9790812631254084e-06
predicted O 0 3.288196921857889e-06
to O 0 1.0571857167462895e-08
cause O 0 4.853537305393729e-08
frameshifts O 0 1.8289281342731556e-06
, O 0 3.3215736827685305e-09
1 O 0 9.123354516304971e-09
was O 0 4.1155313823537654e-08
a O 0 2.1928232563084293e-09
mutation O 0 9.405408718521358e-08
to O 0 3.990794805730502e-09
a O 0 3.6403613457025585e-09
stop O 0 4.650814489082222e-08
codon O 0 9.358166863648876e-08
, O 0 2.5341260201372506e-09
1 O 0 5.0920525573872055e-09
was O 0 3.064289089138583e-08
a O 0 1.1676139166638677e-08
missense O 0 1.8384833992968197e-06
mutation O 0 8.915991998037498e-07
, O 0 4.255932495311754e-09
and O 0 9.469125039629489e-09
1 O 0 3.031571083056406e-08
was O 0 8.361781510757282e-06
predicted O 0 2.0756101548613515e-07
to O 0 4.009303999907843e-09
cause O 0 1.7597033163951892e-08
insertion O 0 3.536378656576744e-08
of O 0 1.9078703061836677e-09
an O 0 9.059540673206357e-09
isoleucine O 0 0.0017947901505976915
in O 0 1.895770296300725e-08
the O 0 6.9491594700821224e-09
hect O 0 7.035120574983011e-07
domain O 0 5.773422984134413e-08
of O 0 2.5009270210318846e-09
the O 0 1.1178295622471524e-08
UBE3A O 0 8.779888958088122e-07
protein O 0 2.4500451445419458e-08
, O 0 2.0888215601644333e-09
which O 0 9.738522210867018e-10
functions O 0 4.401242925666793e-09
in O 0 1.0303900843666725e-08
E2 O 0 7.098464038790553e-07
binding O 0 1.7525897533232637e-07
and O 0 3.454010411019226e-08
ubiquitin O 0 7.404452162518282e-07
transfer O 0 1.6570269281146466e-06
. O 0 1.826360858103726e-06

Eight O 0 8.834778668642684e-07
of O 0 1.4363266132022545e-08
the O 0 1.7832636700632065e-08
cases O 0 6.378260053452323e-08
were O 0 1.8116884348273743e-07
familial O 0 0.0006664479151368141
, O 0 7.414040936737365e-08
and O 0 4.881100679199335e-08
five O 0 1.0942413553038932e-07
were O 0 1.001261352939764e-06
sporadic O 0 2.1921146981185302e-05
. O 0 1.2500777302193455e-05

In O 0 1.1315249821564066e-06
two O 0 6.163290322547255e-08
familial O 0 9.936335118254647e-06
cases O 0 8.84220469288266e-07
and O 0 4.6837786982223406e-08
one O 0 2.314096825273282e-08
sporadic O 0 5.804144507237652e-07
case O 0 9.297983751821448e-07
, O 0 1.904955126974528e-08
mosaicism O 0 3.459771278357948e-06
for O 0 1.7995274603777034e-08
UBE3A O 0 6.052161097613862e-06
mutations O 0 1.3040150861343136e-06
was O 0 8.363780779063745e-08
detected O 0 1.6346542963674437e-07
in O 0 3.190928188345765e-09
the O 0 3.575865825666824e-09
mother O 0 1.5918841711481946e-07
of O 0 5.12934472673976e-10
three O 0 1.3125688269610691e-07
AS B-Disease 1 0.9999997615814209
sons O 0 8.858478395268321e-06
, O 0 1.7676614616490838e-09
in O 0 2.8335647161981115e-09
the O 0 3.782547608466302e-09
maternal O 0 1.7004930441544275e-07
grandfather O 0 1.224349688300208e-07
of O 0 5.058343743868932e-10
two O 0 1.3622829087012178e-08
AS B-Disease 1 0.9999880790710449
first O 0 5.996382412831736e-08
cousins O 0 9.79431774794648e-07
, O 0 2.4087172256770373e-09
and O 0 6.317478096207196e-09
in O 0 8.942524942767704e-09
the O 0 2.9413159907676345e-08
mother O 0 1.3216179013397777e-06
of O 0 2.4887782945626213e-09
an O 0 2.552269791067374e-07
AS B-Disease 1 0.9999997615814209
daughter O 0 0.005401978734880686
. O 0 3.639502892838209e-06

The O 0 2.125228917293498e-07
frequencies O 0 5.588704539150058e-07
with O 0 5.304094941038784e-09
which O 0 7.855498473929856e-09
we O 0 7.374435728735307e-09
detected O 0 6.010180442217461e-08
mutations O 0 1.5345631254604086e-07
were O 0 6.90701940087024e-09
5 O 0 1.9243235893640076e-09
( O 0 9.031621006627688e-10
14 O 0 1.8726933337376295e-09
% O 0 1.1439708069715948e-09
) O 0 4.360015404270001e-10
of O 0 3.233051049100766e-10
35 O 0 3.1658546895130257e-09
in O 0 2.987542435661794e-09
sporadic O 0 2.048269465149133e-07
cases O 0 1.2044042705383617e-06
and O 0 3.668914771992604e-08
8 O 0 6.094911686460591e-09
( O 0 8.380907634553125e-10
80 O 0 2.214997074645453e-09
% O 0 2.373540919364814e-09
) O 0 8.75737093952722e-10
of O 0 1.0206311351623754e-09
10 O 0 1.1738551464191005e-08
in O 0 3.748742471998412e-08
familial O 0 0.00035250227665528655
cases O 0 2.3498663722421043e-05
. O 0 1.3353476333577419e-06
. O 0 1.97743088392599e-06

The O 0 1.5394985894090496e-05
hemochromatosis B-Disease 1 0.9999829530715942
845 O 0 0.00010666387242963538
G O 0 0.001493528950959444
- O 0 0.000774824118707329
- O 0 1.4585452845494729e-05
> O 0 2.0590059079950151e-07
A O 0 1.7449703904048874e-08
and O 0 1.1131487731574907e-08
187 O 0 8.609284662952632e-08
C O 0 1.3364560800255276e-06
- O 0 1.257641201846127e-06
- O 0 1.2246246114955284e-06
> O 0 5.028849727750639e-07
G O 0 2.610053343232721e-06
mutations O 0 1.0914300219155848e-06
: O 0 1.8256779199532502e-08
prevalence O 0 6.647817372140707e-07
in O 0 7.92344252431576e-08
non O 0 3.476739266261575e-06
- O 0 0.0001583225093781948
Caucasian O 0 6.421130819944665e-05
populations O 0 1.5390567568829283e-05
. O 0 3.0506016628351063e-06

Hemochromatosis B-Disease 0 0.41008472442626953
, O 0 8.330438504344784e-06
the O 0 2.6672143576433882e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 2.124450304563652e-08
iron I-Disease 0 0.13301759958267212
metabolism I-Disease 0 0.001754667842760682
, O 0 1.9427641717584265e-08
leads O 0 3.667501502491177e-08
, O 0 7.268793122960915e-09
if O 0 8.876475732222389e-08
untreated O 0 2.546503083067364e-06
, O 0 4.491800709160998e-09
to O 0 1.2147192585132416e-08
progressive O 0 1.318655540671898e-05
iron B-Disease 1 0.9955026507377625
overload I-Disease 0 0.08745924383401871
and O 0 2.0302986740716733e-06
premature B-Disease 0 2.518523069738876e-05
death I-Disease 0 2.508623310859548e-06
. O 0 3.1747229058964876e-06

The O 0 8.331987373821903e-06
hemochromatosis B-Disease 1 0.9999350309371948
gene O 0 1.2652293662540615e-05
, O 0 1.4952856020045147e-07
HFE O 0 8.932326454669237e-05
, O 0 7.133849777574142e-08
recently O 0 1.2518664789240574e-06
has O 0 2.9285081026841908e-08
been O 0 6.669204566378539e-08
identified O 0 6.801041507742411e-08
, O 0 1.182231090801622e-09
and O 0 2.9165276860254608e-09
characterization O 0 2.7234040089751943e-07
of O 0 9.219666696758111e-10
this O 0 2.807708954222221e-09
gene O 0 5.642521827553537e-08
has O 0 7.91181378190231e-08
shown O 0 1.6428320037675803e-08
that O 0 1.2070854316093005e-09
it O 0 1.2447802788528861e-09
contains O 0 7.868045104331145e-10
two O 0 3.925185509956464e-09
mutations O 0 6.048660452506738e-07
that O 0 2.347330863017305e-08
result O 0 6.871818669651475e-08
in O 0 8.893181302482844e-09
amino O 0 9.36325577072239e-08
acid O 0 8.646129856515472e-08
substitutions O 0 7.584158367990312e-08
- O 0 1.8487003217160236e-07
cDNA O 0 4.063711003254866e-07
nucleotides O 0 3.442882245963119e-07
845 O 0 5.837056278323871e-07
G O 0 1.841168000282778e-06
- O 0 1.110734160647553e-06
- O 0 1.0362949751652195e-06
> O 0 1.0383531900970411e-07
A O 0 1.8464726636580053e-08
( O 0 3.3380291863949196e-09
C282Y O 0 1.1842034552955738e-07
) O 0 1.9701231757096593e-09
and O 0 2.852266645092527e-09
187 O 0 4.2606131955835735e-08
C O 0 2.670285539352335e-06
- O 0 3.5286043384985533e-06
- O 0 9.927886821969878e-06
> O 0 7.91442346326221e-07
G O 0 3.929108515876578e-06
( O 0 4.01389712578748e-08
H63D O 0 1.2949279152962845e-05
) O 0 3.6521518609333725e-07
. O 0 9.551843049848685e-07

Although O 0 0.00015832477947697043
hemochromatosis B-Disease 1 0.9999994039535522
is O 0 2.506296254978224e-07
common O 0 2.1827514729011455e-07
in O 0 4.4078401373326415e-08
Caucasians O 0 1.5562261523882626e-06
, O 0 2.024861522897936e-08
affecting O 0 5.6806630510664036e-08
> O 0 1.5903030714525812e-07
= O 0 3.647897983682924e-07
1 O 0 2.1266231442496064e-08
/ O 0 2.541150401214054e-08
300 O 0 1.6125253354815072e-09
individuals O 0 1.114257019985132e-09
of O 0 4.760855043528522e-10
northern O 0 1.4400605152786738e-07
European O 0 1.5740000662844977e-06
origin O 0 5.636412581111472e-08
, O 0 3.124814407229337e-09
it O 0 7.918921518523803e-09
has O 0 1.0368920833059292e-08
not O 0 1.3511144203448566e-08
been O 0 1.9193175049281308e-08
recognized O 0 1.4858744457058037e-08
in O 0 1.260131643476825e-08
other O 0 7.147796310391641e-08
populations O 0 2.887073605961632e-06
. O 0 2.48561173066264e-06

The O 0 3.6851511708846374e-07
present O 0 5.44450315942413e-08
study O 0 1.8155692060872752e-08
used O 0 1.7941125918241596e-08
PCR O 0 1.1470278877823148e-06
and O 0 6.423245491049556e-09
restriction O 0 3.769010348264601e-08
- O 0 1.0109852865980429e-07
enzyme O 0 5.215206400066563e-08
digestion O 0 7.902613674559689e-08
to O 0 2.8619833170040465e-09
analyze O 0 2.76880829375159e-08
the O 0 2.2596362558857663e-09
frequency O 0 5.372181277607524e-08
of O 0 1.3051855152212966e-09
the O 0 8.371357829162207e-09
845 O 0 2.8047458044966334e-07
G O 0 1.966233185157762e-06
- O 0 1.8915787904916215e-06
- O 0 1.4456516055361135e-06
> O 0 7.448540628729461e-08
A O 0 9.339138351549536e-09
and O 0 7.772068322253745e-09
187 O 0 5.066169705969514e-08
C O 0 5.253173185337801e-07
- O 0 7.132671839826799e-07
- O 0 7.260620691340591e-07
> O 0 2.1544678929785732e-07
G O 0 8.408476901422546e-07
mutations O 0 2.1679308304101141e-07
in O 0 1.2341756061573506e-08
HLA O 0 2.769131413060677e-07
- O 0 4.6713598322867256e-08
typed O 0 4.0513626231586386e-08
samples O 0 9.268493528225008e-09
from O 0 1.8378878419156308e-09
non O 0 6.553521814112173e-08
- O 0 7.256162461999338e-07
Caucasian O 0 5.422779736363736e-07
populations O 0 7.098072529743149e-08
, O 0 1.517592052024952e-09
comprising O 0 3.21598569996695e-09
Australian O 0 7.600957019349153e-08
Aboriginal O 0 5.2734115740804555e-08
, O 0 3.722079755519303e-09
Chinese O 0 2.342257943155346e-09
, O 0 4.005925813288513e-09
and O 0 2.487707106979542e-08
Pacific O 0 2.4690308464414557e-07
Islanders O 0 2.8015697353112046e-06
. O 0 2.246263875349541e-06

Results O 0 0.00043464641203172505
showed O 0 2.0123732156207552e-06
that O 0 1.6391291879358505e-08
the O 0 1.720192699394829e-08
845 O 0 5.817072405989165e-07
G O 0 2.372883136558812e-05
- O 0 2.4934035536716692e-05
- O 0 9.000124009617139e-06
> O 0 1.51251910551764e-07
A O 0 2.1247096526622045e-08
mutation O 0 2.0406147882567893e-07
was O 0 3.88909668913584e-08
present O 0 3.893043221125936e-09
in O 0 2.1022912299883956e-09
these O 0 7.466416818147081e-09
populations O 0 1.70207581362547e-08
( O 0 1.3673401300096089e-09
allele O 0 4.956491750363057e-08
frequency O 0 1.5317411339310638e-07
0 O 0 1.3382623009761119e-08
. O 0 3.01191604989981e-09
32 O 0 4.52813564422172e-09
% O 0 2.6504229921897604e-09
) O 0 1.0093428315371966e-09
, O 0 7.895540887759012e-10
and O 0 5.767894606378832e-09
, O 0 9.280977653070011e-10
furthermore O 0 1.4329144981672925e-08
, O 0 8.108426152730885e-10
it O 0 1.3901985340680767e-08
was O 0 3.6689646094600903e-06
always O 0 8.056328226757614e-08
seen O 0 3.144144500311086e-08
in O 0 2.733450799041748e-09
conjunction O 0 2.129773157832915e-08
with O 0 2.1299520369666425e-08
HLA O 0 2.5878430278680753e-06
haplotypes O 0 2.7670828330883523e-06
common O 0 2.194272354927307e-07
in O 0 3.3430708867854264e-08
Caucasians O 0 1.159592898147821e-06
, O 0 7.014785641246135e-09
suggesting O 0 6.07737362656735e-08
that O 0 1.109794922626861e-08
845 O 0 3.0579835197386274e-07
G O 0 8.447768777841702e-06
- O 0 4.230556896800408e-06
- O 0 1.5838476201679441e-06
> O 0 9.389582089625037e-08
A O 0 2.4195990988573612e-08
may O 0 2.6181353973697696e-07
have O 0 3.864581987755855e-09
been O 0 3.1634765917942786e-09
introduced O 0 1.0671898031944238e-08
into O 0 3.786893021384685e-09
these O 0 1.4198826114864005e-08
populations O 0 1.1518418574496536e-07
by O 0 6.981645128689706e-08
Caucasian O 0 1.4144518900138792e-05
admixture O 0 4.021964923595078e-05
. O 0 3.273501306466642e-06

187 O 0 4.260494824848138e-05
C O 0 4.125824852962978e-05
- O 0 1.1106759302492719e-05
- O 0 2.871909600798972e-06
> O 0 6.625235187129874e-07
G O 0 6.902570476086112e-06
was O 0 8.6093336904014e-08
present O 0 5.996826146770218e-09
at O 0 9.02265462343621e-09
an O 0 3.5406420018091467e-09
allele O 0 5.529059876607789e-07
frequency O 0 1.2722365454465034e-06
of O 0 4.710638634719544e-08
2 O 0 8.127290698212164e-07
. O 0 2.5038216335815378e-06

68 O 0 2.631077768455725e-05
% O 0 7.891654263403325e-07
in O 0 2.7366763077907308e-08
the O 0 8.226668235522538e-09
two O 0 1.3540683241330953e-08
populations O 0 3.5298020861773693e-07
analyzed O 0 1.4741109453098034e-06
( O 0 1.8134718615669954e-08
Australian O 0 2.348045455846659e-07
Aboriginal O 0 2.679834381069668e-07
and O 0 6.958472908991098e-08
Chinese O 0 3.749779153849886e-08
) O 0 7.523573941625727e-08
. O 0 5.066518156127131e-07

In O 0 7.33255774321151e-07
the O 0 1.255293540225466e-07
Australian O 0 2.0870490402558062e-07
Aboriginal O 0 2.0148397084085445e-07
samples O 0 5.3560675894459564e-08
, O 0 3.952004501428519e-09
187 O 0 3.581082097525723e-08
C O 0 5.013071699977445e-07
- O 0 9.675687806520727e-07
- O 0 9.109062943934987e-07
> O 0 9.684239898888336e-08
G O 0 1.9385058749321615e-06
was O 0 3.5884735183344674e-08
found O 0 5.962007332271924e-09
to O 0 2.033708534909806e-09
be O 0 5.6964792882752135e-09
associated O 0 2.0878189843642758e-08
with O 0 1.2409192784446077e-08
HLA O 0 2.1487728645297466e-06
haplotypes O 0 1.9862518456648104e-06
common O 0 2.973242487769312e-07
in O 0 2.488409300838157e-08
Caucasians O 0 4.87856937070319e-07
, O 0 3.7199576752300345e-09
suggesting O 0 3.4454696873353896e-08
that O 0 2.748067107205543e-09
it O 0 1.0354454182959216e-08
was O 0 2.512489061246015e-08
introduced O 0 4.904665118488083e-08
by O 0 3.366798395632031e-08
recent O 0 2.0813854462176096e-06
admixture O 0 4.6341716370079666e-05
. O 0 9.828313523030374e-06

In O 0 7.048088264127728e-07
the O 0 3.4963186124059575e-08
Chinese O 0 1.0300737152135753e-08
samples O 0 2.116062880475056e-08
analyzed O 0 1.1366032026671746e-07
, O 0 5.144534132028866e-09
187 O 0 4.778764406410119e-08
C O 0 5.304269734551781e-07
- O 0 8.896304279915057e-07
- O 0 7.819055554136867e-07
> O 0 1.1919033937601853e-07
G O 0 2.883205070247641e-06
was O 0 7.91850212067402e-08
present O 0 5.711133344021846e-09
in O 0 1.1521962939298191e-08
association O 0 5.513303591442309e-09
with O 0 1.3670767851081678e-09
a O 0 7.594345596828589e-09
wide O 0 3.362658773653493e-08
variety O 0 3.4815254679188e-08
of O 0 8.236040294207214e-09
HLA O 0 1.230367843163549e-06
haplotypes O 0 1.4161563512971043e-06
, O 0 4.818916377047344e-09
showing O 0 1.7826515374963492e-08
this O 0 1.5495470462312255e-09
mutation O 0 4.0242920107402824e-08
to O 0 2.76600942150651e-09
be O 0 2.644782171046245e-09
widespread O 0 6.965614307574697e-09
and O 0 3.576603901933595e-08
likely O 0 2.500460816179384e-08
to O 0 2.53840726216481e-09
predate O 0 1.1484340234346746e-07
the O 0 2.5335604725285066e-09
more O 0 3.021461747465537e-09
genetically O 0 3.8759154108447547e-08
restricted O 0 5.2013682250162674e-08
845 O 0 4.347431570295157e-07
G O 0 5.492531727213645e-06
- O 0 1.3436506378639024e-05
- O 0 9.754944585438352e-06
> O 0 1.2176233212812804e-06
A O 0 6.882173693156801e-07
mutation O 0 2.2448492018156685e-05
. O 0 3.4105596569133922e-06

Genotype O 1 0.9207346439361572
- O 0 0.386907696723938
phenotype O 0 0.0009275930351577699
correlations O 0 0.00027418293757364154
in O 0 1.8336420907871798e-05
attenuated B-Disease 1 0.9986171722412109
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999967813491821
coli I-Disease 1 0.9999992847442627
. O 0 0.00016930692072492093

Germ O 0 0.06757403165102005
- O 0 0.07603282481431961
line O 0 7.67190613260027e-06
mutations O 0 2.2718602394888876e-06
of O 0 5.982101036750009e-09
the O 0 3.921319091659825e-08
tumor B-Disease 0 1.1080837793997489e-05
suppressor O 0 9.769366442924365e-06
APC O 0 1.6300696188409347e-06
are O 0 7.28899678392736e-08
implicated O 0 4.2595102058839984e-06
in O 0 7.041986918920884e-06
attenuated B-Disease 1 0.9999423027038574
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
( O 0 5.898734161746688e-05
AAPC B-Disease 1 1.0
) O 0 2.7220485776524583e-07
, O 0 1.635182300674387e-08
a O 0 4.776358508706835e-08
variant O 0 0.08310308307409286
of O 0 0.0002293525030836463
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00044077198253944516
FAP B-Disease 0 0.005796181503683329
) O 0 5.081991730548907e-06
. O 0 8.238271220761817e-06

AAPC B-Disease 1 0.9999974966049194
is O 0 6.856310506009322e-07
recognized O 0 1.3424184430732566e-07
by O 0 7.173716731756485e-09
the O 0 7.261296453009436e-09
occurrence O 0 5.367622861740529e-07
of O 0 8.017954300498786e-09
< O 0 8.214423132812954e-07
100 O 0 3.362030653875081e-08
colonic B-Disease 0 7.926971193228383e-06
adenomas I-Disease 0 9.191952995024621e-05
and O 0 1.2737605636914395e-08
a O 0 4.96334795485609e-09
later O 0 2.9446681537592667e-07
onset O 0 8.3088809333276e-05
of O 0 0.10295389592647552
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.518391870713458e-08
age O 0 1.7715008482355188e-07
> O 0 2.268817382855559e-07
40 O 0 8.520010652546262e-08
years O 0 2.3881582933427126e-07
) O 0 9.122504707193002e-08
. O 0 9.40606923904852e-07

The O 0 4.4760838591173524e-07
aim O 0 6.005722639201849e-07
of O 0 3.8067362595484155e-09
this O 0 3.7176028921948046e-09
study O 0 1.0971961117434148e-08
was O 0 1.8254688427532528e-08
to O 0 2.482109628942908e-08
assess O 0 1.1201622100998065e-06
genotype O 0 7.98884648247622e-05
- O 0 5.061477713752538e-05
phenotype O 0 6.291517638601363e-05
correlations O 0 4.564530900097452e-05
in O 0 5.083863015897805e-06
AAPC B-Disease 1 0.9999908208847046
families O 0 1.2123108717787545e-05
. O 0 8.131344657158479e-06

By O 0 1.2552711723401444e-06
protein O 0 3.672945240396075e-06
- O 0 4.94441974296933e-06
truncation O 0 1.0797759387060069e-05
test O 0 2.679151975826244e-06
( O 0 2.7975911365274442e-08
PTT O 0 5.327737540028465e-07
) O 0 7.711967953127896e-09
assay O 0 3.315385583846364e-07
, O 0 2.8480264813168787e-09
the O 0 1.6360174326379706e-09
entire O 0 2.5497973510368865e-08
coding O 0 2.971670710394392e-06
region O 0 3.2854213571908986e-08
of O 0 2.1458130827767263e-09
the O 0 1.0520864179852651e-08
APC B-Disease 0 7.338084628827346e-08
gene O 0 3.142825732993515e-08
was O 0 3.2236826541520713e-08
screened O 0 1.0280308515575598e-07
in O 0 5.915407719214727e-09
affected O 0 1.720287912121421e-08
individuals O 0 6.7990804097917135e-09
from O 0 1.4723609886857503e-08
11 O 0 3.031843220924202e-07
AAPC B-Disease 1 0.9999982118606567
kindreds O 0 0.00013072678120806813
, O 0 2.5603142717045557e-08
and O 0 1.938489013753042e-08
their O 0 3.270340798167126e-08
phenotypic O 0 1.3314233910932671e-05
differences O 0 0.002050061710178852
were O 0 4.645283297577407e-06
examined O 0 2.8195705453981645e-05
. O 0 3.290568656666437e-06

Five O 0 2.72669899459288e-06
novel O 0 3.358062258485006e-06
germ O 0 0.00021779035159852356
- O 0 0.0009958541486412287
line O 0 8.858427463565022e-06
APC B-Disease 0 1.947507598742959e-06
mutations O 0 1.984716163860867e-06
were O 0 7.54100071276298e-08
identified O 0 3.4841968954424374e-07
in O 0 1.4081189192438615e-07
seven O 0 5.567452490140568e-07
kindreds O 0 0.0004743166209664196
. O 0 7.534496944572311e-06

Mutations O 0 0.00011705678480211645
were O 0 1.6745541131513164e-07
located O 0 2.978224777905325e-08
in O 0 4.7246553336321995e-09
three O 0 2.2680000100194775e-09
different O 0 5.900814503689844e-09
regions O 0 1.4525287639344242e-08
of O 0 1.0833315355895934e-09
the O 0 1.0274110451291563e-08
APC B-Disease 0 1.1565673219138262e-07
gene O 0 3.4308591523313225e-08
( O 0 2.324344938742229e-09
1 O 0 3.1090896523977563e-09
) O 0 2.2151871448272686e-09
at O 0 8.17515832807203e-09
the O 0 3.683335858539749e-09
5 O 0 5.2045607823458795e-09
end O 0 7.730287521212631e-09
spanning O 0 1.4254752933595682e-08
exons O 0 3.6391071489561e-07
4 O 0 1.8372578125536165e-08
and O 0 5.023885307764431e-09
5 O 0 2.3514341584984777e-09
, O 0 1.0300338360025307e-09
( O 0 4.882538817696513e-10
2 O 0 1.3374528151643972e-09
) O 0 5.907129230209307e-10
within O 0 1.0095719815694792e-09
exon O 0 1.5378111584141152e-07
9 O 0 2.1515845105568587e-08
, O 0 1.2524871140229266e-09
and O 0 2.0418784441034177e-09
( O 0 9.848750703866926e-10
3 O 0 3.6827598748345736e-09
) O 0 1.8852044370021304e-09
at O 0 1.6039372496834403e-08
the O 0 6.080246528483713e-09
3 O 0 1.7304996546840812e-08
distal O 0 5.42248017154634e-07
end O 0 4.6104119633127993e-07
of O 0 1.3452514657785741e-08
the O 0 1.3749570371146547e-07
gene O 0 7.695102794968989e-06
. O 0 5.819863417855231e-06

Variability O 0 3.600100171752274e-05
in O 0 1.2547836547582847e-07
the O 0 9.827775926396498e-09
number O 0 2.710018875973219e-08
of O 0 8.921027756514377e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.005183856934309006
most O 0 1.8560097458930613e-08
apparent O 0 2.0758675134402438e-07
in O 0 1.0034273856263098e-08
individuals O 0 4.479660198342117e-09
with O 0 7.334387763791028e-09
mutations O 0 1.5460134363820544e-06
in O 0 4.15161665046071e-08
region O 0 1.2645864444493782e-07
1 O 0 2.2492493201298203e-07
, O 0 1.9089926084348008e-08
and O 0 9.956946769307251e-07
upper O 1 0.951951265335083
- O 1 0.9978294968605042
gastrointestinal O 0 0.2631063759326935
manifestations O 0 6.213611868588487e-06
were O 0 2.95001456152022e-07
more O 0 8.829713848967913e-09
severe O 0 5.2916966524207965e-06
in O 0 7.268199908594397e-08
them O 0 1.3993330583161878e-07
. O 0 1.6579942894168198e-06

In O 0 9.974301065085456e-07
individuals O 0 1.2107157942864433e-07
with O 0 1.6847442552148095e-08
mutations O 0 6.928033258191135e-07
in O 0 1.2294436579907142e-08
either O 0 6.770069660433364e-08
region O 0 4.93335612361534e-08
2 O 0 1.3554870115228823e-08
or O 0 4.022388822022549e-08
region O 0 1.7866783608155856e-08
3 O 0 6.7240866208351235e-09
, O 0 6.554903286826175e-10
the O 0 1.221696299680275e-09
average O 0 9.158328317937503e-09
number O 0 1.2163879903326347e-09
of O 0 7.096671583717296e-10
adenomas B-Disease 0 2.6628392788552446e-06
tended O 0 2.4710001866878883e-07
to O 0 4.027791433713901e-09
be O 0 9.020005187210245e-09
lower O 0 1.7239864646967362e-08
than O 0 1.1152840873052128e-09
those O 0 9.140750378833218e-10
in O 0 1.3853352909265482e-09
individuals O 0 1.0185909893323242e-09
with O 0 2.042010782687953e-09
mutations O 0 7.748321877443232e-07
in O 0 1.746695410531629e-08
region O 0 3.2775844260868325e-08
1 O 0 1.665090998415053e-08
, O 0 3.036048301652272e-09
although O 0 7.702328730374575e-08
age O 0 2.1476284928212408e-07
at O 0 1.4599342534893367e-07
diagnosis O 0 0.00019755367247853428
was O 0 9.80361619440373e-07
similar O 0 6.329456709863734e-07
. O 0 3.1878144000074826e-06

In O 0 4.638103291654261e-06
all O 0 1.6422341104771476e-06
AAPC B-Disease 1 0.9999936819076538
kindreds O 0 0.000539011147338897
, O 0 4.4791754305606446e-08
a O 0 2.1017992679617237e-08
predominance O 0 1.0419176987852552e-06
of O 0 2.6820705656405153e-08
right O 0 0.17050667107105255
- O 1 0.9999959468841553
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0005102544673718512
rectal B-Disease 1 0.9998643398284912
polyp I-Disease 0 0.07575041055679321
sparing O 0 1.0228561222902499e-05
was O 0 3.1676281651016325e-06
observed O 0 2.631312099765637e-06
. O 0 2.550255658206879e-06

No O 0 4.0430997614748776e-05
desmoid B-Disease 1 0.5948672294616699
tumors I-Disease 1 1.0
were O 0 9.194840799864323e-07
found O 0 1.4247908097786421e-07
in O 0 6.024848175911757e-08
these O 0 3.395678334072727e-07
kindreds O 0 0.0003975225845351815
. O 0 6.571748599526472e-06

Our O 0 1.5486518805118976e-06
data O 0 3.4649281133170007e-07
suggest O 0 1.0122858640215782e-07
that O 0 7.959322090300702e-09
, O 0 6.778763328441073e-09
in O 0 8.138709972627112e-08
AAPC B-Disease 1 0.9999998807907104
families O 0 1.0170505504447647e-07
, O 0 1.8820607294856018e-09
the O 0 1.6806032121507997e-09
location O 0 8.700639142489308e-08
of O 0 1.879696620576965e-09
the O 0 2.465759507686016e-08
APC B-Disease 0 3.2565960736974375e-06
mutation O 0 7.115135758795077e-06
may O 0 1.5333035889852908e-06
partially O 0 4.760397132486105e-06
predict O 0 2.023925162575324e-06
specific O 0 2.1907428049416922e-07
phenotypic O 0 1.101811994885793e-05
expression O 0 1.187865564133972e-05
. O 0 7.2873181125032715e-06

This O 0 1.8988468752922927e-07
should O 0 7.719123118477e-08
help O 0 2.712827118500627e-08
in O 0 2.22178808684248e-09
the O 0 2.3224970835400427e-09
design O 0 1.8369797771811136e-07
of O 0 4.603463388264117e-09
tailored O 0 9.744029739522375e-06
clinical O 0 0.0024438854306936264
- O 0 0.0020798451732844114
management O 0 4.7640213551858324e-08
protocols O 0 3.953808302981088e-08
in O 0 3.7600904612133945e-09
this O 0 3.614843757659969e-09
subset O 0 5.143958148323691e-08
of O 0 1.4003244785953939e-08
FAP B-Disease 0 5.8676582739281e-06
patients O 0 8.52333243983594e-07
. O 0 1.397467315200629e-07
. O 0 1.3546931540986407e-06

Wilms B-Disease 0 0.20833519101142883
' I-Disease 0 3.459850267972797e-05
tumor I-Disease 0 1.924516436702106e-05
1 O 0 1.221967664832846e-07
and O 0 5.386525714357049e-08
Dax O 0 0.06061875447630882
- O 0 6.426400432246737e-06
1 O 0 3.2722439868848596e-08
modulate O 0 3.018197958226665e-07
the O 0 2.290804168580962e-08
orphan O 0 1.2097791568521643e-06
nuclear O 0 1.3023286555835512e-06
receptor O 0 4.2640763808776683e-07
SF O 0 0.005762934219092131
- O 0 8.324508371515549e-07
1 O 0 8.365324433157184e-09
in O 0 4.638657458144735e-09
sex O 0 1.242371610032933e-07
- O 0 3.3558262657606974e-07
specific O 0 8.195317491299647e-08
gene O 0 8.633488164377923e-07
expression O 0 1.8604331444294075e-06
. O 0 2.5521826501062606e-06

Products O 0 8.760921446082648e-06
of O 0 1.0732733102258862e-07
steroidogenic O 0 1.3682190001418348e-05
factor O 0 1.055871734934044e-06
1 O 0 7.189663620010833e-08
( O 0 2.2327155235757346e-08
SF O 1 0.9917401075363159
- O 0 0.00020593099179677665
1 O 0 6.466246560421496e-08
) O 0 9.051078109223454e-09
and O 0 5.4770726620745336e-08
Wilms B-Disease 0 0.0008612001547589898
tumor I-Disease 0 8.584820534451865e-06
1 O 0 4.6238110229523954e-08
( O 0 8.733505474367576e-09
WT1 O 0 1.0916351129708346e-06
) O 0 4.236931250289899e-09
genes O 0 1.328564813718458e-08
are O 0 1.8983092875402008e-09
essential O 0 8.739037937743888e-09
for O 0 3.233928680401732e-09
mammalian O 0 2.1384316539752035e-07
gonadogenesis O 0 1.2063953818142181e-06
prior O 0 1.1134740418583533e-07
to O 0 3.179126295549395e-08
sexual O 0 4.0648350818628387e-07
differentiation O 0 4.560591150948312e-06
. O 0 3.312595936222351e-06

In O 0 2.24968994189112e-06
males O 0 1.7636601796766627e-06
, O 0 1.0124808369482707e-07
SF O 1 0.8586680293083191
- O 0 3.346594166941941e-05
1 O 0 3.4651751690262245e-08
participates O 0 3.4156261818907296e-08
in O 0 8.666681594604597e-09
sexual O 0 2.150206057649484e-08
development O 0 3.182934804613069e-09
by O 0 3.043980401074009e-09
regulating O 0 7.303651017309676e-08
expression O 0 3.04766523129274e-08
of O 0 2.811835653204753e-09
the O 0 2.818661748449358e-08
polypeptide O 0 5.4569077292399015e-06
hormone O 0 6.438141099351924e-06
Mullerian O 0 1.96075598069001e-05
inhibiting O 0 2.3792044885340147e-06
substance O 0 1.7799150100472616e-06
( O 0 1.3229541195869388e-07
MIS O 0 4.573523619910702e-05
) O 0 3.8525919876519765e-07
. O 0 1.293582045036601e-06

Here O 0 1.5030060467324802e-06
, O 0 5.993043572516399e-08
we O 0 5.624212917609839e-08
show O 0 1.4999874053955864e-07
that O 0 3.8777340449769326e-08
WT1 O 0 2.8749225748470053e-05
- O 0 7.755271326459479e-06
KTS O 0 2.2068561520427465e-05
isoforms O 0 9.345464491161692e-07
associate O 0 2.3440429686161224e-07
and O 0 3.426569250564171e-08
synergize O 0 2.7919038529944373e-06
with O 0 1.1178001102507551e-07
SF O 1 0.9987730383872986
- O 0 0.00022897013695910573
1 O 0 6.716513922810918e-08
to O 0 2.846029545366946e-08
promote O 0 3.123562066775776e-07
MIS O 0 2.072092866001185e-05
expression O 0 1.5650460909455433e-06
. O 0 1.5512149502683314e-06

In O 0 1.8642695067683235e-06
contrast O 0 2.8331960493233055e-06
, O 0 2.002434342784909e-07
WT1 O 0 3.76687639800366e-05
missense O 0 4.2833493353100494e-05
mutations O 0 3.2802403438836336e-05
, O 0 3.221100897121687e-08
associated O 0 7.046422467738012e-08
with O 0 2.0285568780309404e-08
male B-Disease 0 0.00042474851943552494
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.1775407983805053e-05
Denys B-Disease 1 0.9999969005584717
- I-Disease 1 0.9999978542327881
Drash I-Disease 1 0.9999910593032837
syndrome I-Disease 1 0.9999973773956299
, O 0 1.0163660135731334e-07
fail O 0 4.749713298224378e-06
to O 0 3.6689080218366144e-08
synergize O 0 8.613317731942516e-06
with O 0 1.8004206481236906e-07
SF O 1 0.9998272061347961
- O 0 0.007438621483743191
1 O 0 1.3516578292183112e-06
. O 0 1.3516475974029163e-06

Additionally O 0 1.931107181007974e-05
, O 0 1.092418742132395e-07
the O 0 3.8991164075241613e-08
X O 0 0.000426210870500654
- O 0 0.0002849319134838879
linked O 0 4.9634527385933325e-05
, O 0 1.762192169962873e-08
candidate O 0 1.780324652145282e-07
dosage O 0 1.3690673767996486e-05
- O 0 3.6573942452378105e-06
sensitive O 0 7.087944140948821e-06
sex O 0 3.4613282196005457e-07
- O 0 3.79038596065584e-07
reversal O 0 2.2324775272863917e-07
gene O 0 8.170096066351107e-08
, O 0 6.1562621667121675e-09
Dax O 0 6.361845589708537e-05
- O 0 7.463244173777639e-07
1 O 0 2.32215295881133e-08
, O 0 3.7906802141662865e-09
antagonizes O 0 3.3757788742150296e-07
synergy O 0 1.5403547592995892e-07
between O 0 2.235344531698047e-08
SF O 1 0.6786918044090271
- O 0 1.3235186088422779e-05
1 O 0 1.146199224422162e-08
and O 0 2.526331810415172e-09
WT1 O 0 3.615142531998572e-07
, O 0 1.6174878103569768e-09
most O 0 4.13720435687992e-09
likely O 0 2.7019209980494452e-08
through O 0 1.9381884985847364e-09
a O 0 3.2906937175170015e-09
direct O 0 1.4871956999229496e-08
interaction O 0 4.3531233728799634e-08
with O 0 1.2147962991093664e-07
SF O 1 0.9998964071273804
- O 0 0.009078999049961567
1 O 0 1.1294571322650881e-06
. O 0 1.8290833168066456e-06

We O 0 3.5006310099561233e-06
propose O 0 1.431381292604783e-06
that O 0 5.374405276370453e-08
WT1 O 0 3.951471171603771e-06
and O 0 7.218532971364766e-08
Dax O 0 0.004269926808774471
- O 0 2.534904297135654e-06
1 O 0 2.794721787324761e-08
functionally O 0 1.3340043381049327e-07
oppose O 0 8.889912095355612e-08
each O 0 4.8475121694480094e-09
other O 0 3.6632630262545263e-09
in O 0 1.8257127365473025e-08
testis O 0 2.8751487661793362e-06
development O 0 1.2334225196752868e-08
by O 0 2.0130164202214473e-08
modulating O 0 1.074763622455066e-05
SF O 1 0.9987359642982483
- O 0 0.0005242184270173311
1 O 0 4.0415500279777916e-07
- O 0 1.89938441508275e-06
mediated O 0 3.759730361707625e-06
transactivation O 0 5.0148646550951526e-05
. O 0 5.331560259946855e-07
. O 0 1.4839805544397677e-06

A O 0 2.4333921828656457e-06
mouse O 0 8.975729542726185e-06
model O 0 5.185590907785809e-06
for O 0 2.839688249878236e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
imprinting O 0 0.24695207178592682
- O 1 0.9808779954910278
centre O 0 9.321470133727416e-05
mutations O 0 0.00010756063420558348
. O 0 5.573797352553811e-06

Imprinting O 0 0.00020238150318618864
in O 0 1.2856224884671974e-06
the O 0 1.598456123019787e-07
15q11 O 0 1.3069323358649854e-05
- O 0 6.798201411584159e-06
q13 O 0 1.809438344935188e-06
region O 0 9.243656506896514e-08
involves O 0 5.7424415444984334e-08
an O 0 9.506567089090368e-09
imprinting O 0 1.9382950995350257e-06
centre O 0 5.514404506357096e-07
( O 0 9.189001559661847e-09
IC O 0 7.908206498541404e-07
) O 0 3.731412956398117e-09
, O 0 6.360359461332621e-10
mapping O 0 2.4633619588598776e-08
in O 0 5.802066382898374e-09
part O 0 1.1748407580114417e-08
to O 0 3.2196743049439647e-09
the O 0 2.459276560173862e-09
promoter O 0 7.476666752381789e-08
and O 0 7.68713448451308e-09
first O 0 2.5851193186099408e-08
exon O 0 1.1949973668379243e-06
of O 0 1.0318223075955757e-07
SNRPN O 0 0.00021056376863270998
. O 0 4.493638243729947e-06

Deletion O 0 5.2190265705576167e-05
of O 0 2.2907896379820158e-07
this O 0 1.6070416108959762e-07
IC O 0 1.374918701912975e-05
abolishes O 0 6.481919626821764e-06
local O 0 2.028077972227038e-07
paternally O 0 3.379503596079303e-06
derived O 0 1.4791113756018603e-07
gene O 0 1.4519143576308124e-07
expression O 0 8.498457049199715e-08
and O 0 4.338849279861279e-08
results O 0 2.705928636714816e-06
in O 0 0.0001669267803663388
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.0469603694218677e-05
PWS B-Disease 1 0.9999998807907104
) O 0 2.546071073084022e-06
. O 0 4.215397439111257e-06

We O 0 3.176149220962543e-06
have O 0 7.427473036614174e-08
created O 0 4.794686958575767e-08
two O 0 1.8031522941441835e-08
deletion O 0 2.2674596493743593e-06
mutations O 0 3.086711330979597e-06
in O 0 3.8378093591973084e-08
mice O 0 3.230557013012003e-06
to O 0 7.082033448568836e-08
understand O 0 8.106560017040465e-06
PWS B-Disease 1 0.9999998807907104
and O 0 1.1328416604783342e-07
the O 0 1.1656801746084966e-08
mechanism O 0 6.218220960363396e-08
of O 0 5.676414005506558e-09
this O 0 9.511594356581554e-08
IC O 0 0.0001661585265537724
. O 0 2.8876133910671342e-06

Mice O 0 0.0014484822750091553
harbouring O 0 0.00013239019608590752
an O 0 1.2792904158231977e-07
intragenic O 0 7.839013051125221e-06
deletion O 0 4.699672899732832e-06
in O 0 5.7068135106419504e-08
Snrpn O 0 5.556146334129153e-06
are O 0 4.943661124912069e-08
phenotypically O 0 1.2890845937363338e-06
normal O 0 2.9471266316249967e-07
, O 0 7.918800726258723e-09
suggesting O 0 4.9100282950576e-08
that O 0 8.652790484120487e-09
mutations O 0 1.9850084242989396e-07
of O 0 1.3370854423655487e-09
SNRPN O 0 6.663827662123367e-06
are O 0 1.2577495489551893e-08
not O 0 1.908544788875588e-08
sufficient O 0 8.781214688724504e-08
to O 0 1.7201180924075743e-07
induce O 0 1.2220496500958689e-05
PWS B-Disease 1 0.9999593496322632
. O 0 1.0904408554779366e-05

Mice O 0 0.0001157318038167432
with O 0 8.58048210261586e-08
a O 0 3.522739433492461e-08
larger O 0 2.174183606484803e-07
deletion O 0 9.036347705659864e-07
involving O 0 7.536355894899316e-08
both O 0 1.903364399424845e-08
Snrpn O 0 4.795592758455314e-06
and O 0 4.287531396585109e-08
the O 0 6.096390592347234e-08
putative O 0 0.013768247328698635
PWS O 1 1.0
- O 1 0.8011000156402588
IC O 0 0.004226141609251499
lack O 0 1.8584439942515019e-07
expression O 0 1.047319670988145e-07
of O 0 5.761989552155455e-09
the O 0 3.9513658123269124e-08
imprinted O 0 4.738772986456752e-06
genes O 0 1.2365787824819563e-06
Zfp127 O 0 5.097874691273319e-06
( O 0 3.2487367462863403e-08
mouse O 0 6.026538130754489e-07
homologue O 0 1.8981602352141635e-06
of O 0 2.336730453578184e-08
ZNF127 O 0 1.7965623555937782e-05
) O 0 5.934905544791036e-08
, O 0 1.72249432495164e-08
Ndn O 0 1.4627775044573355e-06
and O 0 2.1620252255161176e-08
Ipw O 0 2.8608878892555367e-06
, O 0 7.046352390460697e-09
and O 0 1.6433521210501567e-08
manifest O 0 2.11557903639914e-07
several O 0 4.4001041032970534e-08
phenotypes O 0 5.195773610466858e-06
common O 0 3.8386992855521385e-06
to O 0 1.8684877431951463e-05
PWS B-Disease 1 1.0
infants O 0 0.2676650285720825
. O 0 1.2111344403820112e-05

These O 0 3.433645474615332e-07
data O 0 1.8744137264548044e-07
demonstrate O 0 3.9734722179218807e-08
that O 0 1.8586623351524167e-09
both O 0 1.7018056963635786e-09
the O 0 3.812302029615466e-09
position O 0 3.842399746645242e-05
of O 0 8.224451120142362e-10
the O 0 6.4918497244548234e-09
IC O 0 7.345274207182229e-05
and O 0 2.1956868323513845e-08
its O 0 8.961682951280636e-09
role O 0 7.422969616754926e-08
in O 0 4.3953707340449455e-09
the O 0 1.880105404694632e-09
coordinate O 0 1.919701908548177e-08
expression O 0 7.661300038819263e-09
of O 0 4.610807291527408e-10
genes O 0 1.5598107694358987e-08
is O 0 8.027682407707459e-10
conserved O 0 2.4893527239555624e-09
between O 0 1.9427262021309843e-09
mouse O 0 1.8475336105439055e-07
and O 0 2.6857156498749646e-08
human O 0 3.81202580612694e-09
, O 0 1.7156144282992614e-09
and O 0 2.794811049255941e-09
indicate O 0 4.7107555189995765e-08
that O 0 1.7637445948182062e-09
the O 0 1.419210415853911e-09
mouse O 0 1.9457945654721698e-07
is O 0 4.81741802005331e-09
a O 0 3.1408162737278644e-09
suitable O 0 3.84513356266325e-07
model O 0 3.2237537084256473e-07
system O 0 3.6121438284908436e-08
in O 0 3.182048624594813e-09
which O 0 3.82644893548445e-09
to O 0 3.9206513591238945e-09
investigate O 0 3.944543536249512e-08
the O 0 4.0708338922001985e-09
molecular O 0 7.052727823975147e-08
mechanisms O 0 1.741047306325072e-08
of O 0 6.779936612133497e-10
imprinting O 0 3.271152593242732e-07
in O 0 3.1637497954761784e-08
this O 0 1.314259279183716e-08
region O 0 5.617255283141276e-08
of O 0 3.982727037055156e-09
the O 0 3.559108208150974e-08
genome O 0 3.1852175652602455e-07
. O 0 1.76629143311402e-07
. O 0 1.4151438563203556e-06

Mutations O 0 5.162665183888748e-05
of O 0 5.66365550014325e-08
the O 0 2.9056849371045246e-08
ATM O 0 2.5440347144467523e-06
gene O 0 6.790346560592297e-07
detected O 0 1.2042009984725155e-06
in O 0 6.244999184445987e-08
Japanese O 0 5.538757977774367e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9173114895820618
: O 0 2.380124719536525e-08
possible O 0 7.344385721808067e-08
preponderance O 0 8.588256150687812e-07
of O 0 3.1912021913882427e-09
the O 0 1.0183351939474505e-08
two O 0 1.8681706848155955e-08
founder O 0 1.206087063110317e-06
mutations O 0 8.06211210147012e-06
4612del165 O 0 5.31788646185305e-06
and O 0 3.7413104791994556e-07
7883del5 O 0 2.689881694095675e-05
. O 0 3.240168325646664e-06

The O 0 8.195503369279322e-07
ATM O 0 4.7491783334407955e-05
( O 0 3.777041968078265e-07
A O 1 0.9999871253967285
- O 1 0.9999986886978149
T O 1 1.0
, O 0 3.952300531295805e-08
mutated O 0 5.812270273963804e-07
) O 0 9.717021853816732e-09
gene O 0 7.910139032674124e-08
on O 0 5.562273841519527e-08
human O 0 2.816620394696656e-07
chromosome O 0 2.724052501434926e-05
11q22 O 0 6.248772115213796e-05
. O 0 4.711699148174375e-06

3 O 0 3.148122459606384e-06
has O 0 1.6353327225715475e-07
recently O 0 3.218691233541904e-07
been O 0 1.914746938780354e-08
identified O 0 2.3387412895203852e-08
as O 0 1.3586129998799379e-09
the O 0 1.2590066766904329e-09
gene O 0 1.8667993373355785e-08
responsible O 0 1.006148853122113e-08
for O 0 1.4734700126695088e-09
the O 0 1.4600115783025558e-08
human O 0 1.6289491213683505e-06
recessive B-Disease 1 0.9999966621398926
disease I-Disease 1 0.999961256980896
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.24704504013061523
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 1.3394634379437775e-06
. O 0 1.2750946325468249e-06

In O 0 8.657075909468404e-07
order O 0 7.00417288612698e-08
to O 0 5.3175872594124485e-09
define O 0 5.173811956638019e-08
the O 0 2.8809714613942106e-09
types O 0 7.307594529493144e-08
of O 0 2.081175232149235e-08
disease O 0 0.00027919336571358144
- O 0 0.002078360179439187
causing O 0 7.365125611613621e-07
ATM O 0 2.5832621759036556e-05
mutations O 0 3.662367817014456e-06
in O 0 2.1528242299950762e-08
Japanese O 0 5.937602327321656e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 4.529098077910021e-06
as O 0 3.5465224090813763e-09
well O 0 1.8427354087080516e-09
as O 0 8.750175584104625e-10
to O 0 1.3835819157037577e-09
look O 0 1.6880347786241146e-08
for O 0 1.3873607818126743e-09
possible O 0 2.117895903097633e-08
mutational O 0 1.2396416195770144e-06
hotspots O 0 6.552903073497873e-07
, O 0 2.1490253132583348e-08
reverse O 0 4.6403156375163235e-06
- O 0 5.249827950137842e-07
transcribed O 0 2.5775526069082844e-07
RNA O 0 6.686718023729554e-08
derived O 0 1.0192835020461644e-08
from O 0 8.24946277955263e-10
ten O 0 4.264627317951408e-09
patients O 0 1.3715591329344079e-08
belonging O 0 1.0108421655274924e-08
to O 0 2.939480658881166e-09
eight O 0 7.2763675085241175e-09
unrelated O 0 6.369239713421848e-07
Japanese O 0 0.000441347568994388
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
families O 0 6.496657789512028e-08
was O 0 6.00418772478406e-08
analyzed O 0 1.1781487785356148e-07
for O 0 3.3997069603941554e-09
mutations O 0 1.472353261533499e-07
by O 0 3.9067220569677374e-09
the O 0 1.4577326901132892e-08
restriction O 0 2.618360213091364e-07
endonuclease O 0 5.420895377028501e-06
fingerprinting O 0 6.134865088824881e-06
method O 0 1.201224858959904e-05
. O 0 6.250854767131386e-06

As O 0 1.1736668739104061e-06
has O 0 1.1667706445450676e-07
been O 0 6.385295847621819e-08
reported O 0 6.030999344375232e-08
by O 0 2.7964373039424117e-09
others O 0 1.9361648284643707e-08
, O 0 2.685432543003685e-09
mutations O 0 1.1996660020940908e-07
that O 0 2.5297988148764716e-09
lead O 0 1.36144127083071e-08
to O 0 3.2189253484915525e-09
exon O 0 2.7349079800842446e-07
skipping O 0 2.8474150326474046e-07
or O 0 1.552965898099501e-07
premature O 0 2.8361301929180627e-07
protein O 0 2.738660320744657e-08
truncation O 0 5.907782565373054e-07
were O 0 2.2528257659359952e-07
also O 0 5.43117515405811e-08
predominant O 0 3.3969654396059923e-06
in O 0 1.405703784485013e-07
our O 0 5.19372520102479e-07
mutants O 0 9.08134097699076e-06
. O 0 2.2682447706756648e-06

Six O 0 1.189695126413426e-06
different O 0 1.293555840220506e-07
mutations O 0 1.0825368690348114e-06
were O 0 1.1660164034310583e-07
identified O 0 1.7483293390796462e-07
on O 0 2.425004907991024e-08
12 O 0 1.2910190250181586e-08
of O 0 1.228315671397695e-09
the O 0 4.304484590988977e-08
16 O 0 2.2954803569064097e-07
alleles O 0 4.733353307528887e-06
examined O 0 2.5112032744800672e-05
. O 0 4.515047749009682e-06

Four O 0 7.880846624175319e-07
were O 0 9.734183947784913e-08
deletions O 0 4.4297877366261673e-07
involving O 0 7.477037655689855e-08
a O 0 7.870679041843687e-08
loss O 0 3.1542543865725747e-07
of O 0 2.196552939537355e-09
a O 0 1.5036304645832388e-08
single O 0 2.1179046427732828e-07
exon O 0 2.6605850962369004e-06
exon O 0 2.6337172585044755e-06
7 O 0 9.697511416106863e-08
, O 0 8.749945656916225e-09
exon O 0 3.6491857713372156e-07
16 O 0 2.336191329277426e-08
, O 0 7.842144711389665e-09
exon O 0 1.0665650052033016e-06
33 O 0 1.6459016194403375e-07
or O 0 1.8085449937643716e-07
exon O 0 1.4250967979023699e-05
35 O 0 1.4187775150276138e-06
. O 0 4.0973668546939734e-06

The O 0 6.61343051433505e-07
others O 0 2.4484342020514305e-07
were O 0 3.40688828259772e-08
minute O 0 1.1478284278609863e-07
deletions O 0 5.707378818442521e-07
, O 0 1.7576905264604648e-08
4649delA O 0 3.0558962293980585e-07
in O 0 1.7990744893836563e-08
exon O 0 9.439065706828842e-07
33 O 0 8.046699662145329e-08
and O 0 2.988387493019218e-08
7883del5 O 0 1.9853162029903615e-06
in O 0 1.2064558063684672e-07
exon O 0 1.2005296412098687e-05
55 O 0 2.135007434844738e-06
. O 0 1.7850657059170771e-06

The O 0 1.4330614703794708e-06
mutations O 0 4.089891262992751e-06
4612del165 O 0 1.333148816229368e-06
and O 0 2.0619213003669756e-08
7883del5 O 0 2.2190835125002195e-07
were O 0 1.4586310825848159e-08
found O 0 3.0216347202127736e-09
in O 0 7.111671251891494e-10
more O 0 3.2573768682375714e-10
than O 0 1.0228821123448029e-09
two O 0 2.0467720851513604e-09
unrelated O 0 7.515685496173319e-08
families O 0 6.538997787686185e-09
; O 0 3.4209644006466533e-09
44 O 0 5.548146830847145e-09
% O 0 2.72900191333747e-09
( O 0 7.795893375295293e-10
7 O 0 3.0990661148422305e-09
of O 0 5.19424447897876e-10
16 O 0 3.8081520159494175e-09
) O 0 8.371656701200436e-10
of O 0 1.8628527886921376e-10
the O 0 9.500997766309638e-10
mutant O 0 5.528965374423933e-08
alleles O 0 2.1175128495087847e-07
had O 0 7.077603640937014e-07
one O 0 2.7503377353355063e-09
of O 0 5.275367365165096e-10
the O 0 1.8527593681483268e-08
two O 0 1.258731572306715e-07
mutations O 0 5.79815823584795e-05
. O 0 2.5934809855243657e-06

The O 0 6.220414547897235e-07
4612del165 O 0 2.824576540660928e-06
mutations O 0 8.898442160898412e-07
in O 0 6.943555064253815e-09
three O 0 1.3896277462066564e-09
different O 0 3.446966712061794e-09
families O 0 5.0020276809448205e-09
were O 0 1.3472286397586686e-08
all O 0 5.483976606157626e-10
ascribed O 0 4.0495468311974037e-08
to O 0 7.825260439631165e-09
the O 0 5.55479617858623e-09
same O 0 1.4743835663466598e-07
T O 0 0.0012036028783768415
- O 0 2.2868589439895004e-05
- O 0 8.626870453554147e-07
> O 0 2.6532871899576094e-08
A O 0 2.9496292075492647e-09
substitution O 0 8.240251148095012e-09
at O 0 5.889491561106297e-09
the O 0 2.8103075422336588e-09
splice O 0 8.692708206581301e-07
donor O 0 8.538768270227592e-08
site O 0 1.969403200519082e-07
in O 0 5.516945833505815e-08
intron O 0 3.698857472045347e-05
33 O 0 4.834688752453076e-06
. O 0 2.234261273770244e-06

Microsatellite O 0 0.00034869101364165545
genotyping O 0 6.123710772953928e-05
around O 0 3.283607838966418e-07
the O 0 3.618225363766214e-08
ATM O 0 2.563358975748997e-06
locus O 0 1.360350324830506e-05
also O 0 1.7678924280062347e-07
indicated O 0 1.229242485578652e-07
that O 0 2.8533222451443407e-09
a O 0 5.6691211725024004e-09
common O 0 1.9290105512936861e-07
haplotype O 0 0.00022625806741416454
was O 0 4.905115201836452e-05
shared O 0 1.9517857552386886e-08
by O 0 3.034126283552041e-09
the O 0 7.498785592474633e-09
mutant O 0 9.152147413260536e-07
alleles O 0 1.2095727015548619e-06
in O 0 7.168276283664454e-08
both O 0 6.515756467706524e-07
mutations O 0 7.182484114309773e-05
. O 0 6.032983037584927e-06

This O 0 4.507780033691233e-07
suggests O 0 2.2169260205373575e-07
that O 0 6.5165246532217225e-09
these O 0 3.998231079549441e-09
two O 0 4.691152355462691e-09
founder O 0 1.318411193551583e-07
mutations O 0 6.697614026052179e-06
may O 0 5.295960363582708e-07
be O 0 1.6134922731225743e-08
predominant O 0 7.022190970928932e-07
among O 0 5.976971095833505e-08
Japanese O 0 5.23114124462154e-07
ATM O 0 1.9836090359603986e-05
mutant O 0 2.1657993784174323e-05
alleles O 0 5.376236731535755e-05
. O 0 6.675849363091402e-06

W474C O 0 0.00020809350826311857
amino O 0 1.6469628462800756e-05
acid O 0 3.0126559522614116e-06
substitution O 0 3.927734439912456e-07
affects O 0 1.3815592581067904e-07
early O 0 2.1386677317991598e-08
processing O 0 2.6857717827510896e-08
of O 0 1.3562855283311137e-09
the O 0 4.352672444696282e-09
alpha O 0 1.627617862709485e-08
- O 0 2.1994509324940736e-08
subunit O 0 9.172995696360431e-09
of O 0 8.838353937612453e-10
beta O 0 3.529572367710898e-08
- O 0 3.837407405171689e-07
hexosaminidase O 0 1.3396141866905964e-06
A O 0 2.065054260924626e-08
and O 0 9.690555025088088e-09
is O 0 3.836987616523402e-09
associated O 0 1.8245604138655835e-08
with O 0 3.347582122614767e-08
subacute O 0 0.1105465218424797
G B-Disease 0 0.015318598598241806
( I-Disease 0 1.1208766181880492e-07
M2 I-Disease 0 0.00010388371447334066
) I-Disease 0 6.077837610973802e-07
gangliosidosis I-Disease 0 4.432437344803475e-05
. O 0 3.421052269914071e-06

Mutations O 0 0.0005360067589208484
in O 0 1.6793420627436717e-06
the O 0 2.661351743427076e-07
HEXA O 0 5.8494959375821054e-05
gene O 0 1.0840844879567157e-06
, O 0 1.5260306795994438e-08
encoding O 0 6.870796909197452e-08
the O 0 1.2201041066361995e-08
alpha O 0 4.150286514459367e-08
- O 0 6.476739145000465e-08
subunit O 0 2.462652837209589e-08
of O 0 1.2328621457058375e-09
beta O 0 6.697158738688813e-08
- O 0 1.0164857258132542e-06
hexosaminidase O 0 3.5033629046665737e-06
A O 0 3.932689196517458e-08
( O 0 3.0418561003386912e-09
Hex O 0 1.2835970153446397e-07
A O 0 9.73290070760413e-09
) O 0 1.7498089643908088e-09
, O 0 9.409760748368967e-10
that O 0 1.3696528355922055e-09
abolish O 0 1.1338209304767588e-07
Hex O 0 3.4420747851982014e-07
A O 0 1.118588777160312e-08
enzyme O 0 2.3257703674062213e-07
activity O 0 9.299171779275639e-07
cause O 0 0.0335160568356514
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.03698210418224335
( O 0 3.3196183579775607e-08
TSD B-Disease 0 1.16135324788047e-05
) O 0 1.8219312281075872e-08
, O 0 5.444396045106714e-09
the O 0 4.0187920546941314e-08
fatal O 0 0.022828947752714157
infantile B-Disease 0 1.5190506019280292e-05
form I-Disease 0 4.834168407796824e-07
of I-Disease 0 3.114908153634133e-08
G I-Disease 0 0.0002986167964991182
( I-Disease 0 2.010361122017912e-08
M2 I-Disease 0 1.3896722521167248e-05
) I-Disease 0 3.711518559157412e-08
gangliosidosis I-Disease 0 3.908013241016306e-06
, I-Disease 0 2.527890252679299e-08
Type I-Disease 0 8.207986752495344e-07
1 I-Disease 0 4.315257342568657e-07
. O 0 1.0560308965068543e-06

Less O 0 2.707681414904073e-05
severe O 0 0.0004462462093215436
, O 0 3.094363592026639e-07
subacute O 0 0.0001919994392665103
( O 0 1.3725882297421776e-07
juvenile O 0 0.016713548451662064
- O 0 0.48130539059638977
onset O 0 0.055823855102062225
) O 0 1.170666564576095e-06
and O 0 0.00022979530331213027
chronic O 0 0.15981896221637726
( O 0 1.4554184524229186e-08
adult O 0 7.652921340195462e-06
- O 0 0.138747438788414
onset O 0 0.00043230701703578234
) O 0 1.294263718421007e-08
variants O 0 2.2041633940261818e-07
are O 0 6.272991459610466e-09
characterized O 0 3.225096989467602e-08
by O 0 3.2258888893466064e-09
a O 0 9.974852055449901e-09
broad O 0 7.740619878404686e-08
spectrum O 0 1.4676959381176857e-07
of O 0 1.9924490946010565e-09
clinical O 0 5.804326974612195e-07
manifestations O 0 4.0283356383952196e-07
and O 0 1.1622716300507818e-07
are O 0 1.1140790512342846e-08
associated O 0 2.5493791966368917e-08
with O 0 1.6454222873107938e-08
residual O 0 0.026941226795315742
levels O 0 4.686371084972052e-06
of O 0 1.2661644177569542e-08
Hex O 0 2.1724479211115977e-06
A O 0 1.4030894135430572e-07
enzyme O 0 1.510755964773125e-06
activity O 0 2.5871274829114554e-06
. O 0 2.1753585315309465e-06

We O 0 1.4514740541926585e-05
identified O 0 8.94708136911504e-07
a O 0 1.2747842959015543e-07
1422 O 0 1.0595711501082405e-05
G O 0 4.52476269856561e-05
- O 0 6.294254126260057e-05
- O 0 1.4690988791699056e-05
> O 0 7.070372021189542e-07
C O 0 6.861445172035019e-07
( O 0 1.8714259031327174e-09
amino O 0 1.206303501533057e-08
acid O 0 1.6050114126642256e-08
W474C O 0 3.118760361076056e-08
) O 0 2.528119380507121e-10
substitution O 0 8.95412688439734e-10
in O 0 1.0709453324153628e-09
the O 0 1.471099908556539e-09
first O 0 2.308735957967656e-08
position O 0 1.4236402989808994e-07
of O 0 1.04346054019544e-09
exon O 0 2.7148621484229807e-07
13 O 0 8.855687738673623e-09
of O 0 2.055990488969428e-09
HEXA O 0 2.5193426154146437e-06
of O 0 1.6059844565319281e-09
a O 0 1.3807407661658999e-08
non O 0 2.3043152452828508e-07
- O 0 2.43237604991009e-06
Jewish O 0 3.1882808571026544e-07
proband O 0 3.7148233786865603e-06
who O 0 3.3890326989194364e-08
manifested O 0 2.0526438504475664e-07
a O 0 2.56243435359238e-08
subacute O 0 1.910889841383323e-05
variant O 0 4.947017441736534e-05
of O 0 5.135184366622525e-08
G B-Disease 0 0.0017331450944766402
( I-Disease 0 8.708824594805264e-08
M2 I-Disease 0 0.00025245954748243093
) I-Disease 0 5.74591410895664e-07
gangliosidosis I-Disease 0 7.231444760691375e-05
. O 0 2.605902182040154e-06

On O 0 6.785750770177401e-07
the O 0 7.325289175241778e-08
second O 0 2.7407699576542655e-07
maternally O 0 9.010582289192826e-06
inherited O 0 7.048779934848426e-06
allele O 0 1.780995035005617e-06
, O 0 1.801969418124827e-08
we O 0 2.578422098054034e-08
identified O 0 5.925415536012224e-08
the O 0 2.320846625991635e-08
common O 0 0.00029914482729509473
infantile O 1 0.9961451292037964
disease O 1 0.9695746898651123
- O 0 0.14544649422168732
causing O 0 2.247149677714333e-05
4 O 0 1.4985018026436592e-07
- O 0 4.5926003622298595e-06
bp O 0 1.9373894701857353e-06
insertion O 0 2.414537618733448e-07
, O 0 1.8705987869793717e-08
+ O 0 1.7527568729747145e-07
TATC O 0 2.5600027129257796e-06
1278 O 0 1.8081206007991568e-06
, O 0 1.4213187071732136e-08
in O 0 4.3077534428448416e-08
exon O 0 6.1182017816463485e-06
11 O 0 8.185676847460854e-07
. O 0 9.515039778307255e-07

Pulse O 0 0.002000827342271805
- O 0 0.002178715541958809
chase O 0 1.233406783285318e-05
analysis O 0 2.908910516907781e-07
using O 0 1.8655610745099693e-07
proband O 0 3.3932356018340215e-06
fibroblasts O 0 1.0126910865437821e-06
revealed O 0 1.1520312455104431e-06
that O 0 7.921580724712385e-09
the O 0 5.56353363379003e-09
W474C O 0 5.54998507595883e-07
- O 0 1.1674607236500378e-07
containing O 0 2.5045704177273365e-08
alpha O 0 3.7771858529822566e-08
- O 0 2.7390312240527237e-08
subunit O 0 2.4027761114098212e-08
precursor O 0 3.462083597582932e-08
was O 0 1.0441319808762728e-08
normally O 0 2.1840615982426925e-09
synthesized O 0 2.7910672883990628e-08
, O 0 1.4818095639412832e-09
but O 0 2.740247584398503e-09
not O 0 1.1692334878077304e-09
phosphorylated O 0 1.2535871007912647e-08
or O 0 6.438099386940621e-09
secreted O 0 2.8467514567864782e-08
, O 0 2.111131269799671e-09
and O 0 4.419632215757474e-09
the O 0 1.833669394102344e-08
mature O 0 2.394621674284281e-07
lysosomal O 0 2.5357044250995386e-06
alpha O 0 1.0264829342077064e-07
- O 0 1.35058158434731e-07
subunit O 0 2.2216437400857103e-07
was O 0 1.485818330593247e-07
not O 0 9.03941810292963e-08
detected O 0 1.9710803371708607e-06
. O 0 1.1692607131408295e-06

When O 0 4.364385858934838e-06
the O 0 1.2193693521567184e-07
W474C O 0 2.658076937223086e-06
- O 0 4.30158763720101e-07
containing O 0 5.3242782627194174e-08
alpha O 0 2.3052514563914883e-07
- O 0 1.3839091650424962e-07
subunit O 0 3.130531354145205e-07
was O 0 4.977941330253088e-07
transiently O 0 2.631309598655207e-06
co O 0 4.946112767356681e-06
- O 0 9.93113303593418e-07
expressed O 0 7.331086848694213e-09
with O 0 2.0361692332215853e-09
the O 0 4.599057579213195e-09
beta O 0 4.166021838614142e-08
- O 0 3.603816978170471e-08
subunit O 0 4.7723521134912517e-08
to O 0 9.279229828962343e-09
produce O 0 4.128542840931004e-08
Hex O 0 2.3390990122607036e-07
A O 0 1.2453745590335075e-08
( O 0 3.4155267503166442e-09
alphabeta O 0 1.560055409299821e-07
) O 0 3.5872329551267512e-09
in O 0 7.025765746959678e-09
COS O 0 0.00016974918253254145
- O 0 1.4604631360271014e-05
7 O 0 1.8030318571504722e-08
cells O 0 4.965594868622247e-08
, O 0 1.3402976506426967e-09
the O 0 1.008301886429308e-09
mature O 0 8.04516098185104e-09
alpha O 0 4.102534756356135e-09
- O 0 1.035565855289633e-08
subunit O 0 1.579404873552903e-08
was O 0 2.0193962058101533e-08
present O 0 1.2646069746935495e-09
, O 0 1.0060062782812906e-09
but O 0 2.806365140273215e-09
its O 0 2.0496355723764736e-09
level O 0 2.02924574921326e-08
was O 0 6.415534414827562e-08
much O 0 2.0974570968945727e-09
lower O 0 1.8367426690701905e-08
than O 0 8.914625704292689e-10
that O 0 1.4276649862310364e-09
from O 0 1.179892850089459e-09
normal O 0 8.656819261432247e-09
alpha O 0 8.043319787987002e-09
- O 0 1.982646580245273e-08
subunit O 0 2.041723767831627e-08
transfections O 0 1.6787851109256735e-07
, O 0 1.4697676409269889e-09
although O 0 3.6039871087467645e-09
higher O 0 5.141905123906554e-09
than O 0 1.028649831980033e-09
in O 0 4.093709815577995e-09
those O 0 1.4196984920999967e-08
cells O 0 1.3499736439825938e-07
transfected O 0 1.052087327479967e-06
with O 0 5.927322632715004e-09
an O 0 4.8979873490395676e-09
alpha O 0 1.0340840361777737e-07
- O 0 5.492428840625507e-07
subunit O 0 6.647062491538236e-07
associated O 0 4.719487947113521e-07
with O 0 3.0233948677960143e-07
infantile O 0 0.0007721541333012283
TSD B-Disease 0 0.0016201070975512266
. O 0 6.252344974200241e-06

Furthermore O 0 6.250168553378899e-06
, O 0 4.638810224832923e-08
the O 0 7.300931414988554e-09
precursor O 0 1.0909466396924472e-07
level O 0 5.015070669855959e-08
of O 0 2.1477621903187583e-09
the O 0 9.91659465654493e-09
W474C O 0 2.4250979890894087e-07
alpha O 0 2.5866135899832443e-08
- O 0 2.84583947518513e-08
subunit O 0 4.1471608369647583e-08
was O 0 2.459915826591441e-08
found O 0 3.1175573234065723e-09
to O 0 1.3765326656312027e-09
accumulate O 0 2.0754193030825263e-08
in O 0 8.689270414308226e-10
comparison O 0 1.2924505021771893e-08
to O 0 5.518710821661443e-09
the O 0 5.803627356470997e-09
normal O 0 4.986779345017567e-08
alpha O 0 4.769176342733772e-08
- O 0 1.616554783367974e-07
subunit O 0 4.0888940588956757e-07
precursor O 0 1.495509422966279e-06
levels O 0 1.4785671282879775e-06
. O 0 8.674521723150974e-07

We O 0 5.080382834421471e-06
conclude O 0 9.237397193828656e-07
that O 0 2.12158326462486e-08
the O 0 1.836581553504857e-08
1422 O 0 2.845996959877084e-06
G O 0 4.66399342258228e-06
- O 0 5.634656190522946e-06
- O 0 2.885645017158822e-06
> O 0 7.159106871768017e-07
C O 0 6.242799827305134e-06
mutation O 0 2.9333585871427204e-07
is O 0 6.6662009245987974e-09
the O 0 6.271998032048032e-09
cause O 0 4.2246512066412834e-08
of O 0 5.146575610126547e-09
Hex B-Disease 0 0.0006467642378993332
A I-Disease 0 0.00026263415929861367
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.2176195102474594e-07
the O 0 3.220088160560408e-07
proband O 0 0.00032093189656734467
. O 0 3.7679430988646345e-06

The O 0 2.174228256990318e-06
resulting O 0 1.9313974917167798e-06
W474C O 0 2.304676399944583e-06
substitution O 0 3.8006731983841746e-07
clearly O 0 2.4732895553825074e-07
interferes O 0 4.286129069441813e-07
with O 0 6.790850104465562e-09
alpha O 0 2.6648914186466754e-08
- O 0 2.3379207902962662e-08
subunit O 0 2.5790074076326164e-08
processing O 0 1.8878967722457674e-08
, O 0 1.5818552023816324e-09
but O 0 3.4456650865877236e-09
because O 0 2.4306343604507674e-09
the O 0 5.709878125870205e-10
base O 0 3.440910223417859e-09
substitution O 0 8.301887177708522e-09
falls O 0 1.1887412938449415e-06
at O 0 4.5334247467110345e-09
the O 0 1.223874668276892e-09
first O 0 1.4960580330125595e-08
position O 0 6.969537480472354e-08
of O 0 8.421592867513539e-10
exon O 0 2.1979877828925964e-07
13 O 0 9.50807255151176e-09
, O 0 9.344550688794584e-10
aberrant O 0 3.4729168874036986e-08
splicing O 0 5.404688749877096e-07
may O 0 1.0918163297901629e-06
also O 0 1.1204508432172133e-08
contribute O 0 8.762003567142074e-09
to O 0 1.672303184818702e-08
Hex B-Disease 0 1.3556813428294845e-05
A I-Disease 0 1.374354155814217e-06
deficiency I-Disease 0 4.5083274017088115e-05
in O 0 1.515903313986655e-08
this O 0 1.858347609129396e-08
proband O 0 7.007900421740487e-06
. O 0 1.7451576184157602e-07
. O 0 7.535450095019769e-07

Two O 0 7.689256563025992e-06
frequent O 0 7.22108015906997e-05
missense O 0 0.0038101295940577984
mutations O 0 0.3413057327270508
in O 0 0.0044987560249865055
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.388156857108697e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.337579215032747e-05
an O 0 0.003477539634332061
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.006641798187047243
by O 0 1.1018265695383889e-06
early O 0 0.011584567837417126
childhood O 1 0.9989025592803955
deafness B-Disease 1 1.0
and O 1 0.976496160030365
goiter B-Disease 1 1.0
. O 0 8.624422480352223e-05

A O 0 1.949220859387424e-06
century O 0 7.019840495559038e-07
after O 0 5.73994505259634e-08
its O 0 5.736341179840565e-09
recognition O 0 3.9157434628123156e-08
as O 0 9.596165284619929e-08
a O 0 6.178185572025541e-07
syndrome O 0 0.03695319592952728
by O 0 5.134770386661103e-09
Vaughan O 0 4.5616033617079665e-07
Pendred O 0 1.4460375723501784e-06
, O 0 9.657084021341689e-09
the O 0 4.6592223412744715e-08
disease O 0 1.850783291956759e-06
gene O 0 3.7486140058717865e-07
( O 0 2.297131018735854e-08
PDS O 0 1.961135694728e-06
) O 0 1.1939655486514766e-08
was O 0 6.70810251790499e-08
mapped O 0 1.2109784393032896e-06
to O 0 9.980184501046097e-08
chromosome O 0 8.325037015310954e-06
7q22 O 0 1.9951097783632576e-05
- O 0 7.329837535507977e-05
q31 O 0 3.9864829886937514e-05
. O 0 4.514212832873454e-06

1 O 0 1.649465161790431e-06
and O 0 7.184372208257628e-08
, O 0 1.0317234178103263e-08
recently O 0 1.6916582978865335e-07
, O 0 4.361215388826167e-09
found O 0 7.1417161073839e-09
to O 0 3.820979088686727e-09
encode O 0 3.0737666634195193e-07
a O 0 2.633797464568488e-07
putative O 0 3.763170388992876e-05
sulfate O 0 0.002221537521108985
transporter O 0 0.0004244783485773951
. O 0 3.73050784219231e-06

We O 0 1.699267272670113e-06
performed O 0 2.5188930408148735e-07
mutation O 0 4.561407536129991e-07
analysis O 0 4.5438149243182124e-08
of O 0 1.7967348719949428e-09
the O 0 8.55142801015063e-09
PDS B-Disease 0 8.178435564332176e-07
gene O 0 2.0405194334216503e-07
in O 0 3.3062285353935295e-08
patients O 0 1.121083954558344e-07
from O 0 3.0057296651619936e-09
14 O 0 4.638745387808285e-09
Pendred B-Disease 0 1.2069519073065749e-07
families O 0 2.930663489664198e-09
originating O 0 7.867373419401247e-09
from O 0 3.088002742401841e-09
seven O 0 7.442161109594281e-09
countries O 0 6.7056435959500504e-09
and O 0 4.1458005028971456e-08
identified O 0 2.5210391640939633e-07
all O 0 7.23170785477123e-08
mutations O 0 1.0660327461664565e-05
. O 0 1.965760702660191e-06

The O 0 1.2049719089191058e-06
mutations O 0 2.524378714952036e-06
include O 0 2.089504036462131e-08
three O 0 1.839649321766501e-08
single O 0 9.454636540340289e-08
base O 0 8.557370989592528e-08
deletions O 0 6.24736969712103e-07
, O 0 1.6171988193036668e-08
one O 0 1.1026148882820053e-08
splice O 0 1.0458526048751082e-05
site O 0 1.6290050552925095e-06
mutation O 0 3.12873976326955e-06
and O 0 2.3059946840930934e-07
10 O 0 2.5621295662858756e-07
missense O 0 7.568381261080503e-05
mutations O 0 0.000169767314218916
. O 0 9.299728844780475e-06

One O 0 2.6827005967788864e-06
missense O 0 5.760675048804842e-05
mutation O 0 9.249788490706123e-06
( O 0 6.616294712102899e-08
L236P O 0 7.289399377441441e-07
) O 0 2.1102508185322222e-08
was O 0 7.548814551228133e-08
found O 0 1.6826792403890067e-08
in O 0 2.518744546264884e-09
a O 0 3.5430269829106464e-09
homozygous O 0 4.272767171187297e-07
state O 0 8.755154823347766e-09
in O 0 5.833458605053465e-09
two O 0 6.997080248538623e-09
consanguineous O 0 4.661939328798326e-06
families O 0 2.722915048991581e-08
and O 0 2.782258867739529e-09
in O 0 3.0679014884071876e-09
a O 0 7.634022303193433e-09
heterozygous O 0 1.257169657264967e-07
state O 0 4.845256640351181e-09
in O 0 4.358671201742936e-09
five O 0 4.686135479659015e-09
additional O 0 3.853285690524899e-08
non O 0 2.83831536762591e-06
- O 0 0.00018672982696443796
consanguineous O 0 0.00026760651962831616
families O 0 2.1428709260362666e-06
. O 0 3.687914841066231e-06

Another O 0 1.2548434824566357e-05
missense O 0 8.239369344664738e-05
mutation O 0 1.3869780559616629e-05
( O 0 8.126315975687248e-08
T416P O 0 9.64799028224661e-07
) O 0 1.769389434969071e-08
was O 0 8.677734797402081e-08
found O 0 1.7244929040316492e-08
in O 0 2.6432844801860256e-09
a O 0 3.658933822592303e-09
homozygous O 0 2.4081816718535265e-07
state O 0 4.988993662635721e-09
in O 0 8.599335465930835e-09
one O 0 1.2774685309580036e-08
family O 0 2.3410354543784706e-08
and O 0 1.499983959263318e-08
in O 0 7.544651126067947e-09
a O 0 1.0508810710518901e-08
heterozygous O 0 1.690580972990574e-07
state O 0 1.0342729339640755e-08
in O 0 1.4023184391476207e-08
four O 0 5.463633812041735e-08
families O 0 2.1115759807344148e-07
. O 0 9.266036613553297e-07

Pendred B-Disease 0 0.00035711663076654077
patients O 0 3.803702929872088e-05
in O 0 7.315794903206552e-08
three O 0 2.309339386386e-08
non O 0 4.968015332451614e-07
- O 0 1.4093071513343602e-05
consanguineous O 0 1.1177984561072662e-05
families O 0 5.103693823116373e-08
were O 0 5.6650573121430625e-09
shown O 0 6.588247725147767e-09
to O 0 2.329178183657632e-09
be O 0 4.849315171640001e-09
compound O 0 4.798392083671388e-08
heterozygotes O 0 7.660191272407246e-07
for O 0 2.4728903369464206e-08
L236P O 0 2.4973112431325717e-06
and O 0 3.7123371043890074e-07
T416P O 0 2.3996492018341087e-05
. O 0 2.9090124371577986e-06

In O 0 2.3442262886419485e-07
total O 0 1.6988195739031653e-08
, O 0 2.395599496551881e-09
one O 0 1.5341490300357918e-09
or O 0 8.36009306226515e-09
both O 0 1.1283983747389925e-09
of O 0 2.0455767635318978e-10
these O 0 1.9473227474975374e-09
mutations O 0 1.7397569251897949e-07
were O 0 4.8813333819452964e-08
found O 0 2.4128889108965268e-08
in O 0 6.773955618655236e-09
nine O 0 6.167709454274473e-09
of O 0 9.739022921451124e-10
the O 0 2.7604665220337665e-08
14 O 0 4.1148403795432387e-08
families O 0 5.26253955968059e-08
analyzed O 0 3.667400960694067e-06
. O 0 1.0843513109648484e-06

The O 0 2.52163061986721e-07
identification O 0 2.514771892947465e-07
of O 0 6.611737823902786e-09
two O 0 2.6914026562963045e-08
frequent O 0 9.062911772161897e-07
PDS B-Disease 0 0.0010545137338340282
mutations O 0 3.380314592504874e-05
will O 0 2.1083277346178875e-08
facilitate O 0 3.4227937817377097e-08
the O 0 3.391418701426119e-08
molecular O 0 1.825549770728685e-05
diagnosis O 0 0.0385117381811142
of O 0 4.298292424209649e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.8825075787608512e-05

Insertional O 0 0.0006572927231900394
mutation O 0 4.5449938625097275e-05
by O 0 2.6457098556420533e-07
transposable O 0 1.220986268890556e-05
element O 0 1.2994726148463087e-06
, O 0 5.9244662509172485e-08
L1 O 0 2.421123099338729e-05
, O 0 1.3323459668868054e-08
in O 0 1.1226005902642555e-08
the O 0 6.715296763104561e-08
DMD B-Disease 1 0.9999997615814209
gene O 0 6.720422788930591e-06
results O 0 5.116236025060061e-06
in O 0 2.773706455627689e-07
X B-Disease 1 0.999981164932251
- I-Disease 1 0.9999918937683105
linked I-Disease 1 0.9999940395355225
dilated I-Disease 1 0.9999415874481201
cardiomyopathy I-Disease 1 0.9999997615814209
. O 0 3.145784285152331e-05

X B-Disease 1 0.9999638795852661
- I-Disease 1 0.9999938011169434
linked I-Disease 1 0.9995747208595276
dilated I-Disease 1 0.9999096393585205
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 2.8034193633175164e-07
XLDCM B-Disease 0 0.00022793440439272672
) O 0 2.5964551397805735e-08
is O 0 7.865932794004493e-09
a O 0 1.9115503846478532e-08
clinical O 0 6.683736046397826e-06
phenotype O 0 4.951983555656625e-06
of O 0 3.905254786218393e-09
dystrophinopathy B-Disease 0 0.0003388726036064327
which O 0 5.0104329574196527e-08
is O 0 5.164886296427085e-09
characterized O 0 3.136238291290283e-08
by O 0 9.803400757846248e-09
preferential O 0 2.722816816458362e-06
myocardial B-Disease 0 0.2940858006477356
involvement I-Disease 0 6.076841145841172e-07
without O 0 2.2995815029958067e-08
any O 0 3.018065086735078e-08
overt O 0 1.4429738257604185e-06
clinical O 0 1.711645018076524e-05
signs O 0 3.540850912031601e-06
of O 0 1.2410681620167452e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.000349450099747628

To O 0 4.491383265303739e-07
date O 0 4.2290616875106934e-07
, O 0 9.482209684108511e-09
several O 0 2.7273797442717296e-08
mutations O 0 9.628200814404408e-07
in O 0 5.478148779047842e-08
the O 0 2.9695186753997405e-07
Duchenne B-Disease 0 0.002040667226538062
muscular I-Disease 0 1.0310220204701182e-05
dystrophy I-Disease 0 1.5669931599404663e-05
gene O 0 1.24145412883081e-06
, O 0 7.079940189669287e-08
DMD O 1 0.9999998807907104
, O 0 3.5289399846760716e-08
have O 0 2.7323679319124494e-08
been O 0 7.952254321708097e-08
identified O 0 3.2259217164209986e-07
in O 0 1.8807769563977672e-08
patients O 0 1.0652358639617887e-07
with O 0 2.983772562359377e-09
XLDCM B-Disease 0 0.014815465547144413
, O 0 1.3801904508170537e-08
but O 0 1.2167599372503446e-08
a O 0 6.318044309949755e-09
pathogenic O 0 1.4003330761624966e-07
correlation O 0 7.696043269334041e-08
of O 0 1.431318508160473e-09
these O 0 1.7711284883148437e-08
cardiospecific O 0 1.4739220205228776e-05
mutations O 0 1.1928571439057123e-05
in O 0 2.1533587357680517e-07
DMD O 1 0.9999998807907104
with O 0 5.8202694219744444e-08
the O 0 6.245011263672495e-08
XLDCM B-Disease 0 0.29092493653297424
phenotype O 0 0.003292674198746681
has O 0 2.6698475608100125e-07
remained O 0 2.468750892603566e-07
to O 0 2.511650443182134e-08
be O 0 2.179448443939691e-07
elucidated O 0 1.9065357264480554e-05
. O 0 2.337137402719236e-06

We O 0 2.6758205422083847e-05
report O 0 1.8263958168063255e-07
here O 0 4.090798366718218e-09
the O 0 1.588979503530652e-09
identification O 0 1.993658926835451e-08
of O 0 2.0235786379885212e-09
a O 0 3.9109366412048985e-08
unique O 0 2.609856437629787e-07
de O 0 7.857784112275112e-07
novo O 0 7.461650284312782e-07
L1 O 0 2.3022600998956477e-06
insertion O 0 1.9561431940928742e-07
in O 0 9.756486285539268e-09
the O 0 5.419107385051802e-09
muscle O 0 1.883274194369733e-07
exon O 0 3.997494104623911e-07
1 O 0 2.56087577810149e-08
in O 0 1.347508771232242e-08
DMD O 1 0.9999998807907104
in O 0 7.113142430625885e-08
three O 0 4.191055325009074e-08
XLDCM B-Disease 0 0.004858883563429117
patients O 0 1.8748033880910953e-07
from O 0 2.364418216771469e-09
two O 0 1.3985948399408699e-08
unrelated O 0 1.1187593145223218e-06
Japanese O 0 2.316977997907088e-06
families O 0 7.042403922241647e-07
. O 0 1.1132739246022538e-06

The O 0 2.756707715434459e-07
insertion O 0 1.5622530327163986e-06
was O 0 3.132033441488602e-07
a O 0 1.3060778236706483e-08
5 O 0 1.5069780090470886e-08
- O 0 1.3823196809426008e-07
truncated O 0 2.0712521120458405e-07
form O 0 9.139485257492197e-08
of O 0 5.124966229175243e-09
human O 0 1.4509115686678342e-08
L1 O 0 7.427585728692065e-07
inversely O 0 2.7585144835029496e-07
integrated O 0 2.079488695017062e-06
in O 0 2.519846198367759e-08
the O 0 1.608072608405564e-08
5 O 0 1.9936285511334972e-08
- O 0 3.297849673344899e-07
untranslated O 0 4.540247118711704e-06
region O 0 1.3226640760422015e-07
in O 0 1.0427626762066211e-08
the O 0 5.674422265400381e-09
muscle O 0 7.747073738073595e-08
exon O 0 1.3165278289761773e-07
1 O 0 9.867106243177659e-09
, O 0 8.806617102230518e-10
which O 0 2.2682464795309443e-09
affected O 0 3.15781578663632e-09
the O 0 7.673360835624976e-10
transcription O 0 1.130850790787008e-08
or O 0 1.8314889871362539e-07
the O 0 1.655530468269717e-08
stability O 0 1.2982174268927338e-07
of O 0 1.0300987840494713e-09
the O 0 9.61004609223437e-09
muscle O 0 1.1629502694177063e-07
form O 0 1.295093454700691e-08
of O 0 1.2927382497807116e-09
dystrophin O 0 2.4717826363485074e-07
transcripts O 0 1.9008979279533378e-07
but O 0 3.722699304375965e-08
not O 0 2.685053512863078e-09
that O 0 7.693423675902977e-10
of O 0 3.5419103761036297e-10
the O 0 1.0913936421275139e-08
brain O 0 7.78449702920625e-06
or O 0 7.25697972825401e-08
Purkinje O 0 3.9373775507556275e-05
cell O 0 7.038047624519095e-05
form O 0 7.266377224368625e-07
, O 0 1.1740123539993874e-07
probably O 0 5.3673652473662514e-06
due O 0 7.752483810463673e-08
to O 0 6.284703868431052e-09
its O 0 8.685198338298505e-09
unique O 0 7.04859957068038e-08
site O 0 1.9422719788053655e-07
of O 0 1.1941113875479914e-08
integration O 0 1.7020716995830298e-06
. O 0 2.6835091375687625e-06

We O 0 2.5435858788114274e-06
speculate O 0 5.704837917619443e-07
that O 0 4.007132847760886e-09
this O 0 2.0210484397154005e-09
insertion O 0 4.442987489028383e-08
of O 0 1.8763008924338465e-09
an O 0 6.145539188651128e-09
L1 O 0 4.365614131529583e-06
sequence O 0 1.687047443965639e-07
in O 0 2.2020329026872787e-07
DMD O 1 1.0
is O 0 4.5892019073789925e-08
responsible O 0 2.005604393673366e-08
for O 0 8.369980819544764e-10
some O 0 4.875048142949368e-10
of O 0 5.096674748905627e-10
the O 0 5.13154896353285e-09
population O 0 9.741666140428151e-09
of O 0 1.9707768750265586e-09
Japanese O 0 9.73222313405131e-07
patients O 0 1.5427745836404938e-07
with O 0 2.2702689506104434e-08
XLDCM B-Disease 0 0.00018531140813138336
. O 0 3.27036332237185e-07
. O 0 1.4162901607051026e-06

Severe O 0 0.023028388619422913
early O 0 6.655378820141777e-05
- O 1 0.8811459541320801
onset O 1 0.989648699760437
obesity B-Disease 1 1.0
, O 0 1.36981707328232e-05
adrenal B-Disease 1 0.9999977350234985
insufficiency I-Disease 1 1.0
and O 0 1.723696186672896e-05
red O 0 4.654793883673847e-05
hair O 1 0.9999730587005615
pigmentation O 1 0.9971513152122498
caused O 0 3.1889710953691974e-05
by O 0 4.430488615980721e-07
POMC O 0 0.001227312721312046
mutations O 0 4.218006506562233e-05
in O 0 5.013014288124396e-07
humans O 0 4.58101749245543e-06
. O 0 4.182621069048764e-06

Sequential O 0 5.556332689593546e-05
cleavage O 0 0.00011303544306429103
of O 0 1.3235701601388428e-07
the O 0 5.8086353504904764e-08
precursor O 0 3.9416599406649766e-07
protein O 0 4.76650740210971e-07
pre O 0 4.758426075568423e-05
- O 0 4.703537706518546e-05
pro O 0 4.759525381814456e-06
- O 0 4.588412048178725e-05
opiomelanocortin O 0 4.749531581182964e-05
( O 0 6.392033924385032e-08
POMC O 0 6.289122666203184e-06
) O 0 1.646922953568719e-08
generates O 0 5.2165294306405485e-08
the O 0 4.616531867895901e-08
melanocortin O 0 9.194049198413268e-06
peptides O 0 2.4594407932454487e-06
adrenocorticotrophin O 0 1.8059035937767476e-05
( O 0 1.081963461047053e-07
ACTH O 0 7.207566341094207e-06
) O 0 2.2395523657792182e-08
, O 0 6.180687073253921e-09
melanocyte O 0 3.6603289572667563e-06
- O 0 4.1630701161921024e-06
stimulating O 0 1.5658537222407176e-06
hormones O 0 1.0444764484418556e-06
( O 0 1.4112023549728292e-08
MSH O 0 1.5864991382841254e-06
) O 0 2.476712390730995e-09
alpha O 0 4.379621110217613e-09
, O 0 4.948297327445061e-10
beta O 0 3.3407363542181656e-09
and O 0 5.154776605564848e-10
gamma O 0 9.522446831056186e-09
as O 0 2.920373942671972e-09
well O 0 4.687386923052372e-09
as O 0 3.845325391438337e-09
the O 0 9.570826797755672e-09
opioid O 0 6.318697387541761e-07
- O 0 1.3404423953033984e-06
receptor O 0 1.1411991636123275e-06
ligand O 0 2.0969316665286897e-06
beta O 0 6.146002306195442e-06
- O 0 3.3502346923341975e-05
endorphin O 0 0.0008455764618702233
. O 0 7.042188371997327e-06

While O 0 1.1405942359488108e-06
a O 0 7.441667548846453e-08
few O 0 4.404150999448575e-08
cases O 0 3.300217699120367e-08
of O 0 1.4796016856166716e-08
isolated O 0 0.0007303511956706643
ACTH B-Disease 1 0.9994470477104187
deficiency I-Disease 1 0.8493980765342712
have O 0 1.5114088114387414e-07
been O 0 5.820352271257434e-07
reported O 0 9.3450898930314e-07
( O 0 2.1674258832149462e-08
OMIM O 0 5.07559634570498e-05
201400 O 0 1.3090676702631754e-06
) O 0 9.062963712835881e-09
, O 0 2.6087147997344573e-09
an O 0 2.5822215476978272e-08
inherited O 0 0.3759714663028717
POMC O 0 0.42828577756881714
defect O 0 0.020857147872447968
has O 0 4.7496678234892897e-07
not O 0 6.815351127897884e-08
been O 0 4.0667615053280315e-08
described O 0 1.1098165231260282e-07
so O 0 1.2088860046333139e-07
far O 0 7.566342219433864e-07
. O 0 1.9988503936474444e-06

Recent O 0 4.032539436593652e-06
studies O 0 1.3126417570674676e-06
in O 0 4.086550475790318e-08
animal O 0 6.689039366847283e-08
models O 0 3.24874349644233e-07
elucidated O 0 1.5220010709526832e-06
a O 0 1.4373762624586561e-08
central O 0 1.7003822350147857e-08
role O 0 2.8296073040223746e-08
of O 0 2.7938251712100737e-09
alpha O 0 1.9748500790228718e-07
- O 0 2.6029192667920142e-06
MSH O 0 1.843928657763172e-05
in O 0 8.504842163858939e-09
the O 0 1.6604344565962492e-09
regulation O 0 6.249595951857145e-09
of O 0 7.382989219983926e-10
food O 0 8.500139259126627e-09
intake O 0 2.566616608135064e-08
by O 0 1.0710148323767044e-09
activation O 0 1.4972426853887555e-08
of O 0 2.2416453138163206e-09
the O 0 4.71524117529043e-08
brain O 0 2.1879750420339406e-05
melanocortin O 0 2.674471033969894e-05
- O 0 9.082735232368577e-06
4 O 0 1.849423370003933e-07
- O 0 1.7047683513737866e-06
receptor O 0 5.898949098082085e-07
( O 0 1.5318718737944437e-08
MC4 O 0 2.343930464121513e-05
- O 0 5.911028438276844e-06
R O 0 2.770919763861457e-06
; O 0 7.192980433501361e-09
refs O 0 1.1268271293829457e-07
3 O 0 9.782984200512601e-09
- O 0 1.1942427136091283e-07
5 O 0 3.870933795724341e-09
) O 0 8.28522639384488e-10
and O 0 1.0317425802597313e-09
the O 0 9.033447323503196e-10
linkage O 0 5.885440828024002e-07
of O 0 5.276839409873446e-09
human O 0 1.1066543237348014e-07
obesity B-Disease 1 0.9999833106994629
to O 0 8.536793494329231e-09
chromosome O 0 1.4158537453567988e-07
2 O 0 6.0664269163623885e-09
in O 0 3.740362686244225e-09
close O 0 2.70656315137785e-08
proximity O 0 7.546123015345074e-08
to O 0 1.9538232365334807e-08
the O 0 1.7532274299014716e-08
POMC O 0 4.0189943320001476e-06
locus O 0 8.614160833531059e-07
, O 0 3.0765974212698666e-09
led O 0 2.694087175569848e-09
to O 0 2.344461513814622e-09
the O 0 2.18904516735563e-09
proposal O 0 5.229938793149813e-08
of O 0 1.3864878134484115e-09
an O 0 4.313975399128367e-09
association O 0 1.0976816788854649e-08
of O 0 8.788364702638773e-09
POMC O 0 3.311463296995498e-05
with O 0 2.1595199939383747e-07
human O 0 3.5832390494761057e-06
obesity B-Disease 1 0.9999889135360718
. O 0 1.4281253243098035e-05

The O 0 1.214224539580755e-06
dual O 0 7.629513675055932e-06
role O 0 5.980757578072371e-07
of O 0 2.3375594793151322e-08
alpha O 0 4.943557314618374e-07
- O 0 2.394377816017368e-06
MSH O 0 2.06167151191039e-05
in O 0 2.0562737290674704e-08
regulating O 0 1.2036207408527844e-07
food O 0 4.401027098310806e-08
intake O 0 1.3707438029086916e-07
and O 0 9.807664902439228e-09
influencing O 0 6.612818310713919e-07
hair O 0 0.22554296255111694
pigmentation O 0 0.00018416102102492005
predicts O 0 5.18153512985009e-07
that O 0 3.432978346040727e-09
the O 0 9.858077021362988e-09
phenotype O 0 4.2991079681087285e-05
associated O 0 1.6484636944369413e-07
with O 0 1.3806986665088061e-08
a O 0 2.563960492807382e-07
defect O 0 0.0008301166235469282
in O 0 8.70324470270134e-08
POMC O 0 4.7388220991706476e-05
function O 0 2.914055698965967e-07
would O 0 1.214596920817712e-07
include O 0 8.620096281219958e-08
obesity B-Disease 1 0.9999878406524658
, O 0 2.9165901693772867e-08
alteration O 0 1.1079464456997812e-06
in O 0 4.0327756778424373e-07
pigmentation O 0 0.28183284401893616
and O 0 0.004408432636409998
ACTH B-Disease 1 0.9986910223960876
deficiency I-Disease 1 0.7889389395713806
. O 0 3.665190888568759e-06

The O 0 6.204323312886117e-07
observation O 0 1.355366407551628e-06
of O 0 8.718726185463765e-09
these O 0 7.65578107575493e-08
symptoms O 0 7.39665324545058e-07
in O 0 9.437913561782807e-09
two O 0 1.0587415388840782e-08
probands O 0 5.170555141376099e-06
prompted O 0 1.015017687677755e-07
us O 0 1.817391570568816e-08
to O 0 2.7755011622332404e-09
search O 0 2.5367144829147037e-08
for O 0 9.542064027812103e-09
mutations O 0 3.9218954839270737e-07
within O 0 2.3930434522867472e-08
their O 0 1.9176970056378195e-07
POMC O 0 0.00028057509916834533
genes O 0 1.6019970644265413e-05
. O 0 5.442578640213469e-06

Patient O 0 7.883036596467718e-05
1 O 0 8.938110340750427e-07
was O 0 1.5424068067204644e-07
found O 0 1.7965302134825833e-08
to O 0 3.705073359228095e-09
be O 0 5.08475395122332e-09
a O 0 3.4675535776074184e-09
compound O 0 5.937192071314712e-08
heterozygote O 0 9.932952025337727e-07
for O 0 6.097900406842882e-09
two O 0 1.0180691845107503e-08
mutations O 0 3.813147770870273e-07
in O 0 1.2252486136787866e-08
exon O 0 6.170960205054143e-07
3 O 0 3.150525884620947e-08
( O 0 3.1535962730089295e-09
G7013T O 0 2.014853208720524e-07
, O 0 1.0375191372702375e-08
C7133delta O 0 4.5596374320666655e-07
) O 0 3.385645541698068e-09
which O 0 4.099538930546487e-09
interfere O 0 3.288461769557216e-08
with O 0 1.7194078383298006e-09
appropriate O 0 1.8802138512796773e-08
synthesis O 0 1.2726950160413253e-07
of O 0 2.0414432810866856e-08
ACTH O 0 1.0679109436750878e-05
and O 0 8.230421855159875e-08
alpha O 0 9.915838745655492e-07
- O 0 2.2036805603420362e-05
MSH O 0 0.00038921277155168355
. O 0 2.2209560484043323e-06

Patient O 0 8.5464671428781e-05
2 O 0 6.366349225572776e-07
was O 0 9.611314055746334e-08
homozygous O 0 6.205211207088723e-07
for O 0 8.677979224103183e-09
a O 0 2.9768731479862254e-08
mutation O 0 1.5193877516139764e-06
in O 0 6.090126447588773e-08
exon O 0 4.801395334652625e-06
2 O 0 1.9645035820303747e-07
( O 0 1.99312282234132e-08
C3804A O 0 1.4251185120883747e-06
) O 0 5.517734891213877e-08
which O 0 2.2484042005999072e-07
abolishes O 0 2.43113208853174e-05
POMC O 0 0.00027325493283569813
translation O 0 1.802758197300136e-05
. O 0 6.671305527561344e-06

These O 0 4.810396490029234e-07
findings O 0 4.912773192700115e-07
represent O 0 2.075304550430701e-08
the O 0 3.555734151561296e-09
first O 0 5.8287312754146114e-09
examples O 0 3.350002941715502e-08
of O 0 3.805081139063304e-09
a O 0 5.034045443608193e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
within O 0 3.7862669444166386e-08
the O 0 2.7602032659501674e-08
POMC O 0 3.945006028516218e-06
gene O 0 5.148394777165777e-08
and O 0 8.478085788965473e-09
define O 0 1.3770750229014084e-07
a O 0 2.4800558051651933e-08
new O 0 5.504070372808201e-07
monogenic B-Disease 1 0.9838079810142517
endocrine I-Disease 1 0.9688720107078552
disorder I-Disease 0 0.00016757218691054732
resulting O 0 1.9823599473056674e-07
in O 0 7.393099821229043e-08
early O 0 8.109852933557704e-05
- O 1 0.9910781979560852
onset O 1 0.9966887831687927
obesity B-Disease 1 1.0
, O 0 1.1199026630492881e-05
adrenal B-Disease 1 0.9999933242797852
insufficiency I-Disease 1 0.9999998807907104
and O 0 5.273072474665241e-06
red O 0 1.3721023606194649e-05
hair O 1 0.9943400025367737
pigmentation O 0 0.06637901067733765
. O 0 1.7679037682682974e-06
. O 0 4.4319185690255836e-06

A O 0 1.4795991774008144e-05
European O 0 9.251729352399707e-06
multicenter O 0 0.00028476491570472717
study O 0 2.345380607948755e-06
of O 0 6.743186986568617e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 2.5849030294011754e-07
classification O 0 3.791644473949418e-07
of O 0 3.479153853902517e-09
105 O 0 4.5947459170747607e-08
mutations O 0 2.8126364668423776e-06
and O 0 2.2868839266720897e-08
a O 0 4.437099576648507e-09
general O 0 2.631859619128818e-09
system O 0 2.072215465886984e-08
for O 0 6.277850683744646e-09
genotype O 0 3.1034782296046615e-05
- O 0 1.1716410881490447e-05
based O 0 2.3204134436127788e-07
prediction O 0 9.939546998793958e-07
of O 0 6.306055411187117e-08
metabolic O 0 0.003971057012677193
phenotype O 0 0.0019261689158156514
. O 0 6.240335551410681e-06

Phenylketonuria B-Disease 0 0.026599645614624023
( O 0 4.0532559069106355e-06
PKU B-Disease 0 4.758979775942862e-05
) O 0 2.3636128787529742e-07
and O 0 1.650776226824746e-07
mild B-Disease 0 0.0020629565697163343
hyperphenylalaninemia I-Disease 1 1.0
( O 0 1.1533093129401095e-05
MHP B-Disease 1 1.0
) O 0 4.3792104520434805e-07
are O 0 1.0202681011151071e-07
allelic B-Disease 0 0.09100648760795593
disorders I-Disease 1 0.9971926808357239
caused O 0 1.6514565004399628e-06
by O 0 2.9047098948353778e-08
mutations O 0 3.147170900774654e-06
in O 0 2.8839691523785405e-08
the O 0 3.758672662002027e-08
gene O 0 1.2865619964941288e-06
encoding O 0 1.1206462659174576e-05
phenylalanine O 0 0.005896627902984619
hydroxylase O 0 0.14096295833587646
( O 0 1.6382623471145052e-06
PAH O 0 0.0008001739042811096
) O 0 4.647480125186121e-07
. O 0 2.0926624983985675e-06

Previous O 0 6.0942743402847555e-06
studies O 0 8.68475353854592e-07
have O 0 2.992602432527747e-08
suggested O 0 4.212437332284935e-08
that O 0 1.9511781079728507e-09
the O 0 9.57053458705559e-09
highly O 0 3.086653350692359e-07
variable O 0 2.343829874007497e-05
metabolic O 0 0.09115254878997803
phenotypes O 0 0.0002266540250275284
of O 0 1.373963755213481e-06
PAH B-Disease 1 0.9998257756233215
deficiency I-Disease 1 0.995912492275238
correlate O 0 0.00011271586845396087
with O 0 5.675362444890197e-06
PAH O 1 0.8366594910621643
genotypes O 0 0.004390879068523645
. O 0 1.5488836652366444e-05

We O 0 6.081657829781761e-06
identified O 0 1.3052891745246598e-06
both O 0 8.961190900436122e-08
causative O 0 3.8992234294710215e-06
mutations O 0 3.927718807972269e-06
in O 0 7.45644399557932e-08
686 O 0 2.2863989670440787e-06
patients O 0 1.0935659702226985e-06
from O 0 1.882374078832072e-08
seven O 0 5.122682011915458e-08
European O 0 6.529914458042185e-07
centers O 0 9.588496823198511e-07
. O 0 1.8267248833581107e-06

On O 0 5.632048782899801e-07
the O 0 1.3101121076886102e-08
basis O 0 9.33151778070851e-09
of O 0 1.13259657208431e-09
the O 0 7.3311285930799386e-09
phenotypic O 0 3.840431475055084e-07
characteristics O 0 1.1523506060484578e-07
of O 0 4.374962170317076e-09
297 O 0 1.70649116171262e-07
functionally O 0 2.423452542643645e-06
hemizygous O 0 2.6790374249685556e-05
patients O 0 4.453474389265466e-07
, O 0 1.3044214597357495e-09
105 O 0 1.6919569079121288e-09
of O 0 2.42827924434863e-10
the O 0 3.2973721530993316e-09
mutations O 0 3.307957285869634e-07
were O 0 1.7708684296735555e-08
assigned O 0 1.715949160541186e-08
to O 0 3.6660310342995217e-09
one O 0 2.698314460758411e-09
of O 0 1.3964244205411092e-09
four O 0 1.7847437305817948e-08
arbitrary O 0 1.2741951422867714e-06
phenotype O 0 0.005406658630818129
categories O 0 2.3057113139657304e-05
. O 0 3.8044336179154925e-06

We O 0 2.6660054572857916e-06
proposed O 0 2.399509071437933e-07
and O 0 5.559707005886594e-08
tested O 0 2.356311910034492e-07
a O 0 3.95967081345816e-09
simple O 0 2.7955110226685065e-08
model O 0 6.853702672060535e-08
for O 0 5.393379964857559e-09
correlation O 0 2.693752776394831e-07
between O 0 5.0187736633233726e-08
genotype O 0 1.4518603165925015e-05
and O 0 1.2597499221556063e-07
phenotypic O 0 1.0459643817739561e-05
outcome O 0 8.63230525283143e-06
. O 0 2.739925548667088e-06

The O 0 6.347930252559308e-07
observed O 0 1.432659587408125e-06
phenotype O 0 5.2936347856302746e-06
matched O 0 1.3754778365182574e-06
the O 0 4.436517997419287e-08
predicted O 0 1.2259999948582845e-06
phenotype O 0 2.17611182051769e-06
in O 0 2.309793067922783e-08
79 O 0 6.053426204744028e-08
% O 0 9.686822011190088e-09
of O 0 4.2856462822982166e-10
the O 0 7.847560823392996e-09
cases O 0 1.6343363995474647e-07
, O 0 3.340302923149352e-09
and O 0 4.408973186542653e-09
in O 0 2.6432138700016594e-09
only O 0 2.879092964036545e-09
5 O 0 1.2920627900925297e-09
of O 0 3.111733926086657e-10
184 O 0 1.2777122471163693e-08
patients O 0 1.0684021134466093e-07
was O 0 5.461654239979907e-08
the O 0 2.803796972372652e-09
observed O 0 3.9313317046207885e-08
phenotype O 0 1.1679060918368123e-07
more O 0 7.06303349140569e-10
than O 0 1.1500922436624705e-09
one O 0 4.491954808116816e-09
category O 0 9.464181260909754e-08
away O 0 3.061887809963082e-08
from O 0 3.970242801187851e-09
that O 0 2.5746528464765106e-08
expected O 0 4.0737415929470444e-07
. O 0 1.3853447171641164e-06

Among O 0 1.772329937921313e-06
the O 0 2.073136506908213e-08
seven O 0 1.2096375456849273e-08
contributing O 0 2.0208450024483682e-08
centers O 0 1.2769008961299733e-08
, O 0 1.0605336608904281e-09
the O 0 1.0967624586299962e-09
proportion O 0 1.0072820799678084e-07
of O 0 9.971137249209505e-10
patients O 0 4.8432173826995495e-08
for O 0 8.139866558565245e-10
whom O 0 7.969788384798449e-09
the O 0 1.2059510057227385e-09
observed O 0 5.274698722246285e-08
phenotype O 0 3.775861046051432e-07
did O 0 6.350086323436699e-08
not O 0 5.3733879568085285e-09
match O 0 3.3111511754668754e-08
the O 0 7.4279657980014235e-09
predicted O 0 8.531928301636071e-07
phenotype O 0 1.812946379686764e-06
was O 0 1.3176406810089247e-07
4 O 0 1.5576048895127315e-08
% O 0 1.8191707695791592e-08
- O 0 7.625800935784355e-05
23 O 0 6.790930484612545e-08
% O 0 1.5417501941783485e-08
( O 0 4.64160399005209e-09
P O 0 0.00013560130901169032
< O 0 2.500835876162455e-07
. O 0 1.769362434345112e-08
0001 O 0 4.0095207509693864e-07
) O 0 1.1282950129754e-09
, O 0 3.510227108982633e-10
suggesting O 0 6.391385642956493e-09
that O 0 1.805959937151158e-09
differences O 0 2.40092532521885e-08
in O 0 1.1374979846934252e-09
methods O 0 9.524989685871788e-09
used O 0 7.839990878721892e-09
for O 0 1.8495700526699466e-09
mutation O 0 1.1017933587709194e-07
detection O 0 2.760501445209229e-07
or O 0 4.0114409216585045e-07
phenotype O 0 0.0002734001027420163
classification O 0 6.636011676164344e-05
may O 0 5.638234483740234e-07
account O 0 1.1951025058465348e-08
for O 0 1.8138514024101937e-09
a O 0 5.126061353166733e-09
considerable O 0 1.2407150506987819e-07
proportion O 0 1.0625193453961401e-06
of O 0 4.3747977684915895e-08
genotype O 1 0.6277927160263062
- O 1 0.8609926104545593
phenotype O 0 0.008638552390038967
inconsistencies O 0 6.74658949719742e-05
. O 0 5.617990609607659e-06

Our O 0 3.7566696846624836e-06
data O 0 8.152783834702859e-07
indicate O 0 2.221188140083541e-07
that O 0 1.8658807832139246e-08
the O 0 2.409816701742784e-08
PAH O 0 6.74955008435063e-05
- O 0 1.605793477210682e-05
mutation O 0 2.720465090533253e-06
genotype O 0 6.798421509301988e-06
is O 0 4.174292023151338e-09
the O 0 1.703842067435346e-09
main O 0 3.325943254139929e-08
determinant O 0 3.4841968954424374e-07
of O 0 7.520270628447179e-09
metabolic O 0 0.0019045050721615553
phenotype O 0 0.0002447251172270626
in O 0 1.674404046525524e-07
most O 0 1.954798108272371e-06
patients O 0 6.555040454259142e-05
with O 0 7.013870799710276e-06
PAH B-Disease 1 0.9999109506607056
deficiency I-Disease 1 0.9979977011680603
. O 0 8.224697921832558e-06

In O 0 4.828114015253959e-07
the O 0 2.428781797902957e-08
present O 0 4.347912252455899e-08
study O 0 3.3175485469882915e-08
, O 0 3.973659623568437e-09
the O 0 5.971783956226773e-09
classification O 0 1.8522440825563535e-07
of O 0 8.80045902817983e-09
105 O 0 3.972540696395299e-07
PAH O 0 0.0003154465230181813
mutations O 0 8.427877219219226e-06
may O 0 5.125350455159605e-08
allow O 0 9.784328014461607e-09
the O 0 2.832807988184527e-09
prediction O 0 5.520461598962356e-08
of O 0 7.237855315089803e-10
the O 0 4.172166612192996e-09
biochemical O 0 8.461016477667727e-06
phenotype O 0 3.514720674502314e-06
in O 0 1.503573088257326e-08
> O 0 6.735371727017991e-08
10 O 0 3.83965970129907e-09
, O 0 1.121168491380331e-09
000 O 0 5.837064609437448e-09
genotypes O 0 4.475947150694992e-07
, O 0 1.8780841326559994e-09
which O 0 3.0988414057020464e-09
may O 0 2.5364871092392605e-08
be O 0 9.721207172574964e-10
useful O 0 8.749378110906036e-09
for O 0 1.8962214021200907e-09
the O 0 6.2872937967028975e-09
management O 0 4.1066311240456344e-08
of O 0 7.061043305611747e-09
hyperphenylalaninemia B-Disease 1 0.9999996423721313
in O 0 1.1500112123030704e-05
newborns O 0 0.0004123792168684304
. O 0 1.4030508737050695e-06

Somatic O 0 0.00034016394056379795
instability O 0 5.389881334849633e-05
of O 0 9.474928219788126e-08
the O 0 9.534863210092226e-08
CTG O 0 9.121195944317151e-06
repeat O 0 2.254545961477561e-06
in O 0 3.83176761431514e-08
mice O 0 2.77646677204757e-07
transgenic O 0 1.6346091058494494e-07
for O 0 1.0275639006351867e-08
the O 0 9.864495353895109e-08
myotonic B-Disease 1 0.9999969005584717
dystrophy I-Disease 1 0.9999891519546509
region O 0 2.129384711224702e-06
is O 0 3.753815036589003e-08
age O 0 5.672715630566927e-08
dependent O 0 1.3375534990700544e-07
but O 0 3.279848570514332e-08
not O 0 1.1596837268257332e-08
correlated O 0 8.143865670717787e-08
to O 0 4.257117769412844e-09
the O 0 6.346572600790523e-09
relative O 0 1.7560829235208075e-07
intertissue O 0 1.6221977148234146e-06
transcription O 0 8.680489145262982e-07
levels O 0 1.320578462582489e-06
and O 0 4.1326248378936725e-07
proliferative O 0 0.0009053331450559199
capacities O 0 2.7875414161826484e-05
. O 0 6.9031561906740535e-06

A O 0 1.0213686437055003e-05
( O 0 4.880444635091408e-07
CTG O 0 9.678211426944472e-06
) O 0 4.124427022134114e-08
nexpansion O 0 7.70580186326697e-07
in O 0 2.5584396823319366e-08
the O 0 2.2435242996721172e-08
3 O 0 3.680774796066544e-07
- O 0 0.0002680508769117296
untranslated O 0 0.0028297321405261755
region O 0 9.722325557959266e-07
( O 0 1.9155102393142442e-08
UTR O 0 1.2322253724050825e-06
) O 0 5.632669441979488e-09
of O 0 1.747864186718573e-09
the O 0 1.0750024159733584e-07
DM O 1 0.9999972581863403
protein O 0 3.228765592666605e-07
kinase O 0 8.022086035452958e-07
gene O 0 3.5287385458104836e-07
( O 0 2.2050542725082778e-08
DMPK O 0 2.070364644168876e-06
) O 0 9.749064666664253e-09
is O 0 5.1845270299111235e-09
responsible O 0 8.124192873992797e-08
for O 0 1.587611677678069e-07
causing O 0 0.002972411224618554
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.510292536811903e-05
DM B-Disease 1 1.0
) O 0 5.319154297467321e-06
. O 0 3.97822304876172e-06

Major O 0 2.058414429484401e-05
instability O 0 2.114518611051608e-05
, O 0 8.976997634135842e-08
with O 0 9.316543092552365e-09
very O 0 1.652870729174083e-08
large O 0 1.7988377010169643e-08
expansions O 0 3.655936211544031e-07
between O 0 1.574385066760442e-08
generations O 0 8.037266496785378e-08
and O 0 2.2764520934970278e-08
high O 0 1.0399228500546087e-07
levels O 0 2.8157494114111614e-08
of O 0 9.6634911184168e-10
somatic O 0 3.366484406797099e-07
mosaicism O 0 5.634903573081829e-06
, O 0 1.1043450598435811e-08
is O 0 6.6388183839194426e-09
observed O 0 9.959153146610333e-08
in O 0 2.2211605710253934e-07
patients O 0 3.7012548546044854e-06
. O 0 2.0941297407262027e-06

There O 0 1.2188444316052482e-06
is O 0 3.312186791504246e-08
a O 0 2.3871990606494364e-08
good O 0 5.41174536294875e-08
correlation O 0 9.280526569455105e-08
between O 0 2.417292854772768e-08
repeat O 0 1.5332918337662704e-05
size O 0 1.0009500783780823e-06
( O 0 4.14197298681529e-09
at O 0 7.669195056791978e-09
least O 0 4.400134923088217e-09
in O 0 7.625436282410192e-09
leucocytes O 0 4.132165940973209e-06
) O 0 1.3459701797557955e-08
, O 0 1.1409817091134755e-08
clinical O 0 6.976267172831285e-07
severity O 0 1.3073998161416966e-05
and O 0 3.525344709487399e-07
age O 0 1.947186802908618e-07
of O 0 4.625283978043626e-08
onset O 0 7.461291534127668e-05
. O 0 6.381256298482185e-06

The O 0 7.432839993271045e-06
trinucleotide O 0 0.0006373406504280865
repeat O 0 9.426625911146402e-05
instability O 0 2.242708660560311e-06
mechanisms O 0 2.7797523216577247e-07
involved O 0 1.0576701470199623e-07
in O 0 2.0550784540773748e-07
DM B-Disease 1 1.0
and O 0 7.453244421640193e-08
other O 0 4.270587794508174e-08
human O 0 1.7231700439879205e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 5.502789690581267e-07
unknown O 0 6.665022283414146e-06
. O 0 4.337303835200146e-06

We O 0 4.6333821046573576e-06
studied O 0 1.2452936744011822e-06
somatic O 0 5.2144578148727305e-06
instability O 0 2.220056103396928e-06
by O 0 3.920533586665442e-08
measuring O 0 1.312592985414085e-06
the O 0 7.866881901463785e-08
CTG O 0 7.256318895088043e-06
repeat O 0 1.7047505025402643e-06
length O 0 2.0273004963655694e-07
at O 0 1.4694965244643754e-08
several O 0 3.786149616047396e-09
ages O 0 4.648774876159223e-08
in O 0 3.017608607436273e-09
various O 0 3.77014419683519e-09
tissues O 0 1.415015447037149e-07
of O 0 2.213050409594075e-09
transgenic O 0 2.9675200607925944e-07
mice O 0 1.2427382216628757e-06
carrying O 0 4.5230969192289194e-08
a O 0 2.5418483318162544e-08
( O 0 2.271910659601417e-08
CTG O 0 1.7533496929900139e-06
) O 0 1.995089249362536e-08
55expansion O 0 5.247420062914898e-07
surrounded O 0 4.8899998716933624e-08
by O 0 5.1052388982952834e-09
45 O 0 1.0365559077740727e-08
kb O 0 5.88049203997798e-07
of O 0 2.8773250448921317e-09
the O 0 3.232166534417047e-08
human O 0 4.784980092154001e-07
DM B-Disease 1 1.0
region O 0 5.016926820644585e-07
, O 0 6.420269205165141e-09
using O 0 1.04083966334656e-07
small O 0 5.1052904836979e-07
- O 0 5.467069786391221e-05
pool O 0 4.7279841055569705e-06
PCR O 0 4.120182347833179e-05
. O 0 2.1904056666244287e-06

These O 0 8.501211254952068e-07
mice O 0 5.0280382311029825e-06
have O 0 5.6372186918451916e-08
been O 0 1.3806090493062584e-08
shown O 0 7.823976133636279e-09
to O 0 3.583143559637847e-09
reproduce O 0 5.19207560500945e-07
the O 0 6.47545173038111e-09
intergenerational O 0 2.3254244752024533e-07
and O 0 1.0934481764479642e-08
somatic O 0 3.002044479671895e-07
instability O 0 2.375195862214241e-07
of O 0 1.624081757967133e-09
the O 0 1.4453819474624652e-08
55 O 0 4.3644465819170364e-08
CTG O 0 1.2414683396855253e-06
repeat O 0 4.613917212736851e-07
suggesting O 0 9.053136551528951e-08
that O 0 1.091630341676364e-09
surrounding O 0 4.63496929725693e-09
sequences O 0 3.859044639398235e-08
and O 0 1.5394171271054802e-08
the O 0 5.6982178975317765e-09
chromatin O 0 1.8486581154775195e-07
environment O 0 7.708707272513493e-08
are O 0 6.262637963772022e-09
involved O 0 5.972139405230337e-08
in O 0 1.825476374506252e-07
instability O 0 9.672232408775017e-06
mechanisms O 0 8.123772204271518e-06
. O 0 4.501994226302486e-06

As O 0 4.339105998951709e-07
observed O 0 2.707508599542052e-07
in O 0 8.751147362318079e-09
some O 0 8.329020806385756e-10
of O 0 4.732499392368084e-10
the O 0 4.437192835382575e-09
tissues O 0 4.7200913400047284e-07
of O 0 2.6582867462821014e-08
DM B-Disease 1 1.0
patients O 0 0.014613781124353409
, O 0 4.540433806710098e-09
there O 0 8.126157524657174e-09
is O 0 4.072798542864575e-09
a O 0 1.0871469946494017e-08
tendency O 0 3.0990682375886536e-07
for O 0 7.528522694144613e-09
repeat O 0 2.0775657958438387e-06
length O 0 1.3046465596744383e-07
and O 0 7.650377220613791e-09
somatic O 0 8.919958105479964e-08
mosaicism O 0 1.1546667337825056e-06
to O 0 9.851686577633245e-09
increase O 0 8.260834682971563e-09
with O 0 2.2365334029217365e-09
the O 0 1.8113597732849485e-08
age O 0 3.664522907342871e-08
of O 0 3.0177700338640534e-09
the O 0 5.8211572451227767e-08
mouse O 0 1.4893046682118438e-05
. O 0 2.7704572858056054e-06

Furthermore O 0 8.698980309418403e-06
, O 0 1.0779220360745967e-07
we O 0 2.7305341987471365e-08
observed O 0 2.0469876460538217e-08
no O 0 7.611370200777401e-09
correlation O 0 3.169941109604224e-08
between O 0 4.626057759082869e-09
the O 0 7.381866229394518e-09
somatic O 0 7.649248345842352e-07
mutation O 0 3.5057589684583945e-06
rate O 0 1.4602617284253938e-06
and O 0 1.398203153257782e-07
tissue O 0 0.00036536945845000446
proliferation O 0 6.588348333025351e-05
capacity O 0 2.3047423383104615e-06
. O 0 1.2616415006050374e-06

The O 0 4.6531613406841643e-07
somatic O 0 3.3072774385800585e-06
mutation O 0 4.328237992012873e-06
rates O 0 4.5288592787073867e-07
in O 0 2.9730073958234016e-09
different O 0 5.505054634369344e-09
tissues O 0 4.3977672703476856e-07
were O 0 1.7508355654172192e-07
also O 0 1.0053930132869482e-08
not O 0 8.169734222462921e-09
correlated O 0 6.383736916859561e-08
to O 0 1.2638456503566431e-08
the O 0 9.939451039997493e-09
relative O 0 8.513009674970817e-08
inter O 0 3.282080172084534e-07
- O 0 4.631954652722925e-06
tissue O 0 2.2991045625531115e-05
difference O 0 1.444856110310866e-07
in O 0 3.0868134714978623e-09
transcriptional O 0 5.844398032195386e-08
levels O 0 4.9666365242728716e-08
of O 0 2.649127583964628e-10
the O 0 2.212007910173952e-09
three O 0 4.315687363032339e-09
genes O 0 4.693768218544392e-08
( O 0 3.2348845824259342e-09
DMAHP O 0 1.3304511412570719e-06
, O 0 3.786481794776364e-09
DMPK O 0 3.639985607151175e-06
and O 0 6.380364681035644e-08
59 O 0 5.24216297037583e-08
) O 0 3.592265374052772e-09
surrounding O 0 2.4584522861914593e-08
the O 0 3.670552572998531e-08
repeat O 0 3.899795774486847e-05
. O 0 2.201974211857305e-07
. O 0 1.2227131946929148e-06

A O 0 5.252499249763787e-06
novel O 0 3.880707936332328e-06
missense O 0 5.020625758334063e-05
mutation O 0 1.3875522199668922e-05
in O 0 1.8794757750129065e-07
patients O 0 6.070168296901102e-07
from O 0 8.249844363206194e-09
a O 0 4.522596697142944e-08
retinoblastoma B-Disease 0 4.42162090621423e-05
pedigree O 0 0.011070061475038528
showing O 0 2.1854895749129355e-05
only O 0 2.1853924181414186e-07
mild O 0 1.325653443018382e-06
expression O 0 2.491887016731198e-07
of O 0 1.9953480645540367e-08
the O 0 3.4614438959579275e-07
tumor B-Disease 0 0.0006187782855704427
phenotype O 0 0.00030418814276345074
. O 0 5.222495474299649e-06

We O 0 2.490086444595363e-06
have O 0 9.294041802831998e-08
used O 0 1.130521312120436e-07
single O 0 1.6773064714925567e-07
strand O 0 2.83359599961841e-06
conformation O 0 5.828462121826306e-07
polymorphism O 0 1.3473542139763595e-06
analysis O 0 1.3111700525314518e-07
to O 0 2.2402360855267034e-08
study O 0 2.1964241980754196e-08
the O 0 5.462235108666391e-09
27 O 0 6.814075081962301e-09
exons O 0 6.082348846803143e-08
of O 0 1.4157442995710312e-09
the O 0 1.927660342460058e-08
RB1 O 0 7.278921202669153e-06
gene O 0 6.278165187723062e-08
in O 0 4.379387075204022e-09
individuals O 0 3.0374034398761296e-09
from O 0 3.5990823654685755e-09
a O 0 3.060457132164629e-08
family O 0 5.328108727553627e-07
showing O 0 1.1773117876145989e-05
mild O 0 4.037376584165031e-06
expression O 0 5.565679543906299e-07
of O 0 5.159266791565642e-08
the O 0 8.525096291123191e-07
retinoblastoma B-Disease 0 0.0008534704684279859
phenotype O 0 0.003571589943021536
. O 0 1.6859657989698462e-05

In O 0 7.07356207385601e-07
this O 0 5.718363027540363e-08
family O 0 1.0275839201767667e-07
affected O 0 5.444378459174004e-08
individuals O 0 1.0007934925226891e-08
developed O 0 3.4775410995280254e-07
unilateral B-Disease 1 0.7850939631462097
tumors I-Disease 1 1.0
and O 0 5.311180757416878e-06
, O 0 5.609062103673068e-09
as O 0 5.388876012091259e-09
a O 0 1.0976670239415398e-08
result O 0 9.223948893577472e-08
of O 0 1.0327348975991413e-09
linkage O 0 7.088235634000739e-07
analysis O 0 1.0916439663333222e-07
, O 0 8.778195947911627e-09
unaffected O 0 4.7639579747738026e-07
mutation O 0 7.685186460548721e-07
carriers O 0 5.630647024190694e-07
were O 0 1.5166530431542924e-07
also O 0 4.4581909719454416e-08
identified O 0 1.057230463175074e-07
within O 0 3.61835681417233e-08
the O 0 1.9386558847145352e-07
pedigree O 0 0.0004219797847326845
. O 0 5.636510650219861e-06

A O 0 3.5198927434976213e-06
single O 0 5.822773232466716e-07
band O 0 2.439960837818944e-07
shift O 0 2.564748058375699e-07
using O 0 1.408855041518109e-07
SSCP O 0 2.1496834960998967e-05
was O 0 1.448023283501243e-07
identified O 0 4.956983445936203e-08
in O 0 9.041260184972089e-09
exon O 0 1.047159344125248e-06
21 O 0 3.340617027447479e-08
which O 0 8.54254356141837e-09
resulted O 0 6.31744399015588e-08
in O 0 1.5922751117614098e-08
a O 0 3.04121989813666e-08
missense O 0 5.025439804740017e-06
mutation O 0 1.270948700948793e-06
converting O 0 3.6932223679286835e-07
a O 0 1.6073987296749692e-07
cys O 0 0.0009551912662573159
- O 0 3.5620359994936734e-05
- O 0 3.7607776448567165e-06
> O 0 5.465603294396715e-07
arg O 0 5.41796737252298e-07
at O 0 9.877274109726386e-09
nucleotide O 0 1.8446075955580454e-07
position O 0 9.973473424906842e-07
28 O 0 3.685383020979316e-08
in O 0 1.1190753212986237e-08
the O 0 8.978727095154682e-08
exon O 0 2.9925147828180343e-05
. O 0 4.334508503234247e-06

The O 0 4.826503300137119e-06
mutation O 0 3.322756310808472e-05
destroyed O 0 1.2622970643860754e-05
an O 0 1.5490402915929735e-07
NdeI O 0 1.3831197065883316e-05
restriction O 0 1.5583914318995085e-06
enzyme O 0 6.608931016671704e-06
site O 0 5.786282144981669e-06
. O 0 1.8299365365237463e-06

Analysis O 0 1.3326352927833796e-06
of O 0 1.5495981386948188e-08
all O 0 6.864663060213161e-09
family O 0 1.6302463379247456e-08
members O 0 2.758522743562253e-09
demonstrated O 0 2.5262561820227347e-08
that O 0 2.8105004989953386e-09
the O 0 1.1379021280788493e-08
missense O 0 7.993821782292798e-06
mutation O 0 6.092082912800834e-06
co O 0 1.1598148375924211e-05
- O 0 4.206462108413689e-06
segregated O 0 3.3621560646679427e-07
with O 0 1.2615144484584562e-08
patients O 0 3.3643920005488326e-07
with O 0 1.621851453137424e-07
tumors B-Disease 1 1.0
or O 0 0.0014535492518916726
who O 0 4.276815559478564e-07
, O 0 9.59022861124481e-10
as O 0 2.1074662015507784e-09
a O 0 4.391264685210672e-09
result O 0 9.819760293794388e-08
of O 0 1.1482664818984745e-09
linkage O 0 5.554359177040169e-07
analysis O 0 1.0845104725376586e-06
had O 0 7.639817340532318e-06
been O 0 1.4028540817889734e-07
predicted O 0 8.544991914050115e-08
to O 0 6.2181704230113155e-09
carry O 0 6.139870833976602e-08
the O 0 5.709797079589407e-08
predisposing O 0 8.407230779994279e-06
mutation O 0 9.615513590688352e-06
. O 0 1.6317509334839997e-06

These O 0 3.8468829188786913e-07
observations O 0 3.121832037322747e-07
point O 0 1.5376423334600986e-07
to O 0 9.269429668279372e-09
another O 0 3.972113749028949e-09
region O 0 1.6932910185119e-08
of O 0 2.287153133551101e-09
the O 0 3.240759482991962e-08
RB1 O 0 1.3508663869288284e-05
gene O 0 9.22644787237914e-08
where O 0 1.8998063566755263e-08
mutations O 0 1.3608057258807094e-07
only O 0 1.9545081109129114e-09
modify O 0 1.308037695935127e-07
the O 0 2.329586745730694e-09
function O 0 6.449788259033085e-09
of O 0 6.643920413829107e-10
the O 0 2.5100879152972766e-09
gene O 0 2.4856200653289307e-08
and O 0 1.4713868345950232e-08
raise O 0 8.597269562926613e-09
important O 0 3.94421073579565e-09
questions O 0 1.2038166019578966e-08
for O 0 1.8650332389569257e-09
genetic O 0 1.1228173946165043e-07
counseling O 0 6.957875342550324e-08
in O 0 1.8506684185126687e-08
families O 0 1.5777459339005873e-08
with O 0 4.749121540470469e-09
these O 0 1.2870734167336195e-07
distinctive O 0 0.00034065626095980406
phenotypes O 0 0.00022205867571756244
. O 0 8.682318934916111e-07
. O 0 2.8277029286982724e-06

Maternal B-Disease 0 0.0009126306395046413
disomy I-Disease 0 0.009288263507187366
and O 0 0.0053681135177612305
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999992847442627
consistent O 0 2.338120339118177e-06
with O 0 5.6848573848355954e-08
gamete O 0 4.17592946178047e-06
complementation O 0 4.136153802392073e-05
in O 0 7.397528634101036e-08
a O 0 2.3726006048718773e-08
case O 0 1.371689251072894e-07
of O 0 1.0210034595559137e-08
familial O 0 3.2633419323246926e-05
translocation O 0 5.0007702157017775e-06
( O 0 4.557868038546076e-08
3 O 0 4.5895959033259714e-08
; O 0 3.064698006483013e-08
15 O 0 1.4845628726334326e-08
) O 0 6.087499393458984e-09
( O 0 2.877863058969865e-09
p25 O 0 1.0295536156945673e-07
; O 0 1.1390030252300676e-08
q11 O 0 5.230721740190347e-07
. O 0 3.030402950798816e-08
2 O 0 5.1390451005772775e-08
) O 0 6.416281195242846e-08
. O 0 7.430193704749399e-07

Maternal B-Disease 0 0.00590615626424551
uniparental I-Disease 0 0.04058127477765083
disomy I-Disease 0 0.00999125000089407
( I-Disease 0 3.886434114974691e-06
UPD I-Disease 1 0.9999971389770508
) I-Disease 0 1.2544917638024344e-07
for I-Disease 0 9.125268540799425e-09
chromosome I-Disease 0 1.1613923334152787e-06
15 I-Disease 0 2.8277513663965692e-08
is O 0 4.038992695853949e-09
responsible O 0 1.3199215942449882e-08
for O 0 1.5545410514405944e-09
an O 0 8.281513808050533e-10
estimated O 0 7.181752970097932e-09
30 O 0 3.4841545204500335e-09
% O 0 1.8425524439535934e-09
of O 0 9.618751350970456e-10
cases O 0 4.300381704069878e-07
of O 0 3.5726848182093818e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.155776383006014e-05
PWS B-Disease 1 0.9999998807907104
) O 0 5.819696980324807e-06
. O 0 9.344108548248187e-06

We O 0 1.1514268408063799e-05
report O 0 1.6976315464489744e-07
on O 0 9.037915305043498e-09
an O 0 2.451679970150167e-09
unusual O 0 2.533900200774042e-08
case O 0 2.344529725917255e-08
of O 0 1.6817512937805645e-09
maternal B-Disease 0 2.9692128578062693e-07
disomy I-Disease 0 5.1699830692086834e-06
15 I-Disease 0 1.7299418786365095e-08
in O 0 5.08873405635768e-08
PWS B-Disease 1 1.0
that O 0 1.8238701215977926e-07
is O 0 5.132880787073191e-09
most O 0 1.1975508584782801e-08
consistent O 0 8.377191562658481e-08
with O 0 5.266071134713002e-09
adjacent O 0 5.07615652622917e-07
- O 0 0.0010410650866106153
1 O 0 3.330520215172328e-08
segregation O 0 6.271833541404703e-08
of O 0 1.7815254826913929e-09
a O 0 2.2865743076749823e-08
paternal O 0 2.3872548808867577e-06
t O 0 8.871049431036226e-06
( O 0 8.879367463521248e-09
3 O 0 8.752816249568696e-09
; O 0 8.103405946258135e-09
15 O 0 4.006047937821222e-09
) O 0 1.972055407861717e-09
( O 0 1.0734627631237004e-09
p25 O 0 9.273235690443471e-08
; O 0 7.67472574381145e-09
q11 O 0 1.4913463530774607e-07
. O 0 4.601496961242901e-09
2 O 0 3.9089136372183475e-09
) O 0 1.6437180505590732e-09
with O 0 2.7070521380068158e-09
simultaneous O 0 6.032691430846171e-07
maternal O 0 3.894979272445198e-06
meiotic O 0 3.225551699870266e-05
nondisjunction O 0 4.1397408494958654e-05
for O 0 1.9714515531177312e-07
chromosome O 0 2.2298474505078048e-05
15 O 0 1.5991727195796557e-06
. O 0 2.7844132546306355e-06

The O 0 1.2767056887241779e-06
patient O 0 2.8882604965474457e-06
( O 0 3.296807804531454e-08
J O 0 6.63488608552143e-05
. O 0 4.7278128079142334e-08
B O 0 4.182102657068754e-06
. O 0 2.940944376916832e-09
) O 0 7.909558563667929e-10
, O 0 4.0120559652301324e-10
a O 0 2.5822299853928143e-09
17 O 0 1.2920487790779589e-08
- O 0 1.658158794271003e-06
year O 0 2.6151084853154316e-07
- O 0 0.00023604191665071994
old O 0 0.0003555241855792701
white O 0 1.4969634776207386e-06
male O 0 1.0581220521999057e-07
with O 0 1.3652716290835087e-08
PWS B-Disease 1 1.0
, O 0 9.906178988217107e-09
was O 0 2.8926681494567674e-08
found O 0 6.934131935310006e-09
to O 0 2.2650818998215527e-09
have O 0 8.256125560990313e-09
47 O 0 6.619031100996153e-09
chromosomes O 0 2.1468457234163907e-08
with O 0 3.8632776977465255e-09
a O 0 2.092734696645948e-08
supernumerary O 0 1.9523873561411165e-05
, O 0 1.6976470007534772e-08
paternal O 0 6.375839234351588e-07
der O 0 0.0004365638014860451
( O 0 6.6268381893053174e-09
15 O 0 4.252378449365324e-09
) O 0 7.16172343651067e-10
consisting O 0 8.066545209572951e-10
of O 0 7.484107222843761e-10
the O 0 1.8185392747227525e-08
short O 0 0.00415369076654315
arm O 0 0.05842205509543419
and O 0 4.881352211327794e-08
the O 0 8.093256731456222e-09
proximal O 0 5.156097813596716e-06
long O 0 0.009545067325234413
arm O 0 0.0004106778069399297
of O 0 4.7899311184096405e-09
chromosome O 0 2.7059440981247462e-06
15 O 0 2.983011526680457e-08
, O 0 1.36324196375881e-08
and O 0 1.275142977874566e-07
distal O 0 0.0004524247196968645
chromosome O 1 0.9597747325897217
arm O 1 0.8904350399971008
3p O 0 0.026269249618053436
. O 0 1.695176433713641e-05

The O 0 2.3123159280658e-06
t O 0 6.373490123223746e-06
( O 0 2.0721284244018534e-08
3 O 0 9.116779331463931e-09
; O 0 8.261654471652946e-09
15 O 0 3.7252829709899515e-09
) O 0 1.17737941618401e-09
was O 0 4.626916094707667e-08
present O 0 3.55344265123847e-09
in O 0 4.63911709047693e-09
the O 0 4.02456601378276e-09
balanced O 0 4.7339849373884135e-08
state O 0 6.26267437908723e-09
in O 0 6.867073132355017e-09
the O 0 3.551398108925241e-08
patients O 0 3.194699900177511e-07
father O 0 4.9101782195748456e-08
and O 0 3.7600635494072776e-08
a O 0 2.00362435975876e-07
sister O 0 0.00017027213471010327
. O 0 4.684744453697931e-06

Fluorescent O 0 5.534892625291832e-05
in O 0 4.3536840621527517e-07
situ O 0 1.928136498463573e-06
hybridization O 0 8.692409778632282e-07
analysis O 0 3.566488828710135e-07
demonstrated O 0 2.402682923730026e-07
that O 0 2.2719801151538377e-08
the O 0 8.826688002727678e-08
PWS B-Disease 1 0.9999997615814209
critical O 0 3.5210778150940314e-06
region O 0 2.9914389187979396e-07
resided O 0 6.734228463756153e-07
on O 0 2.2155433043735684e-08
the O 0 5.954620352355278e-09
derivative O 0 1.7915517673827708e-06
chromosome O 0 1.8808541426551528e-06
3 O 0 1.2715273278729455e-08
and O 0 6.45080922012653e-09
that O 0 1.9506423143411666e-09
there O 0 1.42566562999491e-08
was O 0 1.2031077289975656e-07
no O 0 7.0535728369236494e-09
deletion O 0 1.0552057716495256e-07
of O 0 2.02827732387334e-09
the O 0 2.781231671633577e-07
PWS B-Disease 1 1.0
region O 0 9.670715144238784e-07
on O 0 3.989289965034004e-08
the O 0 1.2271032190369624e-08
normal O 0 1.0687016782640057e-07
pair O 0 1.5294742183868948e-07
of O 0 1.134941296498937e-08
15s O 0 9.314082944911206e-07
present O 0 1.649753329502346e-07
in O 0 5.173313866180251e-07
J O 0 0.01634570024907589
. O 0 4.537364475254435e-06

B O 0 0.025917094200849533
. O 0 8.369699935428798e-05

Methylation O 0 4.2560521251289174e-05
analysis O 0 7.117918357835151e-06
at O 0 2.2538701216490153e-07
exon O 0 8.70440487688029e-07
alpha O 0 7.76269359903381e-08
of O 0 2.5255901814347226e-09
the O 0 2.7338902697238154e-08
small O 0 2.16740161818052e-07
nuclear O 0 1.763518957886845e-05
ribonucleoprotein O 0 2.5527044272166677e-05
- O 0 4.749450454255566e-06
associated O 0 2.2673788180327392e-07
polypeptide O 0 3.0114063065411756e-06
N O 0 4.9034770199796185e-06
( O 0 1.4057676800405261e-08
SNRPN O 0 6.584808147636068e-07
) O 0 4.339550496723632e-09
gene O 0 5.290194948770477e-08
showed O 0 1.4094975142597832e-07
a O 0 5.401533442750406e-09
pattern O 0 1.4508169670079951e-06
characteristic O 0 4.959554644301534e-06
of O 0 5.952054404900764e-09
only O 0 2.4199039216910023e-08
the O 0 3.78946758416987e-08
maternal O 0 2.2122426344139967e-06
chromosome O 0 5.5167500249808654e-05
15 O 0 5.387418582358805e-07
in O 0 4.3944385197391966e-07
J O 0 0.21021400392055511
. O 0 7.459525477315765e-06

B O 0 0.009852893650531769
. O 0 6.733689951943234e-05

Maternal B-Disease 0 0.006070388481020927
disomy I-Disease 0 0.10653188824653625
was O 0 2.1335486962925643e-05
confirmed O 0 3.9841998500378395e-07
by O 0 1.1271792388356516e-08
polymerase O 0 6.911805030540563e-07
chain O 0 4.781773441209225e-06
reaction O 0 1.5473158043732838e-07
analysis O 0 8.775371185265612e-08
of O 0 4.761584015966491e-09
microsatellite O 0 5.616715498035774e-06
repeats O 0 1.6764985275585786e-06
at O 0 2.7348916020741854e-08
the O 0 2.0415056312117486e-08
gamma O 0 1.2800779813915142e-06
- O 0 2.322359250683803e-05
aminobutyric O 0 1.837134186644107e-05
acid O 0 1.9128599433315685e-06
receptor O 0 1.5361049463535892e-06
beta3 O 0 5.429525572253624e-06
subunit O 0 3.830281457339879e-06
( O 0 2.531881477807474e-07
GABRB3 O 0 2.0592626242432743e-05
) O 0 5.84733584219066e-07
locus O 0 4.2062209104187787e-05
. O 0 5.346097623259993e-06

A O 0 4.119751338294009e-06
niece O 0 7.93361778050894e-06
( O 0 1.235916897712741e-07
B O 0 3.6196349810779793e-06
. O 0 3.630461620218739e-08
B O 0 1.9117346710118e-06
. O 0 3.3241975838649296e-09
) O 0 7.784496380836003e-10
with O 0 6.5261357429236e-10
45 O 0 2.120878361822065e-09
chromosomes O 0 3.98792820988092e-08
and O 0 5.3885673700904135e-09
the O 0 3.122853975412454e-09
derivative O 0 7.763462122056808e-07
3 O 0 2.5876696341242678e-08
but O 0 5.5002193022346546e-08
without O 0 1.5492377158921045e-08
the O 0 1.3848023172613466e-08
der O 0 9.21449282031972e-06
( O 0 1.4876262444118993e-09
15 O 0 2.0167663095094213e-09
) O 0 1.2384028247325318e-09
demonstrated O 0 3.402692883014424e-08
a O 0 1.6003497194105876e-08
phenotype O 0 4.791140781890135e-06
consistent O 0 1.1665603949495562e-07
with O 0 6.853621226099449e-09
that O 0 3.742262677519648e-08
reported O 0 2.3171494945017912e-07
for O 0 5.420275339673708e-09
haploinsufficiency O 0 1.1671817219394143e-06
of O 0 1.505696722858829e-08
distal O 0 8.324735972564667e-06
3 O 0 2.408910404483322e-06
p O 0 0.0008576622931286693
. O 0 4.021091626782436e-06

Uniparental B-Disease 1 0.9999936819076538
disomy I-Disease 1 0.9999935626983643
associated O 0 1.9204058844479732e-05
with O 0 1.4359545730258105e-07
unbalanced O 0 1.2872080333181657e-05
segregation O 0 1.0686726454878226e-06
of O 0 8.857377942206313e-09
non O 0 3.2192221510740637e-07
- O 0 7.839468594283971e-07
Robertsonian O 0 5.573795647251245e-07
translocations O 0 1.7855102214525687e-06
has O 0 6.252066242495857e-08
been O 0 1.5739978209694527e-08
reported O 0 4.167047151781844e-08
previously O 0 3.704302002915938e-07
but O 0 3.654228351024358e-07
has O 0 1.3843111545952524e-08
not O 0 1.9212366808574188e-08
, O 0 3.7584968470838476e-10
to O 0 7.745249441803992e-10
our O 0 1.1288654455654523e-09
knowledge O 0 2.6337023673050908e-09
, O 0 1.1398587629329882e-09
been O 0 1.084841549925386e-08
observed O 0 1.3193577785841626e-08
in O 0 3.7724028345564875e-09
a O 0 1.6177386541471606e-08
case O 0 7.871983029872354e-07
of O 0 6.375134375957714e-07
PWS B-Disease 1 0.9999995231628418
. O 0 1.070474445441505e-05

Furthermore O 0 2.819823203026317e-05
, O 0 2.0038154957546794e-07
our O 0 6.578117961453245e-08
findings O 0 5.426919358342275e-08
are O 0 5.106037370694594e-09
best O 0 2.4679851051701007e-08
interpreted O 0 7.866401574574411e-08
as O 0 2.4246254781701282e-08
true O 0 2.103159175703695e-07
gamete O 0 4.369712769403122e-06
complementation O 0 1.763091677275952e-05
resulting O 0 4.107911081518978e-06
in O 0 2.4357257188967196e-06
maternal B-Disease 0 0.03531893342733383
UPD I-Disease 1 0.9999998807907104
15 I-Disease 0 2.245851283078082e-05
and O 0 2.201915776822716e-05
PWS B-Disease 1 0.9999972581863403

Schwartz B-Disease 1 0.989827036857605
- I-Disease 1 0.9998749494552612
Jampel I-Disease 1 0.9996101260185242
syndrome I-Disease 1 0.9999750852584839
type I-Disease 0 1.6694670193828642e-05
2 I-Disease 0 1.3221381323091919e-07
and O 0 1.7400093099695368e-07
Stuve B-Disease 1 0.9985519051551819
- I-Disease 1 0.9999996423721313
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.999997615814209
: O 0 1.4891883282075469e-08
a O 0 7.824991321569996e-09
case O 0 1.9490521196985355e-07
for O 0 2.0745090978380176e-08
" O 0 8.243965510246198e-08
lumping O 0 3.0715179946128046e-06
" O 0 1.4527581697620917e-06
. O 0 2.1895366444368847e-06

Recent O 0 7.344648111029528e-06
studies O 0 1.1759615290429792e-06
demonstrated O 0 8.213924473920997e-08
the O 0 3.564507133901884e-09
existence O 0 1.5841990830267605e-08
of O 0 8.367522230656732e-10
a O 0 4.334363534752583e-09
genetically O 0 3.199577847112778e-08
distinct O 0 4.447879575764091e-08
, O 0 3.4010105842696703e-09
usually O 0 6.179626144131589e-09
lethal O 0 2.837671253530516e-08
form O 0 7.7950055299425e-09
of O 0 1.602911914311278e-09
the O 0 9.569717462909466e-08
Schwartz B-Disease 1 0.9849783778190613
- I-Disease 1 0.9998687505722046
Jampel I-Disease 1 0.9999618530273438
syndrome I-Disease 1 0.9999881982803345
( O 0 2.2589786397020362e-07
SJS B-Disease 1 0.9547315239906311
) O 0 2.371899476827366e-08
of O 0 1.1014336109838041e-08
myotonia B-Disease 1 0.7811272144317627
and O 0 6.379619662766345e-06
skeletal B-Disease 1 0.7978631854057312
dysplasia I-Disease 1 0.9992658495903015
, O 0 2.0970345815385372e-07
which O 0 3.6163908134767553e-07
we O 0 3.249685676109948e-07
called O 0 1.7420610447516083e-06
SJS B-Disease 1 0.9404169917106628
type I-Disease 0 2.2796104531153105e-05
2 I-Disease 0 8.742774184611335e-07
. O 0 1.6530178754692315e-06

This O 0 6.2630024331156164e-06
disorder O 0 0.0005720921908505261
is O 0 3.612116472595517e-08
reminiscent O 0 1.4265964409787557e-07
of O 0 2.62213895041441e-09
another O 0 3.1647516607336e-08
rare O 0 8.932188393373508e-07
condition O 0 8.973238436738029e-06
, O 0 8.348078672781867e-09
the O 0 5.542163350469309e-08
Stuve B-Disease 1 0.99676114320755
- I-Disease 1 0.9999973773956299
Wiedemann I-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9999529123306274
( O 0 4.2695372570733525e-08
SWS B-Disease 0 0.0005725959199480712
) O 0 8.96978846753882e-09
, O 0 1.3383715247172745e-09
which O 0 2.4358974837213054e-09
comprises O 0 3.6135339165355163e-09
campomelia B-Disease 0 5.55004544366966e-06
at O 0 6.987639977751314e-08
birth O 0 2.3468791710001824e-07
with O 0 3.586475116890142e-08
skeletal B-Disease 0 0.3646002411842346
dysplasia I-Disease 1 0.9989198446273804
, O 0 2.478363398950023e-07
contractures B-Disease 0 0.005005912389606237
, O 0 1.0257647176104001e-07
and O 0 7.146623914877637e-08
early B-Disease 0 1.2820021311199525e-06
death I-Disease 0 2.290644033564604e-06
. O 0 3.129485548925004e-06

To O 0 9.55485916165344e-07
test O 0 2.9284893798831035e-07
for O 0 6.862790780104433e-09
possible O 0 8.424893849223736e-08
nosologic O 0 2.607461055958993e-06
identity O 0 1.8944298574297136e-07
between O 0 9.057951722013513e-09
these O 0 6.607403690850333e-08
disorders O 0 0.0002148551429854706
, O 0 6.26682039595039e-09
we O 0 4.571778955408945e-09
reviewed O 0 7.033273963230613e-09
the O 0 8.503702186857254e-10
literature O 0 9.607828310720379e-09
and O 0 3.291252159698388e-09
obtained O 0 1.1547879985585041e-08
a O 0 1.543903560552451e-09
follow O 0 1.0188092147700445e-08
- O 0 1.4087062254475313e-06
up O 0 9.27118115612302e-09
of O 0 2.1822575690944035e-10
the O 0 1.0055650756513046e-09
only O 0 1.0282045215248559e-09
two O 0 2.493734330144548e-09
surviving O 0 8.093543328868691e-06
patients O 0 1.8316531225082144e-07
, O 0 8.620828495509159e-10
one O 0 3.6347553855620163e-09
with O 0 2.1084483492472827e-08
SJS B-Disease 1 0.9773651957511902
type I-Disease 0 7.229331913549686e-06
2 I-Disease 0 2.2658737108827154e-08
at O 0 3.2399807281535686e-08
age O 0 6.052523371380403e-09
10 O 0 1.1531806620723728e-09
years O 0 4.373711171012928e-09
and O 0 3.288604055740052e-09
another O 0 5.052946061567809e-09
with O 0 1.5779505702084862e-08
SWS B-Disease 1 0.5281541347503662
at O 0 2.448700229251699e-07
age O 0 5.380703171908863e-08
7 O 0 7.054288886365612e-08
years O 0 2.8359485781948024e-07
. O 0 1.2390541996865068e-06

Patients O 0 0.004527810495346785
reported O 0 3.403749133212841e-06
as O 0 7.32239797684997e-08
having O 0 2.589023040400207e-07
either O 0 2.3680222511757165e-06
neonatal O 1 0.9999754428863525
SJS B-Disease 1 0.9999984502792358
or O 0 7.01321114320308e-05
SWS B-Disease 0 0.05101202055811882
presented O 0 3.512058910359883e-08
a O 0 7.1770012155525365e-09
combination O 0 1.5097867844815482e-07
of O 0 3.0775952897243997e-09
a O 0 4.803061770530803e-08
severe O 0 1.3822059372614603e-05
, O 0 5.015816384457139e-08
prenatal O 1 0.8526743650436401
- O 1 0.9721941351890564
onset O 1 0.652155876159668
neuromuscular B-Disease 1 0.9999723434448242
disorder I-Disease 1 0.9967085123062134
( O 0 1.813147321172437e-07
with O 0 4.418597825406323e-07
congenital B-Disease 1 0.9999911785125732
joint I-Disease 0 0.03795584663748741
contractures I-Disease 1 0.9999703168869019
, O 0 2.517243046895601e-05
respiratory O 0 0.10902700573205948
and O 0 2.350687253738215e-07
feeding O 0 8.293374662571296e-07
difficulties O 0 5.487505404744297e-06
, O 0 9.832106684370956e-09
tendency O 0 2.305154822579425e-07
to O 0 2.3345341659819496e-08
hyperthermia B-Disease 0 7.977707355166785e-06
, O 0 3.2559124285569396e-09
and O 0 3.375709045627673e-09
frequent O 0 8.150858121780402e-08
death O 0 5.607096227322472e-07
in O 0 1.2746748723202472e-07
infancy O 0 0.00040408491622656584
) O 0 6.986104583717179e-09
with O 0 1.921734105181372e-09
a O 0 4.690815202934573e-08
distinct O 0 6.175691396492766e-06
campomelic B-Disease 1 0.9719916582107544
- I-Disease 1 0.8047537207603455
metaphyseal I-Disease 0 0.06079183891415596
skeletal I-Disease 0 0.17541907727718353
dysplasia I-Disease 1 0.9361164569854736
. O 0 2.1129482774995267e-05

The O 0 2.7404223601479316e-07
similarity O 0 2.8618705982808024e-07
of O 0 3.9159955278478265e-09
the O 0 7.660100997952668e-09
clinical O 0 8.069412729128089e-07
and O 0 2.225937656419319e-08
radiographic O 0 0.13927344977855682
findings O 0 5.2575310292013455e-06
is O 0 6.47716857926639e-09
so O 0 3.6824017168868295e-09
extensive O 0 9.299286674036011e-09
that O 0 2.2212383044006856e-08
these O 0 1.2056828779805073e-07
disorders O 0 1.713113124424126e-05
appear O 0 5.284940840510899e-08
to O 0 7.35283434138978e-09
be O 0 1.456773723873539e-08
a O 0 1.991523035371756e-08
single O 0 7.83540997417731e-07
entity O 0 2.7872594728250988e-05
. O 0 4.46168041889905e-06

The O 0 3.17011370043474e-07
follow O 0 2.746408256371069e-07
- O 0 1.4530326097883517e-06
up O 0 3.542812621049052e-08
observation O 0 4.719091961646882e-08
of O 0 7.894291331744796e-10
an O 0 2.852821534560235e-09
identical O 0 2.617523932713084e-06
and O 0 7.532016610412029e-08
unique O 0 7.178222460879624e-08
pattern O 0 8.060282198130153e-06
of O 0 3.2035412544928477e-08
progressive O 0 0.000886384048499167
bone B-Disease 1 0.9989559650421143
dysplasia I-Disease 1 0.9989535808563232
in O 0 2.0688474933194811e-07
the O 0 1.2127863158184482e-08
two O 0 6.003683949984406e-08
patients O 0 5.070036763754615e-07
( O 0 1.9640449266944415e-09
one O 0 1.1860848303513194e-08
with O 0 6.415142905780158e-08
SJS B-Disease 1 0.9994063377380371
type I-Disease 0 0.00024780374951660633
2 I-Disease 0 1.2974867402704149e-08
, O 0 2.868059789662425e-09
one O 0 5.632240007713563e-09
with O 0 2.03393053510581e-08
SWS B-Disease 0 0.2629195749759674
) O 0 1.1573127345343437e-08
surviving O 0 3.226272724532464e-07
beyond O 0 1.2739737087485992e-07
infancy O 0 2.70819282377488e-06
adds O 0 5.5610641425118956e-08
to O 0 3.0159630348691735e-09
the O 0 1.2015862749237272e-09
evidence O 0 1.62934483682875e-08
in O 0 8.255920391775362e-09
favor O 0 6.336318136845875e-08
of O 0 1.9946401863535357e-08
identity O 0 3.7279189655237133e-06
. O 0 2.326086132597993e-06

The O 0 1.0936003036476905e-06
hypothesis O 0 4.618853381543886e-06
that O 0 2.8753524361491145e-07
SWS B-Disease 0 0.000394507369492203
and O 0 4.842210614697251e-07
SJS B-Disease 1 0.9149987697601318
type I-Disease 0 6.883591595396865e-06
2 I-Disease 0 2.1195528887574255e-08
are O 0 3.0323388244823946e-09
the O 0 6.964963272793057e-09
same O 0 7.836844702069357e-07
disorder O 0 5.0863236538134515e-05
should O 0 3.625714484201126e-08
be O 0 3.0295639330546464e-09
testable O 0 8.679638341391183e-08
by O 0 3.741725596029255e-09
molecular O 0 2.410552610854211e-07
methods O 0 7.785868092469173e-07
. O 0 3.194438136233657e-07
. O 0 1.409296032761631e-06

A O 0 2.1111782189109363e-06
mouse O 0 8.370925570488907e-06
model O 0 1.6664912436681334e-06
of O 0 2.925143007814768e-07
severe O 1 0.999792754650116
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.014062623493373394
defects O 1 0.9999909400939941
in O 0 3.2502288377145305e-05
hemostasis O 1 0.9994840621948242
and O 0 0.01566058211028576
thrombosis B-Disease 1 0.9997180104255676
. O 0 2.2981203073868528e-05

von B-Disease 1 0.9889806509017944
Willebrand I-Disease 1 0.8999101519584656
factor I-Disease 0 0.0001803432678570971
( I-Disease 0 3.4400145523250103e-06
vWf I-Disease 0 0.01643482781946659
) I-Disease 0 0.0007119294605217874
deficiency I-Disease 1 0.9996138215065002
causes O 0 0.3231009244918823
severe O 1 0.9999990463256836
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.3098270756017882e-05
humans O 0 2.3707092623226345e-05
. O 0 6.207937985891476e-06

We O 0 1.3007497727812734e-06
generated O 0 6.222918358389506e-08
a O 0 1.1157866630640001e-08
mouse O 0 3.319137533708272e-07
model O 0 3.1668261613049253e-07
for O 0 7.214084440931856e-09
this O 0 2.8803576412883558e-08
disease O 0 2.626811408390495e-07
by O 0 3.6725678054239097e-09
using O 0 1.8071052920731745e-07
gene O 0 2.1491171082743676e-06
targeting O 0 1.328345388174057e-05
. O 0 7.3095079642371275e-06

vWf B-Disease 1 0.5342289209365845
- I-Disease 1 0.9994801878929138
deficient I-Disease 1 0.7092479467391968
mice O 0 5.6813885748852044e-05
appeared O 0 5.029775138609693e-07
normal O 0 3.817346794221521e-07
at O 0 2.842448942885767e-08
birth O 0 5.055011342847138e-08
; O 0 9.434008241271385e-09
they O 0 2.5402490777537423e-08
were O 0 5.765191701812e-08
viable O 0 7.757505954941735e-06
and O 0 1.9169107190464274e-07
fertile O 0 9.303774277213961e-06
. O 0 3.4023601074295584e-06

Neither O 0 0.00019771179358940572
vWf O 0 0.0010025420924648643
nor O 0 8.750617416808382e-05
vWf O 0 0.00042096665129065514
propolypeptide O 0 0.00019359194266144186
( O 0 1.8878519085774315e-06
von B-Disease 0 0.07575085759162903
Willebrand I-Disease 0 0.13800621032714844
antigen O 0 0.004543130751699209
II O 0 0.0008118001860566437
) O 0 1.9920170402087933e-08
were O 0 1.699351059869514e-08
detectable O 0 9.309935649071122e-07
in O 0 1.2643399216472062e-08
plasma O 0 1.550497586322308e-06
, O 0 2.4102901008404842e-08
platelets O 0 9.97734559859964e-07
, O 0 1.787390679908185e-08
or O 0 4.0532640355195326e-08
endothelial O 0 1.8164634241202293e-07
cells O 0 8.054192335293919e-08
of O 0 2.596602266535797e-09
the O 0 7.076686614482242e-08
homozygous O 0 9.820574632612988e-06
mutant O 0 1.0389438102720305e-05
mice O 0 1.8125756469089538e-05
. O 0 2.6832583444047486e-06

The O 0 1.3601495538750896e-06
mutant O 0 1.3171876162232365e-05
mice O 0 2.1248521079542115e-05
exhibited O 0 1.11649223981658e-05
defects O 1 0.890056312084198
in O 0 1.9470307677238452e-07
hemostasis O 0 0.039720576256513596
with O 0 5.28553556478073e-08
a O 0 1.3392842390658188e-07
highly O 0 2.7287378543405794e-05
prolonged O 0 0.015332738868892193
bleeding O 1 0.627038836479187
time O 0 1.9753416324874706e-07
and O 0 3.39046160036105e-08
spontaneous O 0 2.8410676122803125e-07
bleeding O 0 5.259371027932502e-05
events O 0 5.090102916938122e-08
in O 0 8.2988158567332e-09
approximately O 0 1.3563250078618694e-08
10 O 0 2.062527215684895e-08
% O 0 1.5958688592832004e-08
of O 0 2.088069805949999e-08
neonates O 0 0.0005362280062399805
. O 0 4.793425432580989e-06

As O 0 4.855203883380454e-07
in O 0 4.993022884036691e-08
the O 0 1.4319363472736768e-08
human O 0 6.369154448293557e-08
disease O 0 4.833089519706846e-07
, O 0 2.9126303591198166e-09
the O 0 5.085956544803594e-09
factor O 0 9.575833104236153e-08
VIII O 0 2.2258638637140393e-05
level O 0 6.047724809832289e-08
in O 0 6.360278081984916e-09
these O 0 8.559718267520111e-09
mice O 0 1.851309320954897e-06
was O 0 5.47529623418086e-07
reduced O 0 2.056921033499748e-08
strongly O 0 3.4874005905294325e-08
as O 0 9.367897568779426e-09
a O 0 1.5113648998976714e-08
result O 0 1.2974972207757673e-07
of O 0 8.789098338013446e-10
the O 0 2.8735314572259085e-08
lack O 0 6.470639135613965e-08
of O 0 6.872157065629381e-09
protection O 0 1.0521289084408636e-07
provided O 0 1.1119778520196633e-07
by O 0 2.888911296849983e-07
vWf O 0 0.00010430021939100698
. O 0 4.883750079898164e-06

Defective O 0 0.2599082589149475
thrombosis B-Disease 1 0.6399011611938477
in O 0 2.601380515443452e-07
mutant O 0 1.566467744851252e-06
mice O 0 3.3076765248551965e-05
was O 0 2.3458860596292652e-06
also O 0 1.744953692650597e-08
evident O 0 5.726723983912052e-08
in O 0 6.043998634908121e-09
an O 0 3.2778455505422244e-09
in O 0 3.0216821045314646e-08
vivo O 0 7.384773198282346e-06
model O 0 2.78040971579685e-07
of O 0 9.198982553471069e-08
vascular B-Disease 1 0.9655240178108215
injury I-Disease 1 0.9290317893028259
. O 0 6.68314305585227e-06

In O 0 4.249129688105313e-07
this O 0 3.057184372323718e-08
model O 0 1.9674246232170844e-07
, O 0 1.0054888477384338e-08
the O 0 1.451033426747017e-08
exteriorized O 0 4.272056230547605e-06
mesentery O 0 1.719421379675623e-05
was O 0 2.9959213065922086e-07
superfused O 0 5.897385335629224e-07
with O 0 1.1642002917255923e-08
ferric O 0 1.658758264966309e-06
chloride O 0 1.2381679880490992e-05
and O 0 8.214880153900594e-08
the O 0 1.3576241464363648e-08
accumulation O 0 7.687533809530578e-08
of O 0 9.914666421195761e-09
fluorescently O 0 1.2596429769473616e-05
labeled O 0 1.4866581295791548e-05
platelets O 0 2.3340089683188125e-05
was O 0 1.6125206059314223e-07
observed O 0 9.17236988584591e-08
by O 0 3.05569756164914e-08
intravital O 0 7.887020728958305e-06
microscopy O 0 1.4147284673526883e-05
. O 0 4.781431471201358e-06

We O 0 1.6466267425130354e-06
conclude O 0 5.71276984828728e-07
that O 0 9.62870583265385e-09
these O 0 5.533002944702048e-09
mice O 0 1.9644848237021506e-07
very O 0 1.9448366472829548e-08
closely O 0 3.34551771175029e-07
mimic O 0 0.0002556732506491244
severe O 0 0.034490425139665604
human O 0 0.00028910988476127386
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0003981388872489333
will O 0 3.053600394764544e-08
be O 0 3.868822595620713e-09
very O 0 1.7875603219863478e-09
useful O 0 7.0939010221593435e-09
for O 0 1.4133593184695314e-09
investigating O 0 2.2581895464668378e-08
the O 0 2.094506790228934e-09
role O 0 1.3569355417075712e-08
of O 0 1.4664326419833174e-09
vWf O 0 8.027711260183423e-07
in O 0 1.9603520584610123e-08
normal O 0 1.4952856020045147e-07
physiology O 0 4.1558959651410987e-07
and O 0 8.32912334658431e-08
in O 0 1.249469050890184e-06
disease O 0 1.2341810361249372e-05
models O 0 1.7960696823138278e-06
. O 0 2.9823320346622495e-07
. O 0 1.1445233667473076e-06

Oral O 0 4.882866778643802e-05
contraceptives O 0 0.0032181849237531424
and O 0 3.604223195452505e-07
the O 0 1.1342015682203055e-07
risk O 0 1.959112887561787e-05
of O 0 5.691463798029872e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3053573386278003e-05

Hereditary B-Disease 1 0.999998927116394
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9998044371604919
Clinical O 0 0.0005320457275956869
Study O 0 1.3569244401878677e-05
Group O 0 1.0530768122407608e-05
. O 0 9.97303595795529e-06

BACKGROUND O 0 0.0012314011109992862
Women O 0 3.1657405088481028e-06
with O 0 2.6121668383893848e-08
mutations O 0 9.137757501775923e-07
in O 0 1.5367943362321057e-08
either O 0 4.125040220515075e-08
the O 0 3.668725767624892e-08
BRCA1 O 0 1.908576814457774e-05
or O 0 1.2352168710094702e-07
the O 0 1.3432106094057872e-08
BRCA2 O 0 1.938483592311968e-06
gene O 0 1.0706541075933274e-07
have O 0 1.4630724187725264e-08
a O 0 1.163170537665792e-08
high O 0 8.875067578628659e-07
lifetime O 0 1.1685611752909608e-05
risk O 0 0.004909820854663849
of O 0 3.780767656280659e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4182243830873631e-05

Oral O 0 7.074698805809021e-05
contraceptives O 0 0.0676107183098793
protect O 0 0.00013965231482870877
against O 0 0.1498078554868698
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 2.8607241020495167e-08
general O 0 4.200921388530787e-09
, O 0 4.333404746148517e-09
but O 0 2.3881874255948787e-08
it O 0 1.6109707345890456e-08
is O 0 1.558682849456261e-09
not O 0 1.6701315885825352e-09
known O 0 3.5597105263462936e-09
whether O 0 9.2063165979539e-09
they O 0 3.6498743583024407e-08
also O 0 1.68956475476989e-08
protect O 0 5.2456737620332206e-08
against O 0 5.748962195184504e-08
hereditary B-Disease 0 0.00014344166265800595
forms I-Disease 0 6.383765867212787e-05
of I-Disease 0 0.05521825700998306
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.162455646408489e-05

METHODS O 0 1.2496951967477798e-05
We O 0 2.5711520379445574e-07
enrolled O 0 2.217471433141327e-07
207 O 0 1.5803277619852452e-07
women O 0 1.3350708627513086e-07
with O 0 1.988278626186002e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.920407003008222e-08
161 O 0 1.6558811211098146e-08
of O 0 9.208629969670312e-10
their O 0 3.116607771858071e-08
sisters O 0 5.270777023724804e-07
as O 0 1.5565744249101954e-08
controls O 0 1.4436593573918799e-06
in O 0 3.639529921883877e-08
a O 0 3.837765660819059e-08
case O 0 2.0093000784981996e-05
- O 0 0.018182804808020592
control O 0 1.1272832125541754e-05
study O 0 1.2350089946266962e-06
. O 0 1.2386005892039975e-06

All O 0 3.4865499287661805e-07
the O 0 8.652761351868321e-08
patients O 0 2.5671118919490254e-07
carried O 0 6.464939872330433e-08
a O 0 1.878858668646899e-08
pathogenic O 0 6.954438731554546e-07
mutation O 0 4.654577310247987e-07
in O 0 1.9073912227440815e-08
either O 0 1.7557715636939975e-07
BRCA1 O 0 2.075910015264526e-05
( O 0 1.505403801616012e-08
179 O 0 1.0018155904845116e-07
women O 0 8.890810221373613e-08
) O 0 1.014504391605442e-08
or O 0 1.404152243367207e-07
BRCA2 O 0 0.001024389872327447
( O 0 3.3842074032008895e-08
28 O 0 2.3436138008037233e-07
women O 0 7.46039745536109e-07
) O 0 1.7787938588753605e-07
. O 0 1.063997729033872e-06

The O 0 7.142044751162757e-07
control O 0 1.3970397958473768e-06
women O 0 1.3714996782709932e-07
were O 0 1.3124205722192528e-08
enrolled O 0 3.1100285013963e-08
regardless O 0 2.6829967580965786e-08
of O 0 5.577321382510547e-10
whether O 0 1.1818574563449147e-08
or O 0 4.8553612685964254e-08
not O 0 5.027856886385962e-08
they O 0 1.4355740063365374e-07
had O 0 2.5206111331499415e-07
either O 0 2.7685692316481436e-07
mutation O 0 8.969551345217042e-06
. O 0 1.7141096577688586e-06

Lifetime O 0 2.4451524950563908e-05
histories O 0 3.276586994616082e-06
of O 0 3.0743112944264794e-08
oral O 0 1.1998700983895105e-06
- O 0 7.4603158282116055e-06
contraceptive O 0 8.732127753319219e-05
use O 0 5.196796593054387e-08
were O 0 6.2090803609748946e-09
obtained O 0 1.4112911728147992e-08
by O 0 2.130275955636307e-09
interview O 0 5.907331797061488e-07
or O 0 6.461805757140837e-09
by O 0 7.469703744433787e-10
written O 0 2.3176647268030592e-09
questionnaire O 0 2.127572606980266e-08
and O 0 2.3510531299564263e-09
were O 0 5.123519830618761e-09
compared O 0 3.896891254129287e-09
between O 0 2.5298763084435905e-09
patients O 0 2.410623949344881e-07
and O 0 6.473749891711122e-08
control O 0 0.00018383785209152848
women O 0 3.1374474929179996e-07
, O 0 1.280233918876661e-09
after O 0 3.990886288107731e-09
adjustment O 0 2.4650260499470278e-08
for O 0 8.454666411417122e-10
year O 0 2.98782176777479e-09
of O 0 1.2794503234658805e-09
birth O 0 2.97633476975534e-07
and O 0 1.0779672976468646e-07
parity O 0 5.293437880027341e-06
. O 0 1.7166549923786079e-06

RESULTS O 0 1.69495015143184e-05
The O 0 1.0215805446023296e-07
adjusted O 0 4.059522780153202e-06
odds O 0 7.30800602468662e-05
ratio O 0 8.546940080123022e-05
for O 0 0.07847719639539719
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 3.013831531006872e-07
with O 0 2.058996306786298e-09
any O 0 1.1685161283025991e-08
past O 0 1.929911697118314e-08
use O 0 4.1949583362566045e-08
of O 0 4.213953630483047e-09
oral O 0 1.0069148856928223e-06
contraceptives O 0 0.08257873356342316
was O 0 1.4324056110126548e-06
0 O 0 4.476600281577703e-07
. O 0 1.0305708428859361e-06

5 O 0 2.0611428226402495e-06
( O 0 1.0020487195561145e-07
95 O 0 1.51125320257961e-07
percent O 0 9.87066414381843e-07
confidence O 0 9.539191836438476e-08
interval O 0 1.1263415444773273e-07
, O 0 4.0041303606130896e-09
0 O 0 9.438057446686798e-09
. O 0 4.430393385490561e-09
3 O 0 4.2591885573983745e-09
to O 0 7.948975699889615e-09
0 O 0 2.0012482337961046e-08
. O 0 1.9301582554476227e-08
8 O 0 4.6753530824616973e-08
) O 0 4.098211903169613e-08
. O 0 3.729202262547915e-07

The O 0 3.887497769028414e-06
risk O 0 6.979771569604054e-05
decreased O 0 1.1481791943879216e-06
with O 0 2.2343767724919417e-08
increasing O 0 3.9913981453310043e-08
duration O 0 9.845096826666122e-08
of O 0 1.4028045391967225e-09
use O 0 2.5353310562081788e-08
( O 0 5.562334148834225e-09
P O 0 2.846131792466622e-05
for O 0 5.744464903756352e-09
trend O 0 2.4786001517895784e-07
, O 0 4.591554692012778e-09
< O 0 7.431171411553805e-08
0 O 0 1.2363266854720223e-08
. O 0 4.461531588617618e-09
001 O 0 3.628675315781038e-08
) O 0 5.341106446010713e-10
; O 0 2.729661774392156e-10
use O 0 2.1771073832610455e-09
for O 0 5.052182006082262e-10
six O 0 9.403176015609915e-10
or O 0 4.292520561222091e-09
more O 0 5.7168525469109e-10
years O 0 2.37218955589924e-07
was O 0 4.0102818843479326e-07
associated O 0 4.627045857574785e-09
with O 0 9.456071481395156e-10
a O 0 1.5984431556148593e-08
60 O 0 6.392460960569224e-08
percent O 0 1.0008279787143692e-06
reduction O 0 3.3187166081916075e-07
in O 0 6.935284773135209e-07
risk O 0 4.9399983254261315e-05
. O 0 2.8901865789521253e-06

Oral O 0 4.274139064364135e-05
- O 0 3.032461245311424e-05
contraceptive O 0 4.7112687752814963e-05
use O 0 4.4441574686970853e-07
protected O 0 4.513661224336829e-06
against O 0 0.09096634387969971
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
both O 0 9.079538010325905e-09
for O 0 2.756445516283179e-09
carriers O 0 2.7428789906025486e-08
of O 0 1.1925583853766852e-09
the O 0 1.5076825121695947e-08
BRCA1 O 0 3.039142939087469e-05
mutation O 0 1.0835645980478148e-06
( O 0 1.1662762311459574e-08
odds O 0 1.0675322300812695e-05
ratio O 0 3.4288154893147293e-07
, O 0 7.783090616442223e-09
0 O 0 1.1600907789954817e-08
. O 0 2.944862353970734e-09
5 O 0 2.500931683968588e-09
; O 0 2.7477107256146382e-09
95 O 0 1.0557187124504708e-08
percent O 0 4.889202500635292e-07
confidence O 0 4.11223588514531e-08
interval O 0 4.63141027751135e-08
, O 0 1.8593004913469713e-09
0 O 0 1.8543069302268123e-09
. O 0 9.651149879275067e-10
3 O 0 9.929005395648005e-10
to O 0 8.697610964780722e-10
0 O 0 2.7075530706355266e-09
. O 0 1.705984908895175e-09
9 O 0 1.1851005732310682e-09
) O 0 2.46507980694588e-10
and O 0 5.886973131197237e-10
for O 0 7.381425470853742e-10
carriers O 0 1.279516848029516e-08
of O 0 4.123227037577948e-10
the O 0 2.294477319253474e-08
BRCA2 O 0 2.4019022021093406e-05
mutation O 0 5.648514047607023e-07
( O 0 1.015611772459124e-08
odds O 0 8.135563803080004e-06
ratio O 0 2.0297882485920127e-07
, O 0 4.359618888116756e-09
0 O 0 6.277108610674986e-09
. O 0 1.9773889192720162e-09
4 O 0 4.145727761084572e-09
; O 0 3.778127588560665e-09
95 O 0 2.0376077713990526e-08
percent O 0 1.7966144696401898e-06
confidence O 0 5.6849223994959175e-08
interval O 0 4.964638122828546e-08
, O 0 1.702873952957873e-09
0 O 0 3.780427082489268e-09
. O 0 1.1963882107224322e-09
2 O 0 1.9031529685520354e-09
to O 0 3.1838274239248676e-09
1 O 0 8.271303642004568e-09
. O 0 1.0686238560708716e-08
1 O 0 2.8733396106872533e-08
) O 0 5.916900036595507e-08
. O 0 4.4747778815690253e-07

CONCLUSIONS O 0 1.3595915334008168e-05
Oral O 0 4.370862825453514e-06
- O 0 6.66960022499552e-06
contraceptive O 0 2.5165205443045124e-05
use O 0 1.9406500939567195e-07
may O 0 1.357952328362444e-07
reduce O 0 4.487102245320784e-08
the O 0 1.3263367293347983e-08
risk O 0 8.932000127970241e-06
of O 0 4.1579335174901644e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.472238732792903e-08
women O 0 1.2397629234328633e-07
with O 0 1.0140845496664497e-08
pathogenic O 0 3.1626022973796353e-06
mutations O 0 2.4612966171844164e-06
in O 0 4.7867466435036476e-08
the O 0 1.5117548457510566e-07
BRCA1 O 0 0.00029292984982021153
or O 0 5.298468295222847e-06
BRCA2 O 0 0.0005717351450584829
gene O 0 0.0002795526816044003

A O 0 5.461557066155365e-06
Japanese O 0 1.5863765838730615e-06
family O 0 1.0829153040958772e-07
with O 0 2.4947109267259293e-08
adrenoleukodystrophy B-Disease 1 0.9999992847442627
with O 0 3.022494965421174e-08
a O 0 6.519771744706304e-08
codon O 0 2.3674260773987044e-06
291 O 0 3.008272244642285e-07
deletion O 0 1.0160874808207154e-06
: O 0 8.038335330695645e-09
a O 0 4.717685797572813e-09
clinical O 0 4.854565531786648e-07
, O 0 5.105443623421024e-09
biochemical O 0 1.8823974414772238e-06
, O 0 3.7201919322882304e-09
pathological O 0 2.392272904216952e-07
, O 0 1.898628987362372e-08
and O 0 1.2739347710066795e-07
genetic O 0 6.499978189822286e-05
report O 0 6.755687536497135e-06
. O 0 2.344745553273242e-06

We O 0 1.3671899068867788e-05
report O 0 3.368109275925235e-07
a O 0 1.438443053558558e-08
Japanese O 0 7.729303774794971e-08
family O 0 4.765566430364743e-08
with O 0 5.473427933111452e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 1.2330282288530725e-06
ALD B-Disease 1 1.0
) O 0 5.730176866336478e-08
with O 0 4.114406593203057e-09
a O 0 1.8242577226601497e-08
three O 0 2.6548867992914893e-08
base O 0 1.154440525397149e-07
pair O 0 1.92269226317876e-06
deletion O 0 7.327487310249126e-06
( O 0 2.8281560204845846e-08
delGAG O 0 8.674290370436211e-07
291 O 0 2.856411924767599e-07
) O 0 3.401232717692437e-08
in O 0 9.426565128478614e-08
the O 0 2.020122337853536e-06
ALD B-Disease 1 0.9999990463256836
gene O 0 3.341641786391847e-05
. O 0 5.835804131493205e-06

A O 0 1.582174945724546e-06
variety O 0 2.951148303509399e-07
of O 0 2.2820298539727446e-08
phenotypes O 0 3.532897380864597e-06
were O 0 2.5909446321747964e-07
observed O 0 1.967529783541977e-07
within O 0 2.682556754507459e-08
this O 0 7.614394093025112e-08
family O 0 1.8565940536063863e-06
. O 0 3.7053973755973857e-06

While O 0 2.362779696341022e-06
the O 0 1.1346170225579044e-07
proband O 0 3.8320786188705824e-06
( O 0 1.8704918502976398e-08
patient O 0 8.513448079838781e-08
1 O 0 1.5339596259877908e-08
) O 0 4.0825982594583365e-09
was O 0 7.700124626808247e-08
classified O 0 1.2494363943460485e-07
as O 0 1.0527809735094706e-08
having O 0 1.958581066219267e-07
a O 0 1.2015914485630219e-08
rare O 0 7.785766342749412e-08
intermediate O 0 3.2788108228487545e-07
type O 0 3.621198857217678e-06
of O 0 1.1418308076827088e-08
adult O 0 1.7404454411007464e-05
cerebral O 0 0.008096038363873959
and O 0 2.7432304250396555e-07
cerebello O 0 0.3426137864589691
- O 1 0.6540429592132568
brain O 0 0.0010929518612101674
stem O 0 2.9870003004361934e-07
forms O 0 8.406082230294487e-08
, O 0 1.0261987704041076e-08
his O 0 1.2667345394845597e-08
younger O 0 4.958770816188007e-08
brother O 0 3.131922454713276e-08
( O 0 2.764975581825979e-09
patient O 0 8.33966282698384e-08
2 O 0 1.1168469704614381e-08
) O 0 4.956253185639525e-09
and O 0 2.7206827013515067e-08
nephew O 0 4.1640049630586873e-07
( O 0 9.435339620722516e-09
patient O 0 1.5465191438579495e-07
3 O 0 2.5643853263090932e-08
) O 0 1.3767435191880395e-08
had O 0 6.671532446489437e-07
a O 0 3.338942349273566e-07
childhood O 0 0.0878957211971283
ALD B-Disease 1 1.0
type O 1 0.7474313378334045
. O 0 1.2299980880925432e-05

Another O 0 3.8011514789104695e-06
nephew O 0 4.957663350069197e-06
( O 0 7.202194751698698e-08
patient O 0 2.1537242389513267e-07
4 O 0 2.5732436625958144e-08
) O 0 6.51093401415892e-09
of O 0 1.8282728664331671e-09
patient O 0 4.973761065230065e-07
1 O 0 8.717699273574908e-08
was O 0 1.2585290960487328e-06
classified O 0 2.3272215798897378e-07
as O 0 2.6663046881481023e-08
having O 0 3.368594434505212e-07
an O 0 4.511990425726253e-08
adolescent O 0 8.151344445650466e-06
form O 0 2.8508161449281033e-06
. O 0 4.491979780141264e-06

The O 0 9.140406973529025e-07
tau O 0 1.2711874433080084e-06
level O 0 4.0934239109446935e-07
in O 0 4.150429333549255e-08
the O 0 1.325495162518564e-07
cerebrospinal O 0 0.00014527335588354617
fluid O 0 1.1157876542711165e-05
( O 0 4.448651935717862e-08
CSF O 0 0.0014987112954258919
) O 0 7.269417068300754e-09
in O 0 6.077696124151544e-09
patient O 0 7.977214266929877e-08
1 O 0 2.649271912957829e-08
was O 0 7.836209761080681e-07
as O 0 8.391948469466115e-09
high O 0 2.595286652251616e-08
as O 0 2.565538670395995e-09
that O 0 1.4887502342020298e-09
of O 0 3.2566886964957575e-09
patients O 0 5.371842917156755e-07
with O 0 2.7013084036298096e-07
Alzheimers B-Disease 1 0.9999806880950928
disease I-Disease 0 0.01871250569820404
( O 0 1.0070841227616256e-07
AD B-Disease 0 9.044082253240049e-05
) O 0 7.255325158439518e-07
. O 0 2.1983871647535125e-06

His O 0 3.4941167541546747e-06
brain O 0 2.2723197616869584e-05
magnetic O 0 1.6195018588405219e-06
resonance O 0 1.342894847766729e-05
image O 0 7.60871080274228e-06
( O 0 4.4770999352294893e-08
MRI O 0 8.516285015502945e-05
) O 0 5.2348394063983505e-08
showed O 0 1.3403056300376193e-06
abnormalities B-Disease 0 0.008907847106456757
in I-Disease 0 9.973691206255353e-09
the I-Disease 0 1.1776045916178646e-08
bilateral I-Disease 0 2.6299522914996487e-07
cerebellar I-Disease 0 2.6188641641056165e-05
hemispheres I-Disease 0 0.032060056924819946
and O 0 2.7515884539752733e-06
brain O 0 2.9904178518336266e-05
stem O 0 7.225199851745856e-07
, O 0 5.230644362086423e-09
but O 0 1.4048027630053639e-08
not O 0 1.0910981451672797e-08
in O 0 5.228180555150175e-09
the O 0 3.5914382578994264e-08
cerebral O 0 0.0063696675933897495
white O 0 3.556574483809527e-06
matter O 0 1.8181093963676176e-08
, O 0 1.4886366583866106e-09
where O 0 2.0121249111326733e-09
marked O 0 1.116459369399081e-08
reductions O 0 9.729691896609438e-08
of O 0 9.968228464884987e-10
the O 0 2.1818435058662544e-08
cerebral O 0 3.617438051151112e-05
blood O 0 5.632559236801171e-07
flow O 0 1.0454495935618979e-07
and O 0 2.4969434520016875e-08
oxygen O 0 9.889267715834649e-08
metabolism O 0 1.7648972061579116e-07
were O 0 2.718374325638706e-08
clearly O 0 3.016372929209865e-08
demonstrated O 0 1.7510449978885845e-08
by O 0 5.9708158417492996e-09
positron O 0 2.4196767753892345e-06
emission O 0 9.086052727980132e-07
tomography O 0 9.200189197144937e-06
( O 0 1.7174870947656018e-07
PET O 0 4.2501692405494396e-06
) O 0 5.083888936496805e-07
. O 0 2.0578136172844097e-06

In O 0 2.5335605187137844e-06
patients O 0 5.017930561734829e-06
2 O 0 3.98153652270139e-08
and O 0 1.4737545406262598e-08
3 O 0 2.4617134997129142e-08
, O 0 5.541388681251647e-09
the O 0 9.03038532840128e-09
autopsy O 0 0.00015247131523210555
findings O 0 1.2682377246164833e-06
showed O 0 9.88751025943202e-07
massive O 0 9.800027100936859e-07
demyelination B-Disease 1 0.999998927116394
of I-Disease 0 5.819802950668418e-08
the I-Disease 0 6.794467140025517e-07
cerebral I-Disease 0 0.07397042214870453
white I-Disease 0 2.8907654723298037e-06
matter I-Disease 0 1.966474805215057e-08
with O 0 1.7404655494601684e-09
sparing O 0 4.588335400512733e-08
of O 0 1.179424780062277e-09
the O 0 1.4769005574066796e-08
U O 0 0.00016090688586700708
- O 0 0.0022507463581860065
fibers O 0 0.0001915311731863767
, O 0 4.055435098848648e-09
compatible O 0 2.2991734738297964e-08
with O 0 2.8416291542043837e-09
the O 0 2.8857961353878636e-08
findings O 0 3.7178674006099754e-07
of O 0 7.0548807684645e-08
childhood O 0 0.00036495516542345285
ALD B-Disease 1 0.9999996423721313
. O 0 1.612742562429048e-05

Oleic O 0 0.00926136877387762
and O 0 4.729278771264944e-06
erucic O 0 0.000269535172265023
acids O 0 6.0943143580516335e-06
( O 0 6.939295360552933e-08
Lorenzos O 0 1.546152020637237e-06
Oil O 0 1.478014439726394e-07
) O 0 2.0443609027864795e-09
were O 0 1.6556023219038707e-09
administered O 0 8.477957003094616e-09
to O 0 4.4266683651983385e-09
patients O 0 2.087759298774472e-08
1 O 0 2.221728800932965e-09
and O 0 2.787565289708027e-09
4 O 0 2.790272901620483e-09
, O 0 1.0851887166651863e-09
but O 0 5.480048415051897e-09
sufficient O 0 1.2178208663726764e-08
effectiveness O 0 1.5062028069223743e-07
was O 0 6.752775760787699e-08
not O 0 1.876341215734101e-08
obtained O 0 4.73014921453796e-07
. O 0 7.664860959266662e-07

The O 0 8.854702286953398e-07
findings O 0 3.1481658879783936e-07
in O 0 1.481750899756662e-08
this O 0 5.812545111893996e-09
family O 0 1.799057258722314e-08
suggest O 0 4.4858097680844367e-08
that O 0 3.943368298564565e-09
delGAG291 O 0 2.105390706219623e-07
is O 0 3.4970437656767217e-09
part O 0 9.448630322594909e-09
of O 0 2.5029265326992345e-09
the O 0 4.015888421804448e-08
cause O 0 2.3759140788115474e-07
of O 0 1.8515050825840262e-08
Japanese O 0 0.00010274937812937424
ALD B-Disease 1 0.9999995231628418
with O 0 1.4371354950526438e-07
phenotypic O 0 3.445481343078427e-05
variations O 0 3.832606307696551e-05
. O 0 1.3548594324674923e-05

Moreover O 0 1.3457769455271773e-05
, O 0 1.7798153351122892e-07
although O 0 5.318746687521525e-08
the O 0 4.959316957098281e-09
scale O 0 2.1659221260961203e-07
of O 0 1.3642322826967757e-09
the O 0 5.100839750582509e-09
study O 0 1.5630449823333947e-08
is O 0 1.7594239398732725e-09
limited O 0 1.0268664141221961e-08
, O 0 1.726315312922111e-09
there O 0 2.4333386416941494e-09
is O 0 7.554468162140893e-10
a O 0 1.33885147413082e-09
possibility O 0 1.746831834736895e-08
that O 0 2.3751349775835706e-09
PET O 0 7.168262072809739e-08
can O 0 2.206324722919817e-08
detect O 0 1.2590844562510028e-05
an O 0 1.2538835747477606e-08
insidious B-Disease 0 3.784829823416658e-05
lesion I-Disease 1 0.621832549571991
which O 0 6.026549215221166e-08
is O 0 8.786739336130722e-09
undetectable O 0 2.8822213948842546e-07
by O 0 2.3454229669539473e-09
computed O 0 1.9307812237912003e-07
tomogram O 0 1.019959086079325e-06
( O 0 4.699239219974061e-09
CT O 0 0.008446975611150265
) O 0 7.838944604543485e-09
or O 0 1.7169313082376902e-08
MRI O 0 1.7596179532120004e-05
analysis O 0 3.238930190718747e-08
, O 0 1.7064373247777098e-09
and O 0 2.3523269998548813e-09
that O 0 1.4789182101182519e-09
the O 0 4.559822297522942e-09
higher O 0 7.867539579820004e-07
level O 0 2.9499346965167206e-08
of O 0 1.0485020629502628e-09
tau O 0 1.7911004235315886e-08
reflects O 0 1.968696672349779e-08
the O 0 2.607998483838969e-09
process O 0 2.3770034829340148e-08
of O 0 1.1762756990663092e-08
neuronal B-Disease 0 1.3397278053162154e-05
degeneration I-Disease 0 0.0037794688250869513
in O 0 8.943177090259269e-05
ALD B-Disease 1 0.9999998807907104
. O 0 3.121450208709575e-05

Lorenzos O 0 9.129771933658049e-05
Oil O 0 8.3770264609484e-06
should O 0 9.144525137116943e-08
be O 0 3.742039567100619e-09
given O 0 2.970609536134816e-09
in O 0 3.4942571058849126e-09
the O 0 1.3829177802904269e-08
early O 0 3.126872343273135e-06
stage O 0 1.121942295867484e-05
. O 0 2.875695201964845e-07
. O 0 1.1713924550349475e-06

Nonsense O 0 0.00017549139738548547
mutation O 0 3.135247970931232e-05
in O 0 1.5276798137620062e-07
exon O 0 2.3666541437705746e-06
4 O 0 9.037781012466439e-08
of O 0 3.3658464904107177e-09
human O 0 8.730274281276706e-09
complement O 0 6.032978205894324e-08
C9 O 0 3.1020213100418914e-06
gene O 0 1.7988278955272108e-07
is O 0 9.44104616706909e-09
the O 0 1.3505990992257466e-08
major O 0 1.8719092054197972e-07
cause O 0 3.349693429299805e-07
of O 0 2.5096680289493634e-08
Japanese O 0 7.694817213632632e-06
complement B-Disease 0 4.0340069972444326e-05
C9 I-Disease 1 0.9533901214599609
deficiency I-Disease 1 0.7342496514320374
. O 0 6.655824563495116e-06

Deficiency B-Disease 1 0.9939113855361938
of I-Disease 0 3.6839420403111944e-08
the I-Disease 0 2.24724168162993e-08
ninth I-Disease 0 1.3540301324610482e-07
component I-Disease 0 7.146623914877637e-08
of I-Disease 0 1.580009678647798e-09
human I-Disease 0 9.21443277235312e-09
complement I-Disease 0 2.762757667085225e-08
( O 0 3.5174536616722207e-09
C9 O 0 7.150031819946889e-07
) O 0 2.3199027143760986e-09
is O 0 5.636535682640442e-10
the O 0 8.205742196842891e-10
most O 0 1.324193288354536e-08
common O 0 8.133731171255931e-05
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.794817153377153e-08
Japan O 0 1.8742670704341435e-07
but O 0 5.8595109209136353e-08
is O 0 1.733190813091312e-09
rare O 0 9.815711798921711e-09
in O 0 9.993209815206683e-09
other O 0 2.348136973751025e-08
countries O 0 1.1765431651156177e-07
. O 0 1.807615376492322e-06

We O 0 2.611355284898309e-06
studied O 0 4.5102135004526644e-07
the O 0 7.920371913883173e-09
molecular O 0 1.550598085486854e-07
basis O 0 6.66491928313917e-08
of O 0 8.070092150092023e-08
C9 B-Disease 1 0.9922816157341003
deficiency I-Disease 1 0.855778694152832
in O 0 2.887927053052408e-08
four O 0 5.16873228662007e-08
Japanese O 0 7.54907318878395e-07
C9 B-Disease 0 0.1408625692129135
- I-Disease 0 0.14123155176639557
deficient I-Disease 0 0.020325442776083946
patients O 0 1.4568898905054084e-06
who O 0 2.912683214617573e-07
had O 0 3.8012965433154022e-06
suffered O 0 0.04211018979549408
from O 0 2.526473963371245e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.103460352984257e-05

Direct O 0 4.914169494441012e-06
sequencing O 0 4.183127657597652e-06
of O 0 1.1340350170030433e-07
amplified O 0 3.5725995530810906e-06
C9 O 0 1.7506998119642958e-05
cDNA O 0 1.3035524943916244e-06
and O 0 9.854452542867875e-08
DNA O 0 1.2026183640045929e-06
revealed O 0 3.7761776638944866e-07
a O 0 1.7274688346446965e-08
nonsense O 0 3.6403395142770023e-07
substitution O 0 7.026036286106319e-08
( O 0 1.4379356372273833e-08
CGA O 0 6.793987381570332e-07
- O 0 4.763322067447007e-06
- O 0 1.2658535979426233e-06
> O 0 2.784780122055963e-07
TGA O 0 2.0208140085742343e-06
) O 0 5.319078955068335e-09
at O 0 5.584328111041259e-09
codon O 0 2.76154601408507e-08
95 O 0 5.846468642545233e-09
in O 0 3.027282202694437e-09
exon O 0 2.0066362083071e-07
4 O 0 1.3553473898753055e-08
in O 0 3.9960506015290775e-09
the O 0 1.2790971837262077e-08
four O 0 1.7059768708804768e-07
C9 B-Disease 0 0.14953935146331787
- I-Disease 0 0.056784819811582565
deficient I-Disease 0 0.0011222530156373978
individuals O 0 3.3831011592155846e-07
. O 0 1.1935577504118555e-06

An O 0 1.119510670832824e-06
allele O 0 1.654527113714721e-05
- O 0 4.827074008062482e-06
specific O 0 1.9914646998131502e-07
polymerase O 0 9.565571872371947e-07
chain O 0 3.474564891803311e-06
reaction O 0 2.2645868114068435e-07
system O 0 7.145901292915369e-08
designed O 0 1.2065386556514568e-07
to O 0 6.1068856638257785e-09
detect O 0 2.0228007713285479e-07
exclusively O 0 3.111207513839531e-09
only O 0 1.0042232601037426e-09
one O 0 8.606633183916301e-10
of O 0 1.8427204206972192e-10
the O 0 1.9205030898916675e-09
normal O 0 1.0082580992332169e-08
and O 0 2.1623334234277536e-09
mutant O 0 4.452242663433026e-08
alleles O 0 4.543537457379898e-08
indicated O 0 2.2669068400205106e-08
that O 0 8.862104938778259e-10
all O 0 2.784773800446061e-10
the O 0 1.210613165270047e-09
four O 0 5.776614298014238e-09
patients O 0 1.6346426434665773e-08
were O 0 1.7156929210671024e-09
homozygous O 0 2.858324066323803e-08
for O 0 6.011527942106909e-10
the O 0 1.5584122881051599e-09
mutation O 0 6.012507469677075e-08
in O 0 3.789913716190085e-09
exon O 0 1.6067795627350279e-07
4 O 0 1.945552696724917e-08
and O 0 3.726035924245252e-09
that O 0 1.6823993309600382e-09
the O 0 2.833856704853588e-09
parents O 0 1.5164122402211433e-08
of O 0 2.412915423022355e-09
patient O 0 2.73118331506339e-07
2 O 0 8.553912067554847e-08
were O 0 2.6776399408845464e-07
heterozygous O 0 1.256545237993123e-05
. O 0 2.1221717361186165e-06

The O 0 6.266213858907577e-07
common O 0 5.049172386861756e-07
mutation O 0 2.0543607206491288e-06
at O 0 5.7265598485400915e-08
codon O 0 2.496510660421336e-07
95 O 0 2.0850293935836817e-08
in O 0 3.1751310469729788e-09
exon O 0 1.4307984486094938e-07
4 O 0 1.7141694286237907e-08
might O 0 3.1523349264261924e-08
be O 0 2.364372919672064e-09
responsible O 0 5.005683423320306e-09
for O 0 3.781905455468859e-09
most O 0 7.574429616852285e-08
Japanese O 0 2.9926432034699246e-05
C9 B-Disease 1 0.9891842603683472
deficiency I-Disease 0 0.12830552458763123
. O 0 2.3685093708536442e-07
. O 0 1.3624526218336541e-06

BRCA1 O 0 0.00036291274591349065
required O 0 2.151469288946828e-06
for O 0 5.735129704476094e-08
transcription O 0 2.3374582269752864e-06
- O 0 0.0032299519516527653
coupled O 0 4.139693555771373e-05
repair O 0 0.00023398653138428926
of O 0 4.1623366087151226e-08
oxidative O 0 1.7532262063468806e-05
DNA O 0 0.0003553842252586037
damage O 0 0.006794113665819168
. O 0 8.106676432362292e-06

The O 0 1.6368165233870968e-05
breast B-Disease 1 0.9998859167098999
and I-Disease 1 0.9957572817802429
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
susceptibility O 0 0.00016956926265265793
gene O 0 2.3746850274619646e-05
BRCA1 O 0 0.00012711805175058544
encodes O 0 6.539426976814866e-06
a O 0 1.0605442639644025e-06
zinc O 0 0.09134756028652191
finger O 0 0.00012402248103171587
protein O 0 1.7085637864511227e-06
of O 0 7.199297158422269e-08
unknown O 0 2.1608684619423e-06
function O 0 3.292696874268586e-06
. O 0 5.590380169451237e-06

Association O 0 5.089354090159759e-06
of O 0 7.473672525293296e-08
the O 0 5.944410119695931e-08
BRCA1 O 0 2.2817789613327477e-06
protein O 0 5.394226221255849e-08
with O 0 5.126921553966213e-09
the O 0 2.1221499224566287e-08
DNA O 0 7.44511316952412e-06
repair O 0 3.988117168773897e-05
protein O 0 2.1912462955242518e-07
Rad51 O 0 4.638864083972294e-06
and O 0 2.9564064973897075e-08
changes O 0 1.4177582663421617e-08
in O 0 3.01561797755312e-09
the O 0 1.02057273743128e-09
phosphorylation O 0 9.448251958588116e-09
and O 0 1.3878776350395583e-08
cellular O 0 1.4721847207965766e-07
localization O 0 5.990072793338186e-08
of O 0 8.405688922685783e-10
the O 0 1.429970475363973e-09
protein O 0 8.411259244667235e-09
after O 0 1.3680556243400588e-08
exposure O 0 3.458196999872598e-07
to O 0 3.388921143709922e-09
DNA O 0 5.141171186551219e-06
- O 0 6.07978472544346e-06
damaging O 0 1.955512288986938e-06
agents O 0 3.411778237705221e-08
are O 0 1.8573014237688312e-09
consistent O 0 9.98075133651355e-09
with O 0 1.6002756897393056e-09
a O 0 8.271303642004568e-09
role O 0 5.216509535443947e-08
for O 0 1.7851453648631832e-08
BRCA1 O 0 7.481903594452888e-06
in O 0 2.600574475764006e-07
DNA O 0 0.00010593383922241628
repair O 0 0.04720496013760567
. O 0 5.3797411965206265e-06

Here O 0 2.191070052504074e-06
, O 0 5.5479482341525e-08
it O 0 1.0152225726756114e-08
is O 0 1.4622487665150175e-09
shown O 0 8.629107206559183e-09
that O 0 3.35079364255364e-09
mouse O 0 1.4054357677650842e-07
embryonic O 0 5.747579621129262e-07
stem O 0 1.2833232858611154e-06
cells O 0 2.0635523014789214e-06
deficient B-Disease 0 7.017383268248523e-06
in I-Disease 0 1.595817167299174e-08
BRCA1 I-Disease 0 1.7235579434782267e-06
are O 0 1.0241104853037086e-08
defective O 0 6.518006330225035e-07
in O 0 1.4238992207538104e-08
the O 0 4.040256573745182e-09
ability O 0 3.701296336089399e-08
to O 0 2.233996543310468e-09
carry O 0 1.3186835623457682e-08
out O 0 4.550698928795782e-09
transcription O 0 7.545388314156298e-08
- O 0 6.64219123791554e-06
coupled O 0 2.404324732196983e-06
repair O 0 8.688276466273237e-06
of O 0 1.198605881214121e-09
oxidative O 0 3.2547350770073535e-07
DNA O 0 2.0313143977546133e-05
damage O 0 0.0017073594499379396
, O 0 5.726710217146547e-09
and O 0 5.293553595464573e-09
are O 0 5.3882596162679874e-09
hypersensitive O 0 9.708019206300378e-07
to O 0 3.910757584435487e-08
ionizing O 0 5.044405952503439e-06
radiation O 0 7.191541044448968e-06
and O 0 1.0142087347730921e-07
hydrogen O 0 2.313383447472006e-06
peroxide O 0 0.000163169446750544
. O 0 3.84487657356658e-06

These O 0 1.7821060964706703e-06
results O 0 8.998956104733224e-07
suggest O 0 3.425870716000645e-07
that O 0 1.3512922336644806e-08
BRCA1 O 0 2.104430222971132e-06
participates O 0 6.480322412016903e-08
, O 0 4.013558374538206e-09
directly O 0 7.542205082700093e-09
or O 0 2.7559526216691665e-08
indirectly O 0 2.3157753048508312e-07
, O 0 7.663169654392732e-09
in O 0 1.0584648713063416e-08
transcription O 0 6.29442354238563e-07
- O 0 0.01918082684278488
coupled O 0 4.1512452298775315e-05
repair O 0 0.0001321969466516748
of O 0 1.645572922370775e-08
oxidative O 0 5.026648068451323e-06
DNA O 0 4.5294127630768344e-05
damage O 0 0.00040961202466860414
. O 0 5.796272830593807e-07
. O 0 3.1274896628019633e-06

Truncation O 0 0.00018769304733723402
mutations O 0 9.713392500998452e-05
in O 0 1.6361843790946295e-07
the O 0 3.6522557422813406e-08
transactivation O 0 1.4450214621319901e-05
region O 0 5.400927420851076e-07
of O 0 2.3389912229276888e-08
PAX6 O 0 3.108519013039768e-05
result O 0 1.936048420247971e-06
in O 0 1.860472593762097e-07
dominant O 0 0.0243232399225235
- O 0 0.22549022734165192
negative O 0 6.907406350364909e-05
mutants O 0 1.7700967873679474e-05
. O 0 2.6985273962054634e-06

PAX6 O 0 0.0011824843240901828
is O 0 1.428084487997694e-06
a O 0 5.887371656854157e-08
transcription O 0 2.4706537260499317e-07
factor O 0 1.3257808006983396e-07
with O 0 4.103583250980591e-09
two O 0 9.021691838029255e-09
DNA O 0 5.500575571204536e-05
- O 0 0.00017828539421316236
binding O 0 2.7446148465060105e-07
domains O 0 1.5272631515017565e-07
( O 0 6.072863545369955e-09
paired O 0 2.5337658371427096e-07
box O 0 8.429006470578315e-07
and O 0 3.9443104782321825e-08
homeobox O 0 7.701482331867737e-07
) O 0 5.989727824839974e-09
and O 0 3.948795068708932e-09
a O 0 1.109579095270874e-08
proline O 0 2.4504106477252208e-06
- O 0 3.4074096220138017e-06
serine O 0 3.465517238510074e-06
- O 0 2.5921410724549787e-06
threonine O 0 3.851621841022279e-06
( O 0 3.343625820662055e-08
PST O 0 2.6035720566142118e-06
) O 0 4.1178473964009754e-08
- O 0 1.23015422559547e-06
rich O 0 8.627264946881041e-07
transactivation O 0 2.6983141651726328e-05
domain O 0 3.927820216631517e-06
. O 0 1.6722653981560143e-06

PAX6 O 0 0.0014219323638826609
regulates O 0 8.968105248641223e-05
eye O 0 0.03290734067559242
development O 0 3.46615763646696e-07
in O 0 2.6512635642461646e-08
animals O 0 1.523515180679169e-08
ranging O 0 1.4574296436364875e-08
from O 0 6.624310433522851e-09
jellyfish O 0 5.419037663045856e-08
to O 0 5.8889302323450465e-09
Drosophila O 0 3.851632612850153e-08
to O 0 2.5116602131447507e-08
humans O 0 4.851700055041874e-07
. O 0 1.1332009535180987e-06

Heterozygous O 0 0.0002890208561439067
mutations O 0 7.776469283271581e-05
in O 0 1.9818608620880696e-07
the O 0 6.151979903279425e-08
human O 0 1.0088587032441865e-07
PAX6 O 0 6.833092811575625e-06
gene O 0 5.788285193375486e-07
result O 0 2.958816480713722e-07
in O 0 7.349063135819733e-09
various O 0 7.301349747024233e-09
phenotypes O 0 5.410691983342986e-07
, O 0 2.7857636197836655e-09
including O 0 1.657653747599852e-08
aniridia B-Disease 1 1.0
, O 0 3.105908035649918e-06
Peters B-Disease 1 0.9999996423721313
anomaly I-Disease 1 0.9999998807907104
, O 0 7.592943234158156e-07
autosomal B-Disease 0 0.35516199469566345
dominant I-Disease 1 0.646455705165863
keratitis I-Disease 1 0.9969983100891113
, O 0 1.2724744919978548e-06
and O 0 2.8019114779453957e-06
familial B-Disease 1 0.9945670366287231
foveal I-Disease 1 0.9967746138572693
dysplasia I-Disease 1 0.9994180202484131
. O 0 5.019883610657416e-05

It O 0 7.281992679963878e-07
is O 0 2.3073008392771044e-08
believed O 0 6.188911783056028e-08
that O 0 2.0123167576713286e-09
the O 0 3.157617056714912e-09
mutated O 0 2.944176742403215e-07
allele O 0 4.5892548428128066e-07
of O 0 5.6335611731128665e-09
PAX6 O 0 3.4089273412973853e-06
produces O 0 7.315334471513779e-08
an O 0 8.353524982851468e-09
inactive O 0 2.2863655146920792e-07
protein O 0 7.050643802131162e-08
and O 0 1.1452207360207467e-07
aniridia B-Disease 1 0.9999998807907104
is O 0 1.44020191328309e-07
caused O 0 4.56663940440194e-07
due O 0 2.7666922619573597e-07
to O 0 1.7785562533845223e-07
genetic O 0 2.3712904294370674e-05
haploinsufficiency O 0 0.00026132806669920683
. O 0 3.732842515091761e-06

However O 0 1.335592173745681e-06
, O 0 1.9376573234808347e-08
several O 0 9.194103256504604e-09
truncation O 0 1.14344993562554e-06
mutations O 0 8.549523954570759e-06
have O 0 8.769665527097459e-08
been O 0 2.8418634556715006e-08
found O 0 1.1831295054776092e-08
to O 0 2.783723918042824e-09
occur O 0 8.913915827690744e-09
in O 0 2.8947420016578462e-09
the O 0 1.8022342729295815e-08
C O 0 0.031140191480517387
- O 0 1.4640149856859352e-05
terminal O 0 1.2538341707113432e-06
half O 0 9.400867639897115e-09
of O 0 1.3418195443648528e-09
PAX6 O 0 1.20627453270572e-06
in O 0 1.922362002915179e-08
patients O 0 8.057972422648163e-08
with O 0 5.706919381509579e-09
Aniridia B-Disease 1 0.9999998807907104
resulting O 0 9.898077450998244e-07
in O 0 1.1959188306320812e-08
mutant O 0 3.2592506471473826e-08
proteins O 0 9.514893761775056e-09
that O 0 2.3889195066573166e-09
retain O 0 7.104478783048762e-08
the O 0 4.029828026830273e-09
DNA O 0 8.568490557081532e-07
- O 0 1.981093760150543e-07
binding O 0 2.1151993934154234e-08
domains O 0 4.6219238214462166e-08
but O 0 8.518060923279336e-08
have O 0 5.36339719303669e-08
lost O 0 1.1446827556937933e-06
most O 0 4.772194639457439e-09
of O 0 3.843975804329602e-09
the O 0 6.009504005533017e-08
transactivation O 0 5.009860615245998e-05
domain O 0 6.051035597920418e-06
. O 0 2.892417342081899e-06

It O 0 7.433652058352891e-07
is O 0 3.9556336872692555e-08
not O 0 2.5621362809147286e-08
clear O 0 2.406463650572732e-08
whether O 0 9.08431907475915e-09
such O 0 3.4571392415472246e-09
mutants O 0 4.981883421351085e-07
really O 0 1.0114597870369835e-07
behave O 0 2.797047038427536e-08
as O 0 6.320286516370288e-09
loss O 0 1.5273228370915604e-07
- O 0 1.1766502439058968e-06
of O 0 9.935073208566791e-09
- O 0 0.00018401918350718915
function O 0 1.9746937596210046e-07
mutants O 0 7.992396149347769e-07
as O 0 3.014860183725432e-08
predicted O 0 2.0111517073928553e-07
by O 0 2.9375092580607998e-08
haploinsufficiency O 0 1.4696215657750145e-05
. O 0 1.6048330735429772e-06

Contrary O 0 2.3366046661976725e-06
to O 0 5.900131228031569e-08
this O 0 3.86154619391732e-09
theory O 0 1.214904710167275e-08
, O 0 2.4163464562576564e-09
our O 0 4.075813908599457e-09
data O 0 3.321486374829874e-08
showed O 0 3.3405978427936134e-08
that O 0 5.754485776776619e-10
these O 0 9.072522733077903e-10
mutants O 0 1.042987918253857e-07
are O 0 3.7850735878919295e-09
dominant O 0 1.3399054296314716e-05
- O 0 0.000294793484499678
negative O 0 2.151356511603808e-06
in O 0 1.4115953739235465e-08
transient O 0 2.4125949948938796e-07
transfection O 0 4.686612555815373e-06
assays O 0 8.694932148500811e-06
when O 0 1.911186444658597e-07
they O 0 1.4338329634711044e-08
are O 0 3.074028365190884e-09
coexpressed O 0 2.5464566988375736e-07
with O 0 1.5161809585606534e-08
wild O 0 4.575493051106605e-07
- O 0 0.0012488194042816758
type O 0 7.976392953423783e-05
PAX6 O 0 0.00047918781638145447
. O 0 4.40447183791548e-06

We O 0 1.9374706425878685e-06
found O 0 6.533627328053626e-08
that O 0 5.6559881222995045e-09
the O 0 5.384447998579844e-09
dominant O 0 0.00011987269681412727
- O 0 0.09009101241827011
negative O 0 0.0022067963145673275
effects O 0 3.1143408705247566e-05
result O 0 7.56354410214044e-08
from O 0 1.6199145358442024e-09
the O 0 2.404136445477434e-09
enhanced O 0 9.261128042226119e-08
DNA O 0 3.14512277554968e-07
binding O 0 1.3691003175608785e-07
ability O 0 8.320089506241857e-08
of O 0 5.041797646043733e-09
these O 0 8.684904884148636e-08
mutants O 0 8.31738634587964e-06
. O 0 2.7053865778725594e-06

Kinetic O 0 4.277527841622941e-05
studies O 0 2.5729843855515355e-06
of O 0 2.0407657785881383e-08
binding O 0 6.052561047908966e-07
and O 0 7.332501894552479e-08
dissociation O 0 8.849644927977351e-07
revealed O 0 4.6139084020069276e-07
that O 0 5.5712532365248535e-09
various O 0 7.974533033916487e-09
truncation O 0 8.482940643261827e-07
mutants O 0 1.0265226819683448e-06
have O 0 3.085937549940354e-08
3 O 0 1.1393941790061035e-08
- O 0 4.231740433624509e-07
5 O 0 1.6308277395182813e-08
- O 0 1.983954405204713e-07
fold O 0 2.8154738629382337e-07
higher O 0 2.7499037713596408e-08
affinity O 0 1.1102121000305942e-08
to O 0 1.0906792136111676e-09
various O 0 1.1867314908542426e-09
DNA O 0 1.4783583424105018e-07
- O 0 7.230769938360027e-08
binding O 0 2.2768560370423074e-08
sites O 0 2.1672148520224255e-08
when O 0 1.7235359806022643e-08
compared O 0 8.575127274923489e-09
with O 0 8.544348006900293e-10
the O 0 1.578188424389282e-08
wild O 0 3.849066274597135e-07
- O 0 0.0001878423645393923
type O 0 9.652608423493803e-05
PAX6 O 0 0.0006545907817780972
. O 0 1.1065440958191175e-05

These O 0 1.1356036111465073e-06
results O 0 7.768987302370078e-07
provide O 0 2.4102947193682667e-08
a O 0 9.192313576988909e-09
new O 0 1.5445580814343884e-08
insight O 0 2.7787386613908893e-08
into O 0 4.359094862849133e-09
the O 0 5.2863695643168285e-09
role O 0 4.171914014250433e-08
of O 0 5.522628132581531e-09
mutant O 0 1.0845953966054367e-06
PAX6 O 0 1.7832038793130778e-05
in O 0 3.9315986555266136e-07
causing O 0 1.495319065725198e-05
aniridia B-Disease 1 0.9999960660934448
. O 0 1.995597358472878e-06
. O 0 5.3208591452857945e-06

Reversal O 0 0.0002023224369622767
of O 0 1.7071517959266203e-06
severe O 0 0.2496165633201599
hypertrophic B-Disease 1 0.9817426204681396
cardiomyopathy I-Disease 1 1.0
and O 0 2.107554792019073e-05
excellent O 0 5.59775344299851e-06
neuropsychologic O 0 0.0004638876998797059
outcome O 0 6.744576694472926e-06
in O 0 1.1877651218128449e-07
very B-Disease 0 8.561401045881212e-07
- I-Disease 0 0.0801120325922966
long I-Disease 0 0.0011763402726501226
- I-Disease 0 0.00013616468640975654
chain I-Disease 0 8.928622264647856e-05
acyl I-Disease 0 3.6419234675122425e-05
- I-Disease 0 2.7787402359535918e-05
coenzyme I-Disease 0 9.220373613061383e-06
A I-Disease 0 3.104225925198989e-06
dehydrogenase I-Disease 0 0.001009944244287908
deficiency I-Disease 0 0.0268296729773283
. O 0 5.108600817038678e-06

Very B-Disease 0 4.582980545819737e-05
- I-Disease 0 0.02250133641064167
long I-Disease 0 1.7171663785120472e-05
- I-Disease 0 3.897903297911398e-05
chain I-Disease 0 1.7094984286813997e-05
acyl I-Disease 0 1.7077858501579612e-05
- I-Disease 0 8.566500582674053e-06
coenzyme I-Disease 0 1.7164259134005988e-06
A I-Disease 0 1.1410909905862354e-07
dehydrogenase I-Disease 0 2.368718014622573e-06
( I-Disease 0 2.2802286281375928e-08
VLCAD I-Disease 0 5.350362334866077e-05
) I-Disease 0 1.5933542840684822e-07
deficiency I-Disease 0 0.00015610913396812975
is O 0 1.768582968963983e-08
a O 0 2.5016205995598284e-07
disorder O 0 0.00011297919263597578
of O 0 7.920190725485554e-09
fatty O 0 9.240787221642677e-06
acid O 0 8.950682399699872e-07
beta O 0 9.059648675702192e-08
oxidation O 0 1.4602406395169965e-07
that O 0 2.246984642795269e-08
reportedly O 0 8.098693911051669e-07
has O 0 8.765300663071685e-08
high O 0 2.7595248752732005e-07
rates O 0 5.29851604369469e-07
of O 0 1.4885011445642249e-08
morbidity O 0 0.00021973370166961104
and O 0 7.9917708717403e-07
mortality O 0 2.7950958610745147e-05
. O 0 2.86586305264791e-06

We O 0 1.6069081993919099e-06
describe O 0 3.125886394172994e-07
the O 0 7.658845113667212e-09
outcome O 0 2.3873994337009208e-08
of O 0 5.07874187150037e-10
a O 0 4.334479442036354e-09
5 O 0 1.9044684052005323e-08
- O 0 4.62617572338786e-06
year O 0 2.046289608870211e-07
- O 0 1.4960452062950935e-05
old O 0 1.978460932150483e-05
girl O 0 1.120664364862023e-06
with O 0 4.0083275365532245e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.2671366650683922e-07
was O 0 5.1844114778987205e-08
first O 0 1.287102424640807e-08
seen O 0 3.3438337254665385e-07
at O 0 7.856487016510982e-09
5 O 0 1.8397010581594486e-09
months O 0 3.652992575098324e-09
of O 0 9.493877906052717e-10
age O 0 6.79297755823427e-08
with O 0 1.1931612675653014e-07
severe O 1 0.6147385835647583
hypertrophic B-Disease 1 0.9991693496704102
cardiomyopathy I-Disease 1 1.0
, O 0 0.001176998601295054
hepatomegaly B-Disease 1 1.0
, O 0 6.033984391251579e-06
encephalopathy B-Disease 0 0.0014479388482868671
, O 0 1.3039090163147193e-07
and O 0 4.359072534043662e-07
hypotonia B-Disease 0 0.00022447542869485915
. O 0 9.834763659455348e-06

Biochemical O 0 0.003492523217573762
studies O 0 0.0003945641510654241
indicated O 1 0.6715460419654846
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 8.755232556723058e-05
by O 0 4.3636973146021774e-08
a O 0 2.6751638415589696e-07
stable O 0 1.9711089407792315e-05
yet O 0 1.6904162976061343e-06
inactive O 0 6.79667800795869e-06
enzyme O 0 1.179720311483834e-05
. O 0 3.0048367989365943e-06

Molecular O 0 9.03806576388888e-05
genetic O 0 1.9743274606298655e-05
analysis O 0 6.454823733292869e-07
of O 0 1.955329409497608e-08
her O 0 9.878858691081405e-07
VLCAD O 0 0.0005821102531626821
gene O 0 4.241973329044413e-06
revealed O 0 5.314210739015834e-06
a O 0 1.185201057296581e-07
T1372C O 0 3.9470833144150674e-06
( O 0 4.1459667698973135e-08
F458L O 0 1.9838741991407005e-06
) O 0 9.367185072051143e-08
missense O 0 1.2684490684478078e-05
mutation O 0 1.5285646441043355e-05
and O 0 8.867386327437998e-07
a O 0 2.9528196137107443e-06
1668 O 1 0.8860254287719727
ACAG O 0 0.05951864644885063
1669 O 0 0.00012074677943019196
splice O 0 0.0001347447105217725
site O 0 2.7601914553088136e-05
mutation O 0 0.00016925978707149625
. O 0 1.4431429917749483e-05

After O 0 5.310562755767023e-06
initial O 0 8.127150863401766e-07
treatment O 0 4.0430651893075265e-07
with O 0 7.586122841019005e-09
intravenous O 0 2.927757805082365e-07
glucose O 0 4.2508519982220605e-05
and O 0 7.784682054534642e-08
carnitine O 0 6.57270174997393e-06
, O 0 1.7852782363547703e-08
the O 0 8.6772180551975e-09
patient O 0 2.0873855532954622e-07
has O 0 2.3749731070665803e-08
thrived O 0 3.7499515315175813e-07
on O 0 1.4732037811882037e-08
a O 0 1.9161644715381954e-08
low O 0 5.735026206821203e-06
- O 0 1.6260605661955196e-06
fat O 0 1.973550922684808e-07
diet O 0 4.2366345098798774e-08
supplemented O 0 3.6191366348248266e-08
with O 0 7.554644909646413e-09
medium O 0 7.63663319958141e-06
- O 0 3.6604476463253377e-06
chain O 0 5.3260223467077594e-06
triglyceride O 0 1.0056816790893208e-05
oil O 0 1.106735226130695e-06
and O 0 3.7500079486108007e-08
carnitine O 0 2.079557816614397e-06
and O 0 2.3080138689124396e-08
avoidance O 0 2.6594713631311606e-07
of O 0 4.6266869446753844e-08
fasting O 0 8.184527359844651e-06
. O 0 2.9485111099347705e-06

Her O 0 5.4482141422340646e-05
ventricular O 0 0.0001102989845094271
hypertrophy O 0 0.00011484485730761662
resolved O 0 1.4149700291454792e-05
significantly O 0 1.1293063835182693e-06
over O 0 4.255187846524677e-08
1 O 0 2.917619745801403e-08
year O 0 1.1498493712736035e-08
, O 0 2.602294157938445e-09
and O 0 8.27985857654312e-09
cognitively O 0 1.7250148403036292e-06
, O 0 3.6281615489741625e-09
she O 0 8.935161872614117e-07
is O 0 1.6501672250868182e-09
in O 0 4.562362487803284e-09
the O 0 6.563163790218596e-09
superior O 0 4.867675897912704e-07
range O 0 1.164578407042427e-07
for O 0 2.2428995549717e-08
age O 0 6.11919517723436e-07
. O 0 5.921257866248197e-07

Clinical O 0 8.241688192356378e-05
recognition O 0 3.735107384272851e-06
of O 0 1.5087676956682117e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 3.56552902758267e-08
important O 0 1.631947910141207e-08
because O 0 5.892180254818413e-08
it O 0 9.197663963789182e-09
is O 0 1.3498463458105903e-09
one O 0 7.06012415196966e-10
of O 0 3.9479117197593894e-10
the O 0 4.483019289125423e-09
few O 0 2.75790171144763e-07
directly O 0 2.141122422472108e-06
treatable O 1 0.7896845936775208
causes O 0 1.9547742624581588e-07
of O 0 2.1419866769178952e-08
cardiomyopathy B-Disease 1 0.9999992847442627
in O 0 2.430145514153992e-06
children O 0 3.7370634231592703e-07
. O 0 2.6913750161838834e-07
. O 0 2.130063194272225e-06

Cloning O 0 9.092485015571583e-06
of O 0 7.840128546376945e-08
a O 0 4.0198962381055026e-08
novel O 0 1.0641251435572485e-07
member O 0 1.2019214956637825e-08
of O 0 1.6313279616042564e-09
the O 0 4.261003283545506e-08
low O 0 0.0217280276119709
- O 0 0.0019413031404837966
density O 0 2.030045152423554e-06
lipoprotein O 0 0.00019676226656883955
receptor O 0 1.3211832083470654e-05
family O 0 3.254069270042237e-06
. O 0 2.7452140329842223e-06

A O 0 1.715192070150806e-06
gene O 0 2.3282966594706522e-06
encoding O 0 1.521841454632522e-06
a O 0 2.913172068019776e-07
novel O 0 1.082142489394755e-06
transmembrane O 0 2.614136292322655e-06
protein O 0 8.270579883173923e-07
was O 0 6.205684712767834e-07
identified O 0 4.9386091660608145e-08
by O 0 3.0854299115645745e-09
DNA O 0 4.0437205939269916e-07
sequence O 0 4.726262048393437e-08
analysis O 0 3.625396161055505e-08
within O 0 5.640636402404198e-09
the O 0 2.967236234496795e-08
insulin B-Disease 1 0.9307047724723816
- I-Disease 1 0.9995874762535095
dependent I-Disease 1 0.9994556307792664
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 9.926786788128084e-07
IDDM B-Disease 0 0.0006588220712728798
) O 0 1.3444851276744885e-07
locus O 0 1.8208429537480697e-05
IDDM4 O 0 9.626751125324517e-05
on O 0 6.033128556737211e-07
chromosome O 0 5.1885621360270306e-05
11q13 O 0 0.00011817055201390758
. O 0 9.815837074711453e-06

Based O 0 2.792817213048693e-06
on O 0 7.955834746553592e-08
its O 0 4.532527952960663e-08
chromosomal O 0 0.011921839788556099
position O 0 0.00048680821782909334
, O 0 4.829912025883232e-09
this O 0 1.0840509601095505e-09
gene O 0 1.9681110074998287e-08
is O 0 4.488734717256193e-09
a O 0 6.947224573394806e-09
candidate O 0 5.418552007085964e-08
for O 0 3.2202640554146456e-09
conferring O 0 4.3437179897409806e-07
susceptibility O 0 4.2520841816440225e-05
to O 0 6.181518983794376e-06
diabetes B-Disease 1 0.7526548504829407
. O 0 9.214731107931584e-06

The O 0 1.1814729532488855e-06
gene O 0 1.7542662362757255e-06
, O 0 9.482087648393644e-08
termed O 0 1.506896751379827e-06
low O 0 5.08123412146233e-05
- O 0 4.212427302263677e-05
density O 0 1.6604913071205374e-06
lipoprotein O 0 5.4015668865758926e-05
receptor O 0 1.2684602097579045e-06
related O 0 1.632160433473473e-07
protein O 0 2.1756522983196191e-07
5 O 0 2.2517681941280898e-08
( O 0 4.5097596768073345e-09
LRP5 O 0 2.536780812079087e-06
) O 0 7.0194166035264516e-09
, O 0 1.3386778352497686e-09
encodes O 0 1.6284811721334336e-08
a O 0 8.675348439624031e-09
protein O 0 2.7200341534694417e-08
of O 0 4.325989344522441e-09
1615 O 0 9.600162229617126e-07
amino O 0 4.5659515279794505e-08
acids O 0 5.582414175364647e-08
that O 0 9.491415431384098e-10
contains O 0 4.305457379505384e-10
conserved O 0 5.476244790969531e-09
modules O 0 5.947631365188499e-08
which O 0 8.577597299108675e-09
are O 0 1.8846004756767343e-09
characteristic O 0 3.12825676473949e-08
of O 0 2.8057709489104354e-09
the O 0 9.51560537032492e-08
low O 0 0.040685802698135376
- O 0 0.017514143139123917
density O 0 4.163141056778841e-06
lipoprotein O 0 0.0011416623601689935
( O 0 1.7281023190207634e-07
LDL O 0 4.734269168693572e-05
) O 0 1.2938248517002648e-07
receptor O 0 1.6757488765506423e-06
family O 0 1.8592713786347304e-06
. O 0 2.560925850048079e-06

These O 0 9.667754738984513e-07
modules O 0 1.1565546174097108e-06
include O 0 1.007305101552447e-07
a O 0 3.7772721839246515e-08
putative O 0 5.447732860375254e-07
signal O 0 1.879052859976582e-07
peptide O 0 9.342562634628848e-08
for O 0 2.1752355472415275e-09
protein O 0 1.1786135623026439e-08
export O 0 2.1344336076367654e-08
, O 0 3.090866673716164e-09
four O 0 6.897145965467644e-09
epidermal O 0 8.33511364817241e-07
growth O 0 7.332599807341467e-07
factor O 0 3.3198085702679236e-07
( O 0 1.8302417359450374e-08
EGF O 0 2.8392360036377795e-06
) O 0 1.6963102922318285e-08
repeats O 0 1.7271369756599597e-07
with O 0 1.1193486137983655e-08
associated O 0 7.958597336710227e-08
spacer O 0 2.23239976548939e-06
domains O 0 9.33109049583436e-07
, O 0 2.591270131802048e-08
three O 0 3.703372186691922e-08
LDL O 0 0.0020802526269108057
- O 0 8.590495781390928e-06
receptor O 0 3.278935878370248e-07
( O 0 7.794113798809121e-09
LDLR O 0 1.364870286124642e-06
) O 0 7.253323275335788e-09
repeats O 0 8.860642708441446e-08
, O 0 2.8081963421300316e-09
a O 0 3.762500977444461e-09
single O 0 1.4098885969815456e-07
transmembrane O 0 5.238070457380672e-07
spanning O 0 1.9564677700145694e-07
domain O 0 6.088570216888911e-07
, O 0 2.362800977095958e-08
and O 0 4.554991051008983e-08
a O 0 1.333317527496547e-07
cytoplasmic O 0 6.41661390545778e-05
domain O 0 1.720377622405067e-05
. O 0 8.091597919701599e-06

The O 0 1.684626198539263e-07
encoded O 0 1.3210429017362912e-07
protein O 0 1.2539929628019308e-07
has O 0 2.189956838094531e-08
a O 0 4.083704485680073e-09
unique O 0 3.3900217744076144e-08
organization O 0 2.221361405929656e-08
of O 0 3.8547982583736484e-09
EGF O 0 3.8984171624179e-06
and O 0 1.908479241308214e-08
LDLR O 0 1.8918385649158154e-06
repeats O 0 2.1913947989560256e-07
; O 0 6.612620673251968e-09
therefore O 0 6.486453596465935e-09
, O 0 3.0918689830627955e-09
LRP5 O 0 5.039415555074811e-06
likely O 0 6.077060987763616e-08
represents O 0 4.046680768254873e-09
a O 0 6.210489900126959e-09
new O 0 3.5231828121595754e-08
category O 0 1.3354147654354165e-07
of O 0 3.190934183550098e-09
the O 0 8.485078950570824e-08
LDLR O 0 0.009290993213653564
family O 0 1.3019335938224685e-06
. O 0 2.0166728518233867e-06

Both O 0 7.629701030964497e-07
human O 0 1.328610892414872e-07
and O 0 5.359736121590686e-08
mouse O 0 7.565996043013001e-07
LRP5 O 0 4.791469564224826e-06
cDNAs O 0 1.333386535407044e-06
have O 0 2.8293536402657082e-08
been O 0 4.185511670584674e-08
isolated O 0 2.1022447072027717e-07
and O 0 5.7802074238111345e-09
the O 0 1.3022264377937631e-09
encoded O 0 1.4430818318089678e-08
mature O 0 1.710469099691636e-08
proteins O 0 3.549432303628919e-09
are O 0 8.696101061467232e-10
95 O 0 3.010698357286401e-09
% O 0 2.4840927093094933e-09
identical O 0 5.276651791064069e-07
, O 0 7.04122005146246e-09
indicating O 0 2.9618541930176434e-07
a O 0 3.149756722109487e-08
high O 0 1.4474863974101027e-06
degree O 0 3.578296627892996e-07
of O 0 4.8214627845766245e-09
evolutionary O 0 2.771303115878254e-07
conservation O 0 1.8707598314904317e-07
. O 0 2.420836722194508e-07
. O 0 1.7400718661519932e-06

The O 0 2.415690005364013e-06
APC B-Disease 0 9.721410606289282e-06
variants O 0 2.2578381049243035e-06
I1307K O 0 2.4590303837612737e-06
and O 0 2.999288639671249e-08
E1317Q O 0 4.542185934042209e-07
are O 0 9.33977961636856e-09
associated O 0 4.574393699385837e-07
with O 1 0.9963529109954834
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00011038968659704551
but O 0 2.7571441023610532e-06
not O 0 6.057902623979317e-07
always O 0 1.2026993090330507e-07
with O 0 3.619121224929245e-09
a O 0 4.8153996345945416e-08
family O 0 7.204337180155562e-07
history O 0 6.468488209065981e-06
. O 0 3.4247475468873745e-06

Classical O 1 0.8662563562393188
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 7.863065548008308e-05
FAP B-Disease 0 7.865068619139493e-05
) O 0 1.5853164825330168e-07
is O 0 9.582663551555015e-09
a O 0 4.121100616316653e-08
high O 0 0.0050982264801859856
- O 1 0.9989966750144958
penetrance O 1 0.9999226331710815
autosomal B-Disease 1 0.9999673366546631
dominant I-Disease 1 0.9997486472129822
disease I-Disease 0 0.0006734125199727714
that O 0 3.22441251476846e-09
predisposes O 0 1.4352892208080448e-07
to O 0 2.8190365597424716e-09
hundreds O 0 3.460404851551857e-09
or O 0 8.082396973918549e-09
thousands O 0 1.1448402226221788e-08
of O 0 1.293985519623675e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9935165643692017
carcinoma I-Disease 1 1.0
and O 0 2.548773591115605e-05
that O 0 3.833654105278583e-08
results O 0 1.968971332644287e-07
from O 0 1.0166584019088987e-08
truncating O 0 2.479534259691718e-06
mutations O 0 5.65528534934856e-06
in O 0 5.0956984409822326e-08
the O 0 1.921310541774801e-07
APC B-Disease 0 6.341115295072086e-06
gene O 0 8.389074537262786e-06
. O 0 6.250222668313654e-06

A O 0 5.903445526200812e-06
variant O 0 1.3934358321421314e-05
of O 0 1.3733792059156258e-07
FAP B-Disease 0 3.740615284186788e-05
is O 0 1.3285809927765513e-06
attenuated B-Disease 1 0.6944530010223389
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999871253967285
coli I-Disease 1 0.9999996423721313
, O 0 3.917551794074825e-07
which O 0 3.957293870371359e-08
results O 0 8.336084533766552e-08
from O 0 1.0990224730278442e-08
germ O 0 0.000610094633884728
- O 0 0.0003359316906426102
line O 0 1.5514264305238612e-05
mutations O 0 8.793606411927612e-07
in O 0 3.5072238446787196e-09
the O 0 3.531921199950716e-09
5 O 0 6.379170081061147e-09
and O 0 4.883072168837543e-09
3 O 0 5.635108824009194e-09
regions O 0 1.540386307397057e-08
of O 0 2.22899987356584e-09
the O 0 9.184168447973207e-08
APC B-Disease 0 2.5560311769368127e-06
gene O 0 2.9426009859889746e-06
. O 0 2.5759773052413948e-06

Attenuated B-Disease 1 0.999687910079956
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999986886978149
coli I-Disease 1 1.0
patients O 1 0.9756407737731934
have O 0 5.593999503616942e-07
" O 0 1.0115331150473139e-07
multiple O 0 6.0532198403961957e-05
" O 1 0.9997333884239197
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.5020495897365436e-08
typically O 0 3.8427611315228205e-08
fewer O 0 2.3006606397757423e-08
than O 0 8.788348715427219e-09
100 O 0 8.564650322284706e-09
) O 0 4.606484527158727e-09
without O 0 1.4530107783627955e-08
the O 0 4.1897607161445194e-08
florid O 0 0.00036388167063705623
phenotype O 0 5.9709607739932835e-05
of O 0 5.293364324643335e-08
classical O 0 1.600824180059135e-05
FAP B-Disease 0 8.617345156380907e-05
. O 0 3.258367087255465e-06

Another O 0 2.590267740743002e-06
group O 0 2.711058755267004e-07
of O 0 7.92239696068009e-09
patients O 0 1.8278805669069698e-07
with O 0 4.6398165309824435e-09
multiple O 0 1.5934523617033847e-05
adenomas B-Disease 1 0.9911128878593445
has O 0 5.9444832913868595e-06
no O 0 8.35867695059278e-08
mutations O 0 5.725204914597271e-07
in O 0 7.241007349279016e-09
the O 0 4.194228075959927e-09
APC B-Disease 0 5.400753266826541e-08
gene O 0 2.80588476897492e-08
, O 0 2.2075612449157234e-09
and O 0 4.054375501993945e-09
their O 0 1.1593409787735709e-08
phenotype O 0 2.6064537451020442e-05
probably O 0 1.4211663028618204e-06
results O 0 4.707854373009468e-08
from O 0 1.2647203284643638e-09
variation O 0 5.7278597864751646e-08
at O 0 3.082308808188827e-07
a O 0 1.643609337520502e-08
locus O 0 1.493621584813809e-05
, O 0 1.1204059013891765e-08
or O 0 3.3335073368334633e-08
loci O 0 9.39400592869788e-08
, O 0 6.265673757610557e-09
elsewhere O 0 5.8266785174510005e-08
in O 0 1.5451858459414325e-08
the O 0 9.138945955555755e-08
genome O 0 3.33963771481649e-06
. O 0 2.1477587779372698e-06

Recently O 0 4.6957400627434254e-05
, O 0 6.458937207298732e-08
however O 0 3.436550244373393e-08
, O 0 6.343207736847489e-09
a O 0 1.7235624483191714e-08
missense O 0 4.683163297158899e-06
variant O 0 7.343940524151549e-06
of O 0 1.791472747925127e-08
APC B-Disease 0 7.607039833601448e-07
( O 0 7.539299851089254e-09
I1307K O 0 4.6249266461018124e-07
) O 0 8.697465858631404e-09
was O 0 3.443419771542722e-08
described O 0 1.3078027549795479e-08
that O 0 1.3716527913487653e-09
confers O 0 9.525407129729047e-09
an O 0 2.64919486347992e-09
increased O 0 2.102401026604639e-07
risk O 0 0.004019384738057852
of O 0 0.018212061375379562
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.792277141201339e-07
including O 0 3.2728429744111054e-08
multiple O 0 4.888842795480741e-06
adenomas B-Disease 1 0.8055078387260437
, O 0 1.425263747023564e-07
in O 0 4.5343350052462483e-07
Ashkenazim O 0 0.00043117563473060727
. O 0 8.261519724328537e-06

We O 0 1.7929362456925446e-06
have O 0 3.030628903388788e-08
studied O 0 5.902843724925333e-08
a O 0 1.982294106639415e-09
set O 0 9.46968548021232e-09
of O 0 1.9379593485524538e-09
164 O 0 2.610692888538324e-07
patients O 0 4.198648468900501e-07
with O 0 1.088479493205341e-07
multiple O 1 0.9999988079071045
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.12427223473787308
/ I-Disease 0 0.3669589161872864
or I-Disease 1 0.981177568435669
carcinoma I-Disease 1 1.0
and O 0 4.409569373819977e-05
analyzed O 0 1.1860093763971236e-05
codons O 0 1.3831671822117642e-05
1263 O 0 4.018038816866465e-05
- O 0 1.1876797543663997e-05
1377 O 0 1.033212902257219e-05
( O 0 2.3220865230655363e-08
exon O 0 7.667368322472612e-07
15G O 0 1.4781187474000035e-06
) O 0 8.963939812645094e-09
of O 0 8.629201797560881e-10
the O 0 5.345909492859846e-09
APC B-Disease 0 1.0858605037356028e-07
gene O 0 1.3032885703978536e-07
for O 0 2.5238579226538604e-08
germ O 0 0.00027516655973158777
- O 0 0.00015416921814903617
line O 0 1.7116108210757375e-05
variants O 0 1.4996975551184732e-05
. O 0 3.248859911764157e-06

Three O 0 2.192522515542805e-06
patients O 0 2.4554028641432524e-06
with O 0 1.0102466418970835e-08
the O 0 2.094879292258156e-08
I1307K O 0 6.925714615135803e-07
allele O 0 1.0922849469352514e-06
were O 0 4.8838568744713484e-08
detected O 0 3.0726059208063816e-07
, O 0 4.706935730069972e-09
each O 0 9.465080275106175e-09
of O 0 5.120454815710218e-08
Ashkenazi O 0 0.011550689116120338
descent O 0 0.0001556150964461267
. O 0 5.115894509799546e-06

Four O 0 2.272861365781864e-06
patients O 0 7.353345154115232e-06
had O 0 2.128738287865417e-07
a O 0 8.284096253419193e-08
germ O 0 0.003127612406387925
- O 0 0.0010366352507844567
line O 0 4.782439191330923e-06
E1317Q O 0 2.641391802171711e-06
missense O 0 3.353815145601402e-06
variant O 0 1.147823354585853e-06
of O 0 4.26835411460047e-09
APC O 0 9.913440379705207e-08
that O 0 1.0802721384095548e-08
was O 0 1.6460883500712953e-07
not O 0 4.6045083301748946e-09
present O 0 2.089088679824158e-09
in O 0 3.745659782339317e-09
controls O 0 1.0929653626590152e-06
; O 0 6.858277057375517e-09
one O 0 1.1014436029910257e-09
of O 0 1.285474365841921e-10
these O 0 1.3317761338171863e-09
individuals O 0 2.0823613944287445e-09
had O 0 1.6587661377798213e-07
an O 0 1.5862360314145008e-09
unusually O 0 6.675873009953648e-08
large O 0 3.5766994699315546e-08
number O 0 1.3009808341735152e-08
of O 0 9.173747983481917e-09
metaplastic B-Disease 0 0.0001416671002516523
polyps I-Disease 0 2.9844695745850913e-05
of I-Disease 0 1.5918043771989687e-08
the I-Disease 0 2.608577460705419e-07
colorectum I-Disease 0 9.872092050500214e-05
. O 0 5.5384398365276866e-06

There O 0 1.1444557230788632e-06
is O 0 2.9530870193639203e-08
increasing O 0 2.057305437119794e-08
evidence O 0 3.356949207500293e-08
that O 0 2.95263524741074e-09
there O 0 3.3932612275577867e-09
exist O 0 7.064899421038717e-08
germ O 0 0.00018440753046888858
- O 0 1.4695656318508554e-05
line O 0 2.691408269583917e-07
variants O 0 4.644981288493e-08
of O 0 5.481445852772993e-10
the O 0 3.391921632456274e-09
APC B-Disease 0 3.454300312455416e-08
gene O 0 1.2230538359858656e-08
that O 0 1.7460116685796834e-09
predispose O 0 1.86259523360377e-08
to O 0 9.31906218859524e-10
the O 0 1.0129107552714345e-09
development O 0 3.9754333158725785e-09
of O 0 8.692788711073263e-09
multiple O 1 0.9999853372573853
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9988662004470825
carcinoma I-Disease 1 1.0
, O 0 4.3691400719580997e-07
but O 0 1.6065988006630505e-07
without O 0 1.60739794807796e-08
the O 0 9.224174313260392e-09
florid O 0 2.1175312213017605e-05
phenotype O 0 1.5970426829881035e-05
of O 0 3.14583448179917e-09
classical O 0 2.421365650207008e-07
FAP B-Disease 0 4.5415620775202115e-07
, O 0 2.257839692987318e-09
and O 0 1.9482848667706776e-09
possibly O 0 6.853386302907438e-09
with O 0 8.350415359181795e-10
importance O 0 1.07198026455535e-07
for O 1 0.990155816078186
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.6251260638237
in O 0 2.0736466765924888e-08
the O 0 1.1307429659268564e-08
general O 0 1.5904479511164027e-08
population O 0 1.2661878656672343e-07
. O 0 1.690026465439587e-07
. O 0 1.183194854093017e-06

Genomic O 0 0.00010191981709795073
structure O 0 5.408904598880326e-06
of O 0 4.235753792158903e-08
the O 0 1.847723893888542e-07
human O 0 6.104470685386332e-06
congenital B-Disease 1 0.999998927116394
chloride I-Disease 1 0.9999982118606567
diarrhea I-Disease 1 1.0
( O 0 7.507191639888333e-06
CLD B-Disease 1 0.6058602929115295
) O 0 7.655984290977358e-07
gene O 0 1.2729046829917934e-05
. O 0 4.6514624045812525e-06

Congenital B-Disease 1 0.9999986886978149
chloride I-Disease 1 0.9999932050704956
diarrhea I-Disease 1 1.0
( O 0 1.728486495267134e-05
CLD B-Disease 1 0.9847166538238525
) O 0 6.772290248591162e-07
is O 0 4.3133194793654184e-08
caused O 0 1.8234702281461068e-07
by O 0 1.590648146532203e-08
mutations O 0 9.530909665045328e-06
in O 0 3.378402979592465e-08
a O 0 3.248197799621266e-08
gene O 0 3.0372723358595977e-07
which O 0 6.747059444478509e-08
encodes O 0 6.606161946365319e-07
an O 0 3.399819661353831e-07
intestinal O 0 0.010047956369817257
anion O 0 0.0011654299451038241
transporter O 0 0.0006765672005712986
. O 0 1.0335736078559421e-05

We O 0 3.185679452144541e-05
report O 0 3.3437410706937953e-07
here O 0 1.1437576219464063e-08
the O 0 2.2686834633134367e-09
complete O 0 1.450950470882617e-08
genomic O 0 2.689419886792166e-07
organization O 0 8.876048340766829e-09
of O 0 1.7859755896409979e-09
the O 0 2.4981963164805165e-08
human O 0 8.964968856162159e-08
CLD B-Disease 0 3.256642594351433e-05
gene O 0 3.1749908657729975e-07
which O 0 1.710217922834545e-08
spans O 0 9.119391108924901e-08
approximately O 0 3.3563601675723476e-08
39kb O 0 6.187440249050269e-06
, O 0 2.7239019928515518e-08
and O 0 2.8555559694609656e-08
comprises O 0 1.4353028632285714e-07
21 O 0 3.3428099754928553e-07
exons O 0 1.1994218766631093e-05
. O 0 2.9164568786654854e-06

All O 0 2.0934669464622857e-06
exon O 0 3.993095742771402e-05
/ O 0 1.4326611562864855e-05
intron O 0 6.363793363561854e-05
boundaries O 0 2.9260181690915488e-06
conform O 0 3.9189858398458455e-06
to O 0 1.2347504707577173e-07
the O 0 1.9108072990547953e-07
GT O 0 1.561872886668425e-05
/ O 0 2.4561904865549877e-05
AG O 1 0.9939665794372559
rule O 0 9.101663636101875e-06
. O 0 3.776822268264368e-06

An O 0 1.6749470432841917e-07
analysis O 0 1.627925882985437e-07
of O 0 4.814616705317576e-09
the O 0 2.163460877113721e-08
putative O 0 1.7478804466009024e-06
promoter O 0 2.0085424239368876e-06
region O 0 1.903891444499095e-07
sequence O 0 1.773366875568172e-07
shows O 0 2.8696817366835603e-07
a O 0 1.1163597690710958e-07
putative O 0 1.4260498574003577e-05
TATA O 0 0.00992115680128336
box O 0 6.851671059848741e-06
and O 0 1.0997315769145644e-07
predicts O 0 1.0051984418169013e-06
multiple O 0 4.4681084432340867e-07
transcription O 0 2.1294945327099413e-06
factor O 0 9.717226703287452e-07
binding O 0 1.392870558447612e-06
sites O 0 6.3681018218630925e-06
. O 0 3.4413992580084596e-06

The O 0 6.641087679781776e-07
genomic O 0 5.376033186621498e-06
structure O 0 1.5315089285650174e-06
was O 0 2.2948194100536057e-07
determined O 0 4.1025995045629315e-08
using O 0 2.369814744440646e-08
DNA O 0 2.2185122361406684e-07
from O 0 2.7023319137953195e-09
several O 0 1.8687862368693686e-09
sources O 0 5.04260544431645e-09
including O 0 1.564302909429216e-09
multiple O 0 3.0080886403993645e-07
large O 0 5.842257905896986e-06
- O 0 0.0014228872023522854
insert O 0 1.3486445823218673e-05
libaries O 0 3.228012928957469e-06
and O 0 2.5042121265528294e-08
genomic O 0 1.1947398661504849e-06
DNA O 0 2.2089157027949113e-06
from O 0 1.1657250809093966e-07
Finnish O 0 4.947055276716128e-05
CLD B-Disease 0 0.2460210919380188
patients O 0 1.1368356354068965e-05
and O 0 3.743484171536693e-07
controls O 0 3.5113582271151245e-05
. O 0 1.1260187420703005e-05

Exon O 0 8.456635259790346e-05
- O 0 1.233081093232613e-05
specific O 0 1.7547570507758792e-07
primers O 0 2.629964910738636e-06
developed O 0 1.3119580444254098e-07
in O 0 6.144085240578079e-09
this O 0 2.3274016047736268e-09
study O 0 8.887788283118425e-09
will O 0 9.336782458291282e-10
facilitate O 0 6.078182845925539e-09
mutation O 0 1.2591566189712466e-07
screening O 0 1.0530625615956524e-07
studies O 0 2.6777158268487256e-08
of O 0 1.636576096863962e-09
patients O 0 7.119685108136764e-08
with O 0 1.4676898807408634e-08
the O 0 4.997795258532278e-06
disease O 0 0.0012416648678481579
. O 0 4.8862698349694256e-06

Genomic O 0 5.678090383298695e-05
sequencing O 0 5.0529474719951395e-06
of O 0 7.654583811245175e-08
a O 0 2.2874647243043e-07
BAC O 0 1.5939083823468536e-05
clone O 0 1.347274246654706e-05
H O 1 0.9999997615814209
_ O 0 1.7572389765518892e-07
RG364P16 O 0 4.1283314544671157e-07
revealed O 0 1.1762379870106088e-07
the O 0 2.9550351055007695e-09
presence O 0 6.785063177972006e-09
of O 0 6.158043519555179e-10
another O 0 7.928216305685964e-09
, O 0 2.1983634912459138e-09
highly O 0 9.03512376027038e-09
homologous O 0 5.2497675540053024e-08
gene O 0 6.054003165445465e-08
3 O 0 8.084740876768137e-09
of O 0 8.392536665624561e-10
the O 0 1.5413855081192196e-08
CLD B-Disease 0 0.00016994934412650764
gene O 0 1.6153465765000874e-07
, O 0 4.239647299897342e-09
with O 0 1.5916337137156233e-09
a O 0 4.5175254648199825e-09
similar O 0 6.02180421083176e-08
genomic O 0 5.730685188609641e-06
structure O 0 3.906074562110007e-05
, O 0 1.3455543346196919e-08
recently O 0 1.1198338256690477e-07
identified O 0 8.642914650636158e-08
as O 0 5.098430122529862e-08
the O 0 0.00014785595703870058
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.0197549272561446e-05
( O 0 1.035210814848142e-07
PDS B-Disease 0 1.722669185255654e-05
) O 0 1.0837934638630031e-07
. O 0 1.7580634903424652e-07
. O 0 2.179337116103852e-06

The O 0 1.1280329772489495e-06
APCI1307K O 0 2.9031398298684508e-05
allele O 0 1.8283653844264336e-05
and O 0 8.296765372506343e-06
cancer B-Disease 1 0.5550172328948975
risk O 0 2.8687190933851525e-05
in O 0 1.658732351472736e-08
a O 0 2.033542756407769e-08
community O 0 5.4882097089148374e-08
- O 0 4.584414273267612e-05
based O 0 3.0065828582337417e-07
study O 0 1.0231932634496843e-07
of O 0 2.877842675275133e-08
Ashkenazi O 0 6.269029108807445e-05
Jews O 0 3.801655566348927e-06
. O 0 1.8576549791760044e-06

Mutations O 0 0.0004353055264800787
in O 0 1.124741629610071e-06
APC O 0 3.056484047192498e-06
are O 0 1.4012600502155692e-07
classically O 0 0.000512606231495738
associated O 0 8.946808520704508e-06
with O 0 6.968990055611357e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.7471873434260488e-05
FAP B-Disease 0 4.2149986256845295e-05
) O 0 5.0817217100984635e-08
, O 0 1.069431299072221e-08
a O 0 9.935909872638149e-08
highly O 0 0.034283965826034546
penetrant O 1 0.9999954700469971
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 3.182579530403018e-05
by O 0 1.5158518351654493e-07
multiple O 0 0.0026926000136882067
intestinal O 1 0.9985551238059998
polyps B-Disease 1 0.5715015530586243
and O 0 4.6677438803044424e-08
, O 0 3.132500481228817e-09
without O 0 9.426921465660598e-09
surgical O 0 2.686838115550927e-06
intervention O 0 7.605569152246971e-08
, O 0 3.066345399815873e-09
the O 0 5.690159454729837e-09
development O 0 7.80686733037328e-08
of O 0 0.016165729612112045
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.899264010622574e-07
CRC B-Disease 0 1.0141057828150224e-05
) O 0 2.757940933406644e-07
. O 0 1.178058255391079e-06

APC B-Disease 0 7.86840682849288e-05
is O 0 9.35775346988521e-07
a O 0 1.429421104148787e-06
tumour O 1 0.9999998807907104
- O 0 6.114677671575919e-05
suppressor O 0 5.893601155548822e-06
gene O 0 7.052909154481313e-07
, O 0 1.7024980536461953e-08
and O 0 1.9937349549081773e-08
somatic O 0 2.8432623366825283e-06
loss O 0 1.0771769666462205e-05
occurs O 0 1.956678261194611e-06
in O 0 1.559994234412443e-05
tumours B-Disease 1 1.0
. O 0 3.1757575925439596e-05

The O 0 7.122114311641781e-06
germline O 0 0.00016002936172299087
T O 0 0.00023522147967014462
- O 0 7.2563811954751145e-06
to O 0 5.7130211672529185e-08
- O 0 3.336233476147754e-07
A O 0 1.8198370810296183e-08
transversion O 0 2.5333355324619333e-07
responsible O 0 3.133679271627443e-08
for O 0 2.138735855083951e-09
the O 0 6.2381273480127675e-09
APC O 0 1.6035158978411346e-07
I1307K O 0 1.4925387858966133e-07
allele O 0 1.26257646115846e-07
converts O 0 4.995823488229689e-08
the O 0 2.8504500981796355e-09
wild O 0 2.100216356382134e-08
- O 0 6.595441846002359e-07
type O 0 1.6715003425815667e-07
sequence O 0 2.6139659325963294e-08
to O 0 8.655828054315862e-09
a O 0 1.4590818331328137e-08
homopolymer O 0 0.0003309585154056549
tract O 0 0.0006473293760791421
( O 0 1.6430544036438732e-08
A8 O 0 0.0005531457136385143
) O 0 5.6898659117621264e-09
that O 0 2.493349082755003e-09
is O 0 7.629771481276748e-09
genetically O 0 3.410868032460712e-07
unstable O 0 0.0011466164141893387
and O 0 1.4533580383613298e-07
prone O 0 9.847968613030389e-06
to O 0 1.2037986607538187e-07
somatic O 0 1.565868478792254e-05
mutation O 0 5.255555879557505e-05
. O 0 3.053829686905374e-06

The O 0 1.170648602055735e-06
I1307K O 0 1.6025518561946228e-05
allele O 0 1.8002017895923927e-05
was O 0 6.603750080103055e-07
found O 0 1.367826598652755e-07
in O 0 1.3181985991650436e-07
6 O 0 1.1995921340712812e-06
. O 0 3.707787072926294e-06

1 O 0 4.055687895743176e-06
% O 0 2.2286486967004748e-07
of O 0 1.427505047502109e-08
unselected O 0 3.5943568946095183e-05
Ashkenazi O 0 0.0003945432836189866
Jews O 0 8.173585683834972e-07
and O 0 5.1034117376502763e-08
higher O 0 3.2295110941049643e-07
proportions O 0 5.369077484829177e-07
of O 0 1.6104875211198078e-09
Ashkenazim O 0 4.759925104735885e-06
with O 0 1.3387881914184163e-08
family O 0 1.1876812777700252e-07
or O 0 1.8392113076970418e-07
personal O 0 2.644179062372132e-07
histories O 0 2.0857828531006817e-06
of O 0 2.3671676174785716e-08
CRC B-Disease 0 1.3587398825620767e-05
( O 0 3.180254282142414e-08
ref O 0 4.3112278945045546e-05
. O 0 7.41733643394582e-08
2 O 0 9.00067433917684e-08
) O 0 7.74679307369297e-08
. O 0 5.751242611040652e-07

To O 0 1.1765986300815712e-06
evaluate O 0 1.3252932831164799e-06
the O 0 1.9828471309324414e-08
role O 0 2.5784713031384854e-08
of O 0 2.03853955937916e-09
I1307K O 0 4.5433858986143605e-07
in O 0 6.721575829260473e-08
cancer B-Disease 0 1.620707735128235e-05
, O 0 7.10901737477343e-09
we O 0 1.5303241340802742e-08
genotyped O 0 5.19013553912373e-07
5 O 0 2.1437687180991816e-08
, O 0 1.52930006436236e-08
081 O 0 4.688767148763873e-06
Ashkenazi O 0 8.958231774158776e-06
volunteers O 0 1.0120850646444524e-07
in O 0 1.1253124654331259e-08
a O 0 4.417215748730996e-08
community O 0 2.6348777737439377e-07
survey O 0 6.248708814382553e-06
. O 0 2.044168695647386e-06

Risk O 0 0.001564925187267363
of O 0 1.6519385326319025e-07
developing O 0 8.253697887994349e-05
colorectal B-Disease 1 1.0
, I-Disease 0 1.5104592421266716e-06
breast I-Disease 0 0.2650892436504364
and I-Disease 0 1.5452896207079903e-07
other I-Disease 0 6.37506119005593e-08
cancers I-Disease 1 0.9778984189033508
were O 0 4.920959995047269e-08
compared O 0 3.3580249692022335e-08
between O 0 1.1737857796845219e-08
genotyped O 0 1.4701295185659546e-06
I1307K O 0 4.5941195025989146e-07
carriers O 0 9.780618626109572e-08
and O 0 9.369183651131152e-09
non O 0 5.669729929991263e-08
- O 0 1.856305607361719e-05
carriers O 0 2.7417607384450093e-07
and O 0 6.178046962901362e-09
their O 0 7.60974483426935e-09
first O 0 1.823503197329046e-07
- O 0 5.092861829325557e-05
degree O 0 4.272280420991592e-06
relatives O 0 8.308550150104566e-07
. O 0 1.7614413536648499e-06

Sperm O 0 9.583857899997383e-05
DNA O 0 1.5499208529945463e-05
analysis O 0 1.4360027762450045e-06
in O 0 2.5225398303518887e-07
a O 0 4.419993331339356e-07
Friedreich B-Disease 0 0.0006124920910224319
ataxia I-Disease 0 0.02242061123251915
premutation O 0 0.32051151990890503
carrier O 0 0.0008106718887574971
suggests O 0 5.402034730650485e-07
both O 0 4.5599982456678845e-08
meiotic O 0 6.618586667173076e-06
and O 0 5.667383717877783e-08
mitotic O 0 1.0759671340565546e-06
expansion O 0 3.54534478219648e-07
in O 0 7.915210176179244e-08
the O 0 1.8244216448692896e-07
FRDA B-Disease 0 6.048310024198145e-05
gene O 0 7.057544280542061e-06
. O 0 3.2925838695518905e-06

Friedreich B-Disease 0 0.37341567873954773
ataxia I-Disease 1 0.92167067527771
is O 0 2.011815922742244e-05
usually O 0 6.159733402455458e-06
caused O 0 3.7663519947273016e-07
by O 0 4.884320503606432e-09
an O 0 3.625187039446587e-09
expansion O 0 7.140193503119008e-08
of O 0 8.421324082519277e-09
a O 0 1.0544814443846917e-07
GAA O 0 5.6508215493522584e-06
trinucleotide O 0 1.9216204236727208e-05
repeat O 0 1.3513523526853533e-06
in O 0 2.6042220824251672e-08
intron O 0 4.922466814605286e-06
1 O 0 5.140790193536304e-08
of O 0 6.058737511693835e-09
the O 0 6.991279377643878e-08
FRDA B-Disease 0 2.7384850909584202e-05
gene O 0 5.289940872899024e-06
. O 0 3.463894699962111e-06

Occasionally O 0 2.5463923520874232e-05
, O 0 1.1212786432679422e-07
a O 0 1.3664492648501891e-08
fully O 0 5.2748802659152716e-08
expanded O 0 2.5027366845620236e-08
allele O 0 3.5133226106154325e-07
has O 0 1.3500092599372238e-08
been O 0 1.3159899836523437e-08
found O 0 6.470611602082954e-09
to O 0 2.694534373404167e-09
arise O 0 1.881508993051284e-08
from O 0 8.848322630150562e-10
a O 0 4.111096352232835e-09
premutation O 0 3.3828496270871256e-07
of O 0 2.1169459518688427e-09
100 O 0 1.7360999748916583e-08
or O 0 6.448190958963096e-08
less O 0 2.2267725796609739e-07
triplet O 0 0.00026624806923791766
repeats O 0 8.77632264746353e-05
. O 0 1.013797282212181e-05

We O 0 3.993446171079995e-06
have O 0 8.119421579522168e-08
examined O 0 1.9592647504396155e-07
the O 0 5.707659234133189e-09
sperm O 0 2.4611131266283337e-07
DNA O 0 1.9344969359735842e-07
of O 0 6.232443006126687e-09
a O 0 1.2189694587050326e-07
premutation O 0 0.0007427367963828146
carrier O 0 7.80817645136267e-05
. O 0 2.431376742606517e-06

This O 0 6.67772610540851e-07
mans O 0 4.882162102148868e-06
leucocyte O 0 7.838280907890294e-06
DNA O 0 1.9657195480249356e-06
showed O 0 1.2667108251207537e-07
one O 0 7.362911169650488e-09
normal O 0 4.873648862258051e-08
allele O 0 3.551124336809153e-07
and O 0 1.016177630930315e-08
one O 0 8.894130765213504e-09
allele O 0 3.11941533936988e-07
of O 0 7.403552881868336e-09
approximately O 0 1.220821559400065e-07
100 O 0 2.2506181096559885e-07
repeats O 0 1.0068275514640845e-05
. O 0 2.6634286314219935e-06

His O 0 1.2172657761766459e-06
sperm O 0 3.168132707287441e-06
showed O 0 1.1274893552126741e-07
an O 0 3.3840896751513583e-09
expanded O 0 2.9755106822904054e-08
allele O 0 3.723587269632844e-07
in O 0 3.902129108723784e-08
a O 0 3.25367892628492e-08
tight O 0 4.929993338009808e-07
range O 0 3.24200826185006e-08
centering O 0 1.6802131241888674e-08
on O 0 1.1176035208393387e-08
a O 0 1.1270415711805981e-08
size O 0 9.136905987361388e-08
of O 0 9.6686036954452e-09
approximately O 0 1.4240939094634086e-07
320 O 0 1.4915569863660494e-06
trinucleotide O 0 9.481231973040849e-05
repeats O 0 2.516717358957976e-05
. O 0 6.647971076745307e-06

His O 0 7.1332619882014114e-06
affected O 0 6.024209596944274e-06
son O 0 2.713919457164593e-06
has O 0 1.7194815882248804e-07
repeat O 0 1.8391305047771311e-06
sizes O 0 1.0887281405302929e-06
of O 0 2.1565968566505944e-08
1040 O 0 7.042329343676101e-06
and O 0 3.0487993285532866e-07
540 O 0 8.281706868729088e-06
. O 0 3.3912458548002178e-06

These O 0 2.601856863293506e-07
data O 0 2.560456664468802e-07
suggest O 0 5.199840558134383e-08
that O 0 1.832853757655073e-09
expansion O 0 8.078990809678999e-09
occurs O 0 5.387622348251853e-09
in O 0 2.4923649810659754e-09
two O 0 3.2939906358109283e-09
stages O 0 5.791847570435493e-07
, O 0 3.0492626201805706e-09
the O 0 1.3545146115845341e-09
first O 0 1.1890475271059131e-08
during O 0 1.0256508531369946e-08
meiosis O 0 3.558110250878599e-08
followed O 0 1.4196172237745941e-08
by O 0 6.9190049245548835e-09
a O 0 2.5313980245300627e-08
second O 0 2.6687706622396945e-07
mitotic O 0 9.593184586265124e-06
expansion O 0 6.601164841413265e-06
. O 0 3.5328571357240435e-06

We O 0 2.2776609966967953e-06
also O 0 3.248538504863063e-08
show O 0 1.552355222145252e-08
that O 0 8.150617403224203e-10
in O 0 9.249291887947209e-10
all O 0 5.073058639837313e-10
informative O 0 3.2318954623633545e-08
carrier O 0 1.2165480711701093e-07
father O 0 1.642029978654591e-08
to O 0 5.12310949218886e-09
affected O 0 2.1291963747671616e-08
child O 0 3.18977377844476e-08
transmissions O 0 8.768291195337952e-07
, O 0 1.530130799842766e-09
with O 0 6.645187178300205e-10
the O 0 2.5227975264385805e-09
notable O 0 3.850046326192569e-08
exception O 0 3.0083750601761494e-08
of O 0 6.892829085280994e-10
the O 0 9.377568943591541e-09
premutation O 0 0.00038100415258668363
carrier O 0 4.8890901780396234e-06
, O 0 1.924749470916254e-09
the O 0 2.2197126359202457e-09
expansion O 0 1.051406712804237e-07
size O 0 4.2452413140381395e-07
decreases O 0 1.2080716942364234e-06
. O 0 1.5317324653096875e-07
. O 0 7.841113074391615e-07

The O 0 1.260157659999095e-06
R496H O 0 1.3008021596760955e-05
mutation O 0 3.1032520837470656e-06
of O 0 1.5048813750695444e-08
arylsulfatase O 0 6.9348225224530324e-06
A O 0 2.4163529133147676e-07
does O 0 7.282964702426398e-07
not O 0 1.231724922945432e-06
cause O 0 2.397942625975702e-05
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999995231628418
. O 0 3.940318856621161e-05

Deficiency B-Disease 1 0.9988161325454712
of I-Disease 0 9.975424291042145e-07
arylsulfatase I-Disease 0 0.0002529773337300867
A I-Disease 0 1.9840065306198085e-06
( O 0 3.727232638084388e-07
ARSA O 0 0.0004891262506134808
) O 0 2.7558877491173916e-07
enzyme O 0 2.613219066915917e-06
activity O 0 9.798776773095597e-06
causes O 0 0.0004295526596251875
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 1.3663999197888188e-05
MLD B-Disease 1 0.9999973773956299
) O 0 4.864139555138536e-06
. O 0 6.307370313152205e-06

A O 0 3.7655329379049363e-06
number O 0 2.696304761684587e-07
of O 0 1.0460600208261894e-07
ARSA O 0 0.00014748898684047163
gene O 0 2.9763505153823644e-06
mutations O 0 7.169039236032404e-06
responsible O 0 6.0551241176654e-07
for O 0 2.9622779607052507e-07
MLD B-Disease 1 0.9999998807907104
have O 0 1.3027090062678326e-05
been O 0 8.820761081551609e-07
identified O 0 2.4232697342085885e-06
. O 0 1.7136453607236035e-06

Recently O 0 1.9287292161607184e-05
, O 0 5.614909426299164e-08
the O 0 1.57109738552208e-08
R496H O 0 1.2306776397963404e-06
mutation O 0 4.6132660713738005e-07
of O 0 1.1205234962119448e-08
ARSA O 0 0.00028622846002690494
was O 0 1.3135078802406497e-07
proposed O 0 1.345133515684438e-08
to O 0 2.6768516292463573e-09
be O 0 4.643632145473475e-09
a O 0 9.447747473245727e-09
cause O 0 2.1823579743340815e-07
of O 0 4.2909100272936485e-08
MLD B-Disease 1 0.9999996423721313
( O 0 5.337954789297328e-08
Draghia O 0 1.2877777407993563e-05
et O 0 5.393837454903405e-06
al O 0 2.6943849661620334e-05
. O 0 9.87874813063172e-08
, O 0 2.601426984938371e-08
1997 O 0 4.3436850205580413e-07
) O 0 2.317852221267458e-07
. O 0 1.0785386166389799e-06

We O 0 1.9287067516415846e-06
have O 0 4.567048605963464e-08
investigated O 0 1.2962850348685606e-07
the O 0 4.936233199970275e-09
R496H O 0 6.613619234485668e-07
mutation O 0 2.3665720050303207e-07
and O 0 7.267379587005962e-09
found O 0 5.242070333366655e-09
this O 0 1.2584544517579843e-09
mutation O 0 1.8504026400023577e-07
at O 0 3.250751490213588e-08
a O 0 4.012899790239999e-09
relatively O 0 4.3638802793566356e-08
high O 0 6.771955440854072e-08
frequency O 0 5.745640123677731e-07
in O 0 1.621368284077107e-08
an O 0 3.8449292638631505e-09
African O 0 9.676905499134136e-09
American O 0 1.622076517548976e-08
population O 0 9.438921644289167e-09
( O 0 3.198398657033863e-09
f O 0 1.8284069369656208e-07
= O 0 2.557528091529093e-07
0 O 0 2.1294725982556884e-08
. O 0 1.2861918641249304e-08
09 O 0 1.634437722941584e-07
, O 0 8.833707099142885e-09
n O 0 1.4583370102627669e-06
= O 0 1.954354502231581e-06
61 O 0 2.0135124145781447e-07
subjects O 0 1.3257850923764636e-06
) O 0 2.4372053530896665e-07
. O 0 1.106495574276778e-06

The O 0 2.4976352506200783e-06
ARSA O 0 0.00010467106039868668
enzyme O 0 1.6833057543408358e-06
activity O 0 2.6566704036667943e-07
in O 0 1.0372501080269103e-08
subjects O 0 6.109532790787853e-08
with O 0 2.107040319998532e-09
and O 0 8.86555806545175e-09
without O 0 8.195017109358105e-09
the O 0 1.7666502705182552e-09
R496H O 0 2.6584496026771376e-07
mutation O 0 1.987554298921168e-07
was O 0 1.1667172117313385e-07
determined O 0 8.544942886601348e-08
and O 0 7.957393854951533e-09
found O 0 1.9669363027219333e-08
to O 0 9.085982632939249e-09
be O 0 5.148659809606215e-08
normal O 0 9.503332307758683e-07
. O 0 1.810220396691875e-06

It O 0 6.942968298062624e-07
is O 0 5.976971095833505e-08
therefore O 0 4.9909946397974636e-08
concluded O 0 5.922974821714888e-08
that O 0 2.007869426279285e-09
the O 0 3.175760987517151e-09
R496H O 0 3.1763144647811714e-07
mutation O 0 1.534631763888683e-07
of O 0 3.6566663030868085e-09
ARSA O 0 7.612330227857456e-05
does O 0 7.067702512131291e-08
not O 0 1.1416522838203491e-08
negatively O 0 2.58631267513465e-08
influence O 0 1.0752152945769922e-08
the O 0 3.4489000544368764e-09
activity O 0 1.7124964557524436e-08
of O 0 2.746725735747191e-09
ARSA O 0 0.0021077804267406464
and O 0 2.37624178112128e-08
is O 0 7.454194594913588e-09
not O 0 3.199120257590948e-08
a O 0 9.084999419428641e-08
cause O 0 3.235749318264425e-06
of O 0 3.684719331431552e-06
MLD B-Disease 1 0.9999955892562866

Down O 0 8.911949407774955e-05
- O 0 1.2170347872597631e-05
regulation O 0 5.788152748209541e-07
of O 0 2.0820564827772614e-08
transmembrane O 0 1.5472317045350792e-06
carbonic O 0 1.1448638360889163e-05
anhydrases O 0 7.091843144735321e-05
in O 0 3.949583515350241e-06
renal B-Disease 1 0.999953031539917
cell I-Disease 1 0.9999988079071045
carcinoma I-Disease 1 1.0
cell O 1 0.9944186210632324
lines O 0 0.00017508155724499375
by O 0 3.8007740954526525e-08
wild O 0 1.7634398545851582e-06
- O 1 0.9516676664352417
type O 1 0.9908173084259033
von B-Disease 1 0.9999686479568481
Hippel I-Disease 1 0.9995657801628113
- I-Disease 1 0.875555694103241
Lindau I-Disease 1 0.7142398357391357
transgenes O 0 0.0012288953876122832
. O 0 1.8249527784064412e-05

To O 0 1.4280271898314822e-06
discover O 0 2.4563207716710167e-06
genes O 0 8.99270162335597e-07
involved O 0 2.7087483545074065e-07
in O 0 7.11390214291896e-07
von B-Disease 1 0.9999133348464966
Hippel I-Disease 1 0.9999833106994629
- I-Disease 1 0.9999716281890869
Lindau I-Disease 1 0.9997751116752625
( O 0 2.610921967516333e-07
VHL B-Disease 0 6.711989408358932e-05
) O 0 8.747947788378951e-08
- O 0 1.973250846276642e-06
mediated O 0 1.6439045111837913e-06
carcinogenesis O 0 0.00014743978681508452
, O 0 1.654668757566924e-08
we O 0 4.898588201740495e-08
used O 0 3.3014959626598284e-05
renal B-Disease 1 0.9993546605110168
cell I-Disease 1 0.999994158744812
carcinoma I-Disease 1 1.0
cell O 1 0.9989089965820312
lines O 0 0.013928098604083061
stably O 0 0.00011422886746004224
transfected O 0 2.3980384867172688e-05
with O 0 7.574472249416431e-08
wild O 0 9.970250403057435e-07
- O 0 0.025498587638139725
type O 0 0.054841846227645874
VHL O 0 0.12290923297405243
- O 0 5.703308852389455e-05
expressing O 0 4.879034349869471e-06
transgenes O 0 0.00014338272740133107
. O 0 5.9847448028449435e-06

Large O 0 1.5555968275293708e-05
- O 0 5.174094985704869e-05
scale O 0 4.9233071877097245e-06
RNA O 0 1.453620143365697e-06
differential O 0 7.66973755617073e-07
display O 0 1.2833584150939714e-07
technology O 0 1.621832836917747e-07
applied O 0 7.377210664571976e-08
to O 0 5.145221138036504e-09
these O 0 6.74112721199549e-09
cell O 0 9.660953992352006e-07
lines O 0 3.9294236557907425e-06
identified O 0 1.7423771225821838e-07
several O 0 1.0376518311261407e-08
differentially O 0 4.929438546241727e-07
expressed O 0 2.287398714884148e-08
genes O 0 9.456115890316141e-08
, O 0 4.824709964879048e-09
including O 0 2.6771118655233295e-09
an O 0 1.3356332928537995e-08
alpha O 0 6.329306074803753e-07
carbonic O 0 5.897930805076612e-06
anhydrase O 0 1.2204285667394288e-05
gene O 0 1.6677408893883694e-06
, O 0 2.3778203228630446e-07
termed O 0 1.0587600627331994e-05
CA12 O 0 0.0004155800852458924
. O 0 1.0609038326947484e-05

The O 0 7.122516763047315e-07
deduced O 0 7.628107709933829e-07
protein O 0 1.1270936539631293e-07
sequence O 0 1.0197894084740255e-07
was O 0 7.264777224236241e-08
classified O 0 8.497435999288427e-08
as O 0 6.022088605561748e-09
a O 0 9.205157525116192e-09
one O 0 9.996110605925423e-08
- O 0 0.0021424570586532354
pass O 0 1.0751650734164286e-06
transmembrane O 0 3.0742901344638085e-06
CA O 0 2.0747365852002986e-06
possessing O 0 4.4945625887748974e-08
an O 0 1.2279765648770535e-08
apparently O 0 3.422931627028447e-07
intact O 0 4.318291928484541e-07
catalytic O 0 2.4966251999103406e-07
domain O 0 1.985201407705972e-07
in O 0 4.3691109397059336e-08
the O 0 9.31425390149343e-08
extracellular O 0 1.1718231689883396e-05
CA O 0 0.0035150242038071156
module O 0 2.1089863366796635e-05
. O 0 4.624384473572718e-06

Reintroduced O 0 7.408923556795344e-05
wild O 0 1.3313624549482483e-05
- O 0 0.0005617871065624058
type O 0 2.831377787515521e-05
VHL B-Disease 0 7.744780305074528e-05
strongly O 0 5.538812501981738e-07
inhibited O 0 6.712447202517069e-07
the O 0 1.7458626544453182e-08
overexpression O 0 1.033673910910693e-07
of O 0 2.0497568087307627e-09
the O 0 9.57281720559422e-09
CA12 O 0 1.2025311662000604e-06
gene O 0 6.922056883240657e-08
in O 0 1.8438543136767294e-08
the O 0 1.4834240857908298e-07
parental O 0 0.04431896284222603
renal B-Disease 1 0.9999964237213135
cell I-Disease 1 0.9999990463256836
carcinoma I-Disease 1 1.0
cell O 1 0.9996192455291748
lines O 1 0.806883692741394
. O 0 4.6068573283264413e-05

Similar O 0 5.848674391017994e-06
results O 0 4.3562981772993226e-06
were O 0 5.763014954140999e-08
obtained O 0 1.580615531793228e-07
with O 0 2.8715643196619567e-08
CA9 O 0 0.001659488771110773
, O 0 1.9400092199362007e-08
encoding O 0 1.689536617277554e-07
another O 0 2.5782406964935944e-07
transmembrane O 0 0.00010932974691968411
CA O 0 0.005659196991473436
with O 0 1.347274913854335e-08
an O 0 3.6816167892084195e-08
intact O 0 1.258049815078266e-05
catalytic O 0 5.863048954779515e-06
domain O 0 7.716495929344092e-06
. O 0 3.3812250421760837e-06

Although O 0 1.6790729659987846e-06
both O 0 4.5284579641702294e-08
domains O 0 1.824555795337801e-07
of O 0 7.625843956304834e-09
the O 0 2.4090077488381212e-08
VHL B-Disease 0 4.045505193062127e-06
protein O 0 3.8696068571653086e-08
contribute O 0 9.326499572637204e-09
to O 0 1.720844799990573e-09
regulation O 0 7.389487244324755e-09
of O 0 1.6104844124953388e-09
CA12 O 0 1.3658351463163854e-06
expression O 0 4.518457785707142e-08
, O 0 5.3344608730299115e-09
the O 0 5.878829423267007e-09
elongin O 0 4.855019142269157e-07
binding O 0 9.025721681155119e-08
domain O 0 1.6752377973716648e-07
alone O 0 2.563809005096118e-07
could O 0 1.5482575577152602e-07
effectively O 0 8.298525244754273e-07
regulate O 0 5.151845925865928e-06
CA9 O 0 0.00015272654127329588
expression O 0 2.9602688300656155e-06
. O 0 3.5276657399663236e-06

We O 0 1.2230570973770227e-05
mapped O 0 3.048800499527715e-05
CA12 O 0 0.00013696438691113144
and O 0 1.426929998160631e-06
CA9 O 0 0.0001796521246433258
loci O 0 3.6354829262563726e-06
to O 0 1.7328156332041544e-07
chromosome O 0 5.385690201364923e-06
bands O 0 1.5760608675918775e-06
15q22 O 0 1.1584462299651932e-05
and O 0 5.092545620755118e-07
17q21 O 0 3.248249049647711e-05
. O 0 4.199684099148726e-06

2 O 0 2.205575356128975e-06
respectively O 0 1.0530499139349558e-06
, O 0 2.519961483926636e-08
regions O 0 1.4960416194753634e-07
prone O 0 9.36050037125824e-06
to O 0 2.0361625274745165e-08
amplification O 0 8.108393103611888e-07
in O 0 1.7886934600142013e-08
some O 0 2.6402775077372098e-08
human O 0 1.067158223122533e-06
cancers B-Disease 1 0.9273129105567932
. O 0 3.8454559216916095e-06

Additional O 0 1.0461621968715917e-06
experiments O 0 1.263614990421047e-06
are O 0 1.7147973707665187e-08
needed O 0 3.997378783537897e-08
to O 0 4.494303151858503e-09
define O 0 7.99116364191832e-08
the O 0 3.897381972706171e-09
role O 0 4.361550409726078e-08
of O 0 7.368615051461802e-09
CA O 0 0.0007698459085077047
IX O 0 1.3755329746345524e-06
and O 0 1.5329395353091968e-07
CA O 0 2.019344037762494e-06
XII O 0 1.606202033599402e-07
enzymes O 0 4.622875948712135e-08
in O 0 5.7675424436354206e-09
the O 0 2.382380959176089e-09
regulation O 0 2.3442614960345054e-08
of O 0 3.82793086117772e-09
pH O 0 3.7289319720912317e-07
in O 0 1.1984763403916077e-08
the O 0 4.423984290014005e-09
extracellular O 0 8.073202195646445e-08
microenvironment O 0 7.984472745192761e-07
and O 0 2.3797433357231057e-08
its O 0 1.790762027553683e-08
potential O 0 2.9143308211132535e-07
impact O 0 4.79998050195718e-07
on O 0 6.046088287803286e-07
cancer B-Disease 0 3.536920121405274e-05
cell O 0 1.4285325960372575e-05
growth O 0 1.2900763977086172e-05
. O 0 3.2239272513834294e-06

A O 0 2.546515361245838e-06
gene O 0 3.3235196497116704e-06
encoding O 0 1.451367893423594e-06
a O 0 1.4064950448755553e-07
transmembrane O 0 1.527252948108071e-06
protein O 0 1.4207230947249627e-07
is O 0 1.4843391404895101e-08
mutated O 0 5.492240688909078e-07
in O 0 7.823950198826424e-08
patients O 0 8.44146325107431e-06
with O 0 0.0004146235005464405
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.5054695010185242
optic B-Disease 1 0.9999997615814209
atrophy I-Disease 1 0.9998832941055298
( O 0 0.0023595327511429787
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.060130777361337e-06
. O 0 5.075162334833294e-06

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 2.2128704586066306e-05
WFS B-Disease 1 0.5597184896469116
; O 0 1.6231153949775035e-06
OMIM O 0 0.0009759156382642686
222300 O 0 5.517784302355722e-06
) O 0 2.9473813611957667e-08
is O 0 1.6931714696966083e-08
an O 0 2.3520640013430238e-07
autosomal B-Disease 1 0.9999955892562866
recessive I-Disease 1 0.9999996423721313
neurodegenerative I-Disease 1 0.9999921321868896
disorder I-Disease 1 0.9718552231788635
defined O 0 1.6869361161298002e-06
by O 0 9.823731517144552e-08
young O 0 1.0640505934134126e-06
- O 0 0.00013327861961442977
onset O 0 0.00017691847460810095
non O 0 4.4577609514817595e-05
- O 0 0.009093639440834522
immune O 0 0.001092169084586203
insulin B-Disease 1 0.9135680198669434
- I-Disease 1 0.9866454005241394
dependent I-Disease 1 0.953058660030365
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 2.5351666408823803e-05
progressive O 0 0.0006548213423229754
optic B-Disease 1 0.9999456405639648
atrophy I-Disease 0 0.4987453520298004
. O 0 3.574354195734486e-05

Linkage O 0 9.065306221600622e-05
to O 0 9.135718528341386e-07
markers O 0 3.1830174975766568e-06
on O 0 2.2109466613073891e-07
chromosome O 0 3.296292561572045e-05
4p O 1 0.5306776165962219
was O 0 2.2646507204626687e-05
confirmed O 0 5.449333002616186e-07
in O 0 4.6782432150394015e-08
five O 0 1.3924972108725342e-07
families O 0 8.740147450225777e-07
. O 0 1.748390673128597e-06

On O 0 4.6332391434589226e-07
the O 0 1.3414082289386897e-08
basis O 0 1.918336600681414e-08
of O 0 7.098137189132103e-09
meiotic O 0 7.991763595782686e-06
recombinants O 0 0.008551806211471558
and O 0 8.769361738814041e-05
disease O 0 0.0036910076159983873
- O 0 0.0024812105111777782
associated O 0 2.6865409381571226e-06
haplotypes O 0 2.5689467292977497e-05
, O 0 5.1788969557264863e-08
the O 0 2.7646816391779794e-08
WFS B-Disease 0 2.601517189759761e-05
gene O 0 1.8963133641136665e-07
was O 0 6.873745661550856e-08
localized O 0 2.6127554519916885e-07
to O 0 4.5001041115710905e-08
a O 0 7.366173093714679e-08
BAC O 0 1.1898609955096617e-05
/ O 0 4.829288400287624e-07
P1 O 0 7.78632329456741e-06
contig O 0 8.754513487474469e-07
of O 0 1.8668375734165465e-09
less O 0 1.517390302296917e-08
than O 0 1.4544805360117152e-08
250 O 0 1.2777468327840324e-07
kb O 0 2.3996353775146417e-05
. O 0 2.1412979549495503e-06

Mutations O 0 0.000626476772595197
in O 0 4.828394821743132e-07
a O 0 1.1726091742048084e-07
novel O 0 3.578723521968641e-07
gene O 0 1.1300022606519633e-06
( O 0 6.716001621498435e-08
WFS1 O 0 9.997338565881364e-06
) O 0 1.785353198613393e-08
encoding O 0 7.404516111364501e-08
a O 0 3.7394372043308977e-08
putative O 0 7.775784069963265e-07
transmembrane O 0 3.4771662171806383e-07
protein O 0 5.7365408423493136e-08
were O 0 7.997823736616283e-09
found O 0 4.378736040422382e-09
in O 0 1.775145253013477e-09
all O 0 3.028460371368169e-09
affected O 0 1.3539341203738786e-08
individuals O 0 3.935876513594394e-09
in O 0 7.664252343886346e-09
six O 0 1.5459322355582117e-07
WFS B-Disease 0 0.006598064675927162
families O 0 1.0869313449290985e-08
, O 0 7.063087337222385e-10
and O 0 1.2191404552552854e-09
these O 0 2.682002842036013e-09
mutations O 0 2.2785691271565156e-06
were O 0 1.008812517966362e-07
associated O 0 2.2236461560964926e-08
with O 0 1.4753098298569967e-08
the O 0 1.533563954581041e-05
disease O 0 0.014701057225465775
phenotype O 0 0.005675892345607281
. O 0 5.238483026914764e-06

WFS1 O 0 0.00026540536782704294
appears O 0 1.5181535673036706e-06
to O 0 5.5629630679732145e-08
function O 0 1.1217385775807998e-07
in O 0 6.662961737902151e-08
survival O 0 3.302111963421339e-06
of O 0 5.89688786689635e-09
islet O 0 0.0001770953240338713
beta O 0 2.3585605504194973e-06
- O 0 9.9949560535606e-05
cells O 0 7.73940769249748e-07
and O 0 6.467936231047133e-08
neurons O 0 6.329408392957703e-07
. O 0 1.8976756166466657e-07
. O 0 1.2408539760144777e-06

Stable O 0 3.630272840382531e-05
interaction O 0 3.643684181042772e-07
between O 0 3.0770920034228766e-08
the O 0 1.354324030700127e-08
products O 0 5.5790188469018176e-08
of O 0 3.13635672988255e-09
the O 0 3.259057734794624e-08
BRCA1 O 0 7.256769458763301e-05
and O 0 6.87978513269627e-07
BRCA2 O 0 0.00013025954831391573
tumor B-Disease 0 9.553041309118271e-06
suppressor O 0 5.561075795412762e-06
genes O 0 2.1397668206191156e-06
in O 0 8.996246947390318e-08
mitotic O 0 2.3760532712913118e-05
and O 0 1.1352874480508035e-06
meiotic O 0 0.00013810452946927398
cells O 0 8.905799040803686e-05
. O 0 3.5076118365395814e-06

BRCA1 O 0 0.0004413269052747637
and O 0 1.0144094630959444e-06
BRCA2 O 0 1.550089473312255e-05
account O 0 1.5420715726577328e-07
for O 0 6.397129936885904e-09
most O 0 9.526624822342455e-09
cases O 0 2.6914230843999576e-08
of O 0 2.5010749027387646e-09
familial O 0 0.0002629686496220529
, O 0 4.708985557044798e-08
early O 0 2.4369244329136563e-06
onset O 0 0.0025347021874040365
breast B-Disease 1 0.9976634979248047
and I-Disease 0 0.00013180472888052464
/ I-Disease 0 0.31198650598526
or I-Disease 1 0.9999886751174927
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 6.685134223971545e-09
encode O 0 3.376161217261142e-08
products O 0 2.319926579730236e-07
that O 0 4.766581795934144e-09
each O 0 3.965119788063021e-09
interact O 0 4.8065171398548046e-08
with O 0 2.5009901705175253e-08
hRAD51 O 0 2.667840089998208e-05
. O 0 2.175230065404321e-06

Results O 0 1.0120865226781461e-05
presented O 0 3.7517401096920366e-07
here O 0 4.4196934112505915e-08
show O 0 6.790049411620203e-08
that O 0 1.049586995094387e-08
BRCA1 O 0 2.611552190501243e-06
and O 0 4.782302553962836e-08
BRCA2 O 0 1.4048962839297019e-05
coexist O 0 1.6865757288542227e-06
in O 0 1.3195289305656388e-08
a O 0 2.106936847212637e-08
biochemical O 0 2.0383579339977587e-06
complex O 0 3.082849673319288e-07
and O 0 5.1003755885403734e-08
colocalize O 0 3.4217111988255056e-06
in O 0 4.211818804833456e-08
subnuclear O 0 1.7922027382155648e-06
foci O 0 7.758651463518618e-07
in O 0 1.4662264291587235e-08
somatic O 0 3.7385675000223273e-07
cells O 0 1.025809183374804e-06
and O 0 3.5472144332970856e-08
on O 0 1.0883254297766598e-08
the O 0 3.383695990066826e-09
axial O 0 1.8932071554900176e-07
elements O 0 1.5265817410181626e-07
of O 0 4.963359856446914e-08
developing O 0 2.1276939605741063e-06
synaptonemal O 0 4.628492388292216e-05
complexes O 0 1.732298369461205e-05
. O 0 3.3396090657333843e-06

Like O 0 1.9709905245690607e-05
BRCA1 O 0 0.00024953592219389975
and O 0 9.129595355261699e-07
RAD51 O 0 0.00015156362496782094
, O 0 3.318359063086973e-07
BRCA2 O 0 2.13161256397143e-05
relocates O 0 2.449957264616387e-06
to O 0 2.0078211093732534e-07
PCNA O 0 1.8149281459045596e-05
+ O 0 3.1956324164639227e-07
replication O 0 2.0200671713155316e-07
sites O 0 7.525338929781356e-08
following O 0 8.171748078211749e-08
exposure O 0 8.672737749293447e-06
of O 0 1.9327885070197226e-08
S O 0 1.517362215963658e-05
phase O 0 4.542671092622186e-07
cells O 0 7.789151368342573e-07
to O 0 5.6994380770447606e-08
hydroxyurea O 0 8.723886821826454e-06
or O 0 8.02252202447562e-07
UV O 0 5.764581874245778e-05
irradiation O 0 2.89431609417079e-05
. O 0 3.869559350277996e-06

Thus O 0 2.6476182029000483e-06
, O 0 9.48013436641304e-08
BRCA1 O 0 4.277454081602627e-06
and O 0 3.8543003455515645e-08
BRCA2 O 0 2.4382147785217967e-06
participate O 0 1.4614993659733955e-08
, O 0 1.7838580612661303e-09
together O 0 3.741746912311328e-09
, O 0 2.253962794185327e-09
in O 0 3.910218371316887e-09
a O 0 1.4604823128649969e-08
pathway O 0 1.9161851128046692e-07
( O 0 2.1112974479819968e-08
s O 0 3.282167745055631e-05
) O 0 1.1001108468633447e-08
associated O 0 1.983777764280603e-08
with O 0 1.753019285288815e-09
the O 0 3.60343732630497e-09
activation O 0 1.5294604693849578e-08
of O 0 3.650791668974307e-09
double O 0 0.00054140854626894
- O 0 0.1761002391576767
strand O 1 0.5925136804580688
break O 0 0.004183943849056959
repair O 0 0.00290128355845809
and O 0 1.2155402373537072e-07
/ O 0 4.599485521339375e-07
or O 0 1.944021335020807e-07
homologous O 0 6.456433311541332e-06
recombination O 0 2.6464333132025786e-05
. O 0 3.840738827420864e-06

Dysfunction O 0 0.000465523567982018
of O 0 6.420357578917901e-08
this O 0 2.194405901434493e-08
pathway O 0 3.139338957680593e-07
may O 0 1.671269046710222e-06
be O 0 5.325911267561878e-09
a O 0 1.6072132513755832e-09
general O 0 1.5959229493489602e-09
phenomenon O 0 7.976834126566246e-08
in O 0 1.032073715379056e-08
the O 0 5.878538100745345e-09
majority O 0 2.5117463664514617e-08
of O 0 1.2334360199872663e-09
cases O 0 5.985675954889302e-08
of O 0 1.0679717554751278e-08
hereditary B-Disease 1 0.9997881054878235
breast I-Disease 1 0.9999673366546631
and I-Disease 0 0.010815560817718506
/ I-Disease 1 0.8543153405189514
or I-Disease 1 0.9999963045120239
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.487706963933306e-07
. O 0 3.751020813069772e-06

A O 0 4.337738118920242e-06
novel O 0 2.859060259652324e-06
Arg362Ser O 0 1.286877795791952e-05
mutation O 0 3.670588512250106e-06
in O 0 4.692864408184505e-08
the O 0 4.4186059255935106e-08
sterol O 0 0.00010241942800348625
27 O 0 9.04949104096886e-07
- O 0 2.16847593037528e-06
hydroxylase O 0 9.142620001512114e-06
gene O 0 7.627489821970812e-07
( O 0 1.3044520130733872e-08
CYP27 O 0 5.739561856898945e-06
) O 0 8.855654876072094e-09
: O 0 2.1352306589506043e-09
its O 0 1.4244723622880429e-08
effects O 0 2.69108477368718e-06
on O 0 8.912390114801383e-08
pre O 0 1.584859455761034e-05
- O 0 8.22205720396596e-07
mRNA O 0 2.6247903406328987e-07
splicing O 0 5.752065135311568e-07
and O 0 1.0756075141671317e-07
enzyme O 0 9.34248816975014e-07
activity O 0 1.2962223081558477e-06
. O 0 2.0925886019540485e-06

A O 0 3.1761130685481476e-06
novel O 0 3.171736352669541e-06
C O 0 4.12565668739262e-06
to O 0 2.7376316324989602e-08
A O 0 3.8980381589226454e-08
mutation O 0 4.3063613475169404e-07
in O 0 2.2043561642703935e-08
the O 0 2.5723997154614153e-08
sterol O 0 7.756894046906382e-05
27 O 0 4.116607499327074e-07
- O 0 1.1301650602035807e-06
hydroxylase O 0 5.03115597894066e-06
gene O 0 4.745679120787827e-07
( O 0 1.8711769911305964e-08
CYP27 O 0 3.6123342397331726e-06
) O 0 1.321181031244123e-08
was O 0 3.065832387960654e-08
identified O 0 2.202263438277896e-08
by O 0 2.864664727653121e-09
sequencing O 0 1.6036689487464173e-07
amplified O 0 5.38114363735076e-07
CYP27 O 0 1.5853694321776857e-06
gene O 0 1.1518869769133744e-07
products O 0 6.177506861604343e-08
from O 0 5.9496478854725865e-09
a O 0 3.177277463350947e-08
patient O 0 1.2515465641627088e-06
with O 0 7.343895163103298e-07
cerebrotendinous B-Disease 1 0.9999998807907104
xanthomatosis I-Disease 1 0.9999991655349731
( O 0 1.3576782293966971e-06
CTX B-Disease 0 0.020284967496991158
) O 0 1.1152801562275272e-06
. O 0 2.6898583200818393e-06

The O 0 1.7328763988189166e-06
mutation O 0 1.4433122487389483e-05
changed O 0 1.1055441291318857e-06
the O 0 5.0324906908372213e-08
adrenodoxin O 0 2.7526750727702165e-06
cofactor O 0 6.250337492019753e-07
binding O 0 5.443947088679124e-07
residue O 0 2.7820140076073585e-06
362Arg O 0 3.359833499416709e-06
to O 0 4.800616437705685e-08
362Ser O 0 1.7051910390364355e-06
( O 0 2.051983472028951e-08
CGT O 0 8.792029575488414e-07
362Arg O 0 1.0650769581843633e-06
to O 0 2.2987176606648063e-08
AGT O 0 1.2810207863367395e-06
362Ser O 0 1.7362248172503314e-07
) O 0 2.2452439907283406e-09
, O 0 4.935798436633831e-10
and O 0 3.466568365695366e-09
was O 0 4.6226955419115257e-07
responsible O 0 1.914524716539745e-07
for O 0 2.754109118541237e-07
deficiency O 0 0.0009565117652527988
in O 0 1.1385382414630385e-08
the O 0 1.535282478926092e-08
sterol O 0 3.64444604201708e-05
27 O 0 2.260586313695967e-07
- O 0 2.3091592993296217e-07
hydroxylase O 0 9.013961062009912e-07
activity O 0 6.824313913966762e-08
, O 0 3.6893474941734894e-09
as O 0 5.474552811080002e-09
confirmed O 0 1.7338861013627138e-08
by O 0 1.94999505431781e-09
expression O 0 1.2151943451499392e-08
of O 0 1.8314978422750983e-09
mutant O 0 1.1346300254899688e-07
cDNA O 0 2.7001595981346327e-07
into O 0 1.0028308139453657e-07
COS O 0 0.00011839997750939801
- O 0 6.164693331811577e-06
1 O 0 2.60207769997578e-07
cells O 0 2.2795320546720177e-06
. O 0 1.3279957329359604e-06

Quantitative O 0 2.7321098968968727e-05
analysis O 0 2.887729124267935e-06
showed O 0 6.86008490902168e-07
that O 0 1.167823260317391e-08
the O 0 7.168792226508458e-09
expression O 0 5.3268077948587234e-08
of O 0 4.236511141897381e-09
CYP27 O 0 1.375752049170842e-06
gene O 0 7.913308053275614e-08
mRNA O 0 1.1107208308658301e-07
in O 0 2.1542291506193578e-08
the O 0 2.8860549505793642e-08
patient O 0 5.928071686867042e-07
represented O 0 4.203047581086139e-07
52 O 0 2.4498219772794982e-06
. O 0 2.5038216335815378e-06

5 O 0 5.0830676627811044e-06
% O 0 2.749193868112343e-07
of O 0 1.4070606901839255e-08
the O 0 1.0095381952623939e-07
normal O 0 2.664002522578812e-06
level O 0 5.304842943587573e-06
. O 0 6.081842911953572e-06

As O 0 8.191424285541871e-07
the O 0 5.694732863048557e-08
mutation O 0 9.7110569186043e-07
occurred O 0 4.137846190133132e-07
at O 0 3.221100897121687e-08
the O 0 7.666576706810702e-09
penultimate O 0 2.6768483962769096e-07
nucleotide O 0 3.0031182518541755e-07
of O 0 3.854312868867282e-09
exon O 0 5.720020794797165e-07
6 O 0 3.114468682952065e-08
( O 0 4.380072304854821e-09
- O 0 2.803676011353673e-07
2 O 0 1.7097548266065132e-08
position O 0 1.2142633920575463e-07
of O 0 2.2628494633636365e-09
exon O 0 4.7478746978413255e-07
6 O 0 7.130054058279711e-08
- O 0 3.018278391664353e-07
intron O 0 2.786235654639313e-06
6 O 0 2.7063100205282353e-08
splice O 0 1.232204340340104e-06
site O 0 7.942098534385877e-08
) O 0 1.6859521556611412e-09
of O 0 1.5933246388932787e-10
the O 0 1.500718660452094e-09
gene O 0 3.323108899166982e-08
, O 0 3.123372449564954e-09
we O 0 4.185365387598949e-09
hypothesized O 0 1.4328871422719658e-08
that O 0 1.0130208893954773e-09
the O 0 2.2449657688383695e-09
mutation O 0 7.867141675887979e-07
may O 0 7.472688139387174e-07
partially O 0 2.4164412479876773e-06
affect O 0 2.2772947971816393e-08
the O 0 2.227457107650821e-09
normal O 0 1.756132306240943e-08
splicing O 0 3.3679808097986097e-07
efficiency O 0 6.232314575527198e-08
in O 0 7.292900949806835e-09
exon O 0 4.915308409181307e-07
6 O 0 4.5364718204155e-08
and O 0 8.58394777480953e-09
cause O 0 1.5925241569902937e-08
alternative O 0 2.4778191942687045e-08
splicing O 0 3.1853298310124956e-07
elsewhere O 0 4.7230540189957537e-07
, O 0 2.832170720168392e-09
which O 0 6.307761424295677e-09
resulted O 0 6.73845548249119e-08
in O 0 3.3498942286769307e-08
decreased O 0 5.743810334024602e-07
transcript O 0 1.938339437401737e-06
in O 0 7.806762880591123e-08
the O 0 1.9528401651314198e-07
patient O 0 1.1371413165761624e-05
. O 0 2.5508636554150144e-06

Transfection O 0 0.0002726376405917108
of O 0 1.7790517858884414e-07
constructed O 0 2.415077460682369e-06
minigenes O 0 2.1638648831867613e-05
, O 0 9.047885107804632e-09
with O 0 2.3535791093820535e-09
or O 0 7.770085375113922e-08
without O 0 3.2577279540646487e-08
the O 0 1.0759498181300842e-08
mutation O 0 2.691069767024601e-07
, O 0 5.547861281485211e-09
into O 0 1.5427769284315218e-08
COS O 0 0.0002960888668894768
- O 0 3.0343101116159232e-06
1 O 0 1.6861104512599923e-08
cells O 0 5.895125454458139e-08
confirmed O 0 2.093173812056648e-08
that O 0 9.26154375413546e-10
the O 0 1.1279206457714963e-09
mutant O 0 3.174866591848513e-08
minigene O 0 9.000758041111112e-07
was O 0 6.610681424490394e-08
responsible O 0 1.0263299543566973e-08
for O 0 1.6010145431621936e-09
a O 0 5.5809530330463986e-09
mRNA O 0 6.039379485400787e-08
species O 0 8.97384389020317e-09
alternatively O 0 8.016428409973742e-08
spliced O 0 3.125697730865795e-06
at O 0 9.422646485290898e-08
an O 0 1.2979794128398225e-08
activated O 0 3.154428611651383e-07
cryptic O 0 5.591386411651911e-07
5 O 0 2.9864899886433705e-08
splice O 0 1.313983148065745e-06
site O 0 2.6759116167340835e-07
88 O 0 6.149199549554396e-08
bp O 0 2.819173232637695e-07
upstream O 0 3.7072098280077626e-08
from O 0 3.793392266970841e-09
the O 0 4.319936852681394e-09
3 O 0 1.3461421310978494e-08
end O 0 1.9292935249382026e-08
of O 0 7.511511412872096e-09
exon O 0 5.305642389430432e-06
6 O 0 6.291782597145357e-07
. O 0 1.171593567050877e-06

Our O 0 3.3610417631280143e-06
data O 0 7.43061832508829e-07
suggest O 0 1.5412804543757375e-07
that O 0 3.9054484091138875e-09
the O 0 3.943985138477046e-09
C O 0 4.7631763777644665e-07
to O 0 2.917311947570056e-09
A O 0 1.406789618130233e-08
mutation O 0 1.759224232955603e-07
at O 0 9.79566294745382e-09
the O 0 3.513919821784839e-09
penultimate O 0 1.8676081481316942e-07
nucleotide O 0 5.860717777750324e-08
of O 0 1.0079942436291844e-09
exon O 0 1.464918852889241e-07
6 O 0 3.969697903727365e-09
of O 0 1.760866591427046e-10
the O 0 1.269297444927986e-09
CYP27 O 0 5.528416409106285e-07
gene O 0 2.860876691102021e-08
not O 0 8.13073075534021e-09
only O 0 4.450771307062951e-09
causes O 0 5.832682958839541e-08
the O 0 2.372755147916905e-07
deficiency B-Disease 0 0.006053116638213396
in I-Disease 0 1.6876676056654105e-08
the I-Disease 0 2.701122170378767e-08
sterol I-Disease 0 4.0350882045459e-05
27 I-Disease 0 1.582982491754592e-07
- I-Disease 0 1.8877676666306797e-07
hydroxylase I-Disease 0 5.071748887530703e-07
activity I-Disease 0 3.366393741544016e-08
, O 0 4.545563481173076e-09
but O 0 1.7430776821925065e-08
also O 0 7.81022979623458e-09
partially O 0 1.8503033061278984e-06
leads O 0 1.1133738375690427e-08
to O 0 4.923107699283946e-09
alternative O 0 8.14490590528294e-08
pre O 0 1.8436629716234165e-06
- O 0 2.6895867222265224e-07
mRNA O 0 8.639172932589645e-08
splicing O 0 3.777445556352177e-07
of O 0 7.865723183897444e-09
the O 0 3.789633851170038e-08
gene O 0 3.3266273931076284e-06
. O 0 2.6913182864518603e-06

To O 0 9.839340009420994e-07
our O 0 7.07913017095052e-08
knowledge O 0 1.9192478717400263e-08
, O 0 1.3791661146456136e-09
this O 0 8.605287038498943e-10
is O 0 1.2899303847291321e-09
the O 0 3.2066509447759017e-09
first O 0 1.0870893873970999e-07
report O 0 4.666835451416773e-08
regarding O 0 1.3820370625694522e-08
effects O 0 2.3670168047829065e-07
on O 0 1.706434993309358e-08
pre O 0 1.6809924545668764e-06
- O 0 7.388095468741085e-08
mRNA O 0 2.3538898830111066e-08
splicing O 0 1.0853573684244111e-07
of O 0 1.2332125320924092e-09
a O 0 7.084259401324289e-09
mutation O 0 1.2168288776592817e-07
at O 0 1.8695930137369032e-08
the O 0 1.0222252377900531e-08
- O 0 9.660469004302286e-06
2 O 0 5.641876299478099e-08
position O 0 2.7465259790915297e-06
of O 0 4.273421172484859e-09
a O 0 3.705435247525202e-08
5 O 0 9.147019852662197e-08
splice O 0 1.986281858989969e-05
site O 0 5.931181021878729e-06
. O 0 3.3342278129566694e-06

ATM O 0 0.0012835842790082097
germline O 0 0.0008428407018072903
mutations O 0 0.00023546244483441114
in O 0 1.0007764785768813e-06
classical O 0 0.00027598682208918035
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9964487552642822
in O 0 2.99399317782445e-07
the O 0 2.098615112799962e-07
Dutch O 0 0.0026190183125436306
population O 0 1.8623023834152264e-06
. O 0 3.0208493626560085e-06

Germline O 0 0.0009320363751612604
mutations O 0 0.00010488527914276347
in O 0 1.1407210820379987e-07
the O 0 1.4604265352602397e-08
ATM O 0 5.25716757238115e-07
gene O 0 4.7324682839189336e-08
are O 0 2.3935808890485077e-09
responsible O 0 2.8470067192643e-08
for O 0 1.8249641797751792e-08
the O 0 0.0014699844177812338
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6868747472763062
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.8663080254555098e-06
. O 0 1.9919959868275328e-06

In O 0 9.015585646920954e-07
our O 0 1.4740025733317452e-07
study O 0 5.037964712073517e-08
, O 0 3.7233578442652515e-09
we O 0 6.7630079314540126e-09
have O 0 2.4876676274487863e-09
determined O 0 1.566758278670477e-08
the O 0 1.5544195930417004e-09
ATM O 0 3.217325570403773e-07
mutation O 0 7.848103678043117e-08
spectrum O 0 5.8841049366265e-08
in O 0 1.3280125443770885e-08
19 O 0 1.059693044425103e-08
classical O 0 1.1895229363290127e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 6.407160071830731e-06
, O 0 7.850146643839651e-10
including O 0 2.900709394904055e-10
some O 0 1.2802998661243237e-09
immigrant O 0 5.452665163829806e-07
populations O 0 7.921719458181542e-08
, O 0 1.654503756221004e-09
as O 0 1.2481466971081545e-09
well O 0 5.647687206788987e-09
as O 0 6.588373402394154e-09
12 O 0 3.645614476965875e-09
of O 0 2.1678216999276856e-09
Dutch O 0 0.00034668133594095707
ethnic O 0 4.276105869394087e-07
origin O 0 2.0250474335625768e-05
. O 0 4.07218249165453e-06

Both O 0 5.812918857373006e-07
the O 0 4.811414910932399e-08
protein O 0 2.2952745837301336e-07
truncation O 0 3.848758296953747e-06
test O 0 2.641162609506864e-06
( O 0 1.347141331820012e-08
PTT O 0 8.36176866414462e-07
) O 0 4.149928400920544e-09
and O 0 2.0798289757095745e-09
the O 0 3.1396725219678956e-09
restriction O 0 3.248439384151425e-08
endonuclease O 0 1.1454974355729064e-06
fingerprinting O 0 1.01509078831441e-06
( O 0 1.2836038898456081e-08
REF O 0 4.1551507479198335e-07
) O 0 1.516093472986313e-09
method O 0 6.865644941456139e-09
were O 0 3.0135824946597722e-09
used O 0 9.943376788612568e-09
and O 0 4.3094687818268085e-09
compared O 0 2.48623184262442e-08
for O 0 6.436008392896042e-10
their O 0 4.277775911276649e-09
detection O 0 1.5302518363569106e-07
efficiency O 0 3.2778096681340685e-08
, O 0 2.4349962046699147e-09
identifying O 0 2.8235367821594082e-08
76 O 0 2.988831937500436e-08
% O 0 4.825289945387112e-09
and O 0 1.0025818397707553e-08
60 O 0 1.7743067459718986e-08
% O 0 5.325138996425949e-09
of O 0 8.77035943869231e-10
the O 0 5.71608431698678e-08
mutations O 0 4.01936486014165e-05
, O 0 7.150005387757119e-08
respectively O 0 1.1350645081620314e-06
. O 0 2.091034502882394e-06

Most O 0 2.4666896933922544e-06
patients O 0 4.8218885240203235e-06
were O 0 6.152813369908472e-08
found O 0 3.4161800499532546e-08
to O 0 1.8967467596553433e-08
be O 0 5.5314227864755594e-08
compound O 0 1.962211399586522e-06
heterozygote O 0 0.00015561480540782213
. O 0 4.279967924958328e-06

Seventeen O 0 1.8544033082434908e-05
mutations O 0 2.894117460527923e-05
were O 0 1.5058466829032113e-07
distinct O 0 8.217152469569555e-08
, O 0 7.285310132942868e-09
of O 0 1.1484919681947758e-09
which O 0 2.116272668217789e-08
10 O 0 8.371581650123971e-09
were O 0 8.057495648472468e-08
not O 0 2.357584207857144e-07
reported O 0 4.104414529138012e-06
previously O 0 3.1486449643125525e-06
. O 0 2.5020551674970193e-06

Mutations O 0 0.00075749825919047
are O 0 7.959277468216897e-07
small O 0 3.5845403090206673e-07
deletions O 0 6.9249813350324985e-06
or O 0 1.3300299315233133e-06
point O 0 4.521425125858514e-06
mutations O 0 3.072759136557579e-05
frequently O 0 3.14173121296335e-06
affecting O 0 2.373509460085188e-06
splice O 0 0.0001571895118104294
sites O 0 2.489414509909693e-05
. O 0 9.820143532124348e-06

Moreover O 0 9.221055370289832e-05
, O 0 1.3570517012340133e-06
a O 0 7.095310365912155e-07
16 O 0 2.0605550616892288e-06
. O 0 4.371592694951687e-06

7 O 0 2.2785738110542297e-05
- O 0 1.5844785593799315e-05
kb O 0 8.288936442113481e-06
genomic O 0 2.2341907879308565e-06
deletion O 0 9.56533426688111e-07
of O 0 3.0814308882298747e-09
the O 0 3.6803933234352826e-09
3 O 0 5.662259106031797e-09
end O 0 1.2758564871262479e-08
of O 0 3.361584621774938e-10
the O 0 6.826221254918607e-10
gene O 0 8.866590128775442e-09
, O 0 1.4023738836854704e-09
most O 0 2.9496687314889414e-09
likely O 0 6.455316281517298e-08
a O 0 3.0631071012976463e-09
result O 0 1.1854199399863319e-08
of O 0 4.258244312715931e-10
recombination O 0 4.44287735490434e-08
between O 0 8.713223920153723e-09
two O 0 1.6918027867518504e-08
LINE O 0 0.00017569180636201054
elements O 0 7.375654718089208e-07
, O 0 4.565281130908261e-08
was O 0 2.198009951825952e-06
identified O 0 1.8372389831711189e-06
. O 0 1.5898617675702553e-06

The O 0 1.7707002086808643e-07
most O 0 3.651475921628844e-08
frequently O 0 2.0521095223102748e-07
found O 0 4.847782975048176e-08
mutation O 0 3.5568760381465836e-07
, O 0 5.937869307359733e-09
identified O 0 5.6506426204805393e-08
in O 0 1.453554165919968e-08
three O 0 3.627443589948598e-08
unrelated O 0 2.4452621801174246e-05
Turkish O 1 0.6244925856590271
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
individuals O 0 2.301310253471911e-08
, O 0 2.4434403389506087e-09
was O 0 8.563331022060083e-08
previously O 0 1.0784403059460601e-07
described O 0 2.0672651146469434e-08
to O 0 5.937857761040277e-09
be O 0 4.423995036972883e-08
a O 0 4.26676081133337e-08
Turkish O 0 0.0017253891564905643
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999966621398926
T I-Disease 1 0.9999997615814209
founder O 0 9.027596206578892e-06
mutation O 0 2.6389006961835548e-05
. O 0 2.8904180453537265e-06

The O 0 3.859751984691684e-07
presence O 0 1.2002496418972441e-07
of O 0 2.6153308407828035e-09
a O 0 1.8282459990359712e-08
founder O 0 2.3128400528094062e-07
mutation O 0 4.627560485914728e-07
among O 0 1.829194751223895e-08
relatively O 0 4.03272863991333e-08
small O 0 3.029935058407318e-08
ethnic O 0 1.0739532285697351e-07
population O 0 4.7572292771747016e-08
groups O 0 5.9959912590557e-09
in O 0 6.964565368861031e-09
Western O 0 7.17994765864205e-08
Europe O 0 5.788048383692512e-06
could O 0 1.1392751275707269e-07
indicate O 0 1.3217657190978116e-08
a O 0 6.120342455062655e-09
high O 0 8.003014784208062e-08
carrier O 0 2.525539173348079e-07
frequency O 0 4.199377485747391e-07
in O 0 1.6622223597551056e-08
such O 0 4.3951214223625357e-08
communities O 0 1.5419905139424372e-06
. O 0 1.7856208387456718e-06

In O 0 1.1682932381518185e-06
patients O 0 2.2708029518980766e-06
of O 0 1.370800717381826e-08
Dutch O 0 0.0013621947728097439
ethnic O 0 1.4763648437110533e-07
origin O 0 1.7606503206479829e-06
, O 0 1.33618875963748e-08
however O 0 9.374138443263291e-08
, O 0 3.04963498898303e-09
no O 0 8.11218914265055e-09
significant O 0 2.758729600316201e-08
founder O 0 9.835599712459953e-08
effect O 0 2.1327127797121648e-07
could O 0 4.773689852299867e-07
be O 0 7.270737967246532e-08
identified O 0 1.6025451259338297e-06
. O 0 2.272258598168264e-06

The O 0 8.256394607997208e-07
observed O 0 1.507513388787629e-06
genetic O 0 1.344799557045917e-06
heterogeneity O 0 1.5360418501586537e-06
including O 0 3.7347611225868604e-08
the O 0 1.968486351699994e-08
relative O 0 1.3871942883270094e-06
high O 0 2.0375318854348734e-06
percentage O 0 5.530357043426193e-07
of O 0 3.0502513848063018e-09
splice O 0 0.008056056685745716
- O 0 0.013653585687279701
site O 0 8.816775334707927e-06
mutations O 0 2.0956438675057143e-05
had O 0 1.0411519042463624e-06
no O 0 2.6720373469402148e-08
reflection O 0 1.4317593866053357e-07
on O 0 8.407830165424457e-08
the O 0 4.979422669748601e-07
phenotype O 0 0.0002051594346994534
. O 0 4.606101356330328e-06

All O 0 1.4609011032007402e-06
patients O 0 3.378530436748406e-06
manifested O 0 1.284190034311905e-06
classical O 0 0.00012442820298019797
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999949932098389
T I-Disease 1 1.0
and O 0 1.4920236424131872e-07
increased O 0 1.5899601635283034e-07
cellular O 0 1.56948817675584e-06
radioresistant O 0 8.170069122570567e-06
DNA O 0 5.350770152290352e-06
synthesis O 0 7.990140147740021e-06
. O 0 3.497837724353303e-06

Determination O 0 9.078543371288106e-06
of O 0 5.96465952185099e-08
the O 0 2.9497773113007497e-08
genomic O 0 1.1630560265984968e-06
structure O 0 2.906608926878107e-07
of O 0 3.32659522150891e-09
the O 0 1.2853335285001322e-08
COL4A4 O 0 2.643929519763333e-06
gene O 0 6.812297215219587e-08
and O 0 9.990217542110713e-09
of O 0 9.423056113178063e-09
novel O 0 1.790855822036974e-05
mutations O 0 0.14502555131912231
causing O 0 0.009008918888866901
autosomal B-Disease 1 0.9999990463256836
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.00010216298687737435

Autosomal B-Disease 1 0.9999954700469971
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.257769210700644e-06
a O 0 1.055372308655933e-06
progressive O 0 0.0038379011675715446
hematuric B-Disease 1 0.999862551689148
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00032210344215855
by O 0 9.571393775331671e-07
glomerular B-Disease 1 0.996793806552887
basement I-Disease 1 0.9996485710144043
membrane I-Disease 1 0.9822595119476318
abnormalities I-Disease 1 0.9999940395355225
and O 0 5.88507020893303e-07
associated O 0 8.876796897538952e-08
with O 0 8.865727707529913e-09
mutations O 0 5.059486284153536e-06
in O 0 2.7115905965047205e-08
either O 0 9.431456504671587e-08
the O 0 1.866841969899724e-08
COL4A3 O 0 0.00021694807219319046
or O 0 9.513154708429283e-08
the O 0 6.58847421064479e-09
COL4A4 O 0 1.7745151126291603e-06
gene O 0 8.030615106235928e-08
, O 0 2.3649369129685738e-09
which O 0 1.5311671930362536e-09
encode O 0 3.5967303801953676e-08
the O 0 7.998830930944223e-09
alpha3 O 0 1.3513742942450335e-06
and O 0 5.4186450881843484e-08
alpha4 O 0 5.957820121693658e-06
type O 0 1.5030882423161529e-05
IV O 0 5.374228749133181e-06
collagen O 0 2.8891781767015345e-06
chains O 0 4.6926063077989966e-05
, O 0 2.4887137328732933e-07
respectively O 0 2.346266683161957e-06
. O 0 3.1001493425719673e-06

To O 0 2.5995973373937886e-07
date O 0 2.8668944196397206e-07
, O 0 9.272949519356644e-09
mutation O 0 7.620030828547897e-08
screening O 0 7.485713382493486e-08
in O 0 3.434340367647337e-09
the O 0 1.3020574618494152e-09
two O 0 2.835164991665806e-09
genes O 0 1.193656231635032e-07
has O 0 6.040024800313404e-07
been O 0 1.6433276641691918e-06
hampered O 0 6.513385415019002e-06
by O 0 7.307772165177084e-09
the O 0 2.2541359001593264e-08
lack O 0 7.592118578259033e-08
of O 0 6.144109221395411e-09
genomic O 0 3.8635853343294e-06
structure O 0 4.811213784705615e-06
information O 0 1.223060621668992e-06
. O 0 2.787134008030989e-06

We O 0 4.3591837311396375e-05
report O 0 2.669363823315507e-07
here O 0 7.479316721514806e-09
the O 0 1.863241116950576e-09
complete O 0 8.337003087888206e-09
characterization O 0 1.072426201176313e-07
of O 0 1.8290438053014668e-09
the O 0 5.054738849707974e-09
48 O 0 1.0221414825650754e-08
exons O 0 5.45990417322173e-08
of O 0 8.747905733130779e-10
the O 0 5.52156453892394e-09
COL4A4 O 0 2.1374173684307607e-06
gene O 0 5.64649482726054e-08
, O 0 1.823581730064916e-09
a O 0 2.0701997893723956e-09
comprehensive O 0 2.2151967371542014e-08
gene O 0 1.5194501656878856e-07
screen O 0 0.0039390516467392445
, O 0 9.46885414521148e-09
and O 0 3.959753858140402e-09
the O 0 1.8343297991663121e-09
subsequent O 0 1.756588119405933e-08
detection O 0 1.0691012164443237e-07
of O 0 8.276507812432499e-10
10 O 0 4.702628508823636e-09
novel O 0 5.762465349334889e-08
mutations O 0 5.750420086769736e-07
in O 0 2.413045407934078e-08
eight O 0 3.472513583346881e-07
patients O 0 2.8738808396155946e-05
diagnosed O 0 0.06666667759418488
with O 0 3.3875771805469412e-06
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 6.610589480260387e-05

Furthermore O 0 1.2734681149595417e-05
, O 0 2.9743682716798503e-07
we O 0 1.2374252378322126e-07
identified O 0 8.798146922117667e-08
a O 0 1.0035402731034537e-08
glycine O 0 1.5779301065776963e-07
to O 0 8.545689489380948e-09
alanine O 0 2.5802037839639524e-07
substitution O 0 4.0672738066405145e-08
in O 0 1.500241353369347e-08
the O 0 5.7021867228002066e-09
collagenous O 0 2.639233798618079e-06
domain O 0 1.148956485508279e-07
that O 0 8.477148760732689e-09
is O 0 9.34099109173303e-09
apparently O 0 1.56163622477834e-07
silent O 0 2.584545484296541e-07
in O 0 6.4791580989265185e-09
the O 0 8.39607938729614e-09
heterozygous O 0 4.7628765287299757e-07
carriers O 0 1.443386565824767e-07
, O 0 8.073599566671419e-09
in O 0 3.569652307078286e-08
11 O 0 2.1690061657864135e-07
. O 0 9.141523378275451e-07

5 O 0 1.4660693068435648e-06
% O 0 5.498918653756846e-08
of O 0 1.0127291227846058e-09
all O 0 2.40736208745318e-09
control O 0 8.380883542713491e-08
individuals O 0 2.637492668711161e-09
, O 0 1.4636075684748562e-09
and O 0 1.3124757280991162e-08
in O 0 1.783943837097013e-08
one O 0 2.999156833993766e-08
control O 0 1.9665017703118792e-07
individual O 0 2.2164307722505328e-08
homozygous O 0 2.844583946171042e-07
for O 0 3.0716900134564185e-09
this O 0 6.142374608941736e-09
glycine O 0 1.1175073950653314e-06
substitution O 0 1.101980046769313e-06
. O 0 2.022477929131128e-06

There O 0 2.135569275196758e-06
has O 0 1.0529640093182024e-07
been O 0 3.024992167866003e-08
no O 0 5.693003402029717e-09
previous O 0 2.985516189824011e-08
finding O 0 2.281211664012517e-08
of O 0 3.9398401208146083e-10
a O 0 8.694642228412874e-10
glycine O 0 2.506319596307094e-08
substitution O 0 7.610411856262544e-09
that O 0 4.440841472330703e-09
is O 0 1.883137867864093e-09
not O 0 6.727601586931087e-09
associated O 0 4.087803429086989e-09
with O 0 1.2913384805912642e-09
any O 0 6.109591055292185e-08
obvious O 0 1.7050153928721556e-06
phenotype O 0 7.330674634431489e-06
in O 0 1.0269843642163323e-07
homozygous O 0 5.645192686642986e-06
individuals O 0 4.0123822486748395e-07
. O 0 2.002173914661398e-06

Founder O 0 7.365614146692678e-05
BRCA1 O 0 0.0004455884045455605
and O 0 2.1120724795764545e-06
BRCA2 O 0 8.002937101991847e-05
mutations O 0 8.047685696510598e-06
in O 0 1.546073775671175e-07
French O 0 1.1376999282219913e-05
Canadian O 0 0.00012923835311084986
breast B-Disease 1 0.9999969005584717
and I-Disease 1 0.999946117401123
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.63564036990283e-06
. O 0 7.053984973026672e-06

We O 0 5.703413080482278e-06
have O 0 1.1787263787255142e-07
identified O 0 5.7983630341595926e-08
four O 0 9.333386508103558e-09
mutations O 0 1.6014710979561642e-07
in O 0 3.0433069397872714e-09
each O 0 2.2011283906664403e-09
of O 0 2.2619905948317864e-09
the O 0 5.653570497088367e-06
breast B-Disease 1 0.9999985694885254
cancer I-Disease 1 0.9239967465400696
- O 0 0.00010267788456985727
susceptibility O 0 6.066619334887946e-06
genes O 0 5.91469415667234e-07
, O 0 1.4864300013073262e-08
BRCA1 O 0 2.443829544063192e-06
and O 0 3.367157930256326e-08
BRCA2 O 0 3.0183409762685187e-06
, O 0 5.6564415373827615e-09
in O 0 1.2183646092012168e-08
French O 0 5.824694198963698e-06
Canadian O 0 9.853277333604638e-06
breast B-Disease 1 0.9948809146881104
cancer I-Disease 0 0.07831591367721558
and O 0 0.0007003576611168683
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.59210911635455e-07
from O 0 2.583848299764213e-07
Quebec O 0 1.8764108972391114e-05
. O 0 5.429660177469486e-06

To O 0 1.1016784355888376e-06
identify O 0 2.0000384211016353e-06
founder O 0 3.433746940117999e-07
effects O 0 9.443613180337707e-07
, O 0 1.2395307003032485e-08
we O 0 1.2556546025166426e-08
examined O 0 8.61396571849582e-08
independently O 0 1.624197949467998e-07
ascertained O 0 3.6476130844675936e-06
French O 0 6.280947218328947e-06
Canadian O 0 2.1333851236704504e-06
cancer B-Disease 0 1.5020450518932194e-05
families O 0 1.0193515365131134e-08
for O 0 1.2196055276803008e-09
the O 0 1.8228167864009492e-09
distribution O 0 8.383917560195187e-09
of O 0 1.8477858132470715e-09
these O 0 4.650743434808646e-08
eight O 0 3.1513317821918463e-07
mutations O 0 1.7403392121195793e-05
. O 0 1.8417913452140056e-06

Mutations O 0 0.0001272086228709668
were O 0 6.205554541338643e-07
found O 0 1.6222008980548708e-07
in O 0 4.6276401377554066e-08
41 O 0 1.486779268589089e-07
of O 0 2.8148633646196686e-08
97 O 0 1.815083010114904e-06
families O 0 2.068162302748533e-06
. O 0 5.203112323215464e-06

Six O 0 1.0642484085110482e-06
of O 0 1.9004188445137515e-08
eight O 0 6.669624497135374e-08
mutations O 0 1.2322207112447359e-06
were O 0 6.97286139939024e-08
observed O 0 8.268373363762294e-08
at O 0 6.638884286758184e-08
least O 0 7.031425752757059e-08
twice O 0 2.971047479150002e-06
. O 0 2.7932301236432977e-06

The O 0 2.951279384433292e-06
BRCA1 O 0 4.285257455194369e-05
C4446T O 0 7.503956112486776e-06
mutation O 0 7.420926522172522e-06
was O 0 1.5578611112232466e-07
the O 0 3.1418769808055913e-09
most O 0 8.036112220111136e-09
common O 0 1.2099759771899699e-07
mutation O 0 4.60584624306648e-06
found O 0 2.9145394364604726e-07
, O 0 3.73445319112875e-09
followed O 0 1.7331915458385083e-08
by O 0 3.098045198157706e-08
the O 0 2.766497004813573e-07
BRCA2 O 0 0.000523437571246177
8765delAG O 0 0.00010071323777083308
mutation O 0 7.204793655546382e-05
. O 0 4.505219294514973e-06

Together O 0 7.231003564811544e-07
, O 0 2.459080938876923e-08
these O 0 5.260549773566936e-09
mutations O 0 1.823256354782643e-07
were O 0 2.3326334641637914e-08
found O 0 1.8140426050194947e-08
in O 0 9.280946677847624e-09
28 O 0 1.2794437509455747e-08
of O 0 7.64795116126038e-10
41 O 0 4.9309853977774765e-08
families O 0 2.0828352376156545e-08
identified O 0 9.240254428277694e-08
to O 0 1.5780710072021975e-08
have O 0 1.036702670376144e-07
a O 0 1.7413339037375408e-07
mutation O 0 1.7185260730911978e-05
. O 0 2.47224056693085e-06

The O 0 1.2455680007406045e-06
odds O 0 9.244982720701955e-06
of O 0 5.210261999621935e-09
detection O 0 1.3679152743861778e-07
of O 0 1.5406617093205455e-09
any O 0 1.069247623775027e-08
of O 0 7.295818948982458e-10
the O 0 7.683865987928584e-09
four O 0 9.94070603610453e-08
BRCA1 O 0 0.00021915034449193627
mutations O 0 2.08219098567497e-05
was O 0 1.6161029634531587e-06
18 O 0 1.9616804536326526e-07
. O 0 5.520329295904958e-07

7x O 0 0.000268282979959622
greater O 0 1.4721468915013247e-06
if O 0 1.7984986300234596e-07
one O 0 6.032423893742589e-09
or O 0 3.9476426572093715e-09
more O 0 1.182727249471327e-09
cases O 0 7.844347038599153e-08
of O 0 0.0002063360734609887
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 6.108902744017541e-05
also O 0 6.468121682701167e-08
present O 0 3.1830335700533396e-08
in O 0 1.3429831824396388e-07
the O 0 1.0846144249399003e-07
family O 0 1.7961468756766408e-06
. O 0 1.8411960809316952e-06

The O 0 6.484760888270102e-07
odds O 0 5.884996880922699e-06
of O 0 4.292348254608669e-09
detection O 0 1.13060544038035e-07
of O 0 9.525911170982226e-10
any O 0 9.892979768721943e-09
of O 0 1.829776441475417e-09
the O 0 1.6865833174506406e-08
four O 0 1.6390112023145775e-07
BRCA2 O 0 0.0010360907763242722
mutations O 0 2.1816576918354258e-05
was O 0 1.952560523932334e-06
5 O 0 6.753155616934237e-07
. O 0 1.2220532425999409e-06

3x O 0 0.0001238083787029609
greater O 0 6.218979251571e-07
if O 0 1.1509711583812532e-07
there O 0 6.576935440705256e-09
were O 0 6.280138631353793e-09
at O 0 2.7869486718401504e-09
least O 0 1.1415841605355581e-09
five O 0 1.9190162792170895e-09
cases O 0 2.5686638593924727e-08
of O 0 5.353820142772747e-08
breast B-Disease 1 0.9999912977218628
cancer I-Disease 0 0.2663816511631012
in O 0 5.590619167605837e-08
the O 0 2.432280439279566e-07
family O 0 2.425269713057787e-06
. O 0 2.907004727603635e-06

Interestingly O 0 1.4738166100869421e-05
, O 0 1.1137056077359375e-07
the O 0 8.563343811829327e-09
presence O 0 1.4613712906452747e-08
of O 0 3.3137335098132326e-09
a O 0 1.0643118741882063e-07
breast B-Disease 1 0.9777171611785889
cancer I-Disease 0 2.6252631869283505e-05
case O 0 6.963651344449318e-08
< O 0 1.491366390382609e-07
36 O 0 9.092241626262876e-09
years O 0 6.148739739586517e-09
of O 0 4.407625653346514e-10
age O 0 7.276481284179681e-08
was O 0 1.3153781708297174e-07
strongly O 0 8.90130902320152e-09
predictive O 0 2.722936471855064e-07
of O 0 1.0369469727322667e-09
the O 0 3.1090479080120303e-09
presence O 0 4.975034162413294e-09
of O 0 3.3106298258367417e-10
any O 0 2.6651136852962054e-09
of O 0 1.0053502474960396e-09
the O 0 1.4992602714869463e-08
eight O 0 2.4661363795530633e-07
mutations O 0 1.0033088983618654e-05
screened O 0 6.207920250744792e-06
. O 0 1.6235210296144942e-06

Carriers O 0 9.59171029535355e-06
of O 0 1.818102468575944e-08
the O 0 5.833380445352532e-09
same O 0 1.1184778436756915e-08
mutation O 0 1.437227297174104e-07
, O 0 1.2013433581259392e-09
from O 0 3.0958860475216454e-10
different O 0 2.162519052717471e-09
families O 0 5.77465320006354e-09
, O 0 1.4910123136147035e-09
shared O 0 9.410141998955623e-09
similar O 0 2.8497067816601884e-08
haplotypes O 0 3.429339585636626e-06
, O 0 9.729874683728212e-09
indicating O 0 2.8539387741943756e-08
that O 0 1.5752072979324794e-09
the O 0 1.0802798655618062e-09
mutant O 0 2.254471453966289e-08
alleles O 0 4.1972391784383944e-08
were O 0 3.603108922334286e-08
likely O 0 1.0401048911035105e-08
to O 0 1.5226138128099365e-09
be O 0 2.2343502603661136e-09
identical O 0 3.439009432781859e-08
by O 0 6.518128259358491e-09
descent O 0 4.3312688831065316e-06
for O 0 1.6192110763313394e-08
a O 0 3.094029565886558e-08
mutation O 0 1.3832443528372096e-06
in O 0 4.9392873791020975e-08
the O 0 6.413699082941093e-08
founder O 0 1.7723571090755286e-06
population O 0 9.027062333188951e-07
. O 0 2.4906898943299893e-06

The O 0 3.7946864495097543e-07
identification O 0 8.053944497987686e-07
of O 0 1.5944875642048828e-08
common O 0 4.384354213016195e-07
BRCA1 O 0 5.98589213041123e-05
and O 0 2.616031338220637e-07
BRCA2 O 0 3.27578563883435e-05
mutations O 0 1.5056815527714207e-06
will O 0 7.292498160893501e-09
facilitate O 0 1.6244110057073158e-08
carrier O 0 2.3014338523807965e-07
detection O 0 2.674607912922511e-07
in O 0 2.2322300452515265e-08
French O 0 2.562851022958057e-06
Canadian O 0 6.9246248131094035e-06
breast B-Disease 1 0.9870660901069641
cancer I-Disease 0 0.04884880781173706
and O 0 0.0005975821986794472
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0921892680926248e-05
. O 0 4.236725544615183e-06

Are O 0 3.6585488487617113e-06
Dp71 O 0 4.185677971690893e-05
and O 0 8.30635542570235e-07
Dp140 O 0 3.3361044188495725e-05
brain O 0 2.293247052875813e-05
dystrophin O 0 1.6045964002842084e-05
isoforms O 0 2.488460268068593e-06
related O 0 1.1358310985087883e-06
to O 0 2.637205511746288e-07
cognitive B-Disease 0 1.778428486431949e-05
impairment I-Disease 0 0.00010051309800473973
in O 0 4.84764404973248e-06
Duchenne B-Disease 0 0.4474949836730957
muscular I-Disease 0 0.024809380993247032
dystrophy I-Disease 0 0.07226946949958801
? O 0 0.0003218149358872324

Molecular O 0 3.0042439902899787e-05
study O 0 7.245029678415449e-07
and O 0 8.69878036269256e-08
neuropsychological O 0 1.045301587510039e-06
analysis O 0 5.906165867486379e-08
were O 0 1.1306609870587181e-08
performed O 0 1.0130251304474314e-08
concurrently O 0 1.2294249174260585e-08
on O 0 2.6338241809753526e-08
49 O 0 3.263042174239672e-07
patients O 0 4.796269763573946e-07
with O 0 1.5937099817620037e-07
Duchenne B-Disease 0 0.07525454461574554
muscular I-Disease 0 0.0002026866131927818
dystrophy I-Disease 0 0.00010258342808810994
( O 0 1.910176905539629e-07
DMD B-Disease 1 1.0
) O 0 1.2234882262873725e-07
in O 0 7.83235343249089e-09
order O 0 4.450728674498805e-09
to O 0 2.57806664905047e-09
find O 0 2.8746935498702442e-08
a O 0 2.6789661600190584e-09
molecular O 0 7.96448915707515e-08
explanation O 0 2.126680165304151e-08
for O 0 2.9927267330975837e-09
the O 0 1.2141656569042425e-08
cognitive B-Disease 0 1.456853738091013e-06
impairment I-Disease 0 1.6190988390007988e-06
observed O 0 2.7842915528708545e-07
in O 0 1.275640357789598e-07
most O 0 1.1522298336785752e-05
DMD B-Disease 1 1.0
patients O 0 0.01041199266910553
. O 0 5.76879983782419e-06

Complete O 0 3.1608776680513984e-06
analysis O 0 6.898963533785718e-07
of O 0 8.571677589941373e-09
the O 0 8.867147904823014e-09
dystrophin O 0 7.60494401674805e-07
gene O 0 3.3617746453273867e-07
was O 0 1.2783318936726573e-07
performed O 0 2.2138873845278795e-08
to O 0 2.6828164134684584e-09
define O 0 7.31695308786584e-08
the O 0 3.4917251312549524e-09
localization O 0 2.0363527752920163e-08
of O 0 4.698251232504447e-10
deletions O 0 1.1574501002087345e-07
and O 0 1.2215524591852045e-08
duplications O 0 6.731993948960735e-07
in O 0 1.5190350310945178e-08
relation O 0 8.916759952626307e-08
to O 0 2.6498177874145767e-08
the O 0 5.0290363873273236e-08
different O 0 1.8849177649826743e-06
DMD B-Disease 1 0.9999994039535522
promoters O 0 7.878227188484743e-05
. O 0 6.110970844019903e-06

Qualitative O 0 2.8912263587699272e-05
analysis O 0 1.4865031516819727e-06
of O 0 1.0209509682113094e-08
the O 0 1.084827161434987e-08
Dp71 O 0 5.696774678654037e-07
transcript O 0 5.441615940071642e-07
and O 0 2.177490721066988e-08
testing O 0 3.367235024143156e-08
for O 0 4.764516559063736e-10
the O 0 5.380472178906359e-10
specific O 0 1.644395397626397e-09
first O 0 3.4629008549558193e-09
exon O 0 5.23552827758067e-08
of O 0 1.6196086694009182e-09
Dp140 O 0 2.616161225432734e-07
were O 0 4.584381230188228e-08
also O 0 1.4116250390827645e-08
carried O 0 1.498509050179564e-07
out O 0 2.3632208012713818e-07
. O 0 1.4257343536883127e-06

Neuropsychological O 0 0.0002887567097786814
analysis O 0 4.112732312933076e-06
assessed O 0 2.826950549206231e-06
verbal O 0 2.166782678614254e-06
and O 0 1.042962125552549e-07
visuospatial O 0 9.648868399381172e-06
intelligence O 0 4.691280992119573e-06
, O 0 1.3829415834720749e-08
verbal O 0 5.849337867402937e-07
memory O 0 7.16656431904994e-05
, O 0 5.286684867655822e-08
and O 0 5.852798068417542e-08
reading O 0 1.0813068911375012e-06
skills O 0 7.104652468115091e-06
. O 0 3.833731170743704e-06

Comparison O 0 7.907211511337664e-06
of O 0 5.45118474803985e-08
molecular O 0 1.8932554439743399e-06
and O 0 1.0751685408649791e-07
psychometric O 0 4.6120221668388695e-05
findings O 0 4.7633625399612356e-07
demonstrated O 0 3.569026318928081e-08
that O 0 2.8898101689378564e-09
deletions O 0 1.0490990121070354e-07
and O 0 5.690094173615989e-09
duplications O 0 4.1347459500684636e-07
that O 0 9.160931568885644e-09
were O 0 1.1845610714544819e-08
localized O 0 1.1687830436812874e-07
in O 0 1.45090055525543e-08
the O 0 4.283760901557798e-09
distal O 0 6.146983650978655e-07
part O 0 8.439722876119049e-08
of O 0 8.482707869461592e-10
the O 0 1.732506693663538e-09
gene O 0 2.0289748547952513e-08
seemed O 0 3.216607069589372e-08
to O 0 2.8941347096633763e-09
be O 0 3.716496888017673e-09
preferentially O 0 2.1347150891415367e-07
associated O 0 1.4972175677030464e-07
with O 0 8.493190506442261e-08
cognitive B-Disease 0 4.0055401768768206e-05
impairment I-Disease 0 0.00016467210662085563
. O 0 6.652398042206187e-06

Two O 0 1.8929177940663067e-06
altered O 0 6.647685950156301e-06
Dp71 O 0 3.7450304262165446e-06
transcripts O 0 9.80519644144806e-07
and O 0 1.89603426292706e-08
two O 0 4.979676671013067e-09
deleted O 0 2.3690741102200263e-07
Dp140 O 0 2.6175911216341774e-07
DNA O 0 9.912627518815498e-08
sequences O 0 4.1660776162188995e-08
were O 0 1.060776977368505e-08
found O 0 5.603908004303548e-09
in O 0 5.563459026802775e-09
four O 0 6.179816836038299e-08
patients O 0 1.2026343938487116e-06
with O 0 3.8256669654401776e-07
severe O 1 0.9955633878707886
cerebral B-Disease 1 0.9999622106552124
dysfunction I-Disease 1 0.9933379888534546
. O 0 2.274329381179996e-05

These O 0 7.865364182180201e-07
findings O 0 4.864891138822713e-07
suggest O 0 8.901924530846372e-08
that O 0 1.3857105463088715e-09
some O 0 4.905773565155869e-10
sequences O 0 6.916867079098665e-09
located O 0 9.981055981711506e-09
in O 0 3.437820472740327e-09
the O 0 1.2156992079681572e-09
distal O 0 1.6971735306015034e-07
part O 0 6.368959759583959e-08
of O 0 6.851657574635794e-10
the O 0 1.3720138358763734e-09
gene O 0 1.8245430055685574e-08
and O 0 9.051734473075612e-09
, O 0 1.3306387103284578e-09
in O 0 1.2944432192796285e-09
particular O 0 9.177282933592323e-09
, O 0 3.743167553693638e-09
some O 0 8.209252833069058e-09
DMD B-Disease 1 0.9999918937683105
isoforms O 0 5.234364834905136e-07
expressed O 0 1.920910541741705e-08
in O 0 1.2924949110981743e-08
the O 0 2.7481995346079202e-08
brain O 0 0.0019835710991173983
may O 0 1.4181985079630977e-06
be O 0 3.369649004270059e-09
related O 0 6.132880869813562e-09
to O 0 6.554931708535605e-09
the O 0 2.9073980556404422e-08
cognitive B-Disease 0 9.465295079280622e-06
impairment I-Disease 0 1.0632426892698277e-05
associated O 0 5.845093937750789e-07
with O 0 1.2105639370929566e-06
DMD B-Disease 1 1.0
. O 0 1.0356130587751977e-05
. O 0 3.6542598991218256e-06

I1307K O 0 0.0002915951481554657
APC O 0 1.4672758879896719e-05
and O 0 2.503181519841746e-07
hMLH1 O 0 2.954162937385263e-06
mutations O 0 2.7200967451790348e-06
in O 0 3.02663671902792e-08
a O 0 3.55406797325486e-08
non O 0 3.4650840916583547e-06
- O 0 0.0014473791234195232
Jewish O 0 2.738530611168244e-06
family O 0 1.0670559191794382e-07
with O 0 6.741206703964053e-08
hereditary B-Disease 1 0.9997972846031189
non I-Disease 1 0.9993305206298828
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.110136069357395e-05

We O 0 2.926788283730275e-06
describe O 0 1.4098793599259807e-06
a O 0 1.527298110204356e-07
French O 0 3.4877048165071756e-06
Canadian O 0 3.652611894722213e-06
hereditary B-Disease 1 0.9915153980255127
non I-Disease 1 0.9987695813179016
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.5634632240544306e-06
HNPCC B-Disease 1 0.862304151058197
) O 0 3.518543110203609e-07
kindred O 0 1.1645171980489977e-05
which O 0 7.311219718530992e-08
carries O 0 7.926692546789127e-08
a O 0 4.759008120913677e-08
novel O 0 8.5836461494182e-07
truncating O 0 1.648413308430463e-05
mutation O 0 1.3857972589903511e-05
in O 0 1.0949507895929855e-06
hMLH1 O 0 0.00010002775525208563
. O 0 8.202389835787471e-06

Interestingly O 0 2.2299134798231535e-05
, O 0 7.932620604833573e-08
the O 0 1.82518693492284e-08
I1307K O 0 1.0807038961502258e-06
APC O 0 3.049093209028797e-07
polymorphism O 0 1.3503771469913772e-06
, O 0 4.3133665528216625e-09
associated O 0 7.511569144469377e-09
with O 0 6.625874293675338e-10
an O 0 2.7670119528977466e-09
increased O 0 1.111489609684213e-06
risk O 0 0.11472238600254059
of O 0 0.0008672273834235966
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.8216739994823e-07
is O 0 1.5064982150647666e-08
also O 0 3.386474034527964e-08
present O 0 1.5318718737944437e-08
in O 0 5.555403248536095e-08
this O 0 2.079953702605053e-07
family O 0 2.3075442641129484e-06
. O 0 2.660514155650162e-06

The O 0 4.108614177766867e-07
I1307K O 0 2.9869340778532205e-06
polymorphism O 0 2.852850457202294e-06
has O 0 4.209393011933571e-08
previously O 0 2.8722492828592294e-08
only O 0 1.912705549500515e-09
been O 0 1.2312060704289252e-08
identified O 0 3.2523701065656496e-08
in O 0 2.482435146333728e-09
individuals O 0 3.4901470602477502e-09
of O 0 3.9906273840983886e-09
self O 0 0.005704205948859453
- O 1 0.9864740371704102
reported O 0 0.003239481011405587
Ashkenazi O 0 0.00021487522462848574
Jewish O 0 2.367051365581574e-06
origins O 0 9.977431545848958e-06
. O 0 2.552645128162112e-06

In O 0 7.050992394397326e-07
addition O 0 1.2618083644611033e-07
, O 0 1.2555995354546212e-08
in O 0 5.887447418473357e-09
this O 0 7.911705068863739e-09
family O 0 3.807304338465656e-08
, O 0 2.6247608531093647e-09
there O 0 2.430152301613475e-09
appears O 0 2.8734655543871668e-08
to O 0 1.7653206896284246e-08
be O 0 8.313505617252304e-08
no O 0 5.638323585799299e-09
relationship O 0 1.5463593072695403e-08
between O 0 2.4164525935788106e-09
the O 0 3.589614827603782e-09
I1307K O 0 2.2057194826174964e-07
polymorphism O 0 7.766542466924875e-07
and O 0 1.7035016952604565e-08
the O 0 3.6056166941023093e-09
presence O 0 2.3871626453342287e-08
or O 0 9.076027396304198e-08
absence O 0 7.512718269708785e-08
of O 0 3.443683027626321e-08
cancer B-Disease 0 6.180270429467782e-05
. O 0 2.8505829163805174e-07
. O 0 1.1055506092816358e-06

Identification O 0 3.753042619791813e-06
of O 0 3.2207324807131954e-08
a O 0 3.877926246786956e-08
novel O 0 3.5773209106082504e-07
mutation O 0 8.184661624e-07
of O 0 2.6646307382804935e-09
the O 0 1.0523131699358146e-08
CPO O 0 9.201164630212588e-07
gene O 0 2.971598007661669e-07
in O 0 5.68776421516759e-08
a O 0 1.9879942669831507e-07
Japanese O 0 2.0278381271054968e-05
hereditary B-Disease 1 0.8484159111976624
coproporphyria I-Disease 0 0.06622228026390076
family O 0 1.0482252037036233e-05
. O 0 5.658273948938586e-06

Hereditary B-Disease 1 0.9910752773284912
coproporphyria I-Disease 0 0.0207376666367054
( O 0 1.1750377097996534e-06
HCP B-Disease 0 0.00012488810170907527
) O 0 1.5791707141943334e-07
is O 0 3.290438144176733e-08
an O 0 1.8876130525313783e-07
autosomal B-Disease 1 0.9999959468841553
dominant I-Disease 1 0.9999991655349731
disease I-Disease 1 0.8478350639343262
characterized O 0 2.2575195544050075e-06
by O 0 1.1168964419994154e-07
a O 0 1.4986552741902415e-05
deficiency B-Disease 0 0.09616918116807938
of I-Disease 0 7.469422413919347e-09
coproporphyrinogen I-Disease 0 3.252958049415611e-05
oxidase I-Disease 0 3.0886046715750126e-06
( O 0 1.6034295668987397e-08
CPO O 0 2.0898323782603256e-06
) O 0 1.923700843065035e-08
caused O 0 3.708334261887103e-08
by O 0 4.875320147590401e-09
a O 0 3.009253290997549e-08
mutation O 0 1.8487335182726383e-06
in O 0 5.1987996130264946e-08
the O 0 1.3063123560641543e-07
CPO O 0 1.5876761608524248e-05
gene O 0 7.3883161348931026e-06
. O 0 4.032481683680089e-06

Only O 0 2.441556034682435e-06
11 O 0 2.634714348914713e-07
mutations O 0 2.4417485633421165e-07
of O 0 1.2894876277869116e-09
the O 0 2.851662683767131e-09
gene O 0 9.359256836205532e-08
have O 0 2.3515302416399209e-07
been O 0 9.456617817704682e-07
reported O 0 3.837377789750462e-06
in O 0 4.3878179667444783e-07
HCP B-Disease 1 0.5042658448219299
patients O 0 2.2806543711340055e-05
. O 0 2.8867598302895203e-06

We O 0 1.3936046343587805e-05
report O 0 2.97168327278996e-07
another O 0 4.31253823762745e-08
mutation O 0 9.037364634423284e-07
in O 0 4.294848210406599e-08
a O 0 1.593071772276744e-07
Japanese O 0 5.559845703828614e-06
family O 0 3.351158284203848e-06
. O 0 3.545591880538268e-06

Polymerase O 0 0.00022416317369788885
chain O 0 0.0001704056339804083
reaction O 0 2.775328903226182e-05
- O 0 8.353928569704294e-05
single O 0 1.5363743841589894e-06
strand O 0 1.0129063412023243e-05
conformational O 0 7.983559271451668e-07
polymorphism O 0 2.318308588655782e-06
and O 0 2.5931885971886004e-08
direct O 0 2.831356482602132e-08
sequence O 0 1.1607043148842422e-07
analyses O 0 7.081742410264269e-07
demonstrated O 0 1.84605241315694e-07
a O 0 2.441051982771114e-08
C O 0 3.653280771231948e-07
to O 0 8.602977885630025e-09
T O 0 1.1419510315135994e-07
substitution O 0 5.7055369317993154e-09
in O 0 3.562298456216695e-09
exon O 0 8.071554447042217e-08
1 O 0 5.026914440264818e-09
of O 0 7.737394613904769e-10
the O 0 4.924704199993357e-09
CPO O 0 3.438081819240324e-07
gene O 0 4.744008919033149e-08
at O 0 8.44438829972205e-09
nucleotide O 0 1.4668395920125477e-07
position O 0 7.367113425971183e-07
85 O 0 2.1270613714818865e-08
, O 0 3.7392213769749105e-09
which O 0 6.948126074490801e-09
lies O 0 3.357634525968933e-08
in O 0 7.92088616918818e-09
the O 0 9.460838334973687e-09
putative O 0 4.3771436253337015e-07
presequence O 0 7.538274644502962e-07
for O 0 7.501504306617335e-09
targeting O 0 2.1252390070003457e-07
to O 0 6.933975527090297e-08
mitochondria O 0 5.656547727994621e-06
. O 0 3.2737791570980335e-06

This O 0 5.131473699293565e-07
mutation O 0 2.4366527213715017e-06
changes O 0 1.6314383799453935e-07
the O 0 1.2573945440408352e-08
codon O 0 2.742189622040314e-07
for O 0 3.3483784633858704e-09
glutamine O 0 1.7101307037137303e-07
to O 0 1.4608111165159698e-08
a O 0 2.6172138234414888e-08
termination O 0 7.770794923089852e-07
codon O 0 2.288383939230698e-06
at O 0 1.4822009575254924e-07
amino O 0 4.998492499908025e-07
acid O 0 1.199085431835556e-06
position O 0 4.075368451594841e-06
29 O 0 1.1952823797400924e-06
. O 0 1.707365072434186e-06

MaeI O 0 9.876300464384258e-05
restriction O 0 2.0807524379051756e-06
analysis O 0 5.515435645975231e-07
showed O 0 9.981535953329512e-08
two O 0 3.5198364223276712e-09
other O 0 7.079167474444148e-09
carriers O 0 2.9168501214371645e-07
in O 0 2.809290755578786e-08
the O 0 1.0499658031903891e-07
family O 0 1.8014717397818458e-06
. O 0 2.2238534711505054e-06

The O 0 3.5246323477622354e-06
C O 0 0.010494081303477287
- O 0 0.013084152713418007
T O 0 0.00038983591366559267
mutation O 0 5.802528448839439e-07
is O 0 5.0954529484670275e-09
located O 0 1.0023829766225845e-08
within O 0 5.776834566262323e-09
a O 0 2.010568245225386e-08
recently O 0 5.25091934377997e-07
proposed O 0 8.96821816809279e-08
putative O 0 3.0560102004528744e-07
alternative O 0 1.35726992311902e-07
translation O 0 9.564333680600612e-08
initiation O 0 1.1043054115589257e-07
codon O 0 1.0692833711800631e-06
( O 0 1.4138938908558885e-08
TIC O 0 1.391046680510044e-06
- O 0 1.0410039976704866e-06
1 O 0 2.1818642892412754e-08
) O 0 2.6609843217784146e-09
, O 0 1.2128157367286008e-09
supporting O 0 1.2004323757253132e-08
that O 0 1.0092009006257285e-08
TIC O 0 3.627998012234457e-06
- O 0 3.2574660053796833e-06
1 O 0 1.8022994652255875e-08
is O 0 3.286672933811019e-09
the O 0 3.909636614451983e-09
real O 0 6.114557038472412e-08
TIC O 0 3.277860400885402e-07
rather O 0 6.704211408248284e-09
than O 0 7.772423593621625e-09
TIC O 0 4.333574452175526e-06
- O 0 1.0724655794547289e-06
2 O 0 5.3587037029956264e-08
. O 0 6.9588445228419e-08
. O 0 9.283284043704043e-07

Human B-Disease 0 1.4106989510764834e-05
complement I-Disease 0 4.886108945356682e-05
factor I-Disease 0 0.006485899444669485
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998843669891357
associated O 0 0.00015433099179062992
with O 0 0.0006776015507057309
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001077477791113779

This O 0 3.808656003911892e-07
study O 0 2.089821435902195e-07
reports O 0 4.6412971244080836e-08
on O 0 9.769651754254483e-09
six O 0 9.725199312526911e-09
cases O 0 5.223090582262557e-08
of O 0 2.4249121821640074e-08
deficiency B-Disease 0 0.12037237733602524
in I-Disease 0 2.371180052307409e-08
the I-Disease 0 9.479950158208794e-09
human I-Disease 0 1.6609483566298877e-08
complement I-Disease 0 7.9836524946586e-08
regulatory I-Disease 0 1.4367874712206685e-07
protein I-Disease 0 1.7415597142189654e-07
Factor I-Disease 0 6.454879439843353e-07
H I-Disease 1 0.999997615814209
( O 0 3.019291128225632e-08
FH O 0 0.00016187407891266048
) O 0 4.376481399503973e-09
in O 0 1.173169561496934e-09
the O 0 1.4280434612601312e-09
context O 0 1.5055704238875478e-08
of O 0 8.682714991437024e-09
an O 0 9.504360059509054e-05
acute B-Disease 1 0.9999947547912598
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.869123611366376e-05

Five O 0 3.2409701589131146e-07
of O 0 5.881173770205805e-09
the O 0 5.591245244573884e-09
cases O 0 1.280808525905286e-08
were O 0 9.639490983204269e-09
observed O 0 2.889298933439477e-08
in O 0 1.1121619181153619e-08
children O 0 4.968815758843448e-08
presenting O 0 4.847625518777932e-07
with O 0 1.8046950572170317e-05
idiopathic O 1 0.9999997615814209
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00013704235607292503
HUS B-Disease 1 0.9999841451644897
) O 0 9.132885679719038e-06
. O 0 7.532176368840737e-06

Two O 0 8.880557089696595e-08
of O 0 5.380125678300374e-09
the O 0 1.0406089323566903e-08
children O 0 1.7316782674470232e-08
exhibited O 0 9.885042828727819e-08
a O 0 1.2260333903668652e-07
homozygous O 1 0.6742173433303833
deficiency O 0 0.39328792691230774
characterized O 0 3.339375211908191e-07
by O 0 1.04892663443934e-08
the O 0 1.2059860665658562e-08
absence O 0 1.871530308505953e-08
of O 0 6.255198026217101e-10
the O 0 1.992171760889505e-09
150 O 0 7.423575087983636e-09
- O 0 8.386016503436622e-08
kD O 0 3.868131841500144e-07
form O 0 9.798427846874347e-09
of O 0 1.770357416219781e-09
Factor O 0 2.539242416332854e-07
H O 1 1.0
and O 0 4.0880628660033835e-08
the O 0 4.903062844618944e-09
presence O 0 1.1933758869986377e-08
, O 0 1.0912848402711006e-09
upon O 0 2.7453115336584233e-09
immunoblotting O 0 1.4789237923196197e-07
, O 0 1.6524979162824138e-09
of O 0 6.517676953698981e-10
the O 0 9.70899982633e-09
42 O 0 8.012759877829012e-08
- O 0 1.0032131285697687e-06
kD O 0 9.968700396711938e-06
Factor O 0 9.013247677103209e-07
H O 1 0.9999973773956299
- O 0 1.3732811794398003e-06
like O 0 3.266482195840581e-08
protein O 0 4.603491987609232e-08
1 O 0 1.3796428888213086e-08
( O 0 4.50814274799427e-09
FHL O 0 4.007107236247975e-06
- O 0 3.298215688118944e-06
1 O 0 1.6633578070468502e-08
) O 0 1.132715365947945e-09
and O 0 2.58831489574618e-09
other O 0 1.511843450430206e-08
FH O 0 0.2865465581417084
- O 0 4.948471541865729e-06
related O 0 2.508745069462748e-07
protein O 0 2.431331722618779e-07
( O 0 2.6940886854731616e-08
FHR O 0 7.079041097313166e-06
) O 0 6.780368977388207e-08
bands O 0 1.0374093335485668e-06
. O 0 1.879007413663203e-06

Southern O 0 1.627373421797529e-05
blot O 0 8.393182361032814e-05
and O 0 2.283144908687973e-07
PCR O 0 2.5787769573071273e-06
analysis O 0 4.6351665616839455e-08
of O 0 2.024941547773551e-09
DNA O 0 1.2506214375207492e-07
of O 0 1.8537904544757566e-09
one O 0 1.0033508246465317e-08
patient O 0 6.795024631855995e-08
with O 0 7.3797830069111114e-09
homozygous O 0 0.032195497304201126
deficiency O 0 0.048927292227745056
ruled O 0 5.413095095718745e-06
out O 0 1.696847462540063e-08
the O 0 2.910686802692908e-09
presence O 0 4.042137291548897e-09
of O 0 3.011598748159372e-10
a O 0 3.6337362008254104e-09
large O 0 2.083677408393214e-08
deletion O 0 3.805319295224763e-07
of O 0 3.4817229099814995e-09
the O 0 1.780904668180483e-08
FH O 0 0.0002916006778832525
gene O 0 1.371099500602213e-07
as O 0 2.0163632541425613e-08
the O 0 1.969229757037283e-08
underlying O 0 1.2866066754213534e-05
defect O 0 1.5800058463355526e-05
for O 0 7.128640078235549e-08
the O 0 3.3815604183473624e-06
deficiency O 0 0.46428391337394714
. O 0 2.981486886710627e-06

The O 0 1.7618702941035735e-07
other O 0 1.8187751749110248e-08
four O 0 1.1346513062449048e-08
children O 0 1.3567984957774115e-08
presented O 0 1.9831611908216473e-08
with O 0 2.6788805840283203e-08
heterozygous O 0 0.038539279252290726
deficiency O 0 0.10746286064386368
and O 0 2.7279730474560893e-08
exhibited O 0 3.1365053132503817e-07
a O 0 4.822900123713225e-08
normal O 0 4.87394231640792e-07
immunoblotting O 0 9.415633940079715e-06
pattern O 0 1.0701943438107264e-06
of O 0 8.392301076298736e-09
proteins O 0 8.171358700792553e-08
of O 0 1.8763339326710593e-08
the O 0 6.58098485928349e-07
FH O 1 0.9502021670341492
family O 0 3.5337498047738336e-06
. O 0 2.3623604192835046e-06

Factor B-Disease 1 0.9785721302032471
H I-Disease 1 1.0
deficiency I-Disease 1 0.9975754618644714
is O 0 6.040023947662121e-08
the O 0 2.640131668840695e-08
only O 0 1.049781189976784e-06
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
associated O 0 1.5922340026008897e-05
with O 0 2.2782910491514485e-06
HUS B-Disease 1 0.9999833106994629
. O 0 1.9201659597456455e-05

These O 0 7.204687904049933e-07
observations O 0 1.2302245977480197e-06
suggest O 0 4.523709833392786e-07
a O 0 3.087491862174829e-08
role O 0 8.47818668603395e-08
for O 0 3.442317009216822e-08
FH O 0 0.0036961666774004698
and O 0 1.0066097644312322e-07
/ O 0 5.666880724675138e-07
or O 0 4.5307382379178307e-07
FH O 0 0.012582376599311829
receptors O 0 7.80629250130005e-07
in O 0 2.5309876861001612e-08
the O 0 5.022096516427155e-08
pathogenesis O 0 3.294710495538311e-06
of O 0 1.5241697326473513e-07
idiopathic O 1 0.9802023768424988
HUS B-Disease 1 0.9999760389328003
. O 0 4.164642177784117e-06
. O 0 5.567204425460659e-06

Further O 0 5.37046446424938e-07
evidence O 0 2.3982028096725116e-07
for O 0 6.49695319765442e-09
a O 0 1.0577302589354076e-08
major O 0 6.803973917612893e-08
ancient O 0 9.139517942458042e-07
mutation O 0 0.004206881858408451
underlying O 0 0.03296941518783569
myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999775886535645
from O 0 1.8216313435459597e-07
linkage O 0 3.4695807698881254e-05
disequilibrium O 0 0.0017255798447877169
studies O 0 2.799524054353242e-06
in O 0 5.558201365829518e-08
the O 0 5.7035489220425006e-08
Japanese O 0 9.019232152240875e-07
population O 0 1.0966217587338178e-06
. O 0 1.8200752265329356e-06

The O 0 5.8523302868707106e-05
myotonic B-Disease 1 0.999985933303833
dystrophy I-Disease 1 0.9999949932098389
( O 0 7.141594687709585e-05
DM B-Disease 1 1.0
) O 0 1.3711794508708408e-06
mutation O 0 9.008520464703906e-06
is O 0 4.2188215587657396e-08
an O 0 5.876063369214535e-08
unstable O 0 0.012080376036465168
( O 0 4.166840383845738e-08
CTG O 0 2.662961151145282e-06
) O 0 1.3075882598911903e-08
n O 0 1.011168251352501e-06
repeat O 0 7.398919115075842e-05
, O 0 2.1883481693407703e-09
present O 0 3.2331697319420982e-09
at O 0 6.961244913838982e-09
a O 0 1.7823412745698874e-09
copy O 0 6.1922413863158e-08
number O 0 3.2539257954766754e-09
of O 0 1.1746876804608064e-09
5 O 0 1.7149250908232716e-08
- O 0 1.6116701999635552e-06
37 O 0 1.8146620206493935e-08
repeats O 0 4.644121887054098e-08
on O 0 4.929638031114791e-09
normal O 0 2.221912254185554e-08
chromosomes O 0 7.190088524566818e-08
but O 0 1.0060144717272124e-08
amplified O 0 8.343290858192631e-08
to O 0 5.062921193399461e-09
50 O 0 8.941314355581653e-09
- O 0 1.7796456575069897e-07
3000 O 0 2.444630808895454e-07
copies O 0 1.8705387105910631e-07
on O 0 8.743716080061859e-07
DM B-Disease 1 0.9999550580978394
chromosomes O 0 3.0856939702061936e-05
. O 0 2.729894049480208e-06

Previous O 0 1.2651461474888492e-05
findings O 0 3.269629360147519e-06
in O 0 1.0934235916693069e-07
Caucasian O 0 6.294943432294531e-06
populations O 0 4.3052975229329604e-07
of O 0 1.2013760652962446e-08
a O 0 7.966582984408888e-07
DM B-Disease 1 1.0
founder O 0 2.1358525827963604e-06
chromosome O 0 3.90089007851202e-06
raise O 0 1.0219624613228007e-07
a O 0 5.934891245118479e-09
question O 0 1.8033000870332216e-08
about O 0 5.979496342511936e-10
the O 0 1.554158579608611e-09
molecular O 0 6.766816795789055e-08
events O 0 1.6739434727242042e-08
involved O 0 2.6967672539512932e-08
in O 0 1.0289054053203017e-08
the O 0 3.8902463472823e-08
expansion O 0 2.6587310912873363e-06
mutation O 0 2.439576383039821e-05
. O 0 2.597758566480479e-06

To O 0 1.4563953527613194e-06
investigate O 0 2.2098556655691937e-06
whether O 0 1.168755119351772e-07
a O 0 2.8997941825537055e-08
founder O 0 1.5142207132612384e-07
chromosome O 0 1.0425856089568697e-06
for O 0 1.8863742567987174e-08
the O 0 1.9169326037626888e-07
DM B-Disease 1 1.0
mutation O 0 4.3596079194685444e-05
exists O 0 1.254541928119579e-07
in O 0 5.819921877758816e-09
the O 0 4.2449719295234445e-09
Japanese O 0 9.104721954145134e-08
population O 0 1.0431844721381367e-08
, O 0 2.737285731413408e-09
we O 0 5.921638734918133e-09
genotyped O 0 1.6871375407845335e-07
families O 0 3.652142588350671e-09
using O 0 9.498302588895058e-09
polymorphic O 0 9.246475087820727e-07
markers O 0 5.0620874390006065e-06
near O 0 2.2808599453583156e-07
the O 0 2.3155186212875378e-08
( O 0 1.8248213606852914e-08
CTG O 0 2.652791636137408e-06
) O 0 2.3093656764672232e-08
n O 0 1.763387672326644e-06
repeat O 0 0.0001731991214910522
region O 0 8.206741881622293e-07
and O 0 2.35309158824748e-07
constructed O 0 0.00037212984170764685
haplotypes O 0 0.00020192083320580423
. O 0 7.964205906318966e-06

Six O 0 6.776179475309618e-07
different O 0 1.3297518819399556e-07
haplotypes O 0 3.022759983650758e-06
were O 0 1.531650610786528e-07
found O 0 1.3191494474540377e-07
and O 0 6.55409678529395e-07
DM B-Disease 1 1.0
alleles O 0 0.00011766130774049088
were O 0 1.799771553123719e-06
always O 0 1.1030440418835497e-06
haplotype O 0 1.9857363440678455e-05
A O 0 3.04457080346765e-06
. O 0 6.278275577642489e-06

To O 0 5.622367211799428e-07
find O 0 2.2858640136291797e-07
an O 0 3.6204050868349213e-09
origin O 0 3.0861553312888645e-08
of O 0 3.1811080436483508e-09
the O 0 2.807083987477199e-08
( O 0 1.7527593598742897e-08
CTG O 0 1.4680616686746362e-06
) O 0 9.232834941030887e-09
n O 0 2.2475509808828065e-07
repeat O 0 1.4596059827454155e-06
mutation O 0 2.2471353133823868e-07
and O 0 5.061173702358701e-09
to O 0 4.9274664348786246e-09
investigate O 0 1.4789527824632387e-08
the O 0 2.1436450392542383e-09
mechanism O 0 5.3486530759983e-09
of O 0 1.9252552330151218e-10
the O 0 1.109510705532557e-09
expansion O 0 1.4810304094226012e-08
mutation O 0 5.917125633914111e-08
in O 0 4.3523735726580526e-09
the O 0 3.307494722548654e-09
Japanese O 0 3.358838895906047e-08
population O 0 5.947877745882124e-09
we O 0 6.003314734215337e-09
have O 0 3.014145821822467e-09
studied O 0 4.361034910971284e-08
90 O 0 2.3689921135883196e-08
Japanese O 0 5.746505848946981e-07
DM B-Disease 1 0.9999977350234985
families O 0 4.471407422101947e-08
comprising O 0 1.0512860804112734e-08
190 O 0 2.6846196377050546e-08
affected O 0 5.749817688638359e-08
and O 0 3.076669585766467e-08
130 O 0 1.535485267822878e-07
unaffected O 0 3.5687619401869597e-06
members O 0 3.197931164322654e-07
. O 0 1.7367676719004521e-06

The O 0 6.556447829098033e-07
results O 0 1.2121651025154279e-06
suggest O 0 2.1269768524234678e-07
that O 0 4.3141157313186795e-09
a O 0 5.754191789719698e-09
few O 0 3.4714336294427994e-08
common O 0 3.0081285018468407e-08
ancestral O 0 1.9147475427416794e-07
mutations O 0 8.679009624756873e-06
in O 0 1.914936831326486e-08
both O 0 4.317253754493322e-08
Caucasian O 0 9.51719339354895e-05
and O 0 1.5057217694902647e-07
Japanese O 0 1.1530893573308276e-07
populations O 0 4.3453006526306126e-08
have O 0 3.379857949070697e-09
originated O 0 5.7941487163759575e-09
by O 0 6.569886301655004e-10
expansion O 0 6.3408611694626416e-09
of O 0 9.85457493385411e-10
an O 0 5.26098142827891e-09
ancestral O 0 2.4449968805129174e-07
n O 0 1.3275766832521185e-05
= O 0 9.29549173633859e-07
5 O 0 1.6366143995583116e-08
repeat O 0 3.621892687988293e-07
to O 0 1.8234922904980522e-08
n O 0 1.2500603361331741e-06
= O 0 1.5221462490444537e-06
19 O 0 9.034385328732242e-08
- O 0 9.230475939148164e-07
37 O 0 1.6826834325911477e-07
copies O 0 8.521544145878579e-07
. O 0 2.0254638002370484e-06

These O 0 5.930576776336238e-07
data O 0 2.326901977767193e-07
support O 0 2.5031567929545417e-08
multistep O 0 8.651587677377393e-07
models O 0 1.3146760124982393e-07
of O 0 2.063108350824905e-09
triplet O 0 1.9256319774285657e-06
repeat O 0 2.5670506147434935e-06
expansion O 0 4.5046384400393435e-08
that O 0 3.4862417397363288e-09
have O 0 2.032870760615424e-09
been O 0 1.371859403853648e-09
proposed O 0 3.756305932967052e-09
for O 0 2.3568673679363883e-09
both O 0 2.5716693130561907e-07
DM B-Disease 1 1.0
and O 0 2.817689164658077e-06
Friedreichs B-Disease 0 4.5480199332814664e-05
ataxia I-Disease 0 5.2092309488216415e-05
. O 0 9.736893389344914e-07
. O 0 2.9175030249461997e-06

The O 0 6.119545332694543e-07
molecular O 0 2.2332408207148546e-06
basis O 0 3.943306694509374e-07
of O 0 1.3732158095081104e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.6024641524836625e-07
the O 0 1.2812361838143715e-08
western O 0 1.7848806521669758e-07
Cape O 0 2.706063071400422e-07
, O 0 1.4595938679917708e-08
South O 0 7.445571981179455e-08
Africa O 0 4.892780225418392e-07
. O 0 9.158468969872047e-07

Deficiency B-Disease 1 0.9951543807983398
of I-Disease 0 5.541940950593016e-08
the I-Disease 0 3.690201211270505e-08
sixth I-Disease 0 4.2476307271499536e-07
component I-Disease 0 1.4644005830177775e-07
of I-Disease 0 3.6218763543871546e-09
human I-Disease 0 2.244679997431831e-08
complement I-Disease 0 1.2214690059408895e-07
( O 0 6.589328638284542e-09
C6 O 0 1.2292991868889658e-06
) O 0 3.289244210336051e-09
has O 0 2.557067224628895e-09
been O 0 6.404201258192188e-08
reported O 0 5.898420596395226e-08
in O 0 2.6121851348648306e-09
a O 0 1.932455973019387e-09
number O 0 1.511024083633572e-09
of O 0 3.980180907081632e-10
families O 0 1.951379058340308e-09
from O 0 1.411866623612923e-09
the O 0 5.358629540097581e-09
western O 0 9.600100980833304e-08
Cape O 0 2.1109154602072522e-07
, O 0 2.0730020366954705e-08
South O 0 1.0857010579456983e-07
Africa O 0 2.941782781817892e-07
. O 0 9.746685236677877e-07

Meningococcal B-Disease 1 0.9975487589836121
disease I-Disease 1 0.8966718316078186
is O 0 1.9867715650434548e-07
endemic O 0 2.2003325739206048e-07
in O 0 2.406840060587001e-08
the O 0 1.3827331279969712e-08
Cape O 0 8.40042417848963e-08
and O 0 3.7120762019782205e-09
almost O 0 2.895548023573724e-09
all O 0 1.5752553705894456e-09
pedigrees O 0 3.019104610757495e-07
of O 0 2.6171488087811667e-08
total O 0 0.013588692992925644
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.3415663125424544e-08
C6Q0 O 0 4.171614364167908e-06
) O 0 7.3392856236864645e-09
have O 0 9.041622561767326e-09
been O 0 3.4651488789450013e-08
ascertained O 0 1.27226815038739e-06
because O 0 7.347776431743114e-08
of O 0 4.072148485079197e-08
recurrent O 1 0.946333110332489
disease O 0 0.18259617686271667
. O 0 8.950717528932728e-06

We O 0 4.665781943913316e-06
have O 0 8.196271039651037e-08
sequenced O 0 1.9892571856416907e-07
the O 0 1.67758074098856e-08
expressed O 0 1.302761276633646e-08
exons O 0 2.1220856183390424e-07
of O 0 2.9567208681413604e-09
the O 0 5.884854381577043e-09
C6 O 0 8.70438839228882e-07
gene O 0 1.435507712699291e-08
from O 0 9.112706145231186e-10
selected O 0 2.9210536212076477e-09
cases O 0 4.5792321046178586e-09
and O 0 3.718155783261068e-09
have O 0 8.965204578714747e-09
found O 0 2.394942910655118e-08
three O 0 1.6967049987215432e-08
molecular O 0 0.16593417525291443
defects O 1 0.9947564601898193
leading O 0 2.3156562178883178e-07
to O 0 2.5229624611711188e-08
total O 0 1.7288211040522583e-07
deficiency O 0 0.00021461806318257004
879delG O 0 1.9760623217734974e-06
, O 0 3.3404943255987973e-09
which O 0 4.518817764420646e-09
is O 0 2.9217834818240362e-09
the O 0 5.415397907881925e-09
common O 0 3.765296128221962e-07
defect O 0 4.331544550950639e-05
in O 0 2.2728599446963926e-08
the O 0 1.3549906974219539e-08
Cape O 0 7.445543559470025e-08
and O 0 8.607869084187314e-09
hitherto O 0 2.2518742071042652e-07
unreported O 0 1.6095124522053084e-07
, O 0 2.543471877558545e-09
and O 0 1.5401564468220386e-09
1195delC O 0 6.191308443703747e-08
and O 0 4.78540185255838e-09
1936delG O 0 1.6327675211869064e-07
, O 0 2.413145461233057e-09
which O 0 3.4558009787133415e-09
have O 0 1.9157258890345474e-08
been O 0 1.0628269819790148e-07
previously O 0 5.996371328365058e-07
reported O 0 2.6869872726820176e-07
in O 0 3.8800571644515e-08
African O 0 2.2391601817162154e-07
- O 0 2.4743096219026484e-05
Americans O 0 2.5166411887767026e-06
. O 0 1.8051055121759418e-06

We O 0 4.085493856109679e-06
also O 0 3.229510525670776e-08
show O 0 2.238907548246516e-08
that O 0 1.8083278208180786e-09
the O 0 2.079789229725293e-09
879delG O 0 3.4816824268091295e-07
and O 0 3.802260550855863e-08
1195delC O 0 6.810727791162208e-05
defects O 1 0.9034303426742554
are O 0 1.1689040846363241e-08
associated O 0 5.4984777619893066e-08
with O 0 2.5700504835413085e-08
characteristic O 1 0.6527155041694641
C6 O 1 0.9999803304672241
/ O 0 0.0015912774251773953
C7 O 0 0.007167293224483728
region O 0 8.65679567141342e-07
DNA O 0 3.071242645091843e-06
marker O 0 2.090290763590019e-06
haplotypes O 0 1.0275432032358367e-05
, O 0 5.845066652909736e-08
although O 0 4.927619556838181e-08
small O 0 9.079247575982663e-08
variations O 0 1.12715224531712e-06
were O 0 5.93609343013668e-07
observed O 0 4.909124072582927e-06
. O 0 4.054736564285122e-06

The O 0 1.0688040674722288e-06
1936delG O 0 1.6387268260587007e-05
defect O 0 5.3645812840841245e-06
was O 0 1.0251290660789891e-07
observed O 0 3.4452597219569725e-08
only O 0 4.507050732627249e-09
once O 0 1.2894273027086456e-07
in O 0 8.163923759241243e-09
the O 0 1.4898588140965785e-08
Cape O 0 2.591775114524353e-07
, O 0 5.9379368089196305e-09
but O 0 2.4397392550667973e-08
its O 0 1.8286748115770024e-08
associated O 0 1.1709686731364854e-07
haplotype O 0 2.1563846530625597e-06
could O 0 2.0697170839412138e-06
be O 0 1.7515002070922492e-07
deduced O 0 5.939904440310784e-06
. O 0 1.995543925659149e-06

The O 0 2.1298387764545623e-07
data O 0 1.5642149264749605e-07
from O 0 6.5910885638231775e-09
the O 0 5.606837216731719e-09
haplotypes O 0 4.847158834309084e-07
indicate O 0 1.7878858216135995e-07
that O 0 1.4194242448084538e-09
these O 0 2.7449555961567285e-09
three O 0 1.2693707418520717e-08
molecular O 0 0.004975069779902697
defects O 1 0.7372766733169556
account O 0 8.830375719526273e-08
for O 0 8.577793586539428e-09
the O 0 6.390254725374689e-08
defects O 1 0.8450013399124146
in O 0 8.009043206413935e-09
all O 0 1.4391449143502655e-09
the O 0 4.637100037285791e-09
38 O 0 1.4747500998169016e-08
unrelated O 0 4.230392391946225e-08
C6Q0 O 0 1.6475818256367347e-06
individuals O 0 6.095365101543848e-09
we O 0 6.7440466544610445e-09
have O 0 3.925283209582631e-09
studied O 0 4.562260258467177e-08
from O 0 1.0712298603721138e-08
the O 0 9.038022596996598e-08
Cape O 0 2.1797486624564044e-06
. O 0 1.7828948557507829e-06

We O 0 6.278988621488679e-06
have O 0 1.3395028020113386e-07
also O 0 1.7985906097806037e-08
observed O 0 3.595770081687988e-08
the O 0 9.18540887795416e-09
879delG O 0 1.3764935147264623e-06
defect O 0 2.9795880891470006e-06
in O 0 3.753371302650521e-08
two O 0 5.584506084232999e-07
Dutch O 1 0.9999902248382568
C6 B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
deficient I-Disease 1 1.0
kindreds O 0 3.293213376309723e-05
, O 0 7.0729457846141486e-09
but O 0 6.847950206889664e-09
the O 0 3.795701086772851e-09
879delG O 0 6.485688572865911e-07
defect O 0 6.560487690876471e-07
in O 0 6.791135209738286e-09
the O 0 6.6931207243214885e-09
Cape O 0 5.15764320141443e-08
probably O 0 4.6108823426038725e-08
did O 0 1.316655318106541e-08
not O 0 2.4158808287211286e-09
come O 0 4.244591345070603e-09
from O 0 2.4570354639763536e-09
The O 0 1.414452199810512e-08
Netherlands O 0 3.2458308396599023e-06
. O 0 1.8405658863684948e-07
. O 0 1.018711941469519e-06

Complement B-Disease 1 0.9947916269302368
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.6867751873614907e-07
seven O 0 4.7128672520102555e-08
further O 0 1.1220615903084763e-07
molecular O 0 0.03219025209546089
defects O 1 0.9998717308044434
and O 0 1.2435396001819754e-06
their O 0 3.407233180041658e-07
associated O 0 5.669811343977926e-06
marker O 0 8.020485984161496e-05
haplotypes O 0 0.0017313598655164242
. O 0 1.8742788597592153e-05

Seven O 0 1.6219393046412733e-06
further O 0 2.7825501547340536e-07
molecular O 0 2.057837264146656e-06
bases O 0 3.0779660846746992e-06
of O 0 3.0934304504626198e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.11952783754532e-06
described O 0 7.15174928700435e-06
. O 0 7.810433089616708e-06

All O 0 3.0261958272603806e-07
these O 0 5.097555089150774e-08
new O 0 7.897054388195102e-08
molecular O 0 5.992517344566295e-06
defects O 0 0.000341759150614962
involve O 0 4.66849172653383e-08
single O 0 3.8685706726937497e-07
- O 0 8.795593657850986e-07
nucleotide O 0 4.348571849277505e-07
events O 0 2.104454743800943e-08
, O 0 1.4054264418916773e-09
deletions O 0 4.250093965652013e-08
and O 0 3.267895287706324e-09
substitutions O 0 1.767173607447603e-08
, O 0 1.528759674407354e-09
some O 0 3.576927920523332e-10
of O 0 7.131381041247664e-10
which O 0 3.556054650744045e-08
alter O 0 3.6713938698085258e-06
splice O 0 4.5407064135361e-06
sites O 0 4.336569929819234e-07
, O 0 2.065578108556565e-08
and O 0 4.916607210248003e-08
others O 0 2.7092082177659904e-07
codons O 0 8.425643500231672e-06
. O 0 1.929841801029397e-06

They O 0 1.2517278946688748e-06
are O 0 1.3294495282423213e-08
distributed O 0 1.0946772377451452e-08
along O 0 1.218399425795269e-08
the O 0 2.4240105034323278e-08
C7 O 0 4.216438810544787e-06
gene O 0 1.9067515211190766e-07
, O 0 1.6640115063637495e-08
but O 0 2.0721838467352427e-08
predominantly O 0 6.498839155710812e-08
towards O 0 4.531749553393638e-08
the O 0 6.777680283676091e-08
3 O 0 1.6768201760442025e-07
end O 0 8.974324146038271e-07
. O 0 1.1772428933909396e-06

All O 0 3.1679527978667466e-07
were O 0 8.36555145156126e-08
found O 0 4.344322945826207e-08
in O 0 2.0661573785218934e-08
compound O 0 4.4100269747104903e-07
heterozygous O 0 7.714906132605392e-06
individuals O 0 6.234751595002308e-07
. O 0 2.237252601844375e-06

The O 0 1.805915599106811e-05
C6 O 0 0.09211517870426178
/ O 0 0.00030093983514234424
C7 O 0 0.0009839624399319291
marker O 0 1.4221032870409545e-05
haplotypes O 0 1.760584746079985e-05
associated O 0 3.858574473269982e-07
with O 0 3.544035820368663e-08
most O 0 6.266420314204879e-06
C7 B-Disease 1 0.9999430179595947
defects I-Disease 1 0.9999560117721558
are O 0 1.3525060182928428e-07
tabulated O 0 1.2618806067621335e-05
. O 0 2.1974051378492732e-07
. O 0 1.1299150628474308e-06

A O 0 3.270393108323333e-06
genome O 0 4.641315626940923e-06
- O 0 2.656992364791222e-06
wide O 0 1.3804213949697441e-07
search O 0 1.0862727606308908e-07
for O 0 1.8566931103691786e-08
chromosomal O 0 2.0798119294340722e-05
loci O 0 1.298153392781387e-06
linked O 0 2.0791396309505217e-05
to O 0 5.535982268156658e-07
mental O 0 0.00035562485572881997
health O 0 4.1609007439546986e-07
wellness O 0 1.220390828393647e-07
in O 0 9.387250088366272e-09
relatives O 0 3.6763331934253074e-08
at O 0 7.750591635158344e-08
high O 0 1.8865974880100111e-06
risk O 0 1.2911890735267662e-05
for O 0 6.75150033657701e-08
bipolar B-Disease 1 0.7998560070991516
affective I-Disease 0 0.22180457413196564
disorder I-Disease 0 0.42688530683517456
among O 0 1.2703860363671993e-07
the O 0 5.5146315958154446e-08
Old O 0 4.773749878950184e-06
Order O 0 4.542597480394761e-07
Amish O 0 3.381088390597142e-05
. O 0 5.702880116587039e-06

Bipolar B-Disease 1 0.9998651742935181
affective I-Disease 1 0.998156726360321
disorder I-Disease 1 0.999222993850708
( O 0 6.327270057226997e-06
BPAD B-Disease 1 0.9999998807907104
; O 0 3.40991718985606e-05
manic B-Disease 1 0.9999644756317139
- I-Disease 1 0.9999991655349731
depressive I-Disease 1 0.9999995231628418
illness I-Disease 1 0.9833893179893494
) O 0 2.0906128384012845e-07
is O 0 1.3638557838646648e-08
characterized O 0 8.667115736216147e-08
by O 0 7.820694314375487e-09
episodes O 0 1.6346045583759405e-07
of O 0 3.837463236067151e-09
mania B-Disease 0 5.990454155835323e-05
and O 0 9.79901756181789e-07
/ O 0 3.160202368235332e-06
or O 0 2.7925327117372944e-07
hypomania B-Disease 0 2.5626071874285117e-05
interspersed O 0 6.330748760774441e-07
with O 0 1.3164795475972824e-08
periods O 0 3.6713200302074256e-07
of O 0 7.597478202114871e-08
depression B-Disease 0 4.6833210944896564e-05
. O 0 4.080330654687714e-06

Compelling O 0 1.5022513252915815e-05
evidence O 0 9.92381501419004e-07
supports O 0 1.9095557490800275e-07
a O 0 2.319027991859457e-08
significant O 0 8.965823639073278e-08
genetic O 0 9.890698038361734e-07
component O 0 7.60733712468209e-07
in O 0 4.3987860465222184e-08
the O 0 4.231352690453605e-08
susceptibility O 0 6.7997707446920685e-06
to O 0 6.783848789382319e-07
develop O 0 1.9652094124467112e-05
BPAD B-Disease 1 0.9999978542327881
. O 0 7.185919002949959e-06

To O 0 3.663307381884806e-07
date O 0 4.5615556132361235e-07
, O 0 7.657851242015568e-09
however O 0 6.227333315678152e-09
, O 0 1.8744621410604623e-09
linkage O 0 3.074924563861714e-07
studies O 0 1.6850231077114586e-07
have O 0 6.250967299337162e-09
attempted O 0 2.3646855140668777e-08
only O 0 2.023146539187337e-09
to O 0 5.644219758238478e-09
identify O 0 2.951916826532397e-07
chromosomal O 0 3.076815801250632e-06
loci O 0 2.0809714840197557e-07
that O 0 1.266686133760686e-08
cause O 0 8.413299923404338e-08
or O 0 1.0008033513031478e-07
increase O 0 9.859265759359914e-08
the O 0 1.0940869543674125e-07
risk O 0 4.845891908189515e-06
of O 0 4.668661190976309e-08
developing O 0 1.491946113674203e-05
BPAD B-Disease 1 0.9999995231628418
. O 0 1.163434990303358e-05

To O 0 3.0265539407992037e-07
determine O 0 1.5841422396078997e-07
whether O 0 1.0571312714091619e-08
there O 0 3.874612186649529e-09
could O 0 1.638925972713423e-08
be O 0 3.287581984423582e-09
protective O 0 2.6067366931670222e-08
alleles O 0 7.852040795341964e-08
that O 0 3.0687909990945172e-09
prevent O 0 5.4068031829501706e-08
or O 0 1.233886450791033e-07
reduce O 0 3.6186540341986984e-07
the O 0 1.390381410004693e-08
risk O 0 2.6935651931125904e-07
of O 0 6.111753325654945e-10
developing O 0 7.578071148373056e-08
BPAD B-Disease 1 1.0
, O 0 2.5335604725285066e-09
similar O 0 1.7659395057378902e-09
to O 0 1.4736891706945698e-09
what O 0 9.161328917706157e-10
is O 0 3.2581970454970133e-10
observed O 0 3.4497951162393292e-09
in O 0 2.532154708134726e-09
other O 0 4.1041889176085533e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.487490841611816e-08
we O 0 3.0152165209074155e-08
used O 0 9.562210834701546e-06
mental O 0 0.00030334771145135164
health O 0 6.744485858689586e-07
wellness O 0 1.2984577324459678e-07
( O 0 2.4442794455126204e-09
absence O 0 7.007150415461183e-09
of O 0 1.952045414199688e-09
any O 0 8.692014489497524e-06
psychiatric B-Disease 1 0.9207782745361328
disorder I-Disease 0 0.001152234384790063
) O 0 1.2629613799219896e-08
as O 0 1.3528627995640363e-08
the O 0 2.611822935705277e-08
phenotype O 0 8.394126780331135e-05
in O 0 8.381043414829037e-08
our O 0 4.447777968152877e-08
genome O 0 8.604343548768156e-08
- O 0 4.946151079820993e-07
wide O 0 7.012567948549986e-08
linkage O 0 1.228171981892956e-06
scan O 0 8.306955351145007e-06
of O 0 1.2502958668392239e-09
several O 0 7.173142080318939e-09
large O 0 8.420749253446047e-08
multigeneration O 0 3.317428127047606e-05
Old O 0 6.408129706869659e-07
Order O 0 3.67529544575973e-08
Amish O 0 3.6145632975603803e-07
pedigrees O 0 6.400134680006886e-07
exhibiting O 0 2.244342311996661e-07
an O 0 2.3030095164244813e-08
extremely O 0 1.241065774593153e-06
high O 0 9.11359802557854e-06
incidence O 0 0.03420453518629074
of O 0 7.5242763841743e-07
BPAD B-Disease 1 0.9999998807907104
. O 0 1.6889009202714078e-05

We O 0 9.119109563471284e-06
have O 0 1.2045612152178364e-07
found O 0 3.2004994210410587e-08
strong O 0 1.455968146046871e-08
evidence O 0 3.7306886468968514e-08
for O 0 6.361867033177759e-09
a O 0 2.2153065160068763e-08
locus O 0 1.2589091966219712e-05
on O 0 2.962424900943006e-07
chromosome O 0 5.417491775006056e-05
4p O 0 0.003302549244835973
at O 0 1.8774048271552601e-07
D4S2949 O 0 8.892801020010666e-07
( O 0 1.0771447733759487e-08
maximum O 0 4.224151695098044e-08
GENEHUNTER O 0 1.0319316970708314e-05
- O 0 1.1696755564116756e-06
PLUS O 0 1.5062575187130278e-07
nonparametric O 0 5.326299969965476e-07
linkage O 0 1.3626358850160614e-06
score O 0 2.973327468680509e-07
= O 0 5.229290991337621e-07
4 O 0 2.202637183756906e-08
. O 0 7.864763063025748e-09
05 O 0 4.348501079221023e-07
, O 0 1.3907554219372287e-08
P O 0 3.5988964555144776e-06
= O 0 1.8364701759310265e-07
5 O 0 6.620268333534796e-09
. O 0 4.227293182168523e-09
22 O 0 5.384478640735324e-09
x O 0 1.002551570650212e-07
10 O 0 1.0478688139414771e-08
( O 0 3.6125831215372273e-09
- O 0 1.2058776519552339e-06
4 O 0 1.2531018001027405e-08
) O 0 2.569171986266383e-09
; O 0 4.0442191817646744e-09
SIBPAL O 0 7.595622264489066e-07
Pempirical O 0 4.087572449407162e-07
value O 0 1.855216780199953e-08
< O 0 3.3050557846081574e-08
3 O 0 3.282481619848454e-09
x O 0 6.789026940623444e-08
10 O 0 5.174667805363242e-09
( O 0 1.876000244038778e-09
- O 0 5.838381298417517e-07
5 O 0 5.859999596680154e-09
) O 0 1.0759347857103307e-09
) O 0 4.398522102100344e-10
and O 0 2.0020565205669527e-09
suggestive O 0 8.596190781418045e-08
evidence O 0 1.9961779784694045e-08
for O 0 1.8469296092504806e-09
a O 0 1.5458843094506847e-08
locus O 0 1.0110494258697145e-05
on O 0 5.714666144740477e-07
chromosome O 0 0.0008345015812665224
4q O 1 0.9653053879737854
at O 0 2.6160412858189375e-07
D4S397 O 0 9.170644261757843e-07
( O 0 6.509890848604982e-09
maximum O 0 5.19650953378914e-08
GENEHUNTER O 0 7.748573807475623e-06
- O 0 1.0789345878947643e-06
PLUS O 0 2.1860010690488707e-07
nonparametric O 0 9.355175052405684e-07
linkage O 0 1.679247588981525e-06
score O 0 3.7189172985563346e-07
= O 0 2.4483688321197405e-07
3 O 0 7.624723963317592e-09
. O 0 6.621253767491453e-09
29 O 0 1.3428673284465731e-08
, O 0 3.2192630783356435e-09
P O 0 6.319990461634006e-06
= O 0 1.1849208192415972e-07
2 O 0 3.942894455377655e-09
. O 0 3.961642125460685e-09
57 O 0 1.0299578079298044e-08
x O 0 2.976329085413454e-07
10 O 0 8.397424977601986e-09
( O 0 2.334083371025031e-09
- O 0 1.491208422521595e-06
3 O 0 1.9196615852479226e-08
) O 0 4.176434309499655e-09
; O 0 4.9826218706527925e-09
SIBPAL O 0 4.779922164743766e-07
Pempirical O 0 2.4349608906959475e-07
value O 0 1.0963175256506474e-08
< O 0 3.404705495313465e-08
1 O 0 2.281776323442841e-09
x O 0 4.576937939759773e-08
10 O 0 3.1749978202100237e-09
( O 0 1.2117127301536357e-09
- O 0 4.6040889856158174e-07
3 O 0 1.0556784779680584e-08
) O 0 8.683438967871382e-10
) O 0 3.7434652599976914e-10
that O 0 4.862094060698041e-10
are O 0 3.284510885492864e-09
linked O 0 6.261969701881753e-06
to O 0 3.851155554457364e-07
mental O 0 7.668731996091083e-05
health O 0 1.6051023976615397e-06
wellness O 0 7.353857654379681e-06
. O 0 1.4304848718893481e-06

These O 0 6.397059451046516e-07
findings O 0 2.4403800580330426e-07
are O 0 5.090119881145938e-09
consistent O 0 2.0519873800139976e-08
with O 0 1.420114914552073e-09
the O 0 3.060560693768366e-09
hypothesis O 0 9.611405715759247e-08
that O 0 2.3032458162930425e-09
certain O 0 3.4744522814378342e-09
alleles O 0 1.3169749024655175e-07
could O 0 2.0719869553431636e-07
prevent O 0 8.259452499714826e-08
or O 0 1.597434362565764e-08
modify O 0 2.9910395937804424e-07
the O 0 1.118245318565414e-08
clinical O 0 2.127459453049596e-07
manifestations O 0 1.3531781917208718e-07
of O 0 1.1747913752913064e-08
BPAD B-Disease 1 1.0
and O 0 7.456956296891804e-08
perhaps O 0 5.883734743861169e-08
other O 0 3.389763136851798e-08
related O 0 5.744857844547369e-06
affective B-Disease 0 0.06844650954008102
disorders I-Disease 1 0.5768933892250061
. O 0 9.253062671632506e-06

Segregation O 0 0.0009839765261858702
distortion O 0 0.0012812657514587045
in O 0 2.8233482225914486e-05
myotonic B-Disease 1 0.9999725818634033
dystrophy I-Disease 1 0.9999837875366211
. O 0 8.13622900750488e-05

Myotonic B-Disease 1 0.9999892711639404
dystrophy I-Disease 1 0.9999977350234985
( O 0 0.0003152357821818441
DM B-Disease 1 1.0
) O 0 8.397970532314503e-07
is O 0 3.999789299768963e-08
an O 0 7.072287644405151e-08
autosomal B-Disease 1 0.9991500377655029
dominant I-Disease 1 0.999993085861206
disease I-Disease 1 0.6452827453613281
which O 0 8.652167338141226e-08
, O 0 3.347050414603814e-09
in O 0 3.2132205785018186e-09
the O 0 9.436545767016469e-09
typical O 0 1.1237348189752083e-06
pedigree O 0 0.002141379751265049
, O 0 1.3517433394838463e-08
shows O 0 4.291351984875291e-08
a O 0 2.080718708441509e-08
three O 0 4.8625256710010945e-08
generation O 0 1.0562634997768328e-06
anticipation O 0 1.2410207546054153e-06
cascade O 0 2.6866055122809485e-05
. O 0 3.312637318231282e-06

This O 0 1.2827150612793048e-06
results O 0 1.9707683804881526e-06
in O 0 5.224216579335916e-07
infertility B-Disease 0 0.3086445927619934
and O 0 1.352531853626715e-05
congenital B-Disease 1 0.9999984502792358
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.509248249931261e-06
CDM B-Disease 0 0.00013820597087033093
) O 0 1.985401709703183e-08
with O 0 3.5490126393256105e-09
the O 0 2.3582266805988183e-08
disappearance O 0 8.076380595412047e-07
of O 0 4.827133537332884e-08
DM B-Disease 1 1.0
in O 0 1.1532657708812621e-06
that O 0 2.700839729641302e-07
pedigree O 0 0.0001058730558725074
. O 0 3.828039098152658e-06

The O 0 2.861930852304795e-07
concept O 0 1.8137889412628283e-07
of O 0 4.3081209710749135e-09
segregation O 0 3.322510337966378e-07
distortion O 0 2.2023950805305503e-06
, O 0 3.3874087979057776e-09
where O 0 3.1023423829878993e-09
there O 0 1.0564654706612941e-09
is O 0 9.536964551415394e-10
preferential O 0 3.0535304063050717e-08
transmission O 0 1.7530342688587552e-07
of O 0 6.703185229106623e-10
the O 0 2.6808879560746846e-09
larger O 0 4.76224037981865e-08
allele O 0 6.260705731619964e-07
at O 0 3.697168793337369e-08
the O 0 2.665582954364254e-08
DM B-Disease 1 0.9999997615814209
locus O 0 0.00020033563487231731
, O 0 1.5115666940346273e-08
has O 0 1.1729039961494436e-08
been O 0 3.1355089191720253e-08
put O 0 1.5814970666383488e-08
forward O 0 6.223011439487891e-09
to O 0 2.3578834440485252e-09
explain O 0 3.306480778064724e-08
partially O 0 7.563781423414184e-07
the O 0 5.5254099073920315e-09
maintenance O 0 1.0945648654114848e-07
of O 0 1.4252496072231224e-08
DM B-Disease 1 0.9999998807907104
in O 0 7.798101364642207e-08
the O 0 1.26775987041583e-07
population O 0 6.869878461657208e-07
. O 0 1.1387118092898163e-06

In O 0 8.901039905140351e-07
a O 0 2.3010125005384907e-07
survey O 0 7.294253236977966e-07
of O 0 3.912794355187543e-08
DM B-Disease 1 0.9999998807907104
in O 0 5.420877187134465e-07
Northern O 0 6.530630685119831e-07
Ireland O 0 6.638999821007019e-06
, O 0 3.1216647045084756e-08
59 O 0 1.886058242916988e-07
pedigrees O 0 4.5759738895867486e-06
were O 0 1.3111066436977126e-06
ascertained O 0 4.831047772313468e-05
. O 0 2.9886834909120807e-06

Sibships O 0 0.00021374017524067312
where O 0 4.639146311546938e-07
the O 0 7.73339969839526e-09
status O 0 2.140675547934734e-08
of O 0 6.010931752342685e-10
all O 0 9.787290977669727e-10
the O 0 8.146079366611048e-10
members O 0 8.180863764195578e-10
had O 0 4.257720931377662e-08
been O 0 2.8518002181954216e-08
identified O 0 1.1601327898347336e-08
were O 0 2.910914620457561e-09
examined O 0 4.045084978088198e-08
to O 0 2.0944748158058246e-09
determine O 0 2.3189306475046578e-08
the O 0 1.8062287221454199e-09
transmission O 0 1.6860052198808262e-07
of O 0 9.488049235173435e-10
the O 0 2.7001847868746154e-08
DM B-Disease 1 0.9999991655349731
expansion O 0 2.9747958762982307e-08
from O 0 5.6690674377080086e-09
affected O 0 1.752334632953989e-08
parents O 0 1.6134862335093203e-08
to O 0 8.410553142823574e-09
their O 0 8.894168246342815e-08
offspring O 0 3.5531843423086684e-06
. O 0 1.2360175105641247e-06

Where O 0 2.784113348752726e-06
the O 0 1.6487575749124517e-07
transmitting O 0 5.673700798070058e-05
parent O 0 2.436284557916224e-05
was O 0 2.2216127035790123e-06
male O 0 1.203286046802532e-06
, O 0 7.352921471692753e-08
58 O 0 1.4802249097556341e-06
. O 0 1.3496007795765763e-06

3 O 0 1.2958070101376506e-06
% O 0 5.2361276203782836e-08
of O 0 6.689595544173699e-10
the O 0 4.948808918214809e-09
offspring O 0 1.1067155014643504e-07
were O 0 4.4075797234199854e-08
affected O 0 1.2909723068332823e-08
, O 0 1.7743700952976837e-09
and O 0 5.11514208767494e-09
in O 0 5.031806971089736e-09
the O 0 4.367758599244098e-09
case O 0 3.0743581902470396e-08
of O 0 6.272629637926741e-10
a O 0 1.4345059362597112e-08
female O 0 8.367337045456225e-07
transmitting O 0 0.0008485508151352406
parent O 0 3.336810550536029e-06
, O 0 6.848959088756601e-08
68 O 0 1.0780686352518387e-06
. O 0 2.2316526155918837e-06

7 O 0 1.88897338375682e-05
% O 0 1.3818178103974788e-06
were O 0 4.135806648264406e-07
affected O 0 3.3266080663452158e-06
. O 0 5.622278422379168e-06

Studies O 0 6.949917860765709e-06
on O 0 2.2381523478998133e-07
meiotic O 0 7.062513304845197e-06
drive O 0 1.2626707075469312e-06
in O 0 1.7528437012970244e-07
DM B-Disease 1 0.9999998807907104
have O 0 1.0513506509823856e-07
shown O 0 1.0043253340086267e-08
increased O 0 6.601656998839189e-09
transmission O 0 7.14568315629549e-08
of O 0 6.499874527499117e-10
the O 0 2.9388584898981662e-09
larger O 0 7.793268963496303e-08
allele O 0 6.292772809501912e-07
at O 0 5.1312582627360825e-08
the O 0 5.456791285496365e-08
DM B-Disease 1 0.9999997615814209
locus O 0 8.439192606601864e-05
in O 0 1.3803291665226425e-07
non O 0 6.243359621294076e-06
- O 0 0.07633505016565323
DM O 1 0.999998927116394
heterozygotes O 0 1.6765812688390724e-05
for O 0 2.3952244987412996e-07
CTGn O 0 2.7357418730389327e-05
. O 0 2.3935444914968684e-06

This O 0 6.351691581585328e-07
study O 0 2.589398206964688e-07
provides O 0 2.6655218476889786e-08
further O 0 1.101649971246843e-08
evidence O 0 3.493245870345163e-08
that O 0 8.05564859263086e-09
the O 0 5.5902567908105993e-08
DM B-Disease 1 0.9999979734420776
expansion O 0 2.846288111868489e-07
tends O 0 1.580930586442264e-07
to O 0 6.719868217430758e-09
be O 0 2.7546914083131924e-08
transmitted O 0 6.5614193545116e-07
preferentially O 0 5.515658813237678e-06
. O 0 2.343250116609852e-06

Diagnosis O 1 0.8849310278892517
of O 0 3.412324076634832e-05
hemochromatosis B-Disease 1 0.9999995231628418
. O 0 0.00020246794156264514

If O 0 1.4697183360112831e-05
untreated O 0 8.680596511112526e-05
, O 0 2.7307328309689183e-07
hemochromatosis B-Disease 1 0.9999998807907104
can O 0 0.006176032591611147
cause O 0 0.0006279255030676723
serious O 0 0.0179755836725235
illness O 0 0.0006393193616531789
and O 0 1.8405653889885798e-08
early B-Disease 0 3.2146263606591674e-07
death I-Disease 0 3.4228655465540214e-08
, O 0 4.338507331169694e-09
but O 0 1.784632246426554e-07
the O 0 1.1386885034880834e-07
disease O 0 3.5169534839951666e-06
is O 0 1.5831599142757113e-08
still O 0 3.991848132045561e-07
substantially O 0 1.9949520719819702e-06
under O 0 5.994364755679271e-07
- O 1 0.9593660235404968
diagnosed O 1 0.5500773191452026
. O 0 3.5769189707934856e-06

The O 0 8.999438705359353e-08
cornerstone O 0 2.7024421456189884e-07
of O 0 2.5855173557687294e-09
screening O 0 5.286190685183101e-08
and O 0 5.5746118832189495e-09
case O 0 1.2864371790044515e-08
detection O 0 1.2543696925604308e-07
is O 0 3.826186034672219e-09
the O 0 6.295093335495494e-09
measurement O 0 4.086956550963805e-07
of O 0 1.6902061972245974e-08
serum O 0 1.4970534039093764e-06
transferrin O 0 2.1908881535637192e-06
saturation O 0 2.7330747798259836e-06
and O 0 8.253121563939203e-08
the O 0 6.501827698457419e-08
serum O 0 7.2680168159422465e-06
ferritin O 0 7.538963109254837e-05
level O 0 6.004055649100337e-06
. O 0 4.250428901286796e-06

Once O 0 1.2055099432473071e-05
the O 0 1.3491089134731737e-07
diagnosis O 0 1.8698498024605215e-05
is O 0 2.4871281922855815e-08
suspected O 0 7.166306659200927e-07
, O 0 1.036575714152832e-08
physicians O 0 3.434761453036117e-08
must O 0 1.2868568433077598e-08
use O 0 3.849862650895375e-08
serum O 0 1.2836366067858762e-06
ferritin O 0 8.83011452970095e-05
levels O 0 5.511999006557744e-06
and O 0 1.441543133751111e-07
hepatic O 0 9.381001291330904e-05
iron O 0 0.0009571808041073382
stores O 0 1.0245783414575271e-05
on O 0 1.0094746016875433e-07
liver O 0 9.554034477332607e-06
biopsy O 0 0.0016151374438777566
specimens O 0 1.3348901006793312e-07
to O 0 1.557168261001607e-08
assess O 0 5.62251784685941e-07
patients O 0 1.0608866318762011e-07
for O 0 3.1214963946979424e-09
the O 0 1.1516184450499622e-08
presence O 0 1.6963498694622103e-07
of O 0 5.977973671633663e-08
iron B-Disease 1 0.7005773186683655
overload I-Disease 0 0.0023088722955435514
. O 0 5.026302915212e-06

Liver O 0 0.4513794183731079
biopsy O 1 0.984831690788269
is O 0 1.1141623446064841e-07
also O 0 1.0204933786894799e-08
used O 0 5.776639255827831e-08
to O 0 3.3658145159876085e-09
establish O 0 1.3171929325039855e-08
the O 0 2.711553204193251e-09
presence O 0 2.0815086543279904e-08
or O 0 1.9039822518607252e-07
absence O 0 2.772534202222232e-08
of O 0 4.464996372632868e-09
cirrhosis B-Disease 0 0.0047033000737428665
, O 0 9.370756615112441e-09
which O 0 5.337771469271502e-08
can O 0 4.139535576541675e-07
affect O 0 2.310781610503909e-06
prognosis O 0 0.00026674859691411257
and O 0 6.257828886191419e-07
management O 0 3.8085538562881993e-06
. O 0 2.620640998429735e-06

A O 0 3.2761902275524335e-06
DNA O 0 6.231950010260334e-06
- O 0 6.658465736109065e-06
based O 0 8.860051536885294e-08
test O 0 7.853494565779329e-08
for O 0 1.383370751284474e-09
the O 0 1.5095146244092916e-09
HFE O 0 1.2665456097238348e-06
gene O 0 1.6944056824286235e-08
is O 0 8.21211487700424e-10
commercially O 0 5.30090140671291e-08
available O 0 1.9276676255230996e-08
, O 0 8.998607414767434e-10
but O 0 1.937896731973865e-09
its O 0 1.4130682179924747e-09
place O 0 6.36953103594351e-08
in O 0 5.27721200072051e-09
the O 0 1.863466003726444e-08
diagnosis O 0 6.102846236899495e-05
of O 0 1.865236853859642e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.6267415503534721e-06
still O 0 2.0754869183292612e-06
being O 0 5.926912649556471e-07
evaluated O 0 1.6569257468290743e-06
. O 0 1.354793880636862e-06

Currently O 0 1.2847302741647582e-06
, O 0 1.2703202045827311e-08
the O 0 2.2457149473353866e-09
most O 0 3.6856482310554384e-09
useful O 0 1.0881220369185485e-08
role O 0 1.1042755154733186e-08
for O 0 1.6042852601927393e-09
this O 0 2.8909732385784537e-09
test O 0 1.2353324052583048e-07
is O 0 4.688457955204228e-10
in O 0 5.352497889354879e-10
the O 0 1.0290933660783708e-09
detection O 0 1.378977998456321e-07
of O 0 5.516564094421028e-09
hemochromatosis B-Disease 1 1.0
in O 0 4.7792523218959104e-06
the O 0 3.418722371861804e-08
family O 0 2.162041745634724e-08
members O 0 7.509917687720247e-10
of O 0 6.179080580537288e-10
patients O 0 3.4074339794187836e-08
with O 0 1.8675569979365036e-09
a O 0 6.98149875688614e-08
proven O 0 2.8957130780327134e-05
case O 0 7.880021968276196e-08
of O 0 8.499815074003436e-09
the O 0 1.024863763632311e-06
disease O 0 7.683122385060415e-05
. O 0 4.380018253868911e-06

It O 0 5.231824502516247e-07
is O 0 6.196104607170128e-08
crucial O 0 3.150289273889939e-07
to O 0 6.769901119696442e-07
diagnose O 1 0.9960083961486816
hemochromatosis B-Disease 1 1.0
before O 0 0.02964482083916664
hepatic B-Disease 1 0.9999278783798218
cirrhosis I-Disease 1 0.9980940222740173
develops O 0 1.7213360479217954e-05
because O 0 6.202501481311629e-07
phlebotomy O 0 3.5059179936069995e-05
therapy O 0 6.762410976079991e-06
can O 0 7.992479709173494e-07
avert O 0 0.0027149515226483345
serious O 1 0.9636074900627136
chronic O 1 0.9999947547912598
disease O 0 0.07354580610990524
and O 0 4.159472553055821e-07
can O 0 7.820092378096888e-07
even O 0 3.05583228055184e-07
lead O 0 1.8999953965703753e-07
to O 0 2.0580001702796835e-08
normal O 0 1.3168944690278295e-07
life O 0 2.1974889818920929e-07
expectancy O 0 9.753473477758234e-07
. O 0 2.5183285856655857e-07
. O 0 8.733207437217061e-07

Prevalence O 0 0.004733625333756208
of O 0 1.2406121641106438e-07
the O 0 5.7967817213011585e-08
I1307K O 0 2.104227633026312e-06
APC B-Disease 0 3.3034243074325786e-07
gene O 0 2.0914343679123704e-07
variant O 0 2.0272766505513573e-06
in O 0 3.418611171923658e-08
Israeli O 0 4.50116522188182e-06
Jews O 0 1.6035968997130112e-07
of O 0 5.836593985897309e-10
differing O 0 4.240393636223416e-08
ethnic O 0 6.364818716519949e-08
origin O 0 5.453580911307654e-07
and O 0 5.469041752803605e-06
risk O 0 0.22453664243221283
for O 0 0.11081255227327347
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2890126274432987e-05

BACKGROUND O 0 0.0014024630654603243
& O 0 0.00012198043259559199
AIMS O 0 3.0552776024705963e-06
Israeli O 0 5.095293545309687e-06
Jews O 0 5.80685707518569e-07
of O 0 5.287952742349944e-09
European O 0 3.443400942160224e-07
birth O 0 1.8677131663480395e-07
, O 0 9.773435394322405e-09
i O 0 9.769561870598409e-08
. O 0 4.16000922598414e-09
e O 0 2.3778923718964506e-08
. O 0 2.5093509492535304e-09
, O 0 1.3150108779669267e-09
Ashkenazim O 0 1.1319863801872998e-07
, O 0 1.3968746159775947e-09
have O 0 5.1552015989386746e-09
the O 0 8.134209394938807e-08
highest O 1 0.9999978542327881
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.745351254940033
of O 0 1.0188656140996954e-08
any O 0 9.620830496714916e-07
Israeli O 0 0.0804007276892662
ethnic O 0 1.5494864783249795e-05
group O 0 2.5891051336657256e-05
. O 0 4.04777438234305e-06

The O 0 1.8480636754247826e-06
I1307K O 0 2.7643274734145962e-05
APC B-Disease 0 7.319706128328107e-06
gene O 0 2.1651137558365008e-06
variant O 0 4.1729359509190544e-05
was O 0 6.799057246098528e-06
found O 0 4.0233101117337355e-07
in O 0 2.528686593450402e-07
6 O 0 1.5528607946180273e-06
. O 0 2.829326831488288e-06

1 O 0 1.609222408660571e-06
% O 0 4.571929679286768e-08
of O 0 1.4954096849706389e-09
American O 0 1.747365097060083e-08
Jews O 0 5.75668686053632e-08
, O 0 3.784019764196955e-09
28 O 0 1.0314794351984347e-08
% O 0 2.490976980240589e-09
of O 0 1.2128249515797052e-09
their O 0 0.0005320073687471449
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.00032733328407630324
, O 0 3.3088529249880594e-08
but O 0 1.2339994270860188e-07
not O 0 5.035092343064207e-08
in O 0 5.454231910562157e-08
non O 0 1.887976281977899e-06
- O 0 4.247067772666924e-05
Jews O 0 4.546035597741138e-06
. O 0 1.576355543875252e-06

We O 0 2.3742859411868267e-06
assessed O 0 9.638931715016952e-07
the O 0 4.212774484813053e-08
I1307K O 0 2.322185309822089e-06
prevalence O 0 1.9805809188255807e-06
in O 0 1.6245131462255813e-08
Israeli O 0 1.4542663393513067e-06
Jews O 0 1.148724209087959e-07
of O 0 1.7056140944049503e-09
differing O 0 5.883645215476463e-08
ethnic O 0 1.3463994719131733e-07
origin O 0 5.69384155824082e-07
and O 0 9.443547241971828e-06
risk O 0 0.18916472792625427
for O 0 0.15641580522060394
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0203293388476595e-05

METHODS O 0 1.2833420441893395e-05
DNA O 0 3.1738784400658915e-06
samples O 0 3.2698301311029354e-07
from O 0 1.590405496187941e-08
500 O 0 1.1476101846596976e-08
unrelated O 0 3.9604049817398845e-08
Jews O 0 5.470776898164331e-08
of O 0 1.3591987535477301e-09
European O 0 1.6005915881578403e-07
or O 0 2.0319730253959278e-07
non O 0 2.820068402797915e-06
- O 0 0.0008083758875727654
European O 0 2.3123635628508055e-07
origin O 0 1.5056219382358904e-08
, O 0 8.640136939241927e-10
with O 0 5.132995140044727e-10
or O 0 1.318017694984519e-07
without O 0 3.6423219995640466e-08
a O 0 5.1871187345398084e-09
personal O 0 4.4152872646918695e-07
and O 0 5.975688850412553e-07
/ O 0 2.045725068455795e-06
or O 0 1.6072500557129388e-06
family O 0 7.050293504562433e-08
history O 0 2.9424889191886905e-08
of O 0 2.661060261033299e-09
neoplasia B-Disease 0 0.0023915295023471117
, O 0 9.061908556873277e-09
were O 0 1.8266181456283448e-08
examined O 0 2.8665252216342196e-07
for O 0 2.5462676411791563e-09
the O 0 8.020738739844546e-09
I1307K O 0 4.278928997791809e-07
variant O 0 2.278077460005079e-07
by O 0 6.41375752508111e-09
the O 0 2.1369592317910246e-08
allele O 0 2.0708998818008695e-06
- O 0 1.901405084936414e-06
specific O 0 1.321078286764532e-07
oligonucleotide O 0 8.312511636177078e-05
( O 0 5.092676502727045e-08
ASO O 0 5.347357273421949e-06
) O 0 4.783223772619749e-08
method O 0 1.922580395330442e-06
. O 0 3.267690317443339e-06

RESULTS O 0 2.9123657441232353e-05
In O 0 3.002247694894322e-08
persons O 0 1.5544470599593296e-08
at O 0 2.992619840824773e-08
average O 0 4.995685571884678e-07
risk O 0 0.009368020109832287
for O 0 0.24093998968601227
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.738862706219152e-08
I1307K O 0 5.918620445299894e-06
was O 0 3.041367108380655e-06
found O 0 7.27516251686211e-08
in O 0 5.8342848774373124e-08
5 O 0 5.495499522112368e-07
. O 0 1.3945891623734497e-06

0 O 0 9.384848453919403e-06
% O 0 3.9855336808614084e-07
of O 0 2.2252754305895905e-08
120 O 0 8.22400423317049e-08
European O 0 5.2125312777207e-07
and O 0 2.061567982991619e-07
1 O 0 5.191110403757193e-07
. O 0 1.4720121725986246e-06

6 O 0 3.082595640080399e-06
% O 0 1.1407558275777774e-07
of O 0 4.860538638240541e-09
188 O 0 1.6202065467041393e-07
non O 0 1.3556934845837532e-06
- O 0 0.00025306467432528734
European O 0 3.9504283222413505e-07
Jews O 0 2.2488974593670719e-07
( O 0 6.630352711312071e-09
P O 0 9.523278095002752e-06
= O 0 8.343097874785599e-07
0 O 0 1.0342576217681199e-07
. O 0 7.425391146398397e-08
08 O 0 8.498763008901733e-07
) O 0 9.346162954670945e-08
. O 0 9.1140071845075e-07

It O 0 3.5789971661870368e-06
occurred O 0 2.8507238312158734e-06
in O 0 2.672119592261879e-07
15 O 0 1.1258813401582302e-06
. O 0 1.4592036450267187e-06

4 O 0 3.6215719774190802e-06
% O 0 2.2737667393357697e-07
of O 0 2.0895518204611108e-08
52 O 0 4.4026560885868093e-07
Ashkenazi O 0 0.002040807856246829
Israelis O 0 0.0006757050286978483
with O 0 3.1660317745263455e-07
familial O 1 0.997664213180542
cancer B-Disease 1 0.8940836787223816
( O 0 8.647482019341624e-08
P O 0 0.02478797361254692
= O 0 1.2707554560620338e-05
0 O 0 9.219287733230885e-08
. O 0 2.950463695583494e-08
02 O 0 1.151106090446774e-07
) O 0 1.7063560564523073e-09
and O 0 3.081571886554002e-09
was O 0 6.278931152792211e-08
not O 0 1.0714586551330285e-08
detected O 0 1.4311805784927856e-07
in O 0 9.114727639314424e-09
51 O 0 4.536696707191368e-08
non O 0 9.973580716859942e-08
- O 0 3.5060231766692596e-06
European O 0 6.645193195708998e-08
Jews O 0 1.0963367458316498e-07
at O 0 6.70011033321316e-08
increased O 0 4.544438922948757e-07
cancer B-Disease 0 0.00037042066105641425
risk O 0 7.368367732851766e-06
. O 0 1.4749280126125086e-06

Colorectal B-Disease 1 0.9988627433776855
neoplasia I-Disease 0 0.031565532088279724
occurred O 0 1.5255616744980216e-05
personally O 0 2.677553084140527e-06
or O 0 1.5359832161720988e-07
in O 0 1.351617040512565e-08
the O 0 7.334037821493666e-09
families O 0 6.758185122635041e-09
of O 0 5.46455602989937e-10
13 O 0 3.204633225450948e-09
of O 0 1.113309555655917e-09
20 O 0 1.3523338893151049e-08
Ashkenazi O 0 1.3250720485302736e-06
I1307K O 0 4.798108648174093e-07
carriers O 0 1.1029603541601318e-07
, O 0 1.5694672228505624e-09
8 O 0 1.37882150141877e-09
of O 0 3.5724076474785704e-10
whom O 0 1.447658632969251e-07
also O 0 4.7458283347623365e-07
had O 0 2.47834509536915e-06
a O 0 1.564554352739833e-08
personal O 0 9.746120667841751e-06
or O 0 2.440292064420646e-06
family O 0 1.923547330306974e-07
history O 0 3.728160322680196e-07
of O 0 1.0827830010384787e-07
noncolonic O 0 0.06288100779056549
neoplasia B-Disease 0 0.2547120153903961
. O 0 8.811153747956268e-06

CONCLUSIONS O 0 3.0559589504264295e-05
The O 0 3.4564297379802156e-07
I1307K O 0 4.59182092527044e-06
APC O 0 1.5944107190080103e-06
variant O 0 1.863824991232832e-06
may O 0 5.598942820483899e-08
represent O 0 6.493732218615378e-09
a O 0 1.1227312413097934e-08
susceptibility O 0 6.790010047552641e-07
gene O 0 5.560776799029554e-07
for O 0 9.83189238468185e-07
colorectal B-Disease 1 1.0
, I-Disease 0 2.1188657939319455e-08
or I-Disease 0 2.9658272282517828e-08
other I-Disease 0 2.976566548795745e-08
, I-Disease 0 3.9946053220774047e-07
cancers I-Disease 1 0.9840636253356934
in O 0 1.0968575026026883e-07
Ashkenazi O 0 0.0032826366368681192
Jews O 0 8.450223276668112e-07
, O 0 8.09734856943578e-09
and O 0 1.7707906252439898e-08
partially O 0 3.435513008298585e-06
explains O 0 7.45024522075255e-08
the O 0 6.895475301860188e-09
higher O 0 7.786439937262912e-07
incidence O 0 0.4042280316352844
of O 0 0.008776719681918621
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.8444017061701743e-06
European O 0 5.618866634904407e-05
Israelis O 0 0.0018169251270592213
. O 0 5.339571089280071e-06

Systematic O 0 1.4690372154291254e-05
analysis O 0 3.966781605413416e-06
of O 0 6.377688066550036e-08
coproporphyrinogen O 0 2.584891080914531e-05
oxidase O 0 4.025521775474772e-05
gene O 0 0.00020856446644756943
defects O 1 0.9988276362419128
in O 0 1.0012832944994443e-06
hereditary B-Disease 1 0.8753252625465393
coproporphyria I-Disease 0 0.05431718751788139
and O 0 9.95065420283936e-07
mutation O 0 5.042683915235102e-05
update O 0 2.4344730263692327e-05
. O 0 5.771743417426478e-06

Hereditary B-Disease 1 0.9846259951591492
coproporphyria I-Disease 0 0.011891163885593414
( O 0 1.0643153700584662e-06
HC B-Disease 0 5.2607356337830424e-05
) O 0 1.2274220750896347e-07
is O 0 5.566009164681418e-08
an O 0 3.4240022728226904e-07
acute O 1 0.8743861317634583
hepatic B-Disease 1 0.9999710321426392
porphyria I-Disease 1 0.9999914169311523
with O 0 2.242322443635203e-05
autosomal O 1 0.9999858140945435
dominant O 1 0.9998372793197632
inheritance O 1 0.9972558617591858
caused O 0 0.007909026928246021
by O 0 3.6629964483836375e-07
deficient B-Disease 0 0.009018549695611
activity I-Disease 0 3.541151158970024e-07
of I-Disease 0 2.6229004745914608e-08
coproporphyrinogen I-Disease 0 0.001090348931029439
III I-Disease 0 5.9479330957401544e-05
oxidase I-Disease 0 1.2204473023302853e-05
( O 0 1.1746013939273325e-07
CPO O 0 1.1762332178477664e-05
) O 0 3.3327575010844157e-07
. O 0 1.746915586409159e-06

Clinical O 0 8.205794438254088e-05
manifestations O 0 4.371071554487571e-06
of O 0 3.658398384231987e-08
the O 0 4.6497945049850387e-07
disease O 0 2.0990220946259797e-05
are O 0 1.212973721465005e-08
characterized O 0 2.2208493533071305e-07
by O 0 3.766046745568019e-07
acute O 1 0.7292358875274658
attacks O 1 0.977724552154541
of O 0 2.0553404738166137e-06
neurological B-Disease 1 0.9999936819076538
dysfunction I-Disease 0 0.06765495240688324
often O 0 9.96591552393511e-07
precipitated O 0 6.102813472352864e-07
by O 0 6.519532913529247e-09
drugs O 0 1.349137193074057e-07
, O 0 3.2404612326786264e-09
fasting O 0 6.591405110611959e-08
, O 0 2.0333450478915438e-08
cyclical O 0 1.2585826880240347e-05
hormonal O 0 5.323554432834499e-06
changes O 0 1.138087100116536e-07
, O 0 2.5840446227221037e-08
or O 0 1.734885472615133e-06
infectious B-Disease 0 0.00020211865194141865
diseases I-Disease 0 0.00033867015736177564
. O 0 4.992464710085187e-06

Skin O 1 0.9997337460517883
photosensitivity O 1 0.9995903372764587
may O 0 0.01164151169359684
also O 0 2.1802549099447788e-07
be O 0 6.982337197314337e-08
present O 0 5.088506327410869e-07
. O 0 2.9103914584993618e-06

The O 0 1.1161228030687198e-06
seven O 0 2.3519562830642826e-07
exons O 0 1.2514200307123247e-06
, O 0 2.563681000822271e-08
the O 0 2.067328175314742e-08
exon O 0 1.3753966641161242e-06
/ O 0 3.5834534628520487e-07
intron O 0 2.939176511063124e-06
boundaries O 0 2.5762844302334997e-07
and O 0 3.1116361043359575e-08
part O 0 1.2144528938051735e-08
of O 0 2.7850461936651527e-09
3 O 0 1.73941785419629e-08
noncoding O 0 5.989261921968136e-07
sequence O 0 4.9234952115284614e-08
of O 0 3.0204532208699675e-09
the O 0 1.8381236088771402e-08
CPO O 0 4.578841412694601e-07
gene O 0 9.297907155314533e-08
were O 0 2.9213115482207286e-08
systematically O 0 4.5041315388516523e-07
analyzed O 0 1.219762566506688e-07
by O 0 2.167589885360144e-09
an O 0 2.4919704078030236e-09
exon O 0 8.080178304226138e-07
- O 0 8.94823301678116e-07
by O 0 3.9739344259714926e-08
- O 0 1.3689779052583617e-06
exon O 0 7.090412054822082e-06
denaturing O 0 1.88123231055215e-05
gradient O 0 6.338351795420749e-06
gel O 0 7.004388317000121e-05
electrophoresis O 0 1.2405402230797336e-05
( O 0 2.9596057160574674e-08
DGGE O 0 1.3979807818031986e-06
) O 0 6.632224547331589e-09
strategy O 0 1.5726863367149235e-08
followed O 0 3.7086083093385014e-09
by O 0 6.095222659929789e-10
direct O 0 3.391610992053984e-09
sequencing O 0 5.156384474958031e-08
in O 0 8.5041280684095e-09
seven O 0 1.0228201396955683e-08
unrelated O 0 1.6704007066437043e-07
heterozygous O 0 6.54608868444484e-07
HC B-Disease 0 1.3820865660818527e-06
patients O 0 2.758819732662232e-07
from O 0 5.590104379393779e-09
France O 0 1.0335551223761286e-06
, O 0 1.1976582392492219e-08
Holland O 0 9.88237275123538e-07
, O 0 1.6832924387699677e-08
and O 0 6.722742540432591e-08
Czech O 0 6.868162472528638e-06
Republic O 0 1.4247868875827407e-06
. O 0 2.712894911383046e-06

Seven O 0 3.7651843740604818e-06
novel O 0 1.6558294646529248e-06
mutations O 0 3.2579723665548954e-06
and O 0 4.0570231618630714e-08
two O 0 1.6113300915776563e-08
new O 0 9.618337060146587e-08
polymorphisms O 0 2.8980337447137572e-05
were O 0 1.6451811006845674e-06
detected O 0 1.3419679817161523e-05
. O 0 1.8429299188937875e-06

Among O 0 1.0728512052082806e-06
these O 0 9.64837951755726e-08
mutations O 0 9.506341029918985e-07
two O 0 1.53198307373259e-08
are O 0 2.269840315705096e-08
missense O 0 3.0802978017163696e-06
( O 0 1.2184925068936536e-08
G197W O 0 7.588939183733601e-07
, O 0 7.803499180170093e-09
W427R O 0 4.3760041990026366e-07
) O 0 7.553520475767073e-09
, O 0 1.6353529641577325e-09
two O 0 2.3805821758315915e-09
are O 0 5.121116419815053e-09
nonsense O 0 5.312957682690467e-07
( O 0 4.851443247133602e-09
Q306X O 0 1.6374174549582676e-07
, O 0 4.352946447738759e-09
Q385X O 0 1.1284143397460866e-07
) O 0 2.0450041660069473e-09
, O 0 7.749830777115108e-10
two O 0 1.383576697655542e-09
are O 0 4.96965668617122e-09
small O 0 4.32792255367076e-08
deletions O 0 1.4843215012660949e-06
( O 0 1.8572526627735897e-08
662de14bp O 0 4.2414009726599033e-07
; O 0 1.0399839212027473e-08
1168del3bp O 0 3.2132777505466947e-07
removing O 0 4.026303557225219e-08
a O 0 3.0330731259908816e-09
glycine O 0 2.697215393254737e-07
at O 0 2.7896732035515015e-08
position O 0 8.192645140070454e-08
390 O 0 2.598397053077406e-08
) O 0 2.7540070224318924e-09
, O 0 1.3932105469294243e-09
and O 0 2.3119957059947183e-09
one O 0 3.783622748443349e-09
is O 0 2.4007318355501184e-09
a O 0 8.23107804137635e-09
splicing O 0 3.0293167583295144e-06
mutation O 0 1.915163466037484e-06
( O 0 1.658166048912335e-08
IVS1 O 0 4.000581611762755e-06
- O 0 1.883332970464835e-06
15c O 0 7.275589723576559e-06
- O 0 3.0083749607001664e-06
- O 0 1.2067520174241508e-06
> O 0 2.0692934299404442e-07
g O 0 6.380766421898443e-07
) O 0 9.345143325845129e-09
which O 0 7.967402737563134e-09
creates O 0 4.694206978683724e-08
a O 0 1.6268046465484076e-08
new O 0 1.389390575923244e-07
acceptor O 0 1.184656866826117e-06
splice O 0 4.177595110377297e-05
site O 0 9.212674740410876e-06
. O 0 2.765634462775779e-06

The O 0 1.160532178801077e-06
pathological O 0 4.125334271520842e-06
significance O 0 6.424320417863782e-07
of O 0 5.692091242792685e-09
the O 0 9.714946180849893e-09
point O 0 7.97005128561068e-08
mutations O 0 4.491272136419866e-07
G197W O 0 3.735420648354193e-07
, O 0 3.6818117443715437e-09
W427R O 0 1.1466523375247561e-07
, O 0 2.461421066968228e-09
and O 0 1.7937491492148183e-09
the O 0 3.932012049290279e-09
in O 0 2.4622394789730606e-08
- O 0 2.9185241601226153e-06
frame O 0 2.7747757485485636e-05
deletion O 0 1.0495027709112037e-06
390delGly O 0 7.763298981444677e-07
were O 0 1.4981511142764248e-08
assessed O 0 4.404083497888678e-08
by O 0 2.280070798832412e-09
their O 0 9.793588162665401e-09
respective O 0 3.460380426645315e-08
expression O 0 6.496311044656977e-08
in O 0 2.1776816794272236e-08
a O 0 1.1368651797738494e-08
prokaryotic O 0 1.0660469484946589e-07
system O 0 1.0669602801272049e-07
using O 0 1.689565607421173e-07
site O 0 1.7251859389944002e-06
- O 0 8.223977602028754e-06
directed O 0 2.4104731437546434e-06
mutagenesis O 0 2.6039992008008994e-05
. O 0 2.766457328107208e-06

These O 0 1.924976459122263e-06
mutations O 0 7.408481451420812e-06
resulted O 0 4.51579580840189e-07
in O 0 7.401127533057661e-08
the O 0 1.3760715233956944e-08
absence O 0 1.8322261041703314e-07
or O 0 1.295288996061572e-07
a O 0 3.529767766963232e-08
dramatic O 0 0.00010863741772482172
decrease O 0 6.1503528741013724e-06
of O 0 4.426358302112021e-08
CPO O 0 2.4740689696045592e-05
activity O 0 3.1845327157498104e-06
. O 0 3.708211352204671e-06

The O 0 6.490626560662349e-07
two O 0 1.3112625651956478e-07
polymorphisms O 0 5.6831445363059174e-06
were O 0 9.34511135142202e-08
localized O 0 6.812186370552809e-07
in O 0 5.977677375312851e-08
noncoding O 0 5.44645217814832e-06
part O 0 6.042029099262436e-08
of O 0 2.101846252600126e-09
the O 0 3.6266807335039175e-09
gene O 0 4.306939871412396e-08
1 O 0 8.969207598852336e-09
) O 0 3.900326728256687e-09
a O 0 1.0624050084118153e-08
C O 0 2.6882891688728705e-05
/ O 0 2.935801717285358e-07
G O 0 8.651801977066498e-07
polymorphism O 0 2.0807663076993776e-06
in O 0 3.018801564280693e-08
the O 0 2.1143724993066826e-08
promotor O 0 9.891641639114823e-07
region O 0 9.67325561873622e-08
, O 0 8.219844360723982e-09
142 O 0 2.986928748782702e-08
bp O 0 2.6914031536762195e-07
upstream O 0 1.649796566027817e-08
from O 0 1.4497048006489877e-09
the O 0 1.2073456678862726e-09
transcriptional O 0 5.795278568143658e-08
initiation O 0 1.5081916160397668e-08
site O 0 7.627170361956814e-08
( O 0 5.470607522539694e-09
- O 0 2.0500674224877002e-07
142C O 0 8.69657185376127e-07
/ O 0 1.5426805077822792e-07
G O 0 4.54206912081645e-07
) O 0 3.1735627459283933e-09
, O 0 1.5972598799152138e-09
and O 0 5.174944028851769e-09
2 O 0 7.540767121838599e-09
) O 0 3.0447933063726396e-09
a O 0 9.151727375922292e-09
6 O 0 2.8863246015475852e-08
bp O 0 5.526929953703075e-07
deletion O 0 3.141992976907204e-07
polymorphism O 0 1.543915345791902e-06
in O 0 2.074797933460104e-08
the O 0 8.639433168866617e-09
3 O 0 1.712130703879211e-08
noncoding O 0 5.925969048803381e-07
part O 0 1.6525900647934577e-08
of O 0 1.7981507394182472e-09
the O 0 1.3832976542005326e-08
CPO O 0 6.294183663158037e-07
gene O 0 1.3748467608820647e-07
, O 0 6.871658797535929e-09
574 O 0 7.447787453429555e-08
bp O 0 2.3610152766195824e-07
downstream O 0 1.630289858667311e-08
of O 0 4.5116502200848174e-10
the O 0 2.812039490152074e-09
last O 0 2.5371258871587088e-08
base O 0 1.1027789348361239e-08
of O 0 1.1079670514391182e-09
the O 0 1.9318267874268713e-08
normal O 0 2.211629777093549e-07
termination O 0 1.978221234821831e-06
codon O 0 3.4189060897915624e-06
( O 0 5.907461542165038e-08
+ O 0 7.254266165546142e-07
574 O 0 1.8363001572652138e-06
delATTCTT O 0 6.998550361458911e-06
) O 0 4.656308760786487e-07
. O 0 1.3325158079169341e-06

Five O 0 1.9097337826678995e-06
intragenic O 0 9.184233931591734e-06
dimorphisms O 0 1.0225167898170184e-05
are O 0 4.2412107603695404e-08
now O 0 2.4283927757551282e-08
well O 0 9.622995733593598e-09
characterized O 0 4.61597728929064e-08
and O 0 3.600834830308486e-08
the O 0 9.451983196129277e-09
high O 0 2.998576746904291e-07
degree O 0 2.3823828598779073e-07
of O 0 4.2763730334627326e-09
allelic O 0 1.2742340231852722e-06
heterogeneity O 0 6.325791673589265e-06
in O 0 3.39273270810736e-07
HC B-Disease 0 0.00015570595860481262
is O 0 2.9708605353562234e-08
demonstrated O 0 4.542237874716193e-08
with O 0 1.8466548290518858e-09
seven O 0 5.081835396936185e-09
new O 0 3.8527838697177685e-09
different O 0 3.062219144922551e-09
mutations O 0 1.029667444640836e-07
making O 0 6.7635235190266485e-09
a O 0 5.247792866924783e-09
total O 0 6.653409378998276e-09
of O 0 5.0251123262512465e-09
nineteen O 0 6.593020884793077e-07
CPO O 0 7.527296838816255e-05
gene B-Disease 0 3.276932693552226e-05
defects I-Disease 1 0.9920026063919067
reported O 0 3.808659357673605e-06
so O 0 9.823506275097316e-08
far O 0 1.3238856411135203e-07
. O 0 2.8935079399161623e-07
. O 0 1.5562291082460433e-06

Coincidence O 0 7.537055353168398e-06
of O 0 5.990026608060361e-08
two O 0 2.8098694926370626e-08
novel O 0 3.417947027628543e-07
arylsulfatase O 0 6.039810614311136e-06
A O 0 1.0670660799405596e-07
alleles O 0 1.7030588423949666e-06
and O 0 2.1686835793843784e-07
mutation O 0 6.2046415223449e-06
459 O 0 1.4376978469954338e-06
+ O 0 1.7634936284594005e-06
1G O 0 1.1113964319520164e-05
> O 0 9.087924581763218e-07
A O 0 2.4516811691910334e-08
within O 0 8.399155149163562e-09
a O 0 4.580509838092439e-08
family O 0 2.808594956604793e-07
with O 0 6.175652629281103e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
: O 0 1.1518561393586424e-07
molecular O 0 6.063422119950701e-07
basis O 0 1.2149757822044194e-07
of O 0 8.997344735917068e-08
phenotypic O 0 6.902987661305815e-05
heterogeneity O 0 0.0006336454534903169
. O 0 1.962916758202482e-05

In O 0 1.9569674805097748e-06
a O 0 1.229500412591733e-07
family O 0 5.7731252667281296e-08
with O 0 8.733056056087207e-09
three O 0 4.222057370384391e-08
siblings O 0 7.008167699495971e-07
, O 0 5.507963862783072e-09
one O 0 1.302977459261001e-08
developed O 0 1.5377274564798427e-07
classical O 0 3.542029617165099e-06
late O 0 8.286930824397132e-05
infantile O 1 0.9754220247268677
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999996423721313
( O 0 6.931152256584028e-07
MLD B-Disease 1 0.9999949932098389
) O 0 7.719565076058643e-08
, O 0 1.5257658247946893e-08
fatal O 0 0.00015076853742357343
at O 0 1.2693615758507804e-07
age O 0 2.9492596809177485e-08
5 O 0 5.01929742213747e-09
years O 0 1.7107856464804172e-08
, O 0 2.4673483256520967e-09
with O 0 2.4002615006679662e-08
deficient O 0 0.37597283720970154
arylsulfatase O 0 0.0032351512927562
A O 0 3.5974304068986385e-07
( O 0 2.5548651194640115e-08
ARSA O 0 2.4876344468793832e-05
) O 0 1.1463217042262386e-08
activity O 0 2.7091557441849545e-08
and O 0 2.8804182150565794e-08
increased O 0 2.10155320701233e-07
galactosylsulfatide O 0 0.00011663671466521919
( O 0 2.2806206345649116e-07
GS O 1 0.9999992847442627
) O 0 4.400469322263234e-07
excretion O 0 6.873404345242307e-06
. O 0 1.6081913827292738e-06

The O 0 1.4714127871684468e-07
two O 0 2.1137795513936908e-08
other O 0 8.477891277891558e-09
siblings O 0 1.8808133006587013e-07
, O 0 1.1620485018681848e-08
apparently O 0 5.742703592659382e-07
healthy O 0 8.237929449705916e-08
at O 0 2.1470915712029637e-08
12 O 0 5.727485596906945e-09
( O 0 2.1234041192030872e-09
1 O 0 8.009547691756325e-09
/ O 0 2.7991070794541884e-08
2 O 0 6.195747470627566e-09
) O 0 1.4348199295355357e-09
and O 0 4.238434492265242e-09
15 O 0 1.837491825362747e-09
years O 0 7.908115051691311e-09
, O 0 8.371864312906041e-10
respectively O 0 3.984773044862777e-08
, O 0 1.0860252697142414e-09
and O 0 4.064386605051595e-09
their O 0 9.816610635482448e-09
father O 0 1.7017033826505212e-07
, O 0 1.0501096880943805e-08
apparently O 0 9.943435088644037e-07
healthy O 0 2.0481907725411475e-08
as O 0 3.2151883377906643e-09
well O 0 1.0946667572397928e-08
, O 0 5.083551357643046e-09
presented O 0 1.0904348357598792e-07
ARSA O 0 0.0004740530566778034
and O 0 1.7088115100705181e-06
GS O 1 0.9999991655349731
values O 0 1.450233071409457e-07
within O 0 9.543920320709276e-09
the O 0 1.1533661137264062e-08
range O 0 2.079937786447772e-07
of O 0 2.0107739828745252e-07
MLD B-Disease 1 0.9999979734420776
patients O 0 6.447589839808643e-05
. O 0 4.303912191971904e-06

Mutation O 0 5.938349568168633e-05
screening O 0 5.749977390223648e-06
and O 0 7.393043688352918e-08
sequence O 0 9.566195302568303e-08
analysis O 0 2.0685476442849904e-07
disclosed O 0 1.1219369753234787e-06
the O 0 7.76920749956389e-09
involvement O 0 4.614489412801959e-08
of O 0 1.367123636519807e-09
three O 0 1.0108151649035335e-08
different O 0 7.435481563788926e-08
ARSA O 0 0.023926038295030594
mutations O 0 8.491435437463224e-06
being O 0 8.613866953055549e-08
the O 0 9.77351000130966e-09
molecular O 0 1.896161450076761e-07
basis O 0 4.5352258837283443e-08
of O 0 2.5170217909931125e-08
intrafamilial O 0 3.5863933590007946e-05
phenotypic O 0 6.101001417846419e-05
heterogeneity O 0 0.0004135326889809221
. O 0 1.603536293259822e-05

The O 0 1.0862805766009842e-06
late O 0 2.5011199795699213e-06
infantile O 0 0.00012085666821803898
patient O 0 3.138583997497335e-05
inherited O 0 0.0026733619160950184
from O 0 4.979821710549004e-08
his O 0 9.637840747700466e-08
mother O 0 2.2733468085789355e-06
the O 0 6.768569704718175e-09
frequent O 0 2.50093592057965e-07
0 O 0 1.00728175311815e-06
- O 0 0.0005958714173175395
type O 0 0.0004175322246737778
mutation O 0 5.017964213038795e-06
459 O 0 5.899680672882823e-07
+ O 0 3.5091937888864777e-07
1G O 0 1.8775566559270374e-06
> O 0 1.4726424524269532e-07
A O 0 2.6481453474502814e-08
, O 0 1.5302504818848206e-09
and O 0 2.0348802642899955e-09
from O 0 3.1649671772271404e-09
his O 0 1.7932332951886565e-08
father O 0 3.283050773461582e-07
a O 0 1.3318073754930992e-08
novel O 0 1.2776786206813995e-07
, O 0 9.107932186225298e-09
single O 0 4.6083940219432407e-08
basepair O 0 1.1346845667503658e-06
microdeletion O 0 4.319791173656995e-07
of O 0 4.280779730692075e-09
guanine O 0 3.0063966960369726e-07
at O 0 2.9478647078917675e-08
nucleotide O 0 4.048598043482343e-07
7 O 0 4.226956562547457e-08
in O 0 1.5086403237773993e-08
exon O 0 1.4570066468877485e-06
1 O 0 1.5029357314233494e-07
( O 0 4.57912037177266e-08
7delG O 0 4.078852271049982e-06
) O 0 2.7726616735890275e-07
. O 0 1.756583174028492e-06

The O 0 7.237633781187469e-07
two O 0 1.9044871635287564e-07
clinically O 0 1.244446866621729e-05
unaffected O 0 8.382836313103326e-06
siblings O 0 1.389531234963215e-06
carried O 0 1.929669366518283e-07
the O 0 4.573307421651407e-08
maternal O 0 3.9147162169683725e-06
mutation O 0 6.8580370680138e-06
459 O 0 1.0038410209745052e-06
+ O 0 8.811613838588528e-07
1G O 0 7.895517228462268e-06
> O 0 6.740004891980789e-07
A O 0 9.706171510970307e-08
and O 0 2.37098127797708e-08
, O 0 1.9016073160571523e-09
on O 0 4.043756440808011e-09
their O 0 1.8258868195175637e-08
paternal O 0 1.2496394674599287e-06
allele O 0 4.511019142228179e-06
, O 0 1.290209183935076e-08
a O 0 7.056224049506454e-09
novel O 0 1.1997003923625016e-07
cytosine O 0 3.4487447919673286e-07
to O 0 1.5639367134667737e-08
thymidine O 0 7.560297490272205e-07
transition O 0 1.9908249271338718e-07
at O 0 2.63903903174878e-08
nucleotide O 0 6.075340479583247e-07
2435 O 0 1.5455681250386988e-06
in O 0 7.664690215847259e-09
exon O 0 5.661597697326215e-07
8 O 0 2.9538533397044375e-08
, O 0 1.8305305049537424e-09
resulting O 0 7.656771217057212e-09
in O 0 2.68997957242334e-09
substitution O 0 1.521859793740532e-08
of O 0 8.335063306219581e-09
alanine O 0 8.757830983086023e-06
464 O 0 5.428533995655016e-07
by O 0 1.1366249452748889e-07
valine O 0 0.0003892317181453109
( O 0 1.0692011187529715e-07
A464V O 0 5.9583658185147215e-06
) O 0 3.234600001178478e-07
. O 0 1.2401784488247358e-06

The O 0 2.5881120109261246e-06
fathers O 0 1.8176249795942567e-05
genotype O 0 5.24993083672598e-05
thus O 0 2.3474303816328757e-06
was O 0 2.9978668862895574e-06
7delG O 0 5.448043157230131e-05
/ O 0 2.307928843947593e-05
A464V O 0 6.852093792986125e-05
. O 0 7.3870269261533394e-06

Mutation O 0 0.00016433050041086972
A464V O 0 4.5105291064828634e-05
was O 0 1.0623419939292944e-06
not O 0 3.809934057130704e-08
found O 0 2.8529319351378035e-08
in O 0 2.7301330973728e-08
18 O 0 9.746185725134637e-08
unrelated O 0 1.4319535694085062e-05
MLD B-Disease 1 0.9999996423721313
patients O 0 2.298137769685127e-05
and O 0 7.468898388651724e-08
50 O 0 1.1545859024408855e-07
controls O 0 7.687205652473494e-06
. O 0 4.413116585055832e-06

A464V O 0 9.495282574789599e-05
, O 0 3.6323183394415537e-07
although O 0 2.2970769464336627e-07
clearly O 0 3.261937990828301e-07
modifying O 0 1.4259301224228693e-06
ARSA O 0 0.00020831562869716436
and O 0 2.5762155928532593e-06
GS O 1 0.9999998807907104
levels O 0 8.517217793269083e-06
, O 0 2.6513950146522802e-08
apparently O 0 1.7779187544419983e-07
bears O 0 8.797979234032027e-08
little O 0 1.6236922917300944e-08
significance O 0 4.641013973127883e-08
for O 0 1.518652581466995e-08
clinical O 0 4.880662913819833e-07
manifestation O 0 6.755647632417094e-07
of O 0 1.1111254849538454e-07
MLD B-Disease 1 0.9999982118606567
, O 0 1.683912955741107e-07
mimicking O 0 3.076665961998515e-06
the O 0 3.1360116281575756e-07
frequent O 0 1.6942502043093555e-05
ARSA O 0 0.1080210953950882
pseudodeficiency O 0 0.0003034226247109473
allele O 0 0.00036238497705198824
. O 0 2.6456156774656847e-05

Our O 0 4.497745067055803e-06
results O 0 6.577188287337776e-07
demonstrate O 0 8.08219908776664e-08
that O 0 8.855317368272608e-09
in O 0 1.0221433477397568e-08
certain O 0 3.361145672897692e-08
genetic O 0 6.603859219467267e-06
conditions O 0 0.0003263766411691904
MLD B-Disease 1 0.9999992847442627
- O 0 0.0015428573824465275
like O 0 3.8291602777462685e-07
ARSA O 0 0.0011435399064794183
and O 0 3.87953974723132e-07
GS O 1 0.9999982118606567
values O 0 9.21450578061922e-08
need O 0 7.182342276479403e-09
not O 0 1.4613313892297697e-09
be O 0 5.614474996029628e-10
paralleled O 0 2.0612962003951907e-08
by O 0 9.389578004004306e-09
clinical O 0 0.000418246490880847
disease O 0 2.8994184049224714e-06
, O 0 4.128997588281891e-09
a O 0 8.009624075100419e-09
finding O 0 1.0142416329017578e-07
with O 0 2.7842299132885273e-08
serious O 0 7.935517714940943e-06
diagnostic O 0 0.00011643291509244591
and O 0 8.705218306204188e-07
prognostic O 0 0.0067734685726463795
implications O 0 2.272690471727401e-05
. O 0 3.5017094432987506e-06

Moreover O 0 3.521741018630564e-05
, O 0 5.369640234675899e-07
further O 0 3.773607488710695e-07
ARSA O 0 0.00025913259014487267
alleles O 0 4.1617522583692335e-06
functionally O 0 1.1480872217362048e-06
similar O 0 3.2042375863738926e-08
to O 0 1.7458193113384368e-08
A464V O 0 8.702412515049218e-07
might O 0 6.454048673276702e-08
exist O 0 2.8918792693843898e-08
which O 0 3.1225622088015825e-09
, O 0 4.800712605224078e-10
together O 0 1.4567034245516197e-09
with O 0 3.3559361956037037e-09
0 O 0 6.708159503432398e-07
- O 0 0.0058254967443645
type O 0 0.007949906401336193
mutations O 0 5.716555824619718e-05
, O 0 2.383322872390181e-08
may O 0 1.0131084309250582e-06
cause O 0 2.2809990696259774e-07
pathological O 0 2.702792244235752e-06
ARSA O 0 0.06962761282920837
and O 0 6.701888651150512e-06
GS O 1 1.0
levels O 0 6.492015472758794e-06
, O 0 4.3947339101180205e-09
but O 0 1.0737151612261187e-08
not O 0 1.713620356724732e-08
clinical O 0 5.780760830020881e-07
outbreak O 0 2.11254473470035e-07
of O 0 3.541067883361393e-09
the O 0 4.424032908900699e-07
disease O 0 2.1185329387662932e-05
. O 0 2.282853301949217e-07
. O 0 1.6948295069596497e-06

Human O 0 0.00044665116001851857
MLH1 O 1 0.9750468730926514
deficiency O 1 0.7992762923240662
predisposes O 0 0.00018842068675439805
to O 0 4.722261564893415e-06
hematological B-Disease 1 0.9710928797721863
malignancy I-Disease 1 0.9992775321006775
and O 0 2.637438774399925e-05
neurofibromatosis B-Disease 1 0.8391186594963074
type I-Disease 0 0.007337483111768961
1 I-Disease 0 9.150532605417538e-06
. O 0 7.47860121919075e-06

Heterozygous O 0 0.00023143051657825708
germ O 0 0.007421186193823814
- O 0 0.032554030418395996
line O 0 8.031110155570786e-06
mutations O 0 1.9214751318941126e-06
in O 0 2.8458883249982136e-08
the O 0 2.976634760898378e-08
DNA O 0 1.9068993424298242e-05
mismatch O 0 0.007011257577687502
repair O 0 0.0001321343006566167
genes O 0 1.951443664438557e-06
lead O 0 1.582977802172536e-06
to O 0 8.528023158760334e-07
hereditary B-Disease 1 0.9999552965164185
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.514397369348444e-05

The O 0 4.618545062839985e-06
disease O 0 1.7905160348163918e-05
susceptibility O 0 1.6669506521793664e-06
of O 0 1.1585496118016181e-08
individuals O 0 9.868578842997522e-08
who O 0 3.102782386577019e-07
constitutionally O 0 2.5202268716384424e-06
lack O 0 5.40552456129717e-08
both O 0 2.0786323773336335e-08
wild O 0 1.9314663290970202e-07
- O 0 0.008720704354345798
type O 0 0.00507180392742157
alleles O 0 8.077273378148675e-06
is O 0 2.744805840393383e-07
unknown O 0 4.81915776617825e-06
. O 0 1.6653790453347028e-06

We O 0 1.9072020904786768e-06
have O 0 6.026560583904939e-08
identified O 0 4.045810442221409e-08
three O 0 4.298288391879623e-09
offspring O 0 4.543867149209291e-08
in O 0 1.0691926455308476e-08
a O 0 3.0817091101198457e-07
hereditary B-Disease 1 0.9999994039535522
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.820331610564608e-05
who O 0 6.558135510204011e-07
developed O 0 5.327434337232262e-06
hematological B-Disease 1 0.9711539149284363
malignancy I-Disease 1 0.9997879862785339
at O 0 4.514168381319905e-07
a O 0 1.2754136413661854e-08
very O 0 2.2138198829679823e-08
early O 0 6.055817038941314e-07
age O 0 1.8450121785917872e-07
, O 0 2.3457897846412834e-09
and O 0 5.527327928689374e-09
at O 0 1.644192337835193e-08
least O 0 7.370326016165052e-10
two O 0 6.237767524730486e-10
of O 0 3.598195075227295e-10
them O 0 8.080716540348476e-09
displayed O 0 1.8143927604796772e-07
signs O 0 2.1567581143244752e-07
of O 0 4.3307380792612094e-08
neurofibromatosis B-Disease 0 0.2233540117740631
type I-Disease 0 0.009172070771455765
1 I-Disease 0 1.1364595593477134e-06
( O 0 3.2838991614880797e-07
NF1 B-Disease 0 0.0003152177669107914
) O 0 7.206921281976975e-07
. O 0 2.1938299141766038e-06

DNA O 0 1.158493796538096e-05
sequence O 0 6.159013423712167e-07
analysis O 0 4.0590398953099793e-07
and O 0 5.799037694487197e-08
allele O 0 1.6633949826427852e-06
- O 0 9.073557976080338e-07
specific O 0 6.571696786750181e-08
amplification O 0 9.517925718682818e-07
in O 0 2.2010036460073934e-08
two O 0 2.7892314236055427e-08
siblings O 0 1.524179879197618e-06
revealed O 0 8.198012437787838e-07
a O 0 1.6819323889194493e-07
homozygous O 0 2.9021768568782136e-05
MLH1 O 0 0.000235900457482785
mutation O 0 9.828050679061562e-06
( O 0 8.777731608233807e-08
C676T O 0 7.916379217931535e-06
- O 0 0.00039003847632557154
- O 0 0.0008017186773940921
> O 0 7.516339337598765e-06
Arg226Stop O 0 4.612171687767841e-05
) O 0 5.358673433875083e-07
. O 0 1.814546408240858e-06

Thus O 0 6.111250513640698e-06
, O 0 9.660754329843257e-08
a O 0 1.5253679919169372e-07
homozygous O 0 9.137172128248494e-06
germ O 0 0.002430392662063241
- O 0 0.0036712426226586103
line O 0 2.7285428586765192e-05
MLH1 O 0 0.0006565517978742719
mutation O 0 1.4057956832402851e-05
and O 0 3.56158409431373e-07
consequent O 0 0.0004055741592310369
mismatch O 1 0.9998621940612793
repair O 1 0.9999792575836182
deficiency O 1 0.9993159770965576
results O 0 1.793481715139933e-06
in O 0 3.3656810671800486e-08
a O 0 1.3135029064414994e-07
mutator O 0 0.007277441676706076
phenotype O 0 0.0001800240424927324
characterized O 0 8.482843441015575e-07
by O 0 2.4145927568497427e-07
leukemia B-Disease 1 0.9216522574424744
and O 0 8.68394854478538e-05
/ O 1 0.5380544662475586
or O 1 0.999931812286377
lymphoma B-Disease 1 1.0
associated O 0 0.011414625681936741
with O 0 2.2515487216878682e-06
neurofibromatosis B-Disease 1 0.9961159229278564
type I-Disease 0 0.13652119040489197
1 I-Disease 0 2.162501232305658e-06
. O 0 7.109534294613695e-07
. O 0 3.1349850360129494e-06

Missense O 0 0.0008575835381634533
mutations O 0 0.0004994614864699543
in O 0 2.181681679758185e-07
the O 0 1.1985083148147169e-08
most O 0 5.083425236307448e-09
ancient O 0 1.8730835549263247e-08
residues O 0 1.56963338326932e-07
of O 0 2.12400341759178e-09
the O 0 1.5966117317134376e-08
PAX6 O 0 1.352338404103648e-05
paired O 0 1.218524744217575e-06
domain O 0 2.8332104307082773e-07
underlie O 0 1.1536870943018585e-06
a O 0 2.6993145496589932e-08
spectrum O 0 6.563679448845505e-07
of O 0 8.607692336681794e-08
human O 0 7.233718406496337e-06
congenital B-Disease 1 0.9999957084655762
eye I-Disease 1 0.9999566078186035
malformations I-Disease 1 0.9999445676803589
. O 0 9.339638199890032e-05

Mutations O 0 0.00013642889098264277
of O 0 1.3081699989925255e-07
the O 0 1.3584651981091156e-07
human O 0 3.0816445928394387e-07
PAX6 O 0 4.128997534280643e-05
gene O 0 6.221291187102906e-06
underlie O 0 0.00506983557716012
aniridia B-Disease 1 1.0
( O 0 1.903478846543294e-06
congenital B-Disease 1 0.9999557733535767
absence I-Disease 0 9.357468115922529e-07
of I-Disease 0 6.817714837126232e-09
the I-Disease 0 2.4732345949018963e-08
iris I-Disease 0 8.384430839214474e-05
) O 0 4.915594331578177e-08
, O 0 6.826224918654589e-09
a O 0 3.513827806500558e-08
rare O 0 3.577876850613393e-05
dominant O 1 0.9904431700706482
malformation B-Disease 1 0.9997648596763611
of I-Disease 0 9.110853937954744e-08
the I-Disease 0 9.96748326542729e-07
eye I-Disease 1 0.8839195966720581
. O 0 2.4429453333141282e-05

The O 0 1.0003718671214301e-06
spectrum O 0 4.190187155472813e-06
of O 0 5.991546458972152e-08
PAX6 O 0 6.415879761334509e-05
mutations O 0 2.5898385501932353e-05
in O 0 3.6910040535076405e-07
aniridia B-Disease 1 0.9999998807907104
patients O 0 2.8073840439901687e-05
is O 0 1.4806772696829285e-08
highly O 0 6.608159708321182e-08
biased O 0 1.2021505426673684e-06
, O 0 2.9051403505064854e-09
with O 0 1.4197845121799446e-09
92 O 0 3.5635437711789564e-08
% O 0 4.392973540490175e-09
of O 0 6.804071195354311e-10
all O 0 1.2608432520266888e-08
reported O 0 7.44006001696107e-06
mutations O 0 4.220868504489772e-06
leading O 0 2.2507211383526737e-07
to O 0 3.7979045686142854e-08
premature O 0 3.1147541790232935e-07
truncation O 0 3.8501201515828143e-07
of O 0 4.678044618344757e-09
the O 0 7.009329117124707e-09
protein O 0 3.806128034966605e-08
( O 0 4.948290222017704e-09
nonsense O 0 1.0263615735084386e-07
, O 0 1.766653601187329e-09
splicing O 0 1.3851145297394396e-07
, O 0 3.5928067187995794e-09
insertions O 0 1.5465427338767768e-07
and O 0 7.918665723138929e-09
deletions O 0 1.4991721286605753e-07
) O 0 6.164533772334835e-09
and O 0 3.809365267670728e-09
just O 0 7.856127304251004e-09
2 O 0 5.500352617815452e-09
% O 0 2.123177189616854e-09
leading O 0 4.336679459981951e-09
to O 0 5.732772589972512e-10
substitution O 0 3.3479954364423747e-09
of O 0 9.407410406225836e-10
one O 0 1.2756180112205584e-08
amino O 0 9.183100502241359e-08
acid O 0 1.7824397957610927e-07
by O 0 1.2665001491996009e-08
another O 0 9.175064263899912e-08
( O 0 9.272298484575003e-08
missense O 0 2.1255978936096653e-05
) O 0 7.190211590568651e-07
. O 0 1.9819074168481166e-06

The O 0 1.0551549394222093e-06
extraordinary O 0 4.889412252850889e-07
conservation O 0 1.3024462930388836e-07
of O 0 5.386409984708962e-09
the O 0 1.734110988138582e-08
PAX6 O 0 3.42741032000049e-06
protein O 0 1.9100166070984415e-07
at O 0 2.639054130781915e-08
the O 0 9.352971730436366e-09
amino O 0 1.6741262243158417e-07
acid O 0 7.197463105512725e-07
level O 0 6.646993000458679e-08
amongst O 0 3.249139624017516e-08
vertebrates O 0 1.245554557272044e-07
predicts O 0 9.534135614330808e-08
that O 0 2.4484370086952367e-09
pathological O 0 1.255080377404738e-07
missense O 0 2.42912619796698e-06
mutations O 0 3.7493866784643615e-06
should O 0 2.79893086485572e-08
in O 0 1.847916264452465e-09
fact O 0 8.239560145284486e-09
be O 0 4.05104394474165e-09
common O 0 9.606123896332974e-09
even O 0 3.3727243220482706e-08
though O 0 1.7426387444174907e-08
they O 0 5.240140765749857e-09
are O 0 1.1517079512302075e-09
hardly O 0 3.8915601408007205e-08
ever O 0 1.72248846297407e-07
seen O 0 1.8418758429561422e-07
in O 0 2.467578497089562e-07
aniridia B-Disease 1 0.9999998807907104
patients O 0 4.2334282625233755e-05
. O 0 1.942003109434154e-06

This O 0 2.988356584410212e-07
indicates O 0 2.738092064191733e-07
that O 0 7.276200975070424e-09
there O 0 4.320398261370428e-09
is O 0 1.936496074605998e-09
a O 0 1.2595260834302735e-08
heavy O 0 4.8142752348212525e-05
ascertainment O 0 0.00014314775762613863
bias O 0 0.0016975081525743008
in O 0 2.5299499384345836e-08
the O 0 2.6860780266702022e-09
selection O 0 1.131955684741115e-08
of O 0 2.9257820610695262e-09
patients O 0 1.5169307232554274e-07
for O 0 6.695431764569548e-09
PAX6 O 0 6.556793323397869e-06
mutation O 0 7.708198381806142e-07
analysis O 0 8.783592875261093e-08
and O 0 1.6815404180192672e-08
that O 0 5.945768322135336e-09
the O 0 2.8115904271430736e-08
missing O 0 1.5286140069292742e-06
PAX6 O 0 7.386166544165462e-05
missense O 0 0.00012291451275814325
mutations O 0 0.00010485386883374304
frequently O 0 6.216018391569378e-06
may O 0 5.318713192536961e-06
underlie O 0 2.1750394807895645e-05
phenotypes O 0 1.4304111573437694e-05
distinct O 0 3.2737227684265235e-06
from O 0 6.032449846316013e-07
textbook O 0 0.07810503989458084
aniridia B-Disease 1 0.9999991655349731
. O 0 3.042666685360018e-05

Here O 0 2.618230382722686e-06
we O 0 2.1096316515922808e-07
present O 0 3.5675832066317525e-08
four O 0 2.7821062786870243e-08
novel O 0 8.510515385751205e-07
PAX6 O 0 2.9261185773066245e-05
missense O 0 2.3779823095537722e-05
mutations O 0 9.16346562007675e-06
, O 0 8.858797251320993e-09
two O 0 5.064002994714656e-09
in O 0 2.2803895660672424e-08
association O 0 3.9429565390491916e-08
with O 0 2.660046760638579e-08
atypical O 0 2.8992390070925467e-05
phenotypes O 0 0.00028366720653139055
ectopia B-Disease 0 0.00012893295206595212
pupillae I-Disease 0 4.623917266144417e-05
( O 0 5.42510854018019e-08
displaced B-Disease 0 2.7369745225769293e-07
pupils I-Disease 0 1.1917175015696557e-06
) O 0 7.966038850781842e-08
and O 0 2.8062784167559585e-06
congenital B-Disease 1 0.9998866319656372
nystagmus I-Disease 0 3.687144271680154e-05
( O 0 2.968057088992282e-08
searching B-Disease 0 2.36208521187109e-07
gaze I-Disease 0 2.3796742425474804e-06
) O 0 2.598991954982921e-08
, O 0 2.192329651151681e-09
and O 0 5.296654226327746e-09
two O 0 1.3023115918997519e-08
in O 0 3.574871598743812e-08
association O 0 8.334363421624857e-09
with O 0 4.555536392558679e-09
more O 0 3.18350110717347e-08
recognizable O 0 0.16904273629188538
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 0.0005656928406096995
. O 0 6.537605713674566e-06

Strikingly O 0 1.703280213405378e-05
, O 0 1.1404067379316984e-07
all O 0 7.676453250837767e-09
four O 0 1.1433890279022307e-08
mutations O 0 3.004152517860348e-07
are O 0 4.1891352609013666e-09
located O 0 5.169616734690408e-09
within O 0 3.0650473270554812e-09
the O 0 9.140459056311556e-09
PAX6 O 0 3.343522394061438e-06
paired O 0 2.1696723706554621e-07
domain O 0 8.005870455463082e-08
and O 0 3.1935481814571176e-08
affect O 0 4.1187352195493077e-08
amino O 0 2.454975600585385e-08
acids O 0 5.617737386387489e-08
which O 0 5.468218322590701e-09
are O 0 1.3323859793246129e-09
highly O 0 6.1376086435416255e-09
conserved O 0 1.8885307540017493e-08
in O 0 8.056585620863643e-09
all O 0 5.112332779333428e-09
known O 0 9.564899983161013e-08
paired O 0 7.6533126502909e-07
domain O 0 1.229758936460712e-06
proteins O 0 1.6749468159105163e-06
. O 0 3.0239709758461686e-06

Our O 0 6.773997029085876e-06
results O 0 1.9081880964222364e-06
support O 0 4.131449671262999e-08
the O 0 6.071624536474474e-09
hypothesis O 0 1.0854422072270609e-07
that O 0 1.6225862875529629e-09
the O 0 1.4281115179315407e-09
under O 0 5.225718524570766e-09
- O 0 1.4240328027881333e-07
representation O 0 8.269698525964486e-08
of O 0 9.887942908903824e-09
missense O 0 2.7854151994688436e-05
mutations O 0 7.950584404170513e-06
is O 0 2.2037340841052355e-08
caused O 0 1.2220306189192343e-07
by O 0 1.6096683097543973e-08
ascertainment O 0 1.0559156180534046e-05
bias O 0 0.0001140307795139961
and O 0 8.352573388492601e-08
suggest O 0 4.3064716237495304e-08
that O 0 2.541197474670298e-09
a O 0 5.575569339555386e-09
substantial O 0 9.344879714490162e-08
burden O 0 2.2467502276413143e-06
of O 0 6.830548571201689e-09
PAX6 B-Disease 0 0.006942324806004763
- I-Disease 1 0.561346709728241
related I-Disease 0 0.003000206546857953
disease I-Disease 0 0.0001022156939143315
remains O 0 1.1527001220201782e-07
to O 0 1.0497652525032208e-08
be O 0 4.133388742388888e-08
uncovered O 0 1.896773392218165e-05
. O 0 3.818220477569412e-07
. O 0 1.4036598940947442e-06

The O 0 8.297495810438704e-07
chromosomal O 0 3.448459392529912e-05
order O 0 1.2657689296702301e-07
of O 0 7.526125500589842e-09
genes O 0 4.633539560927602e-07
controlling O 0 5.0831795306294225e-06
the O 0 3.210710275425299e-08
major O 0 1.4162696970743127e-07
histocompatibility O 0 5.379500180424657e-06
complex O 0 1.146206258795246e-07
, O 0 7.3488948260092e-09
properdin O 0 3.3195428272847494e-07
factor O 0 2.7059806484430737e-07
B O 0 8.36547405924648e-06
, O 0 1.2356335510332883e-08
and O 0 3.13661018935818e-07
deficiency B-Disease 0 7.580912551929941e-06
of I-Disease 0 1.1462161220165967e-09
the I-Disease 0 8.442874843694881e-09
second I-Disease 0 1.5950297438394045e-07
component I-Disease 0 1.9860915756453323e-07
of I-Disease 0 3.1141599521333774e-08
complement I-Disease 0 1.5452955040018423e-06
. O 0 1.8692561525313067e-06

The O 0 5.684021857632615e-07
relationship O 0 3.5956367128164857e-07
of O 0 6.078322289937432e-09
the O 0 7.176371497052969e-09
genes O 0 1.1472867100792428e-07
coding O 0 9.817078989726724e-07
for O 0 6.349429426677489e-09
HLA O 0 3.794107499288657e-07
to O 0 5.7025451027925556e-09
those O 0 3.440516538333327e-09
coding O 0 1.519029950713957e-07
for O 0 4.625925864587543e-09
properdin O 0 5.852144795426284e-07
Factor O 0 6.757555581771157e-08
B O 0 1.412094121633345e-07
allotypes O 0 1.6595051022250118e-07
and O 0 2.0127016497895056e-08
for O 0 1.2593362797019836e-08
deficiency B-Disease 0 1.2737540373564116e-06
of I-Disease 0 2.974588353410468e-10
the I-Disease 0 3.0899824920993524e-09
second I-Disease 0 3.429851602732015e-08
component I-Disease 0 4.283983656705459e-08
of I-Disease 0 1.0093236246788706e-09
complement I-Disease 0 5.610166908809333e-08
( O 0 7.502291232697189e-09
C2 O 0 1.2878153938800097e-06
) O 0 1.8095942522222686e-09
was O 0 8.512388127712711e-09
studied O 0 2.4113708363415753e-08
in O 0 3.1631446351099157e-09
families O 0 5.323382179511782e-09
of O 0 2.30802155165577e-09
patients O 0 4.567109783693013e-07
with O 0 1.0014297657789939e-07
connective O 1 0.9489100575447083
tissue O 1 0.9999856948852539
disorders O 1 0.999442994594574
. O 0 1.6454321666969918e-05

Patients O 0 0.00010965926776407287
were O 0 1.1345500183779222e-07
selected O 0 3.7348467429865195e-08
because O 0 1.6578276529344294e-08
they O 0 7.310797300874583e-09
were O 0 9.326499572637204e-09
heterozygous O 0 2.959434368676739e-07
or O 0 1.2295637930037628e-07
homozygous O 0 8.956978126661852e-05
for O 0 5.73163888475392e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.2889979188912548e-05

12 O 0 1.9515384792612167e-06
families O 0 1.4753246091459005e-07
with O 0 8.163020481788408e-09
15 O 0 2.276673782830585e-08
matings O 0 3.715581442520488e-06
informative O 0 1.5039943718875293e-05
for O 0 0.010134706273674965
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.143597834627144e-06
found O 0 1.205202920573356e-06
. O 0 2.204324346166686e-06

Of O 0 4.091191385668935e-07
57 O 0 9.963500815501902e-07
informative O 0 7.506193924200488e-07
meioses O 0 3.6473072668741224e-06
, O 0 7.112882283166755e-09
two O 0 1.064609289613827e-09
crossovers O 0 1.0001717498653306e-07
were O 0 4.84656226262814e-08
noted O 0 2.819382238783419e-08
between O 0 7.755308928381055e-08
the O 0 0.06827300041913986
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 3.9022862097226607e-07
and O 0 1.1349953865646967e-08
the O 0 1.781713265813778e-08
HLA O 0 4.89747571918997e-06
- O 0 0.00035834507434628904
B O 0 1.698876872069377e-06
gene O 0 7.321266082271904e-08
, O 0 2.2906763152974463e-09
with O 0 6.800178753429975e-10
a O 0 4.2573367053933e-09
recombinant O 0 6.287812226446476e-08
fraction O 0 1.284297468373552e-07
of O 0 2.3377513258537874e-08
0 O 0 5.142271106706175e-07
. O 0 8.638560871077061e-07

035 O 0 0.15407803654670715
. O 0 0.000812211015727371

A O 0 8.83325446920935e-06
lod O 0 0.00349818030372262
score O 0 5.368421511775523e-07
of O 0 6.787172601718794e-09
13 O 0 1.3554921629577166e-08
was O 0 1.0270074568552445e-08
calculated O 0 3.800310111046201e-08
for O 0 6.530647578273374e-09
linkage O 0 4.497008558246307e-05
between O 0 0.07473018765449524
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.5615364645782392e-07
HLA O 0 1.7855477381090168e-06
- O 0 0.0006396853132173419
B O 0 7.78205503593199e-05
at O 0 8.641427129418844e-09
a O 0 8.318828403908185e-10
maximum O 0 4.620370308572319e-09
likelihood O 0 1.8754001018805866e-08
value O 0 3.0481170920637624e-09
of O 0 4.326432267998115e-10
the O 0 1.594608445287804e-09
recombinant O 0 2.5656230917547873e-08
fraction O 0 4.767612082900996e-08
of O 0 1.5058287061719966e-08
0 O 0 4.403932507557329e-07
. O 0 1.0876707392526441e-06

04 O 0 0.004187456332147121
. O 0 9.677650086814538e-05

18 O 0 5.284353846946033e-06
families O 0 2.8655688311118865e-07
with O 0 2.6011294451677713e-08
21 O 0 3.247150814900124e-08
informative O 0 1.2600672505413968e-07
matings O 0 1.8170401290262816e-06
for O 0 1.1078893358273945e-08
both O 0 1.4844155238336043e-08
properdin O 0 3.354256705279113e-06
Factor O 0 3.667411192509462e-07
B O 0 9.729104704092606e-07
allotype O 0 2.3195955236587906e-06
and O 0 8.389503847183732e-08
HLA O 0 3.7048248486826196e-06
- O 0 0.0011868525762110949
B O 0 6.5328371420037e-05
were O 0 1.97588605033161e-07
found O 0 4.900345516034577e-07
. O 0 1.3123251392244129e-06

Of O 0 2.418104827484058e-07
72 O 0 9.807936294237152e-07
informative O 0 4.311641532694921e-07
meioses O 0 3.912159627361689e-06
, O 0 1.2363620349731264e-08
three O 0 3.871199805161041e-09
recombinants O 0 9.929722182278056e-07
were O 0 5.0091717440636785e-08
found O 0 2.3710217789130184e-08
, O 0 1.3924720265734436e-09
giving O 0 4.826523625212076e-09
a O 0 4.284316457159321e-09
recombinant O 0 6.488361492529293e-08
fraction O 0 1.914097538247006e-07
of O 0 3.6999974639684297e-08
0 O 0 1.2252577334948e-06
. O 0 2.0928359845129307e-06

042 O 0 0.01721959374845028
. O 0 0.000361003476427868

A O 0 4.710791927209357e-06
lod O 0 0.0010521223302930593
score O 0 4.970010536453628e-07
of O 0 1.0645448966783988e-08
16 O 0 1.1542771183314926e-08
between O 0 6.613730452187383e-09
HLA O 0 1.352707499790995e-06
- O 0 5.576194962486625e-05
B O 0 1.6908242059798795e-06
and O 0 6.1835763176532055e-09
Factor O 0 2.7561576132484333e-08
B O 0 6.307017486051336e-08
allotypes O 0 1.2334369614563911e-07
was O 0 1.2396442095052862e-08
calculated O 0 1.5639278316825767e-08
at O 0 3.227255351845315e-09
a O 0 9.785984245169743e-10
maximum O 0 4.40332570406099e-09
likelihood O 0 3.2732305754734625e-08
value O 0 4.997221747515823e-09
of O 0 4.774459161360767e-10
the O 0 2.0494206331989062e-09
recombinant O 0 2.1072583678005685e-08
fraction O 0 6.52028191439058e-08
of O 0 1.0338232492301813e-08
0 O 0 2.7691262971529795e-07
. O 0 5.310637334332569e-07

04 O 0 0.006442200392484665
. O 0 0.0002664481580723077

A O 0 1.0550704701017821e-06
crossover O 0 1.1965482826781226e-06
was O 0 1.7153378450984746e-07
shown O 0 3.002717008371292e-08
to O 0 1.0196821165209258e-08
have O 0 1.3694314127121743e-08
occurred O 0 1.126618265345769e-08
between O 0 2.1692940777029435e-09
genes O 0 5.22084953047397e-08
for O 0 8.64286064938824e-09
Factor O 0 1.266848528302944e-07
B O 0 7.369024501713284e-07
and O 0 3.8975844773858626e-08
HLA O 0 2.2775850538891973e-06
- O 0 0.002325097331777215
D O 0 0.006319785490632057
, O 0 6.284512021892397e-09
in O 0 7.73680763899165e-09
which O 0 6.109894457040355e-08
HLA O 0 3.731902779691154e-06
- O 0 0.0014583852607756853
D O 0 0.00013942905934527516
segregared O 0 7.120445388864027e-07
with O 0 1.5621926863218505e-08
HLA O 0 2.208810428783181e-06
- O 0 5.880351636733394e-06
A O 0 1.8574162652384985e-07
and O 0 3.270254183007637e-07
B O 0 1.8144781279261224e-05
. O 0 1.6782357761258027e-06

These O 0 5.940896130596229e-07
studies O 0 3.730461628492776e-07
suggest O 0 4.9090260745288106e-08
that O 0 1.1680565403793253e-09
the O 0 8.525171124595943e-10
genes O 0 1.3216724603637431e-08
for O 0 5.360152766087367e-09
Factor O 0 1.0753660717455205e-06
B O 0 0.44290152192115784
and O 1 0.8464840054512024
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.7903370986878144e-09
located O 0 5.262777769132754e-09
outside O 0 3.935749059991167e-09
those O 0 1.9440977716556063e-09
for O 0 3.1309772552390314e-09
HLA O 0 3.1070700856616895e-07
, O 0 3.7397991370369255e-09
that O 0 9.14791853379171e-10
the O 0 1.43382961059757e-09
order O 0 4.964607391855225e-09
of O 0 1.4876319065493249e-09
genese O 0 1.8529696035329835e-06
is O 0 1.4819770299823176e-08
HLA O 0 4.7628904553675966e-07
- O 0 1.068169353857229e-06
A O 0 1.9701991149645437e-08
, O 0 6.9892505116797565e-09
- O 0 1.0828146059793653e-06
B O 0 2.431049551887554e-06
, O 0 1.2515133818169488e-08
- O 0 1.3402301419773721e-06
D O 0 3.3712472031766083e-06
, O 0 4.465916525475677e-09
Factor O 0 4.497950101267634e-08
B O 0 3.71547855593235e-07
allotype O 0 8.126043212541845e-06
, O 0 6.5173121583939064e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.5167132822190297e-09
that O 0 8.550070096369211e-10
the O 0 1.809625338466958e-09
genes O 0 1.0138760586642093e-07
coding O 0 0.00011148892372148111
for O 0 0.00033582845935598016
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.741475371858542e-08
Factor O 0 1.563630291911977e-07
B O 0 2.876057010325894e-07
allotypes O 0 1.8682709423956112e-07
are O 0 1.9122714522978868e-09
approximately O 0 2.375397878395802e-09
3 O 0 1.16117995219156e-08
- O 0 1.997398385356064e-06
- O 0 8.972972409537761e-07
5 O 0 9.26582366389539e-09
centimorgans O 0 1.010478314356078e-07
from O 0 1.7745698244198138e-09
the O 0 4.108345219577814e-09
HLA O 0 5.494100605574204e-07
- O 0 1.1462121847216622e-06
A O 0 1.4537620884880198e-08
and O 0 1.7190808776490485e-08
HLA O 0 5.022259870202106e-07
- O 0 1.6399333162553376e-06
B O 0 9.771444808848173e-08
loci O 0 1.2134618643244721e-08
, O 0 5.286457938069589e-10
and O 0 7.507496846415052e-10
that O 0 8.902425463475083e-10
the O 0 2.8936157914216665e-09
apparent O 0 5.826839242217829e-07
lack O 0 2.2467657956326548e-08
of O 0 7.686837277809389e-10
recombinants O 0 2.1169574893065146e-07
between O 0 1.8373725874099023e-09
the O 0 4.963442545857788e-09
Factor O 0 1.4543812199008244e-07
B O 0 6.843050073257473e-07
gene O 0 5.237575919636583e-07
and O 0 0.08778683096170425
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.222682375460863e-07
suggests O 0 1.0437342012892259e-07
that O 0 2.247866337512505e-09
these O 0 1.5400918318420054e-09
two O 0 2.938286947085089e-09
genes O 0 9.262736000437144e-08
lie O 0 4.656273631553631e-06
in O 0 1.4991860197710594e-08
close O 0 4.818513943405378e-08
proximity O 0 1.5482753212836542e-07
to O 0 6.310868627679156e-08
one O 0 9.15532822887144e-08
another O 0 3.227158913432504e-07
. O 0 2.0092588783882093e-06

Distribution O 0 2.4507471607648768e-06
of O 0 6.225673132576048e-08
emerin O 0 8.254132808360737e-06
and O 0 1.316157494102299e-07
lamins O 0 4.598101077135652e-05
in O 0 5.604701769357234e-08
the O 0 5.196915608962627e-08
heart O 0 1.8204605112259742e-06
and O 0 2.275666410866961e-08
implications O 0 2.4007772481127176e-07
for O 0 2.7552799153340857e-08
Emery B-Disease 0 5.692668491974473e-05
- I-Disease 0 0.0014565630117431283
Dreifuss I-Disease 0 0.049449510872364044
muscular I-Disease 0 0.000546391005627811
dystrophy I-Disease 0 0.0011869710870087147
. O 0 1.4021135029906873e-05

Emerin O 0 0.0007968327263370156
is O 0 4.311131931444834e-07
a O 0 9.779592602399134e-08
nuclear O 0 9.181792961499013e-07
membrane O 0 1.8726770179000596e-07
protein O 0 9.367811060201348e-08
which O 0 1.605513588742724e-08
is O 0 9.75029124106186e-09
missing O 0 9.423742852732175e-08
or O 0 5.6931913405833257e-08
defective O 0 8.483527381031308e-06
in O 0 2.2071020566727384e-07
Emery B-Disease 0 0.015992360189557076
- I-Disease 0 0.07677219063043594
Dreifuss I-Disease 0 0.4193419814109802
muscular I-Disease 0 0.0011868083383888006
dystrophy I-Disease 0 0.0004710068751592189
( O 0 1.4401172165889875e-06
EDMD B-Disease 1 0.9999984502792358
) O 0 2.091227997880196e-06
. O 0 2.037498916251934e-06

It O 0 1.5679173657190404e-06
is O 0 4.713217904850353e-08
one O 0 1.3390360820153546e-08
member O 0 5.250816226265442e-09
of O 0 1.0943362882542829e-09
a O 0 1.7237399063674275e-08
family O 0 7.265428081382197e-08
of O 0 7.082895159271629e-09
lamina O 0 0.4225436747074127
- O 0 0.17348003387451172
associated O 0 4.3411256456238334e-07
proteins O 0 3.705810058818315e-08
which O 0 1.0664207295008055e-08
includes O 0 6.4298406599050395e-09
LAP1 O 0 3.1291456252802163e-06
, O 0 1.1509530217779229e-08
LAP2 O 0 3.7478384911082685e-06
and O 0 1.88544689194714e-07
lamin O 0 5.011819666833617e-05
B O 0 5.035452340962365e-05
receptor O 0 5.910689651500434e-06
( O 0 2.6415474962959706e-07
LBR O 0 6.59333381918259e-05
) O 0 3.7064825164634385e-07
. O 0 1.0942409289782518e-06

A O 0 3.539362069204799e-06
panel O 0 1.3351108236747677e-06
of O 0 1.5303445621839273e-08
16 O 0 2.636352469664871e-08
monoclonal O 0 3.6780272694159066e-07
antibodies O 0 2.0905231679080316e-07
( O 0 8.735337786447417e-09
mAbs O 0 3.68485615354075e-07
) O 0 5.11854825191449e-09
has O 0 2.2812802757954387e-09
been O 0 2.3767074974756497e-09
mapped O 0 9.698121061774145e-08
to O 0 1.968530449758532e-09
six O 0 1.2684213679392542e-09
specific O 0 3.3148712663688684e-09
sites O 0 1.9665087336306897e-08
throughout O 0 7.366029119992845e-09
the O 0 5.410782932813163e-09
emerin O 0 1.7610184954719443e-07
molecule O 0 2.4041099777605268e-08
using O 0 2.292937395509398e-08
phage O 0 6.463225759034685e-07
- O 0 8.57390460851093e-08
displayed O 0 1.1199892568924952e-08
peptide O 0 1.3047779745534172e-08
libraries O 0 9.035399095580487e-09
and O 0 2.87718249225577e-09
has O 0 2.0354820051693423e-09
been O 0 1.2924991077412074e-09
used O 0 8.154477093569312e-09
to O 0 6.08783601308005e-09
localize O 0 6.373626320055337e-07
emerin O 0 1.7999124111156561e-06
in O 0 2.043539382157178e-08
human O 0 3.6062029806771534e-08
and O 0 1.585197111353409e-07
rabbit O 0 0.000387083477107808
heart O 0 0.001077837310731411
. O 0 4.51892492492334e-06

Several O 0 1.6196285059777438e-06
mAbs O 0 2.1240193746052682e-05
against O 0 1.4559633143562678e-07
different O 0 6.363641347206794e-08
emerin O 0 2.9595264550152933e-06
epitopes O 0 3.725906935869716e-06
did O 0 1.399857723072273e-07
not O 0 8.860014055755983e-09
recognize O 0 1.9248275862082664e-08
intercalated O 0 1.1331744786957643e-07
discs O 0 8.434370215582021e-07
in O 0 2.0194578453924805e-08
the O 0 2.0099587771937877e-08
heart O 0 1.1236716090934351e-06
, O 0 1.92868521153855e-09
though O 0 1.0677131179193111e-08
they O 0 6.468291680050697e-09
recognized O 0 1.1475248307135644e-08
cardiomyocyte O 0 1.2239340207997884e-07
nuclei O 0 3.446212559765627e-08
strongly O 0 5.421074078526544e-08
, O 0 3.6432370453809426e-09
both O 0 1.0353427448706043e-08
at O 0 5.5198299264702655e-08
the O 0 6.0027653958627525e-09
rim O 0 9.892908536812683e-08
and O 0 2.4887654603844567e-08
in O 0 4.212035520367863e-08
intranuclear O 0 1.1969663319177926e-05
spots O 0 3.797900944846333e-06
or O 0 7.242618949021562e-07
channels O 0 6.275265150179621e-06
. O 0 2.0840529941779096e-06

A O 0 1.3438249879982322e-05
polyclonal O 0 0.00025203675613738596
rabbit O 0 7.415935397148132e-05
antiserum O 0 0.00011603413440752774
against O 0 9.793178605832509e-07
emerin O 0 1.185873679787619e-05
did O 0 2.2291290235898487e-07
recognize O 0 2.0851373960795172e-07
both O 0 1.9440616227939245e-08
nuclear O 0 1.0960018244077219e-06
membrane O 0 1.1545859024408855e-07
and O 0 4.611953041688821e-09
intercalated O 0 8.204983714676928e-08
discs O 0 3.314108312224562e-07
but O 0 2.6709876976838132e-08
, O 0 6.867226787221625e-10
after O 0 1.4281414939532056e-09
affinity O 0 8.86523654486382e-09
purification O 0 1.8625243569658778e-08
against O 0 6.5693757100859784e-09
a O 0 5.478982156859047e-09
pure O 0 6.49949640774139e-08
- O 0 1.6232530697379843e-06
emerin O 0 2.535206476750318e-06
band O 0 4.36721947494334e-08
on O 0 3.224726263795219e-09
a O 0 3.79588227517047e-09
western O 0 4.7138744463381954e-08
blot O 0 8.171490480890498e-05
, O 0 9.534495859497838e-09
it O 0 1.5513872853034627e-08
stained O 0 0.0005828600260429084
only O 0 1.8338129237349676e-08
the O 0 3.7608668179700544e-08
nuclear O 0 4.191661901131738e-06
membrane O 0 6.021068202244351e-06
. O 0 2.308847570020589e-06

These O 0 5.979160278002382e-07
results O 0 4.320783943967399e-07
would O 0 1.2107616242928998e-08
not O 0 3.263416648024986e-09
be O 0 1.971987684257215e-09
expected O 0 4.580813062204925e-09
if O 0 4.833746292121077e-09
immunostaining O 0 2.0795809518858732e-07
at O 0 3.021381145273949e-09
intercalated O 0 3.05872411843211e-08
discs O 0 4.03282143679462e-07
were O 0 4.782694418281608e-08
due O 0 8.052975175587562e-09
to O 0 1.917143332974547e-09
a O 0 1.1076881634153324e-09
product O 0 1.150386896853206e-08
of O 0 5.090719512601538e-10
the O 0 1.9359496228332773e-09
emerin O 0 2.4807803811199847e-07
gene O 0 3.848174046083841e-08
and O 0 8.629255532355273e-09
, O 0 2.289042733139013e-09
therefore O 0 6.5006222627062016e-09
, O 0 1.340379363057309e-09
cast O 0 1.232305546494672e-08
some O 0 9.291480917994477e-10
doubt O 0 1.1605776784051614e-08
upon O 0 1.4349869070784393e-09
the O 0 3.885913812951003e-09
hypothesis O 0 2.552328339788801e-07
that O 0 4.3190325982322975e-08
cardiac B-Disease 0 0.00019040894403588027
defects I-Disease 1 0.8228894472122192
in O 0 1.7982034705710248e-06
EDMD B-Disease 1 1.0
are O 0 1.084994664779515e-06
caused O 0 1.7760444848136103e-07
by O 0 9.380698884342564e-09
absence O 0 9.13636597488221e-08
of O 0 8.513151072975234e-09
emerin O 0 5.762119599239668e-06
from O 0 7.4093762236771e-08
intercalated O 0 7.620606083946768e-06
discs O 0 1.843118116084952e-05
. O 0 3.224856072847615e-06

Although O 0 3.313126853754511e-06
emerin O 0 2.0783309082617052e-05
was O 0 1.7857627199191484e-07
abundant O 0 5.6623917998877005e-08
in O 0 1.0620361479141138e-08
the O 0 1.1106462416421437e-08
membranes O 0 2.6456672230779077e-07
of O 0 4.221491600731042e-09
cardiomyocyte O 0 3.518741209518339e-07
nuclei O 0 8.447260313459992e-08
, O 0 3.6389866675534677e-09
it O 0 1.0087351398624378e-08
was O 0 7.810784552475525e-08
absent O 0 1.9498546777185766e-08
from O 0 1.4213207277791184e-09
many O 0 5.70931479870751e-09
non O 0 2.3109261348963628e-07
- O 0 4.53776692665997e-06
myocyte O 0 4.946744866174413e-06
cells O 0 4.394928794226871e-07
in O 0 2.759718853440063e-08
the O 0 1.940694431823431e-07
heart O 0 4.0889077354222536e-05
. O 0 2.876476173696574e-06

This O 0 2.702797701203963e-07
distribution O 0 1.043505264419764e-07
of O 0 6.032907506892116e-09
emerin O 0 3.4060576581396163e-06
was O 0 1.055264178262405e-07
similar O 0 5.232610345018429e-09
to O 0 3.0362625746960248e-09
that O 0 1.2414940186999956e-09
of O 0 5.173204642439089e-10
lamin O 0 1.654036623222055e-06
A O 0 7.751552288937091e-08
, O 0 2.7291269244500427e-09
a O 0 3.2443077113697427e-09
candidate O 0 5.270455005756958e-08
gene O 0 5.5850556179848354e-08
for O 0 9.6824628315062e-09
an O 0 2.6520526219542262e-08
autosomal O 0 0.00446059787645936
form O 0 1.3311795555637218e-05
of O 0 1.5039234995128936e-06
EDMD B-Disease 1 1.0
. O 0 2.1567924704868346e-05

In O 0 1.242714461113792e-06
contrast O 0 2.2195838482730323e-06
, O 0 2.920109238857549e-07
lamin O 0 0.00011837592319352552
B1 O 0 0.060374774038791656
was O 0 3.432614334997197e-07
absent O 0 1.5635944805580948e-07
from O 0 9.238982912052052e-09
cardiomyocyte O 0 3.13049270062038e-07
nuclei O 0 1.0762313706891291e-07
, O 0 7.494067588709186e-09
showing O 0 9.28780394815476e-08
that O 0 5.2196842403873234e-08
lamin O 0 1.8723549146670848e-05
B1 O 0 0.0006118660676293075
is O 0 5.800329549998651e-09
not O 0 7.28743687616884e-09
essential O 0 5.014427095773044e-09
for O 0 1.982415342993704e-09
localization O 0 4.5547828619874053e-08
of O 0 2.8925397632661998e-09
emerin O 0 1.2096834325348027e-06
to O 0 1.692035134226444e-08
the O 0 7.267743029615303e-08
nuclear O 0 7.624008503626101e-06
lamina O 0 7.452310819644481e-05
. O 0 2.7841347218782175e-06

Lamin O 0 0.3411499857902527
B1 O 1 0.9432268738746643
is O 0 4.597766576353024e-07
also O 0 9.83640617846504e-08
almost O 0 1.02149869007917e-07
completely O 0 5.23478729519411e-06
absent O 0 1.0279392199663562e-06
from O 0 6.042605349421137e-08
skeletal O 0 5.326826430973597e-05
muscle O 0 5.1120623538736254e-05
nuclei O 0 4.274799721315503e-05
. O 0 8.857042303134222e-06

In O 0 4.5694855543843005e-06
EDMD B-Disease 1 0.9999949932098389
, O 0 3.057691699837051e-08
the O 0 3.979644169760377e-09
additional O 0 6.2087370800156805e-09
absence O 0 3.5716414714670464e-08
of O 0 7.723552464256045e-09
lamin O 0 0.0002421797253191471
B1 O 0 0.025141319260001183
from O 0 3.0984647736431725e-08
heart O 0 6.906501312187174e-06
and O 0 7.510683985856303e-08
skeletal O 0 1.7587924958206713e-05
muscle O 0 1.0035317927759024e-06
nuclei O 0 6.917060773048433e-07
which O 0 5.277024115457607e-07
already O 0 6.680713227069646e-07
lack O 0 4.166586009546336e-08
emerin O 0 1.4280884897743817e-05
may O 0 1.4938943593278964e-07
offer O 0 1.1620639561726875e-08
an O 0 6.172578004282059e-10
alternative O 0 1.726335874252527e-08
explanation O 0 1.0081197210354276e-08
of O 0 7.694729298179936e-10
why O 0 2.7004627867199815e-08
these O 0 8.482452962255138e-09
tissues O 0 2.2250893039199582e-07
are O 0 1.782913194858793e-08
particularly O 0 1.0007194362060545e-07
affected O 0 1.8090676690007967e-07
. O 0 1.6155037485532375e-07
. O 0 8.201124614970468e-07

Genetic O 0 6.212783046066761e-05
mapping O 0 1.0714529707911424e-05
of O 0 8.929898598353248e-08
the O 0 1.6415265235991683e-07
copper B-Disease 0 0.00010795378329930827
toxicosis I-Disease 0 0.012248829938471317
locus O 0 1.5406707461806946e-05
in O 0 1.0093302194036369e-07
Bedlington O 0 3.0475657695205882e-06
terriers O 0 1.884475636870775e-06
to O 0 2.1195852184519026e-08
dog O 0 2.406264627552446e-07
chromosome O 0 1.245018097506545e-06
10 O 0 1.087841905444975e-08
, O 0 1.5409878928451803e-09
in O 0 3.1973068637114466e-09
a O 0 2.2602279159400496e-08
region O 0 2.8807320973101014e-07
syntenic O 0 3.0285364118753932e-05
to O 0 3.4347809929613504e-08
human O 0 7.92051153553075e-08
chromosome O 0 7.300040579139022e-06
region O 0 1.7026137584252865e-06
2p13 O 0 4.521678783930838e-05
- O 0 6.051326636224985e-05
p16 O 0 5.466731090564281e-05
. O 0 7.613981324539054e-06

Abnormal O 0 0.021137621253728867
hepatic B-Disease 1 0.8776617646217346
copper I-Disease 0 0.0058718034997582436
accumulation I-Disease 0 2.253516413475154e-06
is O 0 2.5731848651844302e-08
recognized O 0 4.215186066858223e-08
as O 0 4.2809613631789034e-08
an O 0 2.050626244454179e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.667158358031884e-05
man O 0 0.00022381890448741615
, O 0 4.203632641974764e-08
mouse O 0 1.144128304986225e-06
, O 0 4.814655341078833e-08
rat O 0 1.4414593351830263e-05
and O 0 3.251685143368377e-07
dog O 0 1.1545088455022778e-05
. O 0 2.575537791926763e-06

The O 0 8.336576229339698e-07
major O 0 6.534692715831625e-07
cause O 0 4.7512719447695417e-07
of O 0 2.144643929113954e-08
hepatic B-Disease 0 0.13016173243522644
copper I-Disease 0 0.2061067670583725
accumulation I-Disease 0 2.0271027096896432e-06
in O 0 8.560440534211011e-08
man O 0 8.417214303335641e-07
is O 0 1.2720950515188179e-08
a O 0 5.792825419348446e-08
dysfunctional O 0 8.842121133056935e-06
ATP7B O 0 1.7990088963415474e-05
gene O 0 1.7284598925471073e-06
, O 0 1.3339393944988842e-07
causing O 0 1.2995497854717541e-05
Wilson B-Disease 0 0.014242328703403473
disease I-Disease 0 0.001317833666689694
( O 0 8.606671713096148e-07
WD B-Disease 1 0.9999581575393677
) O 0 1.9380825051484862e-06
. O 0 3.3757671644707443e-06

Mutations O 0 0.00015748657460790128
in O 0 2.4747592419771536e-07
the O 0 1.9491110947456036e-08
ATP7B O 0 3.3192275168403285e-06
genes O 0 2.726517323026201e-07
have O 0 4.045316615020056e-08
also O 0 1.2063610554946536e-08
been O 0 2.6074326697766992e-08
demonstrated O 0 5.793797441810966e-08
in O 0 2.0431416558608362e-08
mouse O 0 2.954196816062904e-06
and O 0 1.0076920489154872e-06
rat O 0 0.00020373601000756025
. O 0 4.217436526232632e-06

The O 0 5.020028197577631e-07
ATP7B O 0 6.556248990818858e-06
gene O 0 3.245779964800022e-07
has O 0 3.579654617169581e-08
been O 0 2.128019005454007e-08
excluded O 0 7.64095986482971e-08
in O 0 1.1521210652176705e-09
the O 0 8.599692069566345e-10
much O 0 1.059503063061129e-08
rarer O 0 3.96944597014226e-06
human O 0 6.213738856786222e-08
copper B-Disease 0 0.03671794757246971
overload I-Disease 0 0.0025339480489492416
disease O 0 4.309900032239966e-05
non B-Disease 0 2.363942712690914e-06
- I-Disease 0 0.0005715024308301508
Indian I-Disease 0 9.560728813085007e-07
childhood I-Disease 0 3.345272853039205e-05
cirrhosis I-Disease 0 0.002938443562015891
, O 0 8.341476842588236e-08
indicating O 0 3.4773029256029986e-06
genetic O 0 5.287583189783618e-05
heterogeneity O 0 0.0004611508920788765
. O 0 3.07992086163722e-05

By O 0 6.616357381972193e-07
investigating O 0 1.6934191080508754e-06
the O 0 2.515059804863995e-07
common O 0 4.049388280691346e-06
autosomal O 1 0.977601945400238
recessive O 1 0.9925850033760071
copper B-Disease 1 0.8610182404518127
toxicosis I-Disease 1 0.9634569883346558
( O 0 1.9234592230077396e-07
CT B-Disease 1 0.9500246047973633
) O 0 2.7862220974839147e-08
in O 0 1.2344086641746799e-08
Bedlington O 0 1.6133649296534713e-06
terriers O 0 9.628682164475322e-06
, O 0 1.293286544523653e-08
we O 0 1.3271161947159271e-08
have O 0 3.095303124922566e-09
identified O 0 1.4253502378380745e-08
a O 0 1.8064801876604974e-09
new O 0 4.383894491866158e-08
locus O 0 4.80832841276424e-06
involved O 0 3.6291947935751523e-07
in O 0 4.528588760877028e-06
progressive O 1 0.9997674822807312
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.0371320463018492e-05

We O 0 2.743413233474712e-06
examined O 0 2.110181867465144e-06
whether O 0 9.132689626767387e-08
the O 0 2.543730381887599e-08
WD B-Disease 0 0.17042651772499084
gene O 0 1.229520876222523e-06
ATP7B O 0 0.00010856222070287913
was O 0 2.5040074547177937e-07
also O 0 1.4896343714099203e-08
causative O 0 2.349481320607083e-07
for O 0 1.1274867262045518e-08
CT B-Disease 0 0.37080511450767517
by O 0 2.2152558898369534e-08
investigating O 0 3.21439671324697e-07
the O 0 6.410348163399249e-08
chromosomal O 0 0.23819969594478607
co O 0 0.008412891067564487
- O 0 3.7275917748047505e-06
localization O 0 2.887468042445107e-07
of O 0 3.392381042743864e-09
ATP7B O 0 6.656808182015084e-06
and O 0 1.36381679283204e-08
C04107 O 0 9.452509885932159e-08
, O 0 7.902335452669718e-10
using O 0 6.271926533685246e-09
fluorescence O 0 2.4351467686756223e-07
in O 0 3.004069171197443e-08
situ O 0 9.883550546874176e-07
hybridization O 0 2.0152808701823233e-06
( O 0 7.125798617835244e-08
FISH O 0 7.155502430578053e-07
) O 0 1.325265088780725e-07
. O 0 9.268529197470343e-07

C04107 O 0 0.00010725398897193372
is O 0 4.030399338716961e-07
an O 0 3.729280351194575e-08
anonymous O 0 4.021453321456647e-07
microsatellite O 0 2.049066279141698e-05
marker O 0 2.308834154973738e-06
closely O 0 8.157948627740552e-07
linked O 0 9.397378562425729e-06
to O 0 1.051094500326144e-06
CT B-Disease 1 0.9994233846664429
. O 0 1.1255377103225328e-05

However O 0 8.910831638786476e-06
, O 0 3.59645980552159e-07
BAC O 0 3.839420514850644e-06
clones O 0 4.5377134938462405e-07
containing O 0 1.0140327333374444e-07
ATP7B O 0 6.458755706262309e-06
and O 0 2.295878331892709e-08
C04107 O 0 4.550649634893489e-07
mapped O 0 5.421295554697281e-07
to O 0 1.535525662177406e-08
the O 0 2.042775371080552e-08
canine O 0 1.995675347643555e-06
chromosome O 0 3.7680979403376114e-06
regions O 0 2.5467190312156163e-07
CFA22q11 O 0 3.4593158488860354e-06
and O 0 3.5446173995978825e-08
CFA10q26 O 0 1.5816409586477675e-06
, O 0 4.933371933191211e-09
respectively O 0 4.077861248674708e-08
, O 0 4.064262704162047e-09
demonstrating O 0 2.986222114031989e-08
that O 0 1.3316219238390659e-08
WD B-Disease 1 0.9784848093986511
cannot O 0 3.3348877082062245e-07
be O 0 1.0895300661672991e-08
homologous O 0 2.2343009220548993e-07
to O 0 1.3676074672730465e-07
CT B-Disease 0 0.43002691864967346
. O 0 3.154719479425694e-06

The O 0 1.2542851663965848e-06
copper O 0 7.662970347155351e-06
transport O 0 3.951969347326667e-07
genes O 0 2.1633169922097295e-07
CTR1 O 0 2.003404006245546e-06
and O 0 1.865147858381988e-08
CTR2 O 0 4.918093509331811e-06
were O 0 2.1883534984112885e-08
also O 0 4.958295551915626e-09
excluded O 0 3.2655478321430564e-08
as O 0 2.4919180052762613e-09
candidate O 0 2.6549223264282773e-08
genes O 0 2.3726641984467278e-08
for O 0 4.7447215045792746e-09
CT B-Disease 1 0.8460628986358643
since O 0 3.9408669749718683e-07
they O 0 6.22061424593312e-09
both O 0 3.690663774591485e-09
mapped O 0 1.5130024166865041e-06
to O 0 1.5681700915592955e-07
canine O 0 1.3279235645313747e-05
chromosome O 0 5.7563811424188316e-05
region O 0 6.378433226927882e-06
CFA11q22 O 0 0.00025467187515459955
. O 0 7.335583177336957e-06

2 O 0 0.00012641753710340708
- O 0 0.003471460659056902
22 O 0 1.3938903975940775e-05
. O 0 5.058931037638104e-06

5 O 0 0.0002664898056536913
. O 0 6.899170693941414e-05

A O 0 2.56638713835855e-06
transcribed O 0 2.6466236704436596e-06
sequence O 0 8.41792086703208e-07
identified O 0 3.938552310955856e-07
from O 0 1.0090968949327817e-08
the O 0 1.0529435989781177e-08
C04107 O 0 9.881260893962462e-07
- O 0 3.627624209912028e-07
containing O 0 6.164347610138066e-08
BAC O 0 1.987741370612639e-06
was O 0 3.2260814464279974e-08
found O 0 1.6127407187482845e-09
to O 0 9.21154597044449e-10
be O 0 1.4791381452994301e-09
homologous O 0 1.359930745792326e-08
to O 0 3.2935820737378663e-09
a O 0 3.4283715866223474e-09
gene O 0 4.901504269128054e-08
expressed O 0 6.481976289052227e-09
from O 0 4.657052077305934e-09
human O 0 1.6714007955442867e-08
chromosome O 0 1.4833917703072075e-06
2p13 O 0 2.0491420400503557e-06
- O 0 1.238733943864645e-06
p16 O 0 4.6540665721295227e-07
, O 0 9.711148329927255e-09
a O 0 1.0286188789621065e-08
region O 0 6.349613812517418e-08
devoid O 0 1.9153611674482818e-07
of O 0 3.83838605344522e-09
any O 0 6.9457563256492e-08
positional O 0 4.095273197890492e-06
candidate O 0 1.0490452950762119e-05
genes O 0 1.1124620868940838e-05
. O 0 4.7920452743710484e-06

Molecular O 0 2.844463051587809e-05
analysis O 0 1.071396354745957e-06
of O 0 1.1135436572828894e-08
the O 0 1.729869225641778e-08
APC B-Disease 0 3.972676836383471e-07
gene O 0 2.086167398829275e-07
in O 0 2.6711914458132924e-08
205 O 0 7.619798481073303e-08
families O 0 3.094814715609573e-08
: O 0 4.7417270110372556e-09
extended O 0 3.281175153801996e-08
genotype O 0 0.0018128510564565659
- O 0 0.0068752216175198555
phenotype O 0 1.676245483395178e-05
correlations O 0 2.1567343537753914e-06
in O 0 2.2881405215002815e-08
FAP B-Disease 0 1.3555160194300697e-07
and O 0 3.4942035931351256e-09
evidence O 0 1.061781063071976e-08
for O 0 1.675968142045292e-09
the O 0 2.4011346244634524e-09
role O 0 4.278806287061343e-08
of O 0 4.909913364770091e-09
APC B-Disease 0 3.597293414259184e-07
amino O 0 2.6727875024334935e-07
acid O 0 2.864475732167193e-07
changes O 0 1.113869643631915e-06
in O 0 0.40609535574913025
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.050966113805770874
. O 0 1.1493095371406525e-05

BACKGROUND O 0 0.00047717263805679977
/ O 0 0.00012167953536845744
AIMS O 0 2.1416062736534514e-06
The O 0 1.6669403635205526e-08
development O 0 5.395697755261608e-08
of O 0 5.734427031711675e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1561284196659471e-07
a O 0 1.0894843249786845e-08
variable O 0 1.711568131668173e-07
range O 0 7.639575017037714e-08
of O 0 1.5348668114256725e-08
extracolonic O 0 0.00017449739971198142
manifestations O 0 0.00016557381604798138
in O 0 0.005707043223083019
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 2.7330331704433775e-06
FAP B-Disease 0 9.165065421257168e-06
) O 0 8.196302303531411e-08
is O 0 7.902535514858755e-09
the O 0 3.5299208001049465e-09
result O 0 3.290814376555318e-08
of O 0 1.3353677053018487e-09
the O 0 5.159454019576515e-08
dominant O 0 0.013246828690171242
inheritance O 1 0.612816572189331
of O 0 2.7003448849427514e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
( O 0 1.8238160919281654e-06
APC B-Disease 0 9.284991392632946e-06
) O 0 2.6309430722903926e-07
gene O 0 6.5902445385290775e-06
mutations O 0 6.377450336003676e-05
. O 0 8.872801117831841e-06

In O 0 6.184209837556409e-07
this O 0 2.419377587159488e-08
study O 0 4.035075207298178e-08
, O 0 2.3616464339681897e-09
direct O 0 1.0773296921229303e-08
mutation O 0 2.8093154469388537e-07
analysis O 0 4.8082497983159556e-08
of O 0 1.3245967656061453e-09
the O 0 5.770645739033853e-09
APC B-Disease 0 1.2344514743745094e-07
gene O 0 7.176907956818468e-08
was O 0 8.530238204684792e-08
performed O 0 2.4161172618164528e-08
to O 0 9.221746921639351e-09
determine O 0 2.5435417683183914e-07
genotype O 0 8.639099542051554e-05
- O 0 8.068312126852106e-06
phenotype O 0 1.2406942460074788e-06
correlations O 0 4.196222676000616e-07
for O 0 3.822203886727493e-09
nine O 0 8.52098125392331e-09
extracolonic O 0 3.306966789295984e-07
manifestations O 0 6.96452744364251e-08
and O 0 6.436613908533673e-09
to O 0 4.391474295317721e-09
investigate O 0 6.60280576880723e-08
the O 0 1.6589442708436763e-08
incidence O 0 8.695753422216512e-06
of O 0 9.352936203299578e-09
APC B-Disease 0 6.906092835379241e-07
mutations O 0 1.599979555066966e-06
in O 0 1.278266097415326e-07
non O 0 7.050789281493053e-05
- O 1 0.9999104738235474
FAP O 1 0.9999148845672607
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.2732278011972085e-05

METHODS O 0 3.5553373891161755e-05
The O 0 5.449292075354606e-07
APC B-Disease 0 2.1923719941696618e-06
gene O 0 7.309056968551886e-07
was O 0 1.29406060977999e-07
analysed O 0 4.781444999935047e-07
in O 0 2.2303915159227472e-08
190 O 0 6.566221344428413e-08
unrelated O 0 3.663520544705534e-07
FAP B-Disease 0 1.2803392337445985e-06
and O 0 3.217754596107625e-08
15 O 0 6.462892798708708e-08
non O 0 4.309316864237189e-06
- O 1 0.9998942613601685
FAP O 1 0.9999920129776001
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.7319986202201108e-06
using O 0 2.2166935309542168e-07
denaturing O 0 3.9536731492262334e-05
gradient O 0 1.925810647662729e-05
gel O 0 0.0036864285357296467
electrophoresis O 0 2.1021533029852435e-05
, O 0 1.6040228700830994e-08
the O 0 5.415418335985578e-09
protein O 0 3.8677324454283735e-08
truncation O 0 1.0902222129516304e-06
test O 0 9.39306232794479e-07
, O 0 5.466716856972198e-09
and O 0 9.064657469082249e-09
direct O 0 1.3721380298648e-07
sequencing O 0 6.662486157438252e-06
. O 0 2.674434654181823e-06

RESULTS O 0 6.206368561834097e-05
Chain O 0 4.5704309741267934e-06
terminating O 0 1.60832030360325e-06
signals O 0 5.272984253679169e-07
were O 0 4.3262470938998376e-08
only O 0 3.643834567412796e-09
identified O 0 5.3768559382660897e-08
in O 0 1.2567855200984468e-08
patients O 0 9.030337366766616e-08
belonging O 0 5.807594405382588e-08
to O 0 3.281738614191454e-08
the O 0 4.5710578433499904e-08
FAP B-Disease 0 2.0802326616831124e-06
group O 0 1.0314326459592849e-07
( O 0 7.195409157390031e-09
105 O 0 8.679969454306047e-08
patients O 0 7.324841249101155e-07
) O 0 1.4149627247661556e-07
. O 0 1.3072549336357042e-06

Amino O 0 2.175752706534695e-05
acid O 0 9.935728485288564e-06
changes O 0 2.0410254819580587e-07
were O 0 1.7603982271907626e-08
identified O 0 2.1344336076367654e-08
in O 0 5.0378954341567805e-09
four O 0 2.579204227970422e-08
patients O 0 1.1575670555430406e-07
, O 0 1.9984853771859434e-09
three O 0 1.5002291631205367e-09
of O 0 7.455527306632348e-10
whom O 0 1.028042717621247e-07
belonged O 0 3.032242261724605e-07
to O 0 5.538599356924578e-09
the O 0 9.65894475513096e-09
non O 0 1.3914047940488672e-06
- O 0 0.00017402353114448488
FAP O 0 4.970170266460627e-06
group O 0 1.1353751006026869e-06
of O 0 4.9085818318417296e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0005514592630788684
. O 0 5.58850933884969e-06

Genotype O 1 0.9806724190711975
- O 1 0.7092607617378235
phenotype O 0 0.00023496551148127764
correlations O 0 3.561998892109841e-05
identified O 0 1.6511115745743155e-06
significant O 0 2.4372448592657747e-07
differences O 0 2.0401726942509413e-05
in O 0 7.627796350107019e-08
the O 0 1.0729659827291016e-08
nature O 0 1.1101018770887094e-08
of O 0 1.0687069007531136e-09
certain O 0 2.760666539813883e-08
extracolonic O 0 8.337153303727973e-06
manifestations O 0 2.701931407500524e-06
in O 0 1.400795213157835e-07
FAP B-Disease 0 3.9602723518328276e-06
patients O 0 3.566475186289608e-07
belonging O 0 6.229557669712449e-08
to O 0 1.8237427568124076e-08
three O 0 6.07410584052559e-08
mutation O 0 8.538337169738952e-06
subgroups O 0 1.597676418896299e-05
. O 0 3.7076524677104317e-06

CONCLUSIONS O 0 3.3281798096140847e-05
Extended O 0 3.6255667055229424e-06
genotype O 0 0.0003361093404237181
- O 0 0.0001314802502747625
phenotype O 0 5.564279945247108e-06
correlations O 0 2.233147142760572e-06
made O 0 1.694360385329219e-08
in O 0 6.611006408974163e-09
this O 0 2.8430982013105677e-09
study O 0 1.9169576148669876e-08
may O 0 1.4483090637895657e-07
have O 0 3.0970335185287468e-09
the O 0 6.049519774009582e-10
potential O 0 1.199754784408924e-08
to O 0 1.5630712280056969e-09
determine O 0 1.3071742799297681e-08
the O 0 4.693790911503015e-10
most O 0 1.3250162078648486e-09
appropriate O 0 2.744536597987235e-09
surveillance O 0 1.834711937931388e-08
and O 0 4.30866364808935e-09
prophylactic O 0 2.8055646339453233e-07
treatment O 0 5.243833101076234e-08
regimens O 0 7.773405741318129e-08
for O 0 1.4452268271014646e-09
those O 0 7.46594697176306e-09
patients O 0 6.878362768247825e-08
with O 0 5.623201904114694e-09
mutations O 0 1.4328114048112184e-05
associated O 0 1.8204451635028818e-07
with O 0 5.503073552404203e-08
life O 0 7.136085969250416e-06
threatening O 0 0.004962523002177477
conditions O 0 5.31631703779567e-05
. O 0 7.369141258095624e-06

This O 0 3.8644444089186436e-07
study O 0 7.787533462533247e-08
also O 0 7.528910828114022e-09
provided O 0 4.508624584786958e-09
evidence O 0 2.7720741258008275e-08
for O 0 1.8705159643417346e-09
the O 0 9.149999868895975e-09
pathological O 0 3.080724866322271e-07
nature O 0 3.752011323854276e-08
of O 0 2.2044475134208597e-09
amino O 0 9.679457235733935e-08
acid O 0 5.44646013622696e-07
changes O 0 7.081439434841741e-08
in O 0 1.667652860248836e-08
APC O 0 1.4303168427431956e-07
associated O 0 2.481920091668144e-08
with O 0 2.198635939976157e-09
both O 0 3.121771996461575e-08
FAP B-Disease 0 1.189118847833015e-06
and O 0 1.066575663344338e-07
non O 0 5.706975207431242e-05
- O 1 0.9999415874481201
FAP O 1 0.9999892711639404
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.320572017808445e-05
. O 0 6.438716013690282e-07
. O 0 5.2964069254812784e-06

Inherited B-Disease 1 0.9999902248382568
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999921321868896
and O 1 0.9107473492622375
cancer B-Disease 1 0.999825656414032
risk O 0 0.0017070455942302942
of O 0 5.761761912026486e-08
the O 0 6.730883796990383e-07
APC O 0 3.0760485969949514e-05
I1307K O 0 8.877072104951367e-05
polymorphism O 0 0.0002888597082346678
. O 0 1.2417037396517117e-05

Germ O 0 0.09867725521326065
- O 0 0.021340420469641685
line O 0 1.9865549347741762e-06
and O 0 2.8811818708618375e-08
somatic O 0 5.536140292861091e-07
truncating O 0 3.255313913541613e-06
mutations O 0 1.7243011143364129e-06
of O 0 2.1950410378224205e-09
the O 0 1.0534417782537275e-08
APC B-Disease 0 1.1911614450355046e-07
gene O 0 4.7372367362186196e-08
are O 0 6.239198491186926e-09
thought O 0 4.4356461614825093e-08
to O 0 3.211273735814757e-08
initiate O 0 1.9929228074033745e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00047721181181259453
formation O 0 6.319610747596016e-06
in O 0 0.00016894665895961225
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.002570697106420994
sporadic O 1 0.9998502731323242
colorectal O 1 1.0
carcinogenesis O 1 0.999278724193573
, O 0 2.6892992082139244e-06
respectively O 0 1.2462970516935457e-05
. O 0 6.366327852447284e-06

Recently O 0 1.7310268958681263e-05
, O 0 1.1371670893822738e-07
an O 0 4.699949940345505e-08
isoleucine O 0 0.0004300797882024199
- O 0 0.0008842186653055251
- O 0 2.9770868422929198e-05
> O 0 1.2541619298644946e-06
lysine O 0 1.312029780820012e-06
polymorphism O 0 2.925253511421033e-06
at O 0 1.0849392850786899e-07
codon O 0 7.834221946723119e-07
1307 O 0 1.5790591305631096e-06
( O 0 6.988663425744335e-09
I1307K O 0 1.2108498026464076e-07
) O 0 2.7373325828250472e-09
of O 0 3.249805424765384e-10
the O 0 1.7858835521522565e-09
APC B-Disease 0 3.4307348073525645e-08
gene O 0 3.6049168983254276e-08
has O 0 1.648771075224431e-08
been O 0 2.1488284929205292e-08
identified O 0 3.770901813027194e-08
in O 0 5.383143264481305e-09
6 O 0 1.5797333219325083e-08
% O 0 1.3032259715828332e-08
- O 0 2.3704174964223057e-05
7 O 0 6.146936470941e-08
% O 0 5.987774276405844e-09
of O 0 1.3513894447925168e-09
the O 0 1.0648601289631188e-07
Ashkenazi O 0 0.0004963288665749133
Jewish O 0 3.471179979896988e-06
population O 0 8.409543283960375e-07
. O 0 1.6412147942901356e-06

To O 0 1.75634875176911e-06
assess O 0 5.007986601412995e-06
the O 0 7.63833725159202e-08
risk O 0 4.615268665020267e-07
of O 0 1.520669146160003e-09
this O 0 1.1154718038142164e-08
common O 0 2.589319478829566e-07
APC B-Disease 0 1.5048647128423909e-06
allelic O 0 6.8942281359340996e-06
variant O 0 0.00017940870020538568
in O 0 9.56372678047046e-05
colorectal O 1 1.0
carcinogenesis O 0 0.2879718244075775
, O 0 9.84124781666651e-08
we O 0 3.337559917326871e-08
have O 0 5.159047411495976e-09
analyzed O 0 9.247395382772083e-08
a O 0 1.1875154193319304e-08
large O 0 5.843650896508734e-08
cohort O 0 9.587216709405766e-07
of O 0 1.4521575053549896e-08
unselected O 0 7.314699178095907e-05
Ashkenazi O 0 0.00031419226434081793
Jewish O 0 8.381576890315046e-07
subjects O 0 6.964846193113772e-07
with O 0 6.086456494358572e-08
adenomatous B-Disease 0 0.00026604303275234997
polyps I-Disease 0 0.0007264576852321625
and O 0 1.0517737791815307e-07
. O 0 5.555656912292761e-07
or O 1 0.9995512366294861
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 6.958460119221854e-08
for O 0 3.2632254232112246e-08
the O 0 1.446157398277137e-07
APC O 0 1.0523138371354435e-05
I1307K O 0 3.088485391344875e-05
polymorphism O 0 0.0001312568929279223
. O 0 1.396166771883145e-05

The O 0 3.0108290047792252e-06
APC O 0 8.496514055877924e-06
I1307K O 0 5.228196641837712e-06
allele O 0 5.388454610510962e-06
was O 0 1.1570372748792579e-07
identified O 0 6.099460847508453e-08
in O 0 4.183769330978748e-09
48 O 0 1.3966167777823557e-08
( O 0 1.0449880960550217e-09
10 O 0 1.5260008812134629e-09
. O 0 5.163191652002297e-09
1 O 0 1.150724848741902e-08
% O 0 8.206685997436125e-09
) O 0 4.281955678919758e-09
of O 0 6.284104792086964e-09
476 O 0 7.485379228455713e-06
patients O 0 1.0591397767711896e-05
. O 0 2.9337775231397245e-06

Compared O 0 2.0335096451162826e-06
with O 0 1.6109952483134293e-08
the O 0 2.764036999280961e-09
frequency O 0 2.5118333724094555e-07
in O 0 6.043963551860543e-09
two O 0 2.166122836655404e-09
separate O 0 4.6411994247819166e-08
population O 0 2.881506055985028e-08
control O 0 3.2422684625998954e-07
groups O 0 8.178636434763575e-09
, O 0 2.048971214918538e-09
the O 0 4.774753037395385e-09
APC O 0 1.0779240966485304e-07
I1307K O 0 3.124792726794112e-07
allele O 0 2.321949637007492e-07
is O 0 6.9192953588981254e-09
associated O 0 8.953686680968076e-09
with O 0 1.312064457081874e-09
an O 0 5.020475590811202e-09
estimated O 0 5.2956668383785654e-08
relative O 0 4.455906037037494e-06
risk O 0 1.0719149031501729e-05
of O 0 2.0988547788647338e-08
1 O 0 6.714591904710687e-07
. O 0 2.1432429093692917e-06

5 O 0 1.6052561477408744e-05
- O 0 0.0001395684521412477
1 O 0 3.886037575284718e-06
. O 0 3.0413468721235404e-06

7 O 0 3.591253698687069e-05
for O 0 1.2602630704350304e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9874305725097656
( O 0 2.9849272209503397e-07
both O 0 4.1175576370733324e-07
P O 1 0.9434008598327637
= O 0 0.0011712928535416722
. O 0 1.0440860478411196e-06
01 O 0 2.5921362976077944e-05
) O 0 3.504922858610371e-07
. O 0 1.8540886230766773e-06

Furthermore O 0 7.2763118623697665e-06
, O 0 9.132114797694157e-08
compared O 0 6.543854169649421e-08
with O 0 8.44071745831343e-09
noncarriers O 0 3.0572100513381884e-06
, O 0 2.7271822133911883e-08
APC O 0 3.404744859381026e-07
I1307K O 0 4.4321706127448124e-07
carriers O 0 1.8967365633670852e-07
had O 0 1.7709458788317534e-08
increased O 0 9.212218543552808e-09
numbers O 0 1.9220577129885896e-08
of O 0 5.879704723099621e-09
adenomas B-Disease 0 0.1361909955739975
and O 0 0.06918599456548691
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998635053634644
per O 0 3.7407644981612975e-07
patient O 0 1.4056919326321804e-06
( O 0 4.049678281603519e-08
P O 0 0.028030237182974815
= O 0 2.007756665989291e-05
. O 0 3.5982260726541426e-08
03 O 0 6.037289494997822e-07
) O 0 1.6972188099373398e-09
, O 0 4.4498610352050605e-10
as O 0 9.92289028722837e-10
well O 0 6.4821494838440685e-09
as O 0 3.342068177758506e-09
a O 0 1.600013987967941e-08
younger O 0 2.2947536137962743e-07
age O 0 2.1883414547119173e-07
at O 0 4.3645675873449363e-07
diagnosis O 0 0.00016471325943712145
. O 0 4.1640150811872445e-06

We O 0 6.505364581244066e-06
conclude O 0 1.5405117892441922e-06
that O 0 3.046119445571094e-08
the O 0 3.28238947133741e-08
APC O 0 5.791426929135923e-07
I1307K O 0 9.474997568759136e-07
variant O 0 1.360073042633303e-06
leads O 0 8.181214639080281e-08
to O 0 3.196278086647908e-08
increased O 0 2.77637695944577e-07
adenoma B-Disease 1 0.9999992847442627
formation O 0 7.308891269985907e-08
and O 0 1.0519198845315714e-08
directly O 0 8.837768739056173e-09
contributes O 0 8.376581206448463e-09
to O 0 2.3910757818157435e-09
3 O 0 3.109985158289419e-09
% O 0 3.394018399660581e-09
- O 0 2.2905558694219508e-07
4 O 0 8.707823795361946e-09
% O 0 2.29266516882376e-09
of O 0 1.5609350478840156e-09
all O 0 1.1254889642486887e-07
Ashkenazi O 1 0.9481530785560608
Jewish O 1 0.9999327659606934
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0578354451572523e-05

The O 0 3.8485012510136585e-07
estimated O 0 1.1009173306320008e-07
relative O 0 2.8418239139682555e-07
risk O 0 9.479335858486593e-07
for O 0 6.07430061805303e-09
carriers O 0 1.8609836160976556e-07
may O 0 3.0839309772545676e-08
justify O 0 4.5411464810740654e-08
specific O 0 9.366038611346994e-09
clinical O 0 1.3454496183840092e-07
screening O 0 4.688077837045057e-08
for O 0 1.6048760098641424e-09
the O 0 1.2687648709430732e-09
360 O 0 8.017970287710341e-09
, O 0 9.737054496028463e-10
000 O 0 2.310073909939092e-09
Americans O 0 3.6772782596727893e-09
expected O 0 2.2939248278674995e-09
to O 0 1.0886114232278032e-09
harbor O 0 3.59664120708203e-08
this O 0 6.089354576133132e-10
allele O 0 4.3336964239415465e-08
, O 0 1.6450636408649189e-09
and O 0 4.719503898797939e-09
genetic O 0 1.318910420877728e-07
testing O 0 6.526789064764671e-08
in O 0 3.0330615796714255e-09
the O 0 1.8617064556636365e-09
setting O 0 8.813864305068364e-09
of O 0 1.315482389685485e-09
long O 0 4.4602239768209984e-07
- O 0 3.780472252401523e-05
term O 0 3.5557604860514402e-06
- O 0 3.0533985864167335e-06
outcome O 0 7.256356582274748e-08
studies O 0 3.794218983443898e-08
may O 0 1.8128320178334434e-08
impact O 0 2.835426116121198e-08
significantly O 0 2.5533877305861097e-06
on O 1 0.9632542133331299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.0679899560273043e-06
in O 0 3.532664294425558e-08
this O 0 5.834529659409782e-08
population O 0 1.1127410743938526e-06
. O 0 2.225266143796034e-06

Localization O 0 2.5562125301803462e-05
of O 0 8.236248305593108e-08
human O 0 1.2307955898904765e-07
BRCA1 O 0 9.716534805193078e-06
and O 0 8.577045207402989e-08
its O 0 5.066333841341475e-08
loss O 0 3.3113767585746245e-06
in O 0 6.144943398567193e-08
high O 0 2.8093603759771213e-05
- O 0 0.014839225448668003
grade O 0 0.0002159609430236742
, O 0 1.8889737773974957e-08
non B-Disease 0 2.715871914915624e-06
- I-Disease 1 0.6957491040229797
inherited I-Disease 1 0.9997690320014954
breast I-Disease 1 0.9999880790710449
carcinomas I-Disease 1 1.0
. O 0 5.464432979351841e-05

Although O 0 2.4061482690740377e-06
the O 0 6.21914537646262e-08
link O 0 4.140467524393898e-07
between O 0 1.6947256042953995e-08
the O 0 1.473253519179707e-07
BRCA1 O 1 0.9424636363983154
tumour B-Disease 1 1.0
- O 0 1.8103748516296037e-05
suppressor O 0 6.3968236645450816e-06
gene O 0 1.5881174704190926e-06
and O 0 3.4766588896673056e-07
hereditary B-Disease 1 0.9990881681442261
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 3.154729100174336e-08
established O 0 2.5890617649793057e-08
, O 0 1.7457586487523713e-09
the O 0 1.294509832661106e-09
role O 0 2.1863383992126728e-08
, O 0 2.429800138870064e-09
if O 0 4.48951364973027e-09
any O 0 4.339749004600435e-09
, O 0 1.3455535574635746e-09
of O 0 1.4885003229991867e-09
BRCA1 O 0 6.436986950575374e-06
in O 0 2.455898879816232e-07
non B-Disease 0 0.00011062045086873695
- I-Disease 1 0.9606671333312988
familial I-Disease 1 0.9991901516914368
cancers I-Disease 1 0.9999918937683105
is O 0 5.671395229001064e-07
unclear O 0 4.533039373200154e-06
. O 0 1.6148766235346557e-06

BRCA1 O 0 0.001280294731259346
mutations O 0 7.050883868942037e-05
are O 0 1.0711321607459467e-07
rare O 0 1.1470547889302907e-07
in O 0 3.357973810125259e-08
sporadic B-Disease 0 0.013340636156499386
cancers I-Disease 1 0.9999985694885254
, O 0 5.357651033932598e-08
but O 0 5.668204607900407e-07
loss O 0 4.000369528966985e-07
of O 0 3.2749962741718264e-09
BRCA1 O 0 1.4525306141877081e-05
resulting O 0 2.538941998864175e-07
from O 0 9.951971691180006e-09
reduced O 0 5.42236691103426e-08
expression O 0 3.1314328907683375e-08
or O 0 7.697041581877784e-08
incorrect O 0 7.356708806582901e-07
subcellular O 0 2.6119480480701895e-06
localization O 0 2.7159939008924994e-07
is O 0 4.940915232509724e-09
postulated O 0 3.103734869114305e-08
to O 0 2.1948274309124827e-09
be O 0 1.6099684918557955e-09
important O 0 2.462646753187414e-09
in O 0 1.1278481260035278e-08
non B-Disease 0 1.2300157550271251e-06
- I-Disease 0 0.008750403299927711
familial I-Disease 1 0.9909136295318604
breast I-Disease 1 0.9999980926513672
and I-Disease 1 0.9999736547470093
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.4007935280678794e-05

Epigenetic O 0 0.00021027246839366853
loss O 0 0.0016281130956485868
, O 0 1.0964307506355908e-07
however O 0 1.1002960320638522e-07
, O 0 5.406810998920264e-09
has O 0 6.043168632174911e-09
not O 0 6.419289544368212e-09
received O 0 5.2060298294520635e-09
general O 0 3.554188277021808e-09
acceptance O 0 7.012366864955766e-08
due O 0 1.2704103369287623e-07
to O 0 1.121802206682787e-08
controversy O 0 4.909288620069674e-08
regarding O 0 1.1966056590040353e-08
the O 0 5.182470896869518e-09
subcellular O 0 9.202938144881045e-07
localization O 0 2.2796726284468605e-07
of O 0 3.652671942688812e-09
BRCA1 O 0 7.51407924326486e-07
proteins O 0 3.057341757539689e-08
, O 0 2.9169668902540025e-09
reports O 0 3.936169168383685e-09
of O 0 2.91070223479295e-10
which O 0 7.714850980278243e-09
have O 0 6.054347689854467e-09
ranged O 0 6.802828966812058e-09
from O 0 9.207593576476825e-10
exclusively O 0 9.141539969448331e-09
nuclear O 0 5.351569711820048e-07
, O 0 6.232059313049376e-10
to O 0 7.27005122769242e-10
conditionally O 0 7.2460949240849e-08
nuclear O 0 3.497760303616815e-07
, O 0 1.3557189815216475e-09
to O 0 2.935805154535842e-09
the O 0 1.8530808887362582e-08
ER O 0 2.441206788716954e-06
/ O 0 9.628727326571607e-08
golgi O 0 3.232850076528848e-06
, O 0 1.138533889388782e-08
to O 0 1.7389467643624812e-08
cytoplasmic O 0 8.228371939367207e-07
invaginations O 0 2.862844667106401e-06
into O 0 5.084931231635892e-08
the O 0 1.0502061797978968e-07
nucleus O 0 2.905895826188498e-06
. O 0 2.1127291347511346e-06

In O 0 5.086522492092627e-07
an O 0 2.1207902989317517e-08
attempt O 0 2.0001613165732124e-07
to O 0 1.6973816130416708e-08
resolve O 0 9.291011338063981e-08
this O 0 1.302256191770823e-09
issue O 0 9.886811369597126e-09
, O 0 2.3915820435149726e-09
we O 0 4.131361031056713e-09
have O 0 5.0034021370493065e-09
comprehensively O 0 7.255470677591802e-07
characterized O 0 1.9451969990313955e-07
19 O 0 1.031359886383143e-07
anti O 0 1.332496708528197e-06
- O 0 1.654134212003555e-05
BRCA1 O 0 0.00012371904449537396
antibodies O 0 1.900563256640453e-05
. O 0 2.6046302536997246e-06

These O 0 1.498677647759905e-06
reagents O 0 6.4956630012602545e-06
detect O 0 2.3876420527813025e-05
a O 0 7.260122458774276e-08
220 O 0 1.4379718038526335e-07
- O 0 7.04892840985849e-07
kD O 0 3.6554556572809815e-06
protein O 0 7.823338421530934e-08
localized O 0 2.246867296662458e-07
in O 0 1.1539359690004858e-08
discrete O 0 8.967967914941255e-07
nuclear O 0 7.2711086431809235e-06
foci O 0 6.352345280902227e-07
in O 0 1.0554408902407886e-08
all O 0 4.0201779683002314e-09
epithelial O 0 1.2310061947573558e-06
cell O 0 0.0008517895475961268
lines O 0 1.6328267520293593e-05
, O 0 2.870402138199779e-09
including O 0 1.3988689095967288e-09
those O 0 4.828024202652159e-09
derived O 0 9.116017452015512e-08
from O 0 2.0226117669608357e-07
breast B-Disease 1 0.9889946579933167
malignancies I-Disease 1 0.9512651562690735
. O 0 8.851908205542713e-06

Immunohistochemical O 0 0.0032816678285598755
staining O 0 0.00149603933095932
of O 0 2.2810775135440053e-07
human O 0 7.387897085209261e-07
breast O 0 0.0019074507290497422
specimens O 0 8.356204830306524e-07
also O 0 6.946829955722933e-08
revealed O 0 1.6252978412012453e-06
BRCA1 O 0 4.56764864793513e-05
nuclear O 0 1.6168152114914847e-06
foci O 0 2.1503738025785424e-06
in O 0 1.0625938529074119e-07
benign O 0 0.0006170926499180496
breast O 0 0.3711261451244354
, O 0 2.64160291862936e-07
invasive B-Disease 0 0.017870662733912468
lobular I-Disease 1 0.9999223947525024
cancers I-Disease 1 0.9999887943267822
and O 0 5.473957116919337e-06
low B-Disease 0 0.16970700025558472
- I-Disease 1 0.9779382944107056
grade I-Disease 1 0.7571611404418945
ductal I-Disease 1 0.999138355255127
carcinomas I-Disease 1 1.0
. O 0 8.508280734531581e-05

Conversely O 0 3.4818280255421996e-05
, O 0 3.760577271805232e-07
BRCA1 O 0 5.309160314936889e-06
expression O 0 3.2403457339569286e-07
was O 0 1.4434141348829144e-07
reduced O 0 6.176152567149984e-08
or O 0 5.209897224744964e-08
undetectable O 0 2.5622352950449567e-06
in O 0 9.846145232472736e-09
the O 0 3.4387843683703068e-09
majority O 0 4.7746098630341294e-08
of O 0 2.1656891835419856e-09
high O 0 1.9771914594457485e-05
- O 0 0.0013575531775131822
grade O 0 2.9447815904859453e-05
, O 0 2.349588434924499e-08
ductal B-Disease 0 0.010959701612591743
carcinomas I-Disease 1 1.0
, O 0 5.387594015360264e-08
suggesting O 0 1.7161855225822364e-07
that O 0 4.461982783254825e-09
absence O 0 1.926381187900006e-08
of O 0 1.9468213707796167e-09
BRCA1 O 0 1.4586760698875878e-05
may O 0 1.429690854592991e-07
contribute O 0 5.061743024725729e-09
to O 0 2.6064868041686395e-09
the O 0 2.278501387564802e-09
pathogenesis O 0 3.3643718921894106e-08
of O 0 3.8097267007763946e-10
a O 0 3.3095834961471837e-09
significant O 0 1.0886331125448123e-07
percentage O 0 6.14061491432949e-07
of O 0 1.3422092770554173e-08
sporadic B-Disease 0 0.07295452058315277
breast I-Disease 1 0.9999996423721313
cancers I-Disease 1 0.9999922513961792
. O 0 1.9991516637674067e-06
. O 0 4.896602604276268e-06

